CSA850657

# Industria y Comercio

SUPERINTENDENCIA

Organizacion y Digitalizacion CSA Ltda

1/7

Delegatura de Propiedad Industrial
División de Nuevas Creaciones

DVN OK

PCT 0905

TOMO 1/1 NOV DVN

SOLICITUD

## PATENTE DE INVENCIÓN

09-126923

DE INDUSTRIA Y C... INVENTARIO

21. **EXPEDIENTE N**

54. **TÍTULO** USO DE COMPUESTOS INHIBIDORES DE QUINAXOLINA DE PI3K-ALFA PARA EL TRATAMIENTO DEL CÁNCER.

51. **CLASIFICACIÓN INTERNACIONAL**

71. **SOLICITANTE** EXELIXIS, INC.

**DOMICILIO** CALIFORNIA, USA.

74. **APODERADO** CARLOS ORLANDO MAMA

22. **BOGOTÁ, D.C.,** 9 NOVIEMBRE 2009

FA. 11-11-2009

(FORMA P-10)

1292

# PETITORIO

Industria y Comercio
SUPERINTENDENCIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 09-126923- -00000-0000
Fecha: 2009-11-09 16:43:03 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 1292

**FORMULARIO UNICO DE SOL**

## PCT
## ENTRADA EN FASE NACIONAL

**1. SOLICITUD DE:**

[X] Patente de Invención [ ] Patente de Modelo de Utilidad

[X] Capitulo I [ ] Capitulo II

**2. SOLICITANTE .(71)**

Nombre: **EXELIXIS, INC**
Dirección: **220 East Grand Avenue, P.O. Box 511, South San Francisco, CA 94083, US**
Domicilio: **South Francisco, CA 94083, US**
Lugar de Constitución: **Delaware**
Teléfono: Fax:
E-mail:

**IDENTIFICACION**
C.C. [ ] NIT [ ]
C.E. [ ] Otro [ ]
Cual ____
Número: ____

**3. REPRESENTANTE O APODERADO**

Nombre: **CARLOS ORLANDO MAYA RODRIGUEZ**
Dirección: **Cr. 13 A No 28-38, Mz 2 Bufete 230. Parque Central Bavaria**
Teléfono: **3419841** Fax: **2435423**
E-mail: **patent@tmtamayo.net**

**IDENTIFICACION**
C.C. [X] NIT [ ]
C.E. [ ] Otro [ ]
Cual
Número: **17.117.818** TP: **17.402**

**4. INVENTOR(ES) .(72)**

Nombres:
**1.- LAMB, Peter**
**2.- MATTHEWS, David**

Dirección:
**1.- 814 Mandana Blvd, Oakland, California 94610, USA.**
**2.- 2 Balceta Avenue, San Francisco, California 94127, USA**

Nacionalidad o Domicilio:
1 Ciudadano de USA
2 Ciudadano de REINO UNIDO

**5. PCT (86)**
Solicitud internacional No. **PCT/US2008/004570** Fecha: **ABRIL 08/2008**
Publicación internacional No. **WO 2008/127594 A3** Fecha: **OCTUBRE 23/2008**

**6. Título (54)** **USO DE COMPUESTOS INHIBIDORES DE QUINAXOLINA DE PI3K-ALFA PARA EL TRATAMIENTO DEL CÁNCER**

**7. Clasificación Internacional (51)**

**8. Prioridad** Si [X] No [ ]


| (33) País de Origen | (32) Fecha | (31) Número deSolicidud |
|---|---|---|
| USA | 11-Abr-07 | 60/923,164 |
| | | |
| | | |
| | | |

**9.** Comprobante de pago No. **09-83,653 Y 09-83,662** Fecha **NOVIEMBRE 09/2009**

**10.** **Anexos**

- [X] Comprobante de pago de la tasa de presentación de la solicitud
- [X] Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica(EXP.09-113466
- [X] Poderes, si fuere el caso (LA COPIA AUTENTICA REPOSA EN EL EXPEDIENTE 09-113466)
- [ ] Documento de cesión del inventor al solicitante o a su causante
- [ ] Declaraciones
- [X] Copia de la solicitud Internacional (Resumen, descripción, reivindicaciones, dibujos)
- [X] Traducción de la solicitud internacional al castellano (Resumen, descripción, reivindicaciones, dibujos)
- [ ] Copia del examen preliminar internacional efectuado por la Autoridad Internacional de Examen Preliminar (IPEA)
- [ ] Traducción del examen preliminar internacional efectuado por la IPEA
- [ ] De ser el caso, copia del contrato de acceso
- [ ] De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- [ ] De ser el caso, certificado de depósito del material biológico
- [X] Arte final 12 x 12
- [ ] De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extrajero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- [X] De ser el caso, modificaciones efectuadas a la solicitud internacional (FORMULARIOS IB 306 CON SU TRADUCCIÓN)
- [X] Otros ( CARATULA DE LA PUBLICACION INTERNACIONAL, EL COMPROBANTE DE PAGO POR EXCEDENTE PALABRAS PUBLICACION 09-83,662)

**11.** **FIGURA CARACTERISTICA**




**12.** Solicito la concesión de la patente,

NOMBRE: **CARLOS ORLANDO MAYA RODRIGUEZ**

FIRMA:

C.C. **17.117.818** TP **17.402**

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

No. 09-126923- -00000-0000

Fecha: 2009-11-09 16:43:03 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 1292

424-P Sol.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 09 - 83,653
FECHA : NOVIEMBRE 9 DE 2009

***** C O N S I G N A C I O N *****

| DEPOSITANTE | TIPO PAGO | BANCO | CUENTA | No. PAGO | FECHA PGO | Vr. PAGO |
|---|---|---|---|---|---|---|
| CARLOS TAMAYO Y ASOCIADOS | CONSIGNACION | BANCO DE BOGOTA | 062754387 | 53363170 | 09/11/2009 | 3,564,920.00 |

***** C O N C E P T O *****

| CANT. | RENTISTICO | CONCEPTO | | TOTAL CONCEPTO |
|---|---|---|---|---|
| 1 | 50005-01-01 SOLICITUDES | 1 TRAMITES DE SOL. DE PATENTE DE IN | | 540,000.00 |
| | | TOTAL : | $ | 540,000.00 |

SON: QUINIENTOS CUARENTA MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

4

424-P Sol

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 09-126923- -00000-0000

Fecha: 2009-11-09 16:43:03 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 1292

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 09 - 83,662
FECHA : NOVIEMBRE 9 DE 2009

***** C O N S I G N A C I O N *****

| DEPOSITANTE | TIPO PAGO | BANCO | CUENTA | No. PAGO | FECHA PGO | Vr. PAGO |
|---|---|---|---|---|---|---|
| CARLOS TAMAYO Y ASOCIADOS | CONSIGNACION | BANCO DE BOGOTA | 062754387 | 53363170 | 09/11/2009 | 3,564,920.00 |

***** C O N C E P T O *****


| CANT. | RENTISTICO | CONCEPTO | TOTAL CONCEPTO |
|---|---|---|---|
| 1 | 50005-01-09 OTROS SERVICIOS DE PROPIEDAD I | 99 OTROS SERVCIOS ADMINISTRATIVOS | 799,740.00 |
| | | TOTAL : $ | 799,740.00 |

SON: SETECIENTOS NOVENTA Y NUEVE MIL SETECIENTOS CUARENTA PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No._____

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA COMO PARTE DE LA CANCELACION DE UNA TARIFA VIGENTE Y NO PODRA SER SUSTITUIDA POR NINGUN RECIBO.


Patente
PCT/US 2008/004570
WO 2008/127594 A3

COLEGIO DE ESCRIBANOS · CIUDAD DE BUENOS AIRES · CAPITAL FEDERAL · REPUBLICA ARGENTINA

ACTUACION NOTARIAL
LEY 404

N 007410568

CECBA - LEY404 GCBA
LEGALIZACION
0021903506
$20.00
14:42:24
19/02/2007

CECBA - LEY404 GCBA
APOSTILLE
0702190053883
$39.00
14:42:29
19/02/2007

**FOLIO 336.- PRIMERA COPIA.- ESCRITURA NUMERO CIENTO SESENTA Y OCHO.-** En la Ciudad de Buenos Aires, Capital de la República Argentina, a nueve de febrero de dos mil siete, ante mi, Escribano Autorizante, COMPARECE don **Daniel GOYTIA**, argentino, mayor de edad, casado, Libreta de Enrolamiento número 4.526.965, domiciliado en Bartolomé Mitre 226, 4° piso, de esta Ciudad.- El compareciente es persona de mi conocimiento, doy fe, así como que DICE: I.- Que por escritura del dia de la fecha pasada ante mi, al folio 327 del Protocolo de este mismo Registro, se protocolizó un **Poder** otorgado por **EXELIXIS, INC.**, con domicilio en 170 Harbor Way P.O. Box 511, South San Francisco, California 94083, USA, a su favor.- II.- Que viene por la presente a **SUSTITUIR** el citado mandato, reservándose para si las facultades, a favor de **"CARLOS TAMAYO & ASOCIADOS" y/o Carlos Orlando Maya Rodriguez y/o Gustavo Calderon Rosero y/o Carmen Graciela Florez y/o Clara Cortes Charry y/o Mayerling Rocio Castelblanco S.**, con domicilio en Carrera 13A N° 28-38, Buffette 245, Manzana 02, Parque Central Bavaria, Bogotá, **COLOMBIA**, para actuar en dicho país con las siguientes facultades: "... poder amplio y suficiente para recabar de las autoridades nacionales que corresponda, sean estas administrativas y/o judiciales, la obtención de **"PATENTES, MARCAS, MODELOS, DISEÑOS Y SUS RENOVACIONES"**, y realizar todos los trámites conducentes para proteger los derechos de la mandante, a cuyo efecto, los faculta para efectuar ante dichas autoridades nacionales, administrativas y/o judiciales todos los trámites necesarios a los objetos indicados; presentar solicitudes, alegatos, oposiciones, protestas, apelaciones y demandas; desistir, arreglar y transigir; aceptar cesiones y transferencias; solicitar testimonios; recibir documentos y

N 007410568

otros valores; justificar explotaciones; cobrar y percibir; firmar instrumentos públicos, privados y escrituras públicas; para renunciar o no a las gestiones judiciales; y hacer cuanto fuere necesario ante las autoridades nacionales, judiciales y/o administrativas, sea como demandante o como demandado, para proteger los intereses del mandante, con facultad de substituir este instrumento y revocar tal substitución. Se deja constancia que las facultades enumeradas en este mandato, son meramente ejemplificativas y no limitativas de otras facultades implícitas, por cuyo motivo, los mandatarios quedan autorizados para ejercer sin restricción alguna todos los derechos que acuerde la ley que se relacionen y/o emerjan y/o que sean consecuencia del objeto del presente poder y ya sea ello en razón de la legislación vigente y/o de la legislación que en el futuro se promulgue. Este documento tiene validez a partir del 01 de diciembre de 2006...".- LO TRANSCRIPTO ES COPIA FIEL, doy fe, de las partes pertinentes del mandato relacionado.- LEIDA y ratificada, así lo expresó, otorgó, aceptó y firmó, por ante mi, doy fe.- "SIGUE UNA FIRMA".- Esta mi sello.- Ante mi: ALEJANDRO M. LIPORACE.- CONCUERDA con su escritura matriz que pasó ante mi, al folio 336 del Protocolo del Registro 1331, a mi cargo. PARA LOS APODERADOS expido esta **PRIMERA COPIA** en UNA FOJA de Actuación Notarial número N 007410568 que sello y firmo en el mismo lugar y fecha de su otorgamiento, doy fe.-

ALEJANDRO M. LIPORACE
Matricula 3837
ESCRIBANO PUBLICO

COLEGIO DE ESCRIBANOS · CIUDAD DE BUENOS AIRES · CAPITAL FEDERAL - REPUBLICA ARGENTINA · NIHIL PRIUS FIDE

LEGALIZACION
LEY 404

L 007464707

EL COLEGIO DE ESCRIBANOS de la Ciudad de Buenos Aires, Capital Federal de la República Argentina, en virtud de las facultades que le confiere la ley vigente, LEGALIZA la firma y sello del escribano ALEJANDRO MARIA LIPORACE obrantes en el documento anexo, presentado en el día de la fecha bajo el Nº 070219083506/6 La presente legalización no juzga sobre el contenido y forma del documento.

Buenos Aires, Lunes 19 de Febrero de 2007

COLEGIO DE ESCRIBANOS · LEGALIZACION · CIUDAD DE BUENOS AIRES · CAPITAL FEDERAL - REPUBLICA ARGENTINA

ESC. EDDA ENRIQUETA SINELLI
COLEGIO DE ESCRIBANOS
CONSEJERA

# APOSTILLE

REPUBLICA ARGENTINA

(Convention de La Haye du 5 octobre 1961)

A 00104498

1. PAÍS: REPUBLICA ARGENTINA

El presente documento público

2. Ha sido firmado por EDDA ENRIQUETA SINELLI

3. Quien actúa en calidad de CONSEJERA

4. Lleva el sello / timbre de COLEGIO DE ESCRIBANOS DE LA CIUDAD DE BUENOS AIRES

5. En LA CIUDAD DE BUENOS AIRES 6. El día 19/02/2007

7. Por EL COLEGIO DE ESCRIBANOS DE LA CIUDAD DE BUENOS AIRES

MINISTERIO DE RELACIONES EXTERIORES, COMERCIO INTERNACIONAL Y CULTO

(Convenio 02/09/2003)

8. Bajo el número: 070219053883

9. Sello / Timbre

COLEGIO DE ESCRIBANOS · APOSTILLA · CAPITAL FEDERAL - REPUBLICA ARGENTINA

10. Firma

ESC. HUGO L. R. CHIOCCI
COLEGIO DE ESCRIBANOS
LEGALIZADOR

GRAFICA LATINA S.R.L.

Folio 327/2007

## DANIEL GOYTIA - PATENTS & TRADEMARKS

### Power of Attorney

The undersigned (1)

EXELIXIS, INC.

Residing at (2)
170 Harbor Way P.O. Box 511. South San Francisco, California 94083. USA.

hereby grants to DANIEL GOYTIA

residing in Buenos Aires, Argentina
full and ample power of attorney to represent him (it) and apply to the proper national authorities, either administrative or judiciary for

**Patents, Trademarks, Models, Designs and their Renewals**

and to carry out all the necessary steps to protect our rights, to which effect they are empowered to take all necessary steps before the said national authorities, either administrative and/or judicial, for the aforementioned purposes, including to file petitions, arguments oppositions, protests, appeals and claims, to waive, settle and compromise; to accept assignments and transfers; to apply for certified copy; to receive documents and other valuable things; to prove workings; to collect monies; to sign public and private instruments and deeds; to either waive or not at their discretion the right of resorting to court proceedings; to do all and whatever shall be necessary before any national judicial and/or administrative authorities to protect the constituent's interests, either as plaintiff or defendant, with power to substitute this instrument and to revoke such substitution. It being understood that the above powers enumerated in this mandate are merely exemplifying and not limitative of other powers and therefore the attorneys-in-fact are authorized to exercise without any restriction whatsoever, all the rights granted by Law or emerging from it or which, may be a consequence of the objects of this mandate and whether this be under legislation at present in force or legislation which may be promulgated in the future.

Dated (3)
Day 24 Of January 2007

### Poder

52465

El abajo firmante (1)

EXELIXIS, INC.

Domiciliado en (2)
170 Harbor Way P.O. Box 511. South San Francisco, California 94083. USA

por el presente otorga a DANIEL GOYTIA

domiciliado en Buenos Aires, Argentina
poder amplio y suficiente para recabar de las autoridades nacionales que corresponda, sean éstas administrativas y/o judiciales, la obtención de

**Patentes, Marcas, Modelos, Diseños y sus renovaciones**

y realizar todos los tramites conducentes para proteger los derechos de la mandante, a cuyo efecto, los faculta para efectuar ante dichas autoridades nacionales, administrativas y/o judiciales, todos los tramites necesarios a los objetos indicados; presentar solicitudes, alegatos, oposiciones, protestas, apelaciones y demandas; desistir, arreglar y transigir; aceptar cesiones y transferencias, solicitar testimonios, recibir documentos y otros valores; justificar explotaciones, cobrar y percibir; firmar instrumentos públicos, privados y escrituras publicas; para renunciar o no a las gestiones judiciales; y hacer cuanto fuere necesario ante las autoridades nacionales, judiciales y/o administrativas, sea como demandante o como demandado, para proteger los intereses del mandante, con facultad de substituir este instrumento y revocar tal substitución. Se deja constancia que las facultades enumeradas en este mandato, son meramente ejemplificativas y no limitativas de otras facultades implícitas, por cuyo motivo, los mandatarios quedan autorizados para ejercer sin restricción alguna todos los derechos que acuerde la ley que se relacionen y/o emerjan y/o que sean consecuencia del objeto del presente poder y ya sea ello en razón de la legislación vigente y/o de la legislación que en el futuro se promulgue.

(3) Fechado el
de de 2007

(4) .....
Pamela A. Simonton, Senior Vice President, Patents & Licensing
(1) Applicant's name – (2) Applicant's address – (3) Date – (4) Applicant's Signature

***This document is effective as of December 01, 2006***

ALEJANDRO M. LIPORACE
Matricula 3837
ESCRIBANO PUBLICO

# State of California

## SECRETARY OF STATE

# *APOSTILLE*

*(Convention de La Haye du 5 octobre 1961)*

1. *Country: United States of America*
   *This public document*
2. *has been signed by J. COHEN*
3. *acting in the capacity of Notary Public, State of California*
4. *bears the seal/stamp of J. COHEN, Notary Public, State of California*

***CERTIFIED***

5. *At Sacramento, California*
6. *the 6th day of February 2007*
7. *by Deputy Secretary of State, State of California*
8. *No. 351842*
9. *Seal/Stamp:*



10. *Signature*




Jena Bowen
Secretary of State

NP-24 A (REV. 1-07)

BY

OSP 06 99602

EL GRAN SELLO DEL ESTADO DE CALIFORNIA

ALEJANDRO M. LIPORACE

## CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of San Mateo

On 24 January 2007 before me, J. Cohen, Notary Public
Date Name and Title of Officer (e.g., "Jane Doe, Notary Public")

personally appeared Pamela A. Simonton & Christoph Pereira
Name(s) of Signer(s)

☑ personally known to me

☐ (or proved to me on the basis of satisfactory evidence)

to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

J. COHEN
Commission # 1417900
Notary Public - California
San Mateo County
My Comm. Expires Jun 11, 2007

Place Notary Seal Above

J. Cohen
Signature of Notary Public

### OPTIONAL

*Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.*

**Description of Attached Document**

Title or Type of Document: Power of Attorney

Document Date: _____ Number of Pages: 1 page + certs.

Signer(s) Other Than Named Above: _____

**Capacity(ies) Claimed by Signer(s)**

| | |
|---|---|
| Signer's Name: Pamela A. Simonton | Signer's Name: Christoph Pereira |
| ☐ Individual | ☐ Individual |
| ☑ Corporate Officer — Title(s): Senior Vice President | ☑ Corporate Officer — Title(s): Secretary |
| ☐ Partner — ☐ Limited ☐ General | ☐ Partner — ☐ Limited ☐ General |
| ☐ Attorney in Fact | ☐ Attorney in Fact |
| ☐ Trustee | ☐ Trustee |
| ☐ Guardian or Conservator | ☐ Guardian or Conservator |
| ☐ Other: _____ | ☐ Other: _____ |
| Signer Is Representing: Exelixis, Inc. | Signer Is Representing: Exelixis |
| RIGHT THUMBPRINT OF SIGNER — Top of thumb here | RIGHT THUMBPRINT OF SIGNER — Top of thumb here |

© 2006 National Notary Association • 9350 De Soto Ave., P.O. Box 2402 • Chatsworth, CA 91313-2402 Item No. 5907 Reorder: Call Toll-Free 1-800-876-6827

EL GRAN SELLO DEL ESTADO DE CALIFORNIA

ALEJANDRO M. LIPORACE

TRADUCCIÓN PÚBLICA ----------

[Página 1] ----------

DANIEL GOYTÍA - PATENTES Y MARCAS ----------

[Luego de un PODER, redactado en idiomas inglés y español aparece lo siguiente:] ----------

(3) Fechado a los 24 días de enero de 2007 ----------

(4) [Aparece una firma ilegible debajo de la cual se lee:] Pamela A. Simonton, Vicepresidente Senior, Patentes y Licencias

(1) Nombre del Solicitante, (2) Domicilio del Solicitante, (3) Fecha, (4) Firma del Solicitante ----------

*****Este documento tiene validez a partir del 01 de diciembre de 2006***** ----------

---

[Página 2] ----------

[Siguen dos Certificados Notariales en idiomas español e inglés. Luego del segundo Certificado Notarial aparece lo siguiente:] ----------

Ciudad: San Francisco. ----------

Estado: California, Estados Unidos de Norteamérica. ----------

A los 24 días de enero de 2007. ----------

[Aparece una firma ilegible debajo de la cual se lee:] FUNCIONARIO CERTIFICANTE. Christoph Pereira, Vicepresidente, Asuntos Legales y Secretario. ----------

---

[Página 3] ----------

ESTADO DE CALIFORNIA ----------

EL GRAN SELLO DEL ESTADO DE CALIFORNIA ----------

ALEJANDRO M. LIPORACE
Matrícula 3937

SECRETARIO DE ESTADO ----------

APOSTILLA ----------

[Aparece una frase en otro idioma] ----------

1. País: Estados Unidos de Norteamérica ----------

Este documento público ----------

2. ha sido firmado por J. COHEN ----------

3. actuando en carácter de Escribano Público, Estado de California ----------

4. lleva el sello/timbre de J. COHEN, Escribano Público, Estado de California ----------

CERTIFICADO ----------

5. en Sacramento, California ----------

6. el 06 de febrero de 2007 ----------

7. por el Subsecretario de Estado, Estado de California -------

8. No. 351842 ----------

9. Sello/Timbre: El Gran Sello del Estado de California ------

10. Firma: [Aparece una firma ilegible debajo de la cual se lee:] Secretario de Estado. ----------

Por: [Aparece una firma ilegible] ----------

[Sigue un sello circular que reza:] OFICINA DEL SECRETARIO DE ESTADO, EL GRAN SELLO DEL ESTADO DE CALIFORNIA ----------

---

[Página 4] ----------

CERTIFICACIÓN PARA TODOS LOS PROPÓSITOS DE CALIFORNIA----------

Estado de California. Condado de San Mateo.----------

A los (FECHA) 24 días del mes de enero del año 2007, por ante mí, (NOMBRE Y CARGO DEL FUNCIONARIO (EJ., "JANE DOE, ESCRIBANO

ALEJANDRO M. LIPORACE
Matricula 3837
ESCRIBANO PUBLICO

PÚBLICO)) J. Cohen, Escribano Público, compareció personalmente (NOMBRE DE LA PERSONA(S) FIRMANTE(S)) Pamela A. Simonton & Christoph Pereira, [X] a quienes conozco personalmente---------

[ ] (o demostraron ante mí con pruebas suficientes)----------

que son las personas cuyos nombres suscriben el instrumento adjunto y certificaron ante mí que lo otorgaron en su carácter de autorizados, y que con sus firmas en el instrumento las personas o la persona de existencia ideal en nombre de la cual actuaron las personas, otorgaron el instrumento.----------

CERTIFICO con mi firma y sello oficial.----------

[Aparece una firma ilegible debajo de la cual se lee:] Firma del Escribano Público----------

Colocar el sello notarial más arriba [Aparece un sello que reza:] El Gran Sello del Estado de California. J. COHEN. MANDATO NO. 1417900. ESCRIBANO PÚBLICO - CALIFORNIA. CONDADO DE SAN MATEO. Mi mandato vence el 11 de junio de 2007----------

INFORMACIÓN OPTATIVA----------

*La información que aparece a continuación no ese exigida por ley. Sin embargo, podría ser valiosa para las personas que confían en el documento e impediría que la presente certificación se adjunte en forma fraudulenta a otro documento.*----------

Descripción del Documento Adjunto.----------

Título o Tipo de Documento: **Poder**----------

Fecha del Documento: [en blanco] ----------

Número de Páginas: 1 página más certificaciones.----------

Persona(s) Firmante(s) distinta de la mencionada anteriormente:

ALEJANDRO M. LIPORACE

[en blanco].----------

CARÁCTER INDICADO POR EL FIRMANTE----------

Nombre de la Persona Firmante: Pamela A. Simonton----------

[ ] Persona Física----------

[X] Funcionario de Sociedad Anónima. Cargo(s): Vicepresidente Senior----------

[ ] Socio(s) - [ ] Limitado [ ] General----------

[ ] Apoderado----------

[ ] Síndico----------

[ ] Tutor o Curador----------

[ ] Otro: [en blanco]----------

El firmante representa a: **Exelixis, Inc.**----------

Huella digital del pulgar derecho del firmante----------

[Aparece un casillero en blanco con una leyenda que reza:] Coloque aquí la parte superior de la huella digital del pulgar derecho.----------

Nombre de la Persona Firmante: Christoph Pereira.----------

[ ] Persona Física----------

[X] Funcionario de Sociedad Anónima. Cargo(s): Secretario.-----

[ ] Socio(s) - [ ] Limitado [ ] General----------

[ ] Apoderado----------

[ ] Síndico----------

[ ] Tutor o Curador----------

[ ] Otro: [Aparece una línea en blanco]----------

El firmante representa a: Exelixis----------

Huella digital del pulgar derecho del firmante----------

ALEJANDRO M. UROPACE

[Aparece un casillero en blanco con una leyenda que reza:] Coloque aquí la parte superior de la huella digital del pulgar derecho.----------

2006 Asociación Nacional de Escribanos. 9350 De Soto Ave., P.O. Box 2402, Chatsworth, CA 91313-2402, Ítem No. 5907, Nuevo Pedido: Llamar a la línea gratuita 1-800-876-6827. ----------

---

CERTIFICO POR LA PRESENTE QUE LO QUE ANTECEDE ES TRADUCCIÓN FIEL Y COMPLETA AL ESPAÑOL DE LAS PARTES PERTINENTES EN IDIOMA INGLÉS DEL DOCUMENTO ORIGINAL QUE TUVE ANTE MÍ Y AL CUAL ME REMITO. EN LA CIUDAD DE BUENOS AIRES, A LOS 09 DÍAS DEL MES DE FEBRERO DE DOS MIL SIETE. ----------

COLEGIO DE TRADUCTORES PUBLICOS
DE LA CIUDAD DE BUENOS AIRES
Corresponde a la Legalización
Nº TT— 3424/07
ESTEBAN SANTIAGO ALLEGRETTI

VALERIA FIORI
Libro 100 Fo. 200 Esp.
DANIEL GOYTIA
AGENTE Nº 464

ALEJANDRO M. LIPORACE
Matricula 3837
ESCRIBANO PUBLICO

N° 00960454

COLEGIO DE TRADUCTORES PÚBLICOS
DE LA CIUDAD DE BUENOS AIRES

REPÚBLICA ARGENTINA
LEY 20.305

# LEGALIZACIÓN

Por la presente, el COLEGIO DE TRADUCTORES PÚBLICOS DE LA CIUDAD DE BUENOS AIRES, en virtud de la facultad que le confiere el artículo 10, inc. d) de la Ley 20.305, certifica únicamente que la firma y el sello que aparecen en la traducción adjunta, concuerdan con los correspondientes al Traductor Público **FIORI UGARTE, VALERIA**

que obran en los registros de esta institución en el folio , tomo

| | | |
|---|---|---|
| INGLES | 233 | 13 |

Buenos Aires, **Legalización Número: 3424 / 2007 / T4**

**Fecha: 09/02/07**

MARCELO F. SIGALOFF
Encargado Dto. de Legalizaciones
Colegio de Traductores Públicos
de la Ciudad de Buenos Aires

ESTA LEGALIZACIÓN NO SE CONSIDERARÁ VÁLIDA SIN EL CORRESPONDIENTE TIMBRADO EN LA ÚLTIMA HOJA DE LA TRADUCCIÓN ADJUNTA

Pursuant to Section 10, Paragraph d) of Act 20.305, the *COLEGIO DE TRADUCTORES PUBLICOS DE LA CIUDAD DE BUENOS AIRES* (Sworn Translators Association of the City of Buenos Aires) hereby certifies that the signature and seal affixed hereto appear to match the specimen signature and seal of the *Traductor Público* (Sworn Translator) whose name is subscribed to the attached translation, as such specimen signature and seal are kept on file in our office.
THIS CERTIFICATION IS NOT VALID WITHOUT THE STAMP ON THE LAST PAGE OF THE ATTACHED TRANSLATION.

ALEJANDRO M. ... Matricula ... ESCRIBANO

Vu par le *COLEGIO DE TRADUCTORES PÚBLICOS DE LA CIUDAD DE BUENOS AIRES* (Ordre de Traducteurs Officiels de la ville de Buenos Aires), en vertu des attributions qui lui ont été accordées par l'article 10, alinéa d) de la Loi nº 20.305, pour la seule légalisation matérielle de la signature et du sceau du *Traductor Público* (Traducteur Officiel) apposés sur la traduction du document ci-joint, qui sont conformes à ceux déposés aux archives de cette Institution.
LE TIMBRE APPOSÉ SUR LA DERNIÈRE PAGE DE LA TRADUCTION FERA PREUVE DE LA VALIDITÉ DE LA LÉGALISATION.

Con la presente il *COLEGIO DE TRADUCTORES PÚBLICOS DE LA CIUDAD DE BUENOS AIRES* (Collegio dei Traduttori Giurati della Città di Buenos Aires) ai sensi della facoltà conferitagli dall'articolo 10, comma d), della Legge 20.305, CERTIFICA, esclusivamente, la firma ed il timbro del *Traductor Público* (Traduttore Giurato), apposti in calce alla qui unita traduzione, in conformità alla firma ed al timbro depositati nei propri registri.
LA PRESENTE LEGALIZZAZIONE SARÀ PRIVA DI VALIDITÀ OVE NON VENGA TIMBRATA NELL'ULTIMO FOGLIO DELLA TRADUZIONE.

Através da presente o *COLEGIO DE TRADUCTORES PÚBLICOS DE LA CIUDAD DE BUENOS AIRES* (Colégio de Tradutores Públicos da Cidade de Buenos Aires), em virtude das atribuições conferidas pelo art. 10 inc. d) da Lei 20.305, certifica unicamente que a assinatura e o carimbo do *Traductor Público* (Tradutor Público) que subscreve a tradução adjunta conferem com a assinatura e o carimbo arquivados nos registros desta instituição.
A PRESENTE LEGALIZAÇÃO SÓ SERÁ CONSIDERADA VÁLIDA COM A CORRESPONDENTE CHANCELA MECÂNICA APOSTA NA ÚLTIMA FOLHA DA TRADUÇÃO.

Kraft der Befugnis, die ihr durch Art. 10, Abs. d) im Gesetz 20.305 verliehen wird, bestätigt hiermit der *COLEGIO DE TRADUCTORES PÚBLICOS DE LA CIUDAD DE BUENOS AIRES* (Kammer der Vereidigten Übersetzer der Stadt Buenos Aires) lediglich, dass Unterschrift und Siegel, des *Traductor Público* (Vereidigten Übersetzers), mit denen die beigefügte Übersetzung versehen ist, mit den entsprechenden Registereintragungen dieser Institution übereinstimmen.
VORLIEGENDE BEGLAUBIGUNG IST UNGÜLTIG OHNE DEN ENTSPRECHENDEN GEBÜHRENSTEMPEL AUF DEM LETZTEN BLATT DER BEIGESCHLOSSENEN ÜBERSETZUNG.

CERTIFICO EN SELLO DE ACTUACION NOTARIAL Nº I00590 04431
BUENOS AIRES 14/2 1071

ALEJANDRO M. ... DRACE
Matricula 3837
ESCRIBANO PUBLICO

# APOSTILLE

REPUBLICA ARGENTINA

(Convention de La Haye du 5 octobre 1961)

A 00104499

1. PAÍS: REPUBLICA ARGENTINA

El presente documento público

2. Ha sido firmado por EDDA ENRIQUETA SINELLI

3. Quien actúa en calidad de CONSEJERA

4. Lleva el sello / timbre de COLEGIO DE ESCRIBANOS DE LA CIUDAD DE BUENOS AIRES

5. En LA CIUDAD DE BUENOS AIRES 6. El día 19/02/2007

7. Por EL COLEGIO DE ESCRIBANOS DE LA CIUDAD DE BUENOS AIRES

MINISTERIO DE RELACIONES EXTERIORES, COMERCIO INTERNACIONAL Y CULTO

(Convenio 02/09/2003)

8. Bajo el número: 070219053886

9. Sello / Timbre

COLEGIO DE ESCRIBANOS · APOSTILLA · CIUDAD AUTÓNOMA DE BUENOS AIRES · REPÚBLICA ARGENTINA

10. Firma

ESC. HUGO L. R. CHIOCCI
COLEGIO DE ESCRIBANOS
LEGALIZADOR

GRAFICA LATINA S.R.L.

COLEGIO DE ESCRIBANOS · CIUDAD DE BUENOS AIRES · CAPITAL FEDERAL - REPUBLICA ARGENTINA

**LEGALIZACION**

LEY 404

L 007464710

**EL COLEGIO DE ESCRIBANOS de la Ciudad de Buenos Aires, Capital Federal de la República Argentina, en virtud de las facultades que le confiere la ley vigente, LEGALIZA la firma y sello del escribano** ALEJANDRO MARIA LIPORACE **obrantes en el documento anexo, presentado en el día de la fecha bajo el N°** 0702190835108 **La presente legalización no juzga sobre el contenido y forma del documento.**

**Buenos Aires,** Lunes 19 de Febrero de 2007

COLEGIO DE ESCRIBANOS · LEGALIZACION · CIUDAD DE BUENOS AIRES · CAPITAL FEDERAL - REPUBLICA ARGENTINA

ESC. EDDA ENRIQUETA SINELLI
COLEGIO DE ESCRIBANOS
CONSEJERA

COLEGIO DE ESCRIBANOS · CIUDAD DE BUENOS AIRES CAPITAL FEDERAL - REPUBLICA ARGENTINA · NIHIL PRIUS FIDE

CERTIFICACION DE REPRODUCCIONES
LEY 404

T 005904431

Buenos Aires, 14.- de Febrero.- de 2007.-

En mi carácter de Escribano Titular del Registro 1331 de Capital Federal.-

CERTIFICO que la reproducción anexa, extendida en Diez.-

foja/s, que sello y firmo, es COPIA FIEL de su original, que tengo a la vista, doy fe.

El Autorizante deja constancia que el documento cuyas fotocopias se certifican consiste en un PODER redactado en idioma extranjero con su correspondiente traducción al español.-

ALEJANDRO M. LIPORACE
Matricula 3837
ESCRIBANO PUBLICO

A. LIPORACE
3837
UBLICO

CECBA - LEY404 GCBA

APOSTILLA

070219053886

$39.00

19/02/2007 14:42:29

CECBA - LEY404 GCBA

LEGALIZACION

070219083510

$20.00

19/02/2007 14:42:24

COL
ESCI
de la
BUEN

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 October 2008 (23.10.2008)

PCT

(10) International Publication Number
WO 2008/127594 A3

(51) International Patent Classification:
*A61K 31/337* (2006.01) *A61K 31/517* (2006.01)
*A61K 31/436* (2006.01) *A61K 31/555* (2006.01)
*A61K 31/497* (2006.01) *A61K 45/06* (2006.01)
*A61K 31/498* (2006.01) *A61P 35/00* (2006.01)
*A61K 31/4985* (2006.01)

(21) International Application Number:
PCT/US2008/004570

(22) International Filing Date: 8 April 2008 (08.04.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/923,164 11 April 2007 (11.04.2007) US

(71) Applicant *(for all designated States except US)*: **EXELIXIS, INC.** [US/US]; 210 East Grand Avenue, P.O. Box 511, South San Francisco, California 94083-0511 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LAMB, Peter** [US/US]; 814 Mandana Blvd, Oakland, California 94610 (US). **MATTHEWS, David** [GB/US]; 2 Balceta Avenue, San Francisco, California 94127 (US).

(74) Agents: **WADE, Janice V.** et al.; 210 East Grand Avenue, P.O. Box 511, South San Francisco, California 94083-0511 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
30 April 2009

(54) Title: COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER



(I)

(57) Abstract: The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments.

WO 2008/127594 A3

# METHODS OF TREATING BY INHIBITING WITH QUINAXOLINE INHIBITORS OF PI3K-ALPHA

## Cross-Reference to Related Applications

[0001] The Applicants claim priority under 35 U.S.C. 119(e) to copending Provisional Application No. 60/923,164 filed on April 11, 2007, the disclosure of which is incorporated herein by reference in its entirety.

## FIELD OF THE INVENTION

[0002] This invention relates to methods of treating cancer with a compound that inhibits lipid kinase enzymatic activity and the resultant modulation of cellular activities (such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism) in combination with anticancer agents.

## BACKGROUND OF THE INVENTION

[0003] Improvements in the specificity of agents used to treat various disease states such as cancer, metabolic, and inflammatory diseases is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms.

[0004] Phosphatidylinositol 3-kinase (PI3K or PIK3CA) is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. PTEN, a tumor suppressor which inhibits cell growth through multiple mechanisms, can dephosphorylate PIP3, the major product of PIK3CA. PIP3, in turn, is required for translocation of protein kinase B (AKT1, PKB) to the cell membrane, where it is phosphorylated and activated by upstream kinases. The effect of PTEN on cell death is mediated through the PIK3CA/AKT1 pathway.

[0005] PI3Kα has been implicated in the control of cytoskeletal reorganization, apoptosis, vesicular trafficking, proliferation and differentiation processes. Increased copy number and expression of PIK3CA or activating mutations in the p110a catalytic subunit of PIK3CA are associated with a number of malignancies such as ovarian cancer (Campbell et al., *Cancer Res* **2004**, *64*, 7678-7681; Levine et al., *Clin Cancer Res* **2005**, *11*, 2875-2878; Wang et al., *Hum Mutat* **2005**, *25*, 322; Lee et al., *Gynecol Oncol* **2005**, *97*, 26-34), cervical

cancer, breast cancer (Bachman, et al. *Cancer Biol Ther* **2004**, *3,* 772-775; Levine, et al., supra; Li et al., *Breast Cancer Res Treat* **2006**, *96*, 91-95; Saal et al., *Cancer Res* **2005**, *65*, 2554-2559; Samuels and Velculescu, *Cell Cycle* **2004**, *3,* 1221-1224), colorectal cancer (Samuels, et al. *Science* **2004**, *304,* 554; Velho et al. *Eur J Cancer* **2005**, *41,* 1649-1654), endometrial cancer (Oda et al. *Cancer Res.* **2005**, *65,* 10669-10673), gastric carcinomas (Byun et al., *Int J Cancer* **2003**, *104,* 318-327; Li et al., supra; Velho et al., supra; Lee et al., *Oncogene* **2005**, *24,* 1477-1480), hepatocellular carcinoma (Lee et al., *id.*), small and non-small cell lung cancer (Tang et al., *Lung Cancer* **2006**, *51,* 181-191; Massion et al., *Am J Respir Crit Care Med* **2004**, *170,* 1088-1094), thyroid carcinoma (Wu et al., *J Clin Endocrinol Metab* **2005**, *90,* 4688-4693), acute myelogenous leukemia (AML) (Sujobert et al., *Blood* **1997**, *106,* 1063-1066), chronic myelogenous leukemia (CML) (Hickey and Cotter *J Biol Chem* **2006**, *281,* 2441-2450), and glioblastomas (Hartmann et al. *Acta Neuropathol (Berl)* **2005**, *109,* 639-642; Samuels et al., supra).

**[0006]** In view of the important role of PI3K-α in biological processes and disease states, inhibitors and/or modulators of this lipid kinase are desirable. In addition, it is well established that combining treatments with different mechanisms of action often leads to enhanced anti-tumor activity as compared to single treatments administered alone. This is true for combinations of chemotherapies (e.g. Kyrgiou M. et. al. *J Natl Cancer Inst* **2006**, *98*, 1655) and combinations of antibodies and chemotherapy (e.g. Pasetto LM et. al. *Anticancer Res* **2006**, *26,* 3973.

**[0007]** For example, activation of the PI3K pathway contributes to the resistance of human tumor cells to a wide variety of chemotherapeutic agents, including microtubule stabilizing agents such as taxol (Brognard, J., et. al. *Cancer Res* **2001**, *61*, 3986-3997; Clark, A. S., et. al. *Mol Cancer Ther* **2002**, *1*, 707-717; Kraus, A. C., et. al. *Oncogene* **2002**, *21*, 8683-8695; Krystal, G. W., et. al. *Mol Cancer Ther* **2002**, *1*, 913-922; and Yuan, Z. Q., et. al. *J Biol Chem* **2003**, *278*, 23432-23440). Taxol is widely used to treat advanced cancers including prostate carcinomas, which frequently harbor deletions in the PTEN gene, resulting in elevated signaling downstream of PI3K. A number of preclinical studies suggest that inhibiting signaling downstream of PI3K restores or enhances the ability of chemotherapeutic agents such as taxol to kill tumor cells (Brognard, J., et. al. *Cancer Res* **2001**, *61*, 3986-3997; Clark, A. S., et. al. *Mol Cancer Ther* **2002**, *1*, 707-717; Kraus, A. C., et. al. *Oncogene* **2002**, *21*, 8683-8695; Krystal, G. W., et. al. *Mol Cancer Ther* **2002**, *1*, 913-922; and Saga, Y., et. al. *Clin Cancer Res* **2002**, *8*, 1248-1252).

**[0008]** Rapamycin, another chemotherapeutic agent, is a potent inhibitor of the mTOR/Raptor complex. Inhibition of mTOR/Raptor prevents p70S6K and S6 phosphorylation, but also leads to relief of a negative feedback loop emanating from p70S6K that serves to downregulate PI3K (Sarbassov, D. D., et. al. *Science* **2005,** *307,* 1098-1101). As a result, rapamycin treatment can lead to upregulation of PI3K and increased phosphorylation of AKT (O'Donnell, A., et. al. paper presented at Proc Am Soc Clin Oncol. 2003; and O'Reilly, K. E., et. al. *Cancer Res* **2006,** *66,* 1500-1508). Thus, combining rapamycin with inhibitors of PI3K can enhance the efficacy of rapamycin (Powis, G. et. al. *Clinical Cancer Research* **2006,** *12,* 2964-2966; Sun, S.-Y., et. al. *Cancer Research* **2005,** *65,* 7052-7058).

**[0009]** A growing body of clinical and preclinical data indicates that activation of the PI3K pathway confers resistance to EGFR inhibitors such as erlotinib (Bianco, R., et. al. *Oncogene* **2003,** *22,* 2812-2822; Chakravarti, A., et. al. *Cancer Res* **2002,** *62,* 200-207; and Janmaat, M. L., et. al. *Clin Cancer Res* **2003,** *9,* 2316-2326). Both NSCLC patients with K-Ras mutations and glioblastoma patients with PTEN deletions fail to respond to erlotinib, potentially because of genetic activation of the PI3K pathway (Mellinghoff, I. K., et. al. *N. Eng. J Med.* **2006,** *353,* 2012-2024). Preclinical studies have shown that downregulation of PI3K signaling in EGFR-expressing tumor cells confers increased sensitivity to EGFR inhibitors (Ihle, N. T., et. al. *Mol Cancer Ther* **2005,** *4,* 1349-1357). Thus, treating cancer with a PI3K inhibitor in combination with an EGFR inhibitor, such as erlotinib, is desirable.

**[0010]** Activation of the PI3K pathway also contributes to the resistance of human tumor cells to DNA damaging agents, such as platins. A number of preclinical studies suggest that inhibiting signaling downstream of PI3K restores or enhances the ability of chemotherapeutic agents such as platins to kill tumor cells (Brognard, J., et. al. *Cancer Res* **2001,** *61,* 3986-3997; and Yuan, Z. Q., et. al. *J Biol Chem* **2003,** *278,* 23432-23440). Carboplatin is widely used to treat advanced cancers including non-small cell lung carcinomas (NSCLC), which frequently harbor activating mutations in the K-Ras gene, resulting in activation of PI3K (Aviel-Ronen S., et. al. *Clin Lung Cancer* **2006,** *8,* 30-38). NSCLC patients with K-Ras mutations do not respond to EGFR inhibitors such as Tarceva, and thus represent a significant unmet medical need (Janne PA, et. al. *J Clin Oncology* **2005,** *23,* 3227-3234). Thus, treating NSCLC with a DNA-damaging agent such as a platin in combination with an inhibitor of PI3K is desirable in light of the lack of efficacious treatments.


**[0011]** Treatments that combine an inhibitor of PI3K-α with other anti-cancer agents are desirable and needed.

## SUMMARY OF THE INVENTION

**[0012]** The following only summarizes certain aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below. All references cited in this specification are hereby incorporated by reference in their entirety. In the event of a discrepancy between the express disclosure of this specification and the references incorporated by reference, the express disclosure of this specification shall control.

**[0013]** The compositions of the invention are used to treat diseases associated with abnormal and or unregulated cellular activities. Disease states which can be treated by the methods and compositions provided herein include cancer. The invention is directed to methods of treating these diseases by administering a Compound of Formula I or II in combination with one or more treatments.

**[0014]** One aspect of the Invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a compound of Formula I:




I

or a single isomer thereof where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof; or administering a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I and a pharmaceutically acceptable carrier, excipient, or diluent in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation, where the Compound of Formula I is that wherein:

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; and where each $R^1$ is independently

hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen or halo;

$R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

B is phenyl substituted with $R^{3a}$ and optionally further substituted with one, two, or three $R^3$; or

B is heteroaryl optionally substituted with one, two, or three $R^3$;

$R^{3a}$ is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where $R^8$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected

from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where $R^9$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{9a}$ is hydrogen, $C_2$-$C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$ where $R^{10a}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and $R^{10}$ and $R^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and $R^{11}$ and $R^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

f) $-C(O)R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl;

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2-C_1-C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)-C_1-C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$ where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

r) $-C_0-C_6$-alkylene-$N(R^{23})-C_1-C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)-C_1-C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl; and

where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

each $R^3$ (when $R^3$ is present) is independently alkyl; alkenyl; alkynyl; halo; hydroxy; oxo; alkoxy; cyano; hydroxyamino; carboxy; alkoxycarbonyl; amino; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where $R^8$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl,

cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where $R^9$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{9a}$ is hydrogen, $C_2$-$C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$ where $R^{10a}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or hydroxyalkyl and $R^{10}$ and $R^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and $R^{11}$ and $R^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminooalkyl, dialkylaminoalkyl;

f) $-C(O)R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl);

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2-C_1-C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;


q) $-N(R^{22})C(O)-C_1-C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$, where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

r) $-C_0-C_6$-alkylene-$N(R^{23})-C_1-C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)-C_1-C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;

wherein each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and provided that when $R^{50}$ and $R^{52}$ are hydrogen, $R^{51}$ is hydrogen or methyl, $R^{53}$ is hydrogen or methoxy, and $R^{54}$ is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one $R^3$ where $R^3$ is halo.

**[0015]** A second aspect of the Invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a compound of Formula II:



II

or a pharmaceutically acceptable salt or solvate, thereof; or administering a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula II and

a pharmaceutically acceptable carrier, excipient, or diluent in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more of the hormone therapies, one or more of the antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation wherein the Compound of Formula I is that wherein:

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^{1a})=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^{1a})=$;

$X^1$ is $-N(R^{5a})-$;

A is aryl, $-S(O)_2$-aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo, haloalkyl, haloalkoxy, alkyl, alkoxy, or -alkyl-$N(R^7)R^{7a}$, where each of the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl and alkoxy groups, each either alone or as part of another group within A, are independently optionally substituted with one, two, three, or four $R^{2a}$; or

$B^1$ is aryl, arylalkyl, alkyl, heteroaryl, or heteroaryalkyl, wherein each of the aryl, heteroaryl and alkyl groups are independently optionally substituted with one, two, three, or four $R^{3d}$;

each $R^{1a}$ is independently selected from hydrogen, alkoxy, alkyl, nitro, halo, cyano, and $-C_0$-$C_6$-alkyl-$N(R^7)R^{7a}$, wherein each of the alkyl and alkoxy groups is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, and $-C(O)OR^6$;

each $R^{2a}$ (when $R^{2a}$ is present) is independently selected from alkyl, alkenyl, -alkenyl-$C(O)OR^6$, $-OR^6$, $-N(R^7)C(O)R^6$, $-N(R^7)C(O)$-$C_0$-$C_6$ alkyl-$N(R^{7b})R^{7a}$, $-OC(O)$-$C_0$-$C_6$ alkyl-$N(R^7)R^{7a}$, $-N(R^7)C(O)$-$C_1$-$C_6$ alkyl$C(O)OR^6$, $C_0$-$C_6$-alkyl-$C(O)R^6$, oxo, dioxo, $-S(O)_2$-$N(R^7)R^{7a}$, $-C(O)OR^6$, $-CH(R^6)_2$-$C(O)OR^6$, $-S(O)_2R^6$, cycloalkyl, heterocycloalkyl, heteroaryl, $-C(O)N(R^7)$-alkyl-$OR^6$, $-C_0$-$C_6$ alkyl-$C(O)N(R^7)$-$C_0$-$C_6$-alkyl-$C(O)OR^6$, $-C_0$-$C_6$-alkyl-$C(O)N(R^7)R^{7a}$, aryl, arylalkyl, -S-($C_1$-$C_6$ alkyl), halo, oxo, nitro, -SCN, cyano, and $-C_0$-$C_6$ alkyl-$N(R^7)R^{7a}$, wherein each of the alkyl (including, for example the alkyl within alkoxy), aryl, cycloalkyl, heterocycloalkyl, and heteroaryl groups, either alone or as part of another group within $R^2$, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, oxo, nitro, cyano, hydroxy, $-N(R^8)R^{8a}$, alkoxy, and $-C(O)OR^9$;

each $R^{3d}$ (when $R^{3d}$ is present) is independently oxo, nitro, halo, cyano, alkyl, alkenyl, alkynyl, alkoxy, $C_3$-$C_6$-cycloalkyl, $-C_0$-$C_6$-alkyl-heterocycloalkyl, $-C_0$-$C_6$ alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-$N(R^{7b})R^{7a}$, $-C_0$-$C_6$ alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-$N(R^{7b})C(O)R^{7a}$, $-C_0$-$C_6$ alkyl-$C(O)$-$C_0$-$C_6$-alkyl-$N(R^7)R^{7a}$, $-C_0$-$C_6$-alkyl-$C(O)N(R^7)$-$C_0$-$C_6$-alkyl-$N(R^{7b})R^{7a}$, $-C_0$-$C_6$-alkyl-$C(O)N(R^7)$-$C_1$-$C_6$alkyl$C(O)OR^{7a}$, $-C_0$-$C_6$ alkyl-

$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-($R^{7a}$), -$C_0$-$C_6$ alkyl-$N(R^7)$-$C_0$-$C_6$-alkyl-$N(R^{7b})R^{7a}$, -$C_0$-$C_6$ alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-$N(R^{7b})$-$N(R^{7c})R^{7a}$, -$C_0$-$C_6$ alkyl-$N(R^7)C(O)O$-$C_0$-$C_6$-alkyl-aryl, -$C_0$-$C_6$ alkyl-$C(O)N(R^7)$-$C_0$-$C_6$-alkyl-$N(R^{7b})R^{7a}$, -$C_0$-$C_6$ alkyl-$N(R^7)$-$C_0$-$C_6$ alkyl-$C(=N(R^{7b})(R^{7a}))(NR^{7c}R^{7d})$, -$C_0$-$C_6$-alkyl-aryl, -$C_0$-$C_6$-alkyl-heteroaryl, -$C_0$-$C_6$ alkyl-heterocycloalkyl, -O-$C_0$-$C_6$ alkyl-$N(R^7)R^{7a}$, -$C_0$-$C_6$ alkyl-$OR_6$, -$C_0$-$C_6$ alkyl-$C(O)OR_6$, $C_0$-$C_6$-alkyl-$N(R^7)R^{7a}$, -$C_0$-$C_6$ alkyl-$C(O)NR_7R^{7a}$, -$C_0$-$C_6$ alkyl-$C(O)R^7$, -$SR_7$, -$S(O)_2R_7$, -$S(O)_3R_7$, -$S(O)R^7$, -$SO_2N(R^7)R^{7a}$, -$SO_2N(R^7)$-$C_0$-$C_6$ alkyl-$N(R^{7b})R^{7a}$, -$C_0$-$C_6$-alkyl-$N(R^7)$-aryl, -$C_0$-$C_6$-alkyl-$N(R^7)$-heteroaryl, -$C_0$-$C_6$-alkyl-$N(R^7)$-heterocycloalkyl, -$C_0$-$C_6$-alkyl-$C(O)N(R^7)$-$C_0$-$C_6$-alkyl-cycloalkyl, $C_0$-$C_6$-alkyl-$C(O)N(R^7)$-$C_0$-$C_6$-alkyl-aryl, $C_0$-$C_6$ alkyl-$C(O)N(R^7)$-$C_0$-$C_6$ alkyl-heteroaryl, $C_0$-$C_6$ alkyl-$C(O)N(R^7)$-$C_0$-$C_6$-alkyl-heterocycloalkyl, -$C_0$-$C_6$-alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-cycloalkyl, -$C_0$-$C_6$-alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-aryl, $C_0$-$C_6$-alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-heteroaryl, -$C_0$-$C_6$-alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-heterocycloalkyl, $C_0$-$C_6$-alkyl-$N(R^7)C(O)$-$C_0$-$C_6$-alkyl-heterocycloalkyl-aryl, -$N(R^7)C(O)OR^6$, or -NHC(O)H, wherein each of the alkyl, alkenyl, cycloalkyl, aryl, (including, for example the alkyl within alkoxy), heterocycloalkyl, and heteroaryl groups, either alone or as part of another group within $R^{3d}$, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, alkenyl, -$C_0$-$C_6$-alkyl-$OR^9$, cycloalkyl, halo, haloalkyl, haloalkoxy, -$C(O)R^9$, nitro, cyano, oxo, -$C_0$-$C_6$-alkyl-$N(R^8)R^{8a}$, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -$C(O)OR^9$, alkylthio, and hydroxyalkyl;

$R^4$ is hydrogen, aryl, -$C_0$-$C_6$-alkyl-$N(R^7)R^{7a}$, alkoxy, or $C_1$-$C_6$ alkyl, wherein each of the alkyl and aryl groups, either alone or as part of another group in $R^4$, is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -$N(R^8)R^{8a}$, alkoxy, and -$C(O)OR^6$; or

$R^4$ and $X^1$ together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein $R^{5a}$ is absent when X is -$N(R^{5a})$-, wherein each of the heterocycloalkyl or heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -$N(R^7)R^{7a}$, alkoxy, and -$C(O)OR^6$;

$R^{5a}$ is hydrogen, -$C_1$-$C_6$ alkyl-$N(R^7)R^{7a}$, alkoxy, alkyl, or aryl, wherein each of the alkyl and aryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, -$N(R^8)R^{8a}$, $C_1$-$C_6$ alkoxy, or -$C(O)OR^6$; or

$R^{5a}$ and $R^4$ together with the atoms to which they are attached form a heterocycloalkyl or heteroaryl group, wherein the heterocycloalkyl and heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 groups selected from alkyl, halo, haloalkyl, haloalkoxy, nitro, cyano, hydroxy, $-N(R^7)R^{7a}$, $C_1$-$C_6$ alkoxy, and $-C(O)OR^6$;

$R^6$ and $R^9$ are independently hydrogen, hydroxy, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, or aryl, each alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl, either alone or as part of another group within $R^6$ and $R^9$, is independently optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from amino, hydroxy, alkoxy, alkyl, and halo; and

$R^7$, $R^{7a}$ $R^{7b}$, $R^{7c}$, $R^{7d}$, $R^8$, and $R^{8a}$ are independently hydrogen, alkyl, alkenyl, hydroxy, alkyloxy, alkenyloxy, $-O$-$C_0$-$C_6$ alkyl-aryl, $-C_0$-$C_6$ alkyl-$C(O)OR^6$, $-C_0$-$C_6$ alkyl-$C(O)R^6$, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, wherein each of the alkyl, aryl, heteroaryl, and heterocycloalkyl, either alone or part of another group within $R^7$, $R^{7a}$ $R^{7b}$, $R^{7c}$, $R^{7d}$, $R^8$, and $R^{8a}$ is independently optionally substituted with 1, 2, 3, 4, or 5 groups selected from amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, $-S$-$C_1$-$C_6$ alkyl, cyano, nitro, hydroxy, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ alkyl, halo, aryl, heterocycloalkylalkyl, and heteroaryl optionally substituted with one or two $C_1$-$C_6$ alkyl.

## DETAILED DESCRIPTION OF THE INVENTION

### Abbreviations and Definitions

**[0016]** The following abbreviations and terms have the indicated meanings throughout:

| Abbreviation | Meaning |
|---|---|
| br | broad |
| °C | degrees Celsius |
| CBZ | CarboBenZoxy = benzyloxycarbonyl |
| d | doublet |
| dd | doublet of doublet |
| dt | doublet of triplet |
| EI | Electron Impact ionization |
| Et | Ethyl |
| g | gram(s) |
| GC | gas chromatography |

| Abbreviation | Meaning |
|---|---|
| h or hr | hour(s) |
| HPLC | high pressure liquid chromatography |
| L | liter(s) |
| M | molar or molarity |
| m | Multiplet |
| mg | milligram(s) |
| MHz | megahertz (frequency) |
| Min | minute(s) |
| mL | milliliter(s) |
| mM | Millimolar |
| mmol | millimole(s) |
| mol | mole(s) |
| MS | mass spectral analysis |
| N | normal or normality |
| nM | Nanomolar |
| NMR | nuclear magnetic resonance spectroscopy |
| q | Quartet |
| RT | Room temperature |
| s | Singlet |
| s- | Secondary |
| t- | Tertiary |
| t or tr | Triplet |
| TFA | trifluoroacetic acid |
| THF | Tetrahydrofuran |
| μL | microliter(s) |
| μM | Micromole(s) or micromolar |

**Definitions for a Compound of Formula I, Ia, and II**

**[0017]** The symbol "-" means a single bond, "=" means a double bond, "≡" means a triple bond, and "---" means a single bond and optionally a double bond. When chemical

structures are depicted or described, unless explicitly stated otherwise, all carbons are assumed to have hydrogen substitution to conform to a valence of four.

**[0018]** "Administration" and variants thereof (e.g., "administering" a compound) in reference to a compound of the invention means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment. When a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., surgery, radiation, and chemotherapy, etc.), "administration" and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.

**[0019]** "Alkenyl" or "lower alkenyl" means a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms and at least one double bond and includes ethenyl, propenyl, 1-but-3-enyl, 1-pent-3-enyl, 1-hex-5-enyl and the like.

**[0020]** "Alkenylcarbonyl" means a C(O)R group where R is alkenyl, as defined herein.

**[0021]** "Alkenyloxy" or "lower alkenyloxy" means an –OR group where R is alkenyl, as defined herein. Representative examples include methoxy, ethoxy, 1-methoxyprop-1-en-3-yl, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

**[0022]** "Alkoxy" or "lower alkoxy" means an –OR group where R is alkyl, as defined herein. Representative examples include methoxy, ethoxy, 1-methoxyprop-1-en-3-yl, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

**[0023]** "Alkoxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three alkoxy groups, as defined herein.

**[0024]** "Akoxycarbonyl" means a –C(O)OR group where R is alkyl as defined herein.

**[0025]** "Alkoxyycarbonylalkyl" means an alkyl group, as defined herein, substituted with one, two, or three alkoxycarbonyl groups, as defined herein.

**[0026]** "Alkyl" or "lower alkyl" means a linear or branched hydrocarbon group having one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl and the like. A "$C_0$" alkyl (as in "$C_0$-$C_6$-alkyl") is a covalent bond. "$C_6$ alkyl" refers to, for example, *n*-hexyl, *iso*-hexyl, and the like.

**[0027]** "Alkylamino" means a -NHR radical where R is alkyl as defined herein, or an N-oxide derivative thereof, e.g., methylamino, ethylamino, *n*-, *iso*-propylamino, *n*-, *iso*-, *tert*-butylamino, or methylamino-N-oxide, and the like.

**[0028]** "Alkylaminoalkyl" means an alkyl group substituted with one or two alkylamino groups, as defined herein.

[0029] "Alkylaminoalkyloxy" means an -OR group where R is alkylaminoalkyl, as defined herein.

[0030] "Alkylcarbonyl" means a C(O)R group where R is alkyl, as defined herein.

[0031] "Alkylcarbonylamino" means a -NRC(O)R' group where R is hydrogen or alkyl, as defiend herein, and R' is alkyl, as defiend herein.

[0032] "Alkylene" refers to straight or branched divalent hydrocarbon, containing no unsaturation and having from two to eight carbon atoms. Examples of alkylene include eth-diyl ($-CH_2CH_2-$), prop-1,3-diyl ($-CH_2CH_2CH_2-$), 2,2-dimethylprop-1,3-diyl ($-CH_2C(CH_3)_2CH_2-$), and the like.

[0033] "Alkylsulfonyl" means a $-S(O)_2R$ group where R is lakyl, as defined herien.

[0034] "Alkylthio" means a -SR group where R is alkyl, as defined herein. Examples of alkylthio include methylthio and ethylthio, and the like.

[0035] "Alkylthioalkyl" means an alkyl group substituted with one or two alkylthio groups, as defined herein, e.g. 2-(methylthio)-ethyl and 2-(ethylthio)-ethyl.

[0036] "Alkynyl" or "lower alkynyl" means a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms and at least one triple bond and includes ethynyl, propynyl, butynyl, pentyn-2-yl and the like.

[0037] "Amino" means a $-NH_2$.

[0038] "Aminoalkyl" means an alkyl group subsitutted with at least one, for example one, two, or three, amino groups.

[0039] "Aminoalkyloxy" means an -OR group where R is aminoalkyl, as defined herein.

[0040] "Aryl" means a monovalent six- to fourteen-membered, mono- or bi-carbocyclic ring, wherein the monocyclic ring is aromatic and at least one of the rings in the bicyclic ring is aromatic. Representative examples include phenyl, naphthyl, and indanyl, and the like.

[0041] "Arylalkyl" means an alkyl group, as defined herein, subsituted with one or two aryl groups, as defined herein. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like.

[0042] "Aryloxy"means a -OR group where R is aryl as defined herein.

[0043] "Arylalkyloxy" means a -OR group where R is arylalkyl as defined herein.

[0044] "Arylsulfonyl" means a $-SO_2R$ group where R is aryl as defined herein.

[0045] "Carboxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three -C(O)OH groups.

[0046] "Carboxy ester" means a -C(O)OR group where R is lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl or arylalkyl, each of which is defined herein. Representative examples include methoxycarbonyl, ethoxycarbonyl, and benzyloxycarbonyl, and the like.

[0047] "Cyanoalkyl" means an alkyl, alkenyl, or alkynyl radical, as defined herein, substituted with at least one, for example one, two, or three, cyano groups.

[0048] "Cycloalkyl" means a monocyclic or polycyclic hydrocarbon radical having three to thirteen carbon atoms. The cycloalkyl can be saturated or partially unsaturated, but cannot contain an aromatic ring. Cycloalkyl includes fused, bridged, and spiro ring systems. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0049] "Cycloalkylalkyl" means alkyl group substituted with one or two cycloalkyl groups, as defined herein. Representative examples include cyclopropylmethyl and 2-cyclobutyl-ethyl, and the like.

[0050] "Cycloalkylcarbonyl" means a -C(O)R group where R is cycloalkyl as defined herein.

[0051] "Dialkylamino" means a -NRR' radical where R and R' are independently alkyl as defined herein, or an N-oxide derivative, or a protected derivative thereof, e.g., dimethylamino, diethylamino, *N,N*-methylpropylamino or *N,N*-methylethylamino, and the like.

[0052] "Dialkylaminoalkyl" means an alkyl group substituted with one or dialkylamino groups, as defined herein.

[0053] "Dialkylaminoalkyloxy" means an -OR group where R is dialkylaminoalkyl, as defined herein.

[0054] "Fused ring system" and "fused ring" refer to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic. In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure. The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (*i.e.* saturated ring structures) can contain two substitution groups.

[0055] "Haloalkoxy" means an -OR' group where R' is haloalkyl as defined herein, e.g., trifluoromethoxy or 2,2,2-trifluoroethoxy, and the like.

[0056] "Haloalkoxyalkyl" means an alkyl group, as defined herein, substituted with one, two, or three haloalkoxy, as defined herein.

[0057] "Halogen" or "halo" means fluoro, chloro, bromo and iodo.

[0058] "Haloalkenyl means an alkenyl group, as defined herein, substituted with one or more halogens, for example one to five halo atoms.

[0059] "Haloalkyl" means an alkyl group, as defined herein, substituted with one or more halogens, for example one to five halo atoms. Representative examples includes 2,2-difluoroethyl, trifluoromethyl, and 2-chloro-1-fluoroethyl, and the like.

[0060] "Heteroaryl" means a monocyclic, fused bicyclic, or fused tricyclic, monovalent radical of 5 to 14 ring atoms containing one or more, for example one, two, three, or four ring heteroatoms independently selected from -O-, $-S(O)_n-$ (n is 0, 1, or 2), -N-, $-N(R^x)-$, and the remaining ring atoms being carbon, wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic. One or two ring carbon atoms of any nonaromatic rings comprising a bicyclic or tricyclic radical may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. $R^x$ is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl. Fused bicyclic radical includes bridged ring systems. Unless stated otherwise, the valency may be located on any atom of any ring of the heteroaryl group, valency rules permitting. In particular, when the point of valency is located on the nitrogen, $R^x$ is absent. In another embodiment, the term heteroaryl includes, but is not limited to, 1,2,4-triazolyl, 1,3,5-triazolyl, phthalimidyl, pyridinyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro-1*H*-indolyl (including, for example, 2,3-dihydro-1*H*-indol-2-yl or 2,3-dihydro-1*H*-indol-5-yl, and the like), isoindolyl, indolinyl, isoindolinyl, benzimidazolyl, benzodioxol-4-yl, benzofuranyl, cinnolinyl, indolizinyl, naphthyridin-3-yl, phthalazin-3-yl, phthalazin-4-yl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazoyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isooxazolyl, oxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinolin-4-yl or tetrahydroisoquinolin-6-yl, and the like), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridin-2-yl or pyrrolo[3,2-c]pyridin-7-yl, and the like), benzopyranyl, thiazolyl, isothiazolyl, thiadiazolyl, benzothiazolyl, benzothienyl, and the derivatives thereof, or N-oxide or a protected derivative thereof.

[0061] "Hetereoarylalkyl" means an alkyl group substituted with one or two heteroaryl groups as defined herein.

**[0062]** "Heterocycloalkyl" means a saturated or partially unsaturated monovalent monocyclic group of 3 to 8 ring atoms or a saturated or partially unsaturated monovalent fused bicyclic group of 5 to 12 ring atoms in which one or more, for example one, two, three, or four ring heteroatoms independently selected from -O-, -S(O)$_n$- (n is 0, 1, or 2), -N=, -N($R^y$)- (where $R^y$ is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkylsulfonyl), the remaining ring atoms being carbon. One or two ring carbon atoms may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. Fused bicyclic radical includes bridged ring systems. Unless otherwise stated, the valency of the group may be located on any atom of any ring within the radical, valency rules permitting. In particular, when the point of valency is located on a nitrogen atom, $R^y$ is absent. In another embodiment the term heterocycloalkyl includes, but is not limited to, azetidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, 2,5-dihydro-1*H*-pyrrolyl, piperidinyl, 4-piperidonyl, morpholinyl, piperazinyl, 2-oxopiperazinyl, tetrahydropyranyl, 2-oxopiperidinyl, thiomorpholinyl, thiamorpholinyl, perhydroazepinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, oxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, quinuclidinyl, isothiazolidinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, tetrahydrofuryl, and tetrahydropyranyl, and the derivatives thereof and N-oxide or a protected derivative thereof.

**[0063]** "Heterocycloalkylalkyl" means an alkyl group, as defined herein, substituted with one or two heterocycloalkyl groups, as defined herein.

**[0064]** "Hydroxyalkyl" means an alkyl radical, as defined herein, substituted with at least one, for example one, two, or three, hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, for example 2-hydroxyethyl, 2,3-dihydroxypropyl, or 1-(hydroxymethyl)-2-hydroxyethyl, and the like.

**[0065]** "Hydroxyamino" means a -NH(OH) group.

**[0066]** "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that with respect to any molecule described as containing one or more optional substituents, only sterically practical and/or synthetically feasible compounds are

meant to be included. "Optionally substituted " refers to all subsequent modifiers in a term. So, for example, in the term "optionally substituted aryl$C_{1-8}$ alkyl," both the "$C_{1-8}$ alkyl" portion and the "aryl" portion of the molecule may or may not be substituted. A list of exemplary optional substitutions is presented below in the definition of "substituted."

**[0067]** "Optionally substituted alkyl" means an alkyl radical, as defined herein, optionally substituted with one or more groups, for example one, two, three, four, or five groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano, cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, carboxy, alkylcarbonylamino, alkylcarbonyloxy, alkyl-$S(O)_{0-2}$-, alkenyl-$S(O)_{0-2}$-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl-$NR^c$- (where $R^c$ is hydrogen, alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl), alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkoxyalkyloxy, and -$C(O)NR^aR^b$ (where $R^a$ and $R^b$ are independently hydrogen, alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyl).

**[0068]** "Optionally substituted alkenyl" means an alkenyl radical, as defined herein, optionally substituted with one or more groups, for example one, two, or three groups, independently selected from alkylcarbonyl, alkenylcarbonyl, cycloalkylcarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cyano, cyanoalkylaminocarbonyl, alkoxy, alkenyloxy, hydroxy, hydroxyalkoxy, carboxy, alkylcarbonylamino, alkylcarbonyloxy, alkyl-$S(O)_{0-2}$-, alkenyl-$S(O)_{0-2}$-, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl-$NR^c$- (where $R^c$ is hydrogen, optionally substituted alkyl, optionally substituted alkynyl, hydroxy, alkoxy, or alkenyloxy), alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkoxycarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, alkoxyalkyloxy, and -$C(O)NR^aR^b$ (where $R^a$ and $R^b$ are independently hydrogen, optionally substituted alkyl, alkenyl, optionally substituted alkynyl, hydroxy, alkoxy, or alkenyloxy).

**[0069]** "Optionally substituted aryl" means an aryl group, as defined herein, which is optionally substituted with one, two, three, four, of five groups selected from halo, haloalkyl,


haloalkoxy, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, carboxy, carboxy ester, amino, alkylamino, dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, -C(O)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(O)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), and -$NHS(O)_2R$' (where R' is alkyl, aryl, or heteroaryl).

**[0070]** "Optionally substituted heteroaryl" means a heteroaryl group, as defined herein, optionally substituted with one, two, three, four, or five groups selected from halo, haloalkyl, haloalkoxy, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, hydroxy, oxo (valency rules permitting), carboxy, carboxy ester, amino, alkylamino, dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, heteroaryl, optionally substituted aryl, -C(O)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(O)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), and -$NHS(O)_2R$' (where R' is alkyl, aryl, or heteroaryl).

**[0071]** "Optionally substituted heterocycloalkyl" means a heterocycloalkyl, as defined herein, optionally substituted with one, two, three, four, or five groups selected from halo, haloalkyl, haloalkoxy, hydroxy, oxo, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, optionally substituted cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylaminoalkyl, dialkylaminoalkyl, carboxy, carboxy ester, -C(O)NR'R" (where R' is hydrogen or alkyl and R" is hydrogen, alkyl, aryl, heteroaryl, or heterocycloalkyl), -NR'C(O)R" (where R' is hydrogen or alkyl and R" is alkyl, aryl, heteroaryl, or heterocycloalkyl), amino, alkylamino, dialkylamino, and -$NHS(O)_2R$' (where R' is alkyl, aryl, or heteroaryl).

**[0072]** "Saturated bridged ring system" refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class "saturated bridged ring system."

**[0073]** "Spirocyclyl" or "spirocyclic ring" refers to a ring originating from a particular annular carbon of another ring. For example, as depicted below, a ring atom of a saturated bridged ring system (rings C and C'), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocyclyl (ring D) attached thereto. A spirocyclyl can be carbocyclic or heteroalicyclic.




[0074] "Yield" for each of the reactions described herein is expressed as a percentage of the theoretical yield.

**Definitions for the Compound of formula 100**

[0075] The terms used to describe the scope of formula 100 are defined in WO 2004/006846 (US Nat'l Stage Application Serial No. 10/522,004) which is herein incorporated by reference. For example "optionally substituted alkyl" for formula 100 has the meaning given in WO 2004/006846 (US Nat'l Stage Application Serial No. 10/522,004). Whenever a compound of formula 100 is described in this application, whether by structure or by use of the term "formula 100," the terms used to describe that compound are defined by WO 2004/006846 (US Nat'l Stage Application Serial No. 10/522,004).

**Other Definitions**

[0076] "AKT inhibitor" includes, for example, LY294002, PKC 412, perifosine, compounds in Table 2a, compounds in Table 2b, and compounds described in WO 2006/071819 and WO05/117909. These references also describe in vitro assays that can be used to determine the inhibitory activity of AKT.

[0077] "Alkylating agent" includes, for example, one or more of the following: Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Carmustine, Streptozocin, Fotemustine, Lomustine, Streptozocin, Carboplatin, Cisplatin, Oxaliplatin, BBR3464, Busulfan, Dacarbazine, Mechlorethamine, Procarbazine, Temozolomide, ThioTEPA, and Uramustine.

[0078] "Antibody" includes, for example, one or more of the following: an IGF1R antibody (including, for example, αIGF-1R A12 MoAb, 19D12, h7C10 and CP-751871), an EGFR antibody (including, for example, Cetuximab (Erbitux®) and Panitumumab), an ErbB2 antibody (including, for example, Trastuzumab (Herceptin®)), a VEGF antibody (including, for example, Bevacizumab (Avastin®)), an IgG1 antibody (including, for example, Ibritumomab (tiuxetan)), a CD20 antibody (including, for example, Rituximab and Tositumomab), a CD33 antibody (including, for example, Gemtuzumab and Gemtuzumab ozogamicin), and a CD52 antibody (including, for example, Alemtuzumab).

[0079] "Antimetabolite" include, for example, methotrexate, Pemetrexed, Raltitrexed, Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Thioguanine, Capecitabine,

Cytarabine, fluorouracil (administered with or without leucovorin or folinic acid), and Gemcitabine.

**[0080]** "Antimicrotubule agent" includes, for example, Vincristine,Vinblastine, Vinorelbine, Vinflunine, and Vindesine.

**[0081]** "Aromatase inhibitor" includes, for example, one or more of the following: Aminoglutethimide, Anastrozole (Arimidex®), Letrozole (Femara®), Exemestane (Aromasin®), and Formestane (Lentaron®).

**[0082]** "Cancer" refers to cellular-proliferative disease states, including but not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hanlartoma, inesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinorna, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinorna, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformians), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastorna multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor

cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; Adrenal Glands: neuroblastoma; and breast cancer. Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above-identified conditions.

**[0083]** "Chemotherapeutic agent" includes, but is not limited to, an AKT inhibitor, an alkylating agent, an antimetabolite, an antimicrotubule agent, an aromatase inhibitor, a c-KIT inhibitor, a cMET inhibitor, an EGFR inhibitor, an ErbB2 inhibitor, a Flt-3 inhibitor, an HSP90 inhibitor, an IGF1R inhibitor, a platin, a Raf inhibitor, rapamycin, a Rapamycin analogue, a Receptor Tyrosine Kinase inhibitor, a taxane, a topoisomerase inhibitor, a SRC and/or ABL kinase inhibitor, and a VEGFR inhibitor. A pharmaceutically acceptable salt, solvate, and/or hydrate of a chemotherapeutic agent can be prepared by one of ordinary skill in the art and such salt, solvate, and/or hydrates thereof can be used to practice the invention.

**[0084]** "c-KIT inhibitor" includes, for example, imatinib, sunitinib, nilotinib, AMG 706, sorafenib, compounds in Table 3b, compounds in Table 3c, compounds in Table 8, compounds in Table 9, and compounds described in WO 2006/108059, WO/2005/020921, WO/2006/033943, and WO 2005/030140.

**[0085]** "cMET inhibitor" includes, for example, compounds in Table 3a, compounds in Table 3b, compounds in Table 3c, compounds described in WO06/108059, WO 2006/014325, and WO 2005/030140.

**[0086]** "EGFR inhibitor"includes, for example, one or more of the following: pelitinib, lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474, vandetinib), AEE788 and HKI-272, EKB-569, CI-1033, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine,

*N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, compounds in Table 4, compounds in Table 7, and compounds described in WO 2004/006846 and WO 2004/050681.

**[0087]** "ErbB2 inhibitor" includes, for example, lapatinib (GW572016), PKI-166, canertinib, CI-1033, HKI272, and EKB-569.

**[0088]** "Flt-3 inhibitor" includes, for example, CEP-701, PKC 412, MLN518, sunitinib, sorafenib, compounds in Table 3a, compounds in Table 3b, compounds in Table 3c, compounds in Table 9, and compounds described in WO 2006/108059, WO/2006/033943, WO 2006/014325, and WO 2005/030140.

**[0089]** "Hormone therapy" or "hormonal therapy" includes, for example, treatment with one or more of the following: steroids (e.g. dexamethasone), finasteride, tamoxifen, and an aromatase inhibitor.

**[0090]** "HSP90 inhibitor" includes, for example, 17-AAG, 17-DMAG, Geldanamycin, 5-(2,4-dihydroxy-5-isopropylphenyl)-*N*-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide [NVP-AUY922 (VER 52296)], 6-chloro-9-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-9*H*-purin-2-amine (CNF2024, also named BIIB021), compounds disclosed in WO2004072051 (which is herein incorporated by reference), compounds disclosed in WO2005028434 (which is herein incorporated by reference), compounds disclosed in WO2007035620 (which is herein incorporated by reference) and compounds disclosed in WO2006091963 (which is herein incorporated by reference).

**[0091]** "IGF1R inhibitor" includes, for example, Tyrphostin AG 1024, compounds in Table 5a, compounds in Table 5b, and compounds described in WO06/074057.

**[0092]** "Kinase-dependent diseases or conditions" refer to pathologic conditions that depend on the activity of one or more lipid kinases. Kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities including proliferation, adhesion, migration, differentiation and invasion. Diseases associated with kinase activities include tumor growth, the pathologic neovascularization that supports solid tumor growth, and associated with other diseases where excessive local vascularization is involved such as ocular diseases (diabetic retinopathy, age-related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like).

**[0093]** While not wishing to be bound to theory, phosphatases can also play a role in "kinase-dependent diseases or conditions" as cognates of kinases; that is, kinases

phosphorylate and phosphatases dephosphorylate, for example lipid substrates. Therefore compounds of the invention, while modulating kinase activity as described herein, may also modulate, either directly or indirectly, phosphatase activity. This additional modulation, if present, may be synergistic (or not) to activity of compounds of the invention toward a related or otherwise interdependent kinase or kinase family. In any case, as stated previously, the compounds of the invention are useful for treating diseases characterized in part by abnormal levels of cell proliferation (*i.e.* tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth.

**[0094]** "Metabolite" refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics" 8.sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of biotransformation). As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In one example, a prodrug may be used such that the biologically active form, a metabolite, is released *in vivo*. In another example, a biologically active metabolite is discovered serendipitously, that is, no prodrug design *per se* was undertaken. An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure.

**[0095]** "Patient" for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In another embodiment the patient is a mammal, and in another embodiment the patient is human.

**[0096]** A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in *Remington's Pharmaceutical Sciences*, 17$^{th}$ ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference or S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19 both of which are incorporated herein by reference.

**[0097]** Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic

acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid and the like.

**[0098]** Examples of a pharmaceutically acceptable base addition salts include those formed when an acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferable salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, *N*-methylglucamine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

**[0099]** "Platin," and "platin-containing agent" include, for example, cisplatin, carboplatin, and oxaliplatin.

**[00100]** "Prodrug" refers to compounds that are transformed (typically rapidly) *in vivo* to yield the parent compound of the above formulae, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl. Examples of pharmaceutically acceptable amides of

the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons). Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.

**[00101]** "Raf inhibitor" includes, for example, sorafenib, RAF 265 (CHIR 265), compounds in Table 6, and compounds described in WO 2005/112932. These references also describe in vitro assays that can be used to determine the inhibitory activity of RAF.

**[00102]** "Rapamycin analogue" includes for example, CCI-779, AP23573, RAD 001, TAFA 93, and compounds described in WO 2004/101583 and US 7,160,867 which are each incorporated herein by reference in their entireties.

**[00103]** "Receptor Tyrosine Kinase inhibitor" includes, for example, inhibitors of AKT, EGFR, ErbB2, IGF1R, KIT, Met, Raf, and VEGFR2. Examples of receptor tyrosine kinase inhibitors can be found in WO 2006/108059 (US Nat'l Stage Application Serial No. 11/910,720), WO 2006/074057 (US Nat'l Stage Application Serial No. 11/722,719), WO 2006/071819 (US Nat'l Stage Application Serial No. 11/722,291), WO 2006/014325 (US Nat'l Stage Application Serial No. 11/571,140), WO 2005/117909 (US Nat'l Stage Application Serial No. 11/568,173), WO 2005/030140 (US Nat'l Stage Application Serial No. 10/573,336), WO 2004/050681 US Nat'l Stage Application Serial No. 10/533,555), WO 2005/112932 (US Nat'l Stage Application Serial No. 11/568,789), and WO 2004/006846 (US Nat'l Stage Application Serial No. 10/522,004), each of which is incorporated herein by reference for all purposes. In particular, the applications cited in this paragraph are incorporated for the purpose of providing specific examples and generic embodiments (and the definitions associated with the terms used in the embodiments) of compounds that are useful in the practice of the invention. These references also describe in vitro assays useful in the practice of this invention.

**[00104]** "Taxane" includes, for example, one or more of the following: Paclitaxel (Taxol®) and Docetaxel (Taxotere®).

**[00105]** "Therapeutically effective amount" is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary

depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure.

**[00106]** "Topoisomerase inhibitor" includes, for example, one or more of the following: amsacrine, camptothecin, etoposide, etoposide phosphate, exatecan, irinotecan, lurtotecan, and teniposide, and topotecan.

**[00107]** "Treating" or "treatment" of a disease, disorder, or syndrome, as used herein, includes (i) preventing the disease, disorder, or syndrome from occurring in a human, i.e. causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syndrome; (ii) inhibiting the disease, disorder, or syndrome, *i.e.*, arresting its development; and (iii) relieving the disease, disorder, or syndrome, *i.e.*, causing regression of the disease, disorder, or syndrome. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.

**[00108]** "SRC and/or ABL kinase inhibitor" includes, for example, dasatinib, imatinib (Gleevec®), and compounds described in WO 2006/074057.

**[00109]** "VEGFR inhibitor" includes, for example, one or more of the following: VEGF Trap, ZD6474 (vandetanib, Zactima), sorafenib, Angiozyme, AZD2171 (cediranib), pazopanib, sorafenib, axitinib, SU5416 (semaxanib), PTK787 (vatalanib), AEE778, RAF 265, sunitinib (Sutent), *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, compounds in Table 7, and compounds described in WO 2004/050681 and WO 2004/006846.

**Embodiments of the Invention**

**[00110]** The following paragraphs present a number of embodiments of compounds of the invention. In each instance, the embodiment includes both the recited compounds as well as individual isomers and mixtures of isomers. In addtion, in each instance, the embodiment optionally includes the pharmaceutically acceptable salts, hydrates, and/or solvates of the recited compounds and any individual isomers or mixture of isomers thereof.

**[00111]** For each of the following embodiments, the Compound of Formula I can, for example, be of Formula I(a) or be selected from a Compound in Table 1.

**[00112]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, where growth and/or survival of tumor cells of the cancer is enhanced, at least in part, by the activity of PI3K; in combination with one or more treatments selected from surgery, one or more chemotherapeutic agents, one or more hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation.

**[00113]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation; where the cancer is selected from breast cancer, colon cancer, rectal cancer, endometrial cancer, gastric carcinoma (including gastrointestinal carcinoid tumors and gastrointestinal stromal tumors), glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer (NSCLC), melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), non-Hodgkin's lymphoma, and thyroid carcinoma. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation; where the cancer is selected from prostate cancer, NSCLC, ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastoma. In another embodiment, the invention

is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation; where the cancer is selected from NSCLC, breast cancer, prostate cancer, glioblastoma, and ovarian cancer.

**[00114]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or more chemotherapeutic agents.

**[00115]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, a rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, temozolomide, paclitaxel, docetaxel, carboplatin, cisplatin, oxaliplatin, gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), HKI-272, pelitinib, canertinib, a compound selected from Table 4, a compound in Table 7, and lapatinib. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, temozolomide, paclitaxel, docetaxel, carboplatin, trastuzumab, erlotinib, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-

({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, a compound in Table 7, and lapatinib. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, paclitaxel, carboplatin, erlotinib, and *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine.

**[00116]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents independently selected from a platin and a taxane. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents independently selected from carboplatin, cisplatin, oxaliplatin, and paclitaxel.

**[00117]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an AKT inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an AKT inhibitor selected from perifosine, PKC 412, a compound in Table 2a, and a compound in Table 2b.

**[00118]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a cMET inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of

the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a cMET inhibitor selected from a compound in Table 3a, a compound in Table 3b, and a compound in Table 3c.

**[00119]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an EGFR inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an EGFR inhibitor selected from lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), AEE788, HKI-272, EKB-569, CI 1033, a compound selected from Table 4, and a compound in Table 7. In another embodiment, In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an EGFR inhibitor selected from lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), AEE788, HKI-272, EKB-569, CI 1033, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, and *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine.

**[00120]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an ErbB2 inhibitor. In another embodiment, the invention is

directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an ErbB2 inhibitor selected from lapatinib, EKB-569, HKI272, CI 1033, PKI-166, and a compound selected from Table 4.

**[00121]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an HSP90 inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an HSP90 inhibitor selected from 17-AAG, 17-DMAG, Geldanamycin, and CNF2024. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an HSP90 inhibitor selected from 17-AAG, 17-DMAG, and Geldanamycin.

**[00122]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an IGF1R inhibitor. In another embodiment, In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is an IGF1R inhibitor selected from Table 5a and Table 5b.

**[00123]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a

treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a Raf inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a Raf inhibitor selected from sorafenib, RAF 265 (CHIR-265), and a compound in Table 6.

**[00124]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a VEGFR inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a VEGFR inhibitor selected from VEGF Trap, ZD6474 (Zactima), cediranib (AZ2171), pazopanib, sunitinib, sorafenib, axitinib, AEE788, RAF 265 (CHIR-265), a compound selected from Table 4, and a compound selected from Table 7.


**[00125]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a cKIT inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a cKIT inhibitor selected from imatinib, sunitinib, nilotinib, AMG 706, sorafenib, a compound in Table 3b, a compound in Table 3c, a compound in Table 8, and a compound in Table 9.

**[00126]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the

chemotherapeutic agents is a FLT3 inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a FLT3 inhibitor selected from CEP-701, PKC 412, sunitinib, MLN518, sunitinib, sorafenib, a compound in Table 3a, a compound in Table 3b, a compound in Table 3c, and a compound in Table 9.

**[00127]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from rapamycin, a rapamycin analogue, PI103, and SF 1126. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from rapamycin, CCI-779, AP23573, RAD 001, TAFA 93, PI103, and SF 1126. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is rapamycin.

**[00128]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is of formula **100**:




**100**

where q is 1, 2, or 3; E is $-NR^9-$, -O-, or absent and Y is $-CH_2CH_2-$, $-CH_2-$, or absent provided that when E is $-NR^9-$ or -O-, then Y is $-CH_2CH_2-$; $R^2$ is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, and lower alkyl; $R^8$ is selected from -H, lower alkyl, $-C(O)OR^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$; $R^9$ is hydrogen or lower alkyl; $R^3$ is hydrogen or $R^4$; $R^4$ is selected from lower alkyl, aryl, lower arylalkyl, heterocyclyl, and lower heterocyclylalkyl; or $R^3$ and $R^4$, when taken together with a common nitrogen to which they are attached, form a five- to seven-membered heterocyclyl, said five- to seven-membered heterocyclyl optionally containing one or more additional heteroatom selected from N, O, S, and P; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt, additionally optionally as a solvate, and additionally as a hydrate thereof. The terms used to describe the scope of formula 100 are defined in WO 2004/006846 (US Nat'l Stage Application Serial No. 10/522,004) which is herein incorporated by reference. Whenever a compound of formula 100 is described in this application, whether by structure or by use of the term "formula 100," the terms used to describe that compound are defined by WO 2004/006846 (US Nat'l Stage Application Serial No. 10/522,004). In particular, "alkyl" in formula 100 is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof, inclusively; "lower alkyl" means alkyl groups of from one to six carbon atoms. "Aryl" in formula 100 means an aromatic six- to fourteen-membered carbocyclic rings which include, for example, benzene, naphthalene, indane, tetralin, fluorene and the like. "Lower arylalkyl" in formula 100 means a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkenylene, or alkynylene radical where the "alkyl" portion of the group has one to six carbons; examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. In formula 100, "heterocyclyl" means a stable monocyclic, bicyclic or tricyclic three- to fifteen-membered ring radical (including fused or bridged ring systems) that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur where the nitrogen, phosphorus, carbon and sulfur atoms in the heterocyclyl radical may be optionally oxidized to various oxidation states and the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated or aromatic. "Lower heterocyclylalkyl" means a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkenylene, and alkynylene radical having one to six carbons.

**[00129]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a

Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 2a. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 2a. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 2a.

**[00130]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 2b. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 2b. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 2b.

**[00131]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3a. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two

chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3a. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3a.

**[00132]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3b. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3b. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3b.

**[00133]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3c. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3c. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 3c.

**[00134]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 4. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 4. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 4.

**[00135]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a) in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine,

*N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

**[00136]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a) in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of

Formula I selected from Table 1 in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

**[00137]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 5ac. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 5a. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 5a.

**[00138]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 5b. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 5b. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 5b.

**[00139]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 6. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 6. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 6.

**[00140]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 7. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 7. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 7.

**[00141]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 8. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to

a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 8. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 8.

**[00142]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 9. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a), in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 9. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1, in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agents is selected from a compound in Table 9.

**[00143]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agent is paclitaxel.

**[00144]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agent is rapamycin.

**[00145]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a

Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agent is carboplatin.

**[00146]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agent is erlotinib.

**[00147]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two chemotherapeutic agents where one of the chemotherapeutic agent is lapatinib.

**[00148]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two antibodies where one of the antibodies is trastuzumab.

**[00149]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two antibodies where one of the antibodies is cetuximab.

**[00150]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two antibodies where one of the antibodies is panitumumab.

**[00151]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two antibodies where one of the antibodies is bevacizumab.

**[00152]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is radiation. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a

therapeutically effective amount of a Compound of Formula I according to Formula I(a) in combination with a treatment where the treatment is radiation. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is radiation.

**[00153]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two antibodies. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or two antibodies independently selected from an IGF1R antibody (including, for example, $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C10 MoAb and $^{\alpha}$IGF-1R CP-751871 MoAb), Alemtuzumab, Bevacizumab (Avastin®), Gemtuzumab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Panitumumab, Rituximab, Tositumomab, Omnitarg (pertuzimab), an anti-ErbB2 anibodys (including trastuzumab (Herceptin®)), and an anti-EGFR antibodies (including, for example, cetuximab (Erbitux), panitumumab, nimotuzumab, and EMD72000)).

**[00154]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a) in combination with a treatment where the treatment is one or two antibodies. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a) in combination with a treatment where the treatment is one or two antibodies independently selected from an IGF1R antibody (including, for example, $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C10 MoAb and $^{\alpha}$IGF-1R CP-751871 MoAb), Alemtuzumab, Bevacizumab (Avastin®), Gemtuzumab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Panitumumab, Rituximab, Tositumomab, Omnitarg (pertuzimab), an anti-ErbB2 anibodys (including trastuzumab (Herceptin®)), and an anti-EGFR antibodies (including, for example, cetuximab (Erbitux), panitumumab, nimotuzumab, and EMD72000)).

**[00155]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a

Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two antibodies. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or two antibodies independently selected from an IGF1R antibody (including, for example, $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C10 MoAb and $^{\alpha}$IGF-1R CP-751871 MoAb), Alemtuzumab, Bevacizumab (Avastin®), Gemtuzumab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Panitumumab, Rituximab, Tositumomab, Omnitarg (pertuzimab), an anti-ErbB2 anibodys (including trastuzumab (Herceptin®)), and an anti-EGFR antibodies (including, for example, cetuximab (Erbitux), panitumumab, nimotuzumab, and EMD72000)).

**[00156]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is one or more chemotherapeutic agents where one of the chemotherapeutic agent is temozolomide. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a) in combination with a treatment where the treatment is one or more chemotherapeutic agents where one of the chemotherapeutic agent is temozolomide. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is one or more chemotherapeutic agents where one of the chemotherapeutic agent is temozolomide.

**[00157]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where the treatment is surgery. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I according to Formula I(a) in combination with a treatment where the treatment is surgery. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where the treatment is surgery.

combination with a treatment where one of the treatments is one or two hormone therapies where one of the hormone therapies is an aromatase inhibitors selected from letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where one of the treatments is one or two hormone therapies independently selected from from tamoxifen and an aromatase inhibitor.

**[00160]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with a treatment where one of the treatments is one antibody selected from an EGFR antibody and an ErbB2 antibody, or the treatment is one or two chemotherapeutic agents independently selected from a rapamycin, rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I saccording to Formula I(a) in combination with a treatment where one of the treatments is one antibody selected from an EGFR antibody and an ErbB2 antibody, or the treatment is one or two chemotherapeutic agents independently selected from rapamycin, a rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor. In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I selected from Table 1 in combination with a treatment where one of the treatments is one antibody selected from an EGFR antibody and an ErbB2 antibody, or the treatment is one or two chemotherapeutic agents independently selected from rapamycin, a rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor.

**[00161]** In another embodiment, the invention is directed to a method of treating acute myelogenous leukemia (AML) which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from bone marrow or peripheral blood stem cell transplantation, radiation, one or two antibodies, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating acute myelogenous leukemia (AML) which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as

defined in the Summary of the Invention, in combination with one or t treatments where one of the treatments is one antibody selected from Gemtuzumab ozogamicin (Mylotarg), $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C10 MoAb, $^{\alpha}$IGF-1R CP-751871 MoAb and trastuzumab. In another embodiment, the invention is directed to a method of treating acute myelogenous leukemia (AML) which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents selected from Imatinib (i.e. Gleevec®), PKC 412, CEP-701, daunorubicin, doxorubicin, cytarabine (ara-C), an anthracycline drug such as daunorubicin or idarubicin (Daunomycin, Idamycin), 6-thioguanine, and a granulocyte colony-stimulating factor (such as Neupogen or Leukine).

**[00162]** In another embodiment, the invention is directed to a method of treating chronic myelogenous leukemia (CML) which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from bone marrow or peripheral blood stem cell transplantation, radiation, one or two chemotherapeutic agents, immunotherapy, and one or two antibodies. In another embodiment, the invention is directed to a method of treating chronic myelogenous leukemia (CML) which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the chemotherapeutic agents selected from Imatinib (i.e. Gleevec®), PKC 412, hydroxyurea (Hydrea), cytosine, cytosine arabinoside, dasatinib, AMN107, VX680 (MK0457), and cytarabine (ara-C). In another embodiment, the invention is directed to a method of treating chronic myelogenous leukemia (CML) which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents selected from Imatinib (i.e. Gleevec®) and dasatinib. In another embodiment, the invention is directed to a method of treating chronic myelogenous leukemia (CML) which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is immunotherapy and the immunotherapy is interferon therapy such as interferon-α.

**[00163]** In another embodiment, the invention is directed to a method of treating prostate cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery (including cryosurgery), radiation, one or two chemotherapeutic agents, one or two antibodies, and one or two hormone therapies. In another embodiment, the invention is directed to a method of treating prostate cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an antibody selected from $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C10 MoAb, and $^{\alpha}$IGF-1R CP-751871 MoAb. In another embodiment, the invention is directed to a method of treating prostate cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the chemotherapeutic agents independently selected from rapamycin, mitoxantrone, prednisone, docetaxel (Taxotere), doxorubicin, etoposide, vinblastine, paclitaxel, and carboplatin. In another embodiment, the invention is directed to a method of treating prostate cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the hormone therapy indepependently selected from androgen deprivation therapy and androgen suppression therapy. In another embodiment, the invention is directed to a method of treating prostate cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents where one of the chemotherapeutic agents is a taxanes. In another embodiment, the invention is directed to a method of treating prostate cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents where one of the chemotherapeutic agents is rapamycin.

**[00164]** In another embodiment, the invention is directed to a method of treating melanoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in

combination with one or more treatments independently selected from surgery, radiation, one or two immunotherapies, one or two hormone therapies, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating melanoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from an alkylating agent, a taxane, a platin, and a Raf inhibitor. In another embodiment, the invention is directed to a method of treating melanoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from sorafenib, Paclitaxel (Taxol®), Docetaxel (Taxotere®), dacarbazine, rapamycin, imatinib mesylate (Gleevec®), sorafenib, cisplatin, carboplatin, dacarbazine (DTIC), carmustine (BCNU), vinblastine, temozolomide (Temodar), Melphalan, and imiquimod (Aldara). In another embodiment, the invention is directed to a method of treating melanoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two immunotherapies independently selected from ipilimumab, interferon-alpha and interleukin-2. In another embodiment, the invention is directed to a method of treating melanoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is hormone therapy where the hormone therapy is tamoxifen.

**[00165]** In another embodiment, the invention is directed to a method of treating colon or rectal cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, one or two antibodies, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating colon or rectal cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is surgery selected from local excision, electrofulguration, segmental colon resection, polypectomy, local transanal resection, low anterior resection,

abdominoperineal resection, and pelvic exenteration. In another embodiment, the invention is directed to a method of treating colon or rectal cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from a platinum-containing compound (including cisplatin, oxaliplatin, and carboplatin), 5-fluorouracil (5-FU), leucovorin, capecitabine (Xeloda), irinotecan (Camptosar), FOLFOX (Folinic acid, 5-FU, Oxaliplatin), and leucovorin. In another embodiment, the invention is directed to a method of treating colon or rectal cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two antibodies independently selected from cetuximab (Erbitux) and bevacizumab (Avastin).

**[00166]** In another embodiment, the invention is directed to a method of treating pancreatic cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, one or two antibodies, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating pancreatic cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is selected from one or two chemotherapeutic agents independently selected from platinum-containing compound (including cisplatin, oxaliplatin, and carboplatin), 5-fluorouracil (5-FU), gemcitabine, a taxane (including paclitaxel and docetaxel), topotecan, irinotecan, capecitabine, streptozocin, erlotinib (Tarceva), , leucovorin, and capecitabine (Xeloda). In another embodiment, the invention is directed to a method of treating pancreatic cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an antibody wehre the antibody is cetuximab.

**[00167]** In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, one or two

chemotherapeutic agents, one or two hormone therapies, and one or two antibodies. In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the chemotherapeutic agents independently selected from lapatinib (Tykerb®), Paclitaxel (Taxol®), docetaxel, capecitabine, Cyclophosphamide (Cytoxan), CMF (cyclophosphamide, fluoruracil, and methotrexate), methotrexate, fluorouracil, doxorubicin, epirubicin, gemcitabine, carboplatin (Paraplatin), cisplatin (Platinol), vinorelbine (Navelbine), capecitabine (Xeloda), pegylated liposomal doxorubicin (Doxil), albumin-bound paclitaxel (Abraxane), AC (adriamycin and Cyclophosphamide), adriamyclin, and pamidronate or zoledronic acid (to treat bone weakness). In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two hormone therapies independently selected from tamoxifen, Toremifene (Fareston), Fulvestrant (Faslodex), Megestrol acetate (Megace), ovarian ablation, Raloxifene, a luteinizing hormone-releasing hormone (LHRH) analogs (including goserelin and leuprolide), Megestrol acetate (Megace), and one or more aromatase inhibitors. In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two hormone therapies and one of the hormone therapies is an aromatase inhibitors selected from letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two antibodies independently selected from $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C10 MoAb, $^{\alpha}$IGF-1R CP-751871 MoAb, bevacizumab (Avastin), and trastuzumab.

**[00168]** In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination

with one or more treatments where one of the treatments is one or two chemotherapeutic agents and one of the chemotherapeutic agents is erlotinib.

**[00169]** In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the chemotherapeutic agents and one or two of the chemotherapeutic agents are independently selected from rapamycin, lapatinib, erlotinib, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof, and *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

**[00170]** In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the antibodies. In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two antibodies and one of the antibodies is trastuzumab.

**[00171]** In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the

chemotherapeutic agents and one of the chemotherapeutic agents is selected from *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, and *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

**[00172]** In another embodiment, the invention is directed to a method of treating breast cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two of the chemotherapeutic agents and one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

**[00173]** In another embodiment, the invention is directed to a method of treating non-small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, one or more antibodies, and one or more chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating non-small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from cisplatin, oxaliplatin, carboplatin, Zactima (ZD6474), Paclitaxel, Docetaxel (Taxotere®), Gemcitabine (Gemzar®), Vinorelbine, Irinotecan, Etoposide, Vinblastine, Erlotinib (Tarceva®), gefitinib (Iressa), and Pemetrexed. In another embodiment, the invention is directed to a method of treating non-small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an antibody and the antibody is Bevacizumab. In

another embodiment, the invention is directed to a method of treating non-small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from cisplatin, oxaliplatin, carboplatin, Paclitaxel, Docetaxel (Taxotere®), and erlotinib (Tarceva®).

**[00174]** In another embodiment, the invention is directed to a method of treating non-small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents and one of the chemotherapeutic agents is carboplatin.

**[00175]** In another embodiment, the invention is directed to a method of treating non-small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents and one of the chemotherapeutic agents is selected from *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, and *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof. In another embodiment, the invention is directed to a method of treating non-small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents and one of the chemotherapeutic agents is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

**[00176]** In another embodiment, the invention is directed to a method of treating small cell lung cancer which method comprises administering to a patient a therapeutically effective

amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating small cell lung cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapy agents independently selected from a platin (such as cisplatin, oxaliplatin, and carboplatin), gefitinib, vinorelbine, docetaxel, paclitaxel, etoposide, fosfamide, ifosfamide, cyclophosphamide, cyclophosphamide/doxorubicin/vincristine (CAV), doxorubicin, vincristine, gemcitabine, paclitaxel, vinorelbine, topotecan, irinotecan, methotrexate, and docetaxel.

**[00177]** In another embodiment, the invention is directed to a method of treating papillary or anaplastic thyroid cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, radioactive iodine therapy, one or two hormone therapies, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating papillary or anaplastic thyroid cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from thyroid hormone pills, Doxorubucin and a platin. In another embodiment, the invention is directed to a method of treating papillary or anaplastic thyroid cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is hormone therapy and the hormone therapy is radioiodine ablation.

**[00178]** In another embodiment, the invention is directed to a method of treating endometrial cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, one or two hormone therapies, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating endometrial cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with

one or more treatments where one of the treatments is one or two hormone therapies independently selected from megestrol acetate, Tamoxifen, and a progestin including medroxyprogesterone acetate (Provera) and megestrol acetate (Megace). In another embodiment, the invention is directed to a method of treating endometrial cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from a platinum-containing compound (including cisplatin, oxaliplatin, and carboplatin, more for example cisplatin), a taxane (including paclitaxel), doxorubicin (Adriamycin), cyclophosphamide, fluorouracil (5-FU), methotrexate, and vinblastine.

**[00179]** In another embodiment, the invention is directed to a method of treating ovarian cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, one or two antibodies, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating ovarian cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an antibody and the antibody is bevacizumab. In another embodiment, the invention is directed to a method of treating ovarian cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from a platinum-containing compound (including cisplatin, oxaliplatin and carboplatin), a taxane (including paclitaxel and docetaxel), topotecan, an anthracyclines (including doxorubicin and liposomal doxorubicin), gemcitabine, cyclophosphamide, vinorelbine (Navelbine), hexamethylmelamine, ifosfamide, etoposide, bleomycin, vinblastine, ifosfamide, vincristine, and cyclophosphamide. In another embodiment, the invention is directed to a method of treating ovarian cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from a platin and a taxane. In another embodiment, the invention is directed to a method of treating ovarian cancer which method

comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from cisplatin, oxaliplatin, carboplatin, paclitaxel, and docetaxel.

**[00180]** In another embodiment, the invention is directed to a method of treating glioblastoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, one or two chemotherapeutic agents, one or two anti-seizure agents, and one or two agents to reduce swelling. In another embodiment, the invention is directed to a method of treating glioblastoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is radiation selected from external beam radiation, interstitial radiotherapy, and stereotactic radiosurgery. In another embodiment, the invention is directed to a method of treating glioblastoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from carmustine (BCNU), Erlotinib (Tarceva), bevacizumab, gefitinib (Iressa), rapamycin, temozolomide, cisplatin, BCNU, lomustine, procarbazine, and vincristine. In another embodiment, the invention is directed to a method of treating glioblastoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an anti-seizure agent and the anti-seizure agent is diphenylhydantoin (Dilantin). In another embodiment, the invention is directed to a method of treating glioblastoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an agents to reduce swelling and the agent is dexamethasone (Decadron). In another embodiment, the invention is directed to a method of treating glioblastoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of

treating glioblastoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from erlotinib and temozolomide.

**[00181]** In another embodiment, the invention is directed to a method of treating cervical cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating cervical cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is surgery selceted from cryosurgery, laser surgery, loop electrosurgical excision, conization, simple hysterectomy, and radical hysterectomy and pelvic lymph node dissection. In another embodiment, the invention is directed to a method of treating cervical cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is radiation selected from called external beam radiation therapy and brachytherapy. In another embodiment, the invention is directed to a method of treating cervical cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from a platinum compound (such as cisplatin, carboplatin, and oxaliplatin), paclitaxel, topotecan, ifosfamide, gemcitabine, vinorelbine, and fluorouracil.

**[00182]** In another embodiment, the invention is directed to a method of treating a gastrointestinal carcinoid tumor which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, immunotherapy, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating a gastrointestinal carcinoid tumor which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is surgery selected from excision

and electrofulguration. In another embodiment, the invention is directed to a method of treating a gastrointestinal carcinoid tumor which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from cyproheptadine, SOM230, octreotide and lanreotide. In another embodiment, the invention is directed to a method of treating a gastrointestinal carcinoid tumor which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is immunotherapy and the immunotherapy is an interferon.

**[00183]** In another embodiment, the invention is directed to a method of treating a gastrointestinal stromal tumor which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiation, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating a gastrointestinal stromal tumor which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents independently selected from imatinib mesylate (Gleevec), sunitinib (Sutent), and nilotinib (AMN107).

**[00184]** In another embodiment, the invention is directed to a method of treating hepatocellular carcinoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from surgery, radiofrequency ablation, ethanol ablation, cryosurgery, hepatic artery embolization, chemoembolization, radiation, and one or two chemotherapeutic agents. In another embodiment, the invention is directed to a method of treating hepatocellular carcinoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is surgery selected from resection and transplantation. In another embodiment, the invention is directed to a method of treating hepatocellular carcinoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one

or two chemotherapeutic agents independently selected from sorafenib, 5-fluorouracil and cisplatin.

**[00185]** In another embodiment, the invention is directed to a method of treating non-Hodgkin's lymphoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments independently selected from radiation, one or two chemotherapeutic agents, interferon therapy, one or two antibodies, and bone marrow or peripheral blood stem cell transplantation. In another embodiment, the invention is directed to a method of treating non-Hodgkin's lymphoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is one or two chemotherapeutic agents selected from CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), chlorambucil, fludarabine, and etoposide. In another embodiment, the invention is directed to a method of treating non-Hodgkin's lymphoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an antibody selected from rituximab, ibritumomab tiuxetan, tositumomab, and alemtuzumab. In another embodiment, the invention is directed to a method of treating non-Hodgkin's lymphoma which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is an antibody and the anitbody is rituximab.

**[00186]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is radiation and another treatment is surgery.

**[00187]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is radiation and another treatment is one or two chemotherapeutic agents.

**[00188]** In another embodiment, the invention is directed to a method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a Compound of Formula I, as defined in the Summary of the Invention, in combination with one or more treatments where one of the treatments is surgery and another treatment is one or two chemotherapeutic agents.

**[00189]** For each of the foregoing embodiments, the Compound of Formula I is selected from any of the following embodiments, including from the Representative Compounds in Table 1.

**[00190]** One embodiment (A) of the invention is directed to a compound of Formula I where $W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; where each $R^1$ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino; and all other groups are as defined in the Summary of the Invention. In another embodiment, $W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$ and each $R^1$ is independently hydrogen or alkyl; or one of $W^1$ and $W^4$ is $-N=$ and the other is $-C(H)=$. In another embodiment, $W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$ where each $R^1$ is independently hydrogen or alkyl. In another embodiment, $R^1$ is hydrogen.

**[00191]** Another embodiment (B) of the invention is a Compound of Formula I where $R^{50}$ is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino; where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{50}$ is hydrogen.

**[00192]** Another embodiment (C) of the invention is a Compound of Formula I where $R^{51}$ is hydrogen or alkyl; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{51}$ is alkyl, In another embodiment, $R^{51}$ is methyl.

**[00193]** Another embodiment (D) of the invention is a Compound of Formula I where $R^{52}$ is hydrogen or halo; and all other groups are as defined in the Summary of the Invention. In another embodiment $R^{52}$ is hydrogen or fluoro. In another embodiment, $R^{52}$ is hydrogen.

**[00194]** Another embodiment (E) of the invention is a Compound of Formula I where $R^{53}$ is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-


$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino; where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{53}$ is hydrogen, alkoxy, nitro, amino, or $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$. In another embodiment, $R^{53}$ is hydrogen, methoxy, nitro, amino, or $-NHC(O)CH_2N(CH_3)_2$. In another embodiment, $R^{53}$ is hydrogen or methoxy.

**[00195]** Another embodiment (F) of the invention is a Compound of Formula I where $R^{54}$ is hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino; where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{54}$ is hydrogen, alkyl, alkoxy, or halo. In another embodiment, $R^{54}$ is hydrogen, methyl, methoxy, bromo, or chloro. In another embodiment, $R^{54}$ is hydrogen, methoxy, or chloro.

**[00196]** Another embodiment (G) of the invention is directed to a compound of Formula I where $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is halo or alkoxy; $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is alkoxy; or $R^{50}$ and $R^{52}$ are hydrogen and $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is chloro or methoxy; $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is methoxy; or $R^{50}$ and $R^{52}$ are hydrogen and $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form pyridinyl. Even more speicfically, $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is chloro or methoxy; or $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is methoxy.

**[00197]** In another embodiment (G1) of embodiment G is a compound of Formula I where $R^{51}$ is methyl.

**[00198]** Another embodiment (H) of the invention is a compound of Formula I where B is phenyl substituted with $R^{3a}$ and optionally further substituted with one, two, or three $R^3$; and all other groups are as defined in the Summary of the Invention. In another embodiment, B is phenyl substituted with $R^{3a}$. In another embodiment the Compound is of Formula I(a):



I(a).

In another embodiment, B is phenyl substituted with $R^{3a}$ as depicted in **Ia** and is not further substituted with $R^3$.

**[00199]** Another embodiment of the Invention (J) is directed to a compound of Formula I where B is heteroaryl optionally substituted with one, two, or three $R^3$. In another embodiment, B is thien-3-yl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, or thiazolyl, each of which is optionally substituted with one or two $R^3$. In another embodiment, B is thien-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, imidazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, imidazol-4-yl, imidazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl, each of which is optionally substituted with one or two $R^3$. In another embodiment, B is thien-3-yl, pyridin-3-yl, pyridin-4-yl, isoxazol-4-yl, or pyrazol-4-yl, each of which is optionally substituted with one or two $R^3$. In another embodiment, B is pyridin-3-yl, 2-hydroxy-pyridin-5-yl, isoxazol-4-yl, or pyrazol-4-yl, each of which is optionally substituted with one or two $R^3$.

**[00200]** Another embodiment (K) provides a compound of Formula I or Ia where $R^{3a}$ is cyano; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -$N(R^7)C(O)$-$C_1$-$C_6$-alkylene-$N(R^{7a})(R^{7b})$; -$C(O)NR^8R^{8a}$; -$NR^9C(O)R^{9a}$; -$C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$; -$NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$; -$C(O)R^{12}$; -$NR^{13}C(O)OR^{13a}$; -$C(O)N(R^{14})N(R^{14a})(R^{14b})$; -$S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$; -$C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; -$N(R^{17})$-$C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; -$N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$; -$C(O)N(R^{19})$-$C_1$-$C_6$-alkylene-$C(O)R^{19a}$; -$N(R^{22})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$; -$C_0$-$C_6$-alkylene-$N(R^{23})$-$C_1$-$C_6$-alkylene-$N(R^{23b})R^{23a}$; or -$NR^{24}C(O)$-$C_1$-$C_6$-alkylene-$OR^{24a}$; where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5

groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and all other groups are as defined in the Summary of the Invention.

**[00201]** In another embodiment, $R^{3a}$ is -NHC(O)$CH_2NH(CH_3)$, -NHC(O)$CH_2NH(CH_2CH_3)$, -NHC(O)$CH(CH_3)NH_2$, -NHC(O)$C(CH_3)_2NH_2$, -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH(NH_2)CH_2CH_3$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH(CH_3)NH(CH_3)$, -NHC(O)$CH_2NH_2$, -NHC(O)H, -NHC(O)$CH_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), -NHC(O)$CH(NH_2)CH_2OH$, -NHC(O)(azetidin-4-yl), -NHC(O)$C(CH_3)_2NH(CH_3)$, -$NH_2$, -NHC(O)$CH_2NH(CH_2CH_2CH_3)$, -NHC(O)$CH_2CH_2NH_2$, -NHOH, -NHC(O)(piperidin-3-yl), -NHC(O)$CH_2$(4-methyl-1,4-diazepan-1-yl), -NHC(O)$CH(NH_2)(CH_2CH_3)$, -NHC(O)$CH_2NH(CH_2CH(OH)(CH_3))$, -NHC(O)$CH_2NHCH_2CH_2F$, -NHC(O)$CH_2NH(OCH_2CH(CH_3)_2)$, -NHC(O)(1-aminocycloprop-1-yl), -NHC(O)$CH_2NH(CH_2$cyclopropyl), -NHC(O)$CH_2$(3-(dimethylamino)-azetidin-1-yl), -NHC(O)(piperidin-2-yl), -NHC(O)(morpholin-4-yl), -NHC(O)$CH_2$(pyrrolidin-1-yl), -NHC(O)$CH(NH_2)CH_2CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)$CH_2$(imidazol-5-yl), -NHC(O)(1-aminocyclopent-1-yl), -NHC(O)$CH_2NH(CH_2CH(CH_3)_2)$, -NHC(O)$CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)(*N*-(imidazol-4-ylmethyl)-azetidin-3-yl), -NHC(O)(*N*-ethyl-azetidin-3-yl), -$NHCH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)$(*N*-methyl-pyrrolidin-3-yl), -NHC(O)$CH_2N(CH_3)(CH_2CH_2N(CH_3)_2)$, -NHC(O)$CH_2$(3-hydroxy-pyrrolidin-1-yl), -NHC(O)(1-amino-cyclobut-1-yl), -NHC(O)$CH_2NH(CH_2)_3CH_3$, -NHC(O)$CH_2$(3-piperidin-1-ylazetidin-1yl), -$NHC(O)NH_2$, -NHC(O)(1-hydroxycyclopropyl), -NHC(O)$CH_2NHN(CH_3)_2$, -NHC(O)$NH(CH_2)_2N(CH_3)_2$, -NHC(O)$CH_2OH$, -NHC(O)(pyridazin-4-yl), -NHC(O)(N-methyl-piperidin-4-yl), -NHC(O)$CH_2NHCH(CH_3)_3$, -NHC(O)$CH_2$(3-dimethylamino-pyrrolidin-1yl), -NHC(O)$CH_2NH(CH_2)_2N(CH_3)_2$, -NHC(O)(1-cyclopropylmethyl-azetidin-3-yl), -NHC(O)$CH_2NH(CH_3)_3$, -NHC(O)(imidazol-2-yl), -NHC(O)(imidazol-4-yl), -NHC(O)(1,2-oxazol-5-yl), -NHC(O)$CH_2NHCH_2CF_3$, -NHC(O)$CH_2CH_2$(piperidin-1-yl), -NHC(O)(3-oxo-cyclopent-1-yl), -NHC(O)(2-hydroxy-pyridin-6-yl), -NHC(O)$CH_2NH$(3-fluoro-4-hydroxyphenyl), -NHC(O)$(CH_2)_3N(CH_3)_2$, -NHC(O)(1-(furan-2-ylmethyl)-azetidin-3-yl), -NHC(O)(pyrimidin-5-yl), -NHC(O)(pyrrol-2-yl), -NHC(O)$CH_2N(CH_3)CH(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)_2$, -NHC(O)$CH_2$(3-methyl-1,2-oxazol-5-yl), -NHC(O)$CH_2NHCH_2$(3-hydroxyphenyl), -NHC(O)(*N*-methyl-pyrrol-2-yl), -NHC(O)(2-amino-tetrahydropyran-2-yl), -NHC(O)$CH_2$(4-methylamino-piperidin-1-

yl), -NHC(O)(piperidin-1-yl), -NHC(O)(*N*-methyl-pyrrolidin-2yl), -NHC(O)(thien-3yl), -NHC(O)(*N*-(cyclopropylcarbonyl)azetidin-3-yl), -NHC(O)$CH_2$(4-methylpiperazin-1-yl), -NHC(O)(*N*-benzylazetidin-3-yl), -NHC(O)(2-chloro-pyridin-3-yl), -NHC(O)$CH_2$(pyridin-4-yl), -NHC(O)$CH_2N(CH_3)(CH_2CH{=}CH_2)$, -NHC(O)$CH_2$NH(benzyl), -NHC(O)$CH_2OCH_3$, -NHC(O)[1-(C(O)$CH_2CH_3$)-azetidin-3-yl], -NHC(O)(pyridin-3-yl), -NHC(O)$CH_2NHCH_2CH_2OCH_3$, -NHC(O)(1-[C(O)$CH_3$]piperidin-4-yl), -NHC(O)$CH_2$(2-methyl-pyrrolidin-1-yl), -NHC(O)(furan-3-yl), -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)(2-chloro-pyridin-5-yl), -NHC(O)(2-chlorophenyl), -NHC(O)$CH_2$(pyridin-2-yl), -NHC(O)$CH_2$(3-dimethylamino-azetidin-1-yl), -NHC(O)$CH_2$(pyridin-3-yl), -NHC(O)$CH_2$(2-chlorophenyl), -NHC(O)$CH_2N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)CH_2CH_2OH$, -NHC(O)$CH_2$(2-benzyl-pyrrolidin-1-yl), -NHC(O)(furan-2-yl, -NHC(O)(2-chloro-pyridin-4-yl), -NHC(O)$CH_2$NHC(O)$CH_3$, -NHC(O)$CH_2CH_2CH_3$, -NHC(O)(4-chlorophenyl), -NHC(O)(4-methyl-phenyl), -NHC(O)$CH_2$NHC(O)O$(CH_3)_3$, -NHC(O)(benzo[d][1,3]dioxol-5-yl), -NHC(O)$CH_2$NHO$CH_2$(2-methoxyphenyl), -NHC(O)(pyridin-4-yl), -NHC(O)$CH_2$[4-(3,4-dichlorophenyl)-piperazin-1-yl], -NHC(O)$CH_2CH_2$(pyridin-3-yl), -NHC(O)(tetrahydrofuran-3-yl), -NHC(O)$CH_2$NH$CH_2$(2-methylphenyl), -NHC(O)$CH(CH_3)CH_2CH_3$, -NHC(O)$CH_2$(3-fluorophenyl), -NHC(O)$CH_2C(CH_3)_2$phenyl, -NHC(O)(2-methyl-cycloprop-1-yl), -NHC(O)(2-methyl-4-methoxyphenyl), -NHC(O)(2-methylpyridin-3-yl), -NHC(O)(4-methoxyphenyl), -NHC(O)$CH_2$(4-ethylpiperazin-1-yl), -NHC(O)(thien-2-yl), -NHC(O)(3-fluoro-2-methylphenyl), -NHC(O)(2-bromo-thien-3-yl), -NHC(O)(4-fluorophenyl), -NHC(O)$CH_2$(3-methylpiperidin-1-yl), -NHC(O)$CH(CH_3)_2$, -NHC(O)$(CH_2)_3CH_3$, -NHC(O)$CH_2OCH_2CH_3$, -NHC(O)$CH_2$NH(2-fluorophenyl), -NHC(O)(3-dimethylaminophenyl), -NHC(O)$CH_2$(4-methylpiperidin-1-yl), -NHC(O)$CH_2$NH(2-*n*-propylphenyl), -NHC(O)phenyl, -NHC(O)(pyrazin2-yl), -NHC(O)(3-fluoro-4-methoxyphenyl), -NHC(O)$C(CH_3)_2CH_2CH_3$, -NHC(O)$CH_2$O(4-fluorophenyl), -NHC(O)(1-methylcarbonyl-azetidin-3-yl), -NHC(O)$CH_2$NH(4-methylphenyl), -NHC(O)$CH_2$NH(phenyl), -NHC(O)$CH_2$(4-allyl-piperazin-1-yl), -NHC(O)(2-methylphenyl), -NHC(O)$CH_2CH_2OCH_3$, -NHC(O)(3-methyl-furan-2-yl), -NHC(O)$C(CH_3)_3$, -NHC(O)$CH_2$NHObenzyl, -NHC(O)$CH_2$NH(3-chlorophenyl), -NHC(O)cyclobutyl, -NHC(O)$CH_2$(3-methoxyphenyl), -NHC(O)(1-methylcycloprop-1-yl), -NHC(O)(3-flurophenyl), -NHC(O)(4-dimethylaminophenyl), -NHC(O)(3,4-dichlorophenyl), -NHC(O)$CH_2$NH$CH_2$(2-methylthiophenyl), -NHC(O)$CH_2$(2-fluorophenyl),

-NHC(O)$CH_2N(CH_2CH_3)CH(CH_3)_2$, -NHC(O)(thiazol-4-yl), -NHC(O)$CH_2N(CH_3)$benzyl, -NHC(O)$CH_2NHCH_2$(thien-2-yl), -NHC(O)$CH_2NHCH_2$(pyridin-2-yl), -NHC(O)(3-methoxyphenyl), -NHC(O)$CH_2NHCH_2$(3-chloro-4-methylphenyl), -NHC(O)$CH(CH_3)CH_2CH_2CH_3$, -NHC(O)$CH_2$(4-chlorophenyl), -NHC(O)(3-fluoro-4-methylphenyl), -NHC(O)$CH_2O$(2-methylphenyl), -NHC(O)$CH_2$(cyclohexyl), -NHC(O)(2-phenyl-cycloprop-1-yl), -NHC(O)(3-chlorophenyl), -NHC(O)$CH_2$(2-methoxyphenyl), -NHC(O)$CH_2CH_2$(3-methoxyphenyl), -NHC(O)$CH_2$NH(2-fluoro-4-methyl-phenyl), -NHC(O)$CH_2NHCH_2$(3-fluoro-phenyl), -NHC(O)$CH_2$(4-methoxy-phenyl), -NHC(O)benzyl, -NHC(O)(2,4-dichlorophenyl), -NHC(O)(3-oxo-cyclohex-1-yl), -NHC(O)$CH_2$NH(3-fluorophenyl), -NHC(O)$CH_2$(3-chlorophenyl), -NHC(O)$CH_2NHCH_2CH(CH_3)$phenyl, -NHC(O)$CH_2NHCH_2$(2,4-dimethylphenyl), -NHC(O)$CH_2$(2-methyl-piperidin-1-yl), -NHC(O)$CH_2$NH(2-methoxyphenyl), -NHC(O)$CH_2$(1,2,3,4-tetrahydroisoquinolin-2-yl), -NHC(O)$CH_2CH_2CH{=}CH_2$, -NHC(O)$CH_2$NH(2-methylphenyl), -NHC(O)$CH_2$(4-oxo-piperidin-1-yl), -NHC(O)(2-fluorophenyl), -NHC(O)$CH_2NHCH(CH_3)$phenyl, -NHC(O)(2-fluoro-6-methoxyphenyl), -NHC(O)$CH_2$NH(2-isopropylphenyl), -NHC(O)$CH_2CH_2$(2-methoxyphenyl), -NHC(O)$CH_2CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(2-phenyl-morpholin-4-yl), -NHC(O)$CH_2CH_2$(4-methoxyphenyl), -NHC(O)$CH_2N$(allyl)cyclopentyl, -NHC(O)$CH_2N(CH_3)CH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2C$(O)cyclopropyl, -NHC(O)$CH_2$NH(3-*tert*-butylphenyl), -NHC(O)$CH_2N$(*n*-propyl)(cyclopropylmethyl), -NHC(O)$CH_2$(2-oxo-cyclopentyl), -NHC(O)$CH_2$NH(4-chlorophenyl), -NHC(O)$CH_2$(4-piperidin-1-ylpiperidin-1-yl), -NHC(O)$CH_2$(4-cyclopentylpiperazin-1-yl), -NHC(O)$CH_2$(2-methylphenyl), -NHC(O)$CH_2NHCH_2$(3-fluoro-6-methylphenyl), -NHC(O)$CH_2C(CH_3)_3$, -NHC(O)$CH_2$NH(2-chlorophenyl), -NHC(O)(3-fluoro-6-methylphenyl), -NHC(O)(4-fluoro-3-methylphenyl), -NHC(O)(2,3-dichlorophenyl), -NHC(O)$CH_2$Ophenyl, -NHC(O)$CH_2$NH(2,3-dimethylphenyl), -NHC(O)(2-fluoro-5-methylphenyl), -NHC(O)$CH_2NHOCH_2$(4-methylphenyl), -NHC(O)$CH_2$(4-isopropylpiperazin-1-yl), -NHC(O)$CH_2$(4-fluorophenyl), -NHC(O)$CH_2CH(CH_3)_2$, -NHC(O)(2-methoxy-4-methylphenyl), -NHC(O)$CH_2$(4-*n*-propylpiperidin-1-yl), -NHC(O)$CH_2O$(3-methylphenyl), -NHC(O)(tetrahydrofuran-2-yl), -NHC(O)$CH_2$(3-hydroxymethylpiperidin-1-yl), -NHC(O)(1-*tert*-butoxycarbonylpiperidin-2-yl), -NHC(O)$CH_2N(CH_3)CH_2$(pyridin-3-yl), -NHC(O)$CH_2N(CH_2CH_3)$phenyl, -NHC(O)$CH_2OCH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2$(cyclopentyl), -NHC(O)(2,5-dichlorophenyl), -NHC(O)$CH_2$(4-methylcarbonylpiperazin-1-yl), -NHC(O)(5-fluoro-2-

methoxyphenyl), -NHC(O)$CH_2N(CH_2CH_3)$cyclohexyl, -NHC(O)(5-methyl-1,2-oxazol-3-yl), -NHC(O)(3-methylpyridin-3-yl), -NHC(O)(2-methoxypyridin-3-yl), -NHC(O)(3,5-dichlorophenyl), -NHC(O)$CH_2$(thiazolidin3-yl), -NHC(O)$CH_2$(4-[C(O)H]-piperazin-1-yl), -NHC(O)$CH_2$(2-pyridin-4-ylpiperidin-1-yl), -NHC(O)(2-methoxyphenyl), -NHC(O)$CH_2N(CH_3)CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(4-[C(O)H]-homopiperazin-1-yl), -NHC(O)(1-phenylcycloprop-1-yl), -NHC(O)$CH_2$(2,6-dimethylmorpholin-4-yl), NHC(O)$CH_2$(2-phenylpyrrolidin-1-yl), -NHC(O)$CH_2$(morpholin-4-yl), -C(O)$NHCH(CH_3)CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2N(CH_3)_2$, -C(O)NH(pyrrolidin-3-yl), -C(O)$NHCH_2CH_2$(pyrrolidin-1-yl), -C(O)$NHCH_2CH_2NH_2$, -C(O)$N(CH_3)CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2$(piperidin-2-yl), -C(O)NH(1-methylazetidin-3-yl), -C(O)$NHCH_2CH_2$(piperidin-1-yl), -C(O)$NHCH_2CH_2N(CH_2CH_3)_2$, -C(O)NH(1-methylpiperidin-3-yl), -C(O)NH(piperidin-3-yl), -C(O)$NHCH_2$(1-methylpiperidin-3-yl), -C(O)$NHCH_2CH_2N(CH_2CH_2OH)_2$, -C(O)NH(1-ethylpiperidin-3-yl), -C(O)$NH_2$, -C(O)(3-aminopyrrolidin-1-yl), -C(O)(3-methylaminopyrrolidin-1-yl), -C(O)OH, -C(O)$NHCH_2CH_2$(morpholin-4-yl), -C(O)$NHCH_2$(1-ethylpyrrolidin-2-yl), -C(O)(4-amino-3-oxo-pyrazolidin-1-yl), -C(O)$NHCH_3$, -C(O)(3-aminocyclobut-1-yl), -C(O)$NHCH_2$(pyridin-3-yl), -C(O)$NHCH_2CH_2OH$, -C(O)NH(3-oxo-pyrazolidin-4-yl), -$NHCH_2CH_2$(imidazol-4-yl), -C(O)(3-dimethylaminopyrrolidin-1-yl), -C(O)$NHCH_2$(pyridin-4-yl), -C(O)$N(CH_3)$(1-methyl-pyrrolidin-3-yl), -C(O)(3-diethylaminopyrrolidin-1-yl), -C(O)NH(pyrrol-1-yl), -C(O)$NHCH_2CH_2CH_2$(pyrrolidin-1-yl), -C(O)$N(CH_3)CH_2CH_2CN$, -C(O)$NHCH_2CH_2OCH_3$, -C(O)$N(CH_2CH_3)CH_2CH_2CN$, -C(O)(3-aminopiperidin-1-yl), -C(O)$NHCH_2CH_2CH_2N(CH_3)_2$, -C(O)NH(morpholin-4-yl), -C(O)$NHN(CH_3)_2$, -C(O)$NHCH_2CH_2CH_2$(imidazol-1-yl), -C(O)$NHCH_2CH_2CH_2N(CH_2CH_3)_2$, -C(O)$NHCH_2CH_2CN$, -C(O)$NHCH_2CH_2C(O)OCH_3$, -C(O)$NHCH_2CH_2SCH_3$, -C(O)$NHCH_2CH_2SCH_2CH_3$, -C(O)$N(CH_2CH_3)CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2CH_2$(2-oxo-pyrrolidin-1-yl), -C(O)$NHCH_2CH_2$(pyridin-4-yl), -C(O)$NHCH_2CH_2CH_2OCH_2CH_3$, -C(O)$NHCH_2CH_2CH_2$(morpholin-4-yl), -C(O)$NHCH_2CH_2CH_2OCH_3$, -C(O)$N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2CH_2OCH_2CH_2CH_3$, -C(O)$NHCH_2CH_2C(O)OCH_2CH_3$, -C(O)$NHCH_2CH_2CH_2OCH(CH_3)_2$, -C(O)$NHC(CH_3)_2CH_2$(piperidin-1-yl), -C(O)$N(CH_3)CH_2CH_2CH_3$, -C(O)NH(piperidin-1-yl), -C(O)$NHCH(CH_3)CH_2OCH_3$, -C(O)$NHC(CH_3)_2CH_2$(morpholin-4-yl), -C(O)(2-dimethylaminomethylpiperidin-1-yl), -C(O)$NH(CH_2)_3O(CH_2)_3CH_3$, -C(O)$NHCH(CH_3)(CH_2)_3N(CH_2CH_3)_2$, -C(O)$NHC(CH_3)_2C(O)$(piperidin-1-yl), -C(O)(4-methylpiperazin-1-yl), -C(O)(2-piperidin-1-ylmethyl-piperidin-1-yl),

cyano, -$NHCH_3$, -$CH(CH_3)NHCH_2CH_2N(CH_3)_2$, -$C(O)CH_3$, -$S(O)_2NHCH_2CH_2N(CH_3)_2$, -$S(O)_2NH(CH_2)_3N(CH_3)_2$, 5-(*N,N*-dimethylaminomethyl)-1,3,4-oxadiazol-2-yl, -$NHCH_2CH_2N(CH_3)_2$, -$N(CH_3)_2$, -$OCH_2CH_2N(CH_3)_2$, -$NHC[N(CH_3)_2][=N(CH_3)_2]$, -$OCHF_2$, -$S(O)_2CH_3$, -$OCF_3$, or -$NHC(O)CH_2$(4-dimethylaminopiperidin-1-yl).

**[00202]** In another embodiment (L), the compound of Formula I or Ia is that where $R^{3a}$ is hydroxyamino, -$N(R^7)C(O)$-$C_1$-$C_6$-alkylene-$N(R^{7a})(R^{7b})$, -$C(O)NR^8R^{8a}$, -$NR^9C(O)R^{9a}$, -$C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$, -$NR^{11}C(O)NR^{11a}R^{11b}$, -$N(R^{22})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, -$NR^{13}C(O)OR^{13a}$, -$N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$, -$NR^{24}C(O)$-$C_1$.$C_6$-alkylene-$OR^{24a}$, or -$N(R^{20})C(O)$-$C_1$-$C_6$-alkylene-$C(O)R^{20a}$; where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{3a}$ is -$NHC(O)CH_2NH(CH_3)$, -$NHC(O)CH(CH_3)NH_2$, -$NHC(O)C(CH_3)_2NH_2$, -$NHC(O)CH_2N(CH_3)_2$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -$NHC(O)CH(NH_2)CH_2CH_3$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -$NHC(O)CH(CH_3)NH(CH_3)$, -NHC(O)H, -$NHC(O)CH_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), -$NHC(O)CH(NH_2)CH_2OH$, -NHC(O)(azetidin-4-yl), -$NHC(O)C(CH_3)_2NH(CH_3)$, -$NH_2$, -$NHC(O)CH_2NH(CH_2CH_2CH_3)$, -$NHC(O)CH_2CH_2NH_2$, -NHOH, or -NHC(O)(piperidin-3-yl).

**[00203]** In another embodiment (M) the compound is of Formula I or Ia and $R^{3a}$ -$N(R^7)C(O)$-$C_1$-$C_6$-alkylene-$N(R^{7a})(R^{7b})$; and $R^7$ is hydrogen or alkyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{3a}$ is -$NHC(O)CH_2NH(CH_3)$, -$NHC(O)CH(CH_3)NH_2$, -$NHC(O)C(CH_3)_2NH_2$, -$NHC(O)CH_2N(CH_3)_2$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -$NHC(O)CH(NH_2)CH_2CH_3$, -$NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, or -$NHC(O)CH(CH_3)NH(CH_3)$.

**[00204]** Embodiment (N) provides a compound of Formula I where each $R^3$ is independently halo; cyano; alkyl; alkenyl; alkoxy; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -$N(R^7)C(O)$-$C_1$-$C_6$-alkylene-$N(R^{7a})(R^{7b})$; -$C(O)NR^8R^{8a}$; -$NR^9C(O)R^{9a}$; -$C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$; -$NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$; -$C(O)R^{12}$; -$NR^{13}C(O)OR^{13a}$; -$C(O)N(R^{14})N(R^{14a})(R^{14b})$; -$S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$; -$C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; -$N(R^{17})$-$C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; -$N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$; -$C(O)N(R^{19})$-$C_1$-$C_6$-alkylene-$C(O)R^{19a}$; -$N(R^{22})C(O)$-

$C_1$-$C_6$-alkylene-N($R^{22b}$)-N($R^{22c}$)($R^{22a}$); -$C_0$-$C_6$-alkylene-N($R^{23}$)-$C_1$-$C_6$-alkylene-N($R^{23b}$)$R^{23a}$; or -$NR^{24}C(O)$-$C_1$.$C_6$-alkylene-$OR^{24a}$; where each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and all other groups are as defined in the Summary of the Invention.

**[00205]** In another embodiment, each $R^3$ is independently methyl, bromo, chloro, fluoro, -NHC(O)$CH_2NH(CH_3)$, -NHC(O)$CH_2NH(CH_2CH_3)$, -NHC(O)$CH(CH_3)NH_2$, -NHC(O)$C(CH_3)_2NH_2$, -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH(NH_2)CH_2CH_3$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH(CH_3)NH(CH_3)$, -NHC(O)$CH_2NH_2$, -NHC(O)H, -NHC(O)$CH_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), -NHC(O)$CH(NH_2)CH_2OH$, -NHC(O)(azetidin-4-yl), -NHC(O)$C(CH_3)_2NH(CH_3)$, $-NH_2$, -NHC(O)$CH_2NH(CH_2CH_2CH_3)$, -NHC(O)$CH_2CH_2NH_2$, -NHOH, -NHC(O)(piperidin-3-yl), -NHC(O)$CH_2$(4-methyl-1,4-diazepan-1-yl), -NHC(O)$CH(NH_2)(CH_2CH_3)$, -NHC(O)$CH_2NH(CH_2CH(OH)(CH_3))$, -NHC(O)$CH_2NHCH_2CH_2F$, -NHC(O)$CH_2NH(OCH_2CH(CH_3)_2)$, -NHC(O)(1-aminocycloprop-1-yl), -NHC(O)$CH_2NH(CH_2$cyclopropyl), -NHC(O)$CH_2$(3-(dimethylamino)-azetidin-1-yl), -NHC(O)(piperidin-2-yl), -NHC(O)(morpholin-4-yl), -NHC(O)$CH_2$(pyrrolidin-1-yl), -NHC(O)$CH(NH_2)CH_2CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)$CH_2$(imidazol-5-yl), -NHC(O)(1-aminocyclopent-1-yl), -NHC(O)$CH_2NH(CH_2CH(CH_3)_2)$, -NHC(O)$CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)(*N*-(imidazol-4-ylmethyl)-azetidin-3-yl), -NHC(O)(*N*-ethyl-azetidin-3-yl), -NHC$H_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)$(*N*-methyl-pyrrolidin-3-yl), -NHC(O)$CH_2N(CH_3)(CH_2CH_2N(CH_3)_2)$, -NHC(O)$CH_2$(3-hydroxy-pyrrolidin-1-yl), -NHC(O)(1-amino-cyclobut-1-yl), -NHC(O)$CH_2NH(CH_2)_3CH_3$, -NHC(O)$CH_2$(3-piperidin-1-ylazetidin-1yl), -NHC(O)$NH_2$, -NHC(O)(1-hydroxycyclopropyl), -NHC(O)$CH_2NHN(CH_3)_2$, -NHC(O)$NH(CH_2)_2N(CH_3)_2$, -NHC(O)$CH_2$OH, -NHC(O)(pyridazin-4-yl), -NHC(O)(N-methyl-piperidin-4-yl), -NHC(O)$CH_2NHCH(CH_3)_3$, -NHC(O)$CH_2$(3-dimethylamino-pyrrolidin-1yl), -NHC(O)$CH_2NH(CH_2)_2N(CH_3)_2$, -NHC(O)(1-cyclopropylmethyl-azetidin-3-yl), -NHC(O)$CH_2NH(CH_3)_3$, -NHC(O)(imidazol-2-yl), -NHC(O)(imidazol-4-yl), -NHC(O)(1,2-oxazol-5-yl), -NHC(O)$CH_2NHCH_2CF_3$, -NHC(O)$CH_2CH_2$(piperidin-1-yl), -NHC(O)(3-oxo-cyclopent-1-yl), -NHC(O)(2-hydroxy-pyridin-6-yl), -NHC(O)$CH_2NH$(3-fluoro-4-hydroxyphenyl), -NHC(O)$(CH_2)_3N(CH_3)_2$, -NHC(O)(1-(furan-2-ylmethyl)-azetidin-3-yl), -NHC(O)(pyrimidin-5-yl), -NHC(O)(pyrrol-2-yl), -NHC(O)$CH_2N(CH_3)CH(CH_3)_2$,

-NHC(O)$CH_2N(CH_2CH_3)_2$, -NHC(O)$CH_2$(3-methyl-1,2-oxazol-5-yl), -NHC(O)$CH_2NHCH_2$(3-hydroxyphenyl), -NHC(O)(*N*-methyl-pyrrol-2-yl), -NHC(O)(2-amino-tetrahydropyran-2-yl), -NHC(O)$CH_2$(4-methylamino-piperidin-1-yl), -NHC(O)(piperidin-1-yl), -NHC(O)(*N*-methyl-pyrrolidin-2yl), -NHC(O)(thien-3yl), -NHC(O)(*N*-(cyclopropylcarbonyl)azetidin-3-yl), -NHC(O)$CH_2$(4-methylpiperazin-1-yl), -NHC(O)(*N*-benzylazetidin-3-yl), -NHC(O)(2-chloro-pyridin-3-yl), -NHC(O)$CH_2$(pyridin-4-yl), -NHC(O)$CH_2N(CH_3)(CH_2CH{=}CH_2)$, -NHC(O)$CH_2$NH(benzyl), -NHC(O)$CH_2OCH_3$, -NHC(O)[1-(C(O)$CH_2CH_3$)-azetidin-3-yl], -NHC(O)(pyridin-3-yl), -NHC(O)$CH_2NHCH_2CH_2OCH_3$, -NHC(O)(1-[C(O)$CH_3$]piperidin-4-yl), -NHC(O)$CH_2$(2-methyl-pyrrolidin-1-yl), -NHC(O)(furan-3-yl), -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)(2-chloro-pyridin-5-yl), -NHC(O)(2-chlorophenyl), -NHC(O)$CH_2$(pyridin-2-yl), -NHC(O)$CH_2$(3-dimethylamino-azetidin-1-yl), -NHC(O)$CH_2$(pyridin-3-yl), -NHC(O)$CH_2$(2-chlorophenyl), -NHC(O)$CH_2N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)CH_2CH_2OH$, -NHC(O)$CH_2$(2-benzyl-pyrrolidin-1-yl), -NHC(O)(furan-2-yl, -NHC(O)(2-chloro-pyridin-4-yl), -NHC(O)$CH_2NHC(O)CH_3$, -NHC(O)$CH_2CH_2CH_3$, -NHC(O)(4-chlorophenyl), -NHC(O)(4-methyl-phenyl), -NHC(O)$CH_2NHC(O)O(CH_3)_3$, -NHC(O)(benzo[d][1,3]dioxol-5-yl), -NHC(O)$CH_2NHOCH_2$(2-methoxyphenyl), -NHC(O)(pyridin-4-yl), -NHC(O)$CH_2$[4-(3,4-dichlorophenyl)-piperazin-1-yl], -NHC(O)$CH_2CH_2$(pyridin-3-yl), -NHC(O)(tetrahydrofuran-3-yl), -NHC(O)$CH_2NHCH_2$(2-methylphenyl), -NHC(O)$CH(CH_3)CH_2CH_3$, -NHC(O)$CH_2$(3-fluorophenyl), -NHC(O)$CH_2C(CH_3)_2$phenyl, -NHC(O)(2-methyl-cycloprop-1-yl), -NHC(O)(2-methyl-4-methoxyphenyl), -NHC(O)(2-methylpyridin-3-yl), -NHC(O)(4-methoxyphenyl), -NHC(O)$CH_2$(4-ethylpiperazin-1-yl), -NHC(O)(thien-2-yl), -NHC(O)(3-fluoro-2-methylphenyl), -NHC(O)(2-bromo-thien-3-yl), -NHC(O)(4-fluorophenyl), -NHC(O)$CH_2$(3-methylpiperidin-1-yl), -NHC(O)$CH(CH_3)_2$, -NHC(O)$(CH_2)_3CH_3$, -NHC(O)$CH_2OCH_2CH_3$, -NHC(O)$CH_2$NH(2-fluorophenyl), -NHC(O)(3-dimethylaminophenyl), -NHC(O)$CH_2$(4-methylpiperidin-1-yl), -NHC(O)$CH_2$NH(2-*n*-propylphenyl), -NHC(O)phenyl, -NHC(O)(pyrazin2-yl), -NHC(O)(3-fluoro-4-methoxyphenyl), -NHC(O)$C(CH_3)_2CH_2CH_3$, -NHC(O)$CH_2$O(4-fluorophenyl), -NHC(O)(1-methylcarbonyl-azetidin-3-yl), -NHC(O)$CH_2$NH(4-methylphenyl), -NHC(O)$CH_2$NH(phenyl), -NHC(O)$CH_2$(4-allyl-piperazin-1-yl), -NHC(O)(2-methylphenyl), -NHC(O)$CH_2CH_2OCH_3$, -NHC(O)(3-methyl-furan-2-yl), -NHC(O)$C(CH_3)_3$, -NHC(O)$CH_2$NHObenzyl, -NHC(O)$CH_2$NH(3-chlorophenyl),

-NHC(O)cyclobutyl, -NHC(O)$CH_2$(3-methoxyphenyl), -NHC(O)(1-methylcycloprop-1-yl), -NHC(O)(3-flurophenyl), -NHC(O)(4-dimethylaminophenyl), -NHC(O)(3,4-dichlorophenyl), -NHC(O)$CH_2NHCH_2$(2-methylthiophenyl), -NHC(O)$CH_2$(2-fluorophenyl), -NHC(O)$CH_2N(CH_2CH_3)CH(CH_3)_2$, -NHC(O)(thiazol-4-yl), -NHC(O)$CH_2N(CH_3)$benzyl, -NHC(O)$CH_2NHCH_2$(thien-2-yl), -NHC(O)$CH_2NHCH_2$(pyridin-2-yl), -NHC(O)(3-methoxyphenyl), -NHC(O)$CH_2NHCH_2$(3-chloro-4-methylphenyl), -NHC(O)$CH(CH_3)CH_2CH_2CH_3$, -NHC(O)$CH_2$(4-chlorophenyl), -NHC(O)(3-fluoro-4-methylphenyl), -NHC(O)$CH_2O$(2-methylphenyl), -NHC(O)$CH_2$(cyclohexyl), -NHC(O)(2-phenyl-cycloprop-1-yl), -NHC(O)(3-chlorophenyl), -NHC(O)$CH_2$(2-methoxyphenyl), -NHC(O)$CH_2CH_2$(3-methoxyphenyl), -NHC(O)$CH_2NH$(2-fluoro-4-methyl-phenyl), -NHC(O)$CH_2NHCH_2$(3-fluoro-phenyl), -NHC(O)$CH_2$(4-methoxy-phenyl), -NHC(O)benzyl, -NHC(O)(2,4-dichlorophenyl), -NHC(O)(3-oxo-cyclohex-1-yl), -NHC(O)$CH_2NH$(3-fluorophenyl), -NHC(O)$CH_2$(3-chlorophenyl), -NHC(O)$CH_2NHCH_2CH(CH_3)$phenyl, -NHC(O)$CH_2NHCH_2$(2,4-dimethylphenyl), -NHC(O)$CH_2$(2-methyl-piperidin-1-yl), -NHC(O)$CH_2NH$(2-methoxyphenyl), -NHC(O)$CH_2$(1,2,3,4-tetrahydroisoquinolin-2-yl), -NHC(O)$CH_2CH_2CH{=}CH_2$, -NHC(O)$CH_2NH$(2-methylphenyl), -NHC(O)$CH_2$(4-oxo-piperidin-1-yl), -NHC(O)(2-fluorophenyl), -NHC(O)$CH_2NHCH(CH_3)$phenyl, -NHC(O)(2-fluoro-6-methoxyphenyl), -NHC(O)$CH_2NH$(2-isopropylphenyl), -NHC(O)$CH_2CH_2$(2-methoxyphenyl), -NHC(O)$CH_2CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(2-phenyl-morpholin-4-yl), -NHC(O)$CH_2CH_2$(4-methoxyphenyl), -NHC(O)$CH_2N$(allyl)cyclopentyl, -NHC(O)$CH_2N(CH_3)CH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2C$(O)cyclopropyl, -NHC(O)$CH_2NH$(3-*tert*-butylphenyl), -NHC(O)$CH_2N$(*n*-propyl)(cyclopropylmethyl), -NHC(O)$CH_2$(2-oxo-cyclopentyl), -NHC(O)$CH_2NH$(4-chlorophenyl), -NHC(O)$CH_2$(4-piperidin-1-ylpiperidin-1-yl), -NHC(O)$CH_2$(4-cyclopentylpiperazin-1-yl), -NHC(O)$CH_2$(2-methylphenyl), -NHC(O)$CH_2NHCH_2$(3-fluoro-6-methylphenyl), -NHC(O)$CH_2C(CH_3)_3$, -NHC(O)$CH_2NH$(2-chlorophenyl), -NHC(O)(3-fluoro-6-methylphenyl), -NHC(O)(4-fluoro-3-methylphenyl), -NHC(O)(2,3-dichlorophenyl), -NHC(O)$CH_2O$phenyl, -NHC(O)$CH_2NH$(2,3-dimethylphenyl), -NHC(O)(2-fluoro-5-methylphenyl), -NHC(O)$CH_2NHOCH_2$(4-methylphenyl), -NHC(O)$CH_2$(4-isopropylpiperazin-1-yl), -NHC(O)$CH_2$(4-fluorophenyl), -NHC(O)$CH_2CH(CH_3)_2$, -NHC(O)(2-methoxy-4-methylphenyl), -NHC(O)$CH_2$(4-*n*-propylpiperidin-1-yl), -NHC(O)$CH_2O$(3-methylphenyl), -NHC(O)(tetrahydrofuran-2-yl), -NHC(O)$CH_2$(3-hydroxymethylpiperidin-1-yl), -NHC(O)(1-*tert*-butoxycarbonylpiperidin-2-

yl), -NHC(O)$CH_2N(CH_3)CH_2$(pyridin-3-yl), -NHC(O)$CH_2N(CH_2CH_3)$phenyl, -NHC(O)$CH_2OCH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2$(cyclopentyl), -NHC(O)(2,5-dichlorophenyl), -NHC(O)$CH_2$(4-methylcarbonylpiperazin-1-yl), -NHC(O)(5-fluoro-2-methoxyphenyl), -NHC(O)$CH_2N(CH_2CH_3)$cyclohexyl, -NHC(O)(5-methyl-1,2-oxazol-3-yl), -NHC(O)(3-methylpyridin-3-yl), -NHC(O)(2-methoxypyridin-3-yl), -NHC(O)(3,5-dichlorophenyl), -NHC(O)$CH_2$(thiazolidin3-yl), -NHC(O)$CH_2$(4-[C(O)H]-piperazin-1-yl), -NHC(O)$CH_2$(2-pyridin-4-ylpiperidin-1-yl), -NHC(O)(2-methoxyphenyl), -NHC(O)$CH_2N(CH_3)CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(4-[C(O)H]-homopiperazin-1-yl), -NHC(O)(1-phenylcycloprop-1-yl), -NHC(O)$CH_2$(2,6-dimethylmorpholin-4-yl), NHC(O)$CH_2$(2-phenylpyrrolidin-1-yl), -NHC(O)$CH_2$(morpholin-4-yl), -C(O)NHCH$(CH_3)CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2N(CH_3)_2$, -C(O)NH(pyrrolidin-3-yl), -C(O)$NHCH_2CH_2$(pyrrolidin-1-yl), -C(O)$NHCH_2CH_2NH_2$, -C(O)$N(CH_3)CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2$(piperidin-2-yl), -C(O)NH(1-methylazetidin-3-yl), -C(O)$NHCH_2CH_2$(piperidin-1-yl), -C(O)$NHCH_2CH_2N(CH_2CH_3)_2$, -C(O)NH(1-methylpiperidin-3-yl), -C(O)NH(piperidin-3-yl), -C(O)$NHCH_2$(1-methylpiperidin-3-yl), -C(O)$NHCH_2CH_2N(CH_2CH_2OH)_2$, -C(O)NH(1-ethylpiperidin-3-yl), -C(O)$NH_2$, -C(O)(3-aminopyrrolidin-1-yl), -C(O)(3-methylaminopyrrolidin-1-yl), -C(O)OH, -C(O)$NHCH_2CH_2$(morpholin-4-yl), -C(O)$NHCH_2$(1-ethylpyrrolidin-2-yl), -C(O)(4-amino-3-oxo-pyrazolidin-1-yl), -C(O)$NHCH_3$, -C(O)(3-aminocyclobut-1-yl), -C(O)$NHCH_2$(pyridin-3-yl), -C(O)$NHCH_2CH_2OH$, -C(O)NH(3-oxo-pyrazolidin-4-yl), -$NHCH_2CH_2$(imidazol-4-yl), -C(O)(3-dimethylaminopyrrolidin-1-yl), -C(O)$NHCH_2$(pyridin-4-yl), -C(O)$N(CH_3)$(1-methyl-pyrrolidin-3-yl), -C(O)(3-diethylaminopyrrolidin-1-yl), -C(O)NH(pyrrol-1-yl), -C(O)$NHCH_2CH_2CH_2$(pyrrolidin-1-yl), -C(O)$N(CH_3)CH_2CH_2CN$, -C(O)$NHCH_2CH_2OCH_3$, -C(O)$N(CH_2CH_3)CH_2CH_2CN$, -C(O)(3-aminopiperidin-1-yl), -C(O)$NHCH_2CH_2CH_2N(CH_3)_2$, -C(O)NH(morpholin-4-yl), -C(O)$NHN(CH_3)_2$, -C(O)$NHCH_2CH_2CH_2$(imidazol-1-yl), -C(O)$NHCH_2CH_2CH_2N(CH_2CH_3)_2$, -C(O)$NHCH_2CH_2CN$, -C(O)$NHCH_2CH_2C(O)OCH_3$, -C(O)$NHCH_2CH_2SCH_3$, -C(O)$NHCH_2CH_2SCH_2CH_3$, -C(O)$N(CH_2CH_3)CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2CH_2$(2-oxo-pyrrolidin-1-yl), -C(O)$NHCH_2CH_2$(pyridin-4-yl), -C(O)$NHCH_2CH_2CH_2OCH_2CH_3$, -C(O)$NHCH_2CH_2CH_2$(morpholin-4-yl), -C(O)$NHCH_2CH_2CH_2OCH_3$, -C(O)$N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2CH_2OCH_2CH_2CH_3$, -C(O)$NHCH_2CH_2C(O)OCH_2CH_3$, -C(O)$NHCH_2CH_2CH_2OCH(CH_3)_2$, -C(O)$NHC(CH_3)_2CH_2$(piperidin-1-yl), -C(O)$N(CH_3)CH_2CH_2CH_3$, -C(O)NH(piperidin-1-yl), -C(O)NHCH$(CH_3)CH_2OCH_3$, -C(O)$NHC(CH_3)_2CH_2$(morpholin-4-yl), -C(O)(2-

dimethylaminomethylpiperidin-1-yl), -C(O)NH$(CH_2)_3O(CH_2)_3CH_3$, -C(O)NHCH$(CH_3)(CH_2)_3N(CH_2CH_3)_2$, -C(O)NHC$(CH_3)_2$C(O)(piperidin-1-yl), -C(O)(4-methylpiperazin-1-yl), -C(O)(2-piperidin-1-ylmethyl-piperidin-1-yl), cyano, -NHCH$_3$, -CH$(CH_3)$NHCH$_2$CH$_2$N$(CH_3)_2$, -C(O)CH$_3$, -S(O)$_2$NHCH$_2$CH$_2$N$(CH_3)_2$, -S(O)$_2$NH$(CH_2)_3$N$(CH_3)_2$, 5-(*N,N*-dimethylaminomethyl)-1,3,4-oxadiazol-2-yl, -NHCH$_2$CH$_2$N$(CH_3)_2$, -N$(CH_3)_2$, -OCH$_2$CH$_2$N$(CH_3)_2$, -NHC[N$(CH_3)_2$][=N$(CH_3)_2$], -OCH$F_2$, -$CF_3$, -S(O)$_2$CH$_3$, -$OCF_3$, -NHC(O)CH$_2$(4-dimethylaminopiperidin-1-yl), or methoxy.

**[00206]** In another embodiment (P), the Compound of Formula I is that where each $R^3$ is independently halo, alkyl, hydroxyamino, -N($R^7$)C(O)-$C_1$-$C_6$-alkylene-N($R^{7a}$)($R^{7b}$), -C(O)N$R^8R^{8a}$ , -N$R^9$C(O)$R^{9a}$, -C(O)N($R^{10}$)-$C_1$-$C_6$-alkylene-N($R^{10a}$)$R^{10b}$-N$R^{11}$C(O)N$R^{11a}R^{11b}$, -N($R^{22}$)C(O)-$C_1$-$C_6$-alkylene-N($R^{22b}$)-N($R^{22c}$)($R^{22a}$), -N$R^{13}$C(O)O$R^{13a}$, -N($R^{18}$)C(O)-$C_1$-$C_6$-alkylene-N($R^{18b}$)C(O)$R^{18a}$ , -N$R^{24}$C(O)-$C_1$.$C_6$-alkylene-O$R^{24a}$, or -N($R^{20}$)C(O)-$C_1$-$C_6$-alkylene-C(O)$R^{20a}$; where each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. In another embodiment, each $R^3$ is independently methyl, chloro, -NHC(O)CH$_2$NH(CH$_3$), -NHC(O)CH(CH$_3$)NH$_2$, -NHC(O)C(CH$_3$)$_2$NH$_2$, -NHC(O)CH$_2$N(CH$_3$)$_2$, -NHC(O)CH$_2$N(CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, -NHC(O)CH(NH$_2$)CH$_2$CH$_3$, -NHC(O)CH$_2$N(CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, -NHC(O)CH(CH$_3$)NH(CH$_3$), -NHC(O)H, -NHC(O)CH$_2$(azetidin-1-yl), -NHC(O)(pyrrolidin-2-yl), -NHC(O)CH(NH$_2$)CH$_2$OH, -NHC(O)(azetidin-4-yl), -NHC(O)C(CH$_3$)$_2$NH(CH$_3$), -NH$_2$, -NHC(O)CH$_2$NH(CH$_2$CH$_2$CH$_3$), -NHC(O)CH$_2$CH$_2$NH$_2$, -NHOH, or -NHC(O)(piperidin-3-yl).

**[00207]** In another embodiment (Q), the Compound of Formula I is that where $R^3$ is alkyl or -N($R^7$)C(O)-$C_1$-$C_6$-alkylene-N($R^{7a}$)($R^{7b}$); and $R^7$ is hydrogen or alkyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; and all other groups are as defined in the Summary of the Invention. In another embodiment, each $R^3$ is independently methyl, -NHC(O)CH$_2$NH(CH$_3$), -NHC(O)CH(CH$_3$)NH$_2$, -NHC(O)C(CH$_3$)$_2$NH$_2$, -NHC(O)CH$_2$N(CH$_3$)$_2$, -NHC(O)CH$_2$N(CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, -NHC(O)CH(NH$_2$)CH$_2$CH$_3$, -NHC(O)CH$_2$N(CH$_3$)CH$_2$CH$_2$N(CH$_3$)$_2$, or -NHC(O)CH(CH$_3$)NH(CH$_3$).


**[00208]** In another embodiment (R), the Compound of Formula I is that where B is phenyl, $R^3$ is not present or $R^3$ is halo, alkyl, or alkoxy; $R^{3a}$ is -C(O)N$R^8R^{8a}$, -N$R^9$C(O)$R^{9a}$, -N($R^7$)C(O)-$C_1$-$C_6$-alkylene-N($R^{7a}$)($R^{7b}$), or -C(O)N($R^{10}$)-$C_1$-$C_6$-alkylene-N($R^{10a}$)$R^{10b}$ where each of the alkylene in $R^{3a}$ is independently optionally further

substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention.

**[00209]** In another embodiment (R1) of embodiment R, the compound is that where $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is halo or alkoxy; $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is alkoxy; or $R^{50}$ and $R^{52}$ are hydrogen and $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is halo or alkoxy; or $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is alkoxy.

**[00210]** In another embodiment of (R2) of embodiment R, the compound is that where $R^{51}$ is methyl.

**[00211]** In another embodiment (S), the compound of Formula Ia:



**I(a)**

is that where $R^3$ is not present or $R^3$ is alkyl and $R^{3a}$ is $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^3$ is is not present or is methyl. In another embodiment, $R^3$ is is not present.

**[00212]** In another embodiment (S1) of embodiment S is that where $R^7$ is hydrogen or alkyl and $R^{7a}$, and $R^{7b}$ are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; $R^8$ is hydrogen or alkyl and $R^{8a}$ is heterocycloalkyl or heterocycloalkylalkyl; $R^9$ is hydrogen or alkyl and $R^{9a}$ is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; and $R^{10}$, $R^{10a}$, and $R^{10b}$ are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl.

**[00213]** In another embodiment (S2) of embodiment S is that where $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is halo or alkoxy; or $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is alkoxy; or $R^{50}$ and $R^{52}$ are hydrogen and $R^{53}$ and $R^{54}$ together with the carbons to which they are


attached form a 6-membered heteroaryl. In another embodiment, $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is halo or alkoxy; or $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is alkoxy.

**[00214]** In another embodiment of (S3) of embodiment S, the compound is that where $R^{51}$ is methyl.

**[00215]** In another embodiment (T), the Compound of Formula I is that where B is heteroaryl, one $R^3$ is halo, alkyl, or alkoxy and a second $R^3$ is $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$ where each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the Summary of the Invention.

**[00216]** In another embodiment (T1) of embodiment T, the compound is that where $R^7$ is hydrogen or alkyl and $R^{7a}$, and $R^{7b}$ are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; $R^8$ is hydrogen or alkyl and $R^{8a}$ is heterocycloalkyl or heterocycloalkylalkyl; $R^9$ is hydrogen or alkyl and $R^{9a}$ is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; $R^{10}$, $R^{10a}$, and $R^{10b}$ are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl.

**[00217]** In another embodiment U, the compound of Formula I is that where B is



; each $R^3$ (when $R^3$ is present) is independently halo, alkyl, alkoxy, aminoalkyloxy, alkylaminoalkyloxy, dialkylaminoalkyloxy, alkylamino, dialkylamino, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; and all other groups are as defined in the Summary of the Invention.

**[00218]** In another embodiment (U1) of embodiment U, the compound of Formula I is that where $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is halo or alkoxy; $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is alkoxy; or $R^{50}$ and $R^{52}$ are hydrogen and $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 6-membered heteroaryl; and all other groups are as defined in the Summary of the Invention. In another embodiment, $R^{50}$, $R^{52}$, and $R^{53}$ are hydrogen and $R^{54}$ is halo or alkoxy; or $R^{50}$, $R^{52}$, and $R^{54}$ are hydrogen and $R^{53}$ is alkoxy.

**[00219]** In another embodiment (U2) of embodiment U1, the compound of Formula I is that where $R^{51}$ is methyl.

**[00220]** In another embodiment (U3) of embodiment U, the Compound of Formula I is that where $R^7$ is hydrogen or alkyl and $R^{7a}$, and $R^{7b}$ are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; $R^8$ is hydrogen or alkyl and $R^{8a}$ is heterocycloalkyl or heterocycloalkylalkyl; $R^9$ is hydrogen or alkyl and $R^{9a}$ is hydrogen, heterocycloalkyl, or heterocycloalkylalkyl; $R^{10}$, $R^{10a}$, and $R^{10b}$ are independently hydrogen, alkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl

**[00221]** In another embodiment of the Invention (V) the Compound of Formula I is that where$W^1$, $W^2$, $W^3$, and $W^4$ are -C(H)=; or $W^2$ and $W^3$ are -C(H)= and one of $W^1$ and $W^4$ is -N= and the other is -C(H)=;

$R^{50}$ is hydrogen;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen;

$R^{53}$ is hydrogen, alkoxy, nitro, amino, or -$N(R^{55})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{55a})R^{55b}$; and $R^{54}$ is hydrogen, alkyl, alkoxy, or halo; or $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 6-membered heteroaryl;

B is phenyl substituted with $R^{3a}$ and optionally further substituted with one $R^3$; or

B is heteroaryl optionally substituted with one or two $R^3$;

$R^{3a}$ is cyano; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -$N(R^7)C(O)$-$C_1$-$C_6$-alkylene-$N(R^{7a})(R^{7b})$; -$C(O)NR^8R^{8a}$; -$NR^9C(O)R^{9a}$; -$C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$; -$NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$; -$C(O)R^{12}$; -$NR^{13}C(O)OR^{13a}$; -$C(O)N(R^{14})N(R^{14a})(R^{14b})$; -$S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$; -$C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; -$N(R^{17})$-$C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; -$N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$; -$C(O)N(R^{19})$-$C_1$-$C_6$-alkylene-$C(O)R^{19a}$; -$N(R^{22})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$; -$C_0$-$C_6$-alkylene-$N(R^{23})$-$C_1$-$C_6$-alkylene-$N(R^{23b})R^{23a}$; or -$NR^{24}C(O)$-$C_1$-$C_6$-alkylene-$OR^{24a}$; where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino;

each $R^3$ (when $R^3$ is present) is independently halo; cyano; alkyl; alkenyl; alkoxy; hydroxyamino; carboxy; alkylsulfonyl, aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; -$N(R^7)C(O)$-$C_1$-$C_6$-alkylene-$N(R^{7a})(R^{7b})$; -$C(O)NR^8R^{8a}$; -$NR^9C(O)R^{9a}$; -$C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-

$N(R^{10a})R^{10b}$; $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$; $-C(O)R^{12}$; $-NR^{13}C(O)OR^{13a}$; $-C(O)N(R^{14})N(R^{14a})(R^{14b})$; $-S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$; $-C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$; heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; $-N(R^{17})$-$C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; $-N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$; $-C(O)N(R^{19})$-$C_1$-$C_6$-alkylene-$C(O)R^{19a}$; $-N(R^{22})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$; $-C_0$-$C_6$-alkylene-$N(R^{23})$-$C_1$-$C_6$-alkylene-$N(R^{23b})R^{23a}$; or $-NR^{24}C(O)$-$C_1$-$C_6$-alkylene-$OR^{24a}$; where each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino;

provided that when $R^{50}$ and $R^{52}$ are hydrogen, $R^{51}$ is hydrogen or methyl, $R^{53}$ is hydrogen or methoxy, and $R^{54}$ is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one $R^3$ where $R^3$ is halo.

**[00222]** Another embodiment (W) of the invention is a Compound of Formula I where $R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl.

**[00223]** Another embodiment (X) of the invention is a Compound of Formula I where $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl.








## Representative Compounds








**[00224]** Representative compounds of Formula I and/or II are depicted below. The examples are merely illustrative and do not limit the scope of the invention in any way. Compounds of the invention are named according to systematic application of the nomenclature rules agreed upon by the International Union of Pure and Applied Chemistry (IUPAC), International Union of Biochemistry and Molecular Biology (IUBMB), and the Chemical Abstracts Service (CAS). Names in Table 1 were generated using ACD/Labs naming software 8.00 release, product version 8.08 with the exception of Compound 374 which was named using ChemDraw v. 9.0.1.









**Table 1**








**Representative PI3K-alpha Inhibitors**






**[00225]** The Compounds in Table 1 can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 1 can be used to practice the invention. In particular, the invention can be practiced with one or two pharmaceutically acceptable salts of a Compound of Table 1 which salt(s) are formed with one or two acids independently selected from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid. In particular, the invention can be practiced with one or two pharmaceutically acceptable salts of a Compound of Table 1 which salt(s) are formed with one or two bases independently selected from sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, *N*-ethylpiperidine, tromethamine, and *N*-methylglucamine. Any individual compound (and any optional salt, optional solvate, and optional hydrate thereof) in Table 1 can be used in combination with any of the above embodiments.

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 1 |  | *N*-(4-{[(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl) amino]sulfonyl}phenyl) acetamide |
| 2 |  | 4-bromo-*N*-[3-(phenylamino)quinoxalin-2-yl] benzene sulfonamide |
| 3 |  | 4-bromo-*N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzene sulfonamide |
| 4 |  | 4-bromo-*N*-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl) benzene sulfonamide |
| 5 |  | 4-chloro-*N*-{3-[(4-chlorophenyl)amino]-6-(methoxy)quinoxalin-2-yl}benzenesulfonamide |
| 6 |  | *N*-(4-{[3-{[(4-chlorophenyl)sulfonyl]amino}-7-(methoxy)quinoxalin-2-yl]amino} phenyl) acetamide |
| 7 |  | 4-chloro-*N*-{6-(methoxy)-3-[(2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 8 |  | *N*-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl) amino]phenyl}acetamide |
| 9 |  | *N*-(3-{[4-(ethyloxy) phenyl]amino}quinoxalin-2-yl)-4-methylbenzene sulfonamide |
| 10 |  | *N*-{3-[(3,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzene sulfonamide |
| 11 |  | *N*-(3-{[3-(dimethylamino)phenyl]amino}quinoxalin-2-yl)-4-methylbenzene sulfonamide |
| 12 |  | 4-methyl-*N*-{6-methyl-3-[(4-methylphenyl)amino]quinoxalin-2-yl} benzene sulfonamide |
| 13 |  | *N*-{3-[(4-hydroxyphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzene sulfonamide |
| 14 |  | *N*-{3-[(2,5-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 15 |  | 4-chloro-*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 16 |  | *N*-{3-[(3-aminophenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide |
| 17 |  | *N*-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 18 |  | 4-chloro-*N*-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 19 |  | 4-chloro-*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 20 |  | 4-chloro-*N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 21 |  | methyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino} quinoxalin-2-yl)amino]benzoate |
| 22 |  | methyl 2-chloro-5-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 23 |  | *N*-{4-[(7-methyl-3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide |
| 24 |  | 4-methyl-*N*-(6-methyl-3-{[2-(methoxy)phenyl]amino} quinoxalin-2-yl)benzenesulfonamide |
| 25 |  | *N*-{3-[(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 26 |  | 4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid |
| 27 |  | 3-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzenesulfonamide |
| 28 |  | *N*-{3-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1*H*-pyrazol-4-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 29 |  | *N*-{3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |

| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 30 |  | *N*-{3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 31 |  | *N*-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide |
| 32 |  | 3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 33 |  | *N*-[4-({[3-(phenylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |
| 34 |  | *N*-(4-{[(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |




































| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 35 |  | *N*-[4-({[3-(naphthalen-1-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |
| 36 |  | *N*-{4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide |
| 37 |  | *N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide |
| 38 |  | *N*-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 39 |  | 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid |
| 40 |  | *N*-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 41 |  | 3-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 42 |  | *N*-(3-{[4-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide |









Table 1







| Cpd. No. | Structure | Name |
|---|---|---|
| 43 |  | *N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide |
| 44 |  | *N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]-4-nitrobenzenesulfonamide |
| 45 |  | *N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 46 |  | *N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 47 |  | 3-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 48 |  | 4-nitro-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide |
| 49 |  | 4-chloro-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide |
| 50 |  | 3-nitro-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 51 |  | 4-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 52 |  | *N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide |
| 53 |  | 4-methyl-*N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 54 |  | *N*-(3-{[3-chloro-4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 55 |  | *N*-{3-[(3-chloro-4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 56 |  | methyl 2-chloro-5-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoate |
| 57 |  | 4-chloro-*N*-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 58 |  | 4-methyl-*N*-[6-methyl-3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide |
| 59 |  | *N*-{4-[({3-[(4-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 60 |  | 1-methylethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate |
| 61 |  | *N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 62 |  | *N*-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 63 |  | *N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 64 |  | 4-methyl-*N*-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 65 |  | 4-methyl-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 66 |  | *N*-{4-[({3-[(4-chlorophenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 67 |  | *N*-(4-{[(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 68 |  | 4-methyl-*N*-{3-[(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 69 |  | 4-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 70 |  | 4-bromo-*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 71 |  | 4-bromo-*N*-{3-[(3-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 72 |  | *N*-{4-[({3-[(2-hydroxyethyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 73 |  | 4-bromo-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 74 |  | 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 75 |  | 3-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 76 |  | *N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 77 |  | 4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 78 |  | *N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide |
| 79 |  | *N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 80 |  | *N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-nitrobenzenesulfonamide |
| 81 |  | 4-chloro-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 82 |  | *N*-{4-[({3-[(phenylmethyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 83 |  | *N*-[4-({[3-(butylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 84 |  | *N*-[3-(butylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide |
| 85 |  | *N*-[3-(cyclohexylamino)quinoxalin-2-yl]benzenesulfonamide |
| 86 |  | 1-(phenylsulfonyl)-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 87 |  | 1-(phenylsulfonyl)-3-[4-(piperidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 88 |  | 2,5-dichloro-*N*-[3-(3,4-dihydroquinolin-1(2*H*)-yl)quinoxalin-2-yl]benzenesulfonamide |
| 89 |  | ethyl 2-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 90 |  | 2,5-dichloro-*N*-{3-[(2-morpholin-4-ylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 91 |  | *N*-{4-[({3-[(3-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 92 |  | 4-chloro-*N*-{3-[(3-chloro-4-piperidin-1-ylphenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide |
| 93 |  | 3-nitro-*N*-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 94 |  | butyl *N*-{[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]carbonyl}glycinate |
| 95 |  | 4-nitro-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 96 |  | *N*-[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]acetamide |
| 97 |  | *N*-{3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide |
| 98 |  | ethyl 3,3,3-trifluoro-2-hydroxy-2-{4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}propanoate |
| 99 |  | *N*-{3-[(4-{[(2,6-dimethylpyrimidin-4-yl)amino]sulfonyl}phenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 100 |  | 4-chloro-*N*-{3-[(3,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide |
| 101 |  | 4-chloro-*N*-(6-methyl-3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 102 |  | butyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 103 |  | 4-chloro-*N*-{3-[(3-chloro-4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 104 |  | 1-methylethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate |
| 105 |  | *N*-{3-[(2,5-dimethylphenyl)amino]-6-nitroquinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 106 |  | *N*-[3-(cyclohexylamino)-6-nitroquinoxalin-2-yl]-4-methylbenzenesulfonamide |
| 107 |  | *N*-{3-[(2,4-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 108 |  | *N*-(3-{[4-(ethyloxy)phenyl]amino}-6-methylquinoxalin-2-yl)-4-methylbenzenesulfonamide |
| 109 |  | 3-({3-[({4-[hydroxy(oxido)amino]phenyl}sulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 110 |  | *N*-{[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]carbonyl}glycine |
| 111 |  | *N*-{3-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]phenyl}acetamide |
| 112 |  | 4-chloro-*N*-{3-[(3,5-dimethyl-1*H*-pyrazol-4-yl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide |
| 113 |  | 4-bromo-*N*-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 114 |  | 4-bromo-*N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 115 |  | *N*-{3-[(4-butylphenyl)amino]-6-methylquinoxalin-2-yl}-4-chlorobenzenesulfonamide |
| 116 |  | *N*-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]phenyl}acetamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 117 |  | 4-chloro-*N*-{6-methyl-3-[(2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 118 |  | propyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}-7-methylquinoxalin-2-yl)amino]benzoate |
| 119 |  | 4-chloro-*N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 120 |  | *N*-[4-({[3-(naphthalen-2-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |
| 121 |  | 4-bromo-*N*-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 122 |  | 2-hydroxy-4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid |
| 123 |  | *N*-(3-{[3-(aminosulfonyl)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 124 |  | 4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 125 |  | *N*-(3-{[3-(butyloxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide |
| 126 |  | *N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 127 |  | 4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-2-hydroxybenzoic acid |
| 128 |  | *N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]-4-nitrobenzenesulfonamide |
| 129 |  | 4-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 130 |  | *N*-{4-[({3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |







| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 131 |  | 3-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 132 |  | 4-bromo-*N*-(3-{[3-(butyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 133 |  | 4-bromo-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 134 |  | 4-methyl-*N*-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 135 |  | 4-chloro-*N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 136 |  | *N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 137 |  | 4-bromo-*N*-[3-(quinolin-5-ylamino)quinoxalin-2-yl]benzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 138 |  | *N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 139 |  | *N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 140 |  | 3-nitro-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 141 |  | 2-hydroxy-4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 142 |  | *N*-{3-[(3-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 143 |  | *N*-[3-(1,3-benzodioxol-5-ylamino)quinoxalin-2-yl]-4-bromobenzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 144 |  | *N*-{3-[(3-acetylphenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide |
| 145 |  | 3-nitro-*N*-(3-{[4-(9*H*-xanthen-9-yl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 146 |  | 4-chloro-*N*-{3-[(4'-nitrobiphenyl-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 147 |  | *N*-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-tolylsulfonamide |
| 148 |  | *N*-{3-[(2-methyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 149 |  | 4-methyl-*N*-[3-(quinolin-5-ylamino)quinoxalin-2-yl]benzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 150 |  | 4-methyl-*N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 151 |  | 4-chloro-*N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 152 |  | 2-hydroxy-5-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 153 |  | *N*-(3-{[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 154 |  | *N*-[3-({2-[(trifluoromethyl)thio]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide |
| 155 |  | *N*-{4-[({3-[(4-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 156 |  | *N*-[3-(1,3-benzodioxol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 157 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 158 |  | *N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 159 |  | *N*-[4-({[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |
| 160 |  | 4-chloro-*N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 161 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 162 |  | 4-bromo-*N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 163 |  | 5-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-2-hydroxybenzoic acid |
| 164 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide |
| 165 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide |
| 166 |  | *N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 167 |  | 4-bromo-*N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 168 |  | 4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}benzoic acid |





























| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 169 |  | *N*-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 170 |  | *N*-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide |
| 171 |  | *N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 172 |  | 4-methyl-*N*-(3-{[3-(trifluoromethyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 173 |  | 5-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-2-hydroxybenzoic acid |
| 174 |  | 3-nitro-*N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |







**Table 1**







| Cpd. No. | Structure | Name |
|---|---|---|
| 175 |  | *N*-{4-[({3-[(2-bromo-4-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 176 |  | *N*-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-4-nitrobenzenesulfonamide |
| 177 |  | *N*-{3-[(2-methyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 178 |  | 4-chloro-*N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 179 |  | *N*-{3-[(1-oxo-1,3-dihydro-2-benzofuran-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 180 |  | *N*-{3-[(2-fluorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 181 |  | *N*-[2-(butyloxy)-2-hydroxyethyl]-4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzamide |
| 182 |  | 3-nitro-*N*-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 183 |  | 4-bromo-*N*-{3-[(4-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 184 |  | 4-methyl-*N*-[3-({2-[(trifluoromethyl)thio]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide |






| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 185 |  | *N*-[4-({3-[2-(methoxy)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl}sulfonyl)phenyl]acetamide |
| 186 |  | 4-(3-{[4-(acetylamino)phenyl]sulfonyl}-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl)benzoic acid |
| 187 |  | 1-naphthalen-2-yl-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 188 |  | *N*-[4-({3-[4-(methoxy)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl}sulfonyl)phenyl]acetamide |
| 189 |  | 1-(3-methylphenyl)-3-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 190 |  | *N*-(4-{[3-(4-methylphenyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide |







| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 191 |  | *N*-{4-[(3-phenyl-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl)sulfonyl]phenyl}acetamide |
| 192 |  | *N*-(4-{[3-(3-methylphenyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide |
| 193 |  | 1-[4-(methoxy)phenyl]-3-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 194 |  | *N*-(4-{[3-(2-methylphenyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxalin-1-yl]sulfonyl}phenyl)acetamide |
| 195 |  | 1-(3-methylphenyl)-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 196 |  | 1-(4-methylphenyl)-3-[(3-nitrophenyl)sulfonyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 197 |  | *N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}-3-(1*H*-tetrazol-1-yl)benzenesulfonamide |
| 198 |  | *N*-(3-{[2-(ethyloxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide |
| 199 |  | *N*-{4-[({3-[(4-ethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 200 |  | 4-bromo-*N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 201 |  | *N*-(4-{[(3-{[4-(ethyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 202 |  | *N*-{4-[({3-[(2-ethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 203 |  | *N*-(4-{[(3-{[2-(ethyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 204 |  | *N*-{3-[(4-nitrophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 205 |  | 4-(ethyloxy)-*N*-(3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 206 |  | methyl *N*-acetyl-*N*-[4-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)phenyl]-beta-alaninate |
| 207 |  | methyl *N*-acetyl-*N*-{4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}-beta-alaninate |
| 208 |  | *N*-{3-[(3-chloro-5-methylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |








| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 209 |  | *N*-{3-[(3-acetylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 210 |  | 4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-*N*-[4-(methoxy)phenyl]benzamide |
| 211 |  | 2-hydroxy-5-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)benzoic acid |
| 212 |  | *N*-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide |
| 213 |  | *N*-[4-(methoxy)phenyl]-4-[(3-{[(4-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzamide |
| 214 |  | 4-chloro-*N*-{3-[(2-oxo-2,3-dihydro-1*H*-benzimidazol-5-yl)amino]quinoxalin-2-yl}benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 215 |  | 4-methyl-*N*-{3-[methyl(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 216 |  | *N*-[3-(3,4-dihydroisoquinolin-2(1*H*)-yl)quinoxalin-2-yl]-2-methylbenzenesulfonamide |
| 217 |  | *N*-[4-({[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |
| 218 |  | 4-bromo-*N*-{3-[(4-phenylquinolin-8-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 219 |  | 4-methyl-*N*-{3-[(4-phenylquinolin-8-yl)amino]quinoxalin-2-yl}benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 220 |  | 1-[(4-chlorophenyl)sulfonyl]-3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 221 |  | 1-(4-morpholin-4-ylphenyl)-3-(phenylsulfonyl)-2,3-dihydro-1*H*-imidazo[4,5-b]quinoxaline |
| 222 |  | methyl 4,5-dimethyl-2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)thiophene-3-carboxylate |
| 223 |  | ethyl 6-methyl-2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 224 |  | ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-6-phenyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 225 |  | ethyl 6-methyl-2-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 226 |  | propyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate |
| 227 |  | *N*-{3-[(4-butylphenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide |
| 228 |  | *N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 229 |  | *N*-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 230 |  | *N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 231 |  | *N*-{4-[({3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |








| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 232 |  | 4-chloro-*N*-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 233 |  | 3-nitro-*N*-(3-{[3,4,5-tris(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 234 |  | 4-chloro-*N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 235 |  | *N*-{3-[(2,3-dimethylphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 236 |  | *N*-{4-[({3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 237 |  | ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4*H*-cyclopenta[b]thiophene-3-carboxylate |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 238 |  | 4-chloro-*N*-(3-{[4-chloro-3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 239 |  | ethyl 2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 240 |  | 4-bromo-*N*-{3-[(2,4-dichlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 241 |  | ethyl 5-ethyl-2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]thiophene-3-carboxylate |
| 242 |  | *N*-(3-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 243 |  | ethyl 2-[(3-{[(4-bromophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 244 |  | 4-methyl-*N*-(3-{[3-(piperidin-1-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |









| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 245 |  | 4-chloro-*N*-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 246 |  | 4-chloro-*N*-(3-{[3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 247 |  | 4-methyl-*N*-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 248 |  | *N*-(3-{[3-(piperidin-1-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 249 |  | *N*-(3-{[4-(phenylamino)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 250 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide |
| 251 |  | ethyl 2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4*H*-cyclopenta[b]thiophene-3-carboxylate |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 252 |  | *N*-{3-[(4'-nitrobiphenyl-4-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 253 |  | ethyl 2-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 254 |  | *N*-(3-{[4-chloro-3-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 255 |  | ethyl 5-ethyl-2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)thiophene-3-carboxylate |
| 256 |  | *N*-[4-({[3-(quinolin-6-ylamino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |
| 257 |  | ethyl 2-[(3-{[(2-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5,6-dihydro-4*H*-cyclopenta[b]thiophene-3-carboxylate |
| 258 |  | 3,4-dichloro-*N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 259 |  | ethyl 2-{[3-({[4-(acetylamino)-3,5-dibromophenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 260 |  | ethyl 2-[(3-{[(2-chloro-5-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 261 |  | *N*-{3-[(3-fluorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 262 |  | *N*-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 263 |  | ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 264 |  | ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-5-ethylthiophene-3-carboxylate |
| 265 |  | *N*,*N*-diethyl-4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzenesulfonamide |









| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 266 |  | ethyl 2-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}-5-ethylthiophene-3-carboxylate |
| 267 |  | ethyl 2-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 268 |  | ethyl 2-({3-[(phenylsulfonyl)amino]quinoxalin-2-yl}amino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 269 |  | *N*-[4-(methoxy)phenyl]-4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzamide |
| 270 |  | *N*-[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]-4-chlorobenzenesulfonamide |
| 271 |  | *N*-[4-({[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]amino}sulfonyl)phenyl]acetamide |
| 272 |  | (2E)-3-{3-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}prop-2-enoic acid |









| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 273 |  | *N*-{3-[(9-ethyl-9*H*-carbazol-3-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 274 |  | *N*-[3-({4-[(4-aminophenyl)oxy]phenyl}amino)quinoxalin-2-yl]benzenesulfonamide |
| 275 |  | 4-bromo-*N*-{3-[(9-ethyl-9*H*-carbazol-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 276 |  | *N*-{3-[(9-ethyl-9*H*-carbazol-3-yl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 277 |  | *N*-{3-[(2-iodophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 278 |  | *N*-{3-[(1-phenylethyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 279 |  | 4-bromo-*N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 280 |  | 4-bromo-*N*-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 281 |  | 4-bromo-*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 282 |  | *N*-{3-[(2,3-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 283 |  | 4-chloro-*N*-{3-[(2-iodophenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 284 |  | *N*-(3-{[4-(octyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 285 |  | *N*-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide |
| 286 |  | *N*-{3-[(2-bromo-4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 287 |  | *N*-[3-({4-[(3-aminophenyl)sulfonyl]phenyl}amino)quinoxalin-2-yl]-4-chlorobenzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 288 |  | *N*-[3-({2-[(difluoromethyl)oxy]phenyl}amino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide |
| 289 |  | 8-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]quinoline-2-carboxylic acid |
| 290 |  | ethyl 3,3,3-trifluoro-2-hydroxy-2-{4-[(3-{[(3-nitrophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}propanoate |
| 291 |  | *N*-[3-(quinolin-6-ylamino)quinoxalin-2-yl]benzenesulfonamide |
| 292 |  | 4-{[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]amino}phenyl thiocyanate |
| 293 |  | 1-[3-({[4-(acetylamino)phenyl]sulfonyl}amino)quinoxalin-2-yl]-4-methylpyridinium |









| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 294 |  | *N*-{3-[(2-chlorophenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 295 |  | 4-methyl-*N*-[3-(phenylamino)quinoxalin-2-yl]benzenesulfonamide |
| 296 |  | 4-methyl-*N*-{3-[(2-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 297 |  | 4-methyl-*N*-{3-[(4-methylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 298 |  | *N*-{3-[(4-chlorophenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 299 |  | 4-methyl-*N*-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 300 |  | *N*-{4-[({3-[(4-bromophenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 301 |  | *N*-{4-[({3-[(2-methylphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}acetamide |
| 302 |  | *N*-{3-[bis(phenylmethyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 303 |  | 4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 304 |  | 2-hydroxy-4-[(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoic acid |
| 305 |  | 4-bromo-*N*-(3-{[2-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 306 |  | *N*-{3-[(3-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 307 |  | *N*-[3-(naphthalen-1-ylamino)quinoxalin-2-yl]benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 308 |  | 3-methyl-1-(3-{[(4-methylphenyl)sulfonyl]amino}quinoxalin-2-yl)pyridinium |
| 309 |  | *N*-(3-{[3-{[(4-chlorophenyl)sulfonyl]amino}-7-(methoxy)quinoxalin-2-yl]amino}phenyl)acetamide |
| 310 |  | *N*-{3-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]phenyl}acetamide |
| 311 |  | *N*-{3-[(4-bromophenyl)amino]quinoxalin-2-yl}-4-chlorobenzenesulfonamide |
| 312 |  | *N*-{3-[(2,4-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 313 |  | *N*-{3-[(3,4-dimethylphenyl)amino]quinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 314 |  | *N*-{3-[(2,5-dimethylphenyl)amino]-6-methylquinoxalin-2-yl}-4-methylbenzenesulfonamide |
| 315 |  | ethyl 4-[(3-{[(4-chlorophenyl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 316 |  | 4-chloro-*N*-{3-[(4-ethylphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 317 |  | 4-chloro-*N*-(6-methyl-3-{[4-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 318 |  | 4-chloro-*N*-{3-[(4-chlorophenyl)amino]-6-methylquinoxalin-2-yl}benzenesulfonamide |
| 319 |  | *N*-(3-{[4-chloro-2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 320 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 321 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-methylbenzenesulfonamide |
| 322 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 323 |  | *N*-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 324 |  | *N*-[3-(2-Chloro-5-methoxy-phenylamino)-quinoxalin-2-yl]-benzensulfonamide |
| 325 |  | 3-amino-*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 326 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide |
| 327 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 328 |  | *N*-(3-{[4-chloro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 329 |  | *N*-(3-{[4-fluoro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 330 |  | 3-amino-*N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 331 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-bromobenzenesulfonamide |
| 332 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 333 |  | 3-amino-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 334 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 335 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}-7-methylquinoxalin-2-yl)benzenesulfonamide |
| 336 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(methoxy)benzenesulfonamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 337 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-bromobenzenesulfonamide |
| 338 |  | *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluorobenzenesulfonamide |
| 339 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-fluorobenzenesulfonamide |
| 340 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(methoxy)benzenesulfonamide |
| 341 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-bromobenzenesulfonamide |
| 342 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylpiperidine-4-carboxamide |
| 343 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-piperidin-1-ylpropanamide |






| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 344 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)butanamide |
| 345 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(hydroxyamino)benzenesulfonamide |
| 346 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide |
| 347 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-*N*-2-methylglycinamide |
| 348 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-L-alaninamide |
| 349 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-2-methylalaninamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 350 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 351 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide |
| 352 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide |
| 353 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-D-alaninamide |
| 354 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide |
| 355 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 356 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide |
| 357 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide |
| 358 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide |
| 359 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 360 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]-*N*-2-methylglycinamide |
| 361 |  | (2S)-2-amino-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide |
| 362 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]-*N*-2-methylglycinamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 363 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 364 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-L-alaninamide |
| 365 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide |
| 366 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide |
| 367 |  | *N*-(2-chloro-5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide |
| 368 |  | 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide |
| 369 |  | *N*-(3-{[(3-{[2-acetyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 370 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide |
| 371 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethylglycinamide |
| 372 |  | *N*-(5-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)glycinamide |
| 373 |  | 2-azetidin-1-yl-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 374 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide |
| 375 |  | *N*-(3-{[(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide |
| 376 |  | *N*-2-,*N*-2-dimethyl-*N*-(3-{[(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 377 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide |
| 378 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-D-alaninamide |
| 379 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide |
| 380 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-serinamide |
| 381 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 382 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,2-dimethylalaninamide |
| 383 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-D-alaninamide |
| 384 |  | *N*-(3-{[(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 385 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-propylglycinamide |
| 386 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-L-alaninamide |
| 387 |  | *N*-(5-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-beta-alaninamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 388 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-3-carboxamide |
| 389 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methyl-1,4-diazepan-1-yl)acetamide |
| 390 |  | (2S)-2-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide |
| 391 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-hydroxypropyl)glycinamide |
| 392 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-fluoroethyl)glycinamide |
| 393 |  | 3-amino-*N*-(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 394 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(2-methylpropyl)oxy]glycinamide |
| 395 |  | 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide |
| 396 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide |
| 397 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(cyclopropylmethyl)glycinamide |
| 398 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide |
| 399 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide |
| 400 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide |









| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 401 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-2-carboxamide |
| 402 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)morpholine-4-carboxamide |
| 403 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide |
| 404 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-6-,*N*-6-dimethyl-L-lysinamide |
| 405 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-methylglycinamide |
| 406 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1*H*-imidazol-4-yl)acetamide |
| 407 |  | 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 408 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-methylpropyl)glycinamide |
| 409 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-methylglycinamide |
| 410 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(1*H*-imidazol-4-ylmethyl)azetidine-3-carboxamide |
| 411 |  | *N*-(5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 412 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-ethylazetidine-3-carboxamide |
| 413 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(1-methylpyrrolidin-3-yl)glycinamide |
| 414 |  | *N*-(3-{[(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]-*N*-2-methylglycinamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 415 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3S)-3-hydroxypyrrolidin-1-yl]acetamide |
| 416 |  | 1-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide |
| 417 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-butylglycinamide |
| 418 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-piperidin-1-ylazetidin-1-yl)acetamide |
| 419 |  | 3-[(aminocarbonyl)amino]-*N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 420 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-hydroxycyclopropanecarboxamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 421 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,2-dimethylhydrazino)acetamide |
| 422 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[({[2-(dimethylamino)ethyl]amino}carbonyl)amino]benzenesulfonamide |
| 423 |  | *N*-(3-{[(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methylglycinamide |
| 424 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-hydroxyacetamide |
| 425 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridazine-4-carboxamide |
| 426 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1-methylethyl)glycinamide |
| 427 |  | 1-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 428 |  | 1-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide |
| 429 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)pyrrolidin-1-yl]acetamide |
| 430 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]glycinamide |
| 431 |  | 2-(dimethylamino)ethyl(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbamate |
| 432 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylmethyl)azetidine-3-carboxamide |
| 433 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1,1-dimethylethyl)glycinamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 434 |  | *N*-2-methyl-*N*-(3-{[(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide |
| 435 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-2-carboxamide |
| 436 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)isoxazole-5-carboxamide |
| 437 |  | *N*-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2,2,2-trifluoroethyl)glycinamide |
| 438 |  | 3-amino-*N*-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 439 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclopentanecarboxamide |
| 440 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-hydroxypyridine-2-carboxamide |
| 441 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(3-fluoro-4-hydroxyphenyl)glycinamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 442 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(furan-2-ylmethyl)azetidine-3-carboxamide |
| 443 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrimidine-5-carboxamide |
| 444 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-pyrrole-2-carboxamide |
| 445 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(1-methylethyl)glycinamide |
| 446 |  | *N*-(3-{[(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 447 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-4-carboxamide |
| 448 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-diethylglycinamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 449 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylisoxazol-5-yl)acetamide |
| 450 |  | *N*-2-,*N*-2-dimethyl-*N*-(3-{[(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide |
| 451 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(3-hydroxyphenyl)methyl]glycinamide |
| 452 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-1*H*-pyrrole-2-carboxamide |
| 453 |  | 4-amino-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydro-2*H*-pyran-4-carboxamide |
| 454 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methylamino)piperidin-1-yl]acetamide |
| 455 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-piperidin-1-ylacetamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 456 |  | *N*-(4-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide |
| 457 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-L-prolinamide |
| 458 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-3-carboxamide |
| 459 |  | 3-amino-*N*-{3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}benzenesulfonamide |
| 460 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylcarbonyl)azetidine-3-carboxamide |
| 461 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperazin-1-yl)acetamide |
| 462 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(phenylmethyl)azetidine-3-carboxamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 463 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-3-carboxamide |
| 464 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-4-ylacetamide |
| 465 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-prop-2-en-1-ylglycinamide |
| 466 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(phenylmethyl)glycinamide |
| 467 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)acetamide |
| 468 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-propanoylazetidine-3-carboxamide |
| 469 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-3-carboxamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 470 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(methoxy)ethyl]glycinamide |
| 471 |  | 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-4-carboxamide |
| 472 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpyrrolidin-1-yl)acetamide |
| 473 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-3-carboxamide |
| 474 |  | *N*-2-,*N*-2-dimethyl-*N*-(3-{[(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide |
| 475 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-chloropyridine-3-carboxamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 476 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chlorobenzamide |
| 477 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-2-ylacetamide |
| 478 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide |
| 479 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-3-ylacetamide |
| 480 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-chlorophenyl)acetamide |
| 481 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[3-(dimethylamino)propyl]-*N*-2-methylglycinamide |
| 482 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-(2-hydroxyethyl)glycinamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 483 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(phenylmethyl)pyrrolidin-1-yl]acetamide |
| 484 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)propanamide |
| 485 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-2-carboxamide |
| 486 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-4-carboxamide |
| 487 |  | *N*-2-acetyl-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide |
| 488 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide |
| 489 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-chlorobenzamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 490 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylbenzamide |
| 491 |  | 1,1-dimethylethyl{2-[(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]-2-oxoethyl}carbamate |
| 492 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-benzodioxole-5-carboxamide |
| 493 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-({[2-(methoxy)phenyl]methyl}oxy)glycinamide |
| 494 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-4-carboxamide |
| 495 |  | *N*-(3-{[(3-{[4-fluoro-3-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-,*N*-2-dimethylglycinamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 496 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(3,4-dichlorophenyl)piperazin-1-yl]acetamide |
| 497 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-pyridin-3-ylpropanamide |
| 498 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-3-carboxamide |
| 499 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(2-methylphenyl)methyl]glycinamide |
| 500 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbutanamide |
| 501 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-fluorophenyl)acetamide |








| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 502 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1-methyl-1-phenylethyl)glycinamide |
| 503 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylcyclopropanecarboxamide |
| 504 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methyl-4-(methoxy)benzamide |
| 505 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpyridine-3-carboxamide |
| 506 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(methoxy)benzamide |
| 507 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-ethylpiperazin-1-yl)acetamide |






| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 508 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-2-carboxamide |
| 509 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-2-methylbenzamide |
| 510 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-bromothiophene-3-carboxamide |
| 511 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluorobenzamide |
| 512 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylpiperidin-1-yl)acetamide |
| 513 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpropanamide |
| 514 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pentanamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 515 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(ethyloxy)acetamide |
| 516 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-fluorophenyl)glycinamide |
| 517 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(dimethylamino)benzamide |
| 518 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperidin-1-yl)acetamide |
| 519 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-propylphenyl)glycinamide |
| 520 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)benzamide |
| 521 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrazine-2-carboxamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 522 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-(methoxy)benzamide |
| 523 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylbutanamide |
| 524 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(4-fluorophenyl)oxy]acetamide |
| 525 |  | 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide |
| 526 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(4-methylphenyl)glycinamide |
| 527 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-phenylglycinamide |
| 528 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-prop-2-en-1-ylpiperazin-1-yl)acetamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 529 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbenzamide |
| 530 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methoxy)propanamide |
| 531 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylfuran-2-carboxamide |
| 532 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide |
| 533 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(phenylmethyl)oxy]glycinamide |
| 534 |  | *N*-{3-[({3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}-*N*-2-,*N*-2-dimethylglycinamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 535 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(3-chlorophenyl)glycinamide |
| 536 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide |
| 537 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(methoxy)phenyl]acetamide |
| 538 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylcyclopropanecarboxamide |
| 539 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluorobenzamide |
| 540 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)benzamide |
| 541 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,4-dichlorobenzamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 542 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-{[2-(methylthio)phenyl]methyl}glycinamide |
| 543 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-fluorophenyl)acetamide |
| 544 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-(1-methylethyl)glycinamide |
| 545 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-thiazole-4-carboxamide |
| 546 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(phenylmethyl)glycinamide |






























| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 547 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-thienylmethyl)glycinamide |
| 548 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(pyridin-2-ylmethyl)glycinamide |
| 549 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methoxy)benzamide |
| 550 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(3-chloro-4-methylphenyl)methyl]glycinamide |
| 551 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpentanamide |







**Table 1**






| Cpd. No. | Structure | Name |
|---|---|---|
| 552 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-chlorophenyl)acetamide |
| 553 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-methylbenzamide |
| 554 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(2-methylphenyl)oxy]acetamide |
| 555 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-cyclohexylacetamide |
| 556 |  | (1R,2R)-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylcyclopropanecarboxamide |
| 557 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-chlorobenzamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 558 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(methoxy)phenyl]acetamide |
| 559 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[3-(methoxy)phenyl]propanamide |
| 560 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-fluoro-4-methylphenyl)glycinamide |
| 561 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(3-fluorophenyl)methyl]glycinamide |
| 562 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methoxy)phenyl]acetamide |
| 563 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylacetamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 564 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,4-dichlorobenzamide |
| 565 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclohexanecarboxamide |
| 566 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(3-fluorophenyl)glycinamide |
| 567 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-chlorophenyl)acetamide |
| 568 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-phenylpropyl)glycinamide |
| 569 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(2,4-dimethylphenyl)methyl]glycinamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 570 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpiperidin-1-yl)acetamide |
| 571 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(methoxy)phenyl]glycinamide |
| 572 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3,4-dihydroisoquinolin-2(1*H*)-yl)acetamide |
| 573 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pent-4-enamide |
| 574 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2-methylphenyl)glycinamide |
| 575 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-oxopiperidin-1-yl)acetamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 576 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluorobenzamide |
| 577 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(1-phenylethyl)glycinamide |
| 578 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-6-(methoxy)benzamide |
| 579 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(1-methylethyl)phenyl]glycinamide |
| 580 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[2-(methoxy)phenyl]propanamide |
| 581 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylpentanamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 582 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylmorpholin-4-yl)acetamide |
| 583 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[4-(methoxy)phenyl]propanamide |
| 584 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-cyclopentyl-*N*-2-prop-2-en-1-ylglycinamide |
| 585 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-[2-(methoxy)ethyl]glycinamide |
| 586 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-cyclopropyl-4-oxobutanamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 587 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[3-(1,1-dimethylethyl)phenyl]glycinamide |
| 588 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(cyclopropylmethyl)-*N*-2-propylglycinamide |
| 589 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-oxocyclopentyl)acetamide |
| 590 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(4-chlorophenyl)glycinamide |
| 591 |  | 2-(1,4'-bipiperidin-1'-yl)-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 592 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-cyclopentylpiperazin-1-yl)acetamide |

























| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 593 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylphenyl)acetamide |
| 594 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-[(5-fluoro-2-methylphenyl)methyl]glycinamide |
| 595 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,3-dimethylbutanamide |
| 596 |  | *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-chlorophenyl)glycinamide |
| 597 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-methylbenzamide |
| 598 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluoro-3-methylbenzamide |

Table 1

| Cpd. No. | Structure | Name |
|---|---|---|
| 599 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,3-dichlorobenzamide |
| 600 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(phenyloxy)acetamide |
| 601 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-(2,3-dimethylphenyl)glycinamide |
| 602 |  | 3-amino-*N*-(3-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide |
| 603 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-5-methylbenzamide |
| 604 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-{[(4-methylphenyl)methyl]oxy}glycinamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 605 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(1-methylethyl)piperazin-1-yl]acetamide |
| 606 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-fluorophenyl)acetamide |
| 607 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylbutanamide |
| 608 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-2-(methoxy)benzamide |
| 609 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-propylpiperidin-1-yl)acetamide |
| 610 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3-methylphenyl)oxy]acetamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 611 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-2-carboxamide |
| 612 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(hydroxymethyl)piperidin-1-yl]acetamide |
| 613 |  | 1,1-dimethylethyl2-{[(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]carbonyl}piperidine-1-carboxylate |
| 614 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(pyridin-3-ylmethyl)glycinamide |
| 615 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-ethyl-*N*-2-phenylglycinamide |
| 616 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-{[2-(methoxy)ethyl]oxy}acetamide |

2/7

DVN








OK







Organizacion y
Digitalizacion CSA Ltda







# PATENTE DE INVENCIÓN







09-126923





2/7
126923
198






| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 617 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-cyclopentylpropanamide |
| 618 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,5-dichlorobenzamide |
| 619 |  | 2-(4-acetylpiperazin-1-yl)-*N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 620 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-(methoxy)benzamide |
| 621 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-cyclohexyl-*N*-2-ethylglycinamide |
| 622 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-methylisoxazole-3-carboxamide |
| 623 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylpyridine-2-carboxamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 624 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)pyridine-3-carboxamide |
| 625 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,5-dichlorobenzamide |
| 626 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1,3-thiazolidin-3-yl)acetamide |
| 627 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formylpiperazin-1-yl)acetamide |
| 628 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-pyridin-4-ylpiperidin-1-yl)acetamide |
| 629 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methoxy)benzamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 630 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-*N*-2-methyl-*N*-2-(2-methylpropyl)glycinamide |
| 631 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formyl-1,4-diazepan-1-yl)acetamide |
| 632 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-phenylcyclopropanecarboxamide |
| 633 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,6-dimethylmorpholin-4-yl)acetamide |
| 634 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylpyrrolidin-1-yl)acetamide |
| 635 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)-1-methylethyl]benzamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 636 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide |
| 637 |  | 5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-fluorobenzamide |
| 638 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-pyrrolidin-3-ylbenzamide |
| 639 |  | 3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide |
| 640 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyrrolidin-1-ylethyl)benzamide |
| 641 |  | *N*-(2-aminoethyl)-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 642 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide |
| 643 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(piperidin-2-ylmethyl)benzamide |
| 644 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylazetidin-3-yl)benzamide |
| 645 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-piperidin-1-ylethyl)benzamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 646 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(diethylamino)ethyl]benzamide |
| 647 |  | 3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide |
| 648 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylpiperidin-3-yl)benzamide |
| 649 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-3-ylbenzamide |
| 650 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-methylpiperidin-2-yl)methyl]benzamide |



























| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 651 |  | *N*-{2-[bis(2-hydroxyethyl)amino]ethyl}-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide |
| 652 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-ethylpiperidin-3-yl)benzamide |
| 653 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide |
| 654 |  | 3-[(3-aminopyrrolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 655 |  | 5-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-(methoxy)benzamide |






**Table 1**






| Cpd. No. | Structure | Name |
|---|---|---|
| 656 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide |
| 657 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid |
| 658 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-morpholin-4-ylethyl)benzamide |
| 659 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-ethylpyrrolidin-2-yl)methyl]benzamide |
| 660 |  | 3-[(4-amino-3-oxopyrazolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 661 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methylbenzamide |
| 662 |  | 3-[(3-aminoazetidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 663 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-3-ylmethyl)benzamide |
| 664 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-2-ylmethyl)benzamide |
| 665 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-hydroxyethyl)benzamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 666 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-oxopyrazolidin-4-yl)benzamide |
| 667 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(1*H*-imidazol-4-yl)ethyl]benzamide |
| 668 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide |
| 669 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-4-ylmethyl)benzamide |
| 670 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-(1-methylpyrrolidin-3-yl)benzamide |
| 671 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(diethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 672 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-1*H*-pyrrol-1-ylbenzamide |
| 673 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-pyrrolidin-1-ylpropyl)benzamide |
| 674 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-methylbenzamide |
| 675 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methoxy)ethyl]benzamide |
| 676 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-ethylbenzamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 677 |  | 3-[(3-aminopiperidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 678 |  | 3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid |
| 679 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]benzamide |
| 680 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-morpholin-4-ylbenzamide |
| 681 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[(2,2-dimethylhydrazino)carbonyl]benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 682 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(1*H*-imidazol-1-yl)propyl]benzamide |
| 683 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(diethylamino)propyl]benzamide |
| 684 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)benzamide |
| 685 |  | methyl*N*-[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate |
| 686 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methylthio)ethyl]benzamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 687 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(ethylthio)ethyl]benzamide |
| 688 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-ethylbenzamide |
| 689 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide |
| 690 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyridin-4-ylethyl)benzamide |
| 691 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(ethyloxy)propyl]benzamide |
| 692 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-morpholin-4-ylpropyl)benzamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 693 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(methoxy)propyl]benzamide |
| 694 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]-*N*-methylbenzamide |
| 695 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(propyloxy)propyl]benzamide |
| 696 |  | ethyl*N*-[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate |
| 697 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-{3-[(1-methylethyl)oxy]propyl}benzamide |
| 698 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-piperidin-1-ylethyl)benzamide |






| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 699 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-propylbenzamide |
| 700 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-1-ylbenzamide |
| 701 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[1-methyl-2-(methoxy)ethyl]benzamide |
| 702 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-morpholin-4-ylethyl)benzamide |
| 703 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-({2-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)benzenesulfonamide |
| 704 |  | *N*-[3-(butyloxy)propyl]-3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 705 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[4-(diethylamino)-1-methylbutyl]benzamide |
| 706 |  | 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-oxo-2-piperidin-1-ylethyl)benzamide |
| 707 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide |
| 708 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{[2-(piperidin-1-ylmethyl)piperidin-1-yl]carbonyl}benzenesulfonamide |
| 709 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide |
| 710 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 711 |  | 3-amino-*N*-(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 712 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)thiophene-2-sulfonamide |
| 713 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide |
| 714 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(methylamino)benzenesulfonamide |
| 715 |  | *N*-(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)-3-nitrobenzenesulfonamide |
| 716 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(1-{[2-(dimethylamino)ethyl]amino}ethyl)benzenesulfonamide |







| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 717 |  | 3-amino-*N*-(3-{[3-(methoxy)-5-nitrophenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 718 |  | 3-acetyl-*N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 719 |  | 3-amino-*N*-(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 720 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-*N'*-[2-(dimethylamino)ethyl]benzene-1,3-disulfonamide |
| 721 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-*N'*-[3-(dimethylamino)propyl]benzene-1,3-disulfonamide |
| 722 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-chloropyridine-3-sulfonamide |

| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 723 |  | *N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}benzenesulfonamide |
| 724 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]amino}pyridine-3-sulfonamide |
| 725 |  | 3-amino-*N*-(3-{[3-amino-5-(methoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide |
| 726 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide |
| 727 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]oxy}pyridine-3-sulfonamide |
| 728 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 729 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-cyanobenzenesulfonamide |
| 730 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluorobenzenesulfonamide |
| 731 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide |
| 732 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-methylbenzenesulfonamide |
| 733 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 734 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-difluorobenzenesulfonamide |
| 735 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-chlorobenzenesulfonamide |
| 736 |  | *N*-(4-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide |
| 737 |  | *N*-(3-{[6-(methoxy)quinolin-8-yl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 738 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(2*H*-tetrazol-5-yl)benzenesulfonamide |
| 739 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)naphthalene-1-sulfonamide |

| Table 1 | | |
|---|---|---|
| **Cpd. No.** | **Structure** | **Name** |
| 740 |  | *N*-{[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)amino](dimethylamino)methylidene}-*N*-methylmethanaminium |
| 741 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluorobenzenesulfonamide |
| 742 |  | *N*-(3-{[2-bromo-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 743 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-[(difluoromethyl)oxy]benzenesulfonamide |
| 744 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2-(trifluoromethyl)benzenesulfonamide |
| 745 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-chloro-4-fluorobenzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 746 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfonamide |
| 747 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(methylsulfonyl)benzenesulfonamide |
| 748 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-dichlorothiophene-3-sulfonamide |
| 749 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-dichlorobenzenesulfonamide |
| 750 |  | *N*-(3-{[2-methyl-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 751 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-[(trifluoromethyl)oxy]benzenesulfonamide |





















| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 752 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(dimethylamino)piperidin-1-yl]acetamide |
| 753 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-2-(methoxy)benzenesulfonamide |
| 754 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(trifluoromethyl)benzenesulfonamide |
| 755 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-bis(methoxy)benzenesulfonamide |
| 756 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-dimethylisoxazole-4-sulfonamide |
| 757 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-bromo-2-(methoxy)benzenesulfonamide |

Table 1

| Cpd. No. | Structure | Name |
|---|---|---|
| 758 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-fluoro-3-(trifluoromethyl)benzenesulfonamide |
| 759 |  | *N*-(3-{[3-fluoro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 760 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-fluoro-4-methylbenzenesulfonamide |
| 761 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-chloro-4-methylbenzenesulfonamide |
| 762 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-2,5-dimethylthiophene-3-sulfonamide |
| 763 |  | *N*-(3-{[3-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 764 |  | *N*-{3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide |
| 765 |  | *N*-(3-{[(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-3-(methoxy)benzamide |
| 766 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-1-phenylmethanesulfonamide |
| 767 |  | *N*-(3-{[3-(methoxy)-5-nitrophenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide |
| 768 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-1-(3-chlorophenyl)methanesulfonamide |
| 769 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4,5-dichlorothiophene-2-sulfonamide |

| Table 1 | | |
|---|---|---|
| Cpd. No. | Structure | Name |
| 770 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-1,3-dimethyl-1*H*-pyrazole-4-sulfonamide |
| 771 |  | *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3,5-bis(trifluoromethyl)benzenesulfonamide |

## Table 2a.

## Representative AKT Inhibitors

**[00226]** The Compounds in Table 2a can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 2a can be used to practice the invention.

| Cmpd No. | *N*ame |
|---|---|
| 1 | 3-(azetidin-3-ylidenemethyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 2 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-fluoropyridin-4-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 3 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-chloropyridin-4-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 4 | 2-({5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)-*N*,*N*-dimethylethanamine |
| 5 | 2-({5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)-*N*,*N*-diethylethanamine |
| 6 | 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 7 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-piperazin-1-yl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 8 | *N*-(3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-yl)acetamide |
| 9 | *N*,*N*-diethyl-2-({3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)ethanamine |
| 10 | 3-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-*N*,*N*-diethylpropan-1-amine |

| Cmpd No. | Name |
|---|---|
| 11 | 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 12 | 3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 13 | 2-({3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}oxy)-*N*,*N*-diethylethanamine |
| 14 | 4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 15 | 5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 16 | 4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 17 | 4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 18 | 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 19 | 3-bromo-4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 20 | 3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 21 | 3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 22 | 4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 23 | *N*'-{5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-*N*,*N*-diethylethane-1,2-diamine |
| 24 | 4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 25 | 4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 26 | 4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 27 | 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 28 | *N*'-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-*N*,*N*-diethylethane-1,2-diamine |
| 29 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 30 | 4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 31 | 4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 32 | *N*,*N*-diethyl-2-({3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)ethanamine |
| 33 | 2-[(5-chloro-3-{4-[1-(1,1-dimethylethyl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-2-methylphenyl)oxy]-*N*,*N*-diethylethanamine |

| Cmpd No. | Name |
|---|---|
| 34 | 2-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-*N*,*N*-diethylethanamine |
| 35 | 4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 36 | 4-[4-(5-chloro-2-methyl-3-{[3-(4-methylpiperazin-1-yl)propyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 37 | 3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 38 | 3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 39 | 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 40 | 4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 41 | 4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 42 | 4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 43 | 4-[4-(5-chloro-3-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 44 | 5-chloro-2-methyl-3-[4-(1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 45 | 5-chloro-2-methyl-3-[4-(3-methyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 46 | *N'*-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-*N*,*N*-dimethylethane-1,2-diamine |
| 47 | 3-({5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)-*N*,*N*-diethylpropan-1-amine |
| 48 | *N'*-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-*N*,*N*-diethylethane-1,2-diamine |
| 49 | 5-chloro-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline |
| 50 | 3-bromo-4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 51 | 4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 52 | 3-methyl-4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 53 | 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 54 | 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-methyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 55 | 4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 56 | 3-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-*N*,*N*-diethylpropan-1-amine |

| Cmpd No. | Name |
|---|---|
| 57 | 5-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 58 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 59 | 4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 60 | 3-bromo-4-{4-[5-fluoro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 61 | 4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 62 | 4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 63 | 3-bromo-4-(4-pyridin-2-ylpiperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 64 | 3-bromo-4-[4-(2,4-dimethylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 65 | 3-bromo-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 66 | 3-bromo-4-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 67 | 3-bromo-4-{4-[4-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 68 | 4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 69 | 4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 70 | 4-[4-(5-chloro-2-methyl-3-{[3-(4-methylpiperazin-1-yl)propyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 71 | 4-[4-(5-chloro-3-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 72 | 3-bromo-4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 73 | 4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 74 | 3-bromo-4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 75 | 3-bromo-4-[4-(3,4-dichlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 76 | 3-bromo-4-[4-(3,4-difluorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 77 | 3-bromo-4-[4-(2,4-dichlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 78 | 3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 79 | 5-fluoro-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline |
| 80 | 4-{4-[3,5-bis(methyloxy)phenyl]piperazin-1-yl}-3-bromo-1*H*-pyrazolo[3,4-d]pyrimidine |
| 81 | 4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 82 | *N*-{5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-*N*,*N*',*N*'-trimethylethane-1,2-diamine |
| 83 | 3-({3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}oxy)-*N*,*N*-diethylpropan-1-amine |

| Cmpd No. | Name |
|---|---|
| 84 | 3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 85 | 3-bromo-4-[4-(5-chloro-2-methyl-3-{[3-(4-methylpiperazin-1-yl)propyl]oxy}phenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 86 | 3-bromo-4-[4-(5-chloro-3-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 87 | 3-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-*N*,*N*-diethylpropan-1-amine |
| 88 | 3-bromo-4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 89 | 3-bromo-4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 90 | 4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 91 | 4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 92 | 4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 93 | 3-bromo-4-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 94 | 1-{4-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}ethanone |
| 95 | 3-bromo-4-[4-(2,5-dichlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 96 | 3-bromo-4-[4-(3,4-dimethylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 97 | 3-bromo-4-[4-(4-nitrophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 98 | 3-ethyl-4-(4-phenylpiperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 99 | 3-ethyl-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 100 | 4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 101 | 4-[4-(3,6-dimethylpyrazin-2-yl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 102 | 1-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]isoquinoline |
| 103 | 3-bromo-4-[4-(2,6-dimethylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 104 | 3-bromo-4-{4-[4-(ethyloxy)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 105 | 3-bromo-4-[4-(2-ethylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 106 | 4-{4-[2,4-bis(methyloxy)phenyl]piperazin-1-yl}-3-bromo-1*H*-pyrazolo[3,4-d]pyrimidine |
| 107 | 3-bromo-4-(4-pyrazin-2-ylpiperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 108 | 3-bromo-4-(4-pyrimidin-2-ylpiperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 109 | 4-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)quinoline |
| 110 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazine-2-carbonitrile |
| 111 | 4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 112 | ethyl 4-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)pyrimidine-5-carboxylate |
| 113 | 4-{4-[3-chloro-5-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 114 | 4-[4-(3-bromo-2-chloro-5-fluorophenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |

| Cmpd No. | Name |
|---|---|
| 115 | 2-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carboxamide |
| 116 | 3-ethyl-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 117 | 3-bromo-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 118 | 3-bromo-4-{4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 119 | 2-({3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazin-2-yl}oxy)-*N*,*N*-dimethylethanamine |
| 120 | 4-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylquinoline |
| 121 | 3-bromo-4-[4-(2-nitrophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 122 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile |
| 123 | 4-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile |
| 124 | 3-bromo-4-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 125 | 3-bromo-4-(4-{4-[(phenylmethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 126 | 4-{4-[5-chloro-2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 127 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carbonitrile |
| 128 | 3-bromo-4-[4-(3,5-dichlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 129 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-fluoro-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 130 | 2-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 131 | 3-bromo-4-[4-(2,5-difluorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 132 | 4-[4-(2,5-difluorophenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 133 | 3-bromo-4-{4-[3-(methyloxy)pyrazin-2-yl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 134 | 3-bromo-4-[4-(3-chlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 135 | 3-bromo-4-{4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 136 | 3-bromo-4-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 137 | 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(1-methylethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 138 | 5-chloro-2-methyl-3-{4-[3-(1-methylethyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 139 | 2-({3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-*N*-ethylacetamide |
| 140 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,*N*-diethylpyrimidin-4-amine |
| 141 | 3-bromo-4-[4-(3-{[(3-methylphenyl)methyl]oxy}phenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 142 | 3-bromo-4-(4-{3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 143 | 3-bromo-4-[4-(4-furan-2-ylpyrimidin-2-yl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |

| Cmpd No. | Name |
|---|---|
| 144 | 6-{2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrimidin-4-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 145 | 3-ethyl-4-{4-[2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 146 | *N*'-{5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-*N*-methyl-*N*-(1-methylethyl)ethane-1,2-diamine |
| 147 | *N*'-{5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-*N*-ethyl-*N*-methylethane-1,2-diamine |
| 148 | *N*'-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-*N*,*N*-dimethylethane-1,2-diamine |
| 149 | 3-({6-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-methylpyrimidin-4-yl}oxy)-*N*,*N*-diethylpropan-1-amine |
| 150 | 3-bromo-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 151 | 3-bromo-4-{4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 152 | 3-bromo-4-(4-phenylpiperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 153 | 3-bromo-4-[4-(4-fluorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 154 | 3-bromo-4-[4-(4-chlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 155 | 3-bromo-4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 156 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-6-amine |
| 157 | 3-bromo-4-[4-(4-bromophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 158 | 3-bromo-4-[3-methyl-4-(3-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 159 | 4-[4-(3-bromo-5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-6-amine |
| 160 | 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-cyclopropyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 161 | 5-chloro-3-[4-(3-cyclopropyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 162 | 5-chloro-2-methyl-3-{4-[3-(2-methylpropyl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 163 | 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(2-methylpropyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 164 | 3-bromo-4-[(3S)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 165 | 5-bromo-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylaniline |
| 166 | 2-({3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-*N*-cyclopropylacetamide |
| 167 | 3-bromo-4-(4-{3-[(2-piperidin-1-ylethyl)oxy]pyrazin-2-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 168 | 4-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6,7-bis(methyloxy)quinazoline |
| 169 | 2-({3-chloro-5-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-*N*,*N*-diethylethanamine |
| 170 | 4-{4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 171 | 3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-*N*-(2-pyrrolidin-1-ylethyl)aniline |

| Cmpd No. | Name |
|---|---|
| 172 | 3-({4-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6-chloro-5-methylpyrimidin-2-yl}oxy)-*N*,*N*-diethylpropan-1-amine |
| 173 | 3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(phenylmethyl)oxy]-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 174 | 3-bromo-4-[(3R)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 175 | 3-[(2S)-4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-*N*-phenylbenzamide |
| 176 | 3-[(2S)-4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-*N*-(phenylmethyl)benzamide |
| 177 | methyl 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate |
| 178 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoic acid |
| 179 | (2E)-3-(4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-enoic acid |
| 180 | 3-(4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-yn-1-ol |
| 181 | 4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-1-(5-chloro-2-methylphenyl)piperazin-2-one |
| 182 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 183 | *N*'-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]phenyl}-*N*,*N*-diethylethane-1,2-diamine |
| 184 | methyl 3-bromo-5-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate |
| 185 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-phenylbenzamide |
| 186 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,4-dimethylbenzamide |
| 187 | 2-({3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-*N*,*N*-diethylethanamine |
| 188 | methyl 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoate |
| 189 | 3-bromo-5-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-phenylbenzamide |
| 190 | 3-bromo-5-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-phenylbenzamide |
| 191 | *N*'-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-*N*-methyl-*N*-(1-methylethyl)ethane-1,2-diamine |
| 192 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-phenyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 193 | *N*'-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]phenyl}-*N*,*N*-dimethylethane-1,2-diamine |
| 194 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,*N*,4-trimethylbenzamide |
| 195 | 3-[4-(3-chloro-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-(2-methylpropyl)benzamide |
| 196 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,*N*,4-trimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |

| Cmpd No. | Name |
|---|---|
| 197 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-2-oxopiperazin-1-yl]-4-methyl-*N*-phenylbenzamide |
| 198 | 3-[(2R)-4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-2-(hydroxymethyl)piperazin-1-yl]-4-methyl-*N*-phenylbenzamide |
| 199 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(pyrrolidin-1-ylcarbonyl)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 200 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,4-dimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 201 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-(4-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 202 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-(2-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 203 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopropylmethyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 204 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(3-methylbutyl)oxy]-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 205 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-ethylbutyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 206 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(butyloxy)-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 207 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 208 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,4-dimethyl-*N*-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 209 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclobutylmethyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 210 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethyloxy)-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 211 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-[2-(dimethylamino)ethyl]-4-methylbenzamide |
| 212 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-(1,1-dimethylethyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 213 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-pyridin-3-yl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 214 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-fluoro-2-methylpropyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 215 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclohexylmethyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 216 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopentylmethyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 217 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-ethyl-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 218 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(1-methylethyl)oxy]-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 219 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,2-dimethylpropyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |

| Cmpd No. | Name |
|---|---|
| 220 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-5-[(tetrahydrofuran-2-ylmethyl)oxy]aniline |
| 221 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-{[2-(methyloxy)ethyl]oxy}-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 222 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(propyloxy)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 223 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2-(dimethylamino)ethyl]amino}-4-methyl-*N*-phenylbenzamide |
| 224 | *N'*-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-fluoro-2-methylpropyl)oxy]-2-methylphenyl}-*N,N*-dimethylethane-1,2-diamine |
| 225 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2-(dimethylamino)ethyl]amino}-4-methyl-*N*-(1-methylethyl)benzamide |
| 226 | 1-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one |
| 227 | *N'*-(3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)-*N,N*-dimethylethane-1,2-diamine |
| 228 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 229 | 5-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-*N*-(2-pyrrolidin-1-ylethyl)biphenyl-3-amine |
| 230 | 1-(3-{5-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbiphenyl-3-yl}propyl)pyridinium |
| 231 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-5-(1,3-thiazol-2-yl)aniline |
| 232 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid |
| 233 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(phenylethynyl)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 234 | {3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(phenyl)methanone |
| 235 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethynyl-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 236 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbut-1-yn-1-yl)-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 237 | 3-bromo-4-{4-[5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 238 | 3-bromo-4-{4-[2-methyl-5-[(2-methylpropyl)oxy]-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 239 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 240 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 241 | 1-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}propan-1-one |
| 242 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |

| Cmpd No. | Name |
|---|---|
| 243 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethyl-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 244 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-5-[2-(trimethylsilyl)ethyl]aniline |
| 245 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-phenylethyl)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 246 | 1-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one |
| 247 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,4-dimethyl-*N*-(methyloxy)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 248 | 3-bromo-4-[4-(3-bromo-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 249 | 4-[4-(3-bromo-5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 250 | 1-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}ethanone |
| 251 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(difluoromethyl)oxy]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 252 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[(difluoromethyl)oxy]methyl}-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 253 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methyloxy)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 254 | 5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 255 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5,6-trifluoro-*N*-(3-methylbutyl)pyridin-4-amine |
| 256 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-[(cyclopropylmethyl)oxy]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide |
| 257 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 258 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethylsulfonyl)-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 259 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methylsulfonyl)-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 260 | 1-{3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one |
| 261 | 3-bromo-4-[4-(5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 262 | 6-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5-difluoro-*N*~4~-(3-methylbutyl)-*N*~2~-(2-pyrrolidin-1-ylethyl)pyridine-2,4-diamine |
| 263 | 3-bromo-5-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 264 | 3-bromo-4-[4-(3',4',6-trifluoro-4-methylbiphenyl-3-yl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 265 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-*N*-(2-pyrrolidin-1-ylethyl)aniline |

| Cmpd No. | Name |
|---|---|
| 266 | {3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}methanol |
| 267 | 3-bromo-4-(4-{4-methyl-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 268 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[(2,2-difluorocyclopropyl)methyl]oxy}-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 269 | 5-bromo-3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 270 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(ethyloxy)methyl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 271 | 3-[4-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-1-methyl-6-(trifluoromethyl)-1*H*-benzimidazol-2-yl]propan-1-ol |
| 272 | 1-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}-4,4,4-trifluorobutan-1-one |
| 273 | {3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(cyclopropyl)methanone |
| 274 | 3-({3'-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)-*N*,*N*-dimethylpropan-1-amine |
| 275 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(1,1-difluorobutyl)-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)aniline |
| 276 | 3-bromo-4-(4-{4-methyl-2'-[(3-morpholin-4-ylpropyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 277 | 3-bromo-4-(4-{4-methyl-2'-[(2-morpholin-4-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 278 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-5-{[(2,2,2-trifluoroethyl)oxy]methyl}aniline |
| 279 | 1-[2-({3'-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)ethyl]pyrrolidine-2,5-dione |
| 280 | 3-bromo-4-(4-{3'-fluoro-4-methyl-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 281 | 1-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one |
| 282 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-5-[(3,3,3-trifluoropropyl)oxy]aniline |
| 283 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]aniline |
| 284 | 1-{3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-ol |
| 285 | 3-bromo-4-(4-{4-chloro-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 286 | 3-[4-(4-{5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol |
| 287 | 3-bromo-4-(4-{4-chloro-4'-fluoro-2'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 288 | 3-bromo-4-(4-{4-methyl-3'-[(2-pyrrolidin-1-ylethyl)oxy]biphenyl-3-yl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |

| Cmpd No. | Name |
|---|---|
| 289 | (2E)-3-[4-(4-{5-{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid |
| 290 | 3-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-*N*-(2-pyrrolidin-1-ylethyl)-5-[4,4,4-trifluoro-1,1-bis(methyloxy)butyl]aniline |
| 291 | 6-(4-phenylpiperazin-1-yl)-9*H*-purine |
| 292 | 6-[4-(3-chlorophenyl)piperazin-1-yl]-9*H*-purine |
| 293 | 4-(4-phenylpiperazin-1-yl)-7*H*-pyrrolo[2,3-d]pyrimidine |
| 294 | 4-[4-(3-chlorophenyl)piperazin-1-yl]-7*H*-pyrrolo[2,3-d]pyrimidine |
| 295 | 4-(4-phenylpiperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 296 | 4-[4-(3-chlorophenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 297 | 6-[4-(2-chlorophenyl)piperazin-1-yl]-9*H*-purine |
| 298 | 6-[4-(2-fluorophenyl)piperazin-1-yl]-9*H*-purine |
| 299 | 4-[4-(2-methylphenyl)piperazin-1-yl]-7*H*-pyrrolo[2,3-d]pyrimidine |
| 300 | 4-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-7*H*-pyrrolo[2,3-d]pyrimidine |
| 301 | 4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-7*H*-pyrrolo[2,3-d]pyrimidine |
| 302 | 4-{4-[4-(methyloxy)phenyl]piperazin-1-yl}-7*H*-pyrrolo[2,3-d]pyrimidine |
| 303 | 4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-7*H*-pyrrolo[2,3-d]pyrimidine |
| 304 | 6-{4-[4-(methyloxy)phenyl]piperazin-1-yl}-9*H*-purine |
| 305 | 6-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-9*H*-purine |
| 306 | 6-[4-(4-chlorophenyl)piperazin-1-yl]-9*H*-purine |
| 307 | 6-[4-(4-fluorophenyl)piperazin-1-yl]-9*H*-purine |
| 308 | 4-[4-(4-chlorophenyl)piperazin-1-yl]-7*H*-pyrrolo[2,3-d]pyrimidine |
| 309 | 4-[4-(2-chlorophenyl)piperazin-1-yl]-7*H*-pyrrolo[2,3-d]pyrimidine |
| 310 | 4-[4-(4-fluorophenyl)piperazin-1-yl]-7*H*-pyrrolo[2,3-d]pyrimidine |
| 311 | 4-[4-(2-fluorophenyl)piperazin-1-yl]-7*H*-pyrrolo[2,3-d]pyrimidine |
| 312 | 6-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-9*H*-purine |
| 313 | 6-[4-(2-methylphenyl)piperazin-1-yl]-9*H*-purine |
| 314 | 4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 315 | 4-[4-(2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 316 | 4-[4-(3-chlorophenyl)piperazin-1-yl]-3-methyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 317 | 3-methyl-4-[4-(2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 318 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 319 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 320 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-6-phenyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 321 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 322 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-methyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 323 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 324 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-(1-methylethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 325 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-phenyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 326 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-({[2-(methyloxy)ethyl]oxy}methyl)-1*H*-pyrazolo[3,4-d]pyrimidine |

| Cmpd No. | Name |
|---|---|
| 327 | 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 328 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-propyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 329 | 4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}phenol |
| 330 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-*N*-phenyl-1*H*-pyrazolo[3,4-d]pyrimidin-3-amine |
| 331 | 4-[4-(3-chlorophenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 332 | 4-{4-[5-chloro-2-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 333 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}phenol |
| 334 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{3-[(phenylmethyl)oxy]phenyl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 335 | 3-(1,3-benzodioxol-5-yl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 336 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-thienyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 337 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}aniline |
| 338 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}benzoic acid |
| 339 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylphenyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 340 | *N*-(4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}phenyl)acetamide |
| 341 | 4-[4-(3-chlorophenyl)-1,4-diazepan-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 342 | 4-[5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 343 | 4-(4-{3-chloro-4-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 344 | methyl 1-(3-chlorophenyl)-4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate |
| 345 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methylbut-2-en-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 346 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 347 | methyl 4-(3-chlorophenyl)-1-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate |
| 348 | 4-(4-{3-chloro-4-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 349 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1-methylethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 350 | 1-(3-chlorophenyl)-4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylic acid |
| 351 | 1-(3-chlorophenyl)-4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-*N*-methylpiperazine-2-carboxamide |

| Cmpd No. | Name |
|---|---|
| 352 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(phenylmethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 353 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methylpropyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 354 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(methyloxy)phenyl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 355 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-fluorophenyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 356 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(phenyloxy)phenyl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 357 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{4-[(piperidin-4-ylmethyl)oxy]phenyl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 358 | 1-(3-chlorophenyl)-*N*-[2-(dimethylamino)ethyl]-4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxamide |
| 359 | 4-[4-(5-chloro-2-methyl-3-morpholin-4-ylphenyl)piperazin-1-yl]-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 360 | 4-(3-chlorophenyl)-1-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-*N*-methylpiperazine-2-carboxamide |
| 361 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[2-(methyloxy)phenyl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 362 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-pyridin-4-yl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 363 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(methyloxy)phenyl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 364 | 4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}benzonitrile |
| 365 | [5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methanol |
| 366 | methyl 5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate |
| 367 | (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoic acid |
| 368 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}propanoic acid |
| 369 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}propan-1-ol |
| 370 | methyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate |
| 371 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{4-[(2-morpholin-4-ylethyl)oxy]phenyl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 372 | 5-chloro-*N*-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzamide |
| 373 | 4-(4-{5-chloro-2-(methyloxy)-3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}piperazin-1-yl)-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 374 | 2-(dimethylamino)ethyl 5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate |

| Cmpd No. | Name |
|---|---|
| 375 | 1-[5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]-*N*,*N*-dimethylmethanamine |
| 376 | *N*'-{[5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methyl}-*N*,*N*-dimethylethane-1,2-diamine |
| 377 | [1-(3-chlorophenyl)-4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-2-yl]methanol |
| 378 | 3-[(4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}phenyl)oxy]-*N*,*N*-dimethylpropan-1-amine |
| 379 | 2-chloro-4-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenol |
| 380 | 1-(3-chlorophenyl)-4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-*N*-(1-methylpiperidin-4-yl)piperazine-2-carboxamide |
| 381 | 1-(3-chlorophenyl)-4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-*N*-(2-morpholin-4-ylethyl)piperazine-2-carboxamide |
| 382 | 2-{[5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]oxy}-*N*,*N*-dimethylethanamine |
| 383 | 3-{5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-*N*,*N*-dimethylprop-2-yn-1-amine |
| 384 | *N*'-{5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-*N*,*N*-dimethylethane-1,2-diamine |
| 385 | 1,1-dimethylethyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate |
| 386 | 3-({2-chloro-4-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-*N*,*N*-dimethylpropan-1-amine |
| 387 | 2-({2-chloro-4-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-*N*,*N*-dimethylethanamine |
| 388 | 4-{4-[5-chloro-2-methyl-4-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |
| 389 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylpiperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 390 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}-*N*,*N*-diethylprop-2-yn-1-amine |
| 391 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-ol |
| 392 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(piperidin-4-ylmethyl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 393 | phenylmethyl (3aR,6aS)-5-({4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}methylidene)hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate |
| 394 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[(E)-(3aR,6aS)-hexahydrocyclopenta[c]pyrrol-5(1*H*)-ylidenemethyl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 395 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 396 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 397 | 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidin-3-yl}-*N*,*N*-diethylpropan-1-amine |
| 398 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylpropyl)-1*H*-pyrazolo[3,4-d]pyrimidine |

| Cmpd No. | Name |
|---|---|
| 399 | 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1,2,3,6-tetrahydropyridin-4-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 400 | 3-{5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-*N*,*N*-diethylpropan-1-amine |
| 401 | 4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine |

**Table 2b.**

**Additional Representative AKT Inhibitors**

**[00227]** The Compounds in Table 2b can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 2b can be used to practice the invention.

| Entry | Name |
|---|---|
| 1 | [1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol |
| 2 | 2-{[[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]oxy}-*N*,*N*-dimethylethanamine |
| 3 | 3-{[[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]oxy}-*N*,*N*-dimethylpropan-1-amine |
| 4 | 3-bromo-4-{4-[(4-bromophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 5 | {4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-1-[(4-chlorophenyl)methyl]piperazin-2-yl}methanol |
| 6 | *N'*-[[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]-*N*,*N*-diethylethane-1,2-diamine |
| 7 | 3-bromo-4-(4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 8 | 4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-1-[(4-chlorophenyl)methyl]piperazin-2-one |
| 9 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(4-chlorophenyl)-*N*-[2-(dimethylamino)ethyl]acetamide |
| 10 | *N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*-(4-chlorophenyl)-*N'*,*N'*-diethylpropane-1,3-diamine |
| 11 | 3-bromo-4-(4-{[4-(trifluoromethyl)phenyl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 12 | *N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*-(4-chlorophenyl)-*N'*-[2-(dimethylamino)ethyl]urea |
| 13 | *N*-[[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]-*N'*-[2-(dimethylamino)ethyl]urea |
| 14 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-2-oxopiperazin-1-yl]-2-(4-chlorophenyl)-*N*-[2-(dimethylamino)ethyl]acetamide |
| 15 | 2-(dimethylamino)ethyl [1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)carbamate |
| 16 | 3-bromo-4-{4-[(4-chloro-3-fluorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 17 | 3-bromo-4-{4-[(4-chloro-2-fluorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |

| Entry | Name |
|---|---|
| 18 | *N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*-(4-chlorophenyl)-*N'*,*N'*-diethylethane-1,2-diamine |
| 19 | 3-bromo-4-{4-[(4-chlorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 20 | [1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-fluorophenyl)methanone |
| 21 | *N*-[[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]-*N'*,*N'*-diethyl-*N*-methylethane-1,2-diamine |
| 22 | [1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-fluorophenyl)methanol |
| 23 | 3-bromo-4-(4-{[2-fluoro-4-(trifluoromethyl)phenyl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 24 | *N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*-(4-chlorophenyl)-*N*~3~,*N*~3~~diethyl-beta-alaninamide |
| 25 | 2-{[[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-fluorophenyl)methyl]oxy}-*N*,*N*-dimethylethanamine |
| 26 | *N*-[[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]-*N*~3~,*N*~3~~diethyl-beta-alaninamide |
| 27 | 3-bromo-4-{4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 28 | *N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*-(4-chlorophenyl)-*N'*-[2-(dimethylamino)ethyl]ethanediamide |
| 29 | *N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*-(4-chlorophenyl)-2-(diethylamino)ethanesulfonamide |
| 30 | 4-[4-(biphenyl-4-ylmethyl)piperazin-1-yl]-3-bromo-1*H*-pyrazolo[3,4-d]pyrimidine |
| 31 | 3-bromo-4-{(3S)-4-[(4-chlorophenyl)methyl]-3-methylpiperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 32 | 3-bromo-4-(4-{[4-(methyloxy)phenyl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 33 | 4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-*N*-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide |
| 34 | 3-bromo-4-{4-[(4-fluorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 35 | *N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*-(4-chlorophenyl)pent-4-enamide |
| 36 | 3-bromo-4-[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 37 | 4-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-3-bromo-1*H*-pyrazolo[3,4-d]pyrimidine |
| 38 | [1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanone |
| 39 | 3-bromo-4-(4-{[4-(phenyloxy)phenyl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 40 | 3-bromo-4-{4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 41 | 4-{[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]methyl}-*N*,*N*-dimethylaniline |
| 42 | methyl 4-{[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]methyl}benzoate |
| 43 | 3-bromo-4-{4-[(2E)-3-phenylprop-2-enoyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |

| Entry | Name |
|---|---|
| 44 | 1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-4-[(4-chlorophenyl)methyl]-*N*-[3-(diethylamino)propyl]piperidine-4-carboxamide |
| 45 | 3-bromo-4-{4-[(2-bromophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 46 | 3-bromo-4-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 47 | 3-bromo-4-{4-[(2,4-dichlorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 48 | 3-bromo-4-{4-[(2-chloro-4-fluorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 49 | 1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-4-(4-chlorophenyl)-*N*-[3-(diethylamino)propyl]piperidine-4-carboxamide |
| 50 | 3-bromo-4-[4-(phenylmethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 51 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*-pyridin-2-ylacetamide |
| 52 | 3-bromo-4-[4-(1*H*-imidazol-2-ylmethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 53 | 3-bromo-4-(4-{[3-(phenyloxy)phenyl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 54 | 3-bromo-4-{4-[(3-methylphenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 55 | 3-{[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]methyl}benzonitrile |
| 56 | 3-bromo-4-{4-[(2-chloro-6-fluorophenyl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 57 | 3-bromo-4-[4-(1-phenylethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 58 | 3-bromo-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 59 | 1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-*N*-(4-chlorophenyl)piperidin-4-amine |
| 60 | 3-bromo-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 61 | 3-bromo-4-(4-{[2,3,4-tris(methyloxy)phenyl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 62 | 3-bromo-4-[4-({3-[(phenylmethyl)oxy]phenyl}methyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 63 | 3-bromo-4-[4-(naphthalen-1-ylmethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 64 | 3-bromo-4-(4-{[5-(4-chlorophenyl)furan-2-yl]methyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 65 | 3-bromo-4-[4-({4-[(4-fluorophenyl)oxy]-3-nitrophenyl}methyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 66 | 3-bromo-4-[4-(furan-2-ylcarbonyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 67 | 3-bromo-4-[4-(1*H*-indol-6-ylcarbonyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 68 | 3-bromo-4-{4-[2-(2-thienyl)ethyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 69 | 3-bromo-4-[4-(3-pyrrolidin-1-ylpropyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |

| Entry | Name |
|---|---|
| 70 | 3-bromo-4-[4-(cyclohexylmethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 71 | 3-bromo-4-{4-[(10-chloroanthracen-9-yl)methyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 72 | 3-bromo-4-[4-(1-methylpropyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 73 | 4-(4-{[4,6-bis(methyloxy)pyrimidin-2-yl]methyl}piperazin-1-yl)-3-bromo-1*H*-pyrazolo[3,4-d]pyrimidine |
| 74 | 3-bromo-4-{4-[2-(methyloxy)ethyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 75 | 3-bromo-4-[4-(2-morpholin-4-yl-2-oxoethyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 76 | 3-bromo-4-{4-[3-(methyloxy)propyl]piperazin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 77 | 4-{4-[[4,6-bis(methyloxy)pyrimidin-2-yl](phenyl)methyl]piperazin-1-yl}-3-bromo-1*H*-pyrazolo[3,4-d]pyrimidine |
| 78 | 3-bromo-4-[4-(6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-yl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 79 | 3-bromo-4-[4-({4-[(phenylmethyl)oxy]phenyl}methyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 80 | 3-bromo-4-[4-({3-chloro-4-[(phenylmethyl)oxy]phenyl}methyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 81 | 4-{[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]methyl}-*N*-(3-morpholin-4-ylpropyl)benzamide |
| 82 | 4-{[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]methyl}-*N*-[3-(methyloxy)propyl]benzamide |
| 83 | 2-[({4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)-1-[(4-chlorophenyl)methyl]piperazin-2-yl}methyl)oxy]-*N*,*N*-dimethylethanamine |
| 84 | 3-bromo-4-[4-({4-[(4-chlorophenyl)oxy]-3-nitrophenyl}methyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-d]pyrimidine |
| 85 | 2-[4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-*N*,*N*-dimethylacetamide |
| 86 | 2-{[(R)-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]oxy}-*N*,*N*-dimethylethanamine |
| 87 | *N*-(4-bromo-3-fluorophenyl)-*N*-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-*N*'-[2-(dimethylamino)ethyl]urea |
| 88 | 2-({(R)-(4-chlorophenyl)[1-(3-ethyl-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]methyl}oxy)-*N*,*N*-dimethylethanamine |
| 89 | 2-{[(S)-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]oxy}-*N*,*N*-dimethylethanamine |
| 90 | 3-bromo-4-(4-{(R)-(4-chlorophenyl)[(2-pyrrolidin-1-ylethyl)oxy]methyl}piperidin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 91 | 1-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-1-(4-chlorophenyl)-4-(dimethylamino)butan-1-ol |
| 92 | 2-{[(R)-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chloro-3-fluorophenyl)methyl]oxy}-*N*,*N*-dimethylethanamine |
| 93 | 3-bromo-4-(4-{(R)-(4-chlorophenyl)[(2-piperidin-1-ylethyl)oxy]methyl}piperidin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 94 | 4-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-4-(4-chlorophenyl)-*N*,*N*-dimethylbutan-1-amine |
| 95 | 3-bromo-4-(4-{(R)-(4-chlorophenyl)[(2-morpholin-4-ylethyl)oxy]methyl}piperidin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |

| Entry | Name |
|---|---|
| 96 | 1-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-1-(4-fluorophenyl)-*N*-(furan-2-ylmethyl)-*N*-methylmethanamine |
| 97 | 1-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]-1-(4-fluorophenyl)-*N*-methyl-*N*-(pyridin-2-ylmethyl)methanamine |
| 98 | 4-{[{[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-fluorophenyl)methyl}(methyl)amino]methyl}-*N*,*N*-dimethylaniline |
| 99 | [4-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl](1*H*-indol-6-yl)methanol |
| 100 | 3-bromo-4-(4-{(R)-(4-chloro-3-fluorophenyl)[(2-pyrrolidin-1-ylethyl)oxy]methyl}piperidin-1-yl)-1*H*-pyrazolo[3,4-d]pyrimidine |
| 101 | 3-bromo-4-{4-[(4-chlorophenyl)oxy]piperidin-1-yl}-1*H*-pyrazolo[3,4-d]pyrimidine |
| 102 | 2-{[(R)-[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methyl]oxy}-*N*,*N*-diethylethanamine |
| 103 | 2-{[1-(3-bromo-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl]oxy}-5-chloro-*N*-(2-pyrrolidin-1-ylethyl)aniline |

**Table 3a.**

**Representative c-MET and/or Flt-3 Inhibitors**

**[00228]** The Compounds in Table 3a can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 3a can be used to practice the invention.

| Cmpd No. | Name |
|---|---|
| 1 | *N*-(4-fluorophenyl)-*N'*-[3-fluoro-4-(7*H*-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]propanediamide |
| 2 | *N*-(4-fluorophenyl)-*N'*-[3-fluoro-4-(7*H*-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]cyclopropane-1,1-dicarboxamide |
| 3 | *N*-({[3-fluoro-4-(7*H*-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]amino}carbonothioyl)-2-phenylacetamide |
| 4 | *N*-(4-fluorophenyl)-*N'*-(4-{[1-(tetrahydro-2*H*-pyran-2-yl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide |
| 5 | 2-phenyl-*N*-{[(4-{[1-(tetrahydro-2*H*-pyran-2-yl)-1*H*-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}phenyl)amino]carbonothioyl}acetamide |
| 6 | *N*-(4-fluorophenyl)-*N'*-[4-(1*H*-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl]cyclopropane-1,1-dicarboxamide |
| 7 | 2-phenyl-*N*-({[4-(1*H*-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl]amino}carbonothioyl)acetamide |
| 8 | *N*-(4-fluorophenyl)-*N'*-(4-{[9-(tetrahydro-2*H*-pyran-2-yl)-9*H*-purin-6-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide |
| 9 | 2-phenyl-*N*-{[(4-{[9-(tetrahydro-2*H*-pyran-2-yl)-9*H*-purin-6-yl]oxy}phenyl)amino]carbonothioyl}acetamide |
| 10 | *N*-(4-fluorophenyl)-*N'*-[4-(9*H*-purin-6-yloxy)phenyl]cyclopropane-1,1-dicarboxamide |

| Cmpd No. | Name |
|---|---|
| 11 | 2-phenyl-*N*-({[4-(9*H*-purin-6-yloxy)phenyl]amino}carbonothioyl)acetamide |
| 12 | *N*-{3-fluoro-4-[(6-{[(2-morpholin-4-ylethyl)amino]carbonyl}-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |

**Table 3b.**

**Additional Representative c-MET, c-KIT, and/or Flt-3 Inhibitors**

**[00229]** The Compounds in Table 3b can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 3b can be used to practice the invention.

| Entry | Name |
|---|---|
| 1 | *N*-[({3-fluoro-4-[(6-(methyloxy)-7-{[(3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-yl)oxy]phenyl}amino)carbonothioyl]-2-phenylacetamide |
| 2 | *N*-{[(3-fluoro-4-{[7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-yl]oxy}phenyl)amino]carbonothioyl}-2-phenylacetamide |
| 3 | *N*-{[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)(methyl)amino]carbonothioyl}-2-phenylacetamide |
| 4 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)imidazolidin-2-one |
| 5 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-(phenylmethyl)imidazolidin-2-one |
| 6 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-(phenylacetyl)imidazolidin-2-one |
| 7 | ethyl [(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)amino](oxo)acetate |
| 8 | *N*-{[(4-{[6,7-bis(methyloxy)quinazolin-4-yl]amino}-3-fluorophenyl)amino]carbonothioyl}-2-phenylacetamide |
| 9 | *N'*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*-methyl-*N*-(2-phenylethyl)sulfamide |
| 10 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-(phenylmethyl)-1,2,4-oxadiazol-5-amine |
| 11 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)piperidin-2-one |
| 12 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(phenylmethyl)ethanediamide |
| 13 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-4-phenyl-1,3-thiazol-2-amine |
| 14 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(2-phenylethyl)ethanediamide |
| 15 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-1- |

| Entry | Name |
|---|---|
| | phenylmethanesulfonamide |
| 16 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-2-phenylethanesulfonamide |
| 17 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-*N*-(phenylmethyl)benzenesulfonamide |
| 18 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-*N*-methyl-*N*-(phenylmethyl)benzenesulfonamide |
| 19 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-*N*-(2-phenylethyl)benzenesulfonamide |
| 20 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-*N*-methyl-*N*-(2-phenylethyl)benzenesulfonamide |
| 21 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-*N*-(3-phenylpropyl)benzenesulfonamide |
| 22 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)pyrrolidin-2-one |
| 23 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl (phenylmethyl)carbamate |
| 24 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl (2-phenylethyl)carbamate |
| 25 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-*N*-methyl-*N*-(3-phenylpropyl)benzenesulfonamide |
| 26 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-phenylethanediamide |
| 27 | *N*-{[(3-fluoro-4-{[7-{[(2-methyloctahydrocyclopenta[c]pyrrol-5-yl)methyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}phenyl)amino]carbonothioyl}-2-phenylacetamide |
| 28 | *N*-[(Z)-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)amino](imino)methyl]-2-phenylacetamide |
| 29 | 4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-*N*-[2-(phenyloxy)ethyl]benzenesulfonamide |
| 30 | *N,N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-bis-(3-phenylpropane-1-sulfonamide) |
| 31 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-phenylpropane-1-sulfonamide |
| 32 | *N*2-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)sulfonyl]-*N*1-phenylglycinamide |
| 33 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-2-phenylacetamide |
| 34 | *N*-{[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)amino]carbonothioyl}-2-phenylacetamide |
| 35 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3-benzothiazol-2-amine |
| 36 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-amine |
| 37 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-phenylacetamide |
| 38 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(2-morpholin-4-ylethyl)ethanediamide |
| 39 | benzyl-{[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylcarbamoyl]-methyl}-carbamic acid tert-butyl ester |
| 40 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2- |

| Entry | Name |
|---|---|
| | (phenylmethyl)glycinamide |
| 41 | *N*2-acetyl-*N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-(phenylmethyl)glycinamide |
| 42 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3-benzothiazol-2-yl)-2-phenylacetamide |
| 43 | benzyl-{[6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylcarbamoyl]-methyl}-carbamic acid tert-butyl ester |
| 44 | *N*1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-*N*2-(phenylmethyl)glycinamide |
| 45 | *N*2-acetyl-*N*1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-*N*2-(phenylmethyl)glycinamide |
| 46 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-3-phenylpropanamide |
| 47 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-4-phenylbutanamide |
| 48 | *N*1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-*N*2-methyl-*N*2-(phenylmethyl)glycinamide |
| 49 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-{2-[4-(methyloxy)phenyl]ethyl}ethanediamide |
| 50 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-methyl-*N*2-(phenylmethyl)glycinamide |
| 51 | 4-[(2-amino-1,3-benzothiazol-6-yl)oxy]-6,7-bis(methyloxy)-1-(2-oxo-2-phenylethyl)quinolinium |
| 52 | *N*-{[(4-{[6,7-bis(methyloxy)quinolin-4-yl]amino}phenyl)amino]carbonothioyl}-2-phenylacetamide |
| 53 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-3-phenylpropanamide |
| 54 | *N*-{[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)amino]carbonothioyl}-2-phenylacetamide |
| 55 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(2,3-dihydro-1*H*-inden-1-yl)ethanediamide |
| 56 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(2,3-dihydro-1*H*-inden-2-yl)ethanediamide |
| 57 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(1,2,3,4-tetrahydronaphthalen-1-yl)ethanediamide |
| 58 | *N'*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*-(2-phenylethyl)-*N*-(phenylmethyl)sulfamide |
| 59 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-(trifluoroacetyl)glycinamide |
| 60 | *N*-{[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylcarbamoyl]-methyl}-benzamide |
| 61 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-*N'*-(4-fluorophenyl)propanediamide |
| 62 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]ethanediamide |
| 63 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-[2-(4-methylphenyl)ethyl]ethanediamide |

| Entry | Name |
|---|---|
| 64 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(2-phenylpropyl)ethanediamide |
| 65 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-[2-(4-chlorophenyl)ethyl]ethanediamide |
| 66 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N,N'*-bis(phenylmethyl)sulfamide |
| 67 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N,N'*-bis(2-phenylethyl)sulfamide |
| 68 | ethyl [(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)amino](oxo)acetate |
| 69 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(2-phenylethyl)ethanediamide |
| 70 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(4-fluorophenyl)propanediamide |
| 71 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(1,2,3,4-tetrahydronaphthalen-2-yl)ethanediamide |
| 72 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-[2-(1-methylpyrrolidin-2-yl)ethyl]ethanediamide |
| 73 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-[2-(phenyloxy)ethyl]ethanediamide |
| 74 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-[2-hydroxy-1-(phenylmethyl)ethyl]urea |
| 75 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-3-[(4-methylphenyl)sulfonyl]-4-(phenylmethyl)imidazolidin-2-one |
| 76 | *N'*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*-methyl-*N*-(2-phenylethyl)ethanediamide |
| 77 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-{[3-(trifluoromethyl)phenyl]methyl}ethanediamide |
| 78 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-{2-[3-(trifluoromethyl)phenyl]ethyl}ethanediamide |
| 79 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-3-oxo-4-phenylbutanamide |
| 80 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-2-[3-(trifluoromethyl)phenyl]acetamide |
| 81 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-*N*-[2-(phenyloxy)ethyl]-1,3-benzothiazol-2-amine |
| 82 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-*N*-(2-piperidin-1-ylethyl)-1,3-benzothiazol-2-amine |
| 83 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-*N*-methyl-*N*-(2-phenylethyl)-1,3-benzothiazol-2-amine |
| 84 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-*N*-(2-pyrrolidin-1-ylethyl)-1,3-benzothiazol-2-amine |
| 85 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-*N*-{[3-(trifluoromethyl)phenyl]methyl}-1,3-benzothiazol-2-amine |
| 86 | 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-*N*-{2-[3-(trifluoromethyl)phenyl]ethyl}-1,3-benzothiazol-2-amine |
| 87 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-[3-(trifluoromethyl)phenyl]propanediamide |

| Entry | Name |
|---|---|
| 88 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[3-(trifluoromethyl)phenyl]acetamide |
| 89 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-{[3-(trifluoromethyl)phenyl]methyl}glycinamide |
| 90 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-(2-phenylethyl)glycinamide |
| 91 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-{2-[3-(trifluoromethyl)phenyl]ethyl}glycinamide |
| 92 | benzyl-{[5-chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylcarbamoyl]-methyl}-carbamic acid tert-butyl ester |
| 93 | *N*1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N*2-(phenylmethyl)glycinamide |
| 94 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[3,5-bis(trifluoromethyl)phenyl]acetamide |
| 95 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-1,3-benzothiazol-2-yl)-2-[2-chloro-5-(trifluoromethyl)phenyl]acetamide |
| 96 | *N*-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]phenyl}-*N'*-(2-phenylethyl)ethanediamide |
| 97 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)ethanediamide |
| 98 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]ethanediamide |
| 99 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-methyl-*N*2-{[3-(trifluoromethyl)phenyl]methyl}glycinamide |
| 100 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-methyl-*N*2-{2-[3-(trifluoromethyl)phenyl]ethyl}glycinamide |
| 101 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N*2-methyl-*N*2-(2-phenylethyl)glycinamide |
| 102 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-4-(phenylmethyl)imidazolidin-2-one |
| 103 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridazin-3-yl)-*N'*-(4-fluorophenyl)propanediamide |
| 104 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(2-chlorophenyl)propanediamide |
| 105 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(3-chlorophenyl)propanediamide |
| 106 | *N*1-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N*2-methyl-*N*2-(phenylmethyl)glycinamide |
| 107 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(4-chlorophenyl)propanediamide |
| 108 | (2E)-*N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-[(methyloxy)imino]propanamide |
| 109 | (2E)-*N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-[(ethyloxy)imino]propanamide |
| 110 | (2E)-*N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-2-{[(phenylmethyl)oxy]imino}propanamide |
| 111 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-1- |

| Entry | Name |
|---|---|
| | (phenylmethyl)prolinamide |
| 112 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-3-[(4-methylphenyl)sulfonyl]-4-(phenylmethyl)imidazolidin-2-one |
| 113 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl)imidazolidin-2-one |
| 114 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl)-4,5-dihydro-1,3-oxazol-2-amine |
| 115 | 6,7-bis(methyloxy)-4-({4-[4-(phenylmethyl)piperazin-1-yl]phenyl}oxy)quinoline |
| 116 | 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-4-(phenylmethyl)piperazin-2-one |
| 117 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N*2-(phenylmethyl)alaninamide |
| 118 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N*2-methyl-*N*2-(phenylmethyl)alaninamide |
| 119 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N*2-(phenylmethyl)leucinamide |
| 120 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N*2-methyl-*N*2-(phenylmethyl)leucinamide |
| 121 | *N*1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N*2-(phenylmethyl)valinamide |
| 122 | 4-(6,7-dimethoxy-quinolin-4-ylamino)-*N*-(3-phenyl-propyl)-benzamide |
| 123 | 4-benzyl-1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-tetrahydro-pyrimidin-2-one |
| 124 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 125 | 2-(Benzyl-methyl-amino)-*N*-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-3-methyl-butyramide<br>(note: Alphabetic order of prefixes ignored while selecting parent chain) |
| 126 | *N*-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-2-phenoxyimino-propionamide |
| 127 | 2-Benzyloxyimino-*N*-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-2-phenyl-acetamide |
| 128 | 4-[4-(4-Benzyl-piperidin-1-yl)-phenoxy]-6,7-dimethoxy-quinoline |
| 129 | *N*-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-*N'*-(2-isopropyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-oxalamide |
| 130 | *N*-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-*N'*-(2-ethyl-1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-oxalamide |
| 131 | 4-(4-{3-Chloro-5-[2-(4-fluoro-phenylcarbamoyl)-acetylamino]-pyridin-2-yloxy}-6-methoxy-quinolin-7-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester |
| 132 | *N*-{5-Chloro-6-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-pyridin-3-yl}-*N'*-(4-fluoro-phenyl)-malonamide |
| 133 | *N*-{5-Chloro-6-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-pyridin-3-yl}-*N'*-(4-fluoro-phenyl)-malonamide |
| 134 | *N*-{4-[7-(3-Diethylamino-propoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-*N'*-phenethyl-oxalamide |

| Entry | Name |
|---|---|
| 135 | *N*-{3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 136 | *N*-{3-Fluoro-4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)-quinolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 137 | *N*-{4-[7-(2-Diethylamino-ethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-*N'*-phenethyl-oxalamide |
| 138 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-methyl-*N'*-phenethyl-oxalamide |
| 139 | *N*-{3-Fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 140 | *N*-{3-Fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 141 | 2-(3,4-Dihydro-1*H*-isoquinolin-2-yl)-*N*-{3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-acetamide |
| 142 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-(3-phenyl-pyrrolidin-1-yl)-acetamide |
| 143 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-(2-phenyl-morpholin-4-yl)-acetamide |
| 144 | *N*-(2-Dimethylamino-2-phenyl-ethyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 145 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-oxo-2-phenyl-ethyl)-oxalamide |
| 146 | *N*-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-2,2-difluoro-*N'*-(4-fluoro-phenyl)-malonamide |
| 147 | *N*-Benzyl-*N'*-{3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 148 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(2-fluoro-phenyl)-ethyl]-oxalamide |
| 149 | *N*-[2-(3-Chloro-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 150 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(2-methoxy-phenyl)-ethyl]-oxalamide |
| 151 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-pyridin-3-yl-ethyl)-oxalamide |
| 152 | *N*-Benzyl-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 153 | *N*-[2-(2,5-Dimethoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 154 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(2-trifluoromethyl-phenyl)-ethyl]-oxalamide |
| 155 | *N*-[2-(2-Ethoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 156 | *N*-[2-(2,4-Dimethyl-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 157 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(1*S*-phenyl-2-p-tolyl-ethyl)-oxalamide |
| 158 | *N*-[2-(4-Chloro-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4- |

| Entry | Name |
|---|---|
| | ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 159 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamic acid |
| 160 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(3-fluoro-phenyl)-ethyl]-oxalamide |
| 161 | *N*-[2-(2-Chloro-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 162 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(3-methoxy-phenyl)-ethyl]-oxalamide |
| 163 | *N*-(1,2-Diphenyl-ethyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 164 | *N*-[2-(2,4-Dichloro-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 165 | *N*-[2-(3,4-Dimethoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 166 | *N*-[2-(4-Ethyl-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 167 | *N*-[2-(4-Ethoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 168 | *N*-[2-(4-Ethoxy-3-methoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 169 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(4-phenoxy-phenyl)-ethyl]-oxalamide |
| 170 | *N*-[2-(3-Ethoxy-4-methoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 171 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-pyridin-2-yl-ethyl)-oxalamide |
| 172 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-pyridin-4-yl-ethyl)-oxalamide |
| 173 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(4-fluoro-phenyl)-ethyl]-oxalamide |
| 174 | *N*-[2-(2-Bromo-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 175 | *N*-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 176 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2*R*-phenyl-propyl)-oxalamide |
| 177 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-indan-1-yl-oxalamide |
| 178 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-isobutyl-oxalamide |
| 179 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(3-methyl-butyl)-oxalamide |
| 180 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2*R*-phenyl-propyl)-oxalamide |
| 181 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-phenyl-propyl)-oxalamide |
| 182 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin- |

| Entry | Name |
|---|---|
| | 4-yloxy]-phenyl}-*N*'-indan-2-yl-oxalamide |
| 183 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-(1*R*-phenyl-ethyl)-oxalamide |
| 184 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-(1*S*-phenyl-ethyl)-oxalamide |
| 185 | *N*-[2-(3-Bromo-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 186 | *N*-[2-(2,6-Dichloro-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 187 | *N*-[2-(2,4-Dichloro-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 188 | *N*-(2-Benzo[1,3]dioxol-5-yl-ethyl)-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 189 | *N*-[2-(3-Bromo-4-methoxy-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 190 | *N*-[2-(3,5-Dimethoxy-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 191 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-(2-o-tolyl-ethyl)-oxalamide |
| 192 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-(2-m-tolyl-ethyl)-oxalamide |
| 193 | *N*-[2-(3-Ethoxy-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 194 | *N*-[2-(3,4-Dimethyl-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 195 | *N*-[2-(2,5-Dimethyl-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 196 | *N*-[2-(3-Chloro-4-propoxy-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 197 | *N*-[2-(4-Butoxy-3-chloro-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 198 | *N*-[2-(4-tert-Butyl-phenyl)-ethyl]-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 199 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-[2-(4-sulfamoyl-phenyl)-ethyl]-oxalamide |
| 200 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-[2-(4-hydroxy-3-methoxy-phenyl)-ethyl]-oxalamide |
| 201 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-[2-(3-hydroxy-4-methoxy-phenyl)-ethyl]-oxalamide |
| 202 | *N*-(2,4-Dichloro-benzyl)-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 203 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-(4-fluoro-2-trifluoromethyl-benzyl)-oxalamide |
| 204 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-(1-p-tolyl-ethyl)-oxalamide |
| 205 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*'-(3-fluoro-4-trifluoromethyl-benzyl)-oxalamide |
| 206 | *N*-(3-Chloro-4-fluoro-benzyl)-*N*'-{3-fluoro-4-[6-methoxy-7-(piperidin-4- |

| Entry | Name |
|---|---|
| | ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 207 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[1-(3-methoxy-phenyl)-ethyl]-oxalamide |
| 208 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(1-naphthalen-2-yl-ethyl)-oxalamide |
| 209 | *N*-(4-Chloro-3-trifluoromethyl-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 210 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(1-p-tolyl-ethyl)-oxalamide |
| 211 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(6-trifluoromethyl-pyridin-3-ylmethyl)-oxalamide |
| 212 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-methyl-benzyl)-oxalamide |
| 213 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(3-methyl-benzyl)-oxalamide |
| 214 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(4-fluoro-3-trifluoromethyl-benzyl)-oxalamide |
| 215 | *N*-(3,5-Dichloro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 216 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(1R,2,3,4-tetrahydro-naphthalen-1-yl)-oxalamide |
| 217 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(1S,2,3,4-tetrahydro-naphthalen-1-yl)-oxalamide |
| 218 | *N*-Cyclopentyl-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 219 | *N*-[1-(4-Bromo-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 220 | *N*-(2-Fluoro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 221 | *N*-[2-(3,4-Dichloro-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 222 | *N*-(4-Fluoro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 223 | *N*-(2,3-Difluoro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 224 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-phenoxy-ethyl)-oxalamide |
| 225 | *N*-(2,2-Diphenyl-ethyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 226 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(4-methoxy-phenyl)-ethyl]-oxalamide |
| 227 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-phenyl-propyl)-oxalamide |
| 228 | *N*-[2-(4-Bromo-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 229 | *N*-{4-[7-(1-Ethyl-piperidin-4-ylmethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-2-oxo-2-(2-phenyl-morpholin-4-yl)-acetamide |
| 230 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]- |

| Entry | Name |
|---|---|
| | phenyl}-*N'*-(3-fluoro-5-trifluoromethyl-benzyl)-oxalamide |
| 231 | *N*-(3,5-Difluoro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 232 | *N*-(2-Chloro-5-trifluoromethyl-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 233 | *N*-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-*N'*-(2-dimethylamino-2-phenyl-ethyl)-oxalamide |
| 234 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(4-methoxy-benzyl)-oxalamide |
| 235 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(4-trifluoromethyl-benzyl)-oxalamide |
| 236 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(3-methoxy-benzyl)-oxalamide |
| 237 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(3-trifluoromethyl-benzyl)-oxalamide |
| 238 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(3-trifluoromethoxy-benzyl)-oxalamide |
| 239 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-methoxy-benzyl)-oxalamide |
| 240 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-trifluoromethyl-benzyl)-oxalamide |
| 241 | *N*-(3-Chloro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 242 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-trifluoromethoxy-benzyl)-oxalamide |
| 243 | *N*-(2-Chloro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 244 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(4-trifluoromethoxy-benzyl)-oxalamide |
| 245 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(4-methoxy-benzyl)-oxalamide |
| 246 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(4-trifluoromethyl-benzyl)-oxalamide |
| 247 | *N*-{4-[7-(Azetidin-3-ylmethoxy)-6-methoxy-quinolin-4-yloxy]-3-fluoro-phenyl}-*N'*-phenethyl-oxalamide |
| 248 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-azetidin-3-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 249 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-hydroxy-2-phenyl-ethyl)-oxalamide |
| 250 | *N*-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-*N'*-(2,4-difluoro-phenyl)-malonamide |
| 251 | *N*-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-*N'*-(4-fluoro-phenyl)-*N'*-methyl-malonamide |
| 252 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(1R-phenyl-propyl)-oxalamide |
| 253 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(1R-phenyl-propyl)-oxalamide |
| 254 | *N*-(3,4-Difluoro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4- |

| Entry | Name |
|---|---|
| | ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 255 | *N*-(2,6-Difluoro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 256 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[2-(4-fluoro-phenyl)-ethyl]-oxalamide |
| 257 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-phenyl-oxalamide |
| 258 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(3-fluoro-phenyl)-oxalamide |
| 259 | *N*-(4-Chloro-3-fluoro-phenyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 260 | *N*-(3,4-Dimethoxy-phenyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 261 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(3-methyl-butyl)-oxalamide |
| 262 | *N*-(3,3-Dimethyl-butyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 263 | *N*-{5-Chloro-6-[6-methoxy-7-(3-piperidin-1-yl-propoxy)-quinolin-4-yloxy]-pyridin-3-yl}-*N'*-(4-fluoro-phenyl)-malonamide |
| 264 | *N*-{5-Chloro-6-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-yloxy]-pyridin-3-yl}-*N'*-(4-fluoro-phenyl)-malonamide |
| 265 | *N*-{5-Chloro-6-[7-(3-diethylamino-propoxy)-6-methoxy-quinolin-4-yloxy]-pyridin-3-yl}-*N'*-(4-fluoro-phenyl)-malonamide |
| 266 | *N*-(4-Chloro-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 267 | *N*-(3,5-Dimethoxy-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 268 | *N*-(4-Butyl-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 269 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-p-tolyl-ethyl)-oxalamide |
| 270 | *N*-(3,5-Bis-trifluoromethyl-benzyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 271 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-pyrazin-2-ylmethyl-oxalamide |
| 272 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-pyridin-2-ylmethyl-oxalamide |
| 273 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 274 | *N*-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 275 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-fluoro-3-trifluoromethyl-benzyl)-oxalamide |
| 276 | *N*-[2-(2-Bromo-6-methoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 277 | *N*-[2-(3,4-Dimethoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*-methyl-oxalamide |
| 278 | *N*-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7- |

| Entry | Name |
|---|---|
| | (piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 279 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-fluoro-5-trifluoromethyl-benzyl)-oxalamide |
| 280 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-[1-(4-fluoro-phenyl)-ethyl]-oxalamide |
| 281 | *N*-(1S-Benzyl-2-oxo-2-pyrrolidin-1-yl-ethyl)-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 282 | *N*-{3-Fluoro-4-[6-methoxy-7-(octahydro-cyclopenta[c]pyrrol-5-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-*N'*-phenethyl-oxalamide |
| 283 | *N*-[2-(4-Amino-phenyl)-ethyl]-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 284 | 2-(4-Benzyl-piperidin-1-yl)-*N*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-acetamide |
| 285 | *N*-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-*N'*-(4-fluoro-phenyl)-malonamide |
| 286 | *N*-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-*N'*-(3-fluoro-phenyl)-malonamide |
| 287 | *N*-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-*N'*-phenyl-malonamide |
| 288 | *N*-[5-Chloro-6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-*N'*-(4-fluoro-phenyl)-2,2-dimethyl-malonamide |
| 289 | *N*-Ethyl-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 290 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-isopropyl-oxalamide |
| 291 | *N*-Butyl-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 292 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-methoxy-ethyl)-oxalamide |
| 293 | *N*-Cyclopropylmethyl-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-oxalamide |
| 294 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N'*-(2-morpholin-4-yl-ethyl)-oxalamide |
| 295 | *N*-{3-Fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-2-oxo-2-pyrrolidin-1-yl-acetamide |
| 296 | *N*-Ethyl-*N'*-{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl}-*N*-methyl-oxalamide |

**Table 3c.**

**Additional Representative c-MET, c-KIT, and/or Flt-3 Inhibitors**

**[00230]** The Compounds in Table 3c can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 3c can be used to practice the invention.

| Entry | Name |
|---|---|
| 1 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 2 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 3 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(phenylmethyl)cyclopropane-1,1-dicarboxamide |
| 4 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-phenylcyclopropane-1,1-dicarboxamide |
| 5 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 6 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 7 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 8 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-yl)-*N'*-(2-phenylethyl)cyclopropane-1,1-dicarboxamide |
| 9 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-methylpyridin-3-yl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 10 | *N*-{4-[(7-chloroquinolin-4-yl)oxy]-3-fluorophenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 11 | *N*-{4-[(7-chloroquinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 12 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 13 | *N*-(4-{[6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 14 | *N*-(4-{[6,7-bis(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 15 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 16 | *N*-{5-chloro-6-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]pyridin-3-yl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 17 | *N*-[5-chloro-6-({6-(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 18 | *N*-[5-chloro-6-({6-(methyloxy)-7-[(phenylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 19 | *N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 20 | *N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 21 | *N*-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinazolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 22 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-methylphenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 23 | *N*-(4-fluorophenyl)-*N'*-[2-methyl-6-({6-(methyloxy)-7-[(3-morpholin-4- |

| Entry | Name |
|---|---|
| | ylpropyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]cyclopropane-1,1-dicarboxamide |
| 24 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 25 | *N*-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-chloro-2-methylpyridin-3-yl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 26 | *N*-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 27 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3,5-difluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 28 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,5-difluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 29 | *N*-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 30 | *N*-{3-fluoro-4-[(6-(methyloxy)-7-(2-methyl octahydrocyclo-penta[c]pyrrol-5-ylmethoxy)quinazolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 31 | *N*-{3-fluoro-4-[(7-(methyloxy)-6-{[(1-methylpiperidin-4-yl)methyl]oxy}quinazolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 32 | *N*-[5-fluoro-2-methyl-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 33 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,3,5-trifluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 34 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-2-methylphenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 35 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-chloro-5-methylphenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 36 | *N*-(3-fluoro-4-{[6-hydroxy-7-(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 37 | *N*-(4-fluorophenyl)-*N'*-[2-methyl-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide |
| 38 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 39 | *N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 40 | *N*-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 41 | *N*-(4-fluorophenyl)-*N'*-[4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide |
| 42 | *N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 43 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2-chloro-5-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 44 | *N*-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4-yl]oxy}-3-fluorophenyl)- |

| Entry | Name |
|---|---|
| | *N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 45 | *N*-(4-fluorophenyl)-*N'*-(4-{[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide |
| 46 | *N*-(4-{[2-amino-6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 47 | *N*-(3-fluoro-4-{[2-(methylamino)-6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 48 | (1S,2R)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 49 | (1R,2R)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 50 | *N*-(4-{[6-{[3-(diethylamino)propyl]oxy}-7-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 51 | *N*-(4-{[6-{[2-(diethylamino)ethyl]oxy}-7-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 52 | 1,1-dimethylethyl 4-(3-{[4-[(2-fluoro-4-{[(1-{[(4-fluorophenyl)amino]carbonyl}cyclopropyl)carbonyl]amino}phenyl)oxy]-6-(methyloxy)quinolin-7-yl]oxy}propyl)piperazine-1-carboxylate |
| 53 | (1R,2R)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 54 | (1R,2R)-*N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 55 | *N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 56 | *N*-(4-{[7-{[3-(4-acetylpiperazin-1-yl)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 57 | 1,1-dimethylethyl 4-(3-{[4-[(2-fluoro-4-{[((1R,2R)-1-{[(4-fluorophenyl)amino]carbonyl}-2-methylcyclopropyl)carbonyl]amino}phenyl)oxy]-6-(methyloxy)quinolin-7-yl]oxy}propyl)piperazine-1-carboxylate |
| 58 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-(4-fluorophenyl)-1-(phenylmethyl)azetidine-3,3-dicarboxamide |
| 59 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-(4-fluorophenyl)azetidine-3,3-dicarboxamide |
| 60 | (1R,2S)-*N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 61 | (1R,2R)-*N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 62 | (1R,2R)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |

| Entry | Name |
|---|---|
| 63 | *N*-(3-fluoro-4-{[7-({3-[4-(1-methylethyl)piperazin-1-yl]propyl}oxy)-6-(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 64 | *N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 65 | (1R,2R)-*N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 66 | (1R,2R)-*N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 67 | (1R,2S)-*N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 68 | (1R,2S)-*N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 69 | *N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 70 | (1R,2S)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 71 | (1R,2R,3S)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 72 | (1R,2R,3S)-*N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 73 | (1R,2R,3S)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 74 | (1R,2R,3S)-*N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 75 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 76 | (2R,3R)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 77 | (2R,3R)-*N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 78 | *N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide |
| 79 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1- |

| Entry | Name |
|---|---|
| | dicarboxamide |
| 80 | (1R,2R,3S)-*N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 81 | *N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide |
| 82 | (1R,2R,3S)-*N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 83 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide |
| 84 | *N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide |
| 85 | *N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dicarboxamide |
| 86 | *N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 87 | *N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 88 | *N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 89 | (2R,3R)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 90 | *N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 91 | *N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)cyclobutane-1,1-dicarboxamide |
| 92 | (1R,2R)-*N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 93 | (1R,2R)-*N*-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4-methylpiperazin-1-yl)propyl]oxy}quinazolin-4-yl)oxy]phenyl}-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 94 | (2R,3R)-*N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 95 | (2R,3R)-*N*-(4-{[7-{[3-(diethylamino)propyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |

| Entry | Name |
|---|---|
| 96 | (1R,2R)-*N*-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1-ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarboxamide |
| 97 | (2R,3R)-*N*-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-*N'*-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1-dicarboxamide |
| 98 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-[(4-fluorophenyl)methyl]cyclopropane-1,1-dicarboxamide |
| 99 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-(2-morpholin-4-ylethyl)cyclopropane-1,1-dicarboxamide |
| 100 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-[2-(piperidin-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide |
| 101 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-[2-(pyrrolidin-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide |
| 102 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-[3-(morpholin-4-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide |
| 103 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-[2-(morpholin-4-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide |
| 104 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-phenylcyclopropane-1,1-dicarboxamide |
| 105 | *N*-[3-(aminomethyl)phenyl]-*N'*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide |
| 106 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-[3-(piperidin-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide |
| 107 | *N*-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-*N'*-[3-(pyrrolidin-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide |

**Table 4.**

**Representative EGFR, ErbB2, and/or VEGFR Inhibitors**

**[00231]** The Compounds in Table 4 can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 4 can be used to practice the invention. In particular, the invention can be practiced with one or two pharmaceutically acceptable salts of a Compound of Table 4 which salt(s) are formed with one or two acids independently selected from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid,

camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p-toluenesulfonic acid, and salicylic acid.

| Entry | Name |
|---|---|
| 1 | *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 2 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 3 | 7-({[(3a*R*,5r,6a*S*)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-*N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 4 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3a*R*,5r,6a*S*)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine |
| 5 | ethyl (3a*R*,6a*S*)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate |
| 6 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine |
| 7 | *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 8 | *N*-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine |
| 9 | *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 10 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 11 | *N*-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 12 | *N*-(4,5-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 13 | *N*-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 14 | *N*-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 15 | *N*-(3,4-dichlorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 16 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 17 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine |
| 18 | *N*-(4-bromo-2,3-dichlorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 19 | *N*-(4,5-dichloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 20 | *N*-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 21 | *N*-(3-chloro-2,4-difluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 22 | *N*-(3,4-dichloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 23 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 24 | *N*-(3-chloro-2,4-difluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 25 | *N*-(3,4-dichlorophenyl)-7-[(hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 26 | *N*-(4,5-dichloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 27 | *N*-(4-bromo-2,3-dichlorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 28 | *N*-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 29 | *N*-(3,4-dichloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 30 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 31 | *N*-(3,4-dichlorophenyl)-7-{[(3*R*,8a*R*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 32 | *N*-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 33 | *N*-(3,4-dichlorophenyl)-7-{[(3*S*,8a*R*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 34 | *N*-(3,4-dichlorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 35 | *N*-(3,4-dichlorophenyl)-7-{[(3*R*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 36 | *N*-(3,4-dichloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 37 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 38 | *N*-(3-chloro-2,4-difluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 39 | *N*-(4-bromo-2,3-dichlorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 40 | *N*-(4,5-dichloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 41 | 1,4:3,6-dianhydro-5-({[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol |
| 42 | 1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-glucitol |
| 43 | 1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-xylo-hexitol |
| 44 | 1,4:3,6-dianhydro-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol |
| 45 | 1,4:3,6-dianhydro-5-({[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol |
| 46 | 1,4:3,6-dianhydro-5-({[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-glucitol |
| 47 | 1,4:3,6-dianhydro-2-deoxy-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-O-methyl-D-threo-hexitol |
| 48 | 1,4:3,6-dianhydro-5-deoxy-5-({[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-glucitol |
| 49 | (3*S*,9a*S*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2*H*-pyrido[1,2-a]pyrazin-1(6*H*)-one |
| 50 | (3*S*,9a*R*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2*H*-pyrido[1,2-a]pyrazin-1(6*H*)-one |
| 51 | (3*S*,8a*S*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one |
| 52 | (3*S*,8a*R*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one |
| 53 | (3*S*,8a*S*)-3-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one |
| 54 | (3*S*,8a*S*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-methylhexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one |
| 55 | *N*-(3,4-dichlorophenyl)-7-({2-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 56 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(8a*R*)-tetrahydro-1*H*-[1,3]thiazolo[4,3-c][1,4]oxazin-6-ylmethyl]oxy}quinazolin-4-amine |

| Entry | Name |
|---|---|
| 57 | *N*-(3,4-dichlorophenyl)-7-{[2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 58 | *N*-(3,4-dichlorophenyl)-7-{[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 59 | *N*-(3,4-dichlorophenyl)-7-{[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 60 | *N*-(3,4-dichlorophenyl)-7-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 61 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 62 | 1,4:3,6-dianhydro-2-O-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 63 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 64 | 1,4:3,6-dianhydro-2-O-methyl-5-O-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-L-iditol |
| 65 | 1,4:3,6-dianhydro-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-D-xylo-hexitol |
| 66 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 67 | 1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)-quinazolin-7-yl]-L-sorbose ethylene glycol acetal |
| 68 | 1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 69 | 1,4:3,6-dianhydro-2-O-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 70 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-(difluoromethyl)-L-iditol |
| 71 | 1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 72 | 1,4:3,6-dianhydro-2-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 73 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 74 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-ethyl-L-iditol |
| 75 | 1,4:3,6-dianhydro-2-O-[4-[(3-bromo-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 76 | 1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol |
| 77 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-D-xylo-hexitol |

| Entry | Name |
|---|---|
| 78 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-D-glucitol |
| 79 | methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-alpha-L-idofuranoside |
| 80 | 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-1,2-O-(1-methylethylidene)-beta-L-xylo-hexofuranose |
| 81 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-5-methylidene-D-xylo-hexitol |
| 82 | methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-beta-L-idofuranoside |
| 83 | *N*-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-[(octahydro-2*H*-quinolizin-3-ylmethyl)oxy]quinazolin-4-amine |
| 84 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{6-(methyloxy)-4-[(2,3,4-trifluorophenyl)amino]quinazolin-7-yl}-D-iditol |
| 85 | 1,4:3,6-dianhydro-5-O-[4-[(2-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 86 | 1,4:3,6-dianhydro-5-O-[4-[(2-bromo-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 87 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 88 | 1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 89 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{[4-fluoro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 90 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 91 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 92 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,3-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 93 | 1,4:3,6-dianhydro-5-O-[4-[(5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 94 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 95 | 1,4:3,6-dianhydro-5-O-[4-[(3-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 96 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 97 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 98 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |

| Entry | Name |
|---|---|
| 99 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{6-(methyloxy)-4-[(2,4,5-trifluorophenyl)amino]quinazolin-7-yl}-D-iditol |
| 100 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{6-(methyloxy)-4-[(2,4,6-trifluorophenyl)amino]quinazolin-7-yl}-D-iditol |
| 101 | 1,4:3,6-dianhydro-5-O-[4-({4-[(4-chlorophenyl)oxy]-3,5-difluorophenyl}amino)-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 102 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 103 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 104 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chloro-5-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 105 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 106 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-D-iditol |
| 107 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{6-(methyloxy)-4-[(3,4,5-trichlorophenyl)amino]quinazolin-7-yl}-D-iditol |
| 108 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 109 | 1,4:3,6-dianhydro-5-O-[4-[(4-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 110 | 1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 111 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 112 | 1,4:3,6-dianhydro-5-O-[4-[(2-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 113 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-[(2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 114 | 1,4:3,6-dianhydro-5-O-[4-[(3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 115 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-[(4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 116 | 1,4:3,6-dianhydro-5-O-[4-[(4-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 117 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 118 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,5-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 119 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |

| Entry | Name |
|---|---|
| 120 | 1,4:3,6-dianhydro-5-O-[4-[(2-bromo-4,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 121 | 1,4:3,6-dianhydro-5-O-[4-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 122 | 1,4:3,6-dianhydro-5-O-[4-{[2-chloro-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 123 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{[2-fluoro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 124 | 1,4:3,6-dianhydro-5-O-[4-{[2-bromo-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 125 | 1,4:3,6-dianhydro-5-O-[4-{[2-bromo-4-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 126 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{[4-fluoro-2-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 127 | 1,4:3,6-dianhydro-5-O-[4-{[3-bromo-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 128 | 1,4:3,6-dianhydro-5-O-[4-[(2-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 129 | 1,4:3,6-dianhydro-5-O-[4-[(3-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 130 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 131 | 1,4:3,6-dianhydro-5-O-[4-[(3-bromo-4-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 132 | 1,4:3,6-dianhydro-5-O-[4-[(5-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 133 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,5-dimethylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 134 | 1,4:3,6-dianhydro-5-O-[4-{[2,5-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 135 | 1,4:3,6-dianhydro-5-O-[4-{[5-chloro-2,4-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 136 | 1,4:3,6-dianhydro-5-O-[4-{[4-chloro-2,5-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 137 | 1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol |
| 138 | *N*-(3,4-dichlorophenyl)-7-[({5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 139 | *N*-(3,4-dichlorophenyl)-7-[({3-[(dimethylamino)methyl]-1,2,4-oxadiazol-5-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 140 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({3-[(4-methylpiperazin-1-yl)methyl]-1,2,4-oxadiazol-5-yl}methyl)oxy]quinazolin-4-amine |

| Entry | Name |
|---|---|
| 141 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-piperidin-4-yl-1,2,4-oxadiazol-3-yl)methyl]oxy}quinazolin-4-amine |
| 142 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[5-(1-methylpiperidin-4-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)quinazolin-4-amine |
| 143 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[3-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-5-yl]methyl}oxy)quinazolin-4-amine |
| 144 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(morpholin-2-ylmethyl)oxy]quinazolin-4-amine |
| 145 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-piperidin-2-yl-1,2,4-oxadiazol-3-yl)methyl]oxy}quinazolin-4-amine |
| 146 | *N*-(3,4-dichlorophenyl)-7-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 147 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(phenylmethyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 148 | 1,1-dimethylethyl 2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholine-4-carboxylate |
| 149 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[2-(morpholin-4-ylmethyl)-1,3-thiazol-4-yl]methyl}oxy)quinazolin-4-amine |
| 150 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({2-[(4-methylpiperazin-1-yl)methyl]-1,3-thiazol-4-yl}methyl)oxy]quinazolin-4-amine |
| 151 | *N*-(3,4-dichlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 152 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(1,4-oxazepan-2-ylmethyl)oxy]quinazolin-4-amine |
| 153 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-piperidin-3-yl-1,2,4-oxadiazol-3-yl)methyl]oxy}quinazolin-4-amine |
| 154 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[5-(1-methylpiperidin-2-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)quinazolin-4-amine |
| 155 | *N*-(3,4-dichlorophenyl)-7-{[(4-methyl-1,4-oxazepan-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 156 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[5-(1-methylpiperidin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)quinazolin-4-amine |
| 157 | *N*-(3,4-dichlorophenyl)-7-({[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 158 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2-phenyl-1,3-thiazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 159 | 7-[(2,1,3-benzothiadiazol-4-ylmethyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 160 | *N*-(3,4-dichlorophenyl)-7-{[(5-methylisoxazol-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 161 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-methyl-4-phenylisoxazol-3-yl)methyl]oxy}quinazolin-4-amine |

| Entry | Name |
|---|---|
| 162 | 7-[(1,3-benzothiazol-2-ylmethyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 163 | 7-[(2,1,3-benzoxadiazol-5-ylmethyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 164 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[2-(2-thienyl)-1,3-thiazol-4-yl]methyl}oxy)quinazolin-4-amine |
| 165 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(1-phenyl-1*H*-pyrazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 166 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}methyl)oxy]quinazolin-4-amine |
| 167 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}methyl)oxy]quinazolin-4-amine |
| 168 | 7-({[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 169 | 7-({[6-bromo-2-(methyloxy)naphthalen-1-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 170 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(1,3-thiazol-4-ylmethyl)oxy]quinazolin-4-amine |
| 171 | 7-{[(6-chloropyridin-3-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 172 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(pyridin-4-ylmethyl)oxy]quinazolin-4-amine |
| 173 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2-methyl-1,3-thiazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 174 | 7-{[(6-chloro-4*H*-1,3-benzodioxin-8-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 175 | 7-{[(5-chloro-1-methyl-3-phenyl-1*H*-pyrazol-4-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 176 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[1-methyl-3-(trifluoromethyl)-1*H*-thieno[2,3-c]pyrazol-5-yl]methyl}oxy)quinazolin-4-amine |
| 177 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(3-phenylisoxazol-5-yl)methyl]oxy}quinazolin-4-amine |
| 178 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2,4,6-trimethylphenyl)methyl]oxy}quinazolin-4-amine |
| 179 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(pyridin-3-ylmethyl)oxy]quinazolin-4-amine |
| 180 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({3-[4-(methyloxy)phenyl]isoxazol-5-yl}methyl)oxy]quinazolin-4-amine |
| 181 | *N*-(3,4-dichlorophenyl)-7-({[5-[(2,4-dichlorophenyl)oxy]-1-methyl-3-(trifluoromethyl)-1*H*-pyrazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 182 | 7-[(cyclopropylmethyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 183 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(tetrahydrofuran-2-ylmethyl)oxy]quinazolin-4-amine |
| 184 | 7-(cyclopentyloxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 185 | 7-[(2-cyclohexylethyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 186 | 7-[(cyclohexylmethyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 187 | 7-[(cyclobutylmethyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 188 | *N*-(3,4-dichlorophenyl)-7-{[2-(1,3-dioxolan-2-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 189 | *N*-(3,4-dichlorophenyl)-7-{[2-(1,3-dioxan-2-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 190 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(2-morpholin-4-ylethyl)oxy]quinazolin-4-amine |
| 191 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(2-pyrrolidin-1-ylethyl)oxy]quinazolin-4-amine |
| 192 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(2-piperidin-1-ylethyl)oxy]quinazolin-4-amine |
| 193 | 2-(2-{[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}ethyl)-1*H*-isoindole-1,3(2*H*)-dione |
| 194 | methyl 6-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-alpha-D-glucopyranoside |
| 195 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(2-morpholin-4-yl-2-oxoethyl)oxy]quinazolin-4-amine |
| 196 | 1,1-dimethylethyl 2-[3-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate |
| 197 | 1,1-dimethylethyl 4-[3-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate |
| 198 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(4-pyrrolidin-1-ylphenyl)-1,3-thiazol-2-yl]methyl}oxy)quinazolin-4-amine |
| 199 | *N*-(3,4-dichlorophenyl)-7-[({4-[4-(diethylamino)phenyl]-1,3-thiazol-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 200 | 5-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,3-thiazol-4-yl]-2-hydroxybenzamide |
| 201 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-pyridin-3-yl-1,3-thiazol-2-yl)methyl]oxy}quinazolin-4-amine |
| 202 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-pyridin-2-yl-1,3-thiazol-2-yl)methyl]oxy}quinazolin-4-amine |
| 203 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-pyridin-4-yl-1,3-thiazol-2- |

| Entry | Name |
|---|---|
| | yl)methyl]oxy}quinazolin-4-amine |
| 204 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2-morpholin-4-yl-1,3-thiazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 205 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(3-morpholin-4-yl-1,2,4-oxadiazol-5-yl)methyl]oxy}quinazolin-4-amine |
| 206 | *N*-(3,4-dichlorophenyl)-7-({[3-(dimethylamino)-1,2,4-oxadiazol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 207 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({4-[(4-methylpiperazin-1-yl)methyl]-1,3-thiazol-2-yl}methyl)oxy]quinazolin-4-amine |
| 208 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[(4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-ylmethyl)oxy]quinazolin-4-amine |
| 209 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(morpholin-4-ylmethyl)-1,3-thiazol-2-yl]methyl}oxy)quinazolin-4-amine |
| 210 | *N*-(3,4-dichlorophenyl)-7-[({4-[(4-methyl-1,4-diazepan-1-yl)methyl]-1,3-thiazol-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 211 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-{[(phenylmethyl)oxy]methyl}-1,2,4-oxadiazol-3-yl)methyl]oxy}quinazolin-4-amine |
| 212 | *N*-(3,4-dichlorophenyl)-7-{[(4-ethylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 213 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2-piperidin-4-yl-1,3-thiazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 214 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[2-(1-methylpiperidin-4-yl)-1,3-thiazol-4-yl]methyl}oxy)quinazolin-4-amine |
| 215 | 1,1-dimethylethyl 4-[5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,2,4-oxadiazol-3-yl]piperazine-1-carboxylate |
| 217 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(3-piperazin-1-yl-1,2,4-oxadiazol-5-yl)methyl]oxy}quinazolin-4-amine |
| 218 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[3-(4-methylpiperazin-1-yl)-1,2,4-oxadiazol-5-yl]methyl}oxy)quinazolin-4-amine |
| 219 | *N*-(3,4-dichlorophenyl)-7-({[5-(1-ethylpiperidin-2-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 220 | *N*-(3,4-dichlorophenyl)-7-({[3-(4-ethylpiperazin-1-yl)-1,2,4-oxadiazol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 221 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({5-[4-(methyloxy)phenyl]-1,2,4-oxadiazol-3-yl}methyl)oxy]quinazolin-4-amine |
| 222 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-4-yl}methyl)oxy]quinazolin-4-amine |
| 223 | 7-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 224 | *N*-(3,4-dichlorophenyl)-7-({[5-(3,5-dimethylisoxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 225 | 7-{[(5-chloro-1-benzothien-3-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 226 | *N*-(3,4-dichlorophenyl)-7-[({3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 227 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({5-[2-(methyloxy)phenyl]-1,2,4-oxadiazol-3-yl}methyl)oxy]quinazolin-4-amine |
| 228 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]methyl}oxy)quinazolin-4-amine |
| 229 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[1-(phenylmethyl)-1*H*-imidazol-2-yl]methyl}oxy)quinazolin-4-amine |
| 230 | *N*-(3,4-dichlorophenyl)-7-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 231 | *N*-(3,4-dichlorophenyl)-7-{[(6-fluoro-4*H*-1,3-benzodioxin-8-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 232 | 7-{[(3,5-dibromophenyl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 233 | *N*-(3,4-dichlorophenyl)-7-{[(2,6-difluorophenyl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 234 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({3-[(pyridin-2-ylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl}methyl)oxy]quinazolin-4-amine |
| 235 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]oxy}quinazolin-4-amine |
| 236 | 7-({[4-chloro-2-(trifluoromethyl)quinolin-6-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 237 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[2-(1-methylpyrrolidin-2-yl)ethyl]oxy}quinazolin-4-amine |
| 238 | *N*-(3,4-dichlorophenyl)-7-({[5-(1-ethylpiperidin-4-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 239 | *N*-(3,4-dichlorophenyl)-7-({[5-(1-ethylpiperidin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 240 | *N*-(3,4-dichlorophenyl)-7-({[2-(dimethylamino)-1,3-thiazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 241 | *N*-(3,4-dichlorophenyl)-7-{[(4-ethyl-1,4-oxazepan-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 242 | *N*-(3,4-dichlorophenyl)-7-({[2-(1-ethylpiperidin-4-yl)-1,3-thiazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 243 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({3-[(2*S*)-pyrrolidin-2-yl]-1,2,4-oxadiazol-5-yl}methyl)oxy]quinazolin-4-amine |
| 244 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({2-[(2*S*)-pyrrolidin-2-yl]-1,3-thiazol-4-yl}methyl)oxy]quinazolin-4-amine |
| 245 | [4-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,3-thiazol-2-yl]methyl benzoate |

| Entry | Name |
|---|---|
| 246 | [4-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,3-thiazol-2-yl]methanol |
| 247 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)methyl]oxy}quinazolin-4-amine |
| 248 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({2-[(4*S*)-1,3-thiazolidin-4-yl]-1,3-thiazol-4-yl}methyl)oxy]quinazolin-4-amine |
| 249 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2-piperidin-2-yl-1,3-thiazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 250 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[2-(1-methylpiperidin-2-yl)-1,3-thiazol-4-yl]methyl}oxy)quinazolin-4-amine |
| 251 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2-piperidin-3-yl-1,3-thiazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 252 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[2-(1-methylpiperidin-3-yl)-1,3-thiazol-4-yl]methyl}oxy)quinazolin-4-amine |
| 253 | *N*-(3,4-dichlorophenyl)-7-({[2-(1-ethylpiperidin-2-yl)-1,3-thiazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 254 | *N*-(3,4-dichlorophenyl)-7-({[2-(1-ethylpiperidin-3-yl)-1,3-thiazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 255 | *N*-(3,4-dichlorophenyl)-7-[({3-[(2*S*)-1-ethylpyrrolidin-2-yl]-1,2,4-oxadiazol-5-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 256 | *N*-(3,4-dichlorophenyl)-7-[({2-[(2*S*)-1-ethylpyrrolidin-2-yl]-1,3-thiazol-4-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 257 | *N*-(3,4-dichlorophenyl)-7-{[(5-ethyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 258 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-propyl-1,4-oxazepan-2-yl)methyl]oxy}quinazolin-4-amine |
| 259 | 7-({[4-(cyclopropylmethyl)-1,4-oxazepan-2-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 260 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({4-[2-(methyloxy)ethyl]-1,4-oxazepan-2-yl}methyl)oxy]quinazolin-4-amine |
| 261 | *N*-(3,4-dichlorophenyl)-7-({[4-(1-methylethyl)-1,4-oxazepan-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 262 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(2-piperazin-1-yl-1,3-thiazol-4-yl)methyl]oxy}quinazolin-4-amine |
| 263 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5-pyrrolidin-2-yl-1,2,4-oxadiazol-3-yl)methyl]oxy}quinazolin-4-amine |
| 264 | *N*-(3,4-dichlorophenyl)-7-({[5-(1-ethylpyrrolidin-2-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 265 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({3-[(2*S*)-1-methylpyrrolidin-2-yl]-1,2,4-oxadiazol-5-yl}methyl)oxy]quinazolin-4-amine |
| 266 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({2-[(2*S*)-1-methylpyrrolidin-2-yl]-1,3-thiazol-4-yl}methyl)oxy]quinazolin-4-amine |

| Entry | Name |
|---|---|
| 267 | *N*-(3,4-dichlorophenyl)-7-({[2-(4-ethylpiperazin-1-yl)-1,3-thiazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 268 | *N*-(3,4-dichlorophenyl)-7-{[(1,4-dimethylpiperazin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 269 | 7-{[(4-cyclopentylmorpholin-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 270 | *N*-(3,4-dichlorophenyl)-7-({[4-(1-methylethyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 271 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(3-phenylpropyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 272 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({4-[2-(methyloxy)ethyl]morpholin-2-yl}methyl)oxy]quinazolin-4-amine |
| 273 | ethyl 2-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]propanoate |
| 274 | *N*-(3,4-dichlorophenyl)-7-{[(4-hex-5-en-1-ylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 275 | 2-({2-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]ethyl}oxy)ethanol |
| 276 | methyl 3-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]propanoate |
| 277 | 6-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]hexanenitrile |
| 278 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(tetrahydro-2*H*-pyran-2-ylmethyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 279 | 4-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]butanenitrile |
| 280 | *N*-(3,4-dichlorophenyl)-7-[({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 281 | methyl 5-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]pentanoate |
| 282 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-oct-7-en-1-ylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 283 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-propylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 284 | 6-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]hexan-1-ol |
| 285 | 7-{[(4-acetylmorpholin-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 286 | 7-({[4-(cyclopropylmethyl)morpholin-2-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 287 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-prop-2-yn-1-ylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |

| Entry | Name |
|---|---|
| 288 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-pyridin-4-ylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 289 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(pyridin-2-ylmethyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 290 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-pent-2-yn-1-ylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 291 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]methyl}oxy)quinazolin-4-amine |
| 292 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[5-(1-methylpyrrolidin-2-yl)-1,2,4-oxadiazol-3-yl]methyl}oxy)quinazolin-4-amine |
| 293 | *N*-(3-chloro-4-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 294 | 7-{[(4-butyl-1,4-oxazepan-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy) quinazolin-4-amine |
| 295 | (3,4-dichlorophenyl)[7-(methyloxy)-6-({[4-(2-methylpropyl)-1,4-oxazepan-2-yl]methyl}oxy) quinazolin-4-amine |
| 296 | 7-{[(4-acetyl-1-ethylpiperazin-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 297 | (3,4-dichlorophenyl)(6-(methyloxy)-7-{[(4-pentyl-1,4-oxazepan-2-yl)methyl]oxy} quinazolin-4-amine |
| 298 | (3,4-dichlorophenyl)[6-(methyloxy)-7-({[4-(tetrahydro-2*H*-pyran-2-ylmethyl)-1,4-oxazepan-2-yl]methyl}oxy)quinazolin-4-amine |
| 299 | (3,4-dichlorophenyl)[6-(methyloxy)-7-({[4-(3-thienylmethyl)-1,4-oxazepan-2-yl]methyl}oxy) quinazolin-4-amine |
| 300 | *N*-[4-chloro-2,5-bis(methyloxy)phenyl]-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 301 | *N*-(3-bromo-2-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 302 | 7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)-*N*-(3,4,5-trichlorophenyl)quinazolin-4-amine |
| 303 | *N*-(3-chloro-2-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 304 | *N*-(3,4-dichlorophenyl)-7-{[(4-ethanimidoyl-1,4-oxazepan-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 305 | *N*-(4-bromo-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 306 | *N*-(5-chloro-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 307 | *N*-(4-chloro-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 308 | *N*-(2,4-dichlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 309 | *N*-(2,4-dibromophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 310 | 7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)-*N*-(2,3,4-trichlorophenyl)quinazolin-4-amine |
| 311 | *N*-(3,4-dichlorophenyl)-7-{[(1-ethyl-4-methylpiperazin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 312 | *N'*-cyano-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholine-4-carboximidamide |
| 313 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[2-(pyrrolidin-1-ylmethyl)-1,3-thiazol-4-yl]methyl}oxy)quinazolin-4-amine |
| 314 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(tetrahydro-2*H*-pyran-4-yl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 315 | *N*-(3,4-dichlorophenyl)-7-({[4-(2-ethylbutyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 316 | 7-({[4-(cyclohexylmethyl)morpholin-2-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 317 | 2-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]ethanol |
| 318 | 7-{[(4-but-2-yn-1-ylmorpholin-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 319 | 7-{[(4-cyclobutylmorpholin-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 320 | *N*-(3,4-dichlorophenyl)-7-[({4-[2-(1,3-dioxolan-2-yl)ethyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 321 | 7-({[4-(2-cyclohexylethyl)morpholin-2-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 322 | *N*-(3,4-dichlorophenyl)-7-[({4-[2-(1,3-dioxan-2-yl)ethyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 323 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-pent-4-en-1-ylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 324 | *N*-(3,4-dichlorophenyl)-7-[({4-[(2*R*)-2-methylbutyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 325 | *N*-(3,4-dichlorophenyl)-7-({[4-(4-fluorobutyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 326 | 3-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]butan-2-one |
| 327 | 1-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]butan-2-one |
| 328 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-pentylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 329 | *N*-(3,4-dichlorophenyl)-7-{[(4-hexylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 330 | *N*-(3,4-dichlorophenyl)-7-{[(4-heptylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 331 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-octylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 332 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(2-phenylethyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 333 | 7-{[(4-butylmorpholin-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 334 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-prop-2-en-1-ylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 335 | 2-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]-1-phenylethanone |
| 336 | *N*-(3,4-dichlorophenyl)-7-({[4-(2-fluoroethyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 337 | *N*-(3,4-dichlorophenyl)-7-({[4-(3-methylbut-2-en-1-yl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 338 | 7-[({4-[(2E)-3-bromoprop-2-en-1-yl]morpholin-2-yl}methyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 339 | 2-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]acetamide |
| 340 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({4-[3-(tetrahydro-2*H*-pyran-2-yloxy)propyl]-1,4-oxazepan-2-yl}methyl)oxy]quinazolin-4-amine |
| 341 | *N*-(3,4-dichlorophenyl)-7-({[4-(3-methylbutyl)-1,4-oxazepan-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 342 | 7-({[4-(cyclohexylmethyl)-1,4-oxazepan-2-yl]methyl}oxy)-4-[(3,4-dichlorophenyl)methyl]-6-(methyloxy)quinazoline |
| 343 | 7-({[4-(2-cyclohexylethyl)-1,4-oxazepan-2-yl]methyl}oxy)-4-[(3,4-dichlorophenyl)methyl]-6-(methyloxy)quinazoline |
| 345 | *N*-(3,4-dichlorophenyl)-7-({[4-(2-ethylbutyl)-1,4-oxazepan-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 346 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(methylsulfonyl)-1,4-oxazepan-2-yl]methyl}oxy)quinazolin-4-amine |
| 347 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(1-methylpiperidin-4-yl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 348 | *N*-(3-chloro-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 349 | *N'*-cyano-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,4-oxazepane-4-carboximidamide |
| 350 | *N*-(3-bromo-4-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 351 | *N*-(3,4-dichlorophenyl)-7-{[(1,4-diethylpiperazin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 352 | 4-({[4-[(4-bromo-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-*N'*-cyanopiperidine-1-carboximidamide |
| 353 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(methylsulfonyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 354 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({4-[(phenylmethyl)sulfonyl]morpholin-2-yl}methyl)oxy]quinazolin-4-amine |
| 355 | *N*-(3,4-dichlorophenyl)-7-[({4-[(4-fluorophenyl)sulfonyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 356 | *N*-(3,4-dichlorophenyl)-7-({[4-(ethylsulfonyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 357 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(phenylsulfonyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 358 | 7-[({4-[(3-chloropropyl)sulfonyl]morpholin-2-yl}methyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 359 | 7-({[4-(butylsulfonyl)morpholin-2-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 360 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({4-[(4-methylphenyl)sulfonyl]morpholin-2-yl}methyl)oxy]quinazolin-4-amine |
| 361 | *N*-(3,4-dichlorophenyl)-7-[({4-[(3,5-dimethylisoxazol-4-yl)carbonyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 362 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-{[3-(methyloxy)phenyl]acetyl}morpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 363 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(2-methylpentanoyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 364 | 7-[({4-[(4-butylphenyl)carbonyl]morpholin-2-yl}methyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 365 | 7-[({4-[(4-chlorophenyl)acetyl]morpholin-2-yl}methyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 366 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(2-propylpentanoyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 367 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(4-methylpentanoyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 368 | *N*-(3,4-dichlorophenyl)-7-[({4-[(2,5-difluorophenyl)carbonyl]morpholin-2-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 369 | 7-({[4-(cyclopentylcarbonyl)morpholin-2-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 370 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(2-phenylbutanoyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 371 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({4-[(2,3,6-trifluorophenyl)carbonyl]morpholin-2-yl}methyl)oxy]quinazolin-4-amine |
| 372 | *N*-(3,4-dichlorophenyl)-7-({[4-(furan-3-ylcarbonyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 373 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-propanoylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 374 | *N*-(3,4-dichlorophenyl)-7-{[(4-hexanoylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 375 | *N*-(3,4-dichlorophenyl)-7-({[4-(2-ethylhexanoyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 376 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(3-phenylpropanoyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 377 | *N*-(3,4-dichlorophenyl)-7-({[4-(2,2-dimethylpropanoyl)morpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 378 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[4-(naphthalen-1-ylcarbonyl)morpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 379 | 7-[({4-[(2-chloropyridin-3-yl)carbonyl]morpholin-2-yl}methyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 380 | 7-[({4-[(6-chloropyridin-3-yl)carbonyl]morpholin-2-yl}methyl)oxy]-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 381 | 7-({[4-(1,3-benzodioxol-5-ylcarbonyl)morpholin-2-yl]methyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |
| 382 | *N*-(3,4-dichlorophenyl)-6-[(1-methylethyl)oxy]-7-[(morpholin-2-ylmethyl)oxy]quinazolin-4-amine |
| 383 | *N*-(3,4-dichlorophenyl)-6-{[2-(methyloxy)ethyl]oxy}-7-[(morpholin-2-ylmethyl)oxy]quinazolin-4-amine |
| 384 | *N*-(3,4-dichlorophenyl)-6-(ethyloxy)-7-[(morpholin-2-ylmethyl)oxy]quinazolin-4-amine |
| 385 | *N*-(3,4-dichlorophenyl)-6-(ethyloxy)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 386 | *N*-(4-bromo-2-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 387 | *N*-(4-chloro-3-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 388 | *N*'-cyano-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-*N*-methylmorpholine-4-carboximidamide |
| 389 | *N*-(4-bromo-3-chlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 390 | *N*-(3,4-dichlorophenyl)-6-[(1-methylethyl)oxy]-7-{[(4-methylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 391 | *N*-(3,4-dichlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-{[2-(methyloxy)ethyl]oxy}quinazolin-4-amine |
| 392 | *N*-(4-bromo-2-chlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 393 | 7-{[(4-acetyl-1,4-oxazepan-2-yl)methyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 394 | 4-[(3,4-dichlorophenyl)amino]-7-{[(4-methylmorpholin-2-yl)methyl]oxy}quinazolin-6-ol |
| 395 | *N*-(3-bromo-4-chlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 396 | 3-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]-3-oxopropanoic acid |
| 397 | methyl 4-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl]-4-oxobutanoate |
| 398 | *N*-(3,4-dichlorophenyl)-7-{[(4-methylmorpholin-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 399 | *N*-(3-bromo-2-chlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 400 | *N'*-cyano-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-*N*-[2-(methyloxy)ethyl]morpholine-4-carboximidamide |
| 401 | *N'*-cyano-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-*N*-ethylmorpholine-4-carboximidamide |
| 402 | [(1E)-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl](piperidin-1-yl)methylidene]cyanamide |
| 403 | [(1E)-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl](pyrrolidin-1-yl)methylidene]cyanamide |
| 404 | [(1E)-[2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)morpholin-4-yl](4-methylpiperazin-1-yl)methylidene]cyanamide |
| 405 | *N*-(3,4-dichlorophenyl)-7-{[(6-ethyl-4,6-dimethylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 406 | *N*-(4-bromo-3-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 407 | *N*-(3,4-dichlorophenyl)-7-{[(6,6-dimethylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 408 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4,6,6-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 409 | *N*-(3,4-dichlorophenyl)-7-{[2-(5,5-dimethylmorpholin-2-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 410 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[2-(4,5,5-trimethylmorpholin-2-yl)ethyl]oxy}quinazolin-4-amine |
| 411 | 1,1-dimethylethyl 2-(2-{[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}ethyl)-5,5-dimethylmorpholine-4-carboxylate |
| 412 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4,5,5-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 413 | *N*-(4-bromo-2,3-dichlorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 414 | *N*-(4,5-dichloro-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |

| Entry | Name |
|---|---|
| 415 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[2-(4,6,6-trimethylmorpholin-2-yl)ethyl]oxy}quinazolin-4-amine |
| 416 | *N*-(4-bromo-2,3-difluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 417 | *N*-(4-bromo-2,5-difluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 418 | *N*-(4-bromo-3,5-difluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 419 | *N*-(3,4-dichloro-2-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 420 | *N*-(3,4-dichlorophenyl)-7-({[(2*R*,5*S*,6*S*)-5,6-dimethylmorpholin-2-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 421 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[(2*R*,5*S*,6*S*)-4,5,6-trimethylmorpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 422 | *N*-(3,4-dichlorophenyl)-6-(methyloxy)-7-({[(2*S*,5*S*,6*S*)-4,5,6-trimethylmorpholin-2-yl]methyl}oxy)quinazolin-4-amine |
| 423 | *N*-(4-bromo-3-chloro-2-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 424 | *N*-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 425 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 426 | *N*-(3,4-dichloro-2-fluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 427 | *N*-(3-chloro-2,4-difluorophenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 428 | *N*-(2,3-dichloro-4-methylphenyl)-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 429 | 6-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-3,3,4-trimethylmorpholin-2-one |
| 430 | *N*-(4-bromo-2,3-dichlorophenyl)-6-(methyloxy)-7-{[(4,5,5-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 431 | *N*-(4-bromo-5-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(4,5,5-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 432 | *N*-(4,5-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[(4,5,5-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 433 | *N*-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[(4,5,5-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 434 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(4,5,5-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |
| 435 | *N*-(3-chloro-2,4-difluorophenyl)-6-(methyloxy)-7-{[(4,5,5-trimethylmorpholin-2-yl)methyl]oxy}quinazolin-4-amine |

| Entry | Name |
|---|---|
| 436 | (6*S*)-6-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-4-methylpiperazin-2-one |
| 437 | (6*S*)-6-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-4-methylpiperazin-2-one |
| 438 | (6*S*)-6-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,4-dimethylpiperazin-2-one |
| 439 | (6*S*)-6-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-1,4-dimethylpiperazin-2-one |
| 440 | *N*-(4-bromo-3-chlorophenyl)-7-{[(3a'*S*,4*R*,6'*S*,6a'*R*)-2,2-dimethyltetrahydrospiro[1,3-dioxolane-4,3'-furo[3,2-b]furan]-6'-yl]oxy}-6-(methyloxy)quinazolin-4-amine |
| 441 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-[(methyloxy)methyl]-L-glucitol |
| 442 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-(methylsulfonyl)-L-glucitol |
| 443 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-glucitol |
| 444 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*S*-methyl-5-thio-D-iditol |
| 445 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-D-iditol |
| 446 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-D-iditol |
| 447 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-D-iditol |
| 448 | 2-O-acetyl-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 449 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 450 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-D-iditol |
| 451 | 2-amino-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-D-iditol |
| 452 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-D-iditol |
| 453 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-D-iditol |
| 454 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-D-iditol |
| 455 | 2-(acetylamino)-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-D-iditol |
| 456 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-(trifluoromethyl)-L-glucitol |

| Entry | Name |
|---|---|
| 457 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-D-iditol |
| 458 | *N*-(4-bromo-3-chlorophenyl)-6-(methyloxy)-7-[(1-methylpyrrolidin-3-yl)oxy]quinazolin-4-amine |
| 459 | *N*-(4-bromo-3-chlorophenyl)-6-(methyloxy)-7-[(3*R*)-tetrahydrofuran-3-yloxy]quinazolin-4-amine |
| 460 | *N*-(4-bromo-3-chlorophenyl)-6-(methyloxy)-7-{[(3*S*,4*R*)-4-(methyloxy)tetrahydrofuran-3-yl]oxy}quinazolin-4-amine |
| 461 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-(6-(methyloxy)-4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}quinazolin-7-yl)-D-iditol |
| 462 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol |
| 463 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-{[2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 464 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol |
| 465 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-C-(trifluoromethyl)-D-glucitol |
| 466 | (3,4-dichlorophenyl)[6-(methyloxy)-7-({[4-(tetrahydrofuran-2-ylmethyl)-1,4-oxazepan-2-yl]methyl}oxy)quinazolin -4-amine |
| 467 | *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 468 | *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclo-penta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 469 | *N*-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 470 | *N*-(4,5-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclo-penta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 471 | *N*-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclo-penta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 472 | *N*-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclo-penta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 473 | *N*-(3,4-dichlorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 474 | *N*-(3,4-dichlorophenyl)-7-[(2-{[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}ethyl)oxy]-6-(methyloxy)quinazolin-4-amine |
| 475 | *N*-(3,4-dichlorophenyl)-7-({2-[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 476 | *N*-(3,4-dichlorophenyl)-7-({[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine |
| 477 | *N*-(3,4-dichlorophenyl)-7-{[(3-*exo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine |







| Entry | Name |
|---|---|
| 478 | 1,4:3,6-Dianhydro-5-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-D-glucitol |
| 479 | 1,4:3,6-dianhydro-5-*O*-{4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}-2-deoxy-2-fluoro-L-iditol |
| 480 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-(methylsulfonyl)-D-glucitol |
| 481 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-glucitol |
| 482 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-S-methyl-5-thio-L-iditol |
| 483 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-L-iditol |
| 484 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-L-iditol |
| 485 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-L-iditol |
| 486 | 2-O-acetyl-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol |
| 487 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol |
| 488 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-L-iditol |
| 489 | 2-amino-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol |
| 490 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-L-iditol |
| 491 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-L-iditol |
| 492 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-L-iditol |
| 493 | 2-(acetylamino)-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol |
| 494 | 1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-(trifluoromethyl)-D-glucitol |
| 495 | 1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-L-iditol |
| 496 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-(6-(methyloxy)-4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}quinazolin-7-yl)-L-iditol |
| 497 | 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-L-iditol |
| 498 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-{[2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-L-iditol |






| Entry | Name |
|---|---|
| 499 | 1,4:3,6-dianhydro-2-deoxy-5-O-[4-{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-L-iditol |
| 500 | 1,4:3,6-Dianhydro-5-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-D-glucitol |
| 501 | 1,4:3,6-Dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-glucitol |







**Table 5a.**







**Representative IGF-1R Inhibitor**








**[00232]** The Compounds in Table 5a can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 5a can be used to practice the invention.








| Entry | Structure |
|---|---|
| 1 |  |
| 2 |  |
| 3 |  |
| 4 |  |
| 5 |  |
| 6 |  |









| Entry | Structure |
|---|---|
| 7 |  |
| 8 |  |
| 9 |  |
| 10 |  |
| 11 |  |









| Entry | Structure |
|---|---|
| 12 |  |
| 13 |  |
| 14 |  |
| 15 |  |
| 16 |  |
| 17 |  |







| Entry | Structure |
|---|---|
| 18 |  |
| 19 |  |
| 20 |  |
| 21 |  |
| 22 |  |
| 23 |  |








| Entry | Structure |
|---|---|
| 24 |  |
| 25 |  |
| 26 |  |
| 27 |  |
| 28 |  |
| 29 |  |
| 30 |  |









| Entry | Structure |
|---|---|
| 31 |  |
| 32 |  |
| 33 |  |
| 34 |  |
| 35 |  |
| 36 |  |
| 37 |  |








| Entry | Structure |
|---|---|
| 38 |  |
| 39 |  |
| 40 |  |
| 41 |  |
| 42 |  |
| 43 |  |
| 44 |  |
| 45 |  |








| Entry | Structure |
|---|---|
| 46 |  |
| 47 |  |
| 48 |  |
| 49 |  |
| 50 |  |
| 51 |  |
| 52 |  |
| 53 |  |








| Entry | Structure |
|---|---|
| 54 |  |
| 55 |  |
| 56 |  |
| 57 |  |
| 58 |  |
| 59 |  |








| Entry | Structure |
|---|---|
| 60 |  |
| 61 |  |
| 62 |  |
| 63 |  |
| 64 |  |
| 65 |  |
| 66 |  |









| Entry | Structure |
|---|---|
| 67 |  |
| 68 |  |
| 69 |  |
| 70 |  |
| 71 |  |
| 72 |  |
| 73 |  |
| 74 |  |








| Entry | Structure |
|---|---|
| 75 |  |
| 76 |  |
| 77 |  |
| 78 |  |
| 79 |  |
| 80 |  |
| 81 |  |








| Entry | Structure |
|---|---|
| 82 |  |
| 83 |  |
| 84 |  |
| 85 |  |
| 86 |  |
| 87 |  |
| 88 |  |








| Entry | Structure |
|---|---|
| 89 | Abs  |
| 90 |  |
| 91 |  |
| 92 |  |
| 93 |  |
| 94 |  |
| 95 |  |








| Entry | Structure |
|---|---|
| 96 |  |
| 97 |  |
| 98 |  |
| 99 |  |
| 100 |  |
| 101 |  |
| 102 |  |








| Entry | Structure |
|---|---|
| 103 |  |
| 104 |  |
| 105 |  |
| 106 |  |
| 107 |  |
| 108 | Abs  |
| 109 |  |
| 110 |  |








| Entry | Structure |
|---|---|
| 111 |  |
| 112 |  |
| 113 |  |
| 114 |  |
| 115 |  |
| 116 |  |
| 117 |  |









| Entry | Structure |
|---|---|
| 118 |  |
| 119 |  |
| 120 |  |
| 121 |  |
| 122 |  |
| 123 |  |
| 124 |  |








| Entry | Structure |
|---|---|
| 125 |  |
| 126 |  |
| 127 |  |
| 128 |  |
| 129 |  |
| 130 |  |
| 131 |  |








| Entry | Structure |
|---|---|
| 132 |  |
| 133 |  |
| 134 |  |
| 135 |  |
| 136 |  |
| 137 |  |
| 138 |  |







| Entry | Structure |
|---|---|
| 139 |  |
| 140 |  |
| 141 |  Abs |
| 142 |  |
| 143 |  |
| 144 |  |
| 145 |  Abs |







| Entry | Structure |
|---|---|
| 146 |  |
| 147 |  |
| 148 |  |
| 149 |  |
| 150 |  |
| 151 |  |
| 152 |  |







| Entry | Structure |
|---|---|
| 153 |  |
| 154 |  |
| 155 |  |
| 156 |  |
| 157 |  |
| 158 |  |
| 159 |  |
| 160 |  |







| Entry | Structure |
|---|---|
| 161 |  |
| 162 |  |
| 163 |  |
| 164 |  |
| 165 |  |
| 166 |  |
| 167 |  |







| Entry | Structure |
|---|---|
| 168 |  |
| 169 |  |
| 170 |  |
| 171 |  |
| 172 |  |
| 173 |  |
| 174 |  |








| Entry | Structure |
|---|---|
| 175 |  |
| 176 |  |
| 177 |  |
| 178 |  |
| 179 |  |
| 180 |  |







| Entry | Structure |
|---|---|
| 181 |  |
| 182 |  |
| 183 |  |
| 184 |  |
| 185 |  |
| 186 |  |








| Entry | Structure |
|---|---|
| 187 |  |
| 188 |  |
| 189 |  |
| 190 |  |
| 191 |  |
| 192 |  |








| Entry | Structure |
|---|---|
| 193 |  |
| 194 |  |
| 195 |  |
| 196 |  |
| 197 |  |
| 198 |  |






| Entry | Structure |
|---|---|
| 199 |  |
| 200 |  |
| 201 |  |
| 202 |  |
| 203 |  |
| 204 |  |







| Entry | Structure |
|---|---|
| 205 |  |
| 206 |  |
| 207 |  |
| 208 |  |
| 209 |  |
| 210 |  |
| 211 |  |







| Entry | Structure |
|---|---|
| 212 |  |
| 213 |  |
| 214 |  |
| 215 |  |
| 216 |  |
| 217 |  |







| Entry | Structure |
|---|---|
| 218 |  |
| 219 |  |
| 220 |  |
| 221 |  |
| 222 |  |
| 223 |  |
| 224 |  |







| Entry | Structure |
|---|---|
| 225 |  |
| 226 |  |
| 227 |  |
| 228 |  |
| 229 |  |
| 230 |  |
| 231 |  |







| Entry | Structure |
|---|---|
| 232 |  |
| 233 |  |
| 234 |  |
| 235 |  |
| 236 |  |







| Entry | Structure |
|---|---|
| 237 |  |
| 238 |  |
| 239 |  |
| 240 |  |
| 241 |  |
| 242 |  |






| Entry | Structure |
|---|---|
| 243 |  |
| 244 |  |
| 245 |  |
| 246 |  |
| 247 |  |
| 248 |  |







| Entry | Structure |
|---|---|
| 249 |  |
| 250 |  |
| 251 |  |
| 252 |  |
| 253 |  |
| 254 |  |








| Entry | Structure |
|---|---|
| 255 |  |
| 256 |  |
| 257 |  |
| 258 |  |
| 259 |  |
| 260 |  |








| Entry | Structure |
|---|---|
| 261 |  |
| 262 |  |
| 263 |  |
| 264 |  |
| 265 |  |
| 266 |  |






| Entry | Structure |
|---|---|
| 267 |  |
| 268 |  |
| 269 |  |
| 270 |  |
| 271 |  |
| 272 |  |






| Entry | Structure |
|---|---|
| 273 |  |
| 274 |  |
| 275 |  |
| 276 |  |
| 277 |  |








| Entry | Structure |
|---|---|
| 278 |  |
| 279 |  |
| 280 |  |
| 281 |  |
| 282 |  |
| 283 |  |







| Entry | Structure |
|---|---|
| 284 |  |
| 285 |  |
| 286 |  |
| 287 |  |
| 288 |  |
| 289 |  |
| 290 |  |







| Entry | Structure |
|---|---|
| 291 |  |
| 292 |  |
| 293 |  |
| 294 |  |
| 295 |  |
| 296 |  |
| 297 |  |







| Entry | Structure |
|---|---|
| 298 |  |
| 299 |  |
| 300 |  |
| 301 |  |
| 302 |  |






| Entry | Structure |
|---|---|
| 303 |  |
| 304 |  |
| 305 |  |
| 306 |  |
| 307 |  |






| Entry | Structure |
|---|---|
| 308 |  |
| 309 |  |
| 310 |  |
| 311 |  |
| 312 |  |
| 313 |  |
| 314 |  |





| Entry | Structure |
|---|---|
| 315 |  |
| 316 |  |
| 317 |  |
| 318 |  |
| 319 |  |
| 320 |  |






| Entry | Structure |
|---|---|
| 321 |  |
| 322 |  |
| 323 |  |
| 324 |  |
| 325 |  |
| 326 |  |





| Entry | Structure |
|---|---|
| 327 |  |
| 328 |  |
| 329 |  |
| 330 |  |
| 331 |  |
| 332 |  |






| Entry | Structure |
|---|---|
| 333 |  |
| 334 |  |
| 335 |  |
| 336 |  |
| 337 |  |







| Entry | Structure |
|---|---|
| 338 |  |
| 339 |  |
| 340 |  |
| 341 |  |
| 342 |  |








| Entry | Structure |
|---|---|
| 343 |  |
| 344 |  |
| 345 |  |
| 346 |  |








| Entry | Structure |
|---|---|
| 347 |  |
| 348 |  |
| 349 |  |
| 350 |  |
| 351 |  |







| Entry | Structure |
|---|---|
| 352 |  |
| 353 |  |
| 354 |  |
| 355 |  |







| Entry | Structure |
|---|---|
| 356 |  |
| 357 |  |
| 358 |  |
| 495 |  |
| 496 |  |






| Entry | Structure |
|---|---|
| 497 |  |
| 498 |  |
| 499 |  |
| 500 |  |
| 501 |  |
| 502 | Chiral  |







| Entry | Structure |
|---|---|
| 503 |  |
| 504 |  |
| 505 |  |
| 506 |  |
| 507 |  |
| 508 |  |
| 509 |  |







| Entry | Structure |
|---|---|
| 510 |  |
| 511 |  |
| 512 |  |
| 513 |  |
| 514 |  |
| 515 |  |
| 516 |  |










| Entry | Structure |
|---|---|
| 517 |  |
| 518 |  |
| 519 |  |
| 520 |  |
| 521 |  |
| 522 |  |








| Entry | Structure |
|---|---|
| 523 |  |
| 524 |  |
| 525 |  |
| 526 |  |
| 527 |  |
| 528 |  |








| Entry | Structure |
|---|---|
| 529 |  |
| 530 |  |
| 531 |  |
| 532 |  |
| 533 |  |

| Entry | Structure |
|---|---|
| 534 |  |
| 535 |  |
| 536 |  |
| 537 |  |
| 538 |  |
| 539 |  |

| Entry | Structure |
|---|---|
| 540 |  |
| 541 |  |
| 542 |  |
| 543 |  |
| 544 |  |
| 545 |  |

| Entry | Structure |
|---|---|
| 546 |  |
| 547 |  |
| 548 |  |
| 549 |  |
| 550 |  |
| 551 |  |
| 552 |  |
| 553 |  |
| 554 |  |

| Entry | Structure |
|---|---|
| 555 |  |
| 556 |  |
| 557 |  Chiral |
| 558 |  |
| 559 |  |
| 560 |  |
| 561 |  |

| Entry | Structure |
|---|---|
| 562 |  |
| 563 |  |
| 564 |  |
| 565 |  |
| 566 |  |
| 567 |  |
| 568 |  |














| Entry | Structure |
|---|---|
| 569 |  |
| 570 |  |
| 571 |  |
| 572 |  |







**Table 5b.**






**Additional Representative IGF1R Inhibitors**







**[00233]** The Compounds in Table 5b can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 5b can be used to practice the invention.






| Entry | Structure | Name |
|---|---|---|
| 573 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^6$-[3-(diethylamino)propyl]-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine |
| 574 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^6$-[2-(diethylamino)ethyl]-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine |
| 575 |  Chiral | $N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-6-[(3S)-3-methylpiperazin-1-yl]pyrimidine-2,4-diamine |
| 576 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine |





| Entry | Structure | Name |
|---|---|---|
| 577 |  | $N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 578 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine |
| 579 |  | $N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-6-[(1-methylpyrrolidin-3-yl)oxy]pyrimidine-2,4-diamine |
| 580 |  | $N^4$-[2-(diethylamino)ethyl]-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^6$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]pyrimidine-2,4,6-triamine |
| 581 |  | $N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]pyrimidine-2,4-diamine |






| Entry | Structure | Name |
|---|---|---|
| 582 |  | $N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 583 |  | $N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine |
| 584 |  | *N*-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-methyl-2-{[(3-phenylisoxazol-5-yl)methyl]oxy}pyrimidin-4-amine |
| 585 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-methyl-$N^2$-[(4-phenyl-1*H*-imidazol-2-yl)methyl]pyrimidine-2,4-diamine |
| 586 |  | 6-{[2-(dimethylamino)ethyl]oxy}-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]pyrimidine-2,4-diamine |
| 587 |  | $N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine |






| Entry | Structure | Name |
|---|---|---|
| 588 |  | $N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-6-[(2-morpholin-4-ylethyl)oxy]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 589 |  | $N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine |
| 590 |  | $N^4$-[3-(diethylamino)propyl]-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^6$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]pyrimidine-2,4,6-triamine |
| 591 |  Chiral | $N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-6-[(3S)-3-methylpiperazin-1-yl]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 592 |  | $N^4$-[2-(diethylamino)ethyl]-$N^6$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine |






| Entry | Structure | Name |
|---|---|---|
| 593 |  | $N^4$-[5-(1-methylethyl)-1*H*-pyrazol-3-yl]-6-[(1-methylpiperidin-4-yl)oxy]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 594 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine |
| 595 |  | $N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine |
| 596 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-[3-(diethylamino)propyl]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 597 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-piperidin-1-ylethyl)oxy]pyrimidine-2,4-diamine |
| 598 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine |






| Entry | Structure | Name |
|---|---|---|
| 599 |  | $N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-$N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine |
| 600 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-methyl-$N^2$-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 601 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-[(3-methylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine |
| 602 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine |
| 603 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1-methylpiperidin-4-yl)oxy]pyrimidine-2,4-diamine |






| Entry | Structure | Name |
|---|---|---|
| 604 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-morpholin-4-ylpyrimidine-2,4-diamine |
| 605 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine |
| 606 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine |
| 607 |  | $N^2$-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-$N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-6-morpholin-4-ylpyrimidine-2,4-diamine |






| Entry | Structure | Name |
|---|---|---|
| 608 |  | $N^2$-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-$N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine |
| 609 |  | $N^2$-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-$N^4$-[3-(1-methylethyl)-1*H*-pyrazol-5-yl]-6-[(2-morpholin-4-ylethyl)oxy]pyrimidine-2,4-diamine |
| 610 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-methyl-$N^2$-[(3-pyridin-3-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 611 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-$N^2$-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 612 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-morpholin-4-yl-$N^2$-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |







| Entry | Structure | Name |
|---|---|---|
| 613 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-piperazin-1-ylpyrimidine-2,4-diamine |
| 614 |  | 6-(4-acetylpiperazin-1-yl)-$N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine |
| 615 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine-2,4-diamine |
| 616 |  | 4-{6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperazine-1-carbaldehyde |
| 617 |  | $N^4$-(3-methyl-1*H*-pyrazol-5-yl)-6-morpholin-4-yl-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |






| Entry | Structure | Name |
|---|---|---|
| 618 |  | 6-(4-methylpiperazin-1-yl)-$N^4$-(3-methyl-1*H*-pyrazol-5-yl)-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 619 |  | $N^4$-(3-methyl-1*H*-pyrazol-5-yl)-6-[(2-morpholin-4-ylethyl)oxy]-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 620 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-methyl-$N^2$-[(3-pyridin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 621 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(3,4-difluorophenyl)isoxazol-5-yl]methyl}-6-methylpyrimidine-2,4-diamine |
| 622 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(2,4-difluorophenyl)isoxazol-5-yl]methyl}-6-methylpyrimidine-2,4-diamine |







| Entry | Structure | Name |
|---|---|---|
| 623 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-methyl-$N^2$-[(3-pyrazin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 624 |  | 5-chloro-$N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-morpholin-4-yl-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 625 |  | 5-chloro-$N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)-$N^2$-[(3-phenylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 626 |  | $N^2$-[(3-methylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)-$N^4$-(3-methyl-1*H*-pyrazol-5-yl)pyrimidine-2,4-diamine |
| 627 |  | $N^2$-[(3-methylisoxazol-5-yl)methyl]-$N^4$-(3-methyl-1*H*-pyrazol-5-yl)-6-morpholin-4-ylpyrimidine-2,4-diamine |






| Entry | Structure | Name |
|---|---|---|
| 628 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-$N^2$-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 629 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-[(3-furan-3-ylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine |
| 630 | Chiral  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^6$-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-$N^2$-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine |
| 631 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-$N^2$-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 632 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine |

| Entry | Structure | Name |
|---|---|---|
| 633 |  | $N^4$-bicyclo[2.2.1]hept-2-yl-$N^6$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4,6-triamine |
| 634 |  | $N^4$-bicyclo[2.2.1]hept-2-yl-$N^6$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4,6-triamine |
| 635 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-[(3-methylisoxazol-5-yl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine |
| 636 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyrimidine-2,4-diamine |
| 637 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-morpholin-4-yl-$N^2$-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |

| Entry | Structure | Name |
|---|---|---|
| 638 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-$N^2$-[(3-pyrimidin-4-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 639 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(5-fluoropyridin-2-yl)isoxazol-5-yl]methyl}-6-methylpyrimidine-2,4-diamine |
| 640 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-$N^2$-{[3-(2-thienyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine |
| 641 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-{[2-(dimethylamino)ethyl]oxy}-$N^2$-[(3-pyridin-2-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 642 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)-$N^2$-[(3-pyrimidin-5-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 643 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-morpholin-4-yl-$N^2$-[(3-pyrimidin-5-ylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |

| Entry | Structure | Name |
|---|---|---|
| 644 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine |
| 645 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine |
| 646 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-{[2-(diethylamino)ethyl]oxy}-$N^2$-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 647 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-$N^2$-[(3-methylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine |
| 648 |  | $N^4$-(5-cyclopropyl-1*H*-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-$N^2$-{[3-(1,3-thiazol-2-yl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine |

| Entry | Structure | Name |
|---|---|---|
| 649 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-[2-(dimethylamino)ethoxy]-$N^2$-[(3-methylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 650 |  | 6-{[2-(dimethylamino)ethyl]oxy}-$N^2$-[(3-methylisoxazol-5-yl)methyl]-$N^4$-(3-methyl-1*H*-pyrazol-5-yl)pyrimidine-2,4-diamine |
| 651 |  | 6-{[2-(diethylamino)ethyl]oxy}-$N^2$-[(3-methylisoxazol-5-yl)methyl]-$N^4$-(3-methyl-1*H*-pyrazol-5-yl)pyrimidine-2,4-diamine |
| 652 |  | $N^2$-[(3-methylisoxazol-5-yl)methyl]-$N^4$-(3-methyl-1*H*-pyrazol-5-yl)-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine |
| 653 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-methyl-$N^2$-[2-(3-phenylisoxazol-5-yl)ethyl]pyrimidine-2,4-diamine |
| 654 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-methyl-$N^2$-[1-(3-phenylisoxazol-5-yl)ethyl]pyrimidine-2,4-diamine |

| Entry | Structure | Name |
|---|---|---|
| 655 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-[(3-ethylisoxazol-5-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine |
| 656 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-[(3-ethylisoxazol-5-yl)methyl]-6-morpholin-4-ylpyrimidine-2,4-diamine |
| 657 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-{[2-(dimethylamino)ethyl]oxy}-$N^2$-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 658 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-{[2-(diethylamino)ethyl]oxy}-$N^2$-[(3-ethylisoxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| 659 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-$N^2$-[(3-ethylisoxazol-5-yl)methyl]-6-[(2-pyrrolidin-1-ylethyl)oxy]pyrimidine-2,4-diamine |





| Entry | Structure | Name |
|---|---|---|
| 660 |  | $N^2$-{[3-(2-aminopyrimidin-4-yl)isoxazol-5-yl]methyl}-$N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine |
| 661 |  | $N^4$-(3-cyclopropyl-1*H*-pyrazol-5-yl)-6-(4-ethylpiperazin-1-yl)-$N^2$-{[3-(1-methylethyl)isoxazol-5-yl]methyl}pyrimidine-2,4-diamine |
| 662 |  | 2-(1-{6-[(3-cyclopropyl-1*H*-pyrazol-5-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperidin-4-yl)ethanol |
| 663 |  | 2-(4-{6-[(3-cyclopropyl-1*H*-pyrazol-5-yl)amino]-2-({[3-(1-methylethyl)isoxazol-5-yl]methyl}amino)pyrimidin-4-yl}piperazin-1-yl)ethanol |

**Table 6.**

**Representative Raf Inhibitors**

**[00234]** The Compounds in Table 6 can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 6 can be used to practice the invention.

| Entry | Name |
|---|---|
| 1 | 6-(2-butyl-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 2 | 6-[1-hydroxy-3-oxo-2-(2-phenylethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 3 | 6-(1-hydroxy-2-{[4-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 4 | 6-(1-hydroxy-2-{[3-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 5 | 6-{2-[(4-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 6 | 6-(1-hydroxy-3-oxo-2-phenyl-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 7 | 6-{2-[(3-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 8 | 6-{2-[(4-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 9 | 6-[1-hydroxy-3-oxo-2-(3-phenylpropyl)-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 10 | 6-{2-[(3,4-dichlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 11 | 6-{1-hydroxy-2-[(4-methylphenyl)methyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 12 | 6-{2-[(4-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 13 | 6-[1-hydroxy-2-(1-methylethyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 14 | methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 15 | 6-{2-[(3,4-dimethylphenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 16 | 6-(2-{[4-chloro-3-(trifluoromethyl)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 17 | 6-(2-{[4-(dimethylamino)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 18 | 6-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |

| Entry | Name |
|---|---|
| 19 | 6-[2-(4-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 20 | 6-[2-(3,4-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 21 | 6-[1-hydroxy-2-(4-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 22 | 3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1*H*-benzimidazol-5-yl)-3-(methyloxy)-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 23 | 3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1*H*-benzimidazol-5-yl)-2-(1-methylethyl)-3-(methyloxy)-2,3-dihydro-1*H*-isoindol-1-one |
| 24 | 3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1*H*-benzimidazol-5-yl)-3-hydroxy-2-phenyl-2,3-dihydro-1*H*-isoindol-1-one |
| 25 | 3-(2-{[3,5-bis(methyloxy)phenyl]amino}-1*H*-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 26 | methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1-methyl-1*H*-benzimidazol-2-yl}carbamate |
| 27 | 3-(1*H*-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 28 | 5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-*N*-methyl-1*H*-benzimidazole-2-carboxamide |
| 29 | 3-hydroxy-3-(2-methyl-1*H*-benzimidazol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 30 | 7-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-3,4-dihydroquinoxalin-2(1*H*)-one |
| 31 | 7-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-3,4-dihydroquinoxalin-2(1*H*)-one |
| 32 | 1,1-dimethylethyl 4-{[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)-1,3-dihydro-2*H*-isoindol-2-yl]methyl}piperidine-1-carboxylate |
| 33 | 6-(1-hydroxy-2-{[2-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 34 | 6-{2-[(3-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 35 | 6-{2-[(2-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 36 | 6-{2-[(3-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 37 | 6-{2-[(2-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 38 | 6-{2-[(2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 39 | 6-[2-(3-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 40 | 6-[1-hydroxy-2-(3-iodophenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |

| Entry | Name |
|---|---|
| 41 | 6-[2-(3-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 42 | 6-[1-hydroxy-2-(3-nitrophenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 43 | 6-{1-hydroxy-2-[3-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 44 | 6-[1-hydroxy-2-(3-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 45 | 3-hydroxy-3-(1*H*-indol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 46 | methyl [6-(1-hydroxy-3-oxo-2-phenyl-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 47 | 6-[2-(2-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 48 | 6-{[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 49 | 6-{[2-(1*H*-benzimidazol-2-yl)phenyl]carbonyl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 50 | 6-(1-hydroxy-3-oxo-2-{[2-(trifluoromethyl)phenyl]methyl}-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 51 | 6-{2-[(5-bromo-2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 52 | 6-{1-hydroxy-2-[(3-nitrophenyl)methyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 53 | 6-(1-hydroxy-3-oxo-2-{[3-(trifluoromethyl)phenyl]methyl}-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 54 | 6-(2-{[2,3-bis(methyloxy)phenyl]methyl}-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 55 | 6-{1-hydroxy-2-[(3-iodophenyl)methyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 56 | 6-[1-hydroxy-3-oxo-2-({3-[(trifluoromethyl)oxy]phenyl}methyl)-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 57 | 6-(1-hydroxy-2-{[2-(methylthio)phenyl]methyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 58 | 6-[2-(3,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 59 | 6-{1-hydroxy-2-[3-(1-methylethyl)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 60 | 6-(1-hydroxy-3-oxo-2-{3-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 61 | 6-{1-hydroxy-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 62 | 3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)-1,3-dihydro-2*H*-isoindol-2-yl]benzenesulfonamide |
| 63 | 6-{2-[5-chloro-2-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |

| Entry | Name |
|---|---|
| 64 | 6-{2-[4-fluoro-3-(trifluoromethyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 65 | 3-hydroxy-3-(1*H*-indol-6-yl)-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 66 | 6-[2-(3-fluoro-5-iodophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 67 | 6-[2-(3-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 68 | 6-[2-(3,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 69 | 6-{1-hydroxy-2-[3-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 70 | ethyl 3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)-1,3-dihydro-2*H*-isoindol-2-yl]benzoate |
| 71 | 3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)-1,3-dihydro-2*H*-isoindol-2-yl]benzonitrile |
| 72 | 6-[2-(2-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 73 | 6-[2-(3-amino-5-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 74 | 6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 75 | 6-[2-(3-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 76 | 6-[2-(3-ethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 77 | 6-[2-(3-ethynylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 78 | 6-[1-hydroxy-2-(3-hydroxyphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 79 | 6-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 80 | 6-(1-hydroxy-3-oxo-2-{3-[(phenylmethyl)oxy]phenyl}-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 81 | 3-[1-hydroxy-3-oxo-1-(3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)-1,3-dihydro-2*H*-isoindol-2-yl]benzamide |
| 82 | 6-{1-hydroxy-2-[3-(hydroxymethyl)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 83 | 6-[2-(2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 84 | 3-hydroxy-3-[2-(methylamino)-1*H*-benzimidazol-5-yl]-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 85 | 6-(2-biphenyl-3-yl-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |

| Entry | Name |
|---|---|
| 86 | 6-(2-{3-[(dimethylamino)methyl]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 87 | 6-[2-(3,5-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 88 | 6-(1-hydroxy-3-oxo-2-piperidin-4-yl-2,3-dihydro-1*H*-isoindol-1-yl)-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 89 | 6-[2-(3-{[2-(dimethylamino)ethyl]oxy}phenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 90 | 6-[1-hydroxy-2-(2-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 91 | *N*-methyl-2-[(3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)carbonyl]-*N*-phenylbenzamide |
| 92 | methyl {5-[1-(ethyloxy)-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 93 | phenylmethyl 2-[(2-{[(methyloxy)carbonyl]amino}-1*H*-benzimidazol-5-yl)carbonyl]benzoate |
| 94 | 3-hydroxy-3-(1*H*-indazol-5-yl)-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 95 | 3-hydroxy-3-(1*H*-indazol-6-yl)-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 96 | ethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 97 | 2-methylpropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 98 | methyl {5-[1-hydroxy-3-oxo-2-(2-thienylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 99 | methyl {5-[1-hydroxy-3-oxo-2-(2-phenylethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 100 | 3-[2-amino-1-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 101 | 3-(2-amino-1*H*-benzimidazol-5-yl)-3-hydroxy-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-one |
| 102 | methyl [5-(1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 103 | 3-(methyloxy)butyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 104 | methyl (5-{1-hydroxy-3-oxo-2-[(1*R*)-1-phenylethyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 105 | methyl (5-{1-hydroxy-3-oxo-2-[(1*S*)-1-phenylethyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 106 | 2-(methyloxy)ethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 107 | methyl {6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1-methyl-1*H*-benzimidazol-2-yl}carbamate |
| 108 | prop-2-yn-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |

| Entry | Name |
|---|---|
| 109 | but-2-yn-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 110 | 1-methylethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 111 | methyl {5-[2-(2,3-dihydro-1*H*-inden-2-yl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 112 | methyl {5-[1-hydroxy-3-oxo-2-(pyridin-4-ylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 113 | methyl {5-[1-hydroxy-3-oxo-2-(pyridin-3-ylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 114 | methyl (6-{2-[(3-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 115 | methyl {5-[1-hydroxy-2-(3-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 116 | methyl [5-(1-hydroxy-2-{[2-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 117 | methyl [5-(1-hydroxy-2-{[3-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 118 | methyl [5-(1-hydroxy-2-{[4-(methyloxy)phenyl]methyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 119 | methyl (6-{2-[(4-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 120 | methyl (6-{2-[(3-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 121 | methyl (5-{1-hydroxy-2-[(3-iodophenyl)methyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 122 | methyl (5-{2-[(3-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 123 | methyl (5-{2-[(2-fluorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 124 | methyl {5-[1-hydroxy-3-oxo-2-(pyridin-2-ylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 125 | phenylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 126 | 2-fluoroethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 127 | propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 128 | methyl (5-{1-hydroxy-2-[4-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 129 | methyl (5-{2-[(2-chlorophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 130 | methyl (5-{2-[(2-bromophenyl)methyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |

| Entry | Name |
|---|---|
| 131 | methyl (5-{1-hydroxy-2-[(3-methylphenyl)methyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 132 | methyl (5-{1-hydroxy-2-[(4-methylphenyl)methyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 133 | methyl (5-{1-hydroxy-2-[(2-methylphenyl)methyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 134 | methyl {5-[2-(3-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 135 | methyl {5-[2-(3-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 136 | methyl {5-[2-(3-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 137 | methyl (5-{1-hydroxy-2-[3-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 138 | methyl {5-[2-(4-bromophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 139 | methyl {5-[2-(4-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 140 | methyl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 141 | methyl {5-[2-(3,5-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 142 | methyl {5-[2-(2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 143 | methyl {5-[2-(2-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 144 | methyl {5-[1-hydroxy-2-(2-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 145 | methyl (5-{1-hydroxy-2-[2-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 146 | methyl {5-[1-hydroxy-2-(4-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 147 | methyl (5-{1-hydroxy-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 148 | but-2-yn-1-yl (5-{1-hydroxy-3-oxo-2-[(1*R*)-1-phenylethyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 149 | *N*-ethyl-*N'*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}urea |
| 150 | phenylmethyl (5-{1-hydroxy-3-oxo-2-[(1*R*)-1-phenylethyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 151 | methyl {6-[2-(3-amino-5-chlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 152 | piperidin-4-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |

| Entry | Name |
|---|---|
| 153 | methyl {5-[2-(cyclopropylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 154 | methyl {5-[2-(2,2-dimethylpropyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 155 | methyl {5-[2-(3,5-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 156 | methyl {5-[2-(3,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 157 | *N*-ethyl-*N'*-(5-{1-hydroxy-3-oxo-2-[(1*R*)-1-phenylethyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)urea |
| 158 | *N'*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-*N*,*N*-dimethylurea |
| 159 | methyl {5-[2-(3-{[2-(dimethylamino)ethyl]oxy}phenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 160 | 3-(4-methylpiperazin-1-yl)propyl {6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 161 | methyl {5-[2-(cyclohexylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 162 | methyl {5-[1-hydroxy-2-(2-methylpropyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 163 | methyl {5-[1-hydroxy-3-oxo-2-(1,3-thiazol-2-ylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 164 | methyl {5-[2-(3,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 165 | methyl (5-{2-[1-(3,5-difluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 166 | methyl (5-{2-[1-(3-fluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 167 | methyl [5-(2-cyclohexyl-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 168 | methyl {5-[2-(2,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 169 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-*N'*-(phenylmethyl)urea |
| 170 | piperidin-4-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 171 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-*N'*-methylurea |
| 172 | methyl (5-{2-[1-(2-fluorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 173 | methyl (5-{1-hydroxy-3-oxo-2-[1-(2-thienyl)ethyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 174 | methyl (5-{2-[1-(3-chlorophenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |

| Entry | Name |
|---|---|
| 175 | methyl (5-{1-hydroxy-2-[3-methyl-5-(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 176 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}propanamide |
| 177 | methyl {5-[2-(3,4-dichlorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 178 | methyl {5-[2-(3-ethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 179 | methyl {5-[2-(3-ethynylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 180 | methyl {5-[2-(4-chloro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 181 | methyl [5-(1-hydroxy-3-oxo-2-{1-[3-(trifluoromethyl)phenyl]ethyl}-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 182 | methyl (5-{1-hydroxy-3-oxo-2-[(1*R*)-1-phenylpropyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 183 | methyl [5-(1-hydroxy-3-oxo-2-{2-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 184 | methyl {5-[2-(2,3-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 185 | cyclohexyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 186 | tetrahydrofuran-2-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 187 | cyclopropylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 188 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}morpholine-4-carboxamide |
| 189 | methyl {5-[2-(cyclopentylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 190 | methyl {5-[2-(2,3-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 191 | methyl {5-[2-(2,3-dihydro-1*H*-inden-1-yl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 192 | methyl (2*S*)-cyclohexyl[1-hydroxy-1-(2-{[(methyloxy)carbonyl]amino}-1*H*-benzimidazol-5-yl)-3-oxo-1,3-dihydro-2*H*-isoindol-2-yl]ethanoate |
| 193 | methyl {5-[2-(2,6-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 194 | methyl {5-[2-(3-chloro-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 195 | but-3-en-1-yl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 196 | 2,2,2-trifluoroethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |

| Entry | Name |
|---|---|
| 197 | methyl {5-[2-(5-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 198 | methyl (5-{2-[1-(5-chloro-2-methylphenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 199 | methyl (5-{1-hydroxy-3-oxo-2-[(1*S*)-1-phenylpropyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 200 | methyl (5-{2-[1-(3-chloro-2-methylphenyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 201 | methyl (5-{1-hydroxy-2-[1-(5-methyl-2-thienyl)ethyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 202 | methyl (5-{2-[1-(5-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 203 | methyl {5-[1-hydroxy-2-(3-iodophenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 204 | methyl (5-{1-hydroxy-2-[3-(1-methylethyl)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 205 | methyl {5-[2-(furan-2-ylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 206 | methyl {5-[1-hydroxy-3-oxo-2-(3-thienylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 207 | methyl {5-[2-(cyclobutylmethyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 208 | 3,3,3-trifluoro-2-hydroxy-*N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-2-(trifluoromethyl)propanamide |
| 209 | methyl (5-{1-hydroxy-2-[1-(4-methyl-2-thienyl)ethyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 210 | methyl (5-{2-[1-(4-bromo-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 211 | methyl {5-[1-hydroxy-2-(3-{[2-(methyloxy)ethyl]oxy}phenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 212 | tetrahydrofuran-3-ylmethyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 213 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}piperidine-1-carboxamide |
| 214 | methyl {5-[2-(3-bromo-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 215 | 2,3-dihydroxypropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 216 | methyl {5-[1-hydroxy-3-oxo-2-(tetrahydrofuran-2-ylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 217 | methyl (5-{2-[3-(aminocarbonyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 218 | 4,4,4-trifluoro-3-hydroxy-*N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-3-(trifluoromethyl)butanamide |

| Entry | Name |
|---|---|
| 219 | methyl (5-{1-hydroxy-2-[3-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 220 | methyl (5-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 221 | methyl [5-(1-hydroxy-3-oxo-2-{3-[(phenylmethyl)oxy]phenyl}-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 222 | methyl [5-(2-biphenyl-3-yl-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 223 | 2,2-dimethyl-3-[(phenylmethyl)oxy]propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 224 | methyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 225 | methyl {5-[2-(3-cyanophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 226 | methyl {5-[2-(3-ethynyl-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 227 | methyl {5-[2-(4-fluoro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 228 | methyl {6-[2-(3,4-dichloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 229 | [(4*S*)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 230 | methyl {5-[2-(5-bromo-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 231 | methyl (5-{2-[3-(acetylamino)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 232 | methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylmethyl)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 233 | methyl (5-{2-[1-(4-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 234 | methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylcarbonyl)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 235 | methyl [5-(2-{3-[(dimethylamino)methyl]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 236 | methyl (5-{2-[3-(aminosulfonyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 237 | methyl {5-[2-(3-acetylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 238 | methyl {5-[2-(3-ethyl-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 239 | methyl {5-[2-(3-chloro-5-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 240 | *N*-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-2-methylpropanamide |

| Entry | Name |
|---|---|
| 241 | methyl (5-{2-[1-(3-chloro-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 242 | methyl [5-(1-hydroxy-3-oxo-2-pyridin-3-yl-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 243 | methyl (5-{1-hydroxy-3-oxo-2-[3-(phenylamino)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 244 | methyl {5-[2-(5-bromo-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 245 | methyl {5-[2-(5-chloro-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 246 | methyl {5-[2-(3,5-dichloro-4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 247 | 2,2-dimethyl-3-(methyloxy)propyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 248 | 3-hydroxy-2,2-dimethylpropyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 249 | methyl (5-{2-[1-(5-bromo-2-thienyl)ethyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 250 | methyl {5-[2-(4,5-dichloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 251 | methyl {5-[2-(3-bromo-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 252 | methyl {5-[2-(3-chloro-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 253 | *N*-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}pent-4-ynamide |
| 254 | methyl (6-{1-methyl-3-oxo-2-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 255 | methyl [5-(1-hydroxy-3-oxo-2-{3-[(1,1,2,2-tetrafluoroethyl)oxy]phenyl}-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 256 | methyl {5-[1-hydroxy-3-oxo-2-(3-piperidin-4-ylphenyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 257 | methyl {5-[2-(3-ethenylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 258 | methyl (5-{2-[3-(dimethylamino)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 259 | 2,2-difluoro-*N*-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}cyclopropanecarboxamide |
| 260 | *N*-ethyl-*N'*-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}urea |
| 261 | methyl {5-[2-(3-aminophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 262 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-4-[(phenylmethyl)oxy]butanamide |

OVN

OK

3/7

# PATENTE DE INVENCIÓN

Organizacion y
Digitalizacion CSA Ltda

09-126923

| Entry | Name |
|---|---|
| 263 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide |
| 264 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-4-(4-methylpiperazin-1-yl)butanamide |
| 265 | *N*-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}butanamide |
| 266 | methyl {6-[2-(3-bromophenyl)-5,6-dichloro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 267 | methyl [5-(1-hydroxy-2-{3-[methyl(phenyl)amino]phenyl}-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 268 | methyl {5-[1-hydroxy-3-oxo-2-(phenylsulfonyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 269 | methyl {5-[(2-{[(phenylamino)carbonyl]amino}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 270 | methyl (5-{[2-({[(phenylmethyl)oxy]carbonyl}amino)phenyl]carbonyl}-1*H*-benzimidazol-2-yl)carbamate |
| 271 | methyl [5-({2-[(2-phenylhydrazino)carbonyl]phenyl}carbonyl)-1*H*-benzimidazol-2-yl]carbamate |
| 272 | methyl {5-[(2-{[(phenyloxy)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 273 | but-2-yn-1-yl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 274 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-3-piperidin-1-ylpropanamide |
| 275 | *N*-{6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}propanamide |
| 276 | *N*-(4-fluorophenyl)-2-{[2-(pent-4-ynoylamino)-1*H*-benzimidazol-6-yl]carbonyl}benzamide |
| 277 | 4-(diethylamino)-*N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}butanamide |
| 278 | *N*-{5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-4-pyrrolidin-1-ylbutanamide |
| 279 | 3-piperidin-1-ylpropyl {6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 280 | 3-(4-methylpiperazin-1-yl)propyl {6-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 281 | methyl {5-[2-(3-bromophenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 282 | methyl {5-[2-(3-ethynyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 283 | 2-piperidin-1-ylethyl {5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 284 | methyl {5-[2-(3-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |

| Entry | Name |
|---|---|
| 285 | methyl {5-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 286 | *N*-{6-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-2,2-dimethyl-3-piperidin-1-ylpropanamide |
| 287 | *N*-{5-[2-(4-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide |
| 288 | *N*-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-4-piperidin-1-ylbutanamide |
| 289 | methyl [6-({2-[(phenylcarbonyl)amino]phenyl}carbonyl)-1*H*-benzimidazol-2-yl]carbamate |
| 290 | methyl {5-[1-hydroxy-2-(3-morpholin-4-ylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 291 | 2-(dimethylamino)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 292 | 2-(diethylamino)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 293 | 2-piperidin-1-ylethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 294 | 3-piperidin-1-ylpropyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 295 | 2-piperidin-1-ylethyl {6-[2-(3-bromophenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 296 | methyl {6-[2-(3-bromophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 297 | 2-[methyl(phenylmethyl)amino]ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 298 | methyl {5-[1-hydroxy-3-oxo-2-(3-pyrrolidin-1-ylphenyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 299 | methyl {5-[2-(5-chloro-2,3-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 300 | methyl {5-[1-hydroxy-3-oxo-2-(pyrrolidin-2-ylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 301 | methyl {5-[1-hydroxy-3-oxo-2-(pyrrolidin-3-ylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 302 | (1-methylpiperidin-2-yl)methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 303 | [(2*S*)-1-methylpyrrolidin-2-yl]methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 304 | octahydro-2*H*-quinolizin-1-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 305 | methyl {5-[2-(5-bromo-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 306 | 5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1,3-dihydro-2*H*-benzimidazol-2-one |

| Entry | Name |
|---|---|
| 307 | methyl {5-[2-(3-bromo-2,5-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 308 | 2-morpholin-4-ylethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 309 | (1-methylpiperidin-3-yl)methyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 310 | methyl (5-{2-[5-chloro-2-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 311 | methyl [5-(2-{3-[cyclohexyl(methyl)amino]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |
| 312 | 8-azabicyclo[3.2.1]oct-3-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 313 | methyl {6-[1-(3-bromophenyl)-5-oxopyrrolidin-2-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 314 | (1-methylpiperidin-4-yl)methyl {5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 315 | 1,1-dimethylethyl 4-({[({5-[1-hydroxy-3-oxo-2-(phenylmethyl)-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}amino)carbonyl]oxy}methyl)piperidine-1-carboxylate |
| 316 | (1-methylpiperidin-4-yl)methyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 317 | 2-(1-methylpiperidin-4-yl)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 318 | methyl ({6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}amino)(oxo)acetate |
| 319 | *N*-(5-{1-hydroxy-3-oxo-2-[3-(phenyloxy)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)-4-piperidin-1-ylbutanamide |
| 320 | methyl {6-[2-(3-bromophenyl)-1-methyl-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 321 | 4-(diethylamino)but-2-yn-1-yl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 322 | methyl {5-[2-(3-chloro-2,6-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 323 | 2-(2-oxopyrrolidin-1-yl)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 324 | 2-(2,5-dioxopyrrolidin-1-yl)ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 325 | 2,2,3,3-tetrafluorocyclobutyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 326 | 1-acetyl-*N*-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}piperidine-4-carboxamide |
| 327 | *N*-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}cyclobutanecarboxamide |
| 328 | methyl [5-(2-{3-[ethyl(phenyl)amino]phenyl}-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl)-1*H*-benzimidazol-2-yl]carbamate |

| Entry | Name |
|---|---|
| 329 | *N*-{6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-2,2-difluorocyclopropanecarboxamide |
| 330 | cyclobutyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 331 | 2,2-difluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 332 | 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyridin-2-ylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 333 | 1-methylethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 334 | cyclopropylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 335 | *N*-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}cyclopropanecarboxamide |
| 336 | 2-(methyloxy)ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 337 | tetrahydrofuran-2-ylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 338 | *N*-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-2-(2-thienyl)acetamide |
| 339 | methyl {6-[2-(3-chloro-2-fluorophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 340 | ethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 341 | 2-fluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 342 | methyl (5-{1-hydroxy-3-oxo-2-[2-(phenyloxy)phenyl]-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 343 | *N'*-{5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}-*N*,*N*-diethylpentanediamide |
| 344 | cyclobutylmethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 345 | 2,2,2-trifluoroethyl {6-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 346 | methyl (5-{2-[3-(1,1-dimethylethyl)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 347 | methyl {6-[2-(3-chloro-2-fluorophenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 348 | 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(phenylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 349 | methyl {6-[4,7-dichloro-2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 350 | phenylmethyl 2-[(2-{[(ethyloxy)carbonyl]amino}-1,3-benzoxazol-5-yl)carbonyl]benzoate |

| Entry | Name |
|---|---|
| 351 | methyl {5-[2-(5-chloro-3-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 352 | methyl {5-[2-(5-ethynyl-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 353 | methyl {5-[2-(3-ethynyl-2,4-difluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 354 | 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 355 | methyl {5-[2-(3-ethynyl-2-fluorophenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 356 | 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(1,3-thiazol-2-ylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 357 | ethyl {5-[2-(3-chloro-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1,3-benzoxazol-2-yl}carbamate |
| 358 | methyl {5-[2-(5-chloro-3-iodo-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 359 | methyl {5-[2-(3-ethyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 360 | methyl {5-[2-(5-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 361 | 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyrazin-2-ylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 362 | methyl {5-[2-(2-fluoro-3-iodophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 363 | methyl {6-[2-(5-ethynyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 364 | 2-(3-ethynyl-2-fluorophenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 365 | methyl {5-[2-(2,5-dimethylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 366 | methyl {5-[2-(3-ethenyl-2-fluorophenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 367 | methyl (6-{2-[2-fluoro-3-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 368 | methyl (5-{1-hydroxy-2-[2-methyl-5-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 369 | methyl {5-[2-(3-ethynyl-2-fluorophenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 370 | methyl {5-[2-(2-fluoro-3-prop-1-yn-1-ylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 371 | methyl {5-[2-(5-chloro-2-methylphenyl)-7-fluoro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 372 | methyl {5-[2-(3-ethynyl-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |

| Entry | Name |
|---|---|
| 373 | 3-hydroxy-2-[3-(methyloxy)phenyl]-3-[2-(pyrimidin-2-ylamino)-1*H*-benzimidazol-6-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 374 | 3-hydroxy-2-(3-methylphenyl)-3-[2-(pyrimidin-2-ylamino)-1*H*-benzimidazol-6-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 375 | 2-(5-chloro-2-methylphenyl)-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1*H*-benzimidazol-6-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 376 | methyl {6-[2-(5-chloro-2-methylphenyl)-4,7-difluoro-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 377 | methyl {5-[2-(3-ethynyl-2-fluorophenyl)-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 378 | 2-(3-chloro-2-fluorophenyl)-3-{2-[(6-chloropyridazin-3-yl)amino]-1*H*-benzimidazol-5-yl}-3-hydroxy-2,3-dihydro-1*H*-isoindol-1-one |
| 379 | 2-(3-chloro-2-fluorophenyl)-4,7-difluoro-3-hydroxy-3-[2-(pyrimidin-2-ylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 380 | methyl {5-[2-(2-fluoro-5-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 381 | methyl (5-{2-[2-fluoro-5-(methyloxy)phenyl]-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 382 | methyl (5-{1-hydroxy-2-[5-methyl-2-(methyloxy)phenyl]-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl}-1*H*-benzimidazol-2-yl)carbamate |
| 383 | methyl {5-[2-(3-ethynyl-5-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 384 | 2-(3-chloro-2-fluorophenyl)-3-{2-[(5-chloropyrimidin-2-yl)amino]-1*H*-benzimidazol-5-yl}-3-hydroxy-2,3-dihydro-1*H*-isoindol-1-one |
| 385 | 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-{2-[(4-methylpyrimidin-2-yl)amino]-1*H*-benzimidazol-5-yl}-2,3-dihydro-1*H*-isoindol-1-one |
| 386 | 3-(2-{[4,6-bis(methyloxy)pyrimidin-2-yl]amino}-1*H*-benzimidazol-5-yl)-2-(3-chloro-2-fluorophenyl)-3-hydroxy-2,3-dihydro-1*H*-isoindol-1-one |
| 387 | 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-(2-{[4-methyl-6-(methyloxy)pyrimidin-2-yl]amino}-1*H*-benzimidazol-5-yl)-2,3-dihydro-1*H*-isoindol-1-one |
| 388 | 3-hydroxy-2-(3-methylphenyl)-3-[2-(pyrazin-2-ylamino)-1*H*-benzimidazol-6-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 389 | 2-(5-chloro-2-methylphenyl)-3-hydroxy-3-[2-(pyrazin-2-ylamino)-1*H*-benzimidazol-6-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 390 | methyl {6-[2-(2-fluoro-3-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1*H*-isoindol-1-yl]-1*H*-benzimidazol-2-yl}carbamate |
| 391 | 3-hydroxy-2-[3-(methyloxy)phenyl]-3-[2-(pyrazin-2-ylamino)-1*H*-benzimidazol-5-yl]-2,3-dihydro-1*H*-isoindol-1-one |
| 392 | methyl {6-[(2-{[(2-thienylmethyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 393 | methyl {6-[(2-{[(3-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 394 | methyl {6-[(2-{[(3-bromophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |

| Entry | Name |
|---|---|
| 395 | methyl {6-[(2-{[(3-chlorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 396 | methyl {6-[(2-{[(3-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 397 | methyl (6-{[2-({[3-(methyloxy)phenyl]amino}carbonyl)phenyl]carbonyl}-1*H*-benzimidazol-2-yl)carbamate |
| 398 | methyl (6-{[2-({[3-(trifluoromethyl)phenyl]amino}carbonyl)phenyl]carbonyl}-1*H*-benzimidazol-2-yl)carbamate |
| 399 | methyl {6-[(2-{[(3-ethylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 400 | methyl {6-[(2-{[(3-ethynylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 401 | methyl {6-[(2-{[(3-chloro-4-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 402 | methyl {6-[(2-{[(5-chloro-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 403 | methyl {6-[(2-{[(3-iodophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 404 | methyl (6-{[2-({[3-(1-methylethyl)phenyl]amino}carbonyl)phenyl]carbonyl}-1*H*-benzimidazol-2-yl)carbamate |
| 405 | methyl {6-[(2-{[(3-thienylmethyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 406 | methyl {6-[(2-{[(3-bromo-4-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 407 | methyl {6-[(2-{[(3-chloro-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 408 | methyl {6-[(2-{[(4-fluoro-3-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 409 | methyl {6-[(2-{[(5-bromo-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 410 | methyl {6-[(2-{[(5-bromo-2,4-difluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 411 | methyl {6-[(2-{[(5-chloro-2,4-difluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 412 | methyl {6-[(2-{[(3-bromo-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 413 | methyl {6-[(2-{[(3-ethenylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 414 | methyl {6-[(2-{[(3-ethynyl-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 415 | methyl {6-[(2-{[(5-chloro-2-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 416 | methyl {6-[(2-{[(5-bromo-2-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |

| Entry | Name |
|---|---|
| 417 | methyl {6-[(2-{[(2-fluoro-3-iodophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 418 | methyl {6-[(2-{[(3-ethenyl-2-fluorophenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |
| 419 | methyl {6-[(2-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenyl)carbonyl]-1*H*-benzimidazol-2-yl}carbamate |

**Table 7.**

**Representative EGFR and/or VEGFR Inhibitors**

**[00235]** The Compounds in Table 7 can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 7 can be used to practice the invention.

| Entry | Name |
|---|---|
| 1 | (3*Z*)-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-5-{[1-(phenylmethyl)pyrrolidin-3-yl]amino}-1,3-dihydro-2*H*-indol-2-one |
| 2 | (3*Z*)-5-[(1-ethylpiperidin-3-yl)amino]-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 3 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 4 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1*H*-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 5 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{[5-(methyloxy)-1*H*-benzimidazol-2-yl][4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one |
| 6 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 7 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 8 | (3*Z*)-3-{1*H*-benzimidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 9 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 10 | (3*Z*)-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 11 | (3*Z*)-3-[(4-aminophenyl)(1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 12 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 13 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1*H*-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 14 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |

| Entry | Name |
|---|---|
| 15 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one |
| 16 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 17 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 18 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 19 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 20 | 3-((*Z*)-1*H*-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene}methyl)benzonitrile |
| 21 | (3*Z*)-3-[(3-aminophenyl)(1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 22 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2*H*-indol-2-one |
| 23 | 3-((*Z*)-1*H*-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene}methyl)benzenecarboximidamide |
| 24 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 25 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 26 | (3*Z*)-3-{1*H*-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 27 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 28 | 2-(2-{2-[(*Z*)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene}(phenyl)methyl]-1*H*-imidazol-4-yl}ethyl)-1*H*-isoindole-1,3(2*H*)-dione |
| 29 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 30 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one |
| 31 | (3*Z*)-5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 32 | (3*Z*)-3-{1*H*-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2*H*-indol-2-one |
| 33 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2*H*-indol-2-one |
| 34 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-{[1-(phenylmethyl)piperidin-4-yl]oxy}-1,3-dihydro-2*H*-indol-2-one |
| 35 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2*H*-indol-2-one |
| 36 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}oxy)-1,3-dihydro-2*H*-indol-2-one |

| Entry | Name |
|---|---|
| 37 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}oxy)-1,3-dihydro-2*H*-indol-2-one |
| 38 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 39 | (3*Z*)-3-{1*H*-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 40 | (3*Z*)-3-[(3-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 41 | (3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 42 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 43 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)(methyl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 44 | (3*Z*)-3-[(3-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2*H*-indol-2-one |
| 45 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 46 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 47 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 48 | (3*Z*)-3-[(3-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 49 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 50 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 51 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 52 | (3*Z*)-3-[1*H*-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 53 | (3*Z*)-3-[(3-chloro-4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 54 | (3*Z*)-3-[(3,4-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 55 | (3*Z*)-3-[(5-chloro-1*H*-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 56 | (3*Z*)-3-[(5-chloro-1*H*-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 57 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 58 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |

| Entry | Name |
|---|---|
| 59 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1*H*-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 60 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one |
| 61 | (3*E*)-3-[(3,5-difluorophenyl)(5-fluoro-1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 62 | (3*Z*)-3-[(3,5-difluorophenyl)(5-fluoro-1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 63 | (3*Z*)-3-[(3-fluoro-4-methylphenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 64 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1*H*-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 65 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 66 | (3*Z*)-3-[(4-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 67 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 68 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-dihydro-2*H*-indol-2-one |
| 69 | (3*Z*)-3-[1*H*-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 70 | (3*Z*)-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 71 | (3*Z*)-3-{1*H*-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 72 | (3*Z*)-3-[(5-chloro-1*H*-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 73 | (3*Z*)-3-[(3,5-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 74 | (3*Z*)-3-[(3,5-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 75 | (3*Z*)-3-[(3,5-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 76 | (3*Z*)-3-[(3,5-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 77 | (3*Z*)-3-[(4-methyl-1*H*-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 78 | (3*Z*)-3-[(4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 79 | (3*Z*)-3-[(3,4-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 80 | (3*Z*)-3-[(3-chloro-4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |

| Entry | Name |
|---|---|
| 81 | (3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2*H*-indol-2-one |
| 82 | (3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(2-piperidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one |
| 83 | (3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(2-morpholin-4-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one |
| 84 | (3*Z*)-5-({1-[2-(diethylamino)ethyl]piperidin-4-yl}amino)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 85 | (3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one |
| 86 | (3*Z*)-3-[1*H*-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 87 | (3*Z*)-3-[(3-fluorophenyl)(1*H*-1,2,4-triazol-5-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 88 | ethyl 2-{(*Z*)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene]methyl}-4-methyl-1*H*-imidazole-5-carboxylate |
| 89 | (3*Z*)-3-[1*H*-imidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 90 | (3*Z*)-3-{1*H*-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 91 | (3*Z*)-3-[(4-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 92 | (3*Z*)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 93 | (3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one |
| 94 | (3*Z*)-3-[1*H*-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 95 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 96 | (3*Z*)-3-[(3-fluorophenyl)(4-phenyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 97 | (3*Z*)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 98 | (3*Z*)-3-{1*H*-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one |
| 99 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1*H*-1,2,4-triazol-5-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 100 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 101 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{(4-methyl-1*H*-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one |
| 102 | (3*Z*)-3-[(4-chlorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |

| Entry | Name |
|---|---|
| 103 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 104 | (3*Z*)-3-[(3,4-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 105 | (3*Z*)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 106 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 107 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 108 | (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one |
| 109 | (3*Z*)-3-[(2,3-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 110 | (3*Z*)-3-[(2,3-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 111 | (3*Z*)-3-[(2,4-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 112 | (3*Z*)-3-[(2,4-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 113 | (3*Z*)-3-[(2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 114 | (3*Z*)-3-[(3-trifluoromethylphenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 115 | (3*Z*)-3-[(3-trifluoromethylphenyl)( 4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 116 | (3*Z*)-3-[(2,4-dichloro-5-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 117 | (3*Z*)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |
| 118 | (3*Z*)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one |

**Table 8. c-KIT Inhibitors**

**[00236]** The Compounds in Table 8 can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 8 can be used to practice the invention.

| Entry | Name |
|---|---|
| 1 | *N*-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 2 | *N*-phenyl-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |

| Entry | Name |
|---|---|
| 3 | *N*-(2-methylphenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 4 | *N*-(2-chlorophenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 5 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 6 | ethyl 2-[({[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate |
| 7 | *N*-(3-chloro-2-methylphenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 8 | *N*-(3-fluorophenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 9 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(2*H*-tetrazol-5-yl)phenyl]oxy}acetamide |
| 10 | *N*-(4-chloro-2-fluorophenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 11 | *N*-(4-bromo-3-methylphenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 12 | *N*-(4-morpholin-4-ylphenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 13 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 14 | *N*-[4-bromo-3-(trifluoromethyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 15 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 16 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}propanamide |
| 17 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(5-methyl-1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 18 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[2-methyl-5-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 19 | *N*-(4-chlorophenyl)-*N*-methyl-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 20 | *N*-[4-chloro-2-(trifluoromethyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 21 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(2,5-dioxopyrrolidin-1-yl)phenyl]oxy}acetamide |
| 22 | (2E)-*N*-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(1*H*-tetrazol-1-yl)phenyl]prop-2-enamide |
| 23 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 24 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(2-methyl-2*H*-tetrazol-5-yl)phenyl]oxy}acetamide |
| 25 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[2,4-dichloro-5-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |

| Entry | Name |
|---|---|
| 26 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]thio}acetamide |
| 27 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*~2~-[3-(1*H*-tetrazol-1-yl)phenyl]glycinamide |
| 28 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[2-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 29 | methyl 1-{3-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1*H*-1,2,3-triazole-4-carboxylate |
| 30 | 1,1-dimethylethyl {4-[({[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carbamate |
| 31 | 1,1-dimethylethyl {4-[({[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetyl)amino]phenyl}carbamate |
| 32 | *N*-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 33 | *N*-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 34 | *N*-(4-aminophenyl)-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 35 | *N*-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 36 | *N*-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 37 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-pyridin-4-ylphenyl)oxy]acetamide |
| 38 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*~2~-methyl-*N*~2~-[3-(1*H*-tetrazol-1-yl)phenyl]glycinamide |
| 39 | *N*-1,3-benzothiazol-2-yl-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 40 | *N*-quinolin-8-yl-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 41 | *N*-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 42 | *N*-isoquinolin-5-yl-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 43 | *N*-{3-[(phenylmethyl)oxy]phenyl}-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 44 | *N*-[5-methyl-2-(methyloxy)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 45 | *N*-[2,5-bis(methyloxy)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 46 | *N*-(6-fluoro-1,3-benzothiazol-2-yl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 47 | methyl 3-[({[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzoate |
| 48 | 5-chloro-2-[({[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetyl)amino]benzamide |
| 49 | *N*-[5-chloro-2,4-bis(methyloxy)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |

| Entry | Name |
|---|---|
| 50 | *N*-[2-(phenyloxy)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 51 | *N*-[3-(aminosulfonyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 52 | *N*-[2-(methyloxy)-5-(trifluoromethyl)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 53 | *N*-(4-{[(4-methylphenyl)sulfonyl]amino}phenyl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 54 | *N*-(5-phenyl-1*H*-pyrazol-3-yl)-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 55 | *N*-1,3-benzothiazol-2-yl-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 56 | *N*-quinolin-8-yl-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 57 | 1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1*H*-pyrrole-1-carboxylate |
| 58 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1*H*-pyrrol-2-yl)phenyl]oxy}acetamide |
| 59 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-pyrimidin-5-ylphenyl)oxy]acetamide |
| 60 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(1*H*-1,2,3-triazol-1-yl)phenyl]oxy}acetamide |
| 61 | 4-chloro-*N*-(2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}ethyl)-3-(trifluoromethyl)aniline |
| 62 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*-(2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}ethyl)formamide |
| 63 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-pyridin-3-ylphenyl)oxy]acetamide |
| 64 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-furan-3-ylphenyl)oxy]acetamide |
| 65 | (2E)-*N*-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[3-(1*H*-tetrazol-1-yl)phenyl]prop-2-enamide |
| 66 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[3-(1*H*-tetrazol-1-yl)phenyl]propanamide |
| 67 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[6-(1*H*-tetrazol-1-yl)pyrimidin-4-yl]oxy}acetamide |
| 68 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(3,5-dimethylisoxazol-4-yl)phenyl]oxy}acetamide |
| 69 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-quinolin-7-ylphenyl)oxy]acetamide |
| 70 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-furan-2-ylphenyl)oxy]acetamide |
| 71 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1*H*-tetrazol-1-yl)phenyl]hydrazinecarboxamide |

| Entry | Name |
|---|---|
| 72 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-dibenzo[b,d]furan-4-ylphenyl)oxy]acetamide |
| 73 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(4-pyrimidin-5-ylphenyl)oxy]acetamide |
| 74 | *N*-methyl-*N*-[4-(methyloxy)phenyl]-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 75 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*'-{[3-(1*H*-tetrazol-1-yl)phenyl]methyl}urea |
| 76 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*-methyl-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 77 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-*N*~2~-[3-(1*H*-tetrazol-1-yl)phenyl]glycinamide |
| 78 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-2-{[3-(pyridin-2-ylamino)phenyl]oxy}acetamide |
| 79 | *N*-[2-fluoro-5-(trifluoromethyl)phenyl]-2-[3-(1*H*-tetrazol-1-yl)phenyl]hydrazinecarboxamide |
| 80 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(4-pyridin-3-ylphenyl)oxy]acetamide |
| 81 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*'-[(3-pyrimidin-5-ylphenyl)methyl]urea |
| 82 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*'-[(4-pyrimidin-5-ylphenyl)methyl]urea |
| 83 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*'-[(4-pyridin-3-ylphenyl)methyl]urea |
| 84 | [3-(1*H*-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 85 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[(4-pyrimidin-5-ylphenyl)oxy]acetamide |
| 86 | *N*~2~-[4-chloro-3-(trifluoromethyl)phenyl]-*N*-[3-(1*H*-tetrazol-1-yl)phenyl]glycinamide |
| 87 | 2-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}-*N*-[3-(1*H*-tetrazol-1-yl)phenyl]acetamide |
| 88 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-methyl-4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 89 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[4-(1*H*-1,2,3-triazol-1-yl)phenyl]oxy}acetamide |
| 90 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-fluoro-4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 91 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[2-fluoro-4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 92 | *N*-({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-3-(1*H*-tetrazol-1-yl)benzenesulfonamide |
| 93 | *N*-({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-*N*-methyl-3-(1*H*-tetrazol-1-yl)benzenesulfonamide |

| Entry | Name |
|---|---|
| 94 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[(4-pyridin-3-ylphenyl)oxy]acetamide |
| 95 | 2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-*N*-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide |
| 96 | 2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-*N*-[4-chloro-3-(trifluoromethyl)phenyl]acetamide |
| 97 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(4-pyridin-4-ylphenyl)oxy]acetamide |
| 98 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*~2~-[3-(methyloxy)-4-(1*H*-tetrazol-1-yl)phenyl]glycinamide |
| 99 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*~2~-[4-(methyloxy)-3-(1*H*-tetrazol-1-yl)phenyl]glycinamide |
| 100 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*~2~-[4-(1*H*-tetrazol-1-yl)phenyl]glycinamide |
| 101 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(2,3,5,6-tetrafluoro-4-pyrimidin-5-ylphenyl)hydrazinecarboxamide |
| 102 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[4-(1*H*-tetrazol-1-yl)phenyl]methyl}urea |
| 103 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-pyrimidin-5-ylphenyl)hydrazinecarboxamide |
| 104 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[(3-pyridin-3-ylphenyl)methyl]urea |
| 105 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-{[3-(1*H*-tetrazol-1-yl)phenyl]oxy}propanamide |
| 106 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[4-(1*H*-tetrazol-1-yl)phenyl]oxy}propanamide |
| 107 | *N*-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 108 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({3-[2-(methyloxy)pyrimidin-5-yl]phenyl}methyl)urea |
| 109 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({3-[6-(methyloxy)pyridin-3-yl]phenyl}methyl)urea |
| 110 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({4-[2-(methyloxy)pyrimidin-5-yl]phenyl}methyl)urea |
| 111 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({4-[6-(methyloxy)pyridin-3-yl]phenyl}methyl)urea |
| 112 | 1,1-dimethylethyl 2-{4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1*H*-indole-1-carboxylate |
| 113 | *N*-({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-4-(1*H*-tetrazol-1-yl)benzenesulfonamide |
| 114 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N*~2~-[3-(2*H*-tetrazol-5-yl)phenyl]glycinamide |

| Entry | Name |
|---|---|
| 115 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[2,6-difluoro-4-(1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |
| 116 | (3-pyridin-3-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 117 | (3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 118 | (3-pyridin-4-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 119 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1*H*-tetrazol-1-yl)phenyl]hydrazinecarboxamide |
| 120 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-pyridin-3-ylphenyl)hydrazinecarboxamide |
| 121 | (4-pyridin-3-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 122 | (4-pyridin-4-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 123 | (4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 124 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[(4-pyridin-4-ylphenyl)methyl]urea |
| 125 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-pyridin-3-ylphenyl)hydrazinecarboxamide |
| 126 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-pyrimidin-5-ylphenyl)hydrazinecarboxamide |
| 127 | *N*-[5-chloro-2,4-bis(methyloxy)phenyl]-*N'*-[(4-pyrimidin-5-ylphenyl)methyl]urea |
| 128 | *N*-[5-chloro-2,4-bis(methyloxy)phenyl]-*N'*-[(4-pyridin-3-ylphenyl)methyl]urea |
| 129 | (4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate |
| 130 | (4-pyridin-3-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate |
| 131 | 1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 132 | 1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 133 | *N*-[5-chloro-2,4-bis(methyloxy)phenyl]-*N'*-[(3-pyridin-3-ylphenyl)methyl]urea |
| 134 | *N*-[5-chloro-2,4-bis(methyloxy)phenyl]-*N'*-[(3-pyrimidin-5-ylphenyl)methyl]urea |
| 135 | (3-pyridin-3-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate |
| 136 | (3-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate |

| Entry | Name |
|---|---|
| 137 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-(3-pyrimidin-5-ylphenyl)hydrazinecarboxamide |
| 138 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-*N'*-[(4-pyridin-3-ylphenyl)methyl]urea |
| 139 | *N*-{[3-(6-aminopyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 140 | *N*-{[4-(6-aminopyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 141 | *N*-{[3-(2-aminopyrimidin-5-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 142 | *N*-{[4-(2-aminopyrimidin-5-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 143 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[1-(4-pyridin-3-ylphenyl)ethyl]urea |
| 144 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[1-(4-pyrimidin-5-ylphenyl)ethyl]urea |
| 145 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[4-(1*H*-indol-2-yl)phenyl]oxy}acetamide |
| 146 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(isoquinolin-7-yloxy)acetamide |
| 147 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-pyridin-4-ylphenyl)hydrazinecarboxamide |
| 148 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-pyridin-4-ylphenyl)hydrazinecarboxamide |
| 149 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[(3-pyridin-4-ylphenyl)methyl]urea |
| 150 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[(3-quinoxalin-6-ylphenyl)methyl]urea |
| 151 | methyl 3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazine-2-carboxylate |
| 152 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[(4-quinoxalin-6-ylphenyl)methyl]urea |
| 153 | *N*-{[3-(2-amino-5-methylpyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 154 | methyl 3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazine-2-carboxylate |
| 155 | [3-(1*H*-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate |
| 156 | *N*-[3-chloro-4-(methyloxy)phenyl]-*N'*-{[3-(1*H*-tetrazol-1-yl)phenyl]methyl}urea |
| 157 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[4-(5-hydroxy-1*H*-tetrazol-1-yl)phenyl]oxy}acetamide |

| Entry | Name |
|---|---|
| 158 | *N*-{[3-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 159 | *N*-{[4-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 160 | *N*-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 161 | *N*-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 162 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[4-(pyrimidin-2-yloxy)phenyl]methyl}urea |
| 163 | *N*-({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-3-(1*H*-tetrazol-1-yl)benzamide |
| 164 | 3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-*N*-[2-(dimethylamino)ethyl]pyrazine-2-carboxamide |
| 165 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[3-(6-fluoropyridin-3-yl)phenyl]methyl}urea |
| 166 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({3-[2-(methyloxy)pyridin-3-yl]phenyl}methyl)urea |
| 167 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[4-(6-fluoropyridin-3-yl)phenyl]methyl}urea |
| 168 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({4-[2-(methyloxy)pyridin-3-yl]phenyl}methyl)urea |
| 169 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[4-(6-methylpyridin-3-yl)phenyl]methyl}urea |
| 170 | *N*-{[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 171 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[3-(6-methylpyridin-3-yl)phenyl]methyl}urea |
| 172 | *N*-{[4-(2-aminopyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 173 | *N*-{[3-(2-aminopyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 174 | [3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 175 | [3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 176 | [3-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 177 | (3-pyrazin-2-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 178 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({3-[6-(hydroxymethyl)pyridin-3-yl]phenyl}methyl)urea |

| Entry | Name |
|---|---|
| 179 | *N*-{[3-(6-acetylpyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 180 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[3-(6-cyanopyridin-3-yl)phenyl]methyl}urea |
| 181 | 1,1-dimethylethyl (3S)-3-({[3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazin-2-yl]carbonyl}amino)piperidine-1-carboxylate |
| 182 | 3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-*N*-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide |
| 183 | 1,1-dimethylethyl (3S)-3-({[3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazin-2-yl]carbonyl}amino)piperidine-1-carboxylate |
| 184 | 3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-*N*-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide |
| 185 | [3-(7*H*-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 186 | *N*-{[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 187 | [6-(1*H*-tetrazol-1-yl)pyridin-2-yl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 188 | [3-(1*H*-benzimidazol-2-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 189 | [3-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 190 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({3-[5-(methylthio)pyridin-3-yl]phenyl}methyl)urea |
| 191 | [4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 192 | [4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 193 | [4-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 194 | (4-pyrazin-2-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 195 | [4-(7*H*-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 196 | [4-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 197 | [3-(1*H*-tetrazol-1-yl)phenyl]methyl 1,3-benzothiazol-2-ylcarbamate |
| 198 | [3-(1*H*-tetrazol-1-yl)phenyl]methyl (5-bromopyridin-2-yl)carbamate |
| 199 | (3-pyridin-3-ylphenyl)methyl (3,5-dimethylphenyl)carbamate |

| Entry | Name |
|---|---|
| 200 | (3-pyridin-3-ylphenyl)methyl [5-chloro-2-(methyloxy)phenyl]carbamate |
| 201 | [4-(1*H*-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 202 | (3-pyrimidin-5-ylphenyl)methyl [5-chloro-2-(methyloxy)phenyl]carbamate |
| 203 | (4-pyrimidin-5-ylphenyl)methyl (3,4-dimethylphenyl)carbamate |
| 204 | (3-pyridin-3-ylphenyl)methyl (3,4-dimethylphenyl)carbamate |
| 205 | 1,1-dimethylethyl 3-({[3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazin-2-yl]carbonyl}amino)piperidine-1-carboxylate |
| 206 | 1,1-dimethylethyl 3-({[3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazin-2-yl]carbonyl}amino)piperidine-1-carboxylate |
| 207 | 3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-*N*-piperidin-3-ylpyrazine-2-carboxamide |
| 208 | 3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)-*N*-piperidin-3-ylpyrazine-2-carboxamide |
| 209 | 1,1-dimethylethyl 4-{[3-amino-6-(3-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazin-2-yl]carbonyl}piperazine-1-carboxylate |
| 210 | 1,1-dimethylethyl 4-{[3-amino-6-(4-{[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]methyl}phenyl)pyrazin-2-yl]carbonyl}piperazine-1-carboxylate |
| 211 | *N*-({3-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 212 | *N*-({4-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 213 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[3-(1*H*-pyrazol-4-yl)phenyl]methyl}urea |
| 214 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[4-(1*H*-pyrazol-4-yl)phenyl]methyl}urea |
| 215 | [3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 216 | [4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 217 | *N*-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |

| Entry | Name |
|---|---|
| 218 | *N*-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 219 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[3-(2-fluoropyridin-3-yl)phenyl]methyl}urea |
| 220 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{[4-(2-fluoropyridin-3-yl)phenyl]methyl}urea |
| 221 | [3-(1*H*-tetrazol-1-yl)phenyl]methyl [3-(trifluoromethyl)phenyl]carbamate |
| 222 | [3-(1*H*-tetrazol-1-yl)phenyl]methyl [6-(trifluoromethyl)pyridin-2-yl]carbamate |
| 223 | [3-(1*H*-tetrazol-1-yl)phenyl]methyl [4-(trifluoromethyl)pyridin-2-yl]carbamate |
| 224 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-({3-[5-(methylthio)pyridin-2-yl]phenyl}methyl)urea |
| 225 | [3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 226 | {3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 227 | 2,3'-bipyridin-6-ylmethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 228 | (6-pyrimidin-5-ylpyridin-2-yl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 229 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[(3-isoquinolin-4-ylphenyl)methyl]urea |
| 230 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[(4-isoquinolin-4-ylphenyl)methyl]urea |
| 231 | [6-(1*H*-tetrazol-1-yl)pyridin-2-yl]methyl [4-(trifluoromethyl)pyridin-2-yl]carbamate |
| 232 | [3-(1*H*-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |
| 233 | [4-(1*H*-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate |

**Table 9. c-KIT and/or Flt-3 Inhibitors**

**[00237]** The Compounds in Table 9 can be prepared as pharmaceutically acceptable salts, solvates, hydrates, and/or isomers thereof. All such salt, solvate, hydrate, and isomer combinations of the Compounds in Table 9 can be used to practice the invention.

| Entry | Name |
|---|---|
| 1 | 4-((*E*)-2-{3-[6-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}ethenyl)phenol |

| Entry | Name |
|---|---|
| 2 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-(4-{3-[5-(4-ethylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 3 | *N*-(3-ethylphenyl)-*N'*-(4-{3-[5-(4-ethylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 4 | *N*-(4-{3-[5-(4-ethylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)-*N'*-[3-(trifluoromethyl)phenyl]urea |
| 5 | *N*-(3-acetylphenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 6 | *N*-(3,4-dichlorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 7 | *N*-(3-bromophenyl)-*N'*-(4-{3-[6-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 8 | *N*-[4-fluoro-3-(trifluoromethyl)phenyl]-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 9 | *N*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)-*N'*-[4-(phenyloxy)phenyl]urea |
| 10 | *N*-(3-chlorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 11 | *N*-[3,5-bis(methyloxy)phenyl]-*N'*-(4-{3-[6-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 12 | *N*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)-*N'*-{4-[(trifluoromethyl)oxy]phenyl}urea |
| 13 | *N*-(4-{3-[6-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)-*N'*-[4-(trifluoromethyl)phenyl]urea |
| 14 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 15 | *N*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)-*N'*-[3-(trifluoromethyl)phenyl]urea |
| 16 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-(4-{3-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 17 | *N*-(3,4-dimethylphenyl)-*N'*-(4-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-3-yl}phenyl)urea |
| 18 | *N*-(4-chlorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 19 | *N*-(3,5-difluorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 20 | *N*-[3-(methyloxy)phenyl]-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 21 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-(4-{3-[4-(4-ethylpiperazin-1-yl)phenyl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 22 | *N*-(3-fluorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 23 | *N*-(4-fluorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |

| Entry | Name |
|---|---|
| 24 | *N*-(3-cyanophenyl)-*N'*-(4-{3-[6-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 25 | *N*-(3,4-difluorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 26 | *N*-[3,4-bis(methyloxy)phenyl]-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 27 | *N*-[5-chloro-2-(methyloxy)phenyl]-*N'*-(4-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-3-yl}phenyl)urea |
| 28 | *N*-(4-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-3-yl}phenyl)-*N'*-[4-(phenyloxy)phenyl]urea |
| 29 | *N*-(2,4-difluorophenyl)-*N'*-(4-{3-[6-(4-ethylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 30 | *N*-{4-[3-(1*H*-benzimidazol-2-yl)-1*H*-pyrazol-5-yl]phenyl}-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea |
| 31 | *N*-{4-[3-(1*H*-benzimidazol-2-yl)-1*H*-pyrazol-5-yl]phenyl}-*N'*-[2-fluoro-5-(trifluoromethyl)phenyl]urea |
| 32 | *N*-(2,4-difluorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 33 | *N*-{4-[3-(1*H*-benzimidazol-2-yl)-1*H*-pyrazol-5-yl]phenyl}-*N'*-phenylurea |
| 34 | *N*-[3,5-bis(trifluoromethyl)phenyl]-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 35 | *N*-(2-fluorophenyl)-*N'*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 36 | 4-((*E*)-2-{5-[(*E*)-2-phenylethenyl]-1*H*-pyrazol-3-yl}ethenyl)phenol |
| 37 | 2-(methyloxy)-4-((*E*)-2-{5-[(*E*)-2-phenylethenyl]-1*H*-pyrazol-3-yl}ethenyl)phenol |
| 38 | *N*-(5-fluoro-2-methylphenyl)-*N'*-(4-{3-[6-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 39 | *N*-(4-{3-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)-*N'*-phenylurea |
| 40 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-(4-{3-[3-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 41 | *N*-(2,4-difluorophenyl)-*N'*-(4-{3-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 42 | *N*-(2,3-dihydro-1,4-benzodioxin-6-yl)-*N'*-(4-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-3-yl}phenyl)urea |
| 43 | *N*-[2,4-bis(methyloxy)phenyl]-*N'*-(4-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-3-yl}phenyl)urea |
| 44 | 4-((*E*)-2-{3-[(*E*)-2-(4-fluorophenyl)ethenyl]-1*H*-pyrazol-5-yl}ethenyl)-2-(methyloxy)phenol |
| 45 | 4-{(*E*)-2-[3-(1-benzofuran-2-yl)-1*H*-pyrazol-5-yl]ethenyl}phenol |

| Entry | Name |
|---|---|
| 46 | *N*-(4-{3-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-5-yl}phenyl)-*N'*-(2-phenylethyl)ethanediamide |
| 47 | 4-{(*E*)-2-[3-(1*H*-benzimidazol-2-yl)-1*H*-pyrazol-5-yl]ethenyl}phenol |
| 48 | 4-((*E*)-2-{3-[(*E*)-2-(4-chlorophenyl)ethenyl]-1*H*-pyrazol-5-yl}ethenyl)-2-(methyloxy)phenol |
| 49 | 4-{(*E*)-2-[3-(1-benzothien-2-yl)-1*H*-pyrazol-5-yl]ethenyl}phenol |
| 50 | *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[4-(3-phenyl-1*H*-pyrazol-5-yl)phenyl]urea |
| 51 | 4-((*E*)-2-{3-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-5-yl}ethenyl)phenol |
| 52 | 1,1-dimethylethyl {4-[3-(1*H*-benzimidazol-2-yl)-1*H*-pyrazol-5-yl]phenyl}carbamate |
| 53 | *N*-(5-fluoro-2-methylphenyl)-*N'*-(4-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-3-yl}phenyl)urea |
| 54 | 4-[(*E*)-2-(3-phenyl-1*H*-pyrazol-5-yl)ethenyl]phenol |
| 55 | 2-(methyloxy)-4-[(*E*)-2-(5-phenyl-1*H*-pyrazol-3-yl)ethenyl]phenol |
| 56 | 4-[(*E*)-2-(5-naphthalen-2-yl-1*H*-pyrazol-3-yl)ethenyl]phenol |
| 57 | 4-{(*E*)-2-[5-(2-fluorophenyl)-1*H*-pyrazol-3-yl]ethenyl}phenol |
| 58 | 4-((*E*)-2-{3-[3-(4-methylpiperazin-1-yl)phenyl]-1*H*-pyrazol-5-yl}ethenyl)phenol |
| 59 | 4-((*E*)-2-{3-[(*E*)-2-(2,4-difluorophenyl)ethenyl]-1*H*-pyrazol-5-yl}ethenyl)-2-(methyloxy)phenol |
| 60 | 4-{(*E*)-2-[5-(4-fluorophenyl)-1*H*-pyrazol-3-yl]ethenyl}phenol |
| 61 | 4-{(*E*)-2-[3-(4-chlorophenyl)-1*H*-pyrazol-5-yl]ethenyl}phenol |
| 62 | 4-[(*E*)-2-(5-pyridin-2-yl-1*H*-pyrazol-3-yl)ethenyl]phenol |
| 63 | 4-{(*E*)-2-[3-(5-chloro-1-benzofuran-2-yl)-1*H*-pyrazol-5-yl]ethenyl}phenol |
| 64 | *N*-(1,1-dimethylethyl)-*N'*-(4-{3-[5-(4-ethylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-5-yl}phenyl)urea |
| 65 | 4-[(*E*)-2-(3-pyridin-4-yl-1*H*-pyrazol-5-yl)ethenyl]phenol |
| 66 | 4-{(*E*)-2-[3-(3-chlorophenyl)-1*H*-pyrazol-5-yl]ethenyl}phenol |
| 67 | 4-((*E*)-2-{5-[2-(methyloxy)phenyl]-1*H*-pyrazol-3-yl}ethenyl)phenol |

| Entry | Name |
|---|---|
| 68 | 4-{(*E*)-2-[3-(2-chlorophenyl)-1*H*-pyrazol-5-yl]ethenyl}phenol |
| 69 | 4-[(*E*)-2-(3-pyridin-3-yl-1*H*-pyrazol-5-yl)ethenyl]phenol |
| 70 | 4-((*E*)-2-{5-[3-(methyloxy)phenyl]-1*H*-pyrazol-3-yl}ethenyl)phenol |
| 71 | 1,1-dimethylethyl (4-{3-[(*E*)-2-phenylethenyl]-1*H*-pyrazol-5-yl}phenyl)carbamate |
| 72 | 4-{(*E*)-2-[3-(3,4-dichlorophenyl)-1*H*-pyrazol-5-yl]ethenyl}phenol |
| 73 | 2-{5-[(*E*)-2-phenylethenyl]-1*H*-pyrazol-3-yl}-1-benzofuran-6-ol |
| 74 | 4-{(*E*)-2-[5-(3-fluorophenyl)-1*H*-pyrazol-3-yl]ethenyl}phenol |
| 75 | 2-(5-phenyl-1*H*-pyrazol-3-yl)-1*H*-benzimidazole |
| 76 | *N*-phenyl-*N*'-[4-(3-phenyl-1*H*-pyrazol-5-yl)phenyl]urea |
| 77 | 4-[3-(1*H*-benzimidazol-2-yl)-1*H*-pyrazol-5-yl]aniline |
| 78 | 4-[(*E*)-2-(5-biphenyl-3-yl-1*H*-pyrazol-3-yl)ethenyl]phenol |
| 79 | 4-((*E*)-2-{5-[5-(4-methylpiperazin-1-yl)-1*H*-benzimidazol-2-yl]-1*H*-pyrazol-3-yl}ethenyl)phenol |

**General Administration**

**[00238]** In one aspect, the invention provides pharmaceutical compositions comprising an inhibitor of PI3K according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent. In certain other specific embodiments, administration may specifically be by the oral route. Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, specifically in unit dosage forms suitable for simple administration of precise

dosages. When treating brain cancers, including glioblastomas, the administration may specifically be by placing a gliadel, a dissolvable material that contains the chemotherapy drug (in particular BCNU), directly into brain tumors during an operation.

**[00239]** The compositions will include a compound of Formula I or II as the/an active agent and can include a conventional pharmaceutical carrier or excipient and in addition may include other medicinal agents and pharmaceutical agents that are generally administered to a patient being treated for cancer.

**[00240]** Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

**[00241]** If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylalted hydroxytoluene, etc.

**[00242]** The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

[00243] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

[00244] One specific route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.

[00245] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

[00246] Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner.

Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

**[00247]** Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt or solvate thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension.

**[00248]** Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

**[00249]** Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.

**[00250]** Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

**[00251]** Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.

**[00252]** Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt or solvate thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt or solvate thereof, with the rest being suitable pharmaceutical excipients.

**[00253]** Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, for treatment of a disease-state in accordance with the teachings of this invention.

**[00254]** The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.

**[00255]** If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the

instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.

**[00256]** Representative pharmaceutical formulations containing a compound of Formula I or II are described below in the Pharmaceutical Composition Examples.

## UTILITY

**[00257]** Certain compounds of Formula I have been tested using the assay described in Biological Example 1 and have been determined to be PI3K inhibitors. As such compounds of Formula I are useful for treating diseases, particularly cancer in which PI3Kactivity contributes to the pathology and/or symptomatology of the disease. For example, cancer in which PI3K activity contributes to its pathology and/or symptomatology include breast cancer, colon cancer, rectal cancer, endometrial cancer, gastric carcinoma, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and thyroid carcinoma, and the like.

Suitable *in vitro* assays for measuring PI3K activity and the inhibition thereof by compounds are known. Typically, the assay will measure PI3K-induced ATP consumption. For further details of an *in vitro* assay for measuring PI3K activity see Biological Examples, Example 1 *infra*. Cellular activity can be determined using assays as described in Biological Examples 2, 3, and 4 *infra*. Suitable *in vivo* models of cancer are known to those of ordinary skill in the art. For further details of *in vivo* assays see Biological Examples 5-10, *infra*. Examples describing the administration of a Compound of Formula I in combination with anticancer agents are described in Biological Examples 11-14, *infra*. Following the examples disclosed herein, as well as that disclosed in the art, a person of ordinary skill in the art can determine what ombinations of a Compound of Formula I and anti-cancer agents would be effective for treating cancer.

## PREPARATIONS OF THE INTERMEDIATES AND COMPOUNDS OF THE INVENTION

**[00258]** Compounds of this invention can be made by the synthetic procedures described in WO 2007/044729, the disclsoure of which is incorporated by reference herein.


**[00259]** The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis.), or Bachem (Torrance, Calif.), or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4$^{th}$ Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this invention can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

**[00260]** Unless specified to the contrary, the reactions described herein take place at atmospheric pressure and over a temperature range from about -78 °C to about 150 °C, in another embodiment from about 0 °C. to about 125 °C and most specifically at about room (or ambient) temperature, e.g., about 20 °C. Unless otherwise stated (as in the case of a hydrogenation), all reactions are performed under an atmosphere of nitrogen.

**[00261]** Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups regenerate original functional groups by routine manipulation or *in vivo*. Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.


**[00262]** The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms or quaternized nitrogen atoms in their structure. Compounds of Formula I that may be prepared through the syntheses described herein may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention. Some of the compounds of the invention may exist as tautomers. For example, where a ketone or aldehyde is present, the molecule may exist in the enol form; where an amide is present, the molecule may exist as the imidic acid; and where an enamine is present, the molecule may exist as an imine. All such tautomers are within the scope of the invention.

**[00263]** In particular, in this application B can be 2-hydroxy-pyridinyl, also described as its structure:




**14.**

Both 2-hydroxy-pyridinyl and the above structure **14** include, and are equivalent to, pyridin-2(1*H*)-one and its structure **15**:




**15.**

Regardless of which structure or which terminology is used, each tautomer is included within the scope of the Invention.


**[00264]** The present invention also includes N-oxide derivatives and protected derivatives of compounds of Formula I. For example, when compounds of Formula I contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. When compounds of Formula I contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable "protecting group" or "protective group". A comprehensive list

of suitable protective groups can be found in T.W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1991, the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula I can be prepared by methods well known in the art.

**[00265]** Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization.

**[00266]** In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

**[00267]** In Compounds of Formula I




the hydrogen on the -$NHS(O)_2$- group is highly acidic. Thus, intermediates leading to Compounds of Formula I, as well as Compounds of Formula I themselves, can be recovered as uncharged or zwitterionic molecules, or cationic salts such a sodium or potassium, depending on the substitutions on the B ring and on reaction conditions. In the examples that follow, unless otherwise specified, the final form of the compound was assumed to be the uncharged molecule in the absence of analytical techniques that would have determined otherwise.

**[00268]** Compounds of Formula I can be prepared using methods known to one of ordinary skill in the art. In another embodiment, fusion of appropriate reagents at 180 °C in the presence of a base such as $K_2CO_3$ and metallic copper is known to provide intermediates of formula 1 (see S. H. Dandegaonker and C. K. Mesta, *J. Med. Chem.* **1965**, *8*, 884).

**[00269]** Alternatively, the intermediate of formula 3 can be prepared according to the scheme below where each $LG^1$ is a leaving group (in one embodiment halo, in another embodiment chloro) and all other groups are as defined in the Detailed Description of the Invention.

**Scheme 1**




**[00270]** In scheme 1, an intermediate of formula 3 can be prepared by briefly heating commercially available 2,3-dichloroquinoxaline and an intermediate of formula 2 (which are commercially available or can be prepared by one of ordinary skill in the art), a base such as $K_2CO_3$, in a solvent, such as DMF or DMSO. Upon completion (about 2 hours), the reaction mixture is then poured into water and followed by 2 N HCl. The product is then extracted into a solvent such as ethyl acetate and washed with water and brine. The organic layers are combined and dried over a drying agent such as sodium sulfate, filtered, and concentrated under vacuum.

**[00271]** The intermediate of formula 3 is then treated with an intermediate of formula 4 in a solvent such as DMF or p-xylene at reflux temperature. Upon completion of the reaction (about 16 hours or less), the reaction is allowed to cool, extracted into DCM, washed with 2 N HCl and brine, dried over a drying agent such as sodium sulfate or magnesium sulfate, filtered, and concentrated to give a compound of Formula I.

**[00272]** Alternatively, other methods to prepare quinoxaline derivatives are known to one skilled in the art and include, but are not limited to S. V. Litvinenko, V. I. Savich, D. D. Bobrovnik, *Chem. Heterocycl. Compd.* (Engl. Transl), **1994**, *30*, 340 and W. C. Lumma, R. D. Hartman, *J. Med. Chem.* **1981**, *24*, 93.

**[00273]** The following compounds were prepared in a manner similar to that described above.

**Example 1:** *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide.

**Example 2:** *N*-(3-{[2,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-4-chlorobenzenesulfonamide.

**Example 3**: *N*-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide.

**Example 4**: 4-chloro-*N*-(3-chloroquinoxalin-2-yl)benzenesulfonamide.


**Example 5: 4-chloro-*N*-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 9.18 (s, 1H), 8.78 (s, 1H), 8.40-8.60 (m, 3H), 7.98 (t, 2H), 7.62 (d, 1H), 7.41 (m, 2H), 6.98 (d, 1H), 6.59 (d, 1H), 3.78 (s, 3H), 3.76 (s, 3H); MS (EI) m/z for $C_{22}H_{19}N_5O_6S$: 482.1 ($MH^+$).

**Example 6: *N*-(3-(2,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** $^1$H NMR (400 MHz, $CDCl_3$) δ 12.68 ( br s, 1H ), 9.18 (s, 1H), 8.55 (s, 1H), 8.08 (d, 2H), 7.98 (d, 1H), 7.78 (d, 2H), 7.62 (dd, 1H), 7.40 (m, 2H), 7.00 (d, 1H), 6.60 (dd, 1H), 3.78 (s, 6H) ; MS (EI) m/z for $C_{22}H_{19}ClN_4O_4S$: 471.1 ($MH^+$).

**Example 7: *N*-(3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-4-methylphenyl)-2-(dimethylamino)acetamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.0 (br s, 1 H), 10.6 (s, 1 H), 10.0 (br s, 1 H), 9.52 (s, 1 H), 8.91 (d, 1 H), 8.25 (d, 1 H), 7.69 (dd, 1H), 7.47 (m, 1 H), 7.39 (d, 1 H), 7.16 (m, 3 H), 6.01 (dd, 1 H); MS (EI) m/z for $C_{26}H_{27}ClN_6O_4S$: 555 ($MH^+$).

**[00274]** Compounds of Formula I where B is phenyl substituted with $R^{3a}$ where $R^{3a}$ is alkylamino or dialkylamino or B is heteroaryl substituted with $R^3$ where $R^3$ is amino, alkylamino, or dialkylamino, and all other groups are as defined in the Summary of the Invention can be prepared according to Scheme 2.

**Scheme 2**





LG is a leaving group such as chloro. **5** is reacted with $NHR^aR^b$ or HO-$C_1$-$C_6$-alkylene-$NHR^aR^b$ where $R^a$ and $R^b$ are independently hydrogen or alkyl. The reaction is carried out in the presence of a base, such as $KHCO_3$, in a solvent such as DMF.

**[00275]** Compounds of Formula I where B is phenyl substituted with $R^{3a}$ where $R^{3a}$ is aminoalkyloxy, alkylaminoalkyloxy, or dialkylaminoalkyloxy or B is heteroaryl

substituted with $R^3$ where $R^3$ is aminoalkyloxy, alkylaminoalkyloxy, or dialkylaminoalkyloxy, and all other groups are as defined in the Summary of the Invention can be prepared according to Scheme 3.

**Scheme 3**




I(c)

The reaction is carried out in the presence of a base such as NaH in a solvent such as DMF.

**[00276]** Compounds of Formula I where B is phenyl substituted with $R^{3a}$ or B is heteroaryl substituted with $R^3$ where $R^{3a}$ and $R^3$ are

i. $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$, $R^{7a}$, and $R^{7b}$ are as defined in the Summary of the Invention;

ii. $-NR^9C(O)R^{9a}$ where $R^9$ is as defined in the Summary of the Invention;

iii. $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$, $R^{11a}$, and $R^{11b}$ are as defined in the Summary of the Invention;

iv. $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ and $R^{13a}$ are as defined in the Summary of the Invention;

v. $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18}$, $R^{18a}$, and $R^{18b}$ are as defined in the Summary of the Invention;

vi. $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ and $R^{20a}$ as defined in the Summary of the Invention;

vii. $-NR^{21}S(O)_2-C_1-C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$, $R^{21a}$, and $R^{21b}$ are as defined in the Summary of the Invention;

viii. $-N(R^{22})C(O)-C_0-C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, where $R^{22}$, $R^{22a}$ and $R^{22b}$ are as defined in the Summary of the Invention;

ix. $-NR^{24}C(O)-C_1.C_6$-alkylene-$OR^{24a}$ where $R^{24}$ and $R^{24a}$ are as defined in the Summary of the Invention;

and where the alkylene in $R^3$ and $R^{3a}$ are independently optionally substituted as described in the Summary of the Invention can be prepared according to Scheme 4 by reacting with an intermediate of formula 9(a), 9(b), 9(c), 9(d), 9(e), 9(f), or 9(g):

9(a) $HOC(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^a$ is $R^{7a}$ or a N-protecting group, such as Boc or Fmoc;

9(b) $HOC(O)R^{9a}$;

9(c) $HOC(O)NR^{11a}R^{11b}$;


9(d) $HOC(O)OR^{13a}$;

9(e) $HOC(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$;

9(f) $HOC(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$;

9(g) $LG-S(O)_2-C_1.C_6$-alkylene-$N(R^{21b})R^a$ where $R^a$ is $R^{21a}$ or a N-protecting group, such as Boc or Fmoc.

**Scheme 4**




8 I(e)

$R^{100}$ in Scheme 4 is $-C(O)R^{9a}$, $-C(O)NR^{11a}R^{11b}$, $-C(O)OR^{13a}$, $-C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$, $-C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$, or $-S(O)_2-C_1.C_6$-alkylene-$N(R^{21b})R^a$. The reaction is carried out under standard amide coupling conditions known to one of ordinary skill in the art. In particular, the reaction is carried out in the presence of a coupling agent such as HATU, a base such as DIEA, and in a solvent such as DMF. Where applicable, the N-protecting group is then removed using procedures known to one of ordinary skill in the art, such as treating with acid where PG is Boc.

**[00277]** Proceeding as described for Scheme 4, compounds of the invention where B is phenyl substituted with $R^{3a}$ or B is heteroaryl substituted with $R^3$ where $R^{3a}$ and $R^3$ are

a) $-C(O)NR^8R^{8a}$;

b) $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$;


c) $-C(O)R^{12}$ where $R^{12}$ is an N-substituted heterocycloalkyl;

d) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$;

e) $-C(O)N(R^{16})-C_1-C_6$-alkylene-$C(O)OR^{16a}$; or

f) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$; or

can be prepared by exchanging the starting materials as necessary. In particular, the intermediate of formula 11:





**11**

is used instead of **8**.

**[00278]** Compounds of Formula I where B is phenyl substituted with $R^{3a}$ or B is heteroaryl substituted with $R^3$ where $R^{3a}$ and $R^3$ are $-NHC(O)CH_2NR^{7a}R^{7b}$ where $R^{7a}$ and $R^{7b}$ are as defined in the Summary of the Invention can be prepared according to Scheme 5.

**Scheme 5**





12 I(f)

LG is a leaving group such as bromo or chloro. **12** is reacted with $NH(R^{7b})R^{7a}$ in the presence of a base, such as DIEA, in a solvent such as ACN.

**[00279]** Compounds of Formula I can be prepared according to Scheme 6.

**Scheme 6**





13 I(h)

LG in Scheme 6 is a leaving group such as chloro. The reaction can be carried out by irradiating in a solvent such as DMA. Alternatively, the reaction can be carried out in the presence of acetic acid in a solvent such as DMA and by heating.

**Example 8**

**6-chloro-*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide**




**[00280] 6-chloropyridine-3-sulfonamide.** 6-chloropyridine-3-sulfonyl chloride (4.1 g, 19.3 mmol) was stirred in ammonium hydroxide (30 mL) at room temperature for 2 hr. The reaction mixture was diluted with EtOAc (150 mL) and any insoluble material filtered. The filtrate was transferred to a separatory funnel and the phases were separated. The aqueous phase was further extracted with EtOAc (1 x 15 mL). The combined EtOAc extractions were washed with $H_2O$ (1 x 50 mL) and saturated NaCl (1 x 50 mL), dried over $Na_2SO_4$, and concentrated *in vacuo* to give 6-chloropyridine-3-sulfonamide (2.58 g, 69%). MS (EI) m/z for $C_5H_5Cl_2N_2O_2S$: 190.9 ($MH^+$).


**[00281] 6-chloro-*N*-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide.** 2,3-dichloroquinoxaline (1.09 g, 5.48 mmol), 6-chloropyridine-3-sulfonamide (1.05 g, 5.45 mmol), $K_2CO_3$ (753 mg, 5.45 mmol) and dry DMSO (30 mL) were combined and heated to 150 °C with vigorous stirring for 3-4 hr. The reaction mixture was allowed to cool to room temperature, then poured into 1% AcOH in ice water (300 mL) with vigorous stirring. The resulting solids were filtered, washed with $H_2O$ and dried under high vacuum to give 6-chloro-*N*-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide (1.87g, 96%). MS (EI) m/z for $C_{13}H_8Cl_2N_4O_2S$: 354.99 ($MH^+$).

**[00282] 6-chloro-*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide.** 6 -Chloro-*N*-(3-chloroquinoxalin-2-yl)pyridine-3-sulfonamide (775 mg, 2.2 mmol), 3,5-dimethoxyaniline (355 mg, 2.3 mmol) and toluene (12 mL) were combined and heated to 125 °C with stirring overnight. The reaction was allowed to cool

to room temperature and diluted with $Et_2O$ with vigorous stirring. The resulting solids were filtered, washed with $Et_2O$ and dried to give 6-chloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide (920 mg, 89%). $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.20 (br s, 1H), 9.12 (d, 1H), 9.01 (br s, 1H), 8.53 (dd, 1H), 7.91 (br d, 1H), 7.77 (d, 1H), 7.60 (dd, 1H), 7.40 (m, 4H), 6.26 (m, 1H), 3.78 (s, 6H). MS (EI) m/z for $C_{21}H_{18}ClN_5O_4S$: 472.0 ($MH^+$).

**Example 9**

***N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-(2-(dimethylamino)-ethylamino)pyridine-3-sulfonamide**





**[00283]** 6-chloro-*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-pyridine-3-sulfonamide (100 mg, 0.21 mmol), prepared using procedures similar to those used in Example 8, $KHCO_3$ (40 mg, 0.40 mmol), $N^1$,$N^1$-dimethylethane-1,2-diamine (225 μL, 2.0 mmol) and dry DMF (1.0 mL) were combined and heated to 130 °C with stirring overnight. The reaction mixture was concentrated *in vacuo* and purified by preparative HPLC to give *N*-(3-(3,5-dimethoxy-phenylamino)-quinoxalin-2-yl)-6-(2-(dimethylamino)ethylamino)pyridine-3-sulfonamide (21.0 mg, 19%). $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.76 (br s, 1H), 8.63 (d, 1H), 8.07 (dd, 1H), 7.40 (m, 1H), 7.34 (m, 1H), 7.28 (d, 2H), 7.14 (m, 4H), 6.47 (d, 1H), 6.12 (m, 1H), 3.75 (s, 6H), 3.35 (m, 2H), 3.14 (m, 2H), 2.74 (s, 6H). MS (EI) m/z for $C_{25}H_{29}N_7O_4S$: 524.1 ($MH^+$).

**[00284]** **Example 10: *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide** was prepared using procedures similar to those used in Example 9. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.00 (br s, 1H), 8.92 (br s, 1H), 8.74 (d, 1H), 8.10 (dd, 1H), 7.38 (br s, 1H), 7.54 (m, 1H), 7.33 (m, 4H), 6.70 (d,

1H), 6.22 (s, 1H), 3.77 (s, 6H), 3.08 (s, 6H). MS (EI) m/z for $C_{23}H_{24}N_6O_4S$: 481.1 ($MH^+$).

**Example 11**


***N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-(2-(dimethylamino)-ethoxy)pyridine-3-sulfonamide**




**[00285]** *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide (100 mg, 0.21 mmol), prepared using procedures similar to those described above in Example 1, 2-(dimethylamino)ethanol (50 μL, 0.50 mmol) and dry DMF were combined and 60% NaH in oil (80 mg, 2.0 mmol) was added. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and purified by preparative HPLC to give *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-(2-(dimethylamino)ethoxy)pyridine-3-sulfonamide (23 mg, 21%). $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.78 (d, 1H), 8.73 (s, 1H), 8.38 (dd, 1H), 7.40 (dd, 1H), 7.31 (m, 3H), 7.14 (m, 2H), 6.85 (d, 1H), 6.12 (m, 1H), 4.56 (m, 2H), 3.76 (s, 6H), 3.43 (m, 2H), 2.77 (s, 6H). MS (EI) m/z for $C_{25}H_{28}N_6O_5S$: 525.1 ($MH^+$).

**Example 12**

***N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide**




**[00286]** *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)pyridine-3-sulfonamide (220 mg, 0.47 mmol), prepared using procedures similar to those described above in Example 8, DMSO (5 mL), and 3N NaOH (5 mL) are combined and heated to 100 °C overnight with stirring. Upon cooling to room temperature, the reaction mixture was diluted with $H_20$ and the pH was adjusted to 7.0 with 1N HCl. The resulting solid was filtered, washed with $H_20$, and air-dried. The solid was then sonicated in EtOAc, filtered, washed with EtOAc, and dried under high vacuum to give *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide (190 mg, 90%). $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.23 (br s, 1H), 12.10 (br s, 1H), 8.97 (s, 1H), 8.23 (s, 1H), 7.95 (m, 2H), 7.59 (m, 1H), 7.37 (m, 4H), 6.43 (d, 1H), 6.25 (s, 1H), 3.77 (s, 6H). MS (EI) m/z for $C_{21}H_{19}N_5O_5S$: 454.0 ($MH^+$).

**[0185]** **Example 13: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide.** The title compound was prepared according to the above Example 12. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.22 (br s, 1H), 12.10 (br s, 1H), 9.16 (s, 1H), 8.60 (s, 1H), 8.14 (d, 1H), 7.94 (m, 1H), 7.85 (dd, 1H), 7.62 (m, 1H), 7.40 (m, 3H) 6.69 (dd, 1H), 6.43 (d, 1H), 3.81 (s, 3H). MS (EI) m/z for $C_{20}H_{16}ClN_5O_4S$: 456.0 ($MH^-$).

**Example 14**


**3-amino-*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide.**




**[00287]** ***N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide**. A flask was charged with *N*-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide (5 g, 13.7 mmol), prepared using procedures similar to those in

Example 1, 3,5-dimethoxyaniline (4.2 g, 27.4 mmol), and 80 mL of xylene. The reaction mixture was stirred under an $N_2$ atmosphere at 150 °C for 3 hours, after which time, solvent was removed on a rotary evaporator, and 10 mL of Dichloromethane and 50 mL of methanol were added. The slurry was heated to reflux and filtered while hot, resulting in 4.6 g (69.7 %) of *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide MS (EI) m/z for $C_{22}H_{19}N_5O_6S$: 482.2 ($MH^+$).

**Example 153-amino-*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide**




**[00288]** A flask was charged with *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-nitro-benzenesulfonamide (3.4g, 7.06 mmol), prepared using procedures similar to those in Example 14, tin chloride solvate (6.4 g, 28.2 mmol), and 30 mL of DMA. A few drops of water were added and the reaction mixture was stirred at 80 °C for 3 hours, after which time, solvent was removed on a rotary evaporator, and 50 mL of water and 10 mL of Methanol were added. The slurry was filtered, and the filtrate was washed with MeOH, water, and diethyl ether (20 mL of each), resulting in 3.25 g 3-amino-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide. $^1$H NMR (400 MHz, DMSO) δ 12.2 (br s, 1H), 8.85 (s, 1H), 7.90 (br s, 1H), 7.50-7.60 (m, 1H), 7.3-7.4 (m, 4H), 7.2 (m, 3H), 6.74 (m, 1H), 6.24 (m, 1H), 5.56 (br s, 2H), 3.76 (s, 6H). MS (EI) m/z for $C_{22}H_{21}N_5O_4S$: 452.0 ($MH^+$).

**[00289]** The following compounds were made using procedures similar to those used in Example 15.

**Example 16:** Proceeding as above, 3-amino-*N*-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide was prepared. $^1$H NMR (400 MHz, DMSO) δ 12.4 (br s, 1H), 9.20 (s, 1H), 8.56 (d, 1H), 7.95 (d, 1H), 7.62 (m, 1H), 7.38 (m, 2H), 7.24 (q, 2H), 7.14 (d, 1H), 6.98 (d, 1H), 6.8 (m, 1H), 6.60 (m, 1H), 5.6 (br s, 2H), 3.78 (d, 6H). MS (EI) m/z for $C_{22}H_{21}N_5O_4S$: 452.3 ($MH^+$).

**Example 17:** Proceeding as above, **3-amino-*N*-(3-(2-chloro-5-hydroxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide** was prepared. MS (EI) m/z for $C_{20}H_{16}ClN_5O_3S$ 1.0 x $C_2H_1O_2F_3$: 442.2, 444.2 ($MH^+$).

**Example 18:** Proceeding as above, **3-amino-*N*-(3-(6-methoxyquinolin-8-ylamino)quinoxalin-2-yl)benzenesulfonamide** was prepared. MS (EI) m/z for $C_{24}H_{20}N_6O_3S$: 473.0 ($MH^+$).


**Example 19: 3-amino-*N*-(3-(3-fluoro-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{21}H_{18}FN_5O_3S$: 439.99 ($MH^+$).

**Example 20: 3-amino-*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{21}H_{18}ClN_5O_3S$: 457.02 ($MH^+$).

**Example 21: 3-amino-*N*-(3-(5-methoxy-2-methyl-phenylamino)quinoxalin-2-yl)benzenesulfonamide**. MS (EI) m/z for $C_{22}H_{21}N_5O_3S$: 436.32 ($MH^+$).

**Example 22a and Example 22b**


**3-amino-*N*-(3-(3-methoxy-5-nitro-phenylamino)quinoxalin-2-yl)benzenesulfonamide and 3-amino-*N*-(3-(3-amino-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide**



**[00290]** To a mixture of *N*-(3-{[3-(methyloxy)-5-nitrophenyl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide (400 mg), THF (2 mL) and EtOH (2 mL) was added formic acid (938 μL), potassium formate (203 mg). After the mixture was flushed with $N_2$, 10%wt Pd/C (50 mg) was added. The resulting mixture was heated at 60 °C with stirring. LC/MS analysis indicated that the reaction mixture contained the complete reduced di-amino compound as the major product and the partially reduced mono-amino compound as a minor product. A portion of the crude mixture was purified by HPLC to give the two products. Product A: 3-amino-*N*-(3-(3-methoxy-5-nitro-phenylamino)quinoxalin-2-yl)benzenesulfonamide. $^1$H NMR (400 MHz, DMSO) δ 12.2 (br s, 1H), 9.51 (s, 1H), 8.77 (s, 1H), 8.21 (s, 1H), 7.92 (s, 1H), 7.48 (m, 1H), 7.43-7.38 (m, 3H), 7.24-7.16 (m, 3H), 6.75 (d, 1H), 5.57 (br s, 2H), 3.90 (s, 3H). MS (EI) for $C_{21}H_{18}N_6O_5S$: 467.00 (MH+). Product B: 3-amino-*N*-(3-(3-amino-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide. $^1$H NMR (400 MHz, DMSO) δ 12.0 (br. s, 1H), 8.53 (s, 1H), 7.84 (s, 1H), 7.56 (d, 1H), 7.37-7.30 (m, 2H), 7.21-7.17 (m, 3H), 6.87 (s, 1H), 6.81 (s, 1H), 6.74 (br s, 2H), 5.91 (s, 1H), 5.56 (br s, 3H), 3.69 (s, 3H). MS (EI) for $C_{21}H_{20}N_6O_3S$: 437.2 (MH+).

**Example 23a and Example 23b**

***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-(hydroxyamino)-benzenesulfonamide** and **3-amino-N-(3-{[3,5-(dimethoxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide**





**[00291]** To a solution *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide (1.3g) in 20 mL of THF and 10 mL of MeOH was added 10%wt Pd/C (100 mg). The mixture was stirred under a $H_2$ balloon overnight. A portion of the reaction mixture was taken out and filtered, then purified by HPLC to afford two products. Product A: *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-

(hydroxyamino)benzenesulfonamide. MS (EI) for $C_{22}H_{21}N_5O_5S$: 468.1 ($MH^+$). Product B: 3-amino-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide. $^1H$ NMR (400 MHz, DMSO) δ 12.2 (br s, 1H), 8.85 (s, 1H), 7.90 (br s, 1H), 7.50-7.60 (m, 1H), 7.3-7.4 (m, 4H), 7.2 (m, 3H), 6.74 (m, 1H), 6.24 (m, 1H), 5.56 (br s, 2H), 3.76 (s, 6H). MS (EI) for $C_{22}H_{21}N_5O_4S$: 452.0 ($MH^+$).

**Example 24**

**(*S*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)propanamide hydrochloride.**




**[00292]** **(*S*)-*tert*-butyl 1-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenylamino)-1-oxopropan-2-ylcarbamate.** 3-amino-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide (1.1 mmol, 500 mg), prepared using procedures similar to those described above in Example 15, (L)-Boc-Ala-OH (1.5 mmol, 284 mg), dichloromethane (15 mL), DMF (10 mL), DIEA (2 mmol, 330 μL), and HATU (2 mmol, 760 mg) stirred at room temperature over night. The crude mixture was column purified using 1/1 ethyl acetate/hexanes on silica to gave 160 mg.

**[00293]** **(*S*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)propanamide hydrochloride.** 4 N HCl is dioxane (10 mL) was added to a solution of (*S*)-*tert*-butyl 1-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenylamino)-1-oxopropan-2-ylcarbamate (160 mg) and DCM (15 mL). The mixture was stirred at room temperature for 3 hours. The solvent decanted and ether added to the solid, ether decanted to gave 80 mg product as HCl salt. $^1$H NMR (400 MHz, $CD_3OD$) δ 8.50-8.49 (t, 1H), 7.89-7.87 (m, 1H), 7.74-7.72 (m, 1H), 7.61-7.5 (m, 3H), 7.40-7.36 (m, 2H), 7.21-7.20 (d, 2H), 6.23-6.21 (t, 1H), 4.09-4.03 (q, 1H), 3.78 (s, 6H), 1.60-1.58 (d, 3H); MS (EI) m/z for $C_{25}H_{26}N_6O_5S$·HCl: 523.1 ($MH^+$).

**[00294]** The following compounds were prepared as the free amine and/or HCl salt using procedures similar to those in Example 24. Where the deprotection step is not necessary, Step B in the above scheme was not preformed.

**Example25: *N*-(2-chloro-5-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)acetamide.** The title compound was prepared according to the Examples above. $^1$H NMR (400 MHz, DMSO-$d_6$) δ 10.50 (s, 1H), 9.14 (s, 1H), 9.03 (m, 2H), 8.63 (d, 1H), 8.44 (d, 1H), 7.98 (m, 1H), 7.91 (dd, 1H), 7.80 (d, 1H), 7.67 (m, 1H), 7.44 (m, 3H), 6.71 (dd, 1H), 4.06 (m, 2H), 3.83 (s, 3H), 2.64 (t, 3H). MS (EI) m/z for $C_{24}H_{22}Cl_2N_6O_4S$: 561.0 ($MH^+$).

**Example 26: (*S*)-2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)propanamide hydrochloride.** $^1$H NMR (400 MHz, $CD_3OD$) δ 8.72-8.71 (d, 1H), 8.48-8.46 (t, 1H), 7.86-7.84 (m, 1H), 7.80-7.78 (m, 1H), 7.63-7.59 (m, 2H), 7.58-7.55 (t, 1H), 7.41-7.38 (m, 2H), 7.24-7.22 (d, 1H), 6.60-6.58 (dd, 1H), 4.10-4.04 (q, 1H), 3.83 (s, 3H), 1.61-1.60 (d, 3H); MS (EI) m/z for $C_{24}H_{23}ClN_6O_4S$·HCl: 527.2 ($MH^+$).

**Example 27: (*S*)-2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)butanamide hydrochloride.** $^1$H NMR (400 MHz, $CD_3OD$) δ 8.74-8.73 (d, 1H), 8.80-8.47 (t, 1H), 7.87-7.85 (m, 1H), 7.80-7.78 (m, 1H), 7.67-7.61 (m, 2H), 7.59-7.55 (t, 1H), 7.42-7.39 (m, 2H), 7.26-7.24 (d, 1H), 6.62-6.59 (dd, 1H), 3.96-3.93 (t, 1H), 3.84 (s, 3H), 2.02-1.94 (m, 2H, 1.09-1.06 (t, 3H); MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$·HCl: 541.3 ($MH^+$).

**Example 28: (*S*)-*N*-(3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pyrrolidine-2-carboxamide hydrochloride.** $^1$H NMR (400 MHz, $CD_3OD$) δ 8.78-8.77 (d, 1H), 8.47-8.46 (t, 1H), 7.87-7.85 (m, 1H), 7.80-7.75 (m, 1H), 7.69-7.65 (m, 2H), 7.59-7.55 (t, 1H), 7.45-7.41 (m, 2H), 7.31-7.28 (d, 1H), 6.65-6.63 (dd, 1H), 4.42-4.38 (m, 1H), 3.86 (s, 3H), 3.48-3.42 (m, 2H), 2.55-2.49 (m, 1H), 2.18-2.08 (m, 3H); MS (EI) m/z for $C_{26}H_{25}ClN_6O_4S{\cdot}HCl$: 553.3 ($MH^+$).

**Exmaple 29: (*S*)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pyrrolidine-2-carboxamide hydrochloride.** $^1$H NMR (400 MHz, $CD_3OD$) δ 10.62 (br s, 1H), 8.50-8.49 (t, 1H), 7.90-7.87 (m, 1H), 7.76-7.73 (m, 1H), 7.63-7.58 (m, 3H), 7.43-7.35 (m, 2H), 7.14 (s, 2H), 6.27-6.26 (t, 1H), 4.43-4.38 (m, 1H), 3.78 (s, 6H), 3.48-3.41 (m, 1H), 3.40-3.36 (m, 1H(, 2.54-2.48 (m, 1H), 2.19-2.05 (m, 3H); MS (EI) m/z for $C_{27}H_{28}N_6O_5S{\cdot}HCl$: 549.3 ($MH^+$).

**Example 30: (*R*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-hydroxypropanamide hydrochloride.** $^1$H NMR (400 MHz, $CD_3OD$) δ 8.49-8.48 (t, 1H), 7.89-7.87 (m, 1H), 7.75-7.72 (m, 1H), 7.65-7.62 (m, 2H), 7.62-7.55 (t, 1H), 7.44-7.38 (m, 2H), 7.23-7.22 (d, 2H), 6.27-6.26 (t, 1H), 4.07-4.05 (m, 1H), 3.99-3.93 (m, 2H), 3.80 (s, 6H); MS (EI) m/z for $C_{25}H_{26}N_6O_6S{\cdot}HCl$: 539.1 ($MH^+$).

**Example 31: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)piperidine-3-carboxamide hydrochloride.** $^1$H NMR (400 MHz, $CD_3OD$) δ 8.79-8.78 (d, 1H), 8.45 (m, 1H), 7.83-7.81 (d, 1H), 7.76-7.74 (m, 1H), 7.636 (m, 2H), 7.54-7.50 (t, 1H), 7.41 (m, 2H), 7.30-7.28 (d, 1H), 6.65-6.62 (dd, 1H), 3.86 (s, 3H), 3.40-3.32 (m, 2H), 3.20-3.13 (m, 3H), 2.93 (m, 1H), 2.15-2.11 (m, 1H), 1.98-1.93 (m, 2H), 1.83 (m, 1H); MS (EI) m/z for $C_{27}H_{27}ClN_6O_4S{\cdot}HCl$: 567.3 ($MH^+$).

**Example32: (*S*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)butanamide hydrochloride.** MS (EI) m/z for $C_{26}H_{28}N_6O_5S{\cdot}HCl$: 537.1 ($MH^+$).

**Example 33: (*R*)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pyrrolidine-2-carboxamide hydrochloride.** MS (EI) m/z for $C_{27}H_{28}N_6O_5S{\cdot}HCl$: 549.1 ($MH^+$).

**Example 34: (*R*)-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pyrrolidine-2-carboxamide hydrochloride.** MS (EI) m/z for $C_{26}H_{25}ClN_6O_4S \cdot HCl$: 553 ($MH^+$).

**Example 35: (*R*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)propanamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 10.2 (br s, 1 H), 8.82 (s, 1 H), 8.27 (m, 1 H), 7.75 (m, 2 H), 7.33 (m, 5 H), 7.13 (m, 2 H), 6.14 (t, 1 H), 3.77 (s, 6 H), 1.39 (d, 3 H); MS (EI) m/z for $C_{25}H_{26}N_6O_5S$: 523 ($MH^+$).

**Example 36:*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)acetamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 10.6 (s, 1 H), 9.48 (s, 1 H), 8.95 (br s, 1 H), 8.75 (br s, 1 H), 8.19 (br s, 1 H), 7.77 (dd, 1 H), 7.69 (dd, 1 H), 7.41 (m, 4 H), 7.17 (m, 2 H), 6.60 (dd, 1 H), 3.91 (s, 2 H), 3.82 (s, 6 H), 2.62 (s, 3 H); MS (EI) m/z for $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

**Example 37: (*R*)-2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)propanamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 10.5 (s, 1 H), 9.47 (s, 1 H), 8.95 (d, 1 H), 8.22 (d, 2 H), 8.14 (br s, 2 H), 7.76 (m, 2 H), 7.40 (m, 4 H), 7.17 (m, 2 H), 6.60 (m, 1 H), 3.97 (q, 1 H), 3.96 (s, 3 H), 1.45 (d, 3 H); MS (EI) m/z for $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

**Example 38: 2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 10.1 (s, 1 H), 9.46 (s, 1 H), 8.95 (d, 1 H), 8.50 (br s, 1 H), 8.27 (m, 1 H), 7.81 (m, 2 H), 7.47 (m, 1 H), 7.37 (m, 3 H), 7.17 (m, 2 H), 6.61 (dd, 1 H), 3.83 (s, 3 H), 1.60 (s, 6 H); MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$: 541 ($MH^+$).

**Example 39: 2-amino-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpropanamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 10.33 (s, 1 H), 8.89 (s, 1 H), 8.32 (br s, 4 H), 7.92 (m, 3 H), 7.59 (m, 2 H), 7.37 (m, 4 H), 6.24 (s, 1 H), 3.76 (s, 6 H), 1.61 (s, 6 H); MS (EI) m/z for $C_{26}H_{28}N_6O_5S$: 537 ($MH^+$).

**Example 40: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-4-methylphenyl)-2-(dimethylamino)acetamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 10.58 (s, 1 H), 9.80 (br s, 1 H), 8.85 (s, 1 H), 8.25 (s, 1 H), 7.67 (dd, 1 H), 7.30 (m, 7 H), 6.16 (m, 1 H), 4.02 (br s, 2 H), 3.77 (s, 6 H), 2.81 (s, 6 H), 2.54 (s, 3 H); MS (EI) m/z for $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

**Example 41: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-((2-(dimethylamino)ethyl)(methyl)amino)acetamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 10.0 (s, 1 H), 9.48 (s, 1 H), 8.96 (d, 1 H), 8.16 (m, 1 H), 7.76 (m, 2 H), 7.39 (m, 4 H), 7.17 (m, 2 H), 6.61 (dd, 1 H), 3.82 (s, 3 H), 3.40 (br s, 2 H), 2.94 (br s, 2 H), 2.71 (br t, 2 H), 2.60 (s, 6 H), 2.33 (s, 3 H); MS (EI) m/z for $C_{28}H_{32}ClN_7O_4S$: 598 ($MH^+$).

**Example 42: 2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 10.5 (s, 1 H), 9.48 (s, 1 H), 8.94 (s, 1 H), 8.15 (s, 1 H), 8.06 (br s, 3 H), 7.74 (m, 2 H), 7.39 (m, 4 H), 7.18 (m, 2 H), 6.61 (dd, 1 H), 3.83 (s, 3 H), 3.77 (s, 2 H); MS (EI) m/z for $C_{23}H_{21}ClN_6O_4S$: 513 ($MH^+$).

**Example 43: *N*-(3-(*N*-(3-(2-acetyl-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.4 (s, 1 H), 10.5 (s, 1 H), 9.27 (s, 1 H), 8.25 (s, 1 H), 8.01 (d, 1 H), 7.82 (d, 1 H), 7.71 (d, 1 H), 7.42 (m, 3 H), 7.21 (m, 2 H), 6.63 (dd, 1H),3.91 (m, 5 H), 2.75 (s, 6 H), 2.61 (s, 3 H); MS (EI) m/z for $C_{27}H_{28}N_6O_5S$: 549 ($MH^+$).

**Example 44: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)formamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.6 (s, 1 H), 10.5 (s, 1 H), 9.16 (s, 1 H), 8.53 (br s, 1 H), 8.35 (m, 2 H), 8.02 (s, 1 H), 7.56 (m, 7 H), 6.70 (dd, 1 H), 3.83 (s, 3 H); MS (EI) m/z for $C_{22}H_{18}ClN_5O_4S$: 484 ($MH^+$).

**Example 45: 2-amino-*N*-(5-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-2-methylphenyl)acetamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.4 (s, 1 H), 10.1 (br s, 1 H), 8.82 (s, 1 H), 8.20 (m, 3 H), 7.82 (m, 1 H), 7.30 (m, 6 H), 6.20 (s, 1 H), 3.85 (s, 2 H), 3.77 (s, 6 H), 2.26 (s, 3 H); MS (EI) m/z for $C_{25}H_{26}N_6O_5S$: 523 ($MH^+$).

**Example 46: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methyl-2-(methylamino)propanamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 10.09 (s, 1 H), 9.46 (s, 1 H), 8.95 (m, 3 H), 8.28 (s, 1 H), 7.81 (m, 2 H), 7.41 (m, 4 H), 7.17 (m, 2 H), 6.60 (dd, 1 H), 3.82 (s, 3 H), 2.53 (s, 3 H), 1.60 (s, 6 H); MS (EI) m/z for $C_{26}H_{27}ClN_6O_4S$: 555 ($MH^+$).

**Example 47: (*S*)-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)propanamide.** $^1$H NMR (400 MHz, DMSO-$d_6$)

δ 10.61 (s, 1 H), 9.47 (s, 1 H), 8.95 (s, 1 H), 8.82 (br s, 2 H), 8.27 (m, 1 H), 7.74 (m, 2 H), 7.42 (m, 4 H), 7.17 (m, 2 H), 6.60 (dd, 1 H), 3.90 (m, 1 H), 3.82 (s, 3 H), 2.59 (s, 3 H), 1.49 (d, 3 H); MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$: 541 ($MH^+$).

**Example 48: 3-amino-*N*-(5-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-2-methylphenyl)propanamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.25 (s, 1 H), 9.77 (s, 1 H), 8.82 (s, 1 H), 7.84 (m, 5 H), 7.50 (d, 1 H), 7.37 (m, 5 H), 6.22 (m, 1 H), 3.74 (s, 6 H), 3.08 (m, 2 H), 2.77 (m, 2 H), 2.27 (s, 3 H); MS (EI) m/z for $C_{26}H_{28}N_6O_5S$: 537 ($MH^+$).

**Example 49: 1-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)cyclopropanecarboxamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 9.54 (br s, 1 H), 9.42 (s, 1 H), 8.91 (s, 1 H), 8.21 (s, 1 H), 8.20 (br s, 2 H), 7.81 (m, 2 H), 7.48 (m, 4 H), 7.22 (m, 2 H), 6.61 (dd, 1 H), 3.82 (s, 3 H), 1.63 (m, 2 H), 1.26 (m, 2 H); MS (EI) m/z for $C_{25}H_{23}ClN_6O_4S$: 539 ($MH^+$).

**Example 50: (*S*)-2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-6-(dimethylamino)hexanamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 9.47 (br s, 1 H), 8.95 (d, 1 H), 8.26 (m, 1 H), 7.73 (m, 2 H), 7.30 (m, 4 H), 7.26 (m, 4 H), 7.16 (m, 2 H), 6.59 (dd, 1 H), 3.82 (s, 3 H), 3.34 (m, 1 H), 2.20 (m, 2 H), 2.09 (s, 6 H), 1.50 (m, 6 H); MS (EI) m/z for $C_{29}H_{34}ClN_7O_4S$: 610 ($MH^+$).

**Example 51: 1-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)cyclopentanecarboxamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 10.12 (br s, 1 H), 9.46 (s, 1 H), 8.95 (d, 1 H), 8.26 (m, 1 H), 8.16 (m, 3 H), 7.84 (m, 2 H), 7.35 (m, 6 H), 6.60 (dd, 1 H), 3.82 (s, 3 H), 2.34 (m, 2 H), 1.91 (m, 6 H); MS (EI) m/z for $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

**Example 52: *N*-(5-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-2-methylphenyl)-2-(dimethylamino)acetamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.0 (br s, 1 H), 9.98 (s, 1 H), 9.43 (s, 1 H), 8.91 (m, 1 H), 8.08 (s, 1 H), 7.84 (dd, 1 H), 7.32 (m, 6 H), 6.61 (dd, 1 H), 4.07 (s, 2 H), 3.82 (s, 3 H), 2.82 (s, 6 H), 2.21 (s, 3 H); MS (EI) m/z for $C_{26}H_{27}ClN_6O_4S$: 555 ($MH^+$).

**Example 53: 1-amino-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)cyclobutanecarboxamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 10.34 (br s, 1 H), 8.81 (s, 1 H), 8.49 (br s, 3 H), 8.34 (s, 1 H), 7.83 (m, 2 H), 7.43 (m, 3

H), 7.31 (m, 2 H), 7.16 (m, 2 H), 6.16 (s, 1 H), 3.77 (s, 6 H), 2.83 (m, 2 H), 2.25 (m, 3 H), 2.05 (m, 1 H); MS (EI) m/z for $C_{27}H_{28}N_6O_5S$: 549 ($MH^+$).

**Example 54: *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-(3-(2-(dimethylamino)ethyl)ureido)benzenesulfonamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 8.91 (br s, 1 H), 8.81 (s, 1 H), 8.08 (s, 1 H), 7.60 (s, 1 H), 7.38 (m, 9 H), 6.28 (m, 1 H), 6.15 (s, 1 H), 3.78 (s, 6 H), 3.40 (m, 2 H), 3.08 (m, 2 H), 2.74 (s, 6 H); MS (EI) m/z for $C_{27}H_{31}N_7O_5S$: 566 ($MH^+$).

**Example 55: 1-amino-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)cyclopentanecarboxamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.40 (br s, 1 H), 10.58 (s, 1 H), 8.46 (m, 4 H), 7.80 (m, 3 H), 7.59 (m, 2 H), 7.34 (m, 4 H), 6.25 (m, 1 H), 3.76 (s, 6 H), 2.35 (m, 2 H), 1.90 (m, 8 H); MS (EI) m/z for $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).

**Example 56: 1-amino-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)cyclopropanecarboxamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 9.54 (br s, 1 H), 8.84 (s, 1 H), 8.29 (s, 1 H), 7.75 (m, 2 H), 7.39 (m, 6 H), 7.17 (m, 2 H), 6.16 (m, 1 H), 3.78 (s, 6 H), 1.52 (m, 2 H), 1.17 (m, 2 H); MS (EI) m/z for $C_{26}H_{26}N_6O_5S$: 535 ($MH^+$).

**Example 57: 2-(dimethylamino)ethyl 3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenylcarbamate.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 9.78 (br s, 1 H), 8.79 (s, 1 H), 8.19 (s, 1 H), 7.66 (d, 1 H), 7.31 (m, 9 H), 6.14 (m, 1 H), 4.17 (t, 2 H), 3.78 (s, 6 H), 2.54 (t, 2 H), 2.21 (s, 6 H): MS (EI) m/z for $C_{27}H_{30}N_6O_6S$: 567 ($MH^+$).

**Example 58: 4-amino-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)tetrahydro-2H-pyran-4-carboxamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 12.2 (br s, 1 H), 10.6 (s, 1 H), 8.74 (m, 5 H), 7.93 (m, 2 H), 7.47 (m, 6 H), 6.24 (m, 1 H), 3.77 (m, 10 H), 2.45 (m, 2 H), 1.81 (m, 2 H); MS (EI) m/z for $C_{28}H_{30}N_6O_6S$: 579 ($MH^+$).

**Example 59: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-*N*3-(2-(dimethylamino)ethyl)benzene-1,3-disulfonamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 9.35 (m, 2 H), 8.92 (m, 1 H), 8.64 (s, 1 H), 8.30 (m, 1 H), 8.11 (s, 1 H), 7.86 (m, 1 H),

7.68 (m, 1 H), 7.49 (s, 1 H), 7.42 (m, 2 H), 7.21 (m, 2 H), 6.61 (m, 1 H), 3.82 (s, 3 H), 3.05 (m, 4 H), 2.74 (s, 6 H); MS (EI) m/z for $C_{25}H_{27}ClN_6O_5S_2$: 591 ($MH^+$).

**Example 60: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-*N*3-(3-(dimethylamino)propyl)benzene-1,3-disulfonamide.** $^1$H NMR (400 MHz, DMSO-$d_6$) δ 9.38 (m, 2 H), 8.90 (m, 1 H), 8.60 (s, 1 H), 8.32 (m, 1 H), 8.12 (s, 1 H), 7.88 (m, 1 H), 7.72 (m, 1 H), 7.59 (s, 1 H), 7.40 (m, 2 H), 7.20 (m, 2 H), 6.67 (m, 1 H), 3.82 (s, 3 H), 2.97 (m, 2 H), 2.78 (m, 2 H), 2.71 (s, 6 H), 1.70 (m, 2 H); MS (EI) m/z for $C_{26}H_{29}ClN_6O_5S_2$: 605 ($MH^+$).

**Example 61: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-4-methylphenyl)-2-(methylamino)acetamide.** MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$: 541.0 ($MH^+$).

**Example 62: (*S*)-2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-4-methylphenyl)propanamide.** MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$: 541.2 ($MH^+$).

**Example 63: (*R*)-2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-4-methylphenyl)propanamide.** MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$: 541.0 ($MH^+$).

**Example 64: (*S*)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)propanamide.** MS (EI) m/z for $C_{26}H_{28}N_6O_5S$: 537.1 ($MH^+$).

**Example 65: (*R*)-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)propanamide.** MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$: 541.1($MH^+$).

**Example 66: (*R*)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)propanamide.** MS (EI) m/z for $C_{26}H_{28}N_6O_5S$: 537.3 ($MH^+$).

**Example 67: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)piperidine-2-carboxamide.** MS (EI) m/z for $C_{28}H_{30}N_6O_5S$: 563.1 ($MH^+$).

**Example 68: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-(dimethylamino)ethylamino)acetamide.** MS (EI) m/z for $C_{28}H_{33}N_7O_5S$: 580.1 ($MH^+$).

**Example 69: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-(methylamino)piperidin-1-yl)acetamide.** MS (EI) m/z for $C_{30}H_{35}N_7O_6S$: 606.1 ($MH^+$).

**Example 70: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-(dimethylamino)piperidin-1-yl)acetamide.** MS (EI) m/z for $C_{31}H_{37}N_7O_5S$: 620.1 ($MH^+$).

**Example 71: *N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 12.4 (br s, 1H), 10.9 (s, 1H), 9.8 (s, 1H), 8.9 (s, 1H), 8.3 (br s, 1H), 7.9 (d, 2H), 7.8 (d, 1H), 7.6 (t, 2H), 7.4 (q, 2H), 7.3 (s, 1H), 6.25 (s, 1H), 4.15 (s, 2H), 3.8 (s, 6H), 2.9 (s, 6H). MS (EI) m/z for $C_{26}H_{28}N_6O_5S$ 2.0 x $C_2H_1O_2F_3$: 537.1 ($MH^+$).

**Example 72: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(ethylamino)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 10.8 (s, 1H), 9.20 (s, 1H), 8.84 (br s, 2H), 8.64 (br s, 1H), 8.30 (s, 1H), 7.9-8.0 (br s, 1H), 7.80 (t, 2H), 7.55-7.68 (m, 2H), 7.4 (d, 3H), 6.70 (m, 1H), 3.97 (br s, 2H), 3.83 (s, 3H), 3.04 (br s, 2H), 1.3 (t, 3H). MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$ 2.0 x $C_2H_1O_2F_3$: 541.3, 543.2 ($MH^+$).

**Example 73: 2-(azetidin-1-yl)-*N*-(3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 10.8 (s, 1H), 10.2 (s, 1H), 9.2 (s, 1H), 8.7 (s, 1H), 8.3 (s, 1H), 7.9-8.0 (br s, 1H), 7.80 (d, 1H), 7.72 (d, 1H), 7.65 (br s, 1H), 7.56 (t, 1H), 7.40 (d, 3H), 6.70 (m, 1H), 4.28 (s, 2H), 4.15 (m, 4H), 3.82 (s, 3H), 2.32 (br s, 1H). MS (EI) m/z for $C_{26}H_{25}ClN_6O_4S$ 2.0 x $C_2H_1O_2F_3$: 553.3, 555.2 ($MH^+$).

**Example 74: *N*-(3-(*N*-(3-(2-bromo-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)acetamide.** The title compound was prepared according to the Examples above. $^1H$ NMR (400 MHz, DMSO) δ 10.6 (s, 1H), 9.5 (s, 1H), 8.95 (d, 1H), 8.18 (t, 1H), 7.78 (m, 1H), 7.70 (m, 1H), 7.54 (d, 1H), 7.46 (m, 1H),

7.38 (t, 1H), 7.32 (d, 1H), 7.12-7.22 (m, 2H), 6.56 (m, 1H), 3.90 (s, 2H), 3.82 (s, 3H), 2.62 (s, 3H). MS (EI) m/z for $C_{24}H_{23}BrN_6O_4S$: 572.77, 570.90 ($MH^+$).

**Example 75: 2-(dimethylamino)-*N*-(3-(*N*-(3-(6-methoxy-quinolin-8-ylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** The title compound was prepared according to the Examples above. $^1$H NMR (400 MHz, DMSO) δ 10.9 (s, 1H), 10.6 (s, 1H), 9.13 (s, 1H), 8.80 (d, 1H), 8.26-8.30 (m, 2H), 7.85 (d, 1H), 7.70 (d, 1H), 7.60 (q, 1H), 7.54 (m, 1H), 7.44 (t, 2H), 7.20 (t, 2H), 6.80 (d, 1H), 4.00 (s, 2H), 3.94 (s, 3H), 2.78 (s, 6H). MS (EI) m/z for $C_{28}H_{27}N_7O_4S$: 558.3 ($MH^+$).

**Example 76: *N*-(3-(*N*-(3-(2-bromo-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** $^1$H NMR (400 MHz, DMSO) δ 10.6 (s, 1H), 9.4 (s, 1H), 8.9 (s, 1H), 8.25 (s, 1H), 7.78 (d, 1H), 7.70 (d, 1H), 7.54 (d, 1H), 7.48 (d, 1H), 7.40 (t, 2H), 6.56 (d, 1H), 4.02 (s, 2H), 3.82 (s, 3H), 2.80 (s, 6H). MS (EI) m/z for $C_{25}H_{25}BrN_6O_4S$: 586.79, 584.91 ($MH^+$).

**Example 77: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-fluoroethylamino)acetamide.** $^1$H NMR (400 MHz, DMSO) δ 10.6 (s, 1H), 9.4 (s, 1H), 8.9 (d, 1H), 8.20 (s, 1H), 7.78 (d, 1H), 7.70 (d, 1H), 7.48 (m, 1H), 7.36-7.44 (m, 3H), 7.20 (q, 3H), 6.6 (m, 1H), 4.78 (t, 1H), 4.66 (t, 1H), 3.94 (s, 2H), 3.82 (s, 3H), 3.4 (t, 1H), 3.3 (t, 1H). MS (EI) m/z for $C_{25}H_{24}ClFN_6O_4S$: 559.2, 561.2 ($MH^+$).

**Example 78: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)formamide.** $^1$H NMR (400 MHz, DMSO) δ 12.4 (br s, 1H), 10.5 (s, 1H), 8.90 (s, 1H), 8.3 (s, 1H), 7.9 (br s, 1H), 7.85 (d, 1H), 7.75 (d, 1H), 7.5-7.6 (m, 2H), 7.3-7.4 (m, 4H), 6.2 (s, 1H), 3.8 (s, 3H). MS (EI) m/z for $C_{23}H_{21}N_5O_5S$: 480.1 ($MH^+$).

**Example 79: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-(dimethylamino)azetidin-1-yl)acetamide.** $^1$H NMR (400 MHz, DMSO) δ 10.2 (br s, 1H), 9.5 (s, 1H), 8.95 (d, 1H), 8.2 (s, 1H), 7.75 (d, 1H), 7.65 (d, 1H), 7.45 (d, 1H), 7.40 (d, 1H), 7.30-7.35 (t, 1H), 7.1-7.2 (q, 2H), 6.60 (m, 1H), 3.82 (s, 3H). MS (EI) m/z for $C_{28}H_{30}ClN_7O_4S$: 480.1 ($MH^+$).

**Example 80:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(pyrrolidin-1-yl)acetamide.** MS (EI) m/z for $C_{28}H_{30}N_6O_5S$: 563.18 ($MH^+$).

**Example 81:** ***N*-(3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(ethyl(methyl)amino)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 12.0 (s, 1H), 10.6 (s, 1H), 9.65 (s, 1H), 9.5 (s, 1H), 8.95 (s, 1H), 8.25 (s, 1H), 7.8 (d, 1H), 7.70 (d, 1H), 7.45-7.50 (d, 1H), 7.3-7.4 (m, 3H), 7.2 (t, 2H), 6.60 (d, 1H), 4.02 (br s, 2H), 3.82 (s, 3H), 3.14 (br s, 2H), 2.80 (s, 3H) 1.2 (t, 3H). MS (EI) m/z for $C_{26}H_{27}ClN_6O_4S$: 555.2, 557.3 ($MH^+$).

**Example 82:** ***N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-(piperidin-1-yl)azetidin-1-yl)acetamide.** MS (EI) m/z for $C_{31}H_{34}ClN_7O_4S$ 2.0 x $C_2H_1O_2F_3$: 636.3, 638.3 ($MH^+$).

**Example 83:** ***N*-(3-(*N*-(3-(3-fluoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)acetamide.** MS (EI) m/z for $C_{24}H_{23}FN_6O_4S$: 511.04 ($MH^+$).

**Example 84:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-methylpiperidine-4-carboxamide.** MS (EI) m/z for $C_{29}H_{32}N_6O_5S$ 1.0 x $C_2H_4O_2$: 577.2 ($MH^+$).

**Example 85:** ***N*-(3-(*N*-(3-(3-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 10.6 (s, 1H), 8.82 (s, 1H), 8.22 (t, 1H), 7.86 (t, 1H), 7.76 (m, 1H), 7.66 (m, 1H), 7.46 (m, 1H), 7.41 (m, 1H), 7.38 (t, 1H), 7.28 (m 1H), 7.24 (t, 1H), 7.12 (m, 2H), 6.56 (d, 1H), 3.88 (s, 2H), 3.80 (s, 3H), 2.60 (s, 3H). MS (EI) m/z for $C_{24}H_{24}N_6O_4S$: 492.99 ($MH^+$).

**Example 86:** ***N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2,2,2-trifluoroethylamino)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 10.4 (s, 1H), 9.2 (s, 1H), 8.65 (s, 1H), 8.4 (s, 1H), 8.00 (m, 1H), 7.80 (d, 1H), 7.75 (d, 1H), 7.65 (q, 1H), 7.55 (t, 1H), 7.40-7.5 (m, 3H), 6.7 (m, 1H), 3.82 (s, 3H), 3.62 (br s, 2H), 3.55 (br d, 2H). MS (EI) m/z for $C_{25}H_{22}ClF_3N_6O_4S$ 1.0 x $C_2H_1O_2F_3$: 595.0, 597.0 ($MH^+$).

**Example 87:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(piperidin-1-yl)propanamide.** MS (EI) m/z for $C_{30}H_{34}N_6O_5S$: 591.2 ($MH^+$).

**Example 88:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-(dimethylamino)butanamide.** MS (EI) m/z for $C_{28}H_{32}N_6O_5S$ 1.0 x $C_2H_4O_2$: 565.2 ($MH^+$).

**Example 89: 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-fluoro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 10.9 (s, 1H), 9.8 (br s, 1H), 9.1 (s, 1H), 8.34 (s, 1H), 7.90 (d, 1H), 7.76 (d, 1H), 7.52-7.68 (m, 4H), 7.40 (m, 2H), 6.54 (m, 1H), 4.16 (s, 2H), 3.82 (s, 3H), 2.86 (s, 6H). MS (EI) m/z for $C_{25}H_{25}FN_6O_4S$: 525.05 ($MH^+$).

**Example 90:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(piperidin-1-yl)acetamide.** MS (EI) m/z for $C_{29}H_{32}N_6O_5S$: 577.37 ($MH^+$).

**Example 91: 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 10.5 (s, 1H), 8.8 (s, 1H), 8.25 (s, 1H), 7.83 (t, 1H), 7.76 (d, 1H), 7.64 (d, 1H), 7.3-7.48 (m, 4H), 7.22 (t, 1H), 7.12 (t, 2H), 6.56 (m, 1H), 3.96 (s, 2H), 3.78 (s, 3H), 2.76 (s, 6H). MS (EI) m/z for $C_{25}H_{26}N_6O_4S$: 507.1 ($MH^+$).

**Example 92:** ***N*-(3-(*N*-(3-(2-chloro-5-hydroxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** $^1H$ NMR (400 MHz, DMSO) δ 10.8 (s, 1H), 9.9 (s, 1H), 9.8 (s, 1H), 9.1 (s, 1H), 8.55 (s, 1H), 8.34 (s, 1H), 7.9-8.0 (br s, 1H), 7.82 (d, 1H), 7.76 (d, 1H), 7.52-7.66 (m, 2H), 7.42 (t, 1H), 7.26 (d, 1H), 6.50 (m, 1H), 4.16 (s, 2H), 2.86 (s, 6H). MS (EI) m/z for $C_{24}H_{23}ClN_6O_4S$: 527.1, 529.0 ($MH^+$).

**Example 93:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-morpholinoacetamide.** MS (EI) m/z for $C_{28}H_{30}N_6O_6S$: 579.1 ($MH^+$).

**Example 94:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z for $C_{24}H_{23}N_5O_5S$: 494.0 ($MH^+$).


**Example 97: 2-amino-*N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-4-methylphenyl)-2-methylpropanamide.** MS (EI) m/z for $C_{26}H_{27}ClN_6O_4S$: 556.12 ($MH^+$).

**Example 98: *N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** MS (EI) m/z for $C_{25}H_{25}ClN_6O_4S$: 542.05 ($MH^+$).

**Example 99: 2-amino-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z for $C_{24}H_{24}N_6O_5S$: 509.59 ($MH^+$).

**Example 100**

**3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzoic acid**




**[00295]** To a solution of *N*-(3-{[2-chloro-5-(methoxy)-phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide (6.02 g, 12.95 mmol), prepared using procedures similar to those in Example 115 or Example 423, in methanol (20 mL) and 1,4-dioxane (20 mL) was added 6.0 *N* aqueous sodium hydroxide (40 mL) at room temperature. The solution was stirred at 90 $^0$C for 3.5 h. The reaction was cooled to room temperature and neutralized slowly by adding 2.0 *N* hydrochloric acid until the pH of the solution became in the 2-3 range at 0° C. The solution was diluted with ethyl acetate (300 mL). The organic layer was washed with saturated aqueous sodium chloride (50 mL) and dried over magnesium sulfate. Filtration and concentration at reduced pressure afforded 3-{[(3-{[2-chloro-5-(methoxy)-phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoic acid (5.921 g, 94%). MS (EI) m/z for $C_{22}H_{17}ClN_4O_5S$: 485.0 ($MH^+$).

**[00296]** The following compounds were preapred using procedures ismilar to those used in Example 100.


**Example 101:** Proceeding as above, **3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)benzoic acid** was prepared. MS (EI) m/z for $C_{23}H_{20}N_4O_6S$: 481.0 ($MH^+$).

**Example 102: 3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-methyl-1-(piperidin-1-yl)propan-2-yl)benzamide**. MS (EI) m/z for $C_{31}H_{35}ClN_6O_4S$: 623.06 ($MH^+$).

**Example 103: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-methyl-1-oxo-1-(piperidin-1-yl)propan-2-yl)benzamide**. MS (EI) m/z for $C_{31}H_{33}ClN_6O_5S$: 637.65 ($MH^+$).

**Example 104**

**3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide**




**[00297]** To a solution of 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoic acid (0.20 g, 0.42 mmol), prepared using procedures similar to Example 100, in dimethylformamide (4 mL) were added 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate ( HATU, 0.32 g, 0.83 mmol) and *N*-ethyldiisopropylamine (DIEA, 0.13 g, 1.04 mmol) at room temperature. The reaction was stirred for 15 min before *N*, *N*-dimethylethane-1,2-diamine (73 mg, 0.83 mmol) was added. The reaction mixture was allowed to stir overnight. The reaction was diluted with ethyl acetate (200 mL) and washed with water (50 mL), saturated aqueous sodium bicarbonate (40 mL), 1.0 *N* aqueous hydrochloric acid (30 mL), and saturated aqueous sodium chloride (25 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated at reduced pressure to afford 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-

(dimethylamino)ethyl]benzamide (0.20 g, 87%) as yellow solid. MS (EI) m/z for $C_{26}H_{27}ClN_6O_4S$: 555.1 ($MH^+$).

**[00298]** The following compounds were prepared using procedures similar to those in Example 104.

**Example 105: 5-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(dimethylamino)ethyl)-2-methoxybenzamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 9.45 (s, 1H), 8.95 (d, 1H), 8.57 (d, 1H), 8.28 (t, 1H), 8.14 (dd, 1H), 7.46 (dd, 1H), 7.39 (m, 2H), 7.17 (m, 4H), 6.60 (dd, 1H), 3.89 (s, 3H), 3.82 (s, 3H), 3.38 (m, 2H), 2.43 (m, 2H), 2.21 (s, 6H). MS (EI) m/z for $C_{27}H_{29}ClN_6O_5S$: 585.3 ($MH^+$).

**Example 106: 5-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(dimethylamino)ethyl)-2-fluorobenzamide.** $^1H$ NMR (400 MHz, DMSO-$d_6$) δ 9.40 (br s, 1H), 9.16 (s, 1H), 8.73 (m, 1H), 8.67 (d, 1H), 8.36 (dd, 1H), 8.26 (m, 1H), 7.94 (br s, 1H), 7.66 (m, 1H), 7.59 (t, 1H), 7.43 (m, 3H), 6.71 (dd, 1H), 3.83 (s, 3H), 3.62 (m, 2H), 3.27 (m, 2H), 2.85 (d, 6H). MS (EI) m/z for $C_{26}H_{26}ClFN_6O_4S$: 573.1 ($MH^+$).

**Example 107: 3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(dimethylamino)ethyl)benzamide.** MS (EI) m/z for $C_{27}H_{30}N_6O_5S$: 551.1 ($MH^+$).

**Example 108: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(dimethylamino)ethyl)-*N*-methylbenzamide.** MS (EI) m/z for $C_{27}H_{29}ClN_6O_4S$: 569.1 ($MH^+$).

**Example 109: 3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(dimethylamino)ethyl)-*N*-methylbenzamide.** MS (EI) m/z for $C_{28}H_{32}N_6O_5S$: 565.1 ($MH^+$).

**Example 110: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzamide.** MS (EI) m/z for $C_{22}H_{18}ClN_5O_4S$: 484.0 ($MH^+$).


**Example 111: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-morpholinoethyl)benzamide.** MS (EI) m/z for $C_{28}H_{29}ClN_6O_5S$: 597.0 ($MH^+$).

**Example 112: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-methylbenzamide.** MS (EI) m/z for $C_{23}H_{20}ClN_5O_4S$: 498.0 ($MH^+$).

**Example 113: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-morpholinobenzamide.** MS (EI) m/z for $C_{26}H_{25}ClN_6O_5S$: 569.0 ($MH^+$).

**Example 114**

***N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}benzenesulfonamide**





**[00299]** To a solution of 3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoic acid (0.25 g, 0.52 mmol), prepared as described above in Example 100, in dimethylformamide (2.6 mL) were added 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 0.25 g, 0.67 mmol) and *N*-ethyldiisopropylamine (DIEA, 0.11 g, 0.88 mmol) at room temperature. The reaction was stirred for 15 min before 2-(dimethylamino)acetohydrazide (78 mg, 0.67 mmol) was added. The reaction mixture was allowed to stir overnight. The reaction was diluted with ethyl acetate (200 mL) and washed with water (30 mL), saturated aqueous sodium bicarbonate (30 mL), 1.0 N aqueous hydrochloric acid (20 mL), and saturated aqueous sodium chloride (25 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated at reduced pressure to afford 180 mg of a coupled intermediate which was then heated in phosphorus oxychloride (5 mL) at 100 0C for 4h. The reaction was cooled to room temperature and treated with ice water (50 mL) and extracted with dichloromethane (3 X 50 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated at reduced pressure to afford a crude product which was subjected to reverse phase HPLC to afford *N*-(3-{[2-chloro-5-(methoxy)-phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}-

benzenesulfonamide (16 mg, 5 %) as yellow solid. MS (EI) m/z for $C_{26}H_{24}ClN_7O_4S$: 566.0 ($MH^+$).

**Example 115**

***N*-(3-(3-methoxy-5-nitro-phenylamino)-quinoxalin-2-yl)-3-nitrobenzenesulfonamide**




**[00300]** ***N*-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide.** 2,3-Dichloroquinoxaline (26.1 g, 131.1 mmol), m-Nitrobenzene sulfonamide (26.5 g, 131.1 mmol) and potassium carbonate (18.1 g, 131.1) were dissolved in anhydrous DMSO (500 mL). The reaction was heated to 150 °C for 2 h. The reaction mixture was poured into water (400 mL), followed by addition of 2M HCl (60 mL). The product was extracted with EtOAc (3 x 500 mL). The organic layers were combined and washed water (2 x 500 mL) and brine (2 x 500 mL). The product was then dried with sodium sulfate to give *N*-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide. MS (EI) m/z for $C_{14}H_9ClN_4O_4S$: 364.94, 366.97 ($MH^+$)

**[00301]** ***N*-(3-(3-methoxy-5-nitrophenylamino)quinoxalin-2-yl)-3-nitro-benzenesulfonamide.** *N*-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide (700 mg, 1.92 mmol), 3-methoxy-5-nitroaniline (645 mg, 3.84 mmol) and p-xylene (7 mL) were combined and heated to 140°C, then stirred for 16 hours at 130 °C. The reaction was allowed to cool, placed in a sep. funnel, diluted with DCM, and washed with 2M HCl and brine and concentrated in vacuo. The resulting solid was washed with $Et_2O$ to give *N*-(3-(3-methoxy-5-nitro-phenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide (400 mg, 42%). MS (EI) m/z for $C_{21}H_{16}N_6O_7S$: 496.94 ($MH^+$).

**[00302]** The following compounds were prepared using procedures similar to those in Example 115.

**Example 116: *N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)-3-cyanobenzenesulfonamide.** MS (EI) m/z for $C_{22}H_{16}ClN_5O_3S$: 465.9 ($MH^+$).

**Example 117: 3-cyano-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{23}H_{19}N_5O_4S$: 462.3 ($MH^+$).

**Example 118: *N*-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-fluorobenzenesulfonamide.** MS (EI) m/z for $C_{22}H_{19}FN_4O_4S$: 456.0 ($MH^+$).

**Example 119: 3-bromo-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{22}H_{19}BrN_4O_4S$: 516.9 ($MH^+$).

**Example 120: 3-bromo-*N*-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{22}H_{19}BrN_4O_4S$: 516.9 ($MH^+$).

**Example 121: *N*-(3-(3-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{21}H_{18}N_4O_3S$: 407.0 ($MH^+$).

**Example 122: *N*-(3-(4-fluoro-3-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{21}H_{17}FN_4O_3S$: 425.0 ($MH^+$).

**Example 123: *N*-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-methoxybenzenesulfonamide.** MS (EI) m/z for $C_{23}H_{22}N_4O_5S$: 467.0 ($MH^+$).

**Example 124: *N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-methoxybenzenesulfonamide.** MS (EI) m/z for $C_{23}H_{22}N_4O_5S$: 467.0 ($MH^+$).

**Example 125: *N*-(3-(4-chloro-3-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{21}H_{17}ClN_4O_3S$: 440.9 ($MH^+$).

**Example 126: *N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)thiophene-2-sulfonamide.** MS (EI) m/z for $C_{20}H_{18}N_4O_4S_2$: 443.0 ($MH^+$).

**Example 127: *N*-(3-(6-methoxyquinolin-8-ylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** MS (EI) m/z for $C_{24}H_{18}N_6O_5S$: 502.95 ($MH^+$).

**Example 128: 3-nitro-*N*-(3-(pyridin-4-ylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{19}H_{14}N_6O_4S$: 423.2 ($MH^+$).

**Example 129: *N*-(3-(2-chloropyridin-4-ylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** MS (EI) m/z for $C_{19}H_{13}ClN_6O_4S$: 456.93, 458.90 ($MH^+$).

**Example 130: *N*-(3-(4,6-dimethoxypyrimidin-2-ylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** MS (EI) m/z for $C_{20}H_{17}N_7O_6S$: 484.03 ($MH^+$).

**Example 131:** ***N*****-(3-(4-hydroxy-6-methoxypyrimidin-2-ylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** MS (EI) m/z for $C_{19}H_{15}N_7O_6S$: 469.97 ($MH^+$).

**Example 132:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2-fluorobenzenesulfonamide.** MS (EI) m/z for $C_{22}H_{19}FN_4O_4S$: 455.3 ($MH^+$).

**Example 133:** ***N*****-(3-(2-bromo-5-methoxy-phenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** MS (EI) m/z for $C_{21}H_{16}BrN_5O_5S$: 531.82, 532.84 ($MH^+$).

**Example 134:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide.** MS (EI) m/z for $C_{23}H_{22}N_4O_4S$: 451.0 ($MH^+$).

**Example 136:** ***N*****-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide.** MS (EI) m/z for $C_{23}H_{22}N_4O_4S$: 451.0 ($MH^+$).

**Example 137:** ***N*****-(3-(3-fluoro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** MS (EI) m/z for $C_{21}H_{16}FN_5O_5S$: 470.0 ($MH^+$).

**Example 138: 4-bromo-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{22}H_{19}BrN_4O_4S$: 516.9, 514.9 ($MH^+$).

**Example 139:** ***N*****-(3-(3-methoxyphenylamino)quinoxalin-2-yl)-3-nitro-benzenesulfonamide.** MS (EI) m/z for $C_{21}H_{17}N_5O_5S$: 451.93 ($MH^+$).

**Example 140:** ***N*****-(3-(2-chloro-5-hydroxy-phenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.** MS (EI) m/z for $C_{20}H_{14}ClN_5O_5S$: 472.15, 474.13 ($MH^+$).

**Example 141: 3-acetyl-*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{23}H_{19}ClN_4O_4S$: 483.08 ($MH^+$).

**Example 142:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{22}H_{20}N_4O_4S$: 437.49 ($MH^+$).

**Example 143:** ***N*****-(3-(5-methoxy-2-methyl-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{22}H_{20}N_4O_3S$: 421.46 ($MH^+$).

**Example 144:** ***N*****-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{21}H_{17}ClN_4O_3S$: 440.59 ($MH^+$).

**Example 145:** ***N*****-(3-(2,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{22}H_{20}N_4O_4S$: 437.53 ($MH^+$).

**Example 146: 4-chloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{22}H_{19}ClN_4O_4S$: 470.54 ($MH^+$).


**Example 147:** ***N*-(3-(5-methoxy-2-methyl-phenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide**. MS (EI) m/z for $C_{22}H_{19}N_5O_5S$: 466.32 ($MH^+$).

**Example 148:** ***N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide**. MS (EI) m/z for $C_{21}H_{16}ClN_5O_5S$: 485.86 ($MH^+$).

**Example 149:** ***N*-(3-(4-chloro-2,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide**. MS (EI) m/z for $C_{22}H_{19}ClN_4O_4S$: 470.99 ($MH^+$).

**Example 150**

***N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(2H-tetrazol-5-yl)benzenesulfonamide**




**[00303]** To a stirred solution of 3-cyano-*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide (0.20 g, 0.44 mmol), prepared using procedures similar to those described in Example 115, in dimethylformamide (1.2 mL) at 50 °C were added sodium azide (0.11 g, 1.76 mmol) and ammonium chloride (94 mg, 1.76 mmol). The crude mixture was heated at 100 $^0$C overnight. The reaction was cooled to room temperature treated with ice water (20 mL) followed by concentrated hydrochloric acid (10 mL). The solid obtained was filtered under reduced pressure and washed with hexane (20 mL), diethyl ether (20 mL), and ethyl acetate (5 mL) to afford *N*-(3-{[3,5-bis(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(2*H*-tetrazol-5-yl)benzenesulfonamide (55 mg, 25%) as light yellow solid. MS (EI) m/z for $C_{23}H_{20}N_8O_4S$: 505.0 ($MH^+$).

**Example 151**

***N*-(3-(2,6-dichloropyridin-4-ylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide.**

**[00304]** A mixture of *N*-(3-chloroquinoxalin-2-yl)-3-nitrobenzenesulfonamide (1 g), 2,6-dichloropyridin-4-amine (760 mg) and p-xylene (10 mL) was heated at 135 °C with stirring overnight. Upon cooling to room temperature, the mixture was dissolved in dichloromethane, washed with 2 N HCl (2 x) and brine, concentrated in vacuo to give a crude product of *N*-{3-[(2,6-dichloropyridin-4-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide. A small portion of this crude product was purified by HPLC to give *N*-{3-[(2,6-dichloropyridin-4-yl)amino]quinoxalin-2-yl}-3-nitro-benzenesulfonamide. $^1$H NMR (400 MHz, DMSO) δ 9.71 (s, 1H), 8.90 (s, 1H), 8.50 (d, 2H), 8.8.41 (d, 1H), 8.30 (s, 2H), 7.88-7.78 (m, 27.65 (d, 1H), 7.47-7.37 (m, 2H); MS (EI) m/z for $C_{19}H_{12}Cl_2N_6O_4S$: 491.1, 493.1 ($MH^+$).


**Example 152**

***N*-(3-(2-chloro-6-methoxypyridin-4-ylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide**

**[00305]** To a crude product of N-{3-[(2,6-dichloropyridin-4-yl)amino]quinoxalin-2-yl}-3-nitrobenzenesulfonamide (1.24 g) prepared using procedures similar to those for Example 151, was added anhydrous DMSO (10 mL), followed by sodium methoxide (273 mg). The resulting mixture was heated at 100 °C for 3 days. The mixture was diluted with EtOAc and water, and the pH was adjusted to about 4 by adding acetic acid. The product was extracted with EtOAc (3 x). The combined extracts were washed with brine to give the crude product. A portion of the crude product was purified by prep HPLC to give *N*-(3-{[2-chloro-6-(methyloxy)pyridin-4-yl]amino}quinoxalin-2-yl)-3-nitrobenzenesulfonamide. 1H NMR (400 MHz, DMSO) δ 9.44 (s, 1H), 8.90 (s, 1H), 8.50 (d, 1H), 8.42 (d, 1H), 7.88-7.84 (m, 2H), 7.77 (s, 1H), 7.74 (s, 1H), 7.64 (d, 1H), 7.45-7.38 (m, 2H), 3.82 (s, 3H); MS (EI) m/z for $C_{20}H_{15}ClN_6O_5S$: 496.94 ($MH^+$).

## Example 153

**2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide**




**[00306] 3-amino-*N*-(3-(3-amino-5-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide**. *N*-(3-(3-Methoxy-5-nitrophenylamino)quinoxalin-2-yl)-3-nitrobenzenesulfonamide (400 mg, 0.81 mmol), prepared as described above in Example 115, was dissolved in 1:1 THF:EtOH (4 mL), to which was added formic acid (938 µl, 2.42 mmol) and potassium formate (203 mg, 2.42 mmol). The system was flushed with nitrogen, and then 10%wt Pd/C (50 mg) was added. The reaction was then heated to 60°C. Once the reaction was determined complete by LC-MS, it was allowed to cool, and DMF was added for solubility. The solution was then filtered through a nylon frit to remove the catalyst. The filtrate was diluted water and the pH adjusted to 7 and extracted with DCM (2x) and EtOAc (2x). All organic layers were combined and evaporated to dryness to give 3-amino-*N*-(3-(3-amino-5-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide (330 mg, 93%). MS (EI) m/z for $C_{21}H_{20}N_6O_3S$: 437.06 ($MH^+$)

**[00307] 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)-acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)-sulfamoyl)phenyl)acetamide**. 3-Amino-*N*-(3-(3-amino-5-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide (330 mg, 0.76 mmol), DMF (4 mL), *N*,*N*,-Dimethylglycine (312 mg, 3.02 mmol), HATU (1.15 g, 3.02 mmol), and 1.29(mL) (7.56 mmol) DIEA (1.29 mL, 7,56 mmol) were combined and heated to 90°C, followed by heating at 50°C for over 16 hours. The reaction was allowed to cool, placed into a sep. funnel diluted with water and aqueous LiCl and extracted with EtOAc. The final compound was then purified by prep. HPLC to give 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)acetamido)-5-methoxy-


phenylamino)-quinoxalin-2-yl)sulfamoyl)phenyl)acetamide. $^1$H NMR (400 MHz, $CD_3OD$) δ 8.45 (t, 1H), 7.93 (t, 1H), 7.85-7.88 (m, 1H), 7.70-7.74 (m, 1H), 7.65-7.68 (m, 1H), 7.58-7.62 (m, 1H), 7.58 (t, 1H), 7.34-7.42 (m, 3H), 7.0 (t, 1H), 4.05 (d, 2H), 3.8 (s, 3H), 2.9-3.0 (d, 12H). MS (EI) m/z for $C_{29}H_{34}N_8O_5S$: 607.2 ($MH^+$).

**[00308]** The following title compounds were prepared using procedures similar to those in Example 153.

**Example 154: *N*-(3-(2,5-dimethoxyphenylamino)-7-methylquinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z for $C_{23}H_{22}N_4O_4S$: 451.0 ($MH^+$).

**Example 155a and Example 155b**

***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-(methylamino)benzenesulfonamide and *N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide.**





**[00309]** To a solution of 3-amino-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide (414 mg) in DMF (4.5 mL) was added iodomethane (114 μL). The reaction mixture was heated at 35-50 °C until the formation of both mono-methylated and di-methylated products was detected by LC/MS. The mixture was diluted with EtOAc, washed with water, 10% LiCl (2 x) and brine. After removal of solvent in vacuo, the crude mixture was purified by flash silica column chromatography eluting with 15% EtOAc in hexanes, affording the mono-methylated and di-methylated products. Product A: *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-(methylamino)-benzenesulfonamide (35 mg). $^1$H NMR (400 MHz, DMSO) δ 12.2 (s, 1H), 8.93 (s, 1H), 7.85 (d, 1H), 7.58 (d, 1H), 7.40-7.20 (m, 7H), 6.76 (m, 1H), 6.24 (m, 1H), 6.16 (br s, 1H), 3.77 (s, 6H), 2.71 (s, 3H). MS (EI) for $C_{23}H_{23}N_5O_4S$: 466.05 (MH+). Product B: *N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide (33 mg). $^1$H NMR (400 MHz, DMSO) δ 1220 (s,

1H), 8.98 (s, 1H), 7.98 (d, 1H), 7.56 (d, 1H), 7.42-7.32 (m, 7H), 6.74 (m, 1H), 6.24 (m, 1H), 3.77 (s, 6H), 2.97 (s, 6H). MS (EI) for $C_{24}H_{25}N_5O_4S$: 480.04 (MH+).

**Example 156**

***N*-(3-{[(2-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]sulfonyl}phenyl)-*N*-2-[2-(dimethylamino)ethyl]-*N*-2-methylglycinamide**



**[00310]** To a THF suspension (1.3 mL) of 3-amino-*N*-(3-{[3,5-(dimethoxy)-phenyl]amino}-quinoxalin-2-yl)benzenesulfonamide (126 mg, 0.28 mmol), prepared using procedures similar to those described for Example 15, was added 0.143 mL of 2M aqeuos $Na_2CO_3$. To this yellow suspension is added dropwise 33 μL (0.42 mmol) of chlororacetyl chloride. The reaction mixture turns clear after a few minutes and is allowed to stir at 23°C for 1h. To the reaction is added a DMSO (1 mL) solution containing 180 μL (1.4 mmol) of *N*,*N*',*N*' trimethylethelyenediamine. The reaction is then warmed to 60°C and stirred for 18h. The product is isolated by preparative RP-HPLC (*N*$H_4$OAc/AC*N*) gradient, the appropriate fractions were pooled and lyophilize to give a solid yellow as the acetic acid salt: 59 mg (51%). $^1$H-NMR (400 MHz, $CDCL_3$): δ 10.1 (br s, 1H), 8.37 (br s, 2H), 8.18 (d, 1H), 7.97 (d, 1H), 7.60 (br d, 1H), 7.27 (s, 2H), 7.20 (br s, 3H), 6.15 (s, 1H), 3.82 (m, 2H), 3.65 (s, 6H), 3.20 (br m, 2H), 2.82 (br s, 8H), 2.42 (s, 3H), 2.02 (s, 3H). MS (EI) m/z for $C_{28}H_{34}N_8O_5S$: 595.84 ($MH^+$).

**[00311]** The following title compounds were prepared using similar procedures to those in Example 156.

**Example 157: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-((3-(dimethylamino)propyl)(methyl)amino)acetamide.** MS (EI) m/z for $C_{30}H_{37}N_7O_5S$: 608.1 ($MH^+$).

**Example 158: 2-(1,4'-bipiperidin-1'-yl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z for $C_{34}H_{41}N_7O_5S$: 660.1 ($MH^+$).

**Example 159: *tert*-butyl 2-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenylcarbamoyl)piperidine-1-carboxylate.** MS (EI) m/z for $C_{33}H_{38}N_6O_7S$: 663.1 ($MH^+$).

**Example 160: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(1-(dimethylamino)propan-2-yl)benzamide.** MS (EI) m/z for $C_{27}H_{29}ClN_6O_4S$: 569.0 ($MH^+$).

**Example 161: *N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-ureidobenzenesulfonamide.** MS (EI) m/z for $C_{23}H_{22}N_6O_5S$: 495.40 ($MH^+$).

**Example 162: 2-(dimethylamino)-*N*-(3-(*N*-(3-(5-methoxy-2-methylphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z for $C_{26}H_{28}N_6O_4S$: 521.69 ($MH^+$).


**Example 163: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-methylpiperazin-1-yl)acetamide.** MS (EI) m/z for $C_{29}H_{33}N_7O_5S$: 592.61 ($MH^+$).

**Example 164: 2-acetamido-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z for $C_{26}H_{26}N_6O_6S$: 550.59 ($MH^+$).

**Example 165: *tert*-butyl 2-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenylamino)-2-oxoethylcarbamate.** MS (EI) m/z for $C_{29}H_{32}N_6O_7S$: 609.32 ($MH^+$).

**Example 166**

***N*-(2-(3,5-dimethoxy-phenylamino)pyrido[2,3-b]pyrazin-3-yl)-3-nitrobenzenesulfonamide**



**[00312]** To a xylene suspension (15 mL) of *N*-(2-chloropyrido[2,3-b]pyrazin-3-yl)-3-nitrobenzenesulfonamide (1 g, 2.7 mmol) (prepared using procedures similar to those in Asier, et al *J. Org Chem* **2005**, *70(7)*, 2878 and Leeson, et al *J. Med.Chem* **1991**, *34*, 1243) was added 420 mg (2.7 mmol) of 3,5 dimethoxyaniline. After refluxing the reaction for 1h, the reaction is cooled , the precipitate is collected by filtration and dried under vacumn to give 830 mg of the product as a ~6:1 mixture of isomers with the major being N-(2-(3,5-dimethoxy-phenylamino)pyrido[2,3-b]pyrazin-3-yl)-3-nitrobenzenesulfonamide which was assigned by known chemical reactivity. Analytical HPLC, ret. time = 3.3 min (14%), 3.05 min (86%), (conditions: Phenomenex Gemini C18 50x4.6 column, gradient 5% to 95% MeCN/$H_2O$, in the presence of 0.1% TFA, 5 min run at 3.5 ml/min flow rate, $\lambda$ =254 nm). $^1$H-NMR (400 MHz, DMSO-d6): major isomer $\delta$ 9.14 (br s, 1H), 8.69 (dd, 1H), 8.60 (dd, 1H), 8.33 (dt, 2H), 7.77 (t, 1H), 7.49 (dd, 1H), 7.37 d, 2H), 7.05 (s, 1H), 6.26 (t, 1H), 3.77 (s, 6H); MS (EI) m/z for $C_{21}H_{18}N_6O_6S$: 483.08 ($MH^+$).


**Example 167**

**3-amino-*N*-(2-(3,5-dimethoxy-phenylamino)pyrido[2,3-b]pyrazin-3-yl)benzenesulfonamide.**

**[00313]** To a 1:1 THF/EtOH suspension (1 mL) of *N*-(3-(3,5-dimethoxyphenylamino)-pyrido[3,2-b]pyrazin-2-yl)-3-nitrobenzenesulfonamide (190 mg, 0.21 mmol) (prepared using procedures similar to those in Examples 166) was added 47 µL (1.26 mmol) of formic acid plus 99 mg (1.17 mmol) of potassium formate and 50 mg of 10% palladium on charcoal. After refluxing the reaction for 1h, hot filtration through celite (washing with a small portion of DMF), dilution with 30 mL of water, the pH was adjusted to 5.5 with 5% $NaHCO_3$, the product is isolated as a precipitate 140 mg (80%) of white powder. Analytical HPLC, ret. time = 2.6 min (90%), 3.05 min (10%), 100% pure (conditions: YMC C18 5x4.6 column, gradient 10% to 90% MeCN/$H_2O$, in the presence of 0.1% TFA, 9 min run at 1 ml/min flow rate, $\lambda$ =254 nm). $^1$H-NMR (400 MHz, $CDCL_3$): $\delta$ 8.48 (br s, 1H), 8.34 (dd, 1H), 7.92 (dd, 1H), 7.41 (dd, 1H), 7.15 (m, 3H), 7.13 (d, 2H), 6.86 (dd, 1H), 6. 28 (t, 1H), 3.83 (s, 6H); MS (EI) m/z for $C_{21}H_{20}N_6O_4S$: 453.03 ($MH^+$).

**Example 168**


**3-amino-*N*-(3-{[3,5-bis(methoxy)phenyl]amino}pyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide**




**[00314]** To a 1:1 THF/EtOH suspension (1 mL) of 3-nitro-*N*-(3-{[3,5-bis(methoxy)-phenyl]amino}pyrido[2,3-b]pyrazin-2-yl)benzenesulfonamide (100 mg, 0.21 mmol) (prepared using procedures similar to those used in Example 166) was added 46 μL (0.63 mmol) of formic acid plus 100mg (0.63 mmol) of potassium formate and 100 mg of 10% palladium on charcoal. After refluxing the reaction for 1h, hot filtration through celite, and concentration, the product is isolated by preparative RP-HPLC (*N*$H_4$OAc/AC*N*) gradient. The appropriate fractions were pooled and lyophilize to give solid yellow product: 3.2 mg (4%). $^1$H-NMR (400 MHz, $CDCl_3$): δ 8.62 (d, 1H), 8.52 (s, 1H), 7.62 (d, 1H), 7.3 (m, 4H), 7.18 (d, 2H), 6.88 (d, 1H), 6.27 (t, 1H), 3.96 (br s, 2H), 3.83 (s, 6H). MS (EI) m/z for $C_{21}H_{20}N_6O_4S$: 453.22 ($MH^+$).

**Example 169**

***N*-(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)-3-(1-{[2-(dimethylamino)-ethyl]amino}ethyl)benzenesulfonamide trifluoracetic acid salt**





**[00315]** To a dichloroethane solution (0.6 mL) of 3-acetyl-*N*-(3-{[2-chloro-5-(methoxy)-phenyl]amino}quinoxalin-2-yl)benzenesulfonamide (150 mg, 0.31 mmol),

prepared using procedures similar to those in Example 115, and 51 μL (0.37 mmol) of *N,N*-dimethylethylenediamine was added 19 μL of acetic acid followed by 132 mg (0.62 mmol) of sodium cyanoborohydride. The reaction mixture was refluxed for 18h under a nitrogen atmosphere. After concentration (in vacuo), the product is isolated by preparative RP-HPLC (0.1 % TFA/AC*N*) gradient, followed by lyophilization of appropriate fractions to give solid yellow solid: 189 mg (90%). $^1$H-NMR (400 MHz, $d_3$-MeOD): δ 8.74 (s, 1H), 8.18 (s, 1H), 8.12 (d, 1H), 7.71 (m, 3H), 7.48 (m, 4H), 7.28 (d, 1H), 6.63 (d, 1H), 4.38 (q, 1H), 3.80 (s, 3H), 3.30 (m, 3H), 3.12 (m, 1H), 2.84 (s, 3H), 1.60 (d, 3H). MS (EI) m/z for $C_{27}H_{31}ClN_6O_3S$: 555.56 ($MH^+$).

**Example 170**


***N,N*-{[(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)amino](dimethylamino)methylidene}-*N*-methylmethanaminium**




**[00316]** To a dimethylformamide solution (1 mL) of 3-amino-*N*-(3-{[2-chloro-5-(methoxy)-phenyl]amino}quinoxalin-2-yl)2-methylbenzenesulfonamide (200 mg, 0.40 mmol), prepared using procedures similar to those described in Example 115, is added 312 μL (1.8 mmol) of DIEA and 122 mg (0.6 mmol) of HATU. After stirring for 18h at 60 °C, the product was precipitated from a 1:1 mixture of hexane/ethyl acetate, filtered and dried to afford 60 mg (26%). $^1$H NMR (400 MHz, DMSO-$d_6$): δ 9.26 (b rs, 1H), 8.96 (br s, 1H), 7.80 (s, 1H), 7.51 (br s, 1H), 7.45 (d, 1H), 7.18 (brm, 4H), 6.91 (br s, 1H), 6.60 (br d, 1H), 3.82 (s, 3H), 3.36 (s, 3H), 2.85 (s, 6H), 2.58 (s, 3H). MS (EI) m/z for $C_{27}H_{31}ClN_7O_3S^+$: 569.32 ($MH^+$).


**Example 171**

**2-Bromo-N-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide**




**[00317]** In a 50 mL round-bottom flask was added 2-bromoacetic acid (1.87 g, 13.5 mmol), *N,N*-diisopropylcarbodiimide (860 mg, 6.8 mmol) and 10 mL DCM. To this mixture was added 3-amino-*N*-(3-(3,5-dimethoxyphenylamino) quinoxalin-2-yl) benzenesulfonamide (2.03 g, 4.5 mmol), prepared using procedures similar to those in Example 168. The reaction was stirred overnight at room temperature. Complete consumption of the starting aniline was confirmed by LCMS. The solvent was evaporated off to yield the crude product (2-bromo-N-(3-(N-(3-(3,5-dimethoxyphenylamino) quinoxalin-2-yl)sulfamoyl) phenyl) acetamide). This was used directly in the next step without purther purification.

**General Alkylation Procedure 1**




**[00318]** Into a 2-dram vial was placed 2-bromo-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl) sulfamoyl) phenyl) acetamide (86 mg, 0.15 mmol), prepared using procedures similar to those in Example 171,along with 2 mL of acetonitrile. Eight equivalents (1.2 mmol) of the desired amine, aniline, hydrazine or alkoxyamine were added followed by the addition of Hunig's Base (41 μL, 0.25 mmol).

The reaction then was stirred at 50 °C for one hour (overnight for aniline reagents). Preparative reverse-phase HPLC was used to isolate the desired product directly from the crude reaction mixture. A Waters Fractionlynx preparative reverse-phase HPLC – equipped with a Waters SunFire Prep C18, OCD 5 μM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile – was used to carry out the purification.

**[0186]** The following title compounds were prepared according to **General Library Alkylation Procedure 1.**

**Example 172: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methylamino)acetamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 8.81 (s, 1H), 8.23 (t, 1H), 7.75 (d, 1H), 7.66 (d, 1H), 7.41-7.38 (m, 1H), 7.35 (m, 1H), 7.32 (d, 2H), 7.29-7.27 (m, 1H), 7.14-7.11 (m, 2H), 6.14 (t, 1H), 3.80 (s, 1H), 3.78 (s, 6H), 2.58 (s, 3H), 1.91 (s, 2H); MS (EI) m/z $C_{25}H_{26}N_6O_5S$: 523.6 ($MH^+$).

**Example 173: 2-(cyclopropylmethylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 10.58 (s, 1H), 8.81 (s, 1H), 8.20 (t, 1H), 7.76 (d, 1H), 7.67 (d, 1H), 7.42-7.36 (m, 2H), 7.32 (d, 2H), 7.27 (s, 1H), 7.14-7.12 (m, 2H), 6.15 (t, 1H), 3.93 (s, 2H), 3.78 (s, 6H), 2.89 (s, 1H), 2.88 (s, 1H), 1.05-1.00 (m, 1H), 0.59 (d, 1H), 0.57 (d, 1H), 0.35 (d, 1H), 0.34 (d, 1H); MS (EI) m/z $C_{28}H_{30}N_6O_5S$: 563.6 ($MH^+$).

**Example 174: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-hydroxy-propylamino)acetamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 10.49 ppm (s, 1H), 8.81 ppm (s, 1H), 8.23 ppm (t, 1H), 8.13 ppm (s, 1H), 7.76 ppm (d, 1H), 7.765-7.763 (dd, 1H), 7.41-7.37 ppm (m, 2H), 7.33-7.32 ppm (d, 1H), 7.30-7.28 ppm (m, 1H), 7.16-7.09 ppm (m, 2H), 6.55 ppm (s, 1H), 6.14 ppm (t, 1H), 5.49 ppm (d, 2H), 5.25 ppm (s, 1H), 3.85 ppm (s, 1H), 3.78 ppm (s, 6H) 3.67-3.59 ppm (m, 1H), 3.00-2.89 ppm (dd, 1H), 2.79-2.76 ppm ( m, 1H), 1.10 ppm (d, 1H), 1.01-0.99 ppm (d, 1H); MS (EI) m/z $C_{27}H_{30}N_6O_6S$: 566.6 ($MH^+$).

**Example 175: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-fluorobenzylamino)acetamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 10.42 ppm (s, 1H), 8.82 ppm (s, 1H), 8.23 ppm (s, 1H), 8.14 ppm (s, 1H), 7.75 ppm (d, 1H), 7.65 ppm (d, 1H), 7.49-7.32 ppm (m, 6H), 7.25-7.20 ppm (m, 1H), 7.14-

7.12 ppm (m, 2H), 6.55 ppm (s, 1H), 6.15 ppm (t, 1H), 4.14 ppm (s, 2H), 3.78 ppm (s, 6H), 3.74 ppm (s, 2H); MS (EI) m/z $C_{31}H_{29}FN_6O_5S$: 616.7 ($MH^+$).

**Example 176: 2-(benzylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

**Example 177: 2-(diethylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

**Example 178: 2-(4-(3,4-dichlorophenyl)piperazin-1-yl)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{34}H_{33}Cl_2N_7O_5S$: 722 ($MH^+$).

**Example 179: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2,2-dimethylhydrazinyl)acetamide.** MS (EI) m/z $C_{26}H_{29}N_7O_5S$: 552 ($MH^+$).

**Example 180: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(p-tolylamino)acetamide.** MS (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

**Example 181: 2-(benzyloxyamino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

**Example 182: 2-(2-chlorophenylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{27}ClN_6O_5S$: 619 ($MH^+$).

**Example 183: *N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(isopropylamino)acetamide.** MS (EI) m/z $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

**Example 184: 2-(4-cyclopentylpiperazin-1-yl)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{33}H_{39}N_7O_5S$: 646 ($MH^+$).

**Example 185: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-propylpiperidin-1-yl)acetamide.** MS (EI) m/z $C_{32}H_{38}N_6O_5S$: 619 ($MH^+$).

**Example 186:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(isobutoxyamino)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_6S$: 581 ($MH^+$).

**Example 187:** **2-(3-*tert*-butylphenylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{34}H_{36}N_6O_5S$: 641 ($MH^+$).

**Example 188:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-phenylpropan-2-ylamino)acetamide.** MS (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

**Example 189:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-fluoro-4-hydroxyphenylamino)acetamide.** MS (EI) m/z $C_{30}H_{27}FN_6O_6S$: 619 ($MH^+$).

**Example 190:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-(methylthio)benzylamino)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_5S_2$: 645 ($MH^+$).

**Example 191:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(5-fluoro-2-methylbenzylamino)acetamide.** MS (EI) m/z $C_{32}H_{31}FN_6O_5S$: 631 ($MH^+$).

**Example192:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-phenylpyrrolidin-1-yl)acetamide.** MS (EI) m/z $C_{34}H_{34}N_6O_5S$: 639 ($MH^+$).

**Example 193:** **2-(2-benzylpyrrolidin-1-yl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{35}H_{36}N_6O_5S$: 653 ($MH^+$).

**Example 194:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-phenylmorpholino)acetamide.** MS (EI) m/z $C_{34}H_{34}N_6O_6S$: 655 ($MH^+$).

**Example 195:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-(pyridin-4-yl)piperidin-1-yl)acetamide.** MS (EI) m/z $C_{34}H_{35}N_7O_5S$: 654 ($MH^+$).

**Example 196:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(o-tolylamino)acetamide.** MS (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

**Example 197:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2,4-dimethylbenzylamino)acetamide.** MS (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

**Example 198:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methyl(pyridin-3-ylmethyl)amino)acetamide.** MS (EI) m/z $C_{31}H_{31}N_7O_5S$: 614 ($MH^+$).

**Example 199: 2-(3-chloro-4-methylbenzylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{32}H_{31}ClN_6O_5S$: 647 ($MH^+$).

**Example 200:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-((2-(dimethylamino)-ethyl)(methyl)amino)acetamide.** MS (EI) m/z $C_{29}H_{35}N_7O_5S$: 594 ($MH^+$).

**Example 201: 2-(4-acetylpiperazin-1-yl)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{33}N_7O_6S$: 620 ($MH^+$).

**Example 202:** ***N*****-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(methyl(1-methylpyrrolidin-3-yl)amino)acetamide.** MS (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

**Example 203:** ***N*****-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-methyl-1,4-diazepan-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

**Example 204: 2-(4-allylpiperazin-1-yl)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{31}H_{35}N_7O_5S$: 618 ($MH^+$).

**Example 205:** ***N*****-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-isopropylpiperazin-1-yl)acetamide** MS (EI) m/z $C_{31}H_{37}N_7O_5S$: 620 ($MH^+$).

**Example 206:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-(dimethylamino)pyrrolidin-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

**Example 207:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-(dimethylamino)azetidin-1-yl)acetamide.** MS (EI) m/z $C_{29}H_{33}N_7O_5S$: 592 ($MH^+$).

**Example 208:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-oxopiperidin-1-yl)acetamide.** MS (EI) m/z $C_{29}H_{30}N_6O_6S$: 591 ($MH^+$).

**Example 209:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-((2-methoxyethyl)(methyl)amino)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_6S$: 581 ($MH^+$).

**Example 210:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-methylbenzyloxyamino)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_6S$: 629 ($MH^+$).

**Example 211:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methoxybenzyloxyamino)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_7S$: 645 ($MH^+$).

**Example 212:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(propylamino)acetamide.** MS (EI) m/z $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

**Example 213:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(ethyl(methyl)amino)acetamide.** MS (EI) m/z $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

**Example 214: 2-(allyl(methyl)amino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).

**Example 215: 2-(*tert*-butylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

**Example 216:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(isobutylamino)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

**Example 217: 2-(butylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

**Example 218:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(isopropyl(methyl)amino)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

**Example 219:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-formylpiperazin-1-yl)acetamide.** MS (EI) m/z $C_{29}H_{31}N_7O_6S$: 606 ($MH^+$).

**Example 220:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-ethylpiperazin-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

**Example 221:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-formyl-1,4-diazepan-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{33}N_7O_6S$: 620 ($MH^+$).

**Example 222:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(ethyl(2-hydroxyethyl)amino)acetamide.** MS (EI) m/z $C_{28}H_{32}N_6O_6S$: 581 ($MH^+$).

**Example 223: (*S*)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-hydroxypyrrolidin-1-yl)acetamide.** MS (EI) m/z $C_{28}H_{30}N_6O_6S$: 579 ($MH^+$).

**Example 224:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2,6-dimethylmorpholino)acetamide.** MS (EI) m/z $C_{30}H_{34}N_6O_6S$: 607 ($MH^+$).

**Example 225:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methylbenzylamino)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

**Example 226:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methoxy-ethylamino)acetamide.** MS (EI) m/z $C_{27}H_{30}N_6O_6S$: 567 ($MH^+$).

**Example 227:** ***N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(thiazolidin-3-yl)acetamide.** MS (EI) m/z $C_{27}H_{28}N_6O_5S_2$: 581 ($MH^+$).

**Example 228:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-(hydroxymethyl)piperidin-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{34}N_6O_6S$: 607 ($MH^+$).

**Example 229:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-phenylpropylamino)acetamide.** MS (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

**Example 230:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(isobutyl(methyl)amino)acetamide.** MS (EI) m/z $C_{29}H_{34}N_6O_5S$: 579 ($MH^+$).

**Example 231:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(phenylamino)acetamide.** MS (EI) m/z $C_{30}H_{28}N_6O_5S$: 585 ($MH^+$).

**Example 232:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-propylphenylamino)acetamide.** MS (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

**Example 233:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-isopropylphenylamino)acetamide.** MS (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

**Example 234:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-fluoro-4-methylphenylamino)acetamide.** MS (EI) m/z $C_{31}H_{29}FN_6O_5S$: 617 ($MH^+$).

**Example 235: 2-(4-chlorophenylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{27}ClN_6O_5S$: 619 ($MH^+$).

**Example 236:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methoxyphenylamino)acetamide.** MS (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

**Example 237: 2-(3-chlorophenylamino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{27}ClN_6O_5S$: 619 ($MH^+$).

**Example 238:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2,3-dimethylphenylamino)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

**Example 239:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-fluorophenylamino)acetamide.** MS (EI) m/z $C_{30}H_{27}FN_6O_5S$: 603 ($MH^+$).

**Example 240:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-fluorophenylamino)acetamide.** MS (EI) m/z $C_{30}H_{27}FN_6O_5S$: 603 ($MH^+$).

**Example 241:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(thiophen-2-ylmethylamino)acetamide.** MS (EI) m/z $C_{29}H_{28}N_6O_5S_2$: 605 ($MH^+$).

**Example 242: 2-(cyclohexyl(ethyl)amino)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{32}H_{38}N_6O_5S$: 619 ($MH^+$).

**Example 243: 2-((cyclopropylmethyl)(propyl)amino)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{31}H_{36}N_6O_5S$: 605 ($MH^+$).

**Example 244: 2-(allyl(cyclopentyl)amino)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{32}H_{36}N_6O_5S$: 617 ($MH^+$).

**Example 245:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(ethyl(isopropyl)amino)acetamide.** MS (EI) m/z $C_{29}H_{34}N_6O_5S$: 579 ($MH^+$).

**Example 246:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(ethyl(phenyl)amino)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

**Example 247:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methylpyrrolidin-1-yl)acetamide.** MS (EI) m/z $C_{29}H_{32}N_6O_5S$: 577 ($MH^+$).

**Example 248:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methylpiperidin-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{34}N_6O_5S$: 591 ($MH^+$).

**Example 249:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(pyridin-2-ylmethylamino)acetamide.** MS (EI) m/z $C_{30}H_{29}N_7O_5S$: 600 ($MH^+$).

**Example 250:** **2-(benzyl(methyl)amino)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

**Example 251:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(1-phenylethylamino)acetamide.** MS (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

**Example 252:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-methylpiperidin-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{34}N_6O_5S$: 591 ($MH^+$).


**Example 253:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-methylpiperidin-1-yl)acetamide.** MS (EI) m/z $C_{30}H_{34}N_6O_5S$: 591 ($MH^+$).

**Example 254:** **2-(3,4-dihydroisoquinolin-2(1H)-yl)-*N*-(3-(*N*-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{33}H_{32}N_6O_5S$: 625 ($MH^+$).

**Example 255:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2,6-dimethylpiperidin-1-yl)acetamide.** MS (EI) m/z $C_{31}H_{36}N_6O_5S$: 605 ($MH^+$).

**Example 256:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-hydroxybenzylamino)acetamide.** MS (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

**General Library Acylation Procedure 1**




**[00319]** Into a 2-dram vial were added 3-amino-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide (54 mg, 0.12 mmol), prepared using procedures similar to those described in Example 15, DMA (2 mL) and the desired carboxylic acid (0.17 mmol). DIEA (70 µL, 0.4 mmol) followed by HATU (53 mg,0.14 mmol) were added to the vial and the reaction mixture stirred at 50 °C overnight. Preparative reverse-phase HPLC was used to isolate the desired product directly from the crude reaction mixture. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 µM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification.

**[00320]** The following title compounds were prepared according to **General Library Acylation Procedure 1.**

**Example 257:** ***N*-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)morpholine-4-carboxamide:** MS (EI) m/z for $C_{26}H_{25}ClN_6O_5S$: 567 ($MH^-$).

**Example 258:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** MS (EI) m/z for $C_{26}H_{28}N_6O_5S$: 535.1 ($MH^-$).

**Example 259:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)propionamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 12.37 (s,1H),

10.20 (s, 1H), 8.88 (s, 1H), 8.37 (s, 1H), 7.93 (s, 1H), 7.77 (t, 2H), 7.59 (t, 1H), 7.51 (t, 1H), 7.41-7.34 (m, 4H), 6.24 (t, 1H), 3.76 (s, 6H), 2.36-2.31 (dd, 2H), 1.10 (s, 1H), 1.08 (s, 1H), 1.06 (s, 1H); MS (EI) m/z $C_{25}H_{25}N_5O_5S$: 508.6 ($MH^+$).

**Example 260: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pyridazine-4-carboxamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 11.01 (s, 1H), 9.66 (dd, 1H), 9.52 (dd, 1H), 8.90 (s, 1H), 8.55 (s, 1H), 8.13 (dd, 1H), 7.99 (d, 1H), 7.93 (d, 1H), 7.65-7.58 (m, 2H), 7.42-7.35 (m, 4H), 6.24 (t, 1H), 3.75 (s, 6H); MS (EI) m/z $C_{27}H_{23}N_7O_5S$: 558.6 ($MH^+$).

**Example 261: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylnicotinamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 10.78 ppm (s, 1H), 8.90 ppm (s, 1H), 8.58-8.57 ppm (dd, 2H), 7.90-7.86 (m, 4H), 7.60-7.56 ppm (m, 2H), 7.42-7.34 (m, 5H), 6.23 ppm (t, 1H), 3.74 ppm (s, 6H), 2.57 ppm (s, 3H); MS (EI) m/z $C_{29}H_{26}N_5O_5S$: 570.6 ($MH^+$).

**Example 262: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(o-tolyloxy)acetamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 12.37 ppm (s, 1H), 10.41 ppm (s, 1H), 8.90 ppm (s, 1H), 8.41 ppm (s, 1H), 7.93 ppm (s, 1H), 7.90-7.8 (m, 2H), 7.59-7.53 ppm (m, 2H), 7.42-7.33 ppm (m, 4H), 7.17-7.12 ppm (m, 2H), 6.89-6.85 ppm (m, 2H), 6.24 ppm (t, 1H), 4.74 ppm (s, 2H), 3.76 ppm (s, 6H), 2.33 ppm (s, 2H); MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 599.7 ($MH^+$).

**Example 263: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 264: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide.** MS (EI) m/z $C_{28}H_{24}N_6O_5S$: 557 ($MH^+$).

**Example 265: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)thiazole-4-carboxamide.** MS (EI) m/z $C_{26}H_{22}N_6O_5S_2$: 563 ($MH^+$).

**Example 266: 2-bromo-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)thiophene-3-carboxamide.** MS (EI) m/z $C_{27}H_{22}BrN_5O_5S_2$ 640 ($MH^+$).

**Example 267:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pivalamide.** MS (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

**Example 268:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pent-4-enamide.** MS (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

**Example 269:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{25}N_5O_5S$: 556 ($MH^+$).

**Example 270:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)butyramide.** MS (EI) m/z $C_{26}H_{27}N_5O_5S$: 522 ($MH^+$).

**Example 271:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methoxyacetamide.** MS (EI) m/z $C_{25}H_{25}N_5O_6S$: 524 ($MH^+$).

**Example 272:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)cyclobutanecarboxamide.** MS (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

**Example 273:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylcyclopropanecarboxamide.** MS (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

**Example 274:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-methylcyclopropanecarboxamide.** MS (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

**Example 275:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methylbutanamide.** MS (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

**Example 276:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-ethoxyacetamide.** MS (EI) m/z $C_{26}H_{27}N_5O_6S$: 538 ($MH^+$).

**Example 277:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxypropanamide.** MS (EI) m/z $C_{26}H_{27}N_5O_6S$: 538 ($MH^+$).

**Example 278:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-hydroxyacetamide.** MS (EI) m/z $C_{24}H_{23}N_5O_6S$: 510 ($MH^+$).

**Example279:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)isobutyramide.** MS (EI) m/z $C_{26}H_{27}N_5O_5S$: 522 ($MH^+$).

**Example 280:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-hydroxycyclopropanecarboxamide.** MS (EI) m/z $C_{26}H_{25}N_5O_6S$: 536 ($MH^+$).

**Example 281:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)furan-3-carboxamide.** MS (EI) m/z $C_{27}H_{23}N_5O_6S$: 546 ($MH^+$).

**Example 282:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)tetrahydrofuran-3-carboxamide.** MS (EI) m/z $C_{27}H_{27}N_5O_6S$: 550 ($MH^+$).

**Example 283:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)tetrahydrofuran-2-carboxamide.** MS (EI) m/z $C_{27}H_{27}N_5O_6S$: 550 ($MH^+$).

**Example 284:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)furan-2-carboxamide.** MS (EI) m/z $C_{27}H_{23}N_5O_6S$: 546 ($MH^+$).

**Example 285:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)isonicotinamide.** MS (EI) m/z $C_{28}H_{24}N_6O_5S$: 557 ($MH^+$).

**Example 286:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1H-pyrrole-2-carboxamide.** MS (EI) m/z $C_{27}H_{24}N_6O_5S$: 545 ($MH^+$).

**Example 287:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pyrazine-2-carboxamide.** MS (EI) m/z $C_{27}H_{23}N_7O_5S$: 558 ($MH^+$).

**Example 288:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-methyl-1H-pyrrole-2-carboxamide.** MS (EI) m/z $C_{28}H_{26}N_6O_5S$: 559 ($MH^+$).

**Example 289:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-5-methylisoxazole-3-carboxamide.** MS (EI) m/z $C_{27}H_{24}N_6O_6S$: 561 ($MH^+$).

**Example 290:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)thiophene-2-carboxamide.** MS (EI) m/z $C_{27}H_{23}N_5O_5S_2$: 562 ($MH^+$).

**Example 291: (*S*)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-methylpyrrolidine-2-carboxamide.** MS (EI) m/z $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).

**Example 292: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylbenzamide.** MS (EI) m/z $C_{30}H_{27}N_5O_5S$: 570 ($MH^+$).

**Example 293: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-phenylacetamide.** MS (EI) m/z $C_{30}H_{27}N_5O_5S$: 570 ($MH^+$).

**Example 294: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methylpicolinamide.** MS (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

**Example 295: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(pyridin-3-yl)acetamide.** MS (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

**Example 296: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-6-hydroxypicolinamide.** MS (EI) m/z $C_{28}H_{24}N_6O_6S$: 573 ($MH^+$).

**Example 297: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-fluorobenzamide** MS (EI) m/z $C_{29}H_{24}FN_5O_5S$: 574 ($MH^+$).

**Example 298: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-fluorobenzamide.** MS (EI) m/z $C_{29}H_{24}FN_5O_5S$: 574 ($MH^+$).

**Example 299: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-fluorobenzamide.** MS (EI) m/z $C_{29}H_{24}FN_5O_5S$: 574 ($MH^+$).

**Example 300: 2-cyclohexyl-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{33}N_5O_5S$: 576 ($MH^+$).

**Example 301: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-oxocyclopentyl)acetamide.** MS (EI) m/z $C_{29}H_{29}N_5O_6S$: 576 ($MH^+$).

**Example 302: 4-cyclopropyl-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-oxobutanamide.** MS (EI) m/z $C_{29}H_{29}N_5O_6S$: 576 ($MH^+$).

**Example 303: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-oxocyclohexanecarboxamide.** MS (EI) m/z $C_{29}H_{29}N_5O_6S$: 576 ($MH^+$).

**Example 304:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(pyridin-3-yl)propanamide.** MS (EI) m/z $C_{30}H_{28}N_6O_5S$: 585 ($MH^+$).

**Example 305:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methoxybenzamide.** MS (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

**Example 306:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxybenzamide.** MS (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

**Example 307:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-phenoxyacetamide.** MS (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

**Example 308:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-methoxybenzamide.** MS (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

**Example 309:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-fluorophenyl)acetamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 310:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-fluorophenyl)acetamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 311:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-fluorophenyl)acetamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 312: 2-chloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{24}ClN_5O_5S$: 590 ($MH^+$).

**Example 313: 4-chloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{24}ClN_5O_5S$: 590 ($MH^+$).

**Example 314: 3-chloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{24}ClN_5O_5S$: 590 ($MH^+$).

**Example 315: (1R,2R)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-phenylcyclopropanecarboxamide.** MS (EI) m/z $C_{32}H_{29}N_5O_5S$: 596 ($MH^+$).

**Example 316:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-phenylcyclopropanecarboxamide.** MS (EI) m/z $C_{32}H_{29}N_5O_5S$: 596 ($MH^+$).

**Example 317:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(1H-imidazol-4-yl)acetamide.** MS (EI) m/z $C_{27}H_{25}N_7O_5S$: 560 ($MH^+$).

**Example 318:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-methoxy-2-methylbenzamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 319:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-fluorophenoxy)acetamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

**Example 320:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-5-fluoro-2-methoxybenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

**Example 321: 2-(4-chlorophenyl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{26}ClN_5O_5S$: 604 ($MH^+$).

**Example 322: 2-(2-chlorophenyl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{26}ClN_5O_5S$: 604 ($MH^+$).

**Example 323: 2-(3-chlorophenyl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{30}H_{26}ClN_5O_5S$: 604 ($MH^+$).

**Example 324: 1-acetyl-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)piperidine-4-carboxamide.** MS (EI) m/z $C_{30}H_{32}N_6O_6S$: 605 ($MH^+$).

**Example 325:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(pyridin-4-yl)acetamide.** MS (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

**Example 326:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(pyridin-2-yl)acetamide.** MS (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

**Example 327: 2,4-dichloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

**Example 328: 3,4-dichloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

**Example 329: 2,5-dichloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

**Example 330: 3,5-dichloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

**Example 331: 2,3-dichloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzamide.** MS (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

**Example 332:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pentanamide.** MS (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

**Example 333:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylbutanamide.** MS (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

**Example 334:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1H-imidazole-2-carboxamide.** MS (EI) m/z $C_{26}H_{23}N_7O_5S$: 546 ($MH^+$).

**Example 335:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1H-imidazole-4-carboxamide.** MS (EI) m/z $C_{26}H_{23}N_7O_5S$: 546 ($MH^+$).

**Example 336:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)isoxazole-5-carboxamide.** MS (EI) m/z $C_{26}H_{22}N_6O_6S$: 547 ($MH^+$).

**Example 337:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3,3-dimethylbutanamide.** MS (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

**Example 338:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methylpentanamide.** MS (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

**Example 339:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2,2-dimethylbutanamide.** MS (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

**Example 340:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-methylpentanamide.** MS (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

**Example 341:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)pyrimidine-5-carboxamide.** MS (EI) m/z $C_{27}H_{23}N_7O_5S$: 558 ($MH^+$).

**Example 342:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methylfuran-2-carboxamide.** MS (EI) m/z $C_{28}H_{25}N_5O_6S$: 560 ($MH^+$).

**Example 343:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)thiophene-3-carboxamide.** MS (EI) m/z $C_{27}H_{23}N_5O_5S_2$: 562 ($MH^+$).

**Example 344:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-oxocyclopentanecarboxamide.** MS (EI) m/z $C_{28}H_{27}N_5O_6S$: 562 ($MH^+$).

**Example 345:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methoxyethoxy)acetamide.** MS (EI) m/z $C_{27}H_{29}N_5O_7S$: 568 ($MH^+$).

**Example 346:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-methylbenzamide.** MS (EI) m/z $C_{30}H_{27}N_5O_5S$: 570 ($MH^+$).

**Example 347:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-methylisoxazol-4-yl)acetamide.** MS (EI) m/z $C_{28}H_{26}N_6O_6S$: 575 ($MH^+$).

**Example 348: 3-cyclopentyl-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)propanamide.** MS (EI) m/z $C_{30}H_{33}N_5O_5S$: 576 ($MH^+$).

**Example 349:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-o-tolylacetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_5S$: 584 ($MH^+$).

**Example 350:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methoxynicotinamide.** MS (EI) m/z $C_{29}H_{26}N_6O_6S$: 587 ($MH^+$).

**Example 351:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-fluoro-3-methylbenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 352:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-fluoro-2-methylbenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 353 :** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-fluoro-4-methylbenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 354:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-fluoro-5-methylbenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 355:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-5-fluoro-2-methylbenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

**Example 356: 6-chloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)nicotinamide.** MS (EI) m/z $C_{28}H_{23}ClN_6O_5S$: 591 ($MH^+$).

**Example 357: 2-chloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)nicotinamide.** MS (EI) m/z $C_{28}H_{23}ClN_6O_5S$: 591 ($MH^+$).

**Example 358: 2-chloro-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)isonicotinamide.** MS (EI) m/z $C_{28}H_{23}ClN_6O_5S$: 591 ($MH^+$).

**Example 359:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-4-(dimethylamino)benzamide.** MS (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

**Example 360:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(dimethylamino)benzamide.** MS (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

**Example 361:** ***N*****-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide.** MS (EI) m/z $C_{30}H_{25}N_5O_7S$: 600 ($MH^+$).

**Example 362:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(m-tolyloxy)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 363:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-methoxyphenyl)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 364:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methoxyphenyl)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 365:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-methoxyphenyl)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 366:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methoxy-4-methylbenzamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 367:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-fluoro-4-methoxybenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

**Example 368:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-fluoro-6-methoxybenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

**Example 369:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(4-methoxyphenyl)propanamide.** MS (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

**Example 370:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(2-methoxyphenyl)propanamide.** MS (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

**Example 371:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(3-methoxyphenyl)propanamide.** MS (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

**Example 362:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(m-tolyloxy)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 363:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(4-methoxyphenyl)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 364:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(2-methoxyphenyl)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 365:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(3-methoxyphenyl)acetamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 366:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-methoxy-4-methylbenzamide.** MS (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

**Example 367:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-fluoro-4-methoxybenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

**Example 368:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-fluoro-6-methoxybenzamide.** MS (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).


**Example 369:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(4-methoxyphenyl)propanamide.** MS (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

**Example 370:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(2-methoxyphenyl)propanamide.** MS (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

**Example 371:** ***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-(3-methoxyphenyl)propanamide.** MS (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

**Example 372**


***N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide.**




**[00321]** Into a 20 mL vial was added 3-amino-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide (0.24 mmol, 1 equiv), prepared using procedures similar to those described in Example 15, DMA ( 5 mL) and 1-(*tert*-butoxycarbonyl)azetidine-3-carboxylic acid (0.336 mmol, 1.4 equiv). Hunig's Base (0.792 mmol, 3.3 equiv) and HATU (0.288 mmol, 1.2 equiv) were added to the vial and the reaction mixture was then stirred at room temperature overnight. Completion of the reaction was indicated by LCMS. The solvent was removed by rotary evaporation. The crude mixture was carried forward without further purification. The residue was suspended in 5 mL ethyl acetate and chilled in an ice bath. A solution of 4 N HCl in dioxane ( 3 mL, 5 equiv) was added with stirring. The reaction mixture was then stirred at room temperature overnight. The solid materials were collected by filtration, washed with ethylacetate then purified further by preparative reverse-phase HPLC (ammonium acetate/ACN). A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 μM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification. *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide was obtained (26 mg, 20%). $^1$H-NMR (400MHz, $d_6$-DMSO): 10.26 (s, 1H), 8.81 (s, 1H), 8.25 (t, 1H), 8.14 (s, 1H), 7.74 (d, 1H), 7.69 (d, 1H), 7.41-7.39 (m, 1H), 7.36 (d, 1H), 7.32 (d, 2H), 7.30-7.28 (dd, 1H), 7.14-7.11 (m, 2H), 6.14 (t, 1H), 4.09 (d, 4H), 3.78 (s, 6H); MS (EI) m/z $C_{26}H_{26}N_6O_5S$: 535.6 ($MH^+$).

**Example 373**

***N*-(3-(4-fluorophenylamino)quinoxalin-2-yl)benzenesulfonamide**




**[00322]** A flask was charged with 2,3-dichloroquinoxaline (3.5 g, 18 mmol), 85 mL of dimethylsulfoxide, benzene sulfonamide (2.8 g, 18 mmol), and cesium carbonate (5.8 g, 18 mmol). The reaction mixture was stirred under an $N_2$ atmosphere for 15 h at 150 °C, after which time, it was transferred to a separatory funnel and 100 mL of water were added. Concentrated HCl was then added in order to acidify the reaction mixture to pH<2. The aqueous layer was subsequently washed three times with 90 mL ethyl acetate. The ethyl acetate layers were then washed two times with 150 mL water, three times with 100 mL brine and then dried over sodium sulfate. The ethyl acetate was removed on a rotary-evaporator. A slurry was formed by adding ethyl acetate and dichloromethane to the dried crude product, filtration yielded *N*-(3-chloroquinoxalin-2-yl)-benzenesulfonamide which was used without further purification. MS (EI) m/z $C_{14}H_{10}ClN_3O_2S$: 319.9 ($MH^+$).


**[00323]** A CEM microwave reaction vessel was charged with *N*-(3-chloroquinoxalin-2-yl)benzenesulfonamide (52 mg, 0.16 mmol), prepared using procedures similar to those described in the above step, 4-fluoroaniline (36 mg, 0.32 mmol), and 0.8 mL of dimethylacetamide. The vessel was sealed and the reaction mixture was heated under microwave radiation for 25 m at 120 °C in a CEM Discover microwave instrument. Methanol (1 mL) was added to the reaction mixture and after 20 minutes the product

precipitated out of the solution. Filtration yielded *N*-(3-(4-fluorophenylamino)quinoxalin-2-yl)benzenesulfonamide (39 mg, 62 %). $^1$H-NMR (400MHz, $d_6$-DMSO): δ 12.30 (s, 1H), 9.11 (s, 1H), 8.16-8.10 (d, 2H), 8.02-7.90 (m, 3H), 7.68-7.58 (m, 3H), 7.55-7.51 (m, 1H), 7.41-7.32 (m, 2H), 7.25-7.16 (m, 2H); MS (EI) m/z $C_{20}H_{15}FN_4O_2S$: 395.0 ($MH^+$).


**Example 374**

***N*-(3-(*N*-(3-chloroquinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide**

**Scheme A**




**Scheme B**





**Scheme A**

**[00324]** A flask was charged with 3-aminobenzene sulfonamide (3.3 g, 19 mmol), and 20 mL of 1:1 acetone:$H_2O$. The solution was stirred at room temperature until the aminobenzene sulfonamide had dissolved. The flask was then cooled in an ice bath and dimethylamino-acetyl chloride HCl (4.6 g, 29 mmol) was added. To the resulting slurry sodium bicarbonate (4.8 g, 57 mmol) was added over a 15 m period. After 30 min the reaction was removed from the ice bath and allowed to stir at room temperature for 15 h. The reaction mixture was then filtered and washed with methanol and acetonitrile. The filtrate was dried on a rotary evaporator to yield 2-(dimethylamino)-*N*-(3-sulfamoyl-phenyl)acetamide, which was submitted to the next step without further purification. MS (EI) m/z $C_{10}H_{15}N_3O_3S$: 258.0 ($MH^+$).

**Scheme B**

**[00325]** A flask was charged with dichloroquinozaline (1.0 g, 5.8 mmol), 10 mL of dimethylacetamide, 2-(dimetyhlamino)-*N*-(3-sulfamoylphenyl)acetamide (0.70 g, 2.7 mmol), and cesium carbonate (1.8 g, 5.5 mmol). The reaction mixture was stirred for 3 h at 140 °C and then filtered. The solvent was evaporated from the filtrate on a rotary-evaporator to yield (*N*-(3-(*N*-(3-chloroquinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide) which was submitted to the next step without further purification. MS (EI) m/z $C_{18}H_{18}ClN_5O_3S$: 420.0 ($MH^+$).

**General Amination Procedure 1a**




**[00326]** A CEM microwave reaction vessel was charged with *N*-(3-(*N*-(3-chloroquinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide (30 mg, 0.071 mmol), prepared using procedures similar to those described in Example 374, the desired aniline (16 mg, 0.14 mmol, 2 eq), and 0.5 mL of dimethylacetamide. The vessel was sealed and the reaction mixture was heated under microwave radiation for 70 min at 140 °C in a CEM Discover microwave instrument. The solvent was then removed by rotary-evaporation. Purification of the final product was accomplished by preparatory reverse-phase HPLC with the eluents 25 mM aqueous $NH_4OAc$/ACN to the desired product.

**[00327]** The following compounds were prepared according to the above **General Amination Procedure 1a.**


**Example 375: 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-fluorophenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** $^1$H-NMR (400MHz, $CDCl_3$): 9.40 ppm (s, 1H), 8.43 ppm (s, 1H), 8.22 ppm (s, 1H), 8.07-8.02 ppm (d, 1H), 7.97-7.93 ppm (d, 1H), 7.76-7.71 (m, 2H), 7.53-7.48 ppm (t, 1H), 7.45-7.36 ppm (m, 4H), 7.35-7.28 ppm (m, 2H), 6.84-

6.77 ppm (t, 1H), 3.10 ppm (s, 2H), 2.38 ppm (s, 6H); MS (EI) m/z $C_{24}H_{23}FN_6O_3S$: 495 ($MH^+$).

**Example 376: 2-(dimethylamino)-*N*-(3-(*N*-(3-(4-fluorophenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{24}H_{23}FN_6O_3S$: 495 ($MH^+$).

**Example 377: *N*-(3-(*N*-(3-(4-chloro-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** MS (EI) m/z $C_{24}H_{23}ClN_6O_3S$: 511 ($MH^+$).

**General Amination Procedure 1b**




**[00328]** A CEM microwave reaction vessel was charged with *N*-(3-(*N*-(3-chloroquinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide (62 mg, 0.147 mmol), prepared using procedures similar to those in Example 374, the desired aniline (0.567 mmol, 4 eq), and 1.0 mL of toluene. The vessel was sealed and the reaction mixture was heated under microwave radiation for 60 min at 180 °C in a CEM Discover microwave instrument. The solvent was removed on a rotary-evaporator. Purification of the final product was done by preparatory HPLC with $NH_4OAc$/ACN as eluent to yield the desired product.

**[00329]** The following compounds were prepared according to the above **General Amination Procedure 1b.**


**Example 378*N*-(3-(*N*-(3-(3-chloro-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide.** MS (EI) m/z $C_{24}H_{23}ClN_6O_3S$: 511 ($MH^+$).

**Example 379: 2-(dimethylamino)-*N*-(3-(*N*-(3-(4-fluoro-3-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** 2-(dimethylamino)-*N*-(3-(*N*-(3-(4-fluoro-3-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl). $^1$H-NMR (400MHz, $CDCl_3$): δ 9.47 (s, 1H), 8.36 (s, 1H), 8.29 (s, 1H), 7.91-7.87 (d, 1H), 7.80-7.73 (m, 2H), 7.66-7.63 (d, 1H), 7.53-7.47 (t, 1H), 7.43-7.30

(m, 4H), 7.10-7.04 (t, 1H), 6.55-5.95 (br s, 1H), 3.96 (s, 3H), 3.12 (s, 2H), 2.39 (s, 6H), 2.08 (s,3H(*Ac*0H*)*; MS (EI) m/z $C_{25}H_{25}FN_6O_4S$: 525 ($MH^+$).

**Example 380**

***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-isopropoxybenzenesulfonamide**




**[00330]** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-isopropoxy-benzenesulfonamide.** A solution of 2,3-dichloroquinoxaline (2.0 mL, 0.38 M) was combined with $K_2CO_3$ (105 mg, 0.76 mmol) in a glass vial. A solution of 4-isopropoxybenzene sulfonamide (1.75 mL, 0.43 M) was added and the solution was stirred overnight at 125 °C. After cooling, acetic acid (45 mL, 0.79 mmol) and 3,5-dimethoxyaniline (230 mg, 1.5 mmol) were added. The reaction mixture was stirred again at 125 °C overnight. Upon cooling, the reaction mixture was diluted with 8 mL of methanol and then 8 mL of water. The precipitate was collected by filtration and recrystallized from *N,N*-dimethylacetamide/water to give *N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-isopropoxy-benzenesulfonamide (45 mg, 12%). $^1$H-NMR (400MHz, $d_6$-DMSO): 12.16 (bs, 1H), 8.93 (s, 1H), 8.03 (d, 2H), 7.92 (bs, 1H), 7.56 (d, 1H), 7.36 (m, 4H), 7.07 (d, 2H), 6.24 (s, 1H), 4.72 (m, 1H), 3.76 (s, 6H), 1.27 (d, 6H); MS (EI) m/z $C_{25}H_{26}N_4O_5S$: 495 ($MH^+$).

**[0187]** Examples 381-411 were synthesized proceeding as above in Example 423. In the cases where the product did not precipitate, the mixture was purified by reverse phase HPLC.

**Example 381: 3-chloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 12.31 (bs, 1H), 8.96 (s, 1H), 8.18 (s, 1H), 7.98 (d, 1H), 7.92 (bs, 1H), 7.58 (d, 2H), 7.43-7.33 (m, 4H), 6.24 (t, 1H), 3.76 (s, 6H), 2.39 (s, 3H); MS (EI) m/z $C_{23}H_{21}ClN_4O_4S$: 485 ($MH^+$).

**Example 382:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)naphthalene-1-sulfonamide.** MS (EI) m/z $C_{26}H_{22}N_4O_4S$: 487 ($MH^+$).

**Example 383:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-fluorobenzenesulfonamide.** MS (EI) m/z $C_{22}H_{19}FN_4O_4S$: 455 ($MH^+$).

**Example 384:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-fluorobenzenesulfonamide.** MS (EI) m/z $C_{22}H_{19}FN_4O_4S$: 455 ($MH^+$).

**Example 385:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-(trifluoromethyl)benzenesulfonamide.** MS (EI) m/z $C_{23}H_{19}F_3N_4O_4S$: 505 ($MH^+$).

**Example 386:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-(trifluoromethyl)benzenesulfonamide.** MS (EI) m/z $C_{23}H_{19}F_3N_4O_4S$: 505 ($MH^+$).

**Example 387:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-(trifluoromethoxy)benzenesulfonamide.** MS (EI) m/z $C_{23}H_{19}F_3N_4O_5S$: 521 ($MH^+$).

**Example 388:** ***N*-(4-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide.** MS (EI) m/z $C_{24}H_{23}N_5O_5S$: 494 ($MH^+$).

**Example 389:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide.** MS (EI) m/z $C_{23}H_{21}FN_4O_4S$: 469 ($MH^+$).

**Example 390:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2-methylbenzenesulfonamide.** MS (EI) m/z $C_{23}H_{22}N_4O_4S$: 451 ($MH^+$).

**Example 391:** **2-chloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z $C_{22}H_{19}ClN_4O_4S$: 471 ($MH^+$).

**Example 392:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3,5-difluorobenzenesulfonamide.** MS (EI) m/z $C_{22}H_{18}F_2N_4O_4S$: 473 ($MH^+$).

**Example 393:** **3,5-dichloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z $C_{22}H_{18}Cl_2N_4O_4S$: 505 ($MH^+$).

**Example 394:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-fluoro-4-methylbenzenesulfonamide.** MS (EI) m/z $C_{23}H_{21}FN_4O_4S$: 469 ($MH^+$).

**Example 395:** ***N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2-(trifluoromethyl)benzenesulfonamide.** MS (EI) m/z $C_{23}H_{19}F_3N_4O_4S$: 505 ($MH^+$).

**Example 396:** **4-cyano-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z $C_{23}H_{19}N_5O_4S$: 462 ($MH^+$).

**Example 397:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-1-phenylmethanesulfonamide.** MS (EI) m/z $C_{23}H_{22}N_4O_4S$: 451 ($MH^+$).

**Example 398: 4,5-dichloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)thiophene-2-sulfonamide.** MS (EI) m/z $C_{20}H_{16}Cl_2N_4O_4S_2$: 511 ($MH^+$).

**Example 399: 1-(3-chlorophenyl)-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)methanesulfonamide.** MS (EI) m/z $C_{23}H_{21}ClN_4O_4S$: 485 ($MH^+$).

**Example 400:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2,5-dimethylthiophene-3-sulfonamide.** MS (EI) m/z $C_{22}H_{22}N_4O_4S_2$: 471 ($MH^+$).

**Example 401:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3,5-bis(trifluoromethyl)benzenesulfonamide.** MS (EI) m/z $C_{24}H_{18}F_6N_4O_4S$: 573 ($MH^+$).

**Example 402:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-fluoro-3-(trifluoromethyl)benzenesulfonamide.** MS (EI) m/z $C_{23}H_{18}F_4N_4O_4S$: 523 ($MH^+$).

**Example 403: 5-chloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide.** MS (EI) m/z $C_{21}H_{21}ClN_6O_4S$: 489 ($MH^+$).

**Example 404: 5-chloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2-methoxybenzenesulfonamide.** MS (EI) m/z $C_{23}H_{21}ClN_4O_5S$: 501 ($MH^+$).

**Example 405: 5-bromo-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2-methoxybenzenesulfonamide.** MS (EI) m/z $C_{23}H_{21}BrN_4O_5S$: 545 ($MH^+$).

**Example 406: 2,5-dichloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)thiophene-3-sulfonamide.** MS (EI) m/z $C_{20}H_{16}Cl_2N_4O_4S_2$: 511 ($MH^+$).

**Example 407:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3,5-dimethylisoxazole-4-sulfonamide.** MS (EI) m/z $C_{21}H_{21}N_5O_5S$: 456 ($MH^+$).


**Example 408:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-2,5-dimethoxybenzenesulfonamide.** MS (EI) m/z $C_{24}H_{24}N_4O_6S$: 497 ($MH^+$).

**Example 409: 3-chloro-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-4-fluorobenzenesulfonamide.** MS (EI) m/z $C_{22}H_{18}ClFN_4O_4S$: 489 ($MH^+$).

**Example 410: 4-(difluoromethoxy)-*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide** MS (EI) m/z $C_{23}H_{20}F_2N_4O_5S$: 503 ($MH^+$).

**Example 411:** ***N*****-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-3-(methylsulfonyl)benzenesulfonamide.** MS (EI) m/z $C_{23}H_{22}N_4O_6S_2$: 515 ($MH^+$).

**General Acylation Procedure 2**




**[00331]** *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)-sulfamoyl)phenyl)azetidine-3-carboxamide (125 mg, 0.23 mmol), prepared using procedures similar to those described in Example 372, was dissolved into 5 mL DCE in a 10 mL round-bottom flask. DIEA (1.17 mmol, 5.0 equiv.) was then added with stirring followed by acid chloride (0.47 mmol, 2.0 equiv.). The reaction was then stirred at room temperature for 1 hour or until complete as indicated by LCMS. The solvent was subsequently removed under reduced pressure on a rotary evaporator. The crude material was then redissolved in methanol. Purification of the final product was accomplished by preparatory reverse-phase HPLC with the eluents 25 mM aqueous $NH_4OAc$/CAN. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 μM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification.


**[00332]** The following compounds were prepared according to **General Acylation Procedure 2.**

**Example 412: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-propionylazetidine-3-carboxamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 12.40 (s, 1H), 10.45 (s, 1H), 8.88 (s, 1H), 8.40 (s, 1H), 7.93 (s, 1H), 7.82 (d, 1H), 7.77 (d, 1H), 7.60-7.45 (m, 2H), 7.41-7.30 (m, 4H), 6.24 (s, 1H), 4.26 (t, 1H), 4.22-4.17 (m, 1H), 3.99 (t, 1H), 3.95-3.89 (m, 1H), 3.76 (s, 6H), 3.59-3.45 (m, 1H), 2.05 (dd, 2H), 0.95 (t, 3H); MS (EI) m/z $C_{29}H_{30}N_6O_6S$: 591 ($MH^+$).

**Example 413: 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methoxy)-phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide.** MS (EI) m/z $C_{28}H_{28}N_6O_6S$: 577 ($MH^+$).

**Example 414: 1-(cyclopropanecarbonyl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide.** MS (EI) m/z $C_{30}H_{30}N_6O_6S$: 603 ($MH^+$).

**General Reductive Amination Procedure 1**




**[00333]** To a solution of *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide (110 mg, 0.19 mmol), prepared using procedures similar to those described in Example 372, in 3 mL of DCE and 200 μL of DMF, aldehyde (0.77 mmol, 4.0 eq.)was added slowly followed by tetramethylammonium triacetoxyborohydride (1.16 mmol, 6.0 eq). The reaction was stirred at room temperature overnight. LC/MS indicated the reaction was completed. The solvent was subsequently removed under reduced pressure on a rotary evaporator. The crude material was then redissolved in methanol. Purification of the final product was accomplished by preparatory reverse-phase HPLC with the eluents 25 mM aqueous $NH_4OAc$/CAN. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 μM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification.

**[00334]** The following title compounds were prepared according to **General Reductive Amination Procedure 1.**

**Example 415: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-ethylazetidine-3-carboxamide.** $^1$H-NMR (400MHz, $d_6$-DMSO): 10.29 (s, 1H), 8.82 (s, 1H), 8.25 (t, 1H), 7.75-7.68 (m, 2H), 7.43-7.38 (m, 1H), 7.375-7.340 (m, 1H), 7.338-7.310 (d, 2H), 7.305-7.262 (m, 1H), 7.15-7.08 (m, 2H), 6.56

(s, 1H), 6.15 (t, 1H), 4.15-4.08 (m, 2H), 4.06-3.95 (m, 2H), 3.78 (s, 6H), 3.65-3.56 (m, 1H), 3.12-3.04 (m, 2H), 1.03 (t, 3H); MS (EI) m/z $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).


**Example 416: 1-(cyclopropylmethyl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide.** MS (EI) m/z $C_{30}H_{32}N_6O_5S$: 589 ($MH^+$).

**Example 417: 1-benzyl-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide.** MS (EI) m/z $C_{33}H_{32}N_6O_5S$: 625 ($MH^+$).

**Example 418: *N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-1-(furan-2-ylmethyl)azetidine-3-carboxamide.** MS (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

**Example 419: 1-((1H-imidazol-5-yl)methyl)-*N*-(3-(*N*-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide.** MS (EI) m/z $C_{30}H_{30}N_8O_5S$: 615 ($MH^+$).

**General Amide Formation Procedure 1a**




**[00335]** Into a small 1 dram vial was added 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)-quinoxalin-2-yl)sulfamoyl)benzoic acid (61 mg, 0.13 mmol, 1.1 equiv), prepared using procedures described for Example 100. The acid was dissolved in DMA (1 mL) and DIEA (42 μL, 0.24 mmol, 2 equiv) was added then added to the solution. The amine reagent (1 mL of 0.12 M solution in DMA) was added to solution with stirring followed by HATU (64 mg, 0.17 mMol, 1.4 equiv). The reaction was stirred overnight at room temperature. Upon completion as indicated by LCMS analysis, 2 mL of methanol was added to the solution. Preparative reverse-phase HPLC was used to isolate the desired product. A Waters Fractionlynx preparative reverse-phase HPLC – equipped with

a Waters SunFire Prep C18, OCD 5 μM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile – was used to carry out the purification.

**[00336]** The following compounds were prepared according to **General Amide Formation Procedure 1.**

**Example 420: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-(dimethylamino)propyl)benzamide.** 3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-(dimethylamino)propyl)benzamide: $^1$H NMR (400 MHz, $d_6$-DMSO): 9.44 (s, 1H), 8.94 (s, 1H), 8.79 (t, 1H), 8.54 (s, 1H), 8.24 (d, 1H), 7.87 (d, 1H), 7.48 (m, 3H), 7.33 (d, 1H), 7.18 (m, 2H), 6.60 (dd, 1H), 3.82 (1H), 3.04 (m, 3H), 2.51 (m, 5H), 1.91 (s, 1H), 1.86 (m, 3H); MS (EI) m/z for $C_{27}H_{29}ClN_6O_4S$: 569 ($MH^+$).

**Example 421: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(1-methylazetidin-3-yl)benzamide.** 3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(1-methylazetidin-3-yl)benzamide: $^1$H NMR (400 MHz, $d_6$-DMSO): 9.43 (s, 1H), 9.23 (d, 1H), 8.94 (d, 1H), 8.58 (s, 1H), 8.29 (d, 1H), 7.89 (d, 1H), 7.56 (t, 1H), 7.47 (d, 1H), 7.44 (d, 1H), 7.33 (d, 1H), 7.18 (m, 2H), 6.60 (dd, 1H), 4.81 (m, 1H), 4.33 (m, 2H), 4.19 (m, 2H), 3.82 (s, 1H), 2.51 (s, 3H); MS (EI) m/z for $C_{26}H_{25}ClN_6O_4S$: 553 ($MH^+$).

**Example 422: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(pyridin-4-ylmethyl)benzamide.** MS (EI) m/z $C_{28}H_{23}ClN_6O_4S$: 575 ($MH^+$).

**Example 423: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-(dimethylamino)propyl)benzamide.** MS (EI) m/z $C_{28}H_{26}ClN_7O_4S$: 592 ($MH^+$).

**Example 424: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(2,2-dimethylhydrazinecarbonyl)benzenesulfonamide.** MS (EI) m/z $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

**Example 425: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-methoxyethyl)benzamide.** MS (EI) m/z $C_{25}H_{24}ClN_5O_5S$: 542 ($MH^+$).

**Example 426:** ***N*****-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(4-methylpiperazine-1-carbonyl)benzenesulfonamide.** MS (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

**Example 427:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(pyrrolidin-1-yl)ethyl)benzamide.** MS (EI) m/z $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

**Example 428:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(pyridin-4-yl)ethyl)benzamide.** MS (EI) m/z $C_{29}H_{25}ClN_6O_4S$: 589 ($MH^+$).

**Example 429:** ***N*****-(2-(1H-imidazol-4-yl)ethyl)-3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)benzamide.** MS (EI) m/z $C_{27}H_{24}ClN_7O_4S$: 578 ($MH^+$).

**Example 430:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(piperidin-1-yl)benzamide.** MS (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

**Example 431:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-hydroxyethyl)benzamide.** MS (EI) m/z $C_{24}H_{22}ClN_5O_5S$: 528 ($MH^+$).

**Example 432:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-ethoxypropyl)benzamide.** MS (EI) m/z $C_{27}H_{28}ClN_5O_5S$: 570 ($MH^+$).

**Example 433:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-(pyrrolidin-1-yl)propyl)benzamide.** MS (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

**Example 434:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-(diethylamino)propyl)benzamide.** MS (EI) m/z $C_{29}H_{33}ClN_6O_4S$: 597 ($MH^+$).

**Example 435:** **3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-(2-oxopyrrolidin-1-yl)propyl)benzamide.** MS (EI) m/z $C_{29}H_{29}ClN_6O_5S$: 609 ($MH^+$).

**Example 436: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(pyridin-2-ylmethyl)benzamide.** MS (EI) m/z $C_{28}H_{23}ClN_6O_4S$: 575 ($MH^+$).

**Example 437: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-cyanoethyl)-*N*-methylbenzamide.** MS (EI) m/z $C_{26}H_{23}ClN_6O_4S$: 551 ($MH^+$).

**Example 438: 3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-cyanoethyl)-*N*-ethylbenzamide.** MS (EI) m/z $C_{27}H_{25}ClN_6O_4S$: 565 ($MH^+$).

**Example 439: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(ethylthio)ethyl)benzamide.** MS (EI) m/z $C_{26}H_{26}ClN_5O_4S_2$: 572 ($MH^+$).

**Example 440: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-propoxypropyl)benzamide.** MS (EI) m/z $C_{28}H_{30}ClN_5O_5S$: 584 ($MH^+$).

**Example 441: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(5-(diethylamino)pentan-2-yl)benzamide.** MS (EI) m/z $C_{31}H_{37}ClN_6O_4S$: 625 ($MH^+$).

**Example 442: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-methoxypropyl)benzamide.** MS (EI) m/z $C_{26}H_{26}ClN_5O_5S$: 556 ($MH^+$).

**Example 443: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-morpholinopropyl)benzamide** MS (EI) m/z $C_{29}H_{31}ClN_6O_5S$: 611 ($MH^+$).

**Example 444: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(pyridin-3-ylmethyl)benzamide** MS (EI) m/z $C_{28}H_{23}ClN_6O_4S$: 575 ($MH^+$).

**Example 445: 3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-cyanoethyl)benzamide.** MS (EI) m/z $C_{25}H_{21}ClN_6O_4S$: 537 ($MH^+$).

**Example 446: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(1-methoxypropan-2-yl)benzamide.** MS (EI) m/z $C_{26}H_{26}ClN_5O_5S$: 556 ($MH^+$).

**Example 447: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(methylthio)ethyl)benzamide.** MS (EI) m/z $C_{25}H_{24}ClN_5O_4S_2$: 558 ($MH^+$).

**Example 448: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-(dimethylamino)propyl)-*N*-methylbenzamide.** MS (EI) m/z $C_{28}H_{31}ClN_6O_4S$: 583 ($MH^+$).

**Example 449: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-isopropoxypropyl)benzamide.** MS (EI) m/z $C_{28}H_{30}ClN_5O_5S$: 584 ($MH^+$).

**Example 450: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(dimethylamino)ethyl)-*N*-ethylbenzamide.** MS (EI) m/z $C_{28}H_{31}ClN_6O_4S$: 583 ($MH^+$).

**Example 451: *N*-(3-butoxypropyl)-3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzamide.** MS (EI) m/z $C_{29}H_{32}ClN_5O_5S$: 598 ($MH^+$).

**Example 452: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(diethylamino)ethyl)benzamide.** MS (EI) m/z $C_{28}H_{31}ClN_6O_4S$: 583 ($MH^+$).

**Example 453: methyl 3-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzamido)propanoate.** MS (EI) m/z $C_{26}H_{24}ClN_5O_6S$: 570 ($MH^+$).

**Example 454: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-methyl-*N*-propylbenzamide.** MS (EI) m/z $C_{26}H_{26}ClN_5O_4S$: 540 ($MH^+$).

**Example 455: ethyl 3-(3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzamido)propanoate.** MS (EI) m/z $C_{27}H_{26}ClN_5O_6S$: 584 ($MH^+$).

**Example 456: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-(piperidin-1-yl)ethyl)benzamide.** MS (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

**Example 457: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-((1-ethylpyrrolidin-2-yl)methyl)benzamide.** MS (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

**Example 458: *N*-(2-(bis(2-hydroxyethyl)amino)ethyl)-3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)benzamide.** MS (EI) m/z $C_{28}H_{31}ClN_6O_6S$: 615 ($MH^+$).

**Example 459: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(3-(diethylamino)pyrrolidine-1-carbonyl)benzenesulfonamide.** MS (EI) m/z $C_{30}H_{33}ClN_6O_4S$: 609 ($MH^+$).

**Example 460: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-methyl-*N*-(1-methylpyrrolidin-3-yl)benzamide.** MS (EI) m/z $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

**Example 461: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(3-(dimethylamino)pyrrolidine-1-carbonyl)benzenesulfonamide.** MS (EI) m/z $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

**Example 462: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(2-methyl-1-morpholinopropan-2-yl)benzamide.** MS (EI) m/z $C_{30}H_{33}ClN_6O_5S$: 625 ($MH^+$).

**Example 463: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(1H-pyrrol-1-yl)benzamide.** MS (EI) m/z $C_{26}H_{21}ClN_6O_4S$: 549 ($MH^+$).

**Example 464: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(3-oxopyrazolidin-4-yl)benzamide.** MS (EI) m/z $C_{25}H_{22}ClN_7O_5S$: 568 ($MH^+$).

**Example 465: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(2-((dimethylamino)methyl)piperidine-1-carbonyl)benzenesulfonamide.** MS (EI) m/z $C_{30}H_{33}ClN_6O_4S$: 609 ($MH^+$).

**Example 466: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(2-(piperidin-1-ylmethyl)piperidine-1-carbonyl)benzenesulfonamide.** MS (EI) m/z $C_{33}H_{37}ClN_6O_4S$: 649 ($MH^+$).

**Example 467: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(1-ethylpiperidin-3-yl)benzamide** MS (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

**General Amide Formation Procedure 1b**

**[00337]** The procedure outlined in **General Amide Formation Procedure 1a** was used to incorporate a number of amines that contained a second amine group protected as the *tert*-butylcarbamate (i.e. where R', within NHR'R", contained a Boc-protected amine group). The deprotection was carried out after HPLC purification of the Boc-protected precursor.

**[00338]** Into a small 1 dram vial was added 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzoic acid (61 mg, 0.13 mmol, 1.1 equiv). The acid was dissolved in 1 mL of DMA and DIEA (42 μL, 0.24 mmol, 2 equiv) was added then added to the solution. The mono-Boc-protected diamine reagent (1 mL of 0.12 M solution in DMA, 1 equiv) was added to solution with stirring followed by HATU (64 mg, 0.17 mmol, 1.4 equiv). The reaction was stirred overnight at room temperature. Upon completion as indicated by LCMS analysis, 2 mL of methanol was added to the solution. Preparative reverse-phase HPLC was used to isolate the desired product directly from this crude reaction solution. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 μM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification. The product fractions were combined and concentrated to dryness under reduced pressure by rotary evaporation. A solution of 4 N HCl in dioxane (2 mL) was added. The solution was then stirred at room temperature until no starting material was detected. The deprotected product precipitated out of solution as an HCL salt and was collected by filtration, washed with ether and dried under vacuum.

**[00339]** The following compounds were prepared according to the above **General Amide Formation Procedure 1b.**

**Example 468: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(piperidin-3-yl)benzamide.** 3-(*N*-(3-(2-chloro-

5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(piperidin-3-yl)benzamide: $^1$H NMR (400 MHz, $d_6$-DMSO): 12.82 (s, 1H), 9.12 (s, 1H), 9.04 (s, 1H), 8.85 (d, 1H), 8.65 (s, 1H), 8.55 (s, 1H), 8.18 (m, 1H), 7.98 (s, 1H), 7.69 (m, 2H), 7.43 (m, 2H), 6.69 (dd, 1H), 4.21 (s, 1H), 3.83 (s, 3H), 3.69 (m, 1H), 3.48 (m, 1H), 3.18 (s, 1H), 2.84 (q, 2H), 1.91 (s, 2H); MS (EI) m/z for $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

**Example 469: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(piperidin-2-ylmethyl)benzamide.** 3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(piperidin-2-ylmethyl)benzamide: NMR (400 MHz, $d_6$-DMSO): 12.78 (s, 1H), 9.16 (s, 1H), 9.09 (s, 1H), 8.79 (s, 1H), 8.59 (d, 2H), 8.22 (t, 2H), 7.99 (s, 1H), 7.74 (t, 1H), 7.66 (s, 1H), 7.42 (m, 2H), 6.69 (dd, 1H), 3.82 (s, 3H), 3.69 (dd, 1H), 3.57 (m, 1H), 3.50 (m, 3H), 3.22 (s, 2H), 2.82 (d, 1H), 1.68 (m, 5H); MS (EI) m/z for $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

**Example 470: 3-(3-aminopyrrolidine-1-carbonyl)-*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z $C_{26}H_{25}ClN_6O_4S$: 553 ($MH^+$).

**Example 471: 3-(3-aminoazetidine-1-carbonyl)-*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z $C_{25}H_{23}ClN_6O_4S$: 539 ($MH^+$).

**Example 472: 3-(3-aminopiperidine-1-carbonyl)-*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

**Example 473: 3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(pyrrolidin-3-yl)benzamide.** MS (EI) m/z $C_{26}H_{25}ClN_6O_4S$: 553 ($MH^+$).

**Example 474: *N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)-3-(3-(methylamino)pyrrolidine-1-carbonyl)benzenesulfonamide.** MS (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

**Example 475: *N*-(2-aminoethyl)-3-(*N*-(3-(2-chloro-5-methoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)benzamide.** MS (EI) m/z $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

**Example 476: 3-(4-amino-3-oxopyrazolidine-1-carbonyl)-*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)benzenesulfonamide.** MS (EI) m/z $C_{25}H_{22}ClN_7O_5S$: 568 ($MH^+$).

**Example 477**

**3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-((1-methylpiperidin-2-yl)methyl)benzamide**

**[00340]** 3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(piperidin-2-ylmethyl)benzamide (299 mg, 0.51 mmol, 1 equiv), prepared using procedures similar to those described for Example 514, was dissolved in 2.3 mL of DMA. Formic acid (388 μL, 10.28 mmol, 20 equiv) was added to solution with stirring followed by the addition of formaldehyde (508 μL of 37% aq. solution). The reaction was then stirred at room temperature overnight. Analysis of an aliquot of the reaction mixture by LCMS indicated the complete consumption of starting material. The reaction was diluted with methanol (2 mL). Preparative reverse-phase HPLC was used to isolate the desired product directly from the crude reaction mixture. A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 μM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification. $^1$H NMR (400 MHz, $d_6$-DMSO): 9.44 (s, 1H), 8.94 (s, 1H), 8.79 (t, 1H), 8.57 (s, 1H), 8.27 (d, 1H), 7.90 (d, 1H) 7.54 (t, 1H), 7.46 (d, 1H), 7.39 (d, 1H), 7.33 (d, 1H), 7.18 (m, 2H), 6.60 (dd, 1H), 3.82 (s, 3H), 3.59 (m, 2H), 3.00 (s, 1H), 2.90 (s, 3H), 1.62 (m, 7H); MS (EI) m/z for $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

**Example 478**

**3-(*N*-(3-(2-chloro-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)-*N*-(1-methylpiperidin-3-yl)benzamide**

**[00341]** The title compound was prepared using similar procedures to those used in Example 522. $^1$H NMR (400 MHz, $d_6$-DMSO): 9.43 (s, 1H), 8.93 (s, 1H), 8.59 (s, 1H), 8.24 (d, 1H), 7.87 (d, 1H), 7.47 (m, 2H), 7.40 (d, 1H), 7.33 (d, 1H), 7.19 (m, 2H), 6.60 (dd, 1H), 4.21 (s, 1H), 3.82 (s, 1H), 2.76 (s, 1H), 2.50 (m, 7H), 1.91 (m, 2H), 1.63 (m, 2H); MS (EI) m/z for $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

## Biological Examples

### Biological Example 1

### PI3Kalpha Luciferase-Coupled Chemiluminescence Assay Protocol

**[00342]** PI3Kα activity is measured as the percent of ATP consumed following the kinase reaction using luciferase-luciferin-coupled chemiluminescence. Reactions were conducted in 384-well white, medium binding microtiter plates (Greiner). Kinase reactions were initiated by combining test compounds, ATP, substrate (PIP2), and kinase in a 20 μL volume in a buffer solution. The standard PI3Kalpha assay buffer is composed 50 mM Tris, pH 7.5, 1 mM EGTA, 10 mM $MgCl_2$, 1 mM DTT and 0.03% CHAPS. The standard assay concentrations for enzyme, ATP, and substrate are 0.5-1.1 nM, 1μM, and 7.5 μM, respectively. The reaction mixture was incubated at ambient temperature for approximately 2 h. Following the kinase reaction, a 10 μL aliquot of luciferase-luciferin mix (Promega Kinase-Glo) was added and the chemiluminescence signal measured using a Victor2 plate reader (Perkin Elmer). Total ATP consumption was limited to 40-60% and IC50 values of control compounds correlate well with literature references.

**[00343]** Certain compounds of the invention demonstrated the ability to bind to PI3K when tested in this assay. The following embodiments are directed to the compounds themselves as well as their use in a method of treating. For example, in one embodiment of the invention, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 8 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 4 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 3 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 2 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 1.5 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 1 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding

affinity of about 0.750 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.5 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.3 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.2 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.1 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.075 μM or less. In another embodiment, the PI3K inhibitor is selected from the compounds in Table 1 having a PI3K-binding affinity of about 0.050 μM or less.

**Biological Example 2**

**Phospho AKT assay**

**[00344]** PC-3 cells were seeded on 6-well plates at 150,000 cells/well. Cells were cultured for 3 days, then treated with compounds in serum-free medium for 3 hr. EGF (100 ng/ml) was added for the last 10 min. Cells were lysed in TENN buffer. Phospho T308 Akt and total Akt were quantfied by ELISA performed according to the Biosource assay protocol. The readings of phospho Akt were normalized to total Akt readings.

**Biological Example 3**

**Phospho S6 assay**

**[00345]** PC-3 cells were seeded on 96-well plates at 8,000 cells/well. For each experiment, cells were seeded and treated in duplicated plates: one plate for phospho S6 CellELISA, and one plate for total S6 CellELISA. Cells were cultured on the plates for 3 days, then treated with compounds in serum-free medium for 3 hr in triplicate. Cells were fixed with 4% formaldehyde, quenched with 0.6% H2O2, blocked with 5% BSA, incubated with either phospho S6 antibody or total S6 antibody overnight, incubated with goat-anti-rabbit-IgG-HRP for 1 hr, and developed in chemiluminescent substrate.

**Biological Example 4**

**$PIP_3$ assay**

**[00346]** MCF-7 cells grown in 10-cm dishes were starved for 3 hours in DMEM, and then treated with compounds for 20 minutes. In the last 2 minutes of the incubation with the compounds, EGF (100 ng/ml) was added to stimulate the production of PIP3. The medium was aspirated and the cells were scraped with 10% trichloroacetic acid. The lipids were extracted from the pellet after the cell lysates were centrifuged. PIP3 in the cellular lipid extraction was quantified with the AlphaScreen [Registered TM of PerkinElmer] assay in which Grp1-PH is used as the PIP3 specific probe. The amount of cellular PIP3 was calculated from the standard curve of $diC_8$ PI (3,4,5) P3.

**Biological Example 5-10**

**In vivo models**

**[00347]** Compound A is a Compound of Formula I. Compound B is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine.

**[00348]** Female and male athymic nude mice (NCr) 5-8 weeks of age and weighing approximately 20-25 g were used in the following model. Prior to initiation of a study, the animals were allowed to acclimate for a minimum of 48 h. During these studies, animals were provided food and water ad libitum and housed in a room conditioned at 70-75°F and 60% relative humidity. A 12 h light and 12 h dark cycle was maintained with automatic timers. All animals were examined daily for compound-induced or tumor-related deaths.

**[00349]** PC-3 human prostate adenocarcinoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 20% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37 °C in a humidified 5% $CO_2$ atmosphere. On day 0, cells were harvested by trypsinization and $3x10^6$ cells (passage 13, 99% viability) in 0.1 mL of ice-cold Hank's balanced salt solution were implanted subcutaneously into the hindflank of 5-8 week old male nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily. Experiments were conducted

with Compound A as a single agent as well as Compound A in combination with Taxol and Compound A in combination with Rapamycin. This model can be used to assess the desirability of treating with Compound A in combination with other anti-cancer agents.

**[00350]** U-87 MG human glioblastoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37°C in a humidified 5% $CO_2$ atmosphere. On day 0, cells were harvested by trypsinization and $2x10^6$ cells (passage 5, 96% viability) in 0.1 mL of ice-cold Hank's balanced salt solution were implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily. Experiments were conducted with Compound A as a single agent and the results are not included. This model can be used to assess the desirability of treating with Compound A in combination with other anti-cancer agents.

**[00351]** A549 human lung carcinoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37°C in a humidified 5% $CO_2$ atmosphere. On day 0, cells were harvested by trypsinization and $10x10^6$ cells (passage 12, 99% viability) in 0.1 mL of ice-cold Hank's balanced salt solution were implanted intradermally into the hindflank of 5-8 week old female nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily. Experiments were conducted with Compound A as a single agent as well as Compound A in combination with Compound B. This model can be used to assess the desirability of treating with Compound A in combination with other anti-cancer agents.

**[00352]** MDA-MB-468 human breast adenocarcinoma cells, passage number <6, were maintained and propagated in log-phase growth in Dulbecco's Modification of Eagles's Medium (DMEM; Mediatech) containing L-Glutamine supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37 °C in a humidified, 5% $CO_2$ atmosphere. On day 0, cells were harvested by trypsinization, and 10 x $10^6$ cells (passage 10, 98% viability) in 50% cold Hanks balanced salt

solution/50% Matrigel (100 µL total volume per mouse) were implanted subcutaneously into the mammary fat pads of female nude mice. Experiments were conducted with Compound A as a single agent as well as Compound A in combination with erlotinib. This model can be used to assess the desirability of treating with Compound A in combination with other anti-cancer agents.

**[00353]** Calu-6 human lung anaplastic carcinoma cells were cultured in vitro in DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum (Hyclone), Penicillin-Streptomycin and non-essential amino acids at 37 °C in a humidified, 5% $CO_2$ atmosphere. On day 0, cells were harvested by trypsinization, and $5x10^6$ cells (passage #8, 96% viability) in 0.1 mL ice-cold Hank's balanced salt solution were implanted intradermally in the hind-flank of 5-8 week old female athymic nude mice. A transponder was implanted in each mouse for identification, and animals were monitored daily for clinical symptoms and survival. Body weights were recorded daily. Experiments were conducted with Compound A as a single agent as well as Compound A in combination with carboplatin. This model can be used to assess the desirability of treating with Compound A in combination with other anti-cancer agents.

**[00354]** MCF7 human mammary adenocarcinoma cells were cultured in vitro in DMEM (Cellgro) supplemented with 10% Fetal Bovine Serum (Cellgro), Penicillin-Streptomycin and non-essential amino acids at 37 °C in a humidified 5% $CO_2$ atmosphere. On day 0, cells were harvested by trypsinization, and 5 x $10^6$ cells (passage 10 and 95.4% viability for Study 1, passage 9 and 90% viability for Study 2) in 100 µL of a solution made of 50% cold Hanks balanced salt solution with 50% growth factor reduced matrigel (R&D Systems for Study 1 and Becton Dickinson for Study 2) implanted subcutaneously into the hindflank of female nude mice.

**[00355]** For subcutaneous or intradermal tumors, the mean tumor weight of each animal in the respective control and treatment groups was determined twice weekly during the study. Tumor weight (TW) was determined by measuring perpendicular diameters with a caliper, using the following formula:

$$\text{tumor weight (mg)} = [\text{tumor volume} = \text{length (mm)} \times \text{width}^2 (\text{mm}^2)]/2$$

These data were recorded and plotted on a tumor weight vs. days post-implantation line graph and presented graphically as an indication of tumor growth rates. Percent inhibition of tumor growth (TGI) is determined with the following formula:

$$\left[1 - \left[\frac{(X_f - X_0)}{(Y_f - X_0)}\right]\right] * 100$$

where $X_0$ = average TW of all tumors on group day

$X_f$ = TW of treated group on Day f

$Y_f$ = TW of vehicle control group on Day f

If tumors regress below their starting sizes, then the percent tumor regression is determined with the following formula:

$$\left[\frac{(X_0 - X_f)}{X_0}\right] * 100$$

Tumor size is calculated individually for each tumor to obtain a mean ± SEM value for each experimental group. Statistical significance is determined using the 2-tailed Student's t-test (significance defined as $P<0.05$).

**Biological Examples 11-14**

**[00356]** Compound A is a Compound of Formula I and is an inhibitor of class I PI3-kinases. Compound B is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine.

**Prostate Cancer Xenograft Model – A Compound of Formula I in Combination with Taxol**

**[00357]** Compound A was tested alone and in combination with taxol in a prostate carcinoma tumor model. PC-3 is a human prostate carcinoma cell line that harbors a homozygous deletion mutation in PTEN, which results in constitutive activation of the PI3K pathway. In single-dose pharmacodynamic experiments, oral administration of

Compound A results in a dose-dependent decrease in the phosphorylation of AKT, p70S6K, and S6 in PC-3 tumors grown ectopically in mice. Repeat-dose administration of a Compound A also inhibits the growth of these tumors, but does not induce regressions.

**[00358]** Oral administration of Compound A at 100mg/kg qd or 300 mg/kg biweekly (biw) resulted in substantial tumor growth inhibition in mice. See Figure 1. Comparable tumor growth inhibition was achieved with 7.5 mg/kg taxol administered i.v. twice weekly. While tumor growth was inhibited substantially with Compound A alone, the combination of either dose ofCompound A with taxol was superior to either agent alone and induced significant regression of the tumors. Body weight loss and dose skipping was minimal in all groups, and was not exacerbated in the combination group indicating that the combination was well tolerated. These results support the use of a Compound of Formula I in combination with taxol in tumors with constitutively activated PI3K signaling.

**Prostate Cancer Xenograft Model – A Compound of Formula I in Combination with Rapamycin**

**[00359]** Compound A was tested alone and in combination with rapamycin in a prostate carcinoma tumor model (PC-3 cell line). Oral administration of Compound A at 100mg/kg qd resulted in substantial tumor growth inhibition. See Figure 2. Comparable tumor growth inhibition was achieved with 5 mg/kg rapamycin administered i.p. daily. While tumor growth was inhibited substantially with Compound A alone, the combination of Compound A with rapamycin was superior to either agent alone and induced significant regression of the tumors. Body weight loss and dose skipping was minimal with each agent alone, but body weight loss was exacerbated in the combination group necessitating dose skipping. The fact that tumor regression was observed despite dose skipping suggests that using an intermittent dosing schedule would maintain efficacy and improve tolerability. These results support the use of a Compound of Formula I in combination with rapamycin in tumors with constitutively activated PI3K signaling.

**Non-Small Cell Lung Cancer Xenograft Model – A Compound of Formula I in Combination with Carboplatin**

**[00360]** Compound A was tested both as a single agent and in combination with carboplatin in a NSCLC tumor model.

**[00361]** Calu-6 is a human NSCLC cell line that harbors a heterozygous activating mutation in K-Ras (Q61K). Oral administration of a Compound A at 100mg/kg qd or 300 mg/kg every fourth day (q4d) to mice bearing Calu-6 tumors resulted in substantial tumor growth inhibition. See Figure 3. Both dose schedules resulted in similar inhibition of tumor growth. Significant tumor growth inhibition was also observed with 50 mg/kg carboplatin administered i.v. q4d, but was not as pronounced as with Compound A. While tumor growth was inhibited substantially with Compound A alone, the combination of the two agents was superior to either agent alone and resulted in almost complete inhibition of tumor growth. Body weight loss and dose skipping was minimal in all groups, and was not exacerbated in the combination group indicating that the combination was well tolerated. These results support the use of a Compound of Formula I both as a single agent and in combination with platins in tumors with activating mutations in K-Ras.

**Non-small Cell Lung Cancer Xenograft Model – A Compound of Formula I in Combination with Compound B**

**[00362]** Compound A was tested both as a single agent and in combination with Compound B. The A549 human non-small cell lung carcinoma cell line harbors a homozygous stop mutation in the gene encoding LKB1, and an activating G12S mutation in K-Ras, promoting activation of both PI3K and mTOR. A549 cells also express wild-type EGFR.

**[00363]** As a single agent, Compound B, an inhibitor of EGFR, was orally administered once-daily at 30 mg/kg and Compound A was orally administered either at 30 mg/kg qd or 100 mg/kg q2d. Combination therapies consisted of Compound B with Compound A at 30 mg/kg or 100 mg/kg. Administration of each agent in the combination groups was separated by 6 h. Single agent administration of Compound B for 18 days caused a significant tumor growth inhibition of 80%. See Figure 4a. A significant tumor growth inhibition of 96% was observed with Compound A at 100 mg/kg q2d, whereas

Compound A at 30 mg/kg qd lead to a lower but still significant TGI of 76%. The combination of Compound B 30 mg/kg qd with Compound A 30 mg/kg qd or with Compound A 100 mg/kg q2d resulted in significant efficacy associated with 15% and 39% regression, respectively, which was significantly higher than either of the single agent treatments alone.

**[00364]** As a single agent Compound B dosed at 30 mg/kg qd was generally well tolerated, with a body weight loss of 1.5-6.9% and no dose omission. Administration of Compound A dosed at 30 mg/kg qd was well tolerated with 4 doses skipped at the beginning of the study, which were not compound-related. Compound A dosed at 100 mg/kg q2d was also well tolerated with 1 dose skipped at the beginning of the study, which was not compound-related. The combination of Compound B at 30 mg/kg qd with Compound A at 30 mg/kg qd was fairly well tolerated with body weight loss of 1 to 8% and 2 doses skipped). However, the combination of Compound B at 30 mg/kg qd with Compound A at 100 mg/kg q2d was associated with body weight loss of 2 to 11% and 13 doses skipped within the first 10 days; however, body weights at the end of the study were not significantly different from the vehicle-treated control group. Single agent administration of Compound B and Compound A were well tolerated with minimal dose skipping. When administered in combination, minor body weight loss was observed that necessitated dose skipping primarily in the 100 mg/kg q2d group.

**Breast Cancer Xenograft Model – A Compound of Formula I in Combination with Compound B**

**[00365]** Compound A was tested both as a single agent and in combination with Compound B, an EGFR inhibitor, in a breast tumor model. The MCF7 human breast carcinoma cell line harbors a heterozygous, activating mutation in PI3K (PI3KCA/E545K) and expresses wild-type EGFR.

**[00366]** Compound B was administered orally once-daily (qd) at 30 mg/kg, and Compound A was administered once-daily at 30 mg/kg or once every other day (q2d) at 100 mg/kg. Combination therapies consisted of Compound B together with Compound A at 30 mg/kg qd or 100 mg/kg q2d. Single agent administration of Compound B at 30 mg/kg qd for 14 days caused a tumor growth inhibition of 38%-61%. See Figures 4b-1 and 4b-2. A significant tumor growth inhibition of 83%-91% was observed with

Compound A at 100 mg/kg q2d, whereas Compound A at 30 mg/kg qd lead to a lower but still significant TGI of 57%. The combination of Compound B at 30 mg/kg qd with Compound A at 100 mg/kg q2d resulted in a significant efficacy associated with 16-22% regression, which was significantly higher than either of the single agent treatments alone. Combining Compound B at 30 mg/kg qd with Compound A at 30 mg/kg qd lead to a lower but still significant tumor growth inhibition of 66%, but did not add any benefit to the anti-tumor efficacy of the single treatments.

**[00367]** As a single agent Compound B dosed at 30 mg/kg qd was generally well tolerated, with a non significant final body weight loss of 4.5 to 6.1% and 7 to 13 dose omissions. Administration of Compound A at 30 mg/kg qd and 100 mg/kg q2d was well tolerated with minimal dose skipping and body weight loss. The combination of Compound B at 30 mg/kg qd with Compound A at 30 mg/kg qd lead to a body weight loss of 4 to 13% throughout the study and 14 doses skipped mostly within the first 9 days. The combination of Compound B at 30 mg/kg qd with Compound A at 100 mg/kg q2d was associated with a body weight loss of 3.7 to 13% throughout the study and 20 to 32 dose omissions.

**Breast Cancer Xenograft Model – A Compound of Formula I in Combination with Erlotinib**

**[00368]** Compound A was tested both as a single agent and in combination with erlotinib, in an erolitinib-resistant tumor model with elevated PI3K signaling.

**[00369]** MDA-MB-468 is a human breast carcinoma cell line that has an increase in the copy number of the EGFR gene and a homozygous deletion of PTEN. In vitro treatment of these cells with EGFR inhibitors such as erlotinib inhibits EGFR activity but fails to downregulate the PI3K pathway. Oral administration of erlotinib at 100 mg/kg qd to mice bearing MDA-MB-468 tumors resulted in significant but incomplete tumor growth inhibition. See Figure 5. Oral administration of Compound A at 100mg/kg qd resulted in a similar level of tumor growth inhibition. While tumor growth was inhibited substantially with Compound A alone, the combination of the two agents was superior to either agent alone and resulted in a regression of the tumors.


**[00370]** Mice administered Compound A at 100 mg/kg qd exhibited a modest (~3%) loss in body weight comparable to vehicle controls. Mice administered erlotinib exhibited

an apparent decrease in their rate of body weight gain relative to vehicle controls. Coadministration with erlotinib resulted in a substantial loss in body weight in mice treated with Compound A (19% body weight loss from start of dosing). Consistent with these data, only minimal dose-skipping was required when Compound A was administered as monotherapy (1-3 doses skipped), but substantial dose-skipping was required for Compound A when erlotinib was coadministered. The fact that tumor regression was observed despite dose skipping suggests that use of an intermittent dosing schedule could maintain efficacy and improve tolerability. These results support the use of a Compound of Formula I in combination with erlotinib in tumors expressing EGF receptors and harboring PTEN deletions.

**[00371]** The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

**What is claimed is:**

1. A method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a compound of Formula I:



I

or a single isomer thereof where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof; or administering a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula I and at least one of a pharmaceutically acceptable carrier, excipient, or diluent in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more of the hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation where the Compound of Formula I is that wherein:

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; and where each $R^1$ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen or halo;

$R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$

together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

B is phenyl substituted with $R^{3a}$ and optionally further substituted with one, two, or three $R^3$; or

B is heteroaryl optionally substituted with one, two, or three $R^3$;

$R^{3a}$ is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where $R^8$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where $R^9$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{9a}$ is hydrogen, $C_2-C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl,

heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$ where $R^{10a}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and $R^{10}$ and $R^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and $R^{11}$ and $R^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

f) $-C(O)R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl;

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})-C_1-C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})-C_1-C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2-C_1-C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)-C_1-C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$ where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

r) $-C_0-C_6$-alkylene-$N(R^{23})-C_1-C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)-C_1-C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl; and

where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

each $R^3$ (when $R^3$ is present) is independently alkyl; alkenyl; alkynyl; halo; hydroxy; oxo; alkoxy; cyano; hydroxyamino; carboxy; alkoxycarbonyl; amino; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently

selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) -C(O)NR$^{8}$R$^{8a}$ where R$^{8}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R$^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R$^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) -NR$^{9}$C(O)R$^{9a}$ where R$^{9}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and R$^{9a}$ is hydrogen, $C_2$-$C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in R$^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) -C(O)N(R$^{10}$)-$C_1$-$C_6$-alkylene-N(R$^{10a}$)R$^{10b}$ where R$^{10a}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or hydroxyalkyl and R$^{10}$ and R$^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, or hydroxyalkyl;

e) -NR$^{11}$C(O)NR$^{11a}$R$^{11b}$ where R$^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and R$^{11}$ and R$^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminooalkyl, dialkylaminoalkyl;

f) -C(O)$R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) -$NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl);

h) -$C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

i) -$S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

j) -$C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) -$N(R^{17})C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

m) -$N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

n) -$C(O)N(R^{19})$-$C_1$-$C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) -$N(R^{20})C(O)$-$C_1$-$C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

p) -$NR^{21}S(O)_2$-$C_1$-$C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;

q) -$N(R^{22})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

r) -$C_0$.$C_6$-alkylene-$N(R^{23})$-$C_1$.$C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

s) -$NR^{24}C(O)$-$C_1$.$C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;

wherein each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

provided that when $R^{50}$ and $R^{52}$ are hydrogen, $R^{51}$ is hydrogen or methyl, $R^{53}$ is hydrogen or methoxy, and $R^{54}$ is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one $R^3$ where $R^3$ is halo.

2. The method of Claim 1 where the cancer is selected from breast cancer, colon cancer, rectal cancer, endometrial cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, and thyroid carcinoma.

3. The method of Claim 1 or 2 where the treatment is one or two chemotherapeutic agents.

4. The method of Claims 1 or 2 where the treatment is one antibody selected from an EGFR antibody and an ErbB2 antibody, or the treatment is one or two chemotherapeutic agents independently selected from rapamycin, a rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor.

5. The method of Claim 4 where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, paclitaxel, carboplatin, lapatinib, erlotinib, and *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

6. The method of Claim 3 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is an EGFR inhibitor.

7. The method of Claim 3 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is a platin.

8. The method of Claim 3 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is a taxane.

9. The method of Claim 3 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is rapamycin or a rapamycin analogue.

10. The method of Claim 3 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

11. The method of Claim 1 where the cancer is prostate cancer and the treatment is one or two chemotherapeutic agents selected from rapamycin, paclitaxel, and docetaxel.

12. The method of Claim 1 where the cancer is breast cancer and the treatment is one chemotherapeutic agent and the chemotherapeutic agent is lapatinib.

13. The method of Claim 1 where the cancer is breast cancer and the treatment is one chemotherapeutic agent and the chemotherapeutic agent is erlotinib.


14. The method of Claim 1 where the cancer is breast cancer and the treatment is one chemotherapeutic agent and the chemotherapeutic agent is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

15. The method of Claim 1 where the cancer is non-small cell lung cancer and the treatment is one chemotherapeutic agent where the chemotherapeutic agent is carboplatin.

16. The method of Claim 1 where the cancer is non-small cell lung cancer and the treatment is one chemotherapeutic agent where the chemotherapeutic agent is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically

acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

17. The method of Claim 1 where the Compound of Formula I is according to Formula I(a)



I(a)

where

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; and where each $R^1$ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen or halo;

$R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

$R^3$ is not present or $R^3$ is alkyl; and

$R^{3a}$ is $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; where each of the alkylene in $R^{3a}$ is

independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and

where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

18. The method of Claim 1 or 2 where the Compound of Formula I is selected from:

| |
|---|
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-2,5-dimethylthiophene-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-2,5-dichlorothiophene-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-chloropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3,5-dimethylisoxazole-4-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-1,3-dimethyl-1*H*-pyrazole-4-sulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-propylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pent-4-enamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)-1-methylethyl]benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$-methylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide; |
| 5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-fluorobenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-pyrrolidin-3-ylbenzamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyrrolidin-1-ylethyl)benzamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(2-chloro-5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-2-methylalaninamide; |
| *N*-(2-aminoethyl)-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-D-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-acetyl-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(piperidin-2-ylmethyl)benzamide; |
| *N*-(5-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylazetidin-3-yl)benzamide; |
| 2-azetidin-1-yl-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide; |
| *N*-(3-{[(3-{[2-bromo-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$- |

| |
|---|
| methylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-piperidin-1-ylethyl)benzamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[6-(methyloxy)quinolin-8-yl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(diethylamino)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylpiperidin-3-yl)benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-D-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-3-ylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-methylpiperidin-2-yl)methyl]benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-cyanobenzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-serinamide; |
| (2S)-2-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide; |
| *N*-{2-[bis(2-hydroxyethyl)amino]ethyl}-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-ethylpiperidin-3-yl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,2-dimethylalaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-D-alaninamide; |

| |
|---|
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| 3-[(3-aminopyrrolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-bromo-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-propylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-L-alaninamide; |
| *N*-(5-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-beta-alaninamide; |
| 5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-(methyloxy)benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(hydroxyamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-3-carboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-morpholin-4-ylethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-ethylpyrrolidin-2-yl)methyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methyl-1,4-diazepan-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-[(4-amino-3-oxopyrazolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| (2S)-2-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-hydroxypropyl)glycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluoroethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2-methylpropyl)oxy]glycinamide; |
| 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(cyclopropylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-L-alaninamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methylbenzamide; |
| 3-[(3-aminoazetidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-3-ylmethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-2-carboxamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)morpholine-4-carboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N~6~,N~6~-dimethyl-L-lysinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1*H*-imidazol-4-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-2-ylmethyl)benzamide; |
| 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-hydroxyethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-oxopyrazolidin-4-yl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-methylpropyl)glycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(1*H*-imidazol-4-ylmethyl)azetidine-3-carboxamide; |
| *N*-(5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(1*H*-imidazol-4-yl)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-ethylazetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$- |

| |
|---|
| (1-methylpyrrolidin-3-yl)glycinamide; |
| *N*-(3-{[(2-{[3,5-bis(methyloxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(methylamino)benzenesulfonamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3S)-3-hydroxypyrrolidin-1-yl]acetamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-butylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-piperidin-1-ylazetidin-1-yl)acetamide; |
| 3-[(aminocarbonyl)amino]-*N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-hydroxycyclopropanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-4-ylmethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,2-dimethylhydrazino)acetamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[({[2-(dimethylamino)ethyl]amino}carbonyl)amino]benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-(1-methylpyrrolidin-3-yl)benzamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(diethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3-fluoro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-hydroxyacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridazine-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylpiperidine-4-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-1*H*-pyrrol-1-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-methylethyl)glycinamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide; |

| |
|---|
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-pyrrolidin-1-ylpropyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)pyrrolidin-1-yl]acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methyloxy)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]glycinamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide; |
| 2-(dimethylamino)ethyl(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbamate; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1,1-dimethylethyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-ethylbenzamide; |
| 3-[(3-aminopiperidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(1-{[2-(dimethylamino)ethyl]amino}ethyl)benzenesulfonamide; |
| $N^2$-methyl-*N*-(3-{[(3-{[3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-2-carboxamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)isoxazole-5-carboxamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2,2,2-trifluoroethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-piperidin-1-ylpropanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-morpholin-4-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclopentanecarboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[(2,2-dimethylhydrazino)carbonyl]benzenesulfonamide; |
| 3-acetyl-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(1*H*-imidazol-1- |

| |
|---|
| yl)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-hydroxypyridine-2-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(diethylamino)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-fluoro-4-hydroxyphenyl)glycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-N'-[2-(dimethylamino)ethyl]benzene-1,3-disulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)butanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-[(difluoromethyl)oxy]benzenesulfonamide; |
| methyl*N*-[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methylthio)ethyl]benzamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-N'-[3-(dimethylamino)propyl]benzene-1,3-disulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(ethylthio)ethyl]benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-ethylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyridin-4-ylethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(ethyloxy)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(furan-2-ylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrimidine-5-carboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(2H-tetrazol-5-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-pyrrole-2-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-morpholin-4-ylpropyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(1-methylethyl)glycinamide; |
| *N*-(3-{[(3-{[3-fluoro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-4- |

| |
|---|
| carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-diethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylisoxazol-5-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(methyloxy)propyl]benzamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[2-methyl-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-hydroxyphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-1*H*-pyrrole-2-carboxamide; |
| 4-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydro-2H-pyran-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methylamino)piperidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-piperidin-1-ylacetamide; |
| *N*-(4-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-L-prolinamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(methylsulfonyl)benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]-*N*-methylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(propyloxy)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylcarbonyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(phenylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-3-carboxamide; |
| ethyl*N*-[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-{3-[(1-methylethyl)oxy]propyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-4-ylacetamide; |

| |
|---|
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-piperidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-prop-2-en-1-ylglycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(phenylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-propanoylazetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(methyloxy)ethyl]glycinamide; |
| 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-4-carboxamide; |
| *N*-{[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)amino](dimethylamino)methylidene}-*N*-methylmethanaminium; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-[(trifluoromethyl)oxy]benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpyrrolidin-1-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-1-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-3-carboxamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[1-methyl-2-(methyloxy)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-chloropyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-2-ylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(dimethylamino)piperidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-3-ylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-chlorophenyl)acetamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[3-(dimethylamino)propyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-(2-hydroxyethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(phenylmethyl)pyrrolidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-4-carboxamide; |
| $N^2$-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylbenzamide; |
| 1,1-dimethylethyl{2-[(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]-2-oxoethyl}carbamate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-morpholin-4-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-benzodioxole-5-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-({[2-(methyloxy)phenyl]methyl}oxy)glycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-({2-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-4-carboxamide; |
| *N*-(3-{[(3-{[4-fluoro-3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(3,4-dichlorophenyl)piperazin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-pyridin-3-ylpropanamide; |
| *N*-[3-(butyloxy)propyl]-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-fluorophenyl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[4-(diethylamino)-1-methylbutyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-methyl-1- |

| |
|---|
| phenylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylcyclopropanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methyl-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-ethylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-bromothiophene-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpropanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pentanamide |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(ethyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(dimethylamino)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperidin-1-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-oxo-2-piperidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-propylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrazine-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(4- |

| |
|---|
| fluorophenyl)oxy]acetamide; |
| 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(4-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-phenylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-prop-2-en-1-ylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methyloxy)propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylfuran-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(phenylmethyl)oxy]glycinamide; |
| *N*-{3-[({3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-chlorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylcyclopropanecarboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]amino}pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,4-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-{[2-(methylthio)phenyl]methyl}glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-fluorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-(1-methylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-thiazole-4-carboxamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(phenylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-thienylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(pyridin-2-ylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-chloro-4-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpentanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-chlorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(2-methylphenyl)oxy]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-cyclohexylacetamide; |
| (1R,2R)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylcyclopropanecarboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[3-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluoro-4-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-fluorophenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,4-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclohexanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-fluorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-chlorophenyl)acetamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-phenylpropyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2,4-dimethylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(methyloxy)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3,4-dihydroisoquinolin-2(1*H*)-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-oxopiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluorobenzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]oxy}pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-phenylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-6-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-3-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(1-methylethyl)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[2-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylpentanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylmorpholin-4-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[4-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-cyclopentyl-$N^2$-prop-2-en-1-ylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-[2-(methyloxy)ethyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-cyclopropyl-4-oxobutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[3-(1,1-dimethylethyl)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(cyclopropylmethyl)-$N^2$-propylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2- |

| |
|---|
| oxocyclopentyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(4-chlorophenyl)glycinamide; |
| 2-(1,4'-bipiperidin-1'-yl)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-cyclopentylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylphenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(5-fluoro-2-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,3-dimethylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-chlorophenyl)glycinamide |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[2-(piperidin-1-ylmethyl)piperidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluoro-3-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,3-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(phenyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2,3-dimethylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-5-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-{[(4-methylphenyl)methyl]oxy}glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(1-methylethyl)piperazin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-fluorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-propylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3-methylphenyl)oxy]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(hydroxymethyl)piperidin-1-yl]acetamide; |

| |
|---|
| 1,1-dimethylethyl2-{[(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]carbonyl}piperidine-1-carboxylate; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(pyridin-3-ylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-phenylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-{[2-(methyloxy)ethyl]oxy}acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-cyclopentylpropanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,5-dichlorobenzamide; |
| 2-(4-acetylpiperazin-1-yl)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-cyclohexyl-$N^2$-ethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-methylisoxazole-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylpyridine-2-carboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)pyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,5-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1,3-thiazolidin-3-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-pyridin-4-ylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(2-methylpropyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formyl-1,4-diazepan-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-phenylcyclopropanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,6-dimethylmorpholin-4-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylpyrrolidin-1-yl)acetamide; and |

*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide;

where the Compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

19. The method of Claims 1, 2, 4, 17, or 18 where the treatment is one antibody selected from an EGFR antibody and an ErbB2 antibody, or the treatment is one or two chemotherapeutic agents independently selected from rapamycin, a rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor.

20. The method of Claim 19 where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, paclitaxel, carboplatin, lapatinib, erlotinib, and *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

21. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

22. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is erlotinib.

23. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is lapatinib.


24. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is carboplatin.

25. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is paclitaxel.

26. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is rapamycin.

27. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one antibody selected from bevacizumab, trastuzumab, cetuximab, and panitumumab.

28. The method of Claim 1, 2, 3, 4, 17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is of formula 100:



**100**

where q is 1, 2, or 3; E is $-NR^9-$, -O-, or absent and Y is $-CH_2CH_2-$, $-CH_2-$, or absent provided that when E is $-NR^9-$ or -O-, then Y is $-CH_2CH_2-$; $R^2$ is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, and lower alkyl; $R^8$ is selected from -H, lower alkyl, $-C(O)OR^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$; $R^9$ is hydrogen or lower alkyl; $R^3$ is hydrogen or $R^4$; $R^4$ is selected from lower alkyl, aryl, lower arylalkyl, heterocyclyl, and lower heterocyclylalkyl; or $R^3$ and $R^4$, when taken together with a common nitrogen to which they are attached, form a five- to seven-membered heterocyclyl, said five- to seven-membered heterocyclyl optionally containing one or more additional heteroatom selected from N, O, S, and P; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt, additionally optionally as a solvate, and additionally as a hydrate thereof.





**Figure 1.** Compound A + Taxol in PC-3 Prostate Carcinoma Tumor Model





**Figure 2.** Compound A + Rapamycin in PC-3 Prostate Carcinoma Tumor Model





**Figure 3.** Compound A + Carboplatin in Calu-6 NSCLC Tumor Model





**Figure 4a.** Compound A + Compound B in A549 Non-small Cell Lung Cancer Tumor Model

**Figure 4b-1.** Compound A + Compound B in MCF7 Breast Cancer Tumor Model (Study 1)






**Figure 4b-2.** Compound A + Compound B in MCF7 Breast Cancer Tumor Model (Study 2)







**Figure 5.** Compound A + Erlotinib in MDA-MB-468 Breast Carcinoma Tumor Model

# USO DE COMPUESTOS INHIBIDORES DE QUINAXOLINA DE PI3K-ALFA PARA EL TRATAMIENTO DEL CÁNCER

## Referencia cruzada a solicitudes relacionadas

**[0001]** Los solicitantes reivindican prioridad bajo 35 U.S.C. 119(e) a la solicitud provisional en trámite No. 60/923,164 presentada el 11 de abril de 2007, cuya descripción se incorpora en la presente como referencia en su totalidad

### CAMPO DE LA INVENCIÓN

**[0002]** Esta invención se refiere a los métodos de tratar el cáncer con un compuesto que inhibe la actividad enzimática de lípido quinasa y la resultante modulación de las actividades celulares (tales como proliferación, diferenciación, muerte celular programada, migración, quimioinvasión y metabolismo) en combinación con agentes anticáncer.

### ANTECEDENTES DE LA INVENCIÓN

**[0003]** Las mejoras de la especificidad de los agentes usados para tratar diversos estados de enfermedad tales como cáncer, enfermedades metabólicas e inflamatorias es de considerable interés a causa de los beneficios terapéuticos que debería realizar si se pueden reducir los efectos secundarios asociados con la administración de estos agentes. En forma tradicional, las mejoras drásticas en el tratamiento del cáncer están asociados con la identificación de los agentes terapéuticos que actúan mediante mecanismos nuevos.

**[0004]** La fosfatidilinositol 3-quinasa (PI3K o PIK3CA) está compuesta de una subunidad reguladora de 85 kDa y una subunidad catalítica de 110 kDa. La proteína codificada por este gen representa la subunidad

catalítica, que usa ATP para fosforilar PtdIns, PtdIns4P y PtdIns(4,5)P2. PTEN, un supresor tumor que inhibe el crecimiento celular a través de múltiples mecanismos, puede desfosforilar PIP3, el principal producto de PIK3CA. PIP3, a su vez, es necesario para la translocación de la proteína quinasa B (AKT1, PKB) en la membrana celular, donde se fosforila y activa por quinasas corriente arriba. El efecto de PTEN en la muerte celular está mediado a través de la vía PIK3CA/AKT1.

**[0005]** PI3Kα ha sido implicado en el control de los procesos de reorganización citoesquelética, apoptosis, tráfico vesicular, proliferación y diferenciación. El aumento de número de copias y la expresión de PIK3CA o las mutaciones por activación en la subunidad catalítica p110a de PIK3CA están asociadas con numerosas neoplasias tales como cáncer ovárico (Campbell et al., *Cancer Res* 2004, *64,* 7678-7681; Levine et al., *Clin Cancer Res* 2005, *11,* 2875-2878; Wang et al., *Hum Mutat* 2005, *25,* 322; Lee et al., *Gynecol Oncol* 2005, *97,* 26-34), cáncer cervical, cáncer de mamas (Bachman, et al. *Cancer Biol Ther* 2004, *3,* 772-775; Levine, et al., supra; Li et al., *Cáncer de mamas Res Treat* 2006, *96,* 91-95; Saal et al., *Cancer Res* 2005, *65,* 2554-2559; Samuels y Velculescu, *Cell Cycle* 2004, *3,* 1221-1224), colocáncer rectal (Samuels, et al. *Science* 2004, *304,* 554; Velho et al. *Eur J Cancer* 2005, *41,* 1649-1654), cáncer de endometrio (Oda et al. *Cancer Res.* 2005, *65,* 10669-10673), carcinomas gástricas (Byun et al., *Int J Cancer* 2003, *104,* 318-327; Li et al., supra; Velho et al., supra; Lee et al., *Oncogene* 2005, *24,* 1477-1480), carcinoma hepatocelular (Lee et al., *id.*), small y cáncer pulmonar de células no pequeñas (Tang et al., *Lung Cancer* 2006, *51,* 181-191; Massion et al., *Am J Respir Crit Care Med* 2004, *170,* 1088-1094),

carcinoma tiroideo (Wu et al., *J Clin Endocrinol Metab* 2005, *90,* 4688-4693), leucemia mielógena aguda (AML) (Sujobert et al., *Blood* 1997, *106,* 1063-1066), leucemia mielógena crónica (CML) (Hickey y Cotter *J Biol Chem* 2006, *281,* 2441-2450), y glioblastomas (Hartmann et al. *Acta Neuropathol (Berl)* 2005, *109,* 639-642; Samuels et al., supra).

**[0006]** En vista del papel importante del PI3K-α en los procesos biológicos y estados de enfermedad, se desean inhibidores y/o moduladores de esta lípido quinasa. Además, está bien establecido que los tratamientos de combinación con mecanismos de acción diferentes a menudo producen aumento de actividad antitumoral en comparación con los tratamientos únicos administrados solos. Esto es verdadero para las combinaciones de quimioterapias (por ejemplo, Kyrgiou M. et. al. *J Natl Cancer Inst* 2006, *98,* 1655) y combinaciones de anticuerpos y quimioterapia (por ejemplo, Pasetto LM et. al. *Anticancer Res* 2006, *26,* 3973.

**[0007]** Por ejemplo, la activación de la vía PI3K contribuye a la resistencia de las células tumorales humanas a una amplia variedad de los agentes quimioterapéuticos, que incluyen agentes estabilizantes de microtúbulos tales como taxol (Brognard, J., et. al. *Cancer Res* 2001, *61,* 3986-3997; Clark, A. S., et. al. *Mol Cancer Ther* 2002, *1,* 707-717; Kraus, A. C., et. al. *Oncogene* 2002, *21,* 8683-8695; Krystal, G. W., et. al. *Mol Cancer Ther* 2002, *1,* 913-922; y Yuan, Z. Q., et. al. *J Biol Chem* 2003, *278,* 23432-23440). Taxol es ampliamente utilizado para tratar cánceres avanzados que incluyen carcinoma prostáticos, que con frecuencia albergan supresiones en el gen de PTEN, lo que produce una elevada señalización corriente abajo de PI3K. Varios estudios

preclínicos sugieren que la inhibición de señalización corriente abajo de PI3K restaura o aumenta la capacidad de los agentes quimioterapéuticos tales como taxol destruir células cancerosas (Brognard, J., et. al. *Cancer Res* 2001, *61*, 3986-3997; Clark, A. S., et. al. *Mol Cancer Ther* 2002, *1*, 707-717; Kraus, A. C., et. al. *Oncogene* 2002, *21*, 8683-8695; Krystal, G. W., et. al. *Mol Cancer Ther* 2002, *1*, 913-922; y Saga, Y., et. al. *Clin Cancer Res* 2002, *8*, 1248-1252).

**[0008]** La rapamicina, otro agente quimioterapéutico, es un potente inhibidor del complejo mTOR/Raptor. La inhibición de mTOR/Raptor impide la fosforilación de p70S6K y S6, pero también lleva a la reducción de un bucle de retroalimentación negativo proveniente de p70S6K que sirve para regular por disminución PI3K (Sarbassov, D. D., et. al. *Science* 2005, *307*, 1098-1101). Como resultado, el tratamiento con rapamicina puede producir regulación por aumento de PI3K y aumento de fosforilación de AKT (O'Donnell, A., et. al. documento presentado en Proc Am Soc Clin Oncol. 2003; y O'Reilly, K. E., et. al. *Cancer Res* 2006, *66*, 1500-1508). En consecuencia, la combinación de la rapamicina con los inhibidores de PI3K puede aumentar la eficacia de la rapamicina (Powis, G. et. al. *Clinical Cancer Research* 2006, *12*, 2964-2966; Sun, S.-Y., et. al. *Cancer Research* 2005, *65*, 7052-7058).

**[0009]** Un cantidad creciente de datos clínicos y preclínicos indica que la activación de la vía de PI3K confiere resistencia a los inhibidores de EGFR tales como erlotinib (Bianco, R., et. al. *Oncogene* 2003, *22*, 2812-2822; Chakravarti, A., et. al. *Cancer Res* 2002, *62*, 200-207; y Janmaat, M. L., et. al. *Clin Cancer Res* 2003, *9*, 2316-2326). Los pacientes con NSCLC con mutaciones K-Ras y los pacientes con glioblastoma con supresiones

PTEN no pudieron responder a erlotinib, probablemente debido a la activación genética de la vía PI3K (Mellinghoff, I. K., et. al. *N. Eng. J Med.* 2006, *353,* 2012-2024). Los estudios preclínicos han demostrado que la regulación por disminución de la señalización de PI3K en las células tumorales que expresan EGFR confiere aumento de sensibilidad a los inhibidores de EGFR (Ihle, N. T., et. al. *Mol Cancer Ther* 2005, *4,* 1349-1357). En consecuencia, es conveniente el tratamiento del cáncer con un inhibidor de PI3K en combinación con un inhibidor de EGFR, tal como erlotinib.

**[0010]** La activación de la vía de PI3K también contribuye a la resistencia de las células tumorales humanas a los agentes que dañan el ADN, tales como los platinos. Varios estudios preclínicos sugieren que la inhibición de la señalización corriente debajo de PI3K restaura o aumenta la capacidad de los agentes quimioterapéuticos tales como platinos de destruir células tumorales (Brognard, J., et. al. *Cancer Res* 2001, *61,* 3986-3997; y Yuan, Z. Q., et. al. *J Biol Chem* 2003, *278,* 23432-23440). El carboplatino es ampliamente usado para tratar cánceres avanzados que incluyen carcinomas pulmonares de células no pequeñas (NSCLC), que a menudo albergan mutaciones activadoras en el gen K-Ras, lo que produce la activación de PI3K (Aviel-Ronen S., et. al. *Clin Lung Cancer* 2006, *8,* 30-38). Los pacientes NSCLC con mutaciones K-Ras no responden a los inhibidores de EGFR tales como Tarceva, y en consecuencia representan una necesidad médica insatisfecha significativa (Janne PA, et. al. *J Clin Oncology* 2005, *23,* 3227-3234). En consecuencia, el tratamiento de NSCLC con un agente de que daña el ADN tal como un platino en combinación con un

inhibitor de PI3K es conveniente a luz de la falta de tratamientos eficaces.


**[0011]** Los tratamientos que combinan un inhibidor de PI3K-α con otros agentes anti-cáncer son convenientes y necesarios.

## SÍNTESIS DE LA INVENCIÓN

**[0012]** A continuación solo se sintetizan ciertos aspectos de la invención y no consideran de naturaleza limitante. Estos aspectos y otros aspectos y formas de realización se describen más completamente más abajo. Todas las referencias mencionadas en esta memoria descriptiva se incorporan en la presente como referencia en su totalidad. En el caso de una discrepancia entre la descripción expresa de esta memoria descriptiva y las referencias incorporadas por referencia, regirá la descripción expresa de esta memoria descriptiva.

**[0013]** Las composiciones de la invención se usan para tratar enfermedades asociadas con actividades celulares anormales o no reguladas. Los estados de enfermedad que se pueden tratar por los métodos y composiciones provistos en la presente incluyen cáncer. La invención se refiere a los métodos de tratar estas enfermedades por la administración de un compuesto de Fórmula I o II en combinación con uno o más tratamientos.

**[0014]** Un aspecto de la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I:



I

o un isómero simple de este donde el compuesto está opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este; o administrar una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de Fórmula I y un portador, excipiente o diluyente farmacéuticamente aceptable en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, uno o más agentes quimioterapéuticos, una o más terapias hormonales, uno o más anticuerpos, una o más inmunoterapias, terapia de yodo radiactivo, y radiación, donde el Compuesto de Fórmula I es aquel donde:

$W^1$, $W^2$, $W^3$, y $W^4$ son $-C(R^1)=$; o uno o dos de $W^1$, $W^2$, $W^3$, y $W^4$ son de modo independiente $-N=$ y los restantes son $-C(R^1)=$; y donde cada $R^1$ es de modo independiente hidrógeno, alquilo, haloalquilo, nitro, alcoxi, haloalcoxi, halo, hidroxi, ciano, amino, alquilamino, o dialquilamino;

$R^{51}$ es hidrógeno o alquilo;

$R^{52}$ es hidrógeno o halo;

$R^{50}$, $R^{53}$, y $R^{54}$ son de modo independiente hidrógeno, alquilo, alquenilo, halo, haloalquilo, haloalquenilo, hidroxi, alcoxi, alqueniloxi, haloalcoxi, nitro, amino, alquilamino, dialquilamino, $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-

$N(R^{55a})R^{55b}$, alquilcarbonilo, alquenilcarbonilo, carboxi, alcoxicarbonilo, ciano, alquiltio, $-S(O)_2NR^{55}R^{55a}$, o alquilcarbonilamino y donde $R^{55}$ y $R^{55b}$ son de modo independiente hidrógeno, alquilo, o alquenilo y $R^{55a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi; o $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 5 o 6 miembros o heterocicloalquilo de 5 o 6 miembros;

B es fenilo sustituido con $R^{3a}$ y opcionalmente también sustituido con uno, dos o tres $R^3$; o

B es heteroarilo opcionalmente sustituido con uno, dos o tres $R^3$;

$R^{3a}$ es ciano; hidroxiamino; carboxi; alcoxicarbonilo; alquilamino; dialquilamino; alquilcarbonilo; haloalcoxi; alquilsulfonilo; aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; o

a) $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$ donde $R^7$ es hidrógeno, alquilo, o alquenilo y $R^{7a}$ y $R^{7b}$ son de modo independiente hidrógeno, alquilo, alquenilo, hidroxialquilo, haloalquilo, alcoxi, alcoxialquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, arilalquilo, o arilalquiloxi y donde los anillos arilo, cicloalquilo, heterocicloalquilo y heteroarilo en $R^{7a}$ y $R^{7b}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, amino, alquilamino, dialquilamino, hidroxi, halo, alcoxi, alquiltio, y oxo);

b) $-C(O)NR^8R^{8a}$ donde $R^8$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{8a}$ es

hidrógeno, alquilo, alquenilo, hidroxialquilo, cianoalquilo, alcoxialquilo, alquiltioalquilo, heterocicloalquilo, heterocicloalquilalquilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo y donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{8a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, halo, haloalquilo, haloalcoxi, hidroxi, hidroxialquilo, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxicarbonilo, y -C(O)H;

c) $-NR^9C(O)R^{9a}$ donde $R^9$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{9a}$ es hidrógeno, alquilo C2-$C_6$, alquenilo, hidroxialquilo, alcoxialquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo; donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{9a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, hidroxi, hidroxialquilo, halo, haloalquilo, haloalcoxi, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, alcoxicarbonilo, -C(O)H, arilo (opcionalmente sustituido con uno o dos halo), arilalquilo, heteroarilo, heteroarilalquilo, heterocicloalquilo,

heterocicloalquilalquilo, ciloalquilo, ciloalquilalquilo, y cicloalquilcarbonilo;

d) $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$ donde $R^{10a}$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, o hidroxialquilo y $R^{10}$ y $R^{10b}$ son de modo independiente hidrógeno, alquilo, alquenilo, haloalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, o hidroxialquilo;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi y $R^{11}$ y $R^{11b}$ son de modo independiente hidrógeno, alquilo, alquenilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo;

f) $-C(O)R^{12}$ donde $R^{12}$ es heterocicloalquilo opcionalmente sustituido con 1, 2, o 3 grupos seleccionados de alquilo, oxo, amino, alquilamino, y heterocicloalquilalquilo;

g) $-NR^{13}C(O)OR^{13a}$ donde $R^{13}$ es hidrógeno, alquilo, o alquenilo y $R^{13a}$ es aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, arilo, o arilalquilo;

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ donde $R^{14}$, $R^{14a}$, y $R^{14b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

i) $-S(O)_2N(R^{15})$-alquilen $C_1$-$C_6$-$N(R^{15a})R^{15b}$ donde $R^{15}$, $R^{15a}$, y $R^{15b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

j) $-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$ donde $R^{16}$ es hidrógeno, alquilo, o alquenilo y $R^{16a}$ es alquilo o alquenilo;

k) heteroarilo opcionalmente sustituido con uno o dos aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ donde $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, y $R^{17d}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

m) $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$ donde $R^{18a}$ es hidrógeno, alquilo, alquenilo, o alcoxi y $R^{18}$ y $R^{18b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

n) $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$ donde $R^{19}$ es hidrógeno, alquilo, o alquenilo y $R^{19a}$ es amino, alquilamino, dialquilamino, o heterocicloalquilo;

o) $-N(R^{20})C(O)$-alquilen $C_1$-$C_6$-$C(O)R^{20a}$ donde $R^{20}$ es hidrógeno, alquilo, o alquenilo y $R^{20a}$ es cicloalquilo o heterocicloalquilo;

p) $-NR^{21}S(O)_2$-alquilen $C_1$-$C_6$-$N(R^{21b})R^{21a}$ donde $R^{21}$ es hidrógeno, alquilo, o alquenilo y $R^{21a}$ y $R^{21b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

q) $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$ donde $R^{22}$, $R^{22a}$ y $R^{22b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

r) -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$ donde $R^{23}$, $R^{23a}$ y $R^{23b}$ son de modo independiente hidrógeno, alquilo, o alquenilo; o

s) $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$ donde $R^{24}$ es hidrógeno, alquilo, o alquenilo y $R^{24a}$ es alcoxialquilo o arilo opcionalmente sustituido con uno o dos halo o alquilo; y

donde cada alquileno en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, amino, alquilamino, y dialquilamino; y

cada $R^3$ (cuando $R^3$ está presente) es de modo independiente alquilo; alquenilo; alquinilo; halo; hidroxi; oxo; alcoxi; ciano; hidroxiamino; carboxi; alcoxicarbonilo; amino; alquilamino; dialquilamino; alquilcarbonilo; haloalcoxi; alquilsulfonilo; aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; o

a) $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$ donde $R^7$ es hidrógeno, alquilo, o alquenilo y $R^{7a}$ y $R^{7b}$ son de modo

independiente hidrógeno, alquilo, alquenilo, hidroxialquilo, haloalquilo, alcoxi, alcoxialquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, arilalquilo, o arilalquiloxi y donde los anillos arilo, cicloalquilo, heterocicloalquilo y heteroarilo en $R^{7a}$ y $R^{7b}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, amino, alquilamino, dialquilamino, hidroxi, halo, alcoxi, alquiltio, y oxo);

b) $-C(O)NR^8R^{8a}$ donde $R^8$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{8a}$ es hidrógeno, alquilo, alquenilo, hidroxialquilo, cianoalquilo, alcoxialquilo, alquiltioalquilo, heterocicloalquilo, heterocicloalquilalquilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo y donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{8a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, halo, haloalquilo, haloalcoxi, hidroxi, hidroxialquilo, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxicarbonilo, y $-C(O)H$;

c) $-NR^9C(O)R^{9a}$ donde $R^9$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{9a}$ es hidrógeno, alquilo $C_2$-$C_6$, alquenilo, hidroxialquilo,

alcoxialquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo; donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{9a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, hidroxi, hidroxialquilo, halo, haloalquilo, haloalcoxi, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, alcoxicarbonilo, -C(O)H, arilo (opcionalmente sustituido con uno o dos halo), arilalquilo, heteroarilo, heteroarilalquilo, heterocicloalquilo, heterocicloalquilalquilo, ciloalquilo, ciloalquilalquilo, y cicloalquilcarbonilo;

d) $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$ donde $R^{10a}$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o hidroxialquilo y $R^{10}$ y $R^{10b}$ son de modo independiente hidrógeno, alquilo, alquenilo, haloalquilo, o hidroxialquilo;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi y $R^{11}$ y $R^{11b}$ son de modo independiente hidrógeno, alquilo, alquenilo, aminoalquilo, alquilaminooalquilo, dialquilaminoalquilo;

f) $-C(O)R^{12}$ donde $R^{12}$ es heterocicloalquilo opcionalmente sustituido con 1, 2, o 3 grupos seleccionados de alquilo, oxo, amino, alquilamino, y heterocicloalquilalquilo;

g) $-NR^{13}C(O)OR^{13a}$ donde $R^{13}$ es hidrógeno, alquilo, o alquenilo y $R^{13a}$ es aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, arilo, o arilalquilo);

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ donde $R^{14}$, $R^{14a}$, y $R^{14b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

i) $-S(O)_2N(R^{15})$-alquilen $C_1$-$C_6$-$N(R^{15a})R^{15b}$ donde $R^{15}$, $R^{15a}$, y $R^{15b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

j) $-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$ donde $R^{16}$ es hidrógeno, alquilo, o alquenilo y $R^{16a}$ es alquilo o alquenilo;

k) heteroarilo opcionalmente sustituido con uno o dos aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ donde $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, y $R^{17d}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

m) $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$ donde $R^{18a}$ es hidrógeno, alquilo, alquenilo, o alcoxi y $R^{18}$ y $R^{18b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

n) $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$ donde $R^{19}$ es hidrógeno, alquilo, o alquenilo y $R^{19a}$ es amino, alquilamino, dialquilamino, o heterocicloalquilo;

o) $-N(R^{20})C(O)$-alquilen $C_1$-$C_6$-$C(O)R^{20a}$ donde $R^{20}$ es hidrógeno, alquilo, o alquenilo y $R^{20a}$ es cicloalquilo o heterocicloalquilo;

p) $-NR^{21}S(O)_2$-alquilen $C_1$-$C_6$-$N(R^{21b})R^{21a}$ donde $R^{21}$ es hidrógeno, alquilo, o alquenilo y $R^{21a}$ y $R^{21b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

q) $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, donde $R^{22}$, $R^{22a}$ y $R^{22b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;


r) -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$ donde $R^{23}$, $R^{23a}$ y $R^{23b}$ son de modo independiente hidrógeno, alquilo, o alquenilo; o

s) $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$ donde $R^{24}$ es hidrógeno, alquilo, o alquenilo y $R^{24a}$ es alcoxialquilo o arilo opcionalmente sustituido con uno o dos halo o alquilo;

donde cada alquileno en $R^3$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, amino, alquilamino, y dialquilamino; y

con la condición de que cuando $R^{50}$ y $R^{52}$ son hidrógeno, $R^{51}$ es hidrógeno o metilo, $R^{53}$ es hidrógeno o metoxi, y $R^{54}$ es hidrógeno o metoxi, por lo tanto B no es 2,3-dihidro-1,4-benzodioxinilo, tien-2-ilo, o tien-2-ilo sustituido con un $R^3$ donde $R^3$ es halo.

**[0015]** Un segundo aspecto de la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula II:



II

o una de sus sales o solvatos farmacéuticamente aceptables; o administrar una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de Fórmula II y a portador, excipiente o diluyente farmacéuticamente aceptable en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, uno o más agentes quimioterapéuticos, una o más de las terapias hormonales, uno o más de los anticuerpos, una o más inmunoterapias, terapia de yodo radiactivo, y radiación donde el Compuesto de Fórmula I es aquel donde:

$W^1$, $W^2$, $W^3$, y $W^4$ son $-C(R^{1a})=$; o uno o dos de $W^1$, $W^2$, $W^3$, y $W^4$ son de modo independiente $-N=$ y los restantes son $-C(R^{1a})=$;

$X^1$ es $-N(R^{5a})-$;

A es arilo, $-S(O)_2$-arilo, heteroarilo, cicloalquilo, heterocicloalquilo, halo, haloalquilo, haloalcoxi, alquilo, alcoxi, o -alquilo-$N(R^7)R^{7a}$, donde cada uno de los grupos arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilo y alcoxi, tanto solo o como parte de otro grupo dentro de A, está opcionalmente sustituido de modo independiente con uno, dos, tres, o cuatro $R^{2a}$; o

$B^1$ es arilo, arilalquilo, alquilo, heteroarilo, o heteroarilalquilo, donde cada uno de los grupos arilo, heteroarilo y alquilo están opcionalmente sustituidos de modo independiente con uno, dos, tres, o cuatro $R^{3d}$;

cada $R^{1A}$ se selecciona de modo independiente de hidrógeno, alcoxi, alquilo, nitro, halo, ciano, y $-C_0$-$C_6$-alquilo-$N(R^7)R^{7a}$, donde cada uno de los grupos alquilo y alcoxi está opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de alquilo, alcoxi, halo, haloalquilo, haloalcoxi, nitro, ciano, hidroxi, $-N(R^8)R^{8a}$, y $-C(O)OR^6$;

cada $R^{2a}$ (cuando $R^{2A}$ está presente) se selecciona de modo independiente de alquilo, alquenilo, -alquenilo-$C(O)OR^6$, $-OR^6$, $-N(R^7)C(O)R^6$, $-N(R^7)C(O)$-alquilo $C_0$-$C_6$-$N(R^{7b})R^{7a}$, $-OC(O)$-alquilo $C_0$-$C_6$-$N(R^7)R^{7a}$, $-N(R^7)C(O)$-alquil $C_1$-$C_6C(O)OR^6$, alquilo $C_0$-$C_6$-$C(O)R^6$, oxo, dioxo, $-S(O)_2$-$N(R^7)R^{7a}$, $-C(O)OR^6$, $-CH(R^6)_2$-$C(O)OR^6$, $-S(O)_2R^6$, cicloalquilo, heterocicloalquilo, heteroarilo, $-C(O)N(R^7)$-alquilo-$OR^6$, -alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquilo $C_0$-$C_6$-$C(O)OR^6$, -alquilo $C_0$-$C_6$-$C(O)N(R^7)R^{7a}$, arilo, arilalquilo, -S-(alquilo $C_1$-$C_6$), halo, oxo, nitro, -SCN,

ciano, y -alquilo $C_0$-$C_6$-$N(R^7)R^{7a}$, donde cada uno de los grupos alquilo (que incluyen, por ejemplo el alquilo dentro de alcoxi), arilo, cicloalquilo, heterocicloalquilo, y heteroarilo, tanto solo o como parte de otro grupo dentro de $R^2$, está de modo independiente opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de alquilo, halo, haloalquilo, haloalcoxi, oxo, nitro, ciano, hidroxi, $-N(R^8)R^{8a}$, alcoxi, y $-C(O)OR^9$;

cada $R^{3d}$ (cuando $R^{3d}$ está presente) es de modo independiente oxo, nitro, halo, ciano, alquilo, alquenilo, alquinilo, alcoxi, cicloalquilo $C_3$-$C_6$, -alquilo $C_0$-$C_6$-heterocicloalquilo, -alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-$N(R^{7b})R^{7a}$, -alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-$N(R^{7b})C(O)R^{7a}$, -alquilo $C_0$-$C_6$-C(O)-alquilo $C_0$-$C_6$-$N(R^7)R^{7a}$, -alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquilo $C_0$-$C_6$-$N(R^{7b})R^{7a}$, -alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquil $C_1$-$C_6C(O)OR^{7a}$, -alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-$(R^{7a})$, -alquilo $C_0$-$C_6$-$N(R^7)$-alquilo $C_0$-$C_6$-$N(R^{7b})R^{7a}$, -alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-$N(R^{7b})$-$N(R^{7c})R^{7a}$, -alquilo $C_0$-$C_6$-$N(R^7)C(O)O$-alquilo $C_0$-$C_6$-arilo, -alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquilo $C_0$-$C_6$-$N(R^{7b})R^{7a}$, -alquilo $C_0$-$C_6$-$N(R^7)$-alquilo $C_0$-$C_6$-$C(=N(R^{7b})(R^{7a}))(NR^{7c}R^{7d})$, -alquilo $C_0$-$C_6$-arilo, -alquilo $C_0$-$C_6$-heteroarilo, -alquilo $C_0$-$C_6$-heterocicloalquilo, -O-alquilo $C_0$-$C_6$-$N(R^7)R^{7a}$, -alquilo $C_0$-$C_6$-$OR_6$, -alquilo $C_0$-$C_6$-$C(O)OR_6$, alquilo $C_0$-$C_6$-$N(R^7)R^{7a}$, -alquilo $C_0$-$C_6$-$C(O)NR_7R^{7a}$, -alquilo $C_0$-$C_6$-$C(O)R^7$, $-SR_7$, $-S(O)_2R_7$, $-S(O)_3R_7$, $-S(O)R^7$, $-SO_2N(R^7)R^{7a}$, $-SO_2N(R^7)$-alquilo $C_0$-$C_6$-$N(R^{7b})R^{7a}$, -alquilo $C_0$-$C_6$-$N(R^7)$-arilo, -alquilo $C_0$-$C_6$-$N(R^7)$-heteroarilo, -alquilo $C_0$-$C_6$-$N(R^7)$-heterocicloalquilo, -alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquilo $C_0$-$C_6$-cicloalquilo, alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquilo $C_0$-$C_6$-arilo, alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquilo $C_0$-$C_6$-heteroarilo, alquilo $C_0$-$C_6$-$C(O)N(R^7)$-alquilo $C_0$-$C_6$-heterocicloalquilo,

-alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-cicloalquilo, -alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-arilo, alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-heteroarilo, -alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-heterocicloalquilo, alquilo $C_0$-$C_6$-$N(R^7)C(O)$-alquilo $C_0$-$C_6$-heterocicloalquilo-arilo, $-N(R^7)C(O)OR^6$, o -NHC(O)H, donde cada uno de los grupos alquilo, alquenilo, cicloalquilo, arilo, (que incluyen, por ejemplo el alquilo dentro de alcoxi), heterocicloalquilo, y heteroarilo, tanto solo o como parte de otro grupo dentro de $R^{3d}$, está de modo independiente opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de alquilo, alquenilo, -alquilo $C_0$-$C_6$-$OR^9$, cicloalquilo, halo, haloalquilo, haloalcoxi, $-C(O)R^9$, nitro, ciano, oxo, -alquilo $C_0$-$C_6$-$N(R^8)R^{8a}$, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, $-C(O)OR^9$, alquiltio, y hidroxialquilo;

$R^4$ es hidrógeno, arilo, -alquilo $C_0$-$C_6$-$N(R^7)R^{7a}$, alcoxi, o alquil $C_1$-$C_6$o, donde cada uno de los grupos alquilo y arilo, tanto solo o como parte de otro grupo en $R^4$, está de modo independiente opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de alquilo, halo, haloalquilo, haloalcoxi, nitro, ciano, hidroxi, $-N(R^8)R^{8a}$, alcoxi, y $-C(O)OR^6$; o

$R^4$ y $X^1$ junto con los átomos a los que están unidos forman un grupo heterocicloalquilo o heteroarilo, donde $R^{5A}$ está ausente cuando X es $-N(R^{5a})-$, donde cada uno de los grupos heterocicloalquilo o heteroarilo está opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de alquilo, halo, haloalquilo, haloalcoxi, nitro, ciano, hidroxi, $-N(R^7)R^{7a}$, alcoxi, y $-C(O)OR^6$;

$R^{5a}$ es hidrógeno, -alquil $C_1$-$C_6$o-$N(R^7)R^{7a}$, alcoxi, alquilo, o arilo, donde cada uno de los grupos alquilo y arilo está opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de alquilo, halo, haloalquilo, haloalcoxi, nitro, ciano, hidroxi, $-N(R^8)R^{8a}$, $C_1$-$C_6$ alcoxi, o $-C(O)OR^6$; o

$R^{5a}$ y $R^4$ junto con los átomos a los que están unidos forman un grupo heterocicloalquilo o heteroarilo, donde el heterocicloalquilo y el heteroarilo están opcionalmente sustituidos con 1, 2, 3, 4, o 5 grupos seleccionados de alquilo, halo, haloalquilo, haloalcoxi, nitro, ciano, hidroxi, $-N(R^7)R^{7a}$, $C_1$-$C_6$ alcoxi, y $-C(O)OR^6$;

$R^6$ y $R^9$ son de modo independiente hidrógeno, hidroxi, alquilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, o arilo, cada alquilo, arilo, cicloalquilo, heterocicloalquilo, y heteroarilo, tanto solo o como parte de otro grupo dentro de $R^6$ y $R^9$, está de modo independiente opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de modo independiente amino, hidroxi, alcoxi, alquilo, y halo; y

$R^7$, $R^{7a}$ $R^{7b}$, $R^{7c}$, $R^{7d}$, $R^8$, y $R^{8a}$ son de modo independiente hidrógeno, alquilo, alquenilo, hidroxi, alquiloxi, alqueniloxi, -O-alquilo $C_0$-$C_6$-arilo, -alquilo $C_0$-$C_6$-$C(O)OR^6$, -alquilo $C_0$-$C_6$-$C(O)R^6$, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, o heterocicloalquilalquilo, donde cada uno de los grupos alquilo, arilo, heteroarilo, y heterocicloalquilo, sea solo o como parte de otro grupo dentro de $R^7$, $R^{7a}$ $R^{7b}$, $R^{7c}$, $R^{7d}$, $R^8$, y $R^{8a}$ está de modo independiente opcionalmente sustituido con 1, 2, 3, 4, o 5 grupos seleccionados de

amino, alquilamino, dialquilamino, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, -S-alquilo $C_1$-$C_6$, ciano, nitro, hidroxi, alcoxi $C_1$-$C_6$, alquilo $C_1$-$C_6$, halo, arilo, heterocicloalquilalquilo, y heteroarilo opcionalmente sustituido con uno o dos alquilo $C_1$-$C_6$.

## DESCRIPCIÓN DETALLADA DE LA INVENCIÓN

### Abreviaturas y definiciones

**[0016]** Las siguientes abreviaturas y términos tiene los significados indicados a lo largo de la memoria:

| Abreviatura | Significado |
|---|---|
| Br | ancho |
| °C | grados Celsius |
| CBZ | CarboBenZoxi = benciloxicarbonilo |
| D | doblete |
| Dd | doblete de doblete |
| Dt | doblete de triplete |
| EI | Ionización por impacto electrónico |
| Et | Etilo |
| G | gramo(s) |
| GC | Cromatografía gaseosa |
| h o hr | horas(s) |
| HPLC | Cromatografía líquida de alta presión |
| L | litro(s) |
| M | molar o molaridad |
| M | Multiplete |
| Mg | miligrano(s) |
| MHz | megahertz (frecuencia) |
| Min | minuto(s) |

| Abreviatura | Significado |
|---|---|
| Ml | mililitro(s) |
| mM | Milimolar |
| Mmol | milimol(es) |
| Mol | mol(es) |
| EM | análisis de espectro de masa |
| N | normal o normalidad |
| nM | Nanomolar |
| NMR | Espectroscopia de resonancia magnética nuclear |
| Q | cuarteto |
| RT | Temperatura ambiente |
| S | Singlete |
| s- | Secundario |
| t- | Terciario |
| t o tr | Triplete |
| TFA | ácido trifluoroacético |
| THF | Tetrahidrofurano |
| µL | Microlitro (s) |
| µM | Micromol(s) o micromolar |

**Definiciones para un compuesto de Fórmula I, Ia, y II**

**[0017]** El símbolo "-" significa un enlace simple, "=" significa un enlace doble, "≡" significa un enlace triple, y "--" significa un enlace simple y opcionalmente un enlace doble. Cuando se grafican o describen estructuras químicas, a menos que se indique explícitamente lo contrario, se asume que todos los

carbonos tienen sustitución de hidrógeno para conformar una valencia de cuatro.

**[0018]** "Administración" y sus variantes (por ejemplo, "administrar" un compuesto) con referencia a un compuesto de la invención significa introducir el compuesto o un profármaco del compuesto en el sistema del animal que necesita tratamiento. Cuando un compuesto de la invención o su profármaco se proporciona en combinación con uno o más agentes activos diferentes (por ejemplo, cirugía, radiación, y quimioterapia, etc.), se entiende que "administración" y sus variantes incluye la introducción concurrente y secuencial del compuesto o sus profármacos y otros agentes.

**[0019]** "Alquenilo" o "alquenilo inferior" significa un radical hidrocarbonado lineal o ramificado que tiene de 2 a 6 átomos de carbono y al menos un enlace doble e incluye etenilo, propenilo, 1-but-3-enilo, 1-pent-3-enilo, 1-hex-5-enil y similares.

**[0020]** "Alquenilcarbonilo" significa un grupos C(O)R donde R es alquenilo, como se define en la presente.

**[0021]** "Alqueniloxi" o "alqueniloxi inferior" significa un grupos -O donde R es alquenilo, como se define en la presente. Los ejemplos representativos incluyen metoxi, ethoxi, 1-metoxiprop-1-en-3-ilo, propoxi, isopropoxi, ciclopropiloxi, ciclohexiloxi y similares.

**[0022]** "Alcoxi" o "alcoxi inferior" significa un grupo -O donde R es alquilo, como se define en la presente. Los ejemplos representativos incluyen metoxi, etoxi, 1-metoxiprop-1-en-3-ilo, propoxi, isopropoxi, ciclopropiloxi, ciclohexiloxi y similares.

**[0023]** "Alcoxialquilo" significa un grupos alquilo como se define en la presente, sustituido con uno, dos o tres grupos alcoxi, como se define en la presente.

**[0024]** "Alcoxicarbonilo" significa un grupo -C(O)O donde R es alquilo como se define en la presente.

**[0025]** "Alcoxicarbonilalquilo" significa un grupo alquilo, como se define en la presente, sustituido con uno, dos o tres grupos alcoxicarbonilo, como se define en la presente.

**[0026]** "Alquilo" o "alquilo inferior" significa un grupo hidrocarbonado lineal o ramificado que tiene uno a seis átomos de carbono. Los ejemplos de grupos alquilo inferior incluyen metilo, etilo, propilo, isopropilo, butilo, *s*-butilo, *t*-butilo, isobutilo, pentilo, hexilo y similares. Un alquilo "$C_0$" (como en el "alquilo $C_0$-$C_6$") es un enlace covalente. "alquilo $C_6$" se refiere, por ejemplo, a *n*-hexilo, *iso*-hexilo, y similares.

**[0027]** "Alquilamino" significa un radical -NHR radical donde R es alquilo como se define en la presente o uno de sus derivados N-óxido, por ejemplo, metilamino, etilamino, *n*-, *iso*-propilamino, *n*-, *iso*-, *ter*-butilamino, o metilamino-N-óxido, y similares.

**[0028]** "Alquilaminoalquilo" significa un grupo alquilo sustituido con uno o dos grupos alquilamino, como se define en la presente.

**[0029]** "Alquilaminoalquiloxi" significa un grupo -O donde R es alquilaminoalquilo, como se define en la presente.

**[0030]** "Alquilcarbonilo" significa un grupo C(O)R donde R es alquilo, como se define en la presente.

**[0031]** "Alquilcarbonilamino" significa un grupos -NRC(O)R' donde R es hidrógeno o alquilo, como se define

en la presente, y R' es alquilo, como se define en la presente.

**[0032]** "Alquileno" se refiere a una cadena hidrocarbonada lineal o ramificada, que no contiene insaturación y que tiene de dos a ocho átomos de carbono. Los ejemplos de alquileno incluye et-diílo ($-CH_2CH_2-$), prop-1,3-diílo ($-CH_2CH_2CH_2-$), 2,2-dimetilprop-1,3-diílo ($-CH_2C(CH_3)_2CH_2-$), y similares.

**[0033]** "Alquilsulfonilo" significa un grupo $-S(O)_2R$ donde R es alquilo, como se define en la presente.

**[0034]** "Alquiltio" significa un grupo -SR donde R es alquilo, como se define en la presente. Los ejemplos de alquiltio incluyen metiltio y etiltio, y similares.

**[0035]** "Alquiltioalquilo" significa un grupo alquilo sustituido con uno o dos grupos alquiltio, como se define en la presente, por ejemplo 2-(metiltio)-etilo y 2-(etiltio)-etilo.

**[0036]** "Alquinilo" o "alquinilo inferior" significa un radical hidrocarbonado lineal o ramificado que tiene de 2 a 6 átomos de carbono y al menos un enlace triple e incluye etinilo, propinilo, butinilo, pentin-2-ilo y similares.

**[0037]** "Amino" significa un $-NH_2$.

**[0038]** "Aminoalquilo" significa un grupo alquilo sustituido con al menos uno, por ejemplo uno, dos o tres, grupos amino.

**[0039]** "Aminoalquiloxi" significa un grupo -O donde R es aminoalquilo, como se define en la presente.

**[0040]** "Arilo" significa un anillo mono o bicarbcíclico monovalente de seis a catorce miembros, donde el anillo monocíclico es aromático y al menos uno de los anillos del anillo bicíclico es aromático. Los ejemplos

representativos incluyen fenilo, naftilo e indanilo, y similares.

**[0041]** "Arilalquilo" significa un grupo alquilo, como se define en la presente, sustituido uno o dos grupos arilo, como se define en la presente. Los ejemplos incluyen bencilo, fenetilo, fenilvinilo, fenilalilo y similares.

**[0042]** "Ariloxi" significa un grupo -O donde R es arilo como se define en la presente.

**[0043]** "Arilalquiloxi" significa un grupo -O donde R es arilalquilo como se define en la presente.

**[0044]** "Arilsulfonilo" significa un grupo $-SO_2R$ donde R es arilo como se define en la presente.

**[0045]** "Carboxialquilo" significa un grupo alquilo, como se define en la presente, sustituido con uno, dos o tres grupos -C(O)OH.

**[0046]** "Carboxi éster" significa un grupo -C(O)O donde R es alquilo inferior, alquenilo inferior, alquinilo inferior, cicloalquilo, arilo o arilalquilo, cad uno de los cuales se define en la presente. Los ejemplos representativos incluyen metoxicarbonilo, etoxicarbonilo, y benciloxicarbonilo, y similares.

**[0047]** "Cianoalquilo" significa un radical alquilo, alquenilo, o alquinilo, como se define en la presente, sustituido con al menos uno, por ejemplo uno, dos o tres, grupos ciano.

**[0048]** "Cicloalquilo" significa un radical hidrocarbonado monocíclico o policíclico que tiene tres a trece átomos de carbono. El cicloalquilo puede estar saturado o parcialmente insaturado, pero no puede contener un anillo aromático. El cicloalquilo incluye sistemas fusionados, con puente y espiro. Los ejemplos de

dichos radicales incluyen ciclopropilo, ciclobutilo, ciclopentil y ciclohexilo.

**[0049]** "Cicloalquilalquilo" significa un grupo alquilo sustituido con uno o dos grupos cicloalquilo, como se definen en la presente. Los ejemplos representativos incluyen ciclopropilmetilo y 2-ciclobutil-etilo, y similares.

**[0050]** "Cicloalquilcarbonilo" significa un grupo -C(O)R donde R es cicloalquilo como se define en la presente.

**[0051]** "Dialquilamino" significa un radical -NRR' donde R y R' son de modo independiente alquilo como se define en la presente, o un derivado de N-óxido, o uno de sus derivados, por ejemplo, dimetilamino, dietilamino, *N,N*-metilpropilamino o *N,N*-metiletilamino, y similares.

**[0052]** "Dialquilaminoalquilo" significa un grupo alquilo sustituido con grupos de mono o dialquilamino, como se define en la presente.

**[0053]** "Dialquilaminoalquiloxi" significa un grupo -O donde R es dialquilaminoalquilo, como se define en la presente.

**[0054]** "Sistema de anillo fusionado" y "anillo fusionado" se refieren a un sistema de anillo policíclico que contiene anillos con puente o fusionados; es decir, donde dos anillos tienen más de un átomo compartido en sus estructuras de anillo. En esta aplicación, los sistemas policíclicos fusionados y de anillos fusionados no todos son necesariamente sistemas de anillos aromáticos. Normalmente, pero no necesariamente, los policíclicos fusionados comparten un conjunto de átomos vecino, por ejemplo naftaleno o 1,2,3,4-tetrahidro-naftaleno. Un sistema anular espiro no es un policíclico fusionado según esta definición, pero los sistemas de

anillo policíclicos fusionados de la invención pueden de tener de por sí anillos espiro unidos por medio de un átomo anular simple del sistema policíclico fusionado. En algunos ejemplos, tal como es apreciado por los expertos en la técnica, dos grupos adyacentes en un sistema aromático pueden fusionarse juntos para formar una estructura anular. La estructura anular fusionada puede contener heteroátomos y opcionalmente puede estar sustituido con uno o más grupos. Cabe mencionar también que los carbonos saturados de dichos grupos fusionados (es decir, estructuras anulares saturadas) pueden contener dos grupos de sustitución.

**[0055]** "Haloalcoxi" significa un grupo -O' donde R' es haloalquilo como se define en la presente, por ejemplo, trifluorometoxi o 2,2,2-trifluoroetoxi, y similares.

**[0056]** "Haloalcoxialquilo" significa un grupo alquilo, como se define en la presente, sustituido con uno, dos o tres haloalcoxi, como se define en la presente.

**[0057]** "Halógeno" o "halo" significa fluoro, cloro, bromo y yodo.

**[0058]** "Haloalquenilo significa un grupo alquenilo, como se define en la presente, sustituido con uno o más halógenos, por ejemplo uno a cinco átomos de halo.

**[0059]** "Haloalquilo" significa un grupo alquilo, como se define en la presente, sustituido con uno o más halógenos, por ejemplo uno a cinco átomos de halo. Los ejemplos representativos incluyen 2,2-difluoroetilo, trifluorometilo, y 2-cloro-1-fluoroetilo y similares.

**[0060]** "Heteroarilo" significa un radical monovalente monocíclico, bicíclico fusionado o tricíclico fusionado, de 5 a 14 átomos anulares que contienen uno o más, por ejemplo uno, dos, tres, o cuatro heteroátomos en el

anillo seleccionados de modo independiente de -O-, $-S(O)_n-$ (n es 0, 1, o 2), -N-, $-N(R^x)-$, y los restantes átomos anulares son carbono, en donde el anillo que comprende un radical monocíclico es aromático y en donde al menos uno de los anillos fusionados que comprende un radical bicíclico o tricíclico es aromático. Uno o dos g átomos anulares de carbono de cualquiera de los anillos no aromáticos que comprende un radical bicíclico o tricíclico puede estar reemplazado con un grupo -C(O)-, -C(S)-, o -C(=NH)-. $R^x$ es hidrógeno, alquilo, hidroxi, alcoxi, acilo, o alquilsulfonilo. El radical bicíclico radical fusionado incluye sistemas anulares con puente. A menos que se indique de otro modo, la valencia se puede ubicar en cualquier átomo de cualquier anillo del grupo heteroarilo, permitido por las reglas de valencia. En particular, cuando el punto de valencia se ubica en el nitrógeno, $R^x$ está ausente. En otra forma de realización, el términio heteroarilo incluye, pero sin limitación, 1,2,4-triazolilo, 1,3,5-triazolilo, ftalimidilo, piridinilo, pirrolilo, imidazolilo, tienilo, furanilo, indolilo, 2,3-dihidro-1*H*-indolil (que incluye, por ejemplo, 2,3-dihidro-1*H*-indol-2-ilo o 2,3-dihidro-1*H*-indol-5-ilo, y similares), isoindolilo, indolinilo, isoindolinilo, bencimidazolilo, benzodioxol-4-ilo, benzofuranilo, cinnolinilo, indolizinilo, naftiridin-3-ilo, ftalazin-3-ilo, ftalazin-4-ilo, pteridinilo, purinilo, quinazolinilo, quinoxalinilo, tetrazoílo, pirazolilo, pirazinilo, pirimidinilo, piridazinilo, oxazolilo, isooxazolilo, oxadiazolilo, benzoxazolilo, quinolinilo, isoquinolinilo, tetrahidroisoquinolinil (que incluye, por ejemplo, tetrahidroisoquinolin-4-ilo o tetrahidroisoquinolin-6-ilo, y similares), pirrolo[3,2-c]piridinilo (que incluye, por ejemplo, pirrolo[3,2-

c]piridin-2-ilo o pirrolo[3,2-c]piridin-7-ilo, y similares), benzopiranilo, tiazolilo, isotiazolilo, tiadiazolilo, benzotiazolilo, benzotienilo, y sus derivados, N-óxido o sus derivados protegidos.

**[0061]** "Hetereoarilalquilo" significa un grupo alquilo sustituido con uno o dos grupos heteroarilo como se define en la presente.

**[0062]** "Heterocicloalquilo" significa un grupo monocíclico monovalente saturado o parcialmente insaturado de 3 a 8 átomos anulares o un grupo bicíclico fusionado monovalente saturado o parcialmente insaturado de 5 a 12 átomos anulares en los que uno o más, por ejemplo uno, dos, tres, o cuatro heteroátomos anulares seleccionados de modo independiente de -O-, $-S(O)_n-$ (n es 0, 1, o 2), -N=, $-N(R^y)-$ (donde $R^y$ es hidrógeno, alquilo, hidroxi, alcoxi, acilo, o alquilsulfonilo), los átomos del anillo restantes son carbono. Uno o dos átomos de carbono del anillo se pueden reemplazar con un grupo -C(O)-, -C(S)-, o -C(=NH)-. El radical bicíclico incluye sistemas de anillo con puente. A menos que se indique de otro modo, la valencia del grupo se puede ubicar en cualquier átomo de cualquier anillo del radical, permitido por las reglas de valencia. En particular, cuando el punto de valencia se ubica en un átomo de nitrógeno, $R^y$ está ausente. En otra forma de realización el término heterocicloalquilo incluye, pero sin limitación, azetidinilo, pirrolidinilo, 2-oxopirrolidinilo, 2,5-dihidro-1*H*-pirrolilo, piperidinilo, 4-piperidonilo, morfolinilo, piperazinilo, 2-oxopiperazinilo, tetrahidropiranilo, 2-oxopiperidinilo, tiomorfolinilo, tiamorfolinilo, perhidroazepinilo, pirazolidinilo, imidazolinilo, imidazolidinilo, dihidropiridinilo, tetrahidropiridinilo, oxazolinilo,

oxazolidinilo, isoxazolidinilo, tiazolinilo, tiazolidinilo, quinuclidinilo, isotiazolidinilo, octahidroindolilo, octahidroisoindolilo, decahidroisoquinolilo, tetrahidrofurilo, y tetrahidropiranilo, y sus derivados y N-óxido o uno de sus derivados protegidos.

**[0063]** "Heterocicloalquilalquilo" significa un grupo alquilo, como se define en la presente, sustituido con uno o dos grupos heterocicloalquilo, como se define en la presente.

**[0064]** "Hidroxialquilo" significa un radical alquilo, como se define en la presente, sustituido con al menos uno, por ejemplo uno, dos o tres, grupos hidroxi, con la condición de que si dos grupos hidroxi están presentes, no están en el mismo átomo de carbono. Los ejemplos representativos incluyen, pero sin limitación, hidroximetilo, 2-hidroxietilo, 2-hidroxipropilo, 3-hidroxipropilo, 1-(hidroximetil)-2-metilpropilo, 2-hidroxibutilo, 3-hidroxibutilo, 4-hidroxibutilo, 2,3-dihidroxipropilo, 1-(hidroximetil)-2-hidroxietilo, 2,3-dihidroxibutilo, 3,4-dihidroxibutilo y 2-(hidroximetil)-3-hidroxipropilo, por ejemplo 2-hidroxietilo, 2,3-dihidroxipropilo, o 1-(hidroximetil)-2-hidroxietilo, y similares.

**[0065]** "Hidroxiamino" significa un grupo -NH(OH).

**[0066]** "Opcional" u "opcionalmente" significa que el evento o circunstancia descripto posteriormente puede ocurrir o no y que la descripción incluye casos donde dichos eventos o circunstancias no ocurren. Los expertos en la técnica deben entender que con respecto a cualquier molécula que como que contiene uno o más sustituyentes opcionales, significa que solo incluyen compuestos estéricamente prácticos y/o realizable por síntesis.

"Opcionalmente sustituido" se refiere a todos los modificadores posteriores de un término. Así, por ejemplo, en el término "opcionalmente arilalquilo $C_{1-8}$" sustituido, tanto la porción "alquilo $C_{1-8}$" y la porción "arilo" de la molécula pueden estar o no sustituidas. Una liste de ejemplos de sustituciones opcionales se presentan a continuación en la definición de "sustituido".

**[0067]** "Alquilo opcionalmente sustituido" significa un radical alquilo, como se define en la presente, opcionalmente sustituido con uno o más grupos, por ejemplo uno, dos, tres, cuatro, o cinco grupos, seleccionados de modo independiente alquilcarbonilo, alquenilcarbonilo, cicloalquilcarbonilo, alquilcarboniloxi, alquenilcarboniloxi, amino, alquilamino, dialquilamino, aminocarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo, ciano, cianoalquilaminocarbonilo, alcoxi, alqueniloxi, hidroxi, hidroxialcoxi, carboxi, alquilcarbonilamino, alquilcarboniloxi, alquilo-$S(O)_{0-2}$-, alquenilo-$S(O)_{0-2}$-, aminosulfonilo, alquilaminosulfonilo, dialquilaminosulfonilo, alquilsulfonil-$NR^c$- (donde $R^c$ es hidrógeno, alquilo, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, hidroxi, alcoxi, alqueniloxi, o cianoalquilo), alquilaminocarboniloxi, dialquilaminocarboniloxi, alquilaminoalquiloxi, dialquilaminoalquiloxi, alcoxicarbonilo, alqueniloxicarbonilo, alcoxicarbonilamino, alquilaminocarbonilamino, dialquilaminocarbonilamino, alcoxialquiloxi, y -$C(O)NR^aR^b$ (donde $R^a$ y $R^b$ son de modo independiente hidrógeno, alquilo, alquenilo opcionalmente

sustituido, alquinilo opcionalmente sustituido, hidroxi, alcoxi, alqueniloxi, o cianoalquilo).

**[0068]** "Alquenilo opcionalmente sustituido" significa un radical alquenilo, como se define en la presente, opcionalmente sustituido con uno o más grupos, por ejemplo uno, dos o tres grupos, seleccionados de modo independiente alquilcarbonilo, alquenilcarbonilo, cicloalquilcarbonilo, alquilcarboniloxi, alquenilcarboniloxi, amino, alquilamino, dialquilamino, aminocarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo, ciano, cianoalquilaminocarbonilo, alcoxi, alqueniloxi, hidroxi, hidroxialcoxi, carboxi, alquilcarbonilamino, alquilcarboniloxi, alquilo-$S(O)_{0-2}$-, alquenilo-$S(O)_{0-2}$-, aminosulfonilo, alquilaminosulfonilo, dialquilaminosulfonilo, alquilsulfonil-$NR^c$- (donde $R^c$ es hidrógeno, alquilo opcionalmente sustituido, alquinilo opcionalmente sustituido, hidroxi, alcoxi, o alqueniloxi), alquilaminocarboniloxi, dialquilaminocarboniloxi, alquilaminoalquiloxi, dialquilaminoalquiloxi, alcoxicarbonilo, alqueniloxicarbonilo, alcoxicarbonilamino, alquilaminocarbonilamino, dialquilaminocarbonilamino, alcoxialquiloxi, y -$C(O)NR^aR^b$ (donde $R^a$ y $R^b$ son de modo independiente hidrógeno, opcionalmente sustituido alquilo, alquenilo, alquinilo opcionalmente sustituido, hidroxi, alcoxi, o alqueniloxi).

**[0069]** "Arilo opcionalmente sustituido" significa un grupo arilo, como se define en la presente, que está opcionalmente sustituido con uno, dos, tres, cuatro, de cinco grupos seleccionados de halo, haloalquilo, haloalcoxi, hidroxi, alquilo inferior, alquenilo inferior, lower alquinilo, alcoxi, carboxi, carboxi ester, amino, alquilamino, dialquilamino, cicloalquilo

opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)NR'R" (donde R' es hidrógeno o alquilo y R" es hidrógeno, alquilo, arilo, heteroarilo, o heterocicloalquilo), -NR'C(O)R" (donde R' es hidrógeno o alquilo y R" es alquilo, arilo, heteroarilo, o heterocicloalquilo), y $-NHS(O)_2R'$ (donde R' es alquilo, arilo, o heteroarilo).


**[0070]** "Heteroarilo Opcionalmente sustituido" significa un grupo heteroarilo, como se define en la presente, opcionalmente sustituido con uno, dos, tres, cuatro, o cinco grupos seleccionados de halo, haloalquilo, haloalcoxi, alquilo inferior, alquenilo inferior, alquinilo inferior, alcoxi, hidroxi, oxo (permitido por reglas de valencia), carboxi, carboxi éster, amino, alquilamino, dialquilamino, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heteroarilo, arilo opcionalmente sustituido, -C(O)NR'R" (donde R' es hidrógeno o alquilo y R" es hidrógeno, alquilo, arilo, heteroarilo, o heterocicloalquilo), -NR'C(O)R" (donde R' es hidrógeno o alquilo y R" es alquilo, arilo, heteroarilo, o heterocicloalquilo), y $-NHS(O)_2R'$ (donde R' es alquilo, arilo, o heteroarilo).

**[0071]** "Heterocicloalquilo Opcionalmente sustituido" significa un heterocicloalquilo, como se define en la presente, opcionalmente sustituido con uno, dos, tres, cuatro, o cinco grupos seleccionados de halo, haloalquilo, haloalcoxi, hidroxi, oxo, alquilo inferior, alquenilo inferior, alquinilo inferior, alcoxi, opcionalmente sustituido cicloalquilo, heterocicloalquilo, opcionalmente sustituido arilo, x heteroarilo Opcionalmente sustituido, alquilaminoalquilo, dialquilaminoalquilo, carboxi, carboxi éster, -C(O)NR'R"

(donde R' es hidrógeno o alquilo y R" es hidrógeno, alquilo, arilo, heteroarilo, o heterocicloalquilo), -NR'C(O)R" (donde R' es hidrógeno o alquilo y R" es alquilo, arilo, heteroarilo, o heterocicloalquilo), amino, alquilamino, dialquilamino, y $-NHS(O)_2R'$ (donde R' es alquilo, arilo, o heteroarilo).

**[0072]** "Sistema anular con puente saturado" se refiere a un sistema anular bicíclico o policíclico que no es aromático. Dicho sistema puede contener instauración aislada o conjugada, pero no anillos aromáticos o heteroaromáticos en su estructura de núcleo (pero no puede tener sustitución aromático). Por ejemplo, también se incluyen hexahidro-furo[3,2-b]furano, 2,3,3a,4,7,7a-hexahidro-1H-indeno, 7-aza-biciclo[2,2,1]heptano, y 1,2,3,4,4a,5,8,8a-octahidro-naftaleno en la clase de "sistema anular con puente saturado".

**[0073]** "Espirocíclico" o "anillo espirocíclico" se refieren a un anillo que se origina de un carbono anular particular de otro anillo. Por ejemplo, como se grafica a continuación, un átomo anular de un sistema anular con puente saturado (anillos C y C'), pero no un átomo cabeza de puente, puede ser un átomo compartido entre el sistema anular con puente saturado y un anillo espirocíclico (anillo D) unido a este. Un espirociclilo puede ser carbocíclico o heteroalicíclico.




**[0074]** "Rendimiento" para cada una de las reacciones que se describen en la presente se expresa como porcentaje del rendimiento teórico.

**Definiciones para el Compuesto de Fórmula 100**

**[0075]** Los términos usados para describir el alcance de la fórmula 100 se definen en WO 2004/006846 (Solicitud de etapa Nat'l US Serie No. 10/522,004) que se incorpora en la presente como referencia. Por ejemplo "opcionalmente sustituido alquilo" para la fórmula 100 tiene el significado dado en WO 2004/006846 (Solicitud de etapa Nat'l US Serie No 10/522,004). Cuando un compuesto de Fórmula 100 se describe en esta solicitud, sea por la estructura o por el uso del término "fórmula 100," los términos usados para describir este compuesto son definidos por WO 2004/006846 (Solicitud de etapa Nat'l US Serie No. 10/522,004).

**Otras definiciones**

**[0076]** "Inhibidor de AKT" incluye, por ejemplo, LY294002, PKC 412, perifosina, los compuestos de la Tabla 2a, compuestos de la Tabla 2b, y compuestos descriptos en WO 2006/071819 y WO05/117909. Estas referencias también describen los ensayos in vitro que se pueden usar para determinar la actividad inhibidora de AKT.

**[0077]** "Agente alquilante" incluye, por ejemplo, uno o más de los siguientes: clorambucilo, clormetina, ciclofosfamida, ifosfamida, melfalan, carmustina, etreptozocina, fotemustina, lomustina, estreptozocina, carboplatino, cisplatino, oxaliplatino, bbr3464, busulfan, dacarbazina mecloretamina, procarbazina, temozolomida, tiotepa, y uramustina.

**[0078]** "Anticuerpo" incluye, por ejemplo, uno o más de los siguientes: un anticuerpo de IGF1R (que incluye, por ejemplo, $^{\alpha}$IGF-1R A12 MoAb, 19D12, h7C$_{10}$ y CP-751871), un anticuerpo EGFR (que incluye, por ejemplo, Cetuximab (Erbitux®) y Panitumumab), un anticuerpo ErbB2 (que incluye, por ejemplo, Trastuzumab (Herceptin®)), un

DVN
OK

4/4

Organizacion y
Digitalizacion CSA Ltda

# PATENTE DE INVENCIÓN

09-126923

anticuerpo VEGF (que incluye, por ejemplo, Bevacizumab (Avastin®)), un anticuerpo IgG1 (que incluye, por ejemplo, Ibritumomab (tiuxetan)), un anticuerpo CD20 (que incluye, por ejemplo, Rituximab y Tositumomab), un anticuerpo CD33 (que incluye, por ejemplo, Gemtuzumab y Gemtuzumab ozogamicina), y un anticuerpo CD52 (que incluye, por ejemplo, Alemtuzumab).

**[0079]** "Antimetabolito" incluye, por ejemplo, metotrexato, pemetrexed, raltitrexed, cladribina, clofarabina, fludarabina, mercaptopurina, tioguanina, capecitabina, citarabina, fluorouracilo (administrado con o sin leucovorina o ácido folínico), y gemcitabina.

**[0080]** "Agente microtúbulo" incluye, por ejemplo, vincristina, vinblastina, vinorelbina, vinflunina, y vindesina.

**[0081]** "Inhibidor de aromatasa" incluye, por ejemplo, uno o más de los siguientes: aminoglutetimida, anastrozol (Arimidex®), letrozol (Femara®), exemestano (Aromasin®), y formestano (Lentaron®).

**[0082]** "Cáncer" se refiere a estados de enfermedad proliferativa celular, que incluyen pero sin limitación: Cardíaco: sarcoma (angiosarcoma, fibrosarcoma, rhabdomiosarcoma, liposarcoma), mixoma, rhabdomioma, fibroma, lipoma y teratoma; Pulmón: carcinoma broncogénico (célula escamosa, célula pequeñas no diferenciado, células grandes no diferenciadas, adenocarcinoma), alveolar (bronquiolar) carcinoma, adenoma bronquial, sarcoma, linfoma, hamartoma condromatoso, mesotelioma, Gastrointestinal: esófago (carcinoma de células esofágicas, adenocarcinoma, leiomiosarcoma, linfoma), estómago (carcinoma, linfoma, leiomiosarcoma), páncreas (adenocarcinoma ductal, insulinoma, glucagonoma, gastrinoma, tumores carcinoides,

vipoma), intestino delgado (adenocarcinoma, linfoma, tumores carcinoides, sarcoma de Karposi, leiomioma, hemangioma, lipoma, neurofibroma, fibroma), intestino grueso (adenocarcinoma, adenoma tubular, adenoma velloso, hamartoma, leiomioma); Aparato genitourinario: riñón (adenocarcinoma, tumor de Wilm [nefroblastoma], linfoma, leucemia), vejiga y uretra (carcinoma de células escamosas, carcinoma de células de transición adenocarcinoma), próstata (adenocarcinoma, sarcoma), testículos (seminoma, teratoma, carcinoma embrionario, teratocarcinoma, coriocarcinoma, sarcoma, carcinoma de células intersticiales, fibroma, fibroadenoma, tumores adenomatoides, lipoma); Hígado: hepatoma (carcinoma hepatocelular), colangiocarcinoma, hepatoblastoma, angiosarcoma, adenoma hepatocelular, hemangioma; Hueso: sarcoma osteogénico (osteosarcoma), fibrosarcoma, histiocitoma fibroso maligno, condrosarcoma, sarcoma de Ewing, linfoma maligno (sarcoma de células reticulares), mieloma múltiple, cordoma tumoral de células gigantes malignas, osteocondroma (exostosis osteocartilaginosos), condroma benigno, condroblastoma, condromixofibroma, osteoma osteoide y tumores de células gigantes; Sistema nervioso: cráneo (osteoma, hemangioma, granuloma, xantoma, osteítis deformante), meninges (meningioma, meningiosarcoma, gliomatosis), cerebro (astrocitoma, meduloblastoma, glioma, ependimoma, germinoma [pinealoma], glioblastorna multiforme, oligodendroglioma, schwannoma, retinoblastoma, tumores congénitos), neurofibroma de médula espinal, meningioma, glioma, sarcoma); Ginecológico: útero (carcinoma de endometrio), cuello uterino (carcinoma cervical, displasia cervical pre-tumoral), ovarios (carcinoma ovárico [cistadenocarcinoma seroso, cistadenocarcinoma mucinoso,

carcinoma no clasificado], tumores de células de granulosa-tecales, tumores de células de Sertoli-Leydig, disgerminoma, teratoma maligno), vulva (carcinoma de células escamosas, carcinoma intraepitelial, adenocarcinoma, fibrosarcoma, melanoma), vagina (carcinoma de células claras, carcinoma de células escamosas, sarcoma botrioide (rhabdomiosarcoma embrionario], trompas de falopio (carcinoma), Hematológico: sangre (leucemia mieloide [aguda y crónica], leucemia linfoblástica aguda, leucemia linfocítica crónica, enfermedades mieloproliferativas, mieloma múltiple, síndrome mielodisplásica), enfermedad de Hodgkin, linfoma no Hodgkin [linfoma maligna]; Piel: melanoma maligno, carcinoma de células basales, carcinoma de células escamosas, sarcoma de Karposi, molas del nervio displásico, lipoma, angioma, dermatofibroma, queloides, psoriasis; Glándulas adrenales: neuroblastoma; y cáncer de mamas. En consecuencia, el término "célula cancerosa" como se proporciona en la presente, incluye una célula afectada por alguna de las enfermedades identificadas anteriormente.

**[0083]** "Agente quimioterapéutico" incluye, pero sin limitación, un inhibidor de AKT, un agente alquilante, un antimetabolito, un agente antimicrotúbulo, un inhibidor de aromatasa, un inhibidor de c-KIT, un inhibidor de cMET, un inhibidor de EGFR, un inhibidor de ErbB2, un inhibidor de Flt-3, un inhibidor de HSP90, un inhibidor de IGF1R, un platino, un inhibidor de Raf, rapamicina, un análogo de rapamicina, un inhibidor del receptor de tirosina quinasa, un taxano, un inhibidor de topoisomerasa, un inhibidor de SRC y/o ABL quinasa, y un inhibidor de VEGFR. Una sal, solvato y/o hidrato farmacéuticamente aceptable de un agente

quimioterapéutico puede ser preparados por los expertos en la técnica y sus sales, solvatos y/o hidratos se pueden usar para practicar la invención

**[0084]** "Inhibidor de c-KIT" incluye, por ejemplo, imatinib, sunitinib, nilotinib, AMG 706, sorafenib, compuestos de la Tabla 3b, compuestos de la Tabla 3c, compuestos de la Tabla 8, compuestos de la Tabla 9, y los compuestos descriptos en WO 2006/108059, WO/2005/020921, WO/2006/033943, y WO 2005/030140.

**[0085]** "Inhibidor de cMET" incluye, por ejemplo, compuestos de la Tabla 3a, compuestos de la Tabla 3b, compuestos de la Tabla 3c, compuestos descriptos en WO06/108059, WO 2006/014325, y WO 2005/030140.

**[0086]** "Inhibidor de EGFR" incluye, por ejemplo, uno o más de los siguientes: pelitinib, lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474, vandetinib), AEE788 y HKI-272, EKB-569, CI-1033, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, compuestos de la Tabla 4, compuestos de la Tabla 7, y los compuestos descriptos en WO 2004/006846 y WO 2004/050681.

**[0087]** "Inhibidor de ErbB2" incluye, por ejemplo, lapatinib (GW572016), PKI-166, canertinib, CI-1033, HKI272, y EKB-569.

**[0088]** "Inhibidor de Flt-3" incluye, por ejemplo, CEP-701, PKC 412, MLN518, sunitinib, sorafenib, compuestos de la Tabla 3a, compuestos de la Tabla 3b, compuestos de la Tabla 3c, compuestos de la Tabla 9, y los compuestos descriptos en WO 2006/108059, WO/2006/033943, WO 2006/014325, y WO 2005/030140.

**[0089]** "Terapia de hormonas" o "terapia hormonal" incluye, por ejemplo, el tratamiento con uno o más de los siguientes: esteroides (por ejemplo dexametasona), finasterida, tamoxifeno y un inhibidor de aromatasa.

**[0090]** "Inhibidor de HSP90" incluye, por ejemplo, 17-AAG, 17-DMAG, geldanamicina, 5-(2,4-dihidroxi-5-isopropilfenil)-*N*-etil-4-(4-(morfolinometil)fenil)isoxazol-3-carboxamida [NVP-AUY922 (VER 52296)], 6-cloro-9-((4-metoxi-3,5-dimetilpiridin-2-il)metil)-9*H*-purin-2-amina (CNF2024, también llamada BIIB021), compuestos descriptos en WO2004072051 (que se incorpora en la presente como referencia), compuestos descriptos en WO2005028434 (que se incorpora en la presente como referencia), compuestos descriptos en WO2007035620 (que se incorpora en la presente como referencia) y compuestos descriptos en WO2006091963 (que se incorpora en la presente como referencia).

**[0091]** "Inhibidor de IGF1R" incluye, por ejemplo, Tyrphostin AG 1024, compuestos de la Tabla 5a, compuestos de la Tabla 5b, y los compuestos descriptos en WO06/074057.

**[0092]** "Enfermedades o patologías dependientes de quinasa" se refieren a condiciones patológicas que dependen de la actividad de una o más lípido quinasas. Las quinasas participan tanto en forma directa como indirecta en las vías de transducción de señales de una

variedad de actividades celulares que incluyen la proliferación, adhesión, migración, diferenciación e invasión. Las enfermedades asociadas con actividades de quinasa incluye crecimiento tumoral, la neovascularización patológica que sostiene el crecimiento del tumor sólido, y asociado con otras enfermedades donde está involucrada una excesiva vascularización local tal como enfermedades oculares (retinopatía diabética, degeneración macular relacionada con la edad y similares) e inflamación (psoriasis, artritis reumatoide, y similares)

**[0093]** Sin desear estar ligado a la teoría, las fosfatasas también pueden cumplir un papel en las "enfermedades o patologías dependientes de quinasa" como cognados de quinasas; es decir, las quinasas fosforilan y las fosfatasas desfosforilan, por ejemplo, sustratos lipídicos. En consecuencia, los compuestos de la invención, a la vez que modulan la actividad quinasa como se describe en la presente, también pueden modular en forma directa o indirecta, la actividad de fosfatasa. Esta modulación adicional, si está presente, puede ser sinérgica (o no) con la actividad de los compuestos de la invención hacia una quinasa relacionada o quinasa interdependiente de otro modo o familia de quinasa. En cualquier caso, como se indicó previamente, los compuestos de la invención son útiles para tratar enfermedades caracterizadas en parte por niveles anormales de proliferación celular (*es decir* crecimiento tumoral), muerte celular programada (apoptosis), migración e invasión celular y angiogénesis asociada con crecimiento tumoral

**[0094]** "Metabolito" se refiere al producto de degradación o final de un compuesto o su sal producida

por el metabolismo o la biotransformación del cuerpo animal o humano; por ejemplo, biotransformación a una molécula más polar tal como por oxidación, reducción, o hidrólisis, o a un conjugado (ver Goodman y Gilman, "The Pharmacological Basis de Therapeutics" 8.sup.th Ed., Pergamon Press, Gilman et al.. (eds), 1990 para una discusión de biotransformación). Como se usa en la presente, el metabolito de un compuesto de la invención o su sal puede ser una forma biológicamente activa del compuesto en el cuerpo. En un ejemplo, se puede usar un profármaco de modo que la forma biológicamente activa, un metabolito, se libere *in vivo*. En otro ejemplo, un metabolito biológicamente activo se descubre casualmente, es decir, no se llevó a cabo un diseño del profármaco *per se*. Un ensayo para determinar la actividad de un metabolito de un compuesto de esta invención es conocido por los expertos en el arte a la luz de la presente descripción.

**[0095]** "Paciente" para los fines de la presente invención incluye seres humanos y otros animales, en particular mamíferos y otros organismos. En consecuencia los métodos son aplicables en aplicaciones de terapia humana y veterinaria. En otra forma de realización preferida el paciente es un mamífero, y en otra forma de realización más preferida el paciente es humano.

**[0096]** Una "sal farmacéuticamente aceptable" de un compuesto significa una sal que es farmacéuticamente aceptable y que posea la actividad farmacológica deseada del compuesto original. Se considera que las sales farmacéuticamente aceptables son no tóxicas. La información adicional de las sales farmacéuticamente aceptables adecuadas en *Remington's Pharmaceutical Sciences*, 17$^{th}$ ed., Mack Publishing Company, Easton, PA,

1985, que se incorpora en la presente como referencia o S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19 las cuales se incorporan en la presente como referencia.

**[0097]** Los ejemplos de sales de adición de ácidos farmacéuticamente aceptables incluyen los formados con ácidos inorgánicos tales como ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido nítrico, ácido fosfórico, y similares; así como ácidos orgánicos tales como ácido acético, ácido trifluoroacético, ácido propiónico, ácido hexanoico, ácido ciclopentanopropiónico, ácido glicólico, ácido pirúvico, ácido láctico, ácido oxálico, ácido maleico, ácido malónico, ácido succínico, ácido fumárico, ácido tartárico, ácido cítrico, ácido benzoico, ácido cinámico, ácido 3-(4-hidroxibenzoil)benzoico, ácido mandélico, ácido metansulfónico, ácido etansulfónico, ácido 1,2-etandisulfónico, ácido 2-hidroxietansulfónico, ácido bencensulfónico, ácido 4-clorobencensulfónico, ácido 2-naftalenosulfónico, ácido 4-toluensulfónico, ácido canforsulfónico, ácido glucoheptónico, ácido 4,4'-metilenbis-(3-hidroxi-2-ene-1-carboxílico), ácido 3-fenilpropiónico, ácido trimetilacético, ácido ter-butilacético, ácido lauril sulfúrico, ácido glucónico, ácido glutámico, ácido hidroxinaftoico, ácido salicílico, ácido esteárico, ácido mucónico ácido p-toluensulfónico y ácido salicílico y similares.

**[0098]** Los ejemplos de las sales de adición de base farmacéuticamente aceptables incluyen las formadas cuando un protón ácido presente en el compuesto original está reemplazado por un ion metálico, tal como sales de sodio, potasio, litio, amonio, calcio, magnesio, hierro, zinc, cobre, manganeso, aluminio y similares. Las sales

preferibles son sales de amonio, potasio, sodio, calcio, y magnesio. Las sales derivadas de bases no tóxicas orgánicas farmacéuticamente aceptables incluyen, pero sin limitación, sales de aminas primarias, secundarias y terciarias, aminas sustituidas que incluyen aminas cíclicas y resinas de intercambio iónico. Los ejemplos de bases orgánicas incluyen isopropilamina, trimetilamina, dietilamina, trietilamina, tripropilamina, etanolamina, 2-dimetilaminoetanol, 2-dietilaminoetanol, diciclohexilamina, lisina, arginina, histidina, cafeína, procaína, hidrabamina, colina, betaína, etilendiamina, glucosamina, metilglucamina, teobromina, purinas, piperazina, piperidina, N-etilpiperidina, trometamina, *N*-metilglucamina, resinas de poliamina, y similares. Los ejemplos de bases orgánicas son isopropilamina, dietilamina, etanolamina, trimetilamina, diciclohexilamina, colina, y cafeína.

**[0099]** "Platino" y "agente que contiene platino" incluye por ejemplo, cisplatino, carboplatino y oxaliplatino.

**[00100]** Profármaco" se refiere a los compuestos que se transforman (normalmente en forma rápida) *in vivo* para producir el compuesto original de las fórmulas anteriores, por ejemplo, por hidrólisis en sangre. Los ejemplos comunes incluyen pero sin limitación, formas éster y amida de un compuesto que tiene una forma activa que porta un residuo ácido carboxílico. Los ejemplos de ésteres farmacéuticamente aceptables de los compuestos de la invención incluyen pero sin limitación, ésteres de alquilo (por ejemplo entre aproximadamente uno y aproximadamente seis carbonos), el grupo alquilo es una cadena lineal o ramificada. Los ésteres aceptables también incluyen ésteres de cicloalquilo y ésteres de arilalquilo tales como, pero sin limitación bencilo. Los

ejemplos de amidas farmacéuticamente aceptables de los compuestos de esta invención incluyen pero sin limitación, amidas primarias y alquilamidas secundarias y terciarias (por ejemplo, con entre aproximadamente uno y aproximadamente seis carbonos). Las amidas y los ésteres de los compuestos de la presente invención se pueden preparar de acuerdo con métodos convencionales. Una descripción completa de profármacos se proporciona en T. Higuchi y V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 de A.C.S. Symposio Series, y en Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association y Pergamon Press, 1987, que se incorporan en la presente como referencia para todos los fines

**[00101]** "Inhibidor de Raf" incluye, por ejemplo, sorafenib, RAF 265 (CHIR 265), compuestos de la Tabla 6, y los compuestos descriptos en WO 2005/112932. Estas referencias también describen ensayos in vitro que se pueden usar para determinar la actividad inhibidora de RAF.

**[00102]** "Análogo de rapamicina" incluye por ejemplo, CCI-779, AP23573, RAD 001, TAFA 93, y los compuestos descriptos en WO 2004/101583 y US 7,160,867 que se incorporan en la presente por referencia en su totalidad.

**[00103]** "Inhibidor del receptor de tirosina quinasa" incluye, por ejemplo, los inhibidores de AKT, EGFR, ErbB2, IGF1R, KIT, Met, Raf, y VEGFR2. Los ejemplos de los inhibidores del receptor de tirosina quinasa se pueden hallar en WO 2006/108059 (Solicitud de etapa Nat'l de US serie No. 11/910,720), WO 2006/074057 (Solicitud de etapa Nat'l de US serie No. 11/722,719), WO 2006/071819 (Solicitud de etapa Nat'l de US serie No. 11/722,291), WO 2006/014325 (Solicitud de etapa Nat'l de US serie No.

11/571,140), WO 2005/117909 (Solicitud de etapa Nat'l de US serie No. 11/568,173), WO 2005/030140 (Solicitud de etapa Nat'l de US serie No. 10/573,336), WO 2004/050681 Solicitud de etapa Nat'l de US serie No. 10/533,555), WO 2005/112932 (Solicitud de etapa Nat'l de US serie No. 11/568,789), y WO 2004/006846 (Solicitud de etapa Nat'l de US serie No. 10/522,004), cada una de las cuales se incorpora en la presente por referencia para todos los fines. En particular, las solicitudes mencionadas en este párrafo se incorporan para el fin de proporcionar ejemplos específicos y formas de realizaciones genéricas (y las definiciones asociadas los términos usados en las formas de realización) de los compuestos que sean útiles en la práctica de la invención. Estas referencias también describen en los ensayos in vitro útiles en la práctica de esta invención.

**[00104]** "Taxano" incluye, por ejemplo, uno o más de los siguientes: Paclitaxel (Taxol®) y Docetaxel (Taxotere®).

**[00105]** Cantidad terapéuticamente efectiva" es una cantidad de un compuesto de la invención, que cuando se administra a un paciente cuando se administra a un paciente, mejora un síntoma de la enfermedad. La cantidad de un compuesto de esta descripción que constituye una "cantidad terapéuticamente efectiva" variará de acuerdo con el compuesto, el estado de enfermedad y su gravedad, la edad del paciente tratado, y similares. La cantidad terapéuticamente efectiva puede ser determinada de rutina por los expertos en el arte tomando en cuenta su conocimiento y esta descripción-

**[00106]** Inhibidor de topoisomerasa" incluye, por ejemplo, no o más de los siguientes: amsacrina, camptotecina, etopósido, fosfato de etopósido, exatecano, irinotecano, lurtotecano y tenipósido, y topotecano.

**[00107]** "Tratar" o "tratamiento" de una enfermedad, trastorno o síndrome, como se usa en la presente, incluye (i) prevenir la enfermedad, trastorno o síndrome que ocurren en un ser humano, es decir, provocar que los síntomas clínicos de la enfermedad, trastorno o síndrome no se desarrollen en un animal que puede estar expuesto o predispuesto a la enfermedad, trastorno o síndrome pero que aún no experimentan o exhiben síntomas de la enfermedad, trastorno o síndrome; (ii) inhibir la enfermedad, trastorno o síndrome, *es decir*, detener su desarrollo; y (iii) aliviar la enfermedad, trastorno o síndrome, *es decir*, causar regresión de la enfermedad, trastorno o síndrome. Como es conocido en el arte, se pueden necesitar ajustes para la administración sistémica versus localizada, edad, peso corporal, salud general, sexo, dieta, tiempo de administración, interacción farmacológica y la gravedad de la condición patológica y podrán ser establecidos con la experimentación de rutina por los expertos en el arte.

**[00108]** "Inhibidor de SRC y/o ABL quinasa" incluye, por ejemplo, dasatinib, imatinib (Gleevec®), y los compuestos descriptos en WO 2006/074057.

**[00109]** "Inhibidor de VEGFR" incluye, por ejemplo, uno o más de los siguientes: VEGF Trap, ZD6474 (vandetanib, Zactima), sorafenib, Angiozyme, AZD2171 (cediranib), pazopanib, sorafenib, axitinib, SU5416 (semaxanib), PTK787 (vatalanib), AEE778, RAF 265, sunitinib (Sutent), *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-

metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, compuestos de la Tabla 7, y los compuestos descriptos en WO 2004/050681 y WO 2004/006846.

**Formas de la realización de la invención**

**[00110]** Los siguientes párrafos presentan numerosas realizaciones de compuestos de la invención. En cada caso, la forma de realización incluye los compuestos mencionados así como los isómeros individuales y las mezclas de isómeros. Además, en cada caso, la forma de realización opcionalmente incluye las sales, hidratos y/o solvatos farmacéuticamente aceptables de los compuestos mencionados y cualquiera de los isómeros individuales o mezclas de los isómeros de estos.

**[00111]** Para cada una de las siguientes formas de realización, el Compuesto de Fórmula I, por ejemplo, puede ser de Fórmula I(a) o se puede seleccionar de un Compuesto de la Tabla 1.

**[00112]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, donde el crecimiento y/o la supervivencia de las células tumorales del cáncer están aumentados, al menos en parte, por la actividad de PI3K; en combinación con uno o más tratamientos seleccionado de cirugía, uno o más agentes quimioterapéuticos, una o más terapias hormonales, uno o más anticuerpos, una o más inmunoterapias, terapia de yodo radiactivo, y radiación.

**[00113]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, uno o más agentes quimioterapéuticos, una o más terapias hormonales, uno o más anticuerpos, una o más inmunoterapias, terapia de yodo radiactivo, y radiación; donde el cáncer se selecciona de cáncer de mamas, cáncer de colon, cáncer rectal, cáncer de endometrio, carcinoma gástrico (que incluye tumores carcinoides gastrointestinales y tumores estromales gastrointestinales), glioblastoma, carcinoma hepatocelular, cáncer pulmonar de células pequeñas, cáncer pulmonar de células no pequeñas (NSCLC), melanoma, cáncer ovárico, cáncer cervical, cáncer pancreático, carcinoma prostático, leucemia mielógena aguda (AML), leucemia mielógena crónica (CML), linfoma no Hodgkin, y carcinoma tiroideo. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, uno o más agentes quimioterapéuticos, una o más terapias hormonales, uno o más anticuerpos, una o más inmunoterapias, terapia de yodo radiactivo, y radiación; donde el cáncer es seleccionado de cáncer de próstata, NSCLC, cáncer ovárico, cáncer cervical, cáncer de mamas, cáncer de colon, cáncer rectal, y glioblastoma. En otra forma de realización, la invención se refiere a un método de

tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, uno o más agentes quimioterapéuticos, una o más terapias hormonales, uno o más anticuerpos, una o más inmunoterapias, terapia de yodo radiactivo, y radiación; donde el cáncer es seleccionado de NSCLC, cáncer de mamas, cáncer de próstata, glioblastoma, y cáncer ovárico.

**[00114]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o más agentes quimioterapéuticos.

**[00115]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, un análogo de rapamicina, un agente alquilante, a taxano, un platino, un inhibidor de EGFR, y un inhibidor de ErbB2. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el

tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, temozolomide, paclitaxel, docetaxel, carboplatino, cisplatino, oxaliplatino, gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), HKI-272, pelitinib, canertinib, un compuesto seleccionado de Tabla 4, un compuesto de la Tabla 7, y lapatinib. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, temozolomide, paclitaxel, docetaxel, carboplatino, trastuzumab, erlotinib, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, un compuesto de la Tabla 7, y lapatinib. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos

seleccionados de modo independiente rapamicina, paclitaxel, carboplatino, erlotinib, y *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina.

**[00116]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente un platino y un taxano. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente carboplatino, cisplatino, oxaliplatino, y paclitaxel.

**[00117]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de AKT. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en

la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de AKT seleccionado de perifosina, PKC 412, un compuesto de la Tabla 2a, y un compuesto de la Tabla 2b.

**[00118]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de cMET. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de cMET seleccionado de un compuesto de la Tabla 3a, un compuesto de la Tabla 3b, y un compuesto de la Tabla 3c.

**[00119]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de EGFR. En otra forma de realización, la invención se refiere a un

método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de EGFR seleccionado de lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), AEE788, HKI-272, EKB-569, CI 1033, un compuesto seleccionado de la Tabla 4, y un compuesto de la Tabla 7. En otra forma de realización, En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de EGFR seleccionado de lapatinib (Tykerb®), gefitinib (Iressa®), erlotinib (Tarceva®), Zactima (ZD6474), AEE788, HKI-272, EKB-569, CI 1033, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, y *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina.

**[00120]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de ErbB2. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de ErbB2 seleccionado de lapatinib, EKB-569, HKI272, CI 1033, PKI-166, y un compuesto seleccionado de la Tabla 4.

**[00121]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de HSP90. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes

quimioterapéuticos es un inhibidor de HSP90 seleccionado de 17-AAG, 17-DMAG, Geldanamicina, y CNF2024. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de HSP90 seleccionado de 17-AAG, 17-DMAG, y Geldanamicina.

**[00122]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de IGF1R. En otra forma de realización, En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de IGF1R seleccionado de la Tabla 5a y Tabla 5b.

**[00123]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es

uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de Raf. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de Raf seleccionado de sorafenib, RAF 265 (CHIR-265), y un compuesto de la Tabla 6.

**[00124]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de VEGFR. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de VEGFR seleccionado de VEGF Trap, ZD6474 (Zactima), cediranib (AZ2171), pazopanib, sunitinib, sorafenib, axitinib, AEE788, RAF 265 (CHIR-265), un compuesto seleccionado de la Tabla 4, y un compuesto seleccionado de la Tabla 7.

**[00125]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de cKIT. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de cKIT seleccionado de imatinib, sunitinib, nilotinib, AMG 706, sorafenib, un compuesto de la Tabla 3b, un compuesto de la Tabla 3c, un compuesto de la Tabla 8, y un compuesto de la Tabla 9.


**[00126]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de FLT3. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes

quimioterapéuticos donde uno de los agentes quimioterapéuticos es un inhibidor de FLT3 seleccionado de CEP-701, PKC 412, sunitinib, MLN518, sunitinib, sorafenib, un compuesto de la Tabla 3a, un compuesto de la Tabla 3b, un compuesto de la Tabla 3c, y un compuesto de la Tabla 9.

**[00127]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de rapamicina, un análogo de rapamicina, PI103, y SF 1126. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de rapamicina, CCI-779, AP23573, RAD 001, TAFA 93, PI103, y SF 1126. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es rapamicina.

**[00128]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es de fórmula 100:



100

donde q es 1, 2, o 3; E es $-NR^9-$, -O-, o ausente e Y es $-CH_2CH_2-$, $-CH_2-$, o ausente con la condición de que cuando E es $-NR^9-$ o -O-, luego Y es $-CH_2CH_2-$; $R^2$ se selecciona de halógeno, trihalometilo, -CN, $-NO_2$, $-OR^3$, y alquilo inferior; $R^8$ se selecciona de -H, alquilo inferior, $-C(O)OR^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, y $-C(O)R^3$; $R^9$ es hidrógeno o alquilo inferior; $R^3$ es hidrógeno o $R^4$; $R^4$ se selecciona de alquilo inferior, arilo, arilalquilo inferior, heterociclilo, y heterociclilalquilo inferior; o $R^3$ y $R^4$, cuando se toman juntos con un nitrógeno común al que están unidos, forman un heterociclilo de cinco a siete miembros, dicho heterociclilo de cinco a siete miembros opcionalmente contiene uno o más heteroátomos adicionales seleccionados de N, O, S, y P; o un isómero geométrico simple, estereoisómero, racemato, enantiómero o diastereómero de este y opcionalmente en forma de sal farmacéuticamente aceptable, en forma adicional opcionalmente como un solvato, y en forma adicional como un hidrato. Los términos usados para describir el alcance de la fórmula 100 se definen en WO 2004/006846 (Solicitud de etapa Nat'l de US serie No. 10/522,004) que se incorpora en la presente como referencia. cuando se

toman juntos con un nitrógeno común al que están unidas, forman un heterociclilo de cinco a siete miembros, dicho heterocicilo de cinco a siete miembros opcionalmente que contiene uno o más heteroátomos adicionales seleccionados de N, O, S, y P; o uno de sus isómero geométricos, estereoisómeros, racematos, enantiómeros o diastereómeros simples y opcionalmente en forma de sal farmacéuticamente aceptable, en forma adicional opcionalmente como un solvato y en forma adicional como un hidrato de este. Los términos usados para describir el alcance de la fórmula 100 se definen en WO 2004/006846 (Solicitud de etapa Nat'l de US serie No. 10/522,004) que se incorpora en la presente como referencia. Cuando un compuesto de Fórmula 100 se describe en esta solicitud, sea por la estructura o por uso del término "fórmula 100", los términos usados para describir este compuesto se definen por WO 2004/006846 (Solicitud de etapa Nat'l de US serie No. 10/522,004). En particular, "alquilo" de la fórmula 100 se considera que incluye estructuras hidrocarbonados lineales, ramificados o cíclicas y sus combinaciones, inclusivamente; "alquilo inferior" significa grupos alquilo de uno a seis átomos de carbono. "Arilo" de la fórmula 100 significa anillos carbocíclicos carbocíclicos aromáticos de seis a catorce miembros que incluyen, por ejemplo, benceno, naftaleno, indano, tetralina, fluoreno y similares. "Arilalquilo inferior" de la fórmula 100 significa un residuo en que un residuo arilo se une a una estructura original por medio de un radical alquileno, alquenileno o alquinileno donde la porción "alquilo" del grupo tiene uno a seis carbonos; los ejemplos incluyen bencilo, fenetilo, fenilvinilo, fenilalilo y similares. En la fórmula 100, "heterociclilo" significa un radical anular estable monocíclico, bicíclico o tricíclico de

tres a quince miembros (que incluyen sistemas anulares fusionados o on puentes) que consisten en átomos de carbono y de uno a cinco heteroátomos seleccionados del grupo que consiste en nitrógeno, fósforo, oxígeno y azufre donde los átomos de nitrógeno, fósforo, carbono y azufre del radical heterociclilo puede estar opcionalmente oxidado a varios estados de oxidación y el átomo de nitrógeno puede estar opcionalmente cuaternizado; y el radical anular puede estar parcial o completamente saturado o aromático. "Heterociclilalquilo inferior" significa un residuo en el que un heterociclilo se une a una estructura original por medio de un radical alquileno, alquenileno y alquinileno que tiene uno a seis carbonos.

**[00129]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 2a. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 2a. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad

terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 2a.

**[00130]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 2b. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 2b. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 2b.

**[00131]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3a. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3a. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3a.

**[00132]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3b. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho

método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3b. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3b.

**[00133]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3c. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3c. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 3c.

**[00134]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 4. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 4. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 4.

**[00135]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, o *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-

(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, o *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, o *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

**[00136]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-

metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

**[00137]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 5ac. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 5a. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 5a.

**[00138]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad

terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 5b. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 5b. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 5b.

**[00139]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 6. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad

terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 6. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 6.

**[00140]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 7. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 7. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad

terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 7.

**[00141]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 8. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 8. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 8.

**[00142]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 9. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a), en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 9. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1, en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos se selecciona de un compuesto de la Tabla 9.

**[00143]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde el agente quimioterapéutico es paclitaxel.

**[00144]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde el agente quimioterapéutico es rapamicina.

**[00145]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde el agente quimioterapéutico es carboplatino.

**[00146]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde el agente quimioterapéutico es erlotinib.

**[00147]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos agentes quimioterapéuticos donde el agente quimioterapéutico es lapatinib.

**[00148]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad

terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos donde uno de los anticuerpos es trastuzumab.

**[00149]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos donde uno de los anticuerpos es cetuximab.

**[00150]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos donde uno de los anticuerpos es panitumumab.

**[00151]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos donde uno de los anticuerpos es bevacizumab.

**[00152]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es radiación. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde el tratamiento es radiación. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es radiación.

**[00153]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos seleccionados de modo independiente un anticuerpo de IGF1R (que incluye, por ejemplo, "IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7$C_{10}$ MoAb y $^{\alpha}$IGF-1R CP-751871 MoAb), alemtuzumab, bevacizumab (Avastin®), gemtuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, panitumumab, rituximab, tositumomab, omnitarg (pertuzimab), anticuerpos de anti-ErbB2 (que incluyen trastuzumab (Herceptin®)), y los anticuerpos anti-EGFR (que incluye, por ejemplo, cetuximab (Erbitux), panitumumab, nimotuzumab, y EMD72000)).

**[00154]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos seleccionados de modo independiente un anticuerpo de IGF1R (que incluye, por ejemplo, $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C$_{10}$ MoAb y $^{\alpha}$IGF-1R CP-751871 MoAb), alemtuzumab, bevacizumab (Avastin®), gemtuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, panitumumab, rituximab, tositumomab, omnitarg (pertuzimab), anticuerpos anti-ErbB2 (que incluyen trastuzumab (Herceptin®)), y anticuerpos anti-EGFR (que incluyen, por ejemplo, cetuximab (Erbitux), panitumumab, nimotuzumab, y EMD72000)).

**[00155]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos anticuerpos. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es

uno o dos anticuerpos seleccionados de modo independiente un anticuerpo de IGF1R (que incluye, por ejemplo, $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C$_{10}$ MoAb y $^{\alpha}$IGF-1R CP-751871 MoAb), alemtuzumab, bevacizumab (Avastin®), gemtuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, panitumumab, rituximab, tositumomab, omnitarg (pertuzimab), anticuerpos anti-ErbB2 (que incluyen trastuzumab (Herceptin®)), y los anticuerpos anti-EGFR (que incluyen, por ejemplo, cetuximab (Erbitux), panitumumab, nimotuzumab, y EMD72000)).

**[00156]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o más agentes quimioterapéuticos donde el agente quimioterapéutico es temozolomida. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde el tratamiento es uno o más agentes quimioterapéuticos donde el agente quimioterapéutico es temozolomida. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o más agentes quimioterapéuticos donde el agente quimioterapéutico es temozolomida.

**[00157]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es cirugía. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde el tratamiento es cirugía. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es cirugía.

**[00158]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos terapias hormonales. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I o I(a), como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos terapias hormonales seleccionadas de modo independiente tamoxifeno, torremifeno (Fareston), fulvestrant

(Faslodex), acetato de megestrol (Megace), extirpación de ovarios, raloxifeno, un análogo de liberación de hormoa luteinizante (LHRH) (que incluyen goserelina y leuprolida), acetato de megestrol (Megace), y uno o más inhibidores de aromatasa. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I o I(a), como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es una o dos terapias hormonales es un inhibidor de aromatasa seleccionado de letrozol (Femara), anastrozol (Arimidex), y exemestane (Aromasin). En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I o I(a), como se define en la Síntesis de la invención, en combinación con un tratamiento donde el tratamiento es uno o dos terapias de hormonas seleccionadas de modo independiente de tamoxifeno y un inhibidor de aromatasa.

**[00159]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde el tratamiento es uno o dos terapias hormonales. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde uno de los tratamientos es uno o dos terapias hormonales

seleccionadas de modo independiente tamoxifeno, torremifeno (Fareston), Fulvestrant (Faslodex), acetato de megestrol (Megace), extirpación de ovarios, raloxifeno, un análogo de liberación de hormona luteinizante (LHRH) (que incluyen goserelina y leuprolida), acetato de megestrol (Megace), y uno o dos inhibidor de aromatasas. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde uno de los tratamientos es uno o dos terapias hormonales donde una de las terapias hormonales es un inhibidor de aromatasas seleccionado de letrozol (Femara), anastrozol (Arimidex), y exemestano (Aromasin). En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde uno de los tratamientos es uno o dos terapias hormonales seleccionados de modo independiente de tamoxifeno y un inhibidor de aromatasa.

**[00160]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con un tratamiento donde uno de los tratamientos es un anticuerpo seleccionado de un anticuerpo EGFR y un anticuerpo ErbB2, o el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente a rapamicina, análogo de rapamicina,

un agente alquilante, un taxano, un platino, un inhibidor de EGFR, y un inhibidor de ErbB2. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I de acuerdo con la Fórmula I(a) en combinación con un tratamiento donde uno de los tratamientos es un anticuerpo seleccionado de un anticuerpo EGFR y un anticuerpo ErbB2, o el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, un análogo de rapamicina, un agente alquilante, un taxano, un platino, un inhibidor de EGFR, y un inhibidor de ErbB2. En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I seleccionado de Tabla 1 en combinación con un tratamiento donde uno de los tratamientos es un anticuerpo seleccionado de un anticuerpo EGFR y un anticuerpo ErbB2, o el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, un análogo de rapamicina, un agente alquilante, un taxano, un platino, un inhibidor de EGFR, y un inhibidor de ErbB2.

**[00161]** En otra forma de realización, la invención se refiere a un método de tratar leucemia mielógena aguda (AML) dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente trasplante de médula ósea o células madre de sangre periférica, radiación, uno o dos anticuerpos, y uno o dos agentes quimioterapéuticos. En

otra forma de realización, la invención se refiere a un método de tratar leucemia mielógena aguda (AML) dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un anticuerpo seleccionado de Gemtuzumab ozogamicina (Milotarg), $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C$_{10}$ MoAb, $^{\alpha}$IGF-1R CP-751871 MoAb y trastuzumab. En otra forma de realización, la invención se refiere a un método de tratar leucemia mielógena aguda (AML) dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionado de Imatinib (es decir Gleevec®), PKC 412, CEP-701, daunorrubicina, doxorrubicina, citarabina (ara-C), un fármaco antraciclina tal como daunorrubicina o idarrubicina (Daunomicina, Idamicina), 6-tioguanina, y un factor estimulante de colonia de granulocitos (tales como Neupogen o Leukine).

**[00162]** En otra forma de realización, la invención se refiere a un método de tratar leucemia mielógena crónica (CML) dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente trasplante de médula ósea o células madre de sangre periférica, radiación, uno o dos agentes quimioterapéuticos, inmunoterapia, y uno o dos anticuerpos. En otra forma de realización, la invención se refiere a un método de tratar leucemia mielógena

crónica (CML) dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de los agentes quimioterapéuticos seleccionado de Imatinib (es decir Gleevec®), PKC 412, hidroxiurea (Hydrea), citosina, citosina arabinoside, dasatinib, AMN107, VX680 (MK0457), y citarabina (ara-C). En otra forma de realización, la invención se refiere a un método de tratar leucemia mielógena crónica (CML) dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionado de Imatinib (es decir Gleevec®) y dasatinib. En otra forma de realización, la invención se refiere a un método de tratar leucemia mielógena crónica (CML) dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es inmunoterapia y la inmunoterapia es terapia de interferón tales como interferón-α.

**[00163]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de próstata dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía (que incluyen criocirugía), radiación, uno o dos agentes quimioterapéuticos, uno o

dos anticuerpos, y uno o dos terapias hormonales. En otra forma de realización, la invención se refiere a un método de tratar cáncer de próstata dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un anticuerpo seleccionado de $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C$_{10}$ MoAb, y $^{\alpha}$IGF-1R CP-751871 MoAb. En otra forma de realización, la invención se refiere a un método de tratar cáncer de próstata dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de los agentes quimioterapéuticos seleccionados de modo independiente rapamicina, mitoxantrona, prednisona, docetaxel (Taxotere), doxorrubicina, etopósido, vinblastina, paclitaxel, y carboplatino. En otra forma de realización, la invención se refiere a un método de tratar cáncer de próstata dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de la terapia hormonal seleccionada de modo independiente de terapia de deprivación de andrógenos y terapia de supresión de andrógenos. En otra forma de realización, la invención se refiere a un método de tratar cáncer de próstata dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en

combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es un taxanos. En otra forma de realización, la invención se refiere a un método de tratar cáncer de próstata dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos donde uno de los agentes quimioterapéuticos es rapamicina.

**[00164]** En otra forma de realización, la invención se refiere a un método de tratar melanoma dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, una o dos inmunoterapias, uno o dos terapias hormonales, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar melanoma dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente un agente alquilante, un taxano, un platino, y un inhibidor de Raf. En otra forma de realización, la invención se refiere a un método de tratar melanoma dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I,

como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente sorafenib, Paclitaxel (Taxol®), Docetaxel (Taxotere®), dacarbazina, rapamicina, imatinib mesilate (Gleevec®), sorafenib, cisplatino, carboplatino, dacarbazine (DTIC), carmustina (BCNU), vinblastina, temozolomida (Temodar), Melphalan, y imiquimod (Aldara). En otra forma de realización, la invención se refiere a un método de tratar melanoma dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es una o dos inmunoterapias seleccionadas de modo independiente ipilimumab, interferon-alfa e interleuquina-2. En otra forma de realización, la invención se refiere a un método de tratar melanoma dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es terapia hormonal donde la terapia hormonal es tamoxifeno.

**[00165]** En otra forma de realización, la invención se refiere a un método de tratar colon o cáncer rectal dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, uno o dos anticuerpos, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un

método de tratar colon o cáncer rectal dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es cirugía seleccionada de escisión local, electrofulguración, resección de colon segmentario, polipectomía, resección transanal local, resección anterior baja, resección abdominoperineal y exenteración pélvica. En otra forma de realización, la invención se refiere a un método de tratar colon o cáncer rectal dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente un compuesto que contiene platino (que incluye cisplatino, oxaliplatino, y carboplatino), 5-fluorouracilo (5-FU), leucovorina, capecitabina (Xeloda), irinotecano (Camptosar), FOLFOX (Ácido folínico, 5-FU, oxaliplatino), y leucovorina. En otra forma de realización, la invención se refiere a un método de tratar colon o cáncer rectal dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos anticuerpos seleccionados de modo independiente cetuximab (Erbitux) y bevacizumab (Avastin).

**[00166]** En otra forma de realización, la invención se refiere a un método de tratar cáncer pancreático dicho método comprende administrar a un paciente una cantidad

terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, uno o dos anticuerpos, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar cáncer pancreático dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos se selecciona de uno o dos agentes quimioterapéuticos seleccionados de modo independiente compuesto que contiene platino (que incluye cisplatino, oxaliplatino, y carboplatino), 5-fluorouracilo (5-FU), gemcitabina, un taxano (que incluye paclitaxel y docetaxel), topotecano, irinotecano, capecitabina, streptozocin, erlotinib (Tarceva), leucovorina, y capecitabina (Xeloda). En otra forma de realización, la invención se refiere a un método de tratar cáncer pancreático dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un anticuerpo donde el anticuerpo es cetuximab.

**[00167]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, uno o dos agentes

quimioterapéuticos, uno o dos terapias hormonales, y uno o dos anticuerpos. En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de los agentes quimioterapéuticos seleccionados de modo independiente lapatinib (Tykerb®), Paclitaxel (Taxol®), docetaxel, capecitabina, Ciclofosfamida (Cytoxan), CMF (ciclofosfamida, fluoruracilo, y metotrexato), metotrexato, fluorouracilo, doxorrubicina, epirrubicina, gemcitabina, carboplatino (Paraplatin), cisplatino (Platinol), vinorelbina (Navelbine), capecitabina (Xeloda), doxorrubicina liposómica pegilada (Doxilo), paclitaxel unida a albúmina (Abraxane), AC (adriamicina y ciclofosfamida), adriamiclina, y pamidronato o ácido zoldrónico (para tratar debilidad ósea). En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos terapias hormonales seleccionados de modo independiente tamoxifeno, torremifeno (Fareston), Fulvestrant (Faslodex), acetato de megestrol (Megace), extirpación ovárica, Raloxifeno, análogos de hormona liberadora de hormona luteinizante (LHRH) (que incluye goserelina y leuprolida), acetato de megestrol (Megace), y uno o más inhibidores de aromatasas. En otra forma de realización, la invención se refiere a un método de tratar cáncer de

mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos terapias hormonales y una de las terapias hormonales es un inhibidor de aromatasas seleccionado de letrozol (Femara), anastrozol (Arimidex), y exemestano (Aromasin). En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos anticuerpos seleccionados de modo independiente $^{\alpha}$IGF-1R A12 MoAb, $^{\alpha}$IGF-1R 19D12 MoAb, $^{\alpha}$IGF-1R h7C$_{10}$ MoAb, $^{\alpha}$IGF-1R CP-751871 MoAb, bevacizumab (Avastin), y trastuzumab.

**[00168]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos y uno de los agentes quimioterapéuticos es erlotinib.

**[00169]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de los agentes quimioterapéuticos y uno o dos de los agentes

quimioterapéuticos se seleccionan de modo independiente rapamicina, lapatinib, erlotinib, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de una sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este, y *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

**[00170]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de los anticuerpos. En otra

forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos anticuerpos y uno de los anticuerpos es trastuzumab.

**[00171]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de los agentes quimioterapéuticos y uno de los agentes quimioterapéuticos se selecciona de *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, y *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina; opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

**[00172]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de mamas dicho método comprende administrar a un paciente una cantidad

terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos de los agentes quimioterapéuticos y uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

**[00173]** En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células no pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, uno o más anticuerpos, y uno o más agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células no pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente cisplatino, oxaliplatino, carboplatino, zactima (zd6474), paclitaxel, docetaxel (Taxotere®), gemcitabine (Gemzar®), vinorelbina, irinotecano, etopósido, vinblastina, erlotinib (Tarceva®), gefitinib (iressa), y pemetrexed. En otra forma de realización, la invención se refiere a un método de tratar cáncer

pulmonar de células no pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un anticuerpo y el anticuerpo es Bevacizumab. En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células no pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente cisplatino, oxaliplatino, carboplatino, paclitaxel, docetaxel (Taxotere®), y erlotinib (Tarceva®).

**[00174]** En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células no pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos y uno de los agentes quimioterapéuticos es carboplatino.

**[00175]** En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células no pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos y uno de los agentes

quimioterapéuticos se selecciona de *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, y *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina; opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este. En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células no pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos y uno de los agentes quimioterapéuticos es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

**[00176]** En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención,

en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar cáncer pulmonar de células pequeñas dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes de quimioterapia seleccionados de modo independiente un platino (tales como cisplatino, oxaliplatino, y carboplatino), gefitinib, vinorelbina, docetaxel, paclitaxel, etopósido, fosfamida, ifosfamida, ciclofosfamida, ciclofosfamida/doxorrubicina/vincristina (CAV), doxorrubicina, vincristina, gemcitabina, paclitaxel, vinorelbina, topotecano, irinotecano, metotrexato, y docetaxel.

**[00177]** En otra forma de realización, la invención se refiere a un método de tratar cáncer tiroideo papilar o anaplásico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, terapia de yodo radiactivo, uno o dos terapias hormonales, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar cáncer tiroideo papilar o anaplásico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos

seleccionados de modo independiente pastillas de hormona tiroidea, doxorrubicina y un platino. En otra forma de realización, la invención se refiere a un método de tratar cáncer tiroideo papilar o anaplásico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es terapia hormonal y la terapia hormonal es ablación con yodo radiactivo.

**[00178]** En otra forma de realización, la invención se refiere a un método de tratar cáncer de endometrio dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, uno o dos terapias hormonales, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar cáncer de endometrio dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos terapias hormonales seleccionados de modo independiente acetato de megestrol, tamoxifeno, y una progestina que incluye acetato de medroxiprogesterona (Provera) y acetato de megestrol (Megace). En otra forma de realización, la invención se refiere a un método de tratar cáncer de endometrio dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en

combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente un compuesto que contiene platino (que incluye cisplatino, oxaliplatino, y carboplatino, más particularmente por ejemplo cisplatino), un taxano (que incluye paclitaxel), doxorrubicina (Adriamicina), ciclofosfamida, fluorouracilo (5-FU), metotrexato, y vinblastina.

**[00179]** En otra forma de realización, la invención se refiere a un método de tratar cáncer ovárico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, uno o dos anticuerpos, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar cáncer ovárico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un anticuerpo y el anticuerpo es bevacizumab. En otra forma de realización, la invención se refiere a un método de tratar cáncer ovárico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente un compuesto que contiene platino (que incluye cisplatino, oxaliplatino y carboplatino), un taxano (que incluye paclitaxel y docetaxel), topotecano,

una antraciclina (que incluye doxorrubicina y doxorrubicina liposómica), gemcitabina, ciclofosfamida, vinorelbina (Navelbine), hexametilmelamina, ifosfamida, etopósido, bleomicina, vinblastina, ifosfamida, vincristina, y ciclofosfamida. En otra forma de realización, la invención se refiere a un método de tratar cáncer ovárico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente un platino y un taxano. En otra forma de realización, la invención se refiere a un método de tratar cáncer ovárico dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente cisplatino, oxaliplatino, carboplatino, paclitaxel, y docetaxel.

**[00180]** En otra forma de realización, la invención se refiere a un método de tratar glioblastoma, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, uno o dos agentes quimioterapéuticos, uno o dos agentes anticonvulsivantes y uno o dos agentes para reducir el edema. En otra forma de realización, la invención se refiere a un método de tratar glioblastoma dicho método comprende administrar a

un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es radiación seleccionada de radiación de rayo externo, radioterapia intersticial y radiocirugía estereotáctica. En otra forma de realización, la invención se refiere a un método de tratar glioblastoma, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente carmustina (BCNU), erlotinib (Tarceva), bevacizumab, gefitinib (Iressa), rapamicina, temozolomida, cisplatino, BCNU, lomustina, procarbazina y vincristina. En otra forma de realización, la invención se refiere a un método de tratar glioblastoma, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un agente anticonvulsivante y el agente anticonvulsivante es difenilhidantoína (Dilantin). En otra forma de realización, la invención se refiere a un método de tratar glioblastoma, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un agente para reducir el edema y el agente es dexametasona (Decadron). En otra forma de realización, la invención se refiere a un método de tratar glioblastoma, dicho método comprende

administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar glioblastoma dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente erlotinib y temozolomida.

**[00181]** En otra forma de realización, la invención se refiere a un método de tratar cáncer cervical dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar cáncer cervical dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es cirugía seleccionado de criocirugía, cirugía láser, escisión con asa electroquirúrgica, cotización, histerectomía simple e histerectomía radical y disección de ganglios linfáticos pélvicos. En otra forma de realización, la invención se refiere a un método de tratar cáncer cervical, dicho método comprende administrar a un paciente una cantidad terapéuticamente

efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es radiación seleccionada de la llamada terapia de radiación de rayo externo y braquiterapia. En otra forma de realización, la invención se refiere a un método de tratar cáncer cervical dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente un compuesto de platino (tales como cisplatino, carboplatino, y oxaliplatino), paclitaxel, topotecano, ifosfamida, gemcitabina, vinorelbina, y fluorouracilo.

**[00182]** En otra forma de realización, la invención se refiere a un método de tratar un tumor carcinoide gastrointestinal, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, inmunoterapia, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar a tumor carcinoide gastrointestinal dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es cirugía seleccionado de extirpación y electrofulguración. En otra forma de realización, la invención se refiere a un método de tratar a tumor carcinoide gastrointestinal dicho método comprende

administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente ciproheptadina, SOM230, octreotide y lanreotide. En otra forma de realización, la invención se refiere a un método de tratar a tumor carcinoide gastrointestinal dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es inmunoterapia y la inmunoterapia es un interferón.

**[00183]** En otra forma de realización, la invención se refiere a un método de tratar un tumor estromal gastrointestinal, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, radiación, y uno o dos agentes quimioterapéuticos. En otra forma de realización, la invención se refiere a un método de tratar a tumor estromal gastrointestinal, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente mesilato de imatinib (Gleevec), sunitinib (Sutent), y nilotinib (AMN107).

**[00184]** En otra forma de realización, la invención se refiere a un método de tratar carcinoma hepatocelular,

dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente cirugía, ablación por radiofrecuencia, ablación por etanol, criocirugía, embolización arterial hepática, embolización química, radiación, y uno o dos agentes quimioterapéuticos. Otra forma de realización, la invención se refiere a un método de tratar carcinoma hepatocelular dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es cirugía seleccionada de resección y trasplante. En otra forma de realización, la invención se refiere a un método de tratar carcinoma hepatocelular dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionados de modo independiente sorafenib, 5-fluorouracilo y cisplatino.

**[00185]** En otra forma de realización, la invención se refiere a un método de tratar linfoma no Hodgkin, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos seleccionados de modo independiente radiación, uno o dos agentes quimioterapéuticos, terapia con interferón, uno o dos anticuerpos, y trasplante de médula ósea o células madre de sangre periférica. En otra forma de realización, la

invención se refiere a un método de tratar linfoma no Hodgkin dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es uno o dos agentes quimioterapéuticos seleccionado de CHOP (ciclofosfamida, doxorrubicina, vincristina y prednisona), clorambucilo, fludarabina y etopósido. En otra forma de realización, la invención se refiere a un método de tratar linfoma no Hodgkin dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un anticuerpo seleccionado de rituximab, ibritumomab tiuxetan, tositumomab, y alemtuzumab. En otra forma de realización, la invención se refiere a un método de tratar linfoma no Hodgkin dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es un anticuerpo y el anticuerpo es rituximab.

**[00186]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es radiación y otro tratamiento es cirugía.

**[00187]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método

comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es radiación y otro tratamiento es uno o dos agentes quimioterapéuticos.

**[00188]** En otra forma de realización, la invención se refiere a un método de tratar cáncer, dicho método comprende administrar a un paciente una cantidad terapéuticamente efectiva de un compuesto de Fórmula I, como se define en la Síntesis de la invención, en combinación con uno o más tratamientos donde uno de los tratamientos es cirugía y otro tratamiento es uno o dos agentes quimioterapéuticos.

**[00189]** Para cada una de las formas de realización anteriores, el Compuesto de Fórmula I se selecciona de alguna de las siguientes formas de realización, que incluye los compuestos representativos de la Tabla 1.

**[00190]** Una forma de realización (A) de la invención se refiere a un compuesto de Fórmula I donde $W^1$, $W^2$, $W^3$, y $W^4$ son $-C(R^1)=$; o uno o dos de $W^1$, $W^2$, $W^3$, y $W^4$ son de modo independiente $-N=$ y los restantes son $-C(R^1)=$; donde cada $R^1$ es de modo independiente hidrógeno, alquilo, haloalquilo, nitro, alcoxi, haloalcoxi, halo, hidroxi, ciano, amino, alquilamino, o dialquilamino; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $W^1$, $W^2$, $W^3$, y $W^4$ son $-C(R^1)=$ y cada $R^1$ es de modo independiente hidrógeno o alquilo; o uno de $W^1$ y $W^4$ es $-N=$ y el otro es $-C(H)=$. En otra forma de realización, $W^1$, $W^2$, $W^3$, y $W^4$ son $-C(R^1)=$ donde cada $R^1$ es de modo independiente hidrógeno o alquilo. En otra forma de realización, $R^1$ es hidrógeno.

**[00191]** Otra forma de realización (B) de la invención es un compuesto de Fórmula I donde $R^{50}$ es hidrógeno, alquilo, alquenilo, halo, haloalquilo, haloalquenilo, hidroxi, alcoxi, alqueniloxi, haloalcoxi, nitro, amino, alquilamino, dialquilamino, $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-$N(R^{55a})R^{55b}$, alquilcarbonilo, alquenilcarbonilo, carboxi, alcoxicarbonilo, ciano, alquiltio, $-S(O)_2NR^{55}R^{55a}$, o alquilcarbonilamino; donde $R^{55}$ y $R^{55b}$ son de modo independiente hidrógeno, alquilo, o alquenilo y $R^{55a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{50}$ es hidrógeno.

**[00192]** Otra forma de realización (C) de la invención es un compuesto de Fórmula I donde $R^{51}$ es hidrógeno o alquilo; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{51}$ es alquilo, En otra forma de realización, $R^{51}$ es metilo.

**[00193]** Otra forma de realización (D) de la invención es un compuesto de Fórmula I donde $R^{52}$ es hidrógeno o halo; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización $R^{52}$ es hidrógeno o fluoro. En otra forma de realización, $R^{52}$ es hidrógeno.

**[00194]** Otra forma de realización (E) de la invención es un compuesto de Fórmula I donde $R^{53}$ es hidrógeno, alquilo, alquenilo, halo, haloalquilo, haloalquenilo, hidroxi, alcoxi, alqueniloxi, haloalcoxi, nitro, amino, alquilamino, dialquilamino, $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-$N(R^{55a})R^{55b}$, alquilcarbonilo, alquenilcarbonilo, carboxi, alcoxicarbonilo, ciano, alquiltio, $-S(O)_2NR^{55}R^{55a}$, o alquilcarbonilamino; donde $R^{55}$ y $R^{55b}$ son de modo

independiente hidrógeno, alquilo, o alquenilo y $R^{55a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{53}$ es hidrógeno, alcoxi, nitro, amino, o $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-$N(R^{55a})R^{55b}$. En otra forma de realización, $R^{53}$ es hidrógeno, metoxi, nitro, amino, o $-NHC(O)CH_2N(CH_3)_2$. En otra forma de realización, $R^{53}$ es hidrógeno o metoxi.


**[00195]** Otra forma de realización (F) de la invención es un compuesto de Fórmula I donde $R^{54}$ es hidrógeno, alquilo, alquenilo, halo, haloalquilo, haloalquenilo, hidroxi, alcoxi, alqueniloxi, haloalcoxi, nitro, amino, alquilamino, dialquilamino, $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-$N(R^{55a})R^{55b}$, alquilcarbonilo, alquenilcarbonilo, carboxi, alcoxicarbonilo, ciano, alquiltio, $-S(O)_2NR^{55}R^{55a}$, o alquilcarbonilamino; donde $R^{55}$ y $R^{55b}$ son de modo independiente hidrógeno, alquilo, o alquenilo y $R^{55a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{54}$ es hidrógeno, alquilo, alcoxi, o halo. En otra forma de realización, $R^{54}$ es hidrógeno, metilo, metoxi, bromo, o cloro. En otra forma de realización, $R^{54}$ es hidrógeno, metoxi, o cloro.

**[00196]** Otra forma de realización (G) de la invención se refiere a un compuesto de Fórmula I donde $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es halo o alcoxi; $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es alcoxi; o $R^{50}$ y $R^{52}$ son hidrógeno y $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 6 miembros; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es cloro o metoxi; $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$

es metoxi; o $R^{50}$ y $R^{52}$ son hidrógeno y $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman piridinilo. Aun más específicamente, $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es cloro o metoxi; o $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es metoxi.

**[00197]** En otra forma de realización (G1) de la forma de realización G es un compuesto de Fórmula I donde $R^{51}$ es metilo.

**[00198]** Otra forma de realización (H) de la invención es un compuesto de Fórmula I donde B es fenilo sustituido con $R^{3a}$ y opcionalmente también sustituido con uno, dos o tres $R^3$; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, B es fenilo sustituido con $R^{3a}$. En otra forma de realización el Compuesto es de Fórmula I(a):



**I(a).**

En otra forma de realización, B es fenilo sustituido con $R^{3a}$ como se describe en **Ia** y no está también sustituido con $R^3$.

**[00199]** Otra forma de realización de la invención (J) se refiere a un compuesto de Fórmula I donde B es heteroarilo opcionalmente sustituido con uno, dos o tres $R^3$. En otra forma de realización, B es tien-3-ilo, piridinilo, pirimidinilo, piridazinilo, pirazinilo, oxazolilo, isoxazolilo, pirrolilo, imidazolilo, pirazolilo, o tiazolilo, cada uno de los cuales está

opcionalmente sustituido con uno o dos $R^3$. En otra forma de realización, B es tien-3-ilo, piridin-2-ilo, piridin-3-ilo, piridin-4-ilo, oxazol-2-ilo, oxazol-4-ilo, oxazol-5-ilo, isoxazol-3-ilo, isoxazol-4-ilo, isoxazol-5-ilo, imidazol-2-ilo, pirrol-2-ilo, pirrol-3-ilo, imidazol-4-ilo, imidazol-5-ilo, pirazol-3-ilo, pirazol-4-ilo, o pirazol-5-ilo, cada uno de los que está opcionalmente sustituido con uno o dos $R^3$. En otra forma de realización, B es tien-3-ilo, piridin-3-ilo, piridin-4-ilo, isoxazol-4-ilo, o pirazol-4-ilo, cada uno de los que está opcionalmente sustituido con uno o dos $R^3$. En otra forma de realización, B es piridin-3-ilo, 2-hidroxi-piridin-5-ilo, isoxazol-4-ilo o pirazol-4-ilo, cada una de las que está opcionalmente sustituido con uno o dos $R^3$.

**[00200]** Otra forma de realización (K) proporciona un compuesto de Fórmula I o Ia donde $R^{3A}$ es ciano; hidroxiamino; carboxi; alquilsulfonilo, aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; $-N(R^7)C(O)$-alquilen$C_1$-$C_6$- $N(R^{7a})(R^{7b})$; $-C(O)NR^8R^{8a}$; $-NR^9C(O)R^{9a}$; $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$; $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$; $-C(O)R^{12}$; $-NR^{13}C(O)OR^{13a}$; $-C(O)N(R^{14})N(R^{14a})(R^{14b})$; $-S(O)_2N(R^{15})$-alquilen $C_1$-$C_6$-$N(R^{15a})R^{15b}$; $-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$; heteroarilo opcionalmente sustituido con uno o dos aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$; $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$; $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$; -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$; o $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$; donde cada uno del alquileno en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, amino,

alquilamino, y dialquilamino; y los otros grupos son como se definieron en la Síntesis de la invención.

**[00201]** En otra forma de realización, $R^{3A}$ es $-NHC(O)CH_2NH(CH_3)$, $-NHC(O)CH_2NH(CH_2CH_3)$, $-NHC(O)CH(CH_3)NH_2$, $-NHC(O)C(CH_3)_2NH_2$, $-NHC(O)CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(NH_2)CH_2CH_3$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(CH_3)NH(CH_3)$, $-NHC(O)CH_2NH_2$, $-NHC(O)H$, $-NHC(O)CH_2$(azetidin-1-ilo), $-NHC(O)$(pirrolidin-2-ilo), $-NHC(O)CH(NH_2)CH_2OH$, $-NHC(O)$(azetidin-4-ilo), $-NHC(O)C(CH_3)_2NH(CH_3)$, $-NH_2$, $-NHC(O)CH_2NH(CH_2CH_2CH_3)$, $-NHC(O)CH_2CH_2NH_2$, $-NHOH$, $-NHC(O)$(piperidin-3-ilo), $-NHC(O)CH_2$(4-metil-1,4-diazepan-1-ilo), $-NHC(O)CH(NH_2)(CH_2CH_3)$, $-NHC(O)CH_2NH(CH_2CH(OH)(CH_3))$, $-NHC(O)CH_2NHCH_2CH_2F$, $-NHC(O)CH_2NH(OCH_2CH(CH_3)_2)$, $-NHC(O)$(1-aminociclooprop-1-ilo), $-NHC(O)CH_2NH(CH_2$ciclopropilo), $-NHC(O)CH_2$(3-(dimetilamino)-azetidin-1-ilo), $-NHC(O)$(piperidin-2-ilo), $-NHC(O)$(morfolin-4-ilo), $-NHC(O)CH_2$(pirrolidin-1-ilo), $-NHC(O)CH(NH_2)CH_2CH_2CH_2CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)(CH_2CH_3)$, $-NHC(O)CH_2$(imidazol-5-ilo), $-NHC(O)$(1-aminociclopent-1-ilo), $-NHC(O)CH_2NH(CH_2CH(CH_3)_2)$, $-NHC(O)CH_2N(CH_3)(CH_2CH_3)$, $-NHC(O)$(*N*-(imidazol-4-ilmetil)-azetidin-3-ilo), $-NHC(O)$(*N*-etil-azetidin-3-ilo), $-NHCH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)$(*N*-metil-pirrolidin-3-ilo), $-NHC(O)CH_2N(CH_3)(CH_2CH_2N(CH_3)_2)$, $-NHC(O)CH_2$(3-hidroxi-pirrolidin-1-ilo), $-NHC(O)$(1-amino-ciclobut-1-ilo), $-NHC(O)CH_2NH(CH_2)_3CH_3$, $-NHC(O)CH_2$(3-piperidin-1-ilazetidin-1-ilo), $-NHC(O)NH_2$, $-NHC(O)$(1-hidroxiciclopropilo), $-NHC(O)CH_2NHN(CH_3)_2$, $-NHC(O)NH(CH_2)_2N(CH_3)_2$, $-NHC(O)CH_2OH$, $-NHC(O)$(piridazin-4-ilo), $-NHC(O)$(N-metil-piperidin-4-ilo), $-NHC(O)CH_2NHCH(CH_3)_3$, $-NHC(O)CH_2$(3-

dimetilamino-pirrolidin-1-ilo), -NHC(O)$CH_2NH(CH_2)_2N(CH_3)_2$, -NHC(O)(1-ciclopropilmetil-azetidin-3-ilo), -NHC(O)$CH_2NH(CH_3)_3$, -NHC(O)(imidazol-2-ilo), -NHC(O)(imidazol-4-ilo), -NHC(O)(1,2-oxazol-5-ilo), -NHC(O)$CH_2NHCH_2CF_3$, -NHC(O)$CH_2CH_2$(piperidin-1-ilo), -NHC(O)(3-oxo-ciclopent-1-ilo), -NHC(O)(2-hidroxi-piridin-6-ilo), -NHC(O)$CH_2$NH(3-fluoro-4-hidroxifenilo), -NHC(O)$(CH_2)_3N(CH_3)_2$, -NHC(O)(1-(furan-2-ilmetil)-azetidin-3-ilo), -NHC(O)(pirimidin-5-ilo), -NHC(O)(pirrol-2-ilo), -NHC(O)$CH_2N(CH_3)CH(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)_2$, -NHC(O)$CH_2$(3-metil-1,2-oxazol-5-ilo), -NHC(O)$CH_2NHCH_2$(3-hidroxifenilo), -NHC(O)(*N*-metil-pirrol-2-ilo), -NHC(O)(2-amino-tetrahidropiran-2-ilo), -NHC(O)$CH_2$(4-metilamino-piperidin-1-ilo), -NHC(O)(piperidin-1-ilo), -NHC(O)(*N*-metil-pirrolidin-2ilo), -NHC(O)(tien-3-ilo), -NHC(O)(*N*-(ciclopropilcarbonil)azetidin-3-ilo), -NHC(O)$CH_2$(4-metilpiperazin-1-ilo), -NHC(O)(*N*-bencilazetidin-3-ilo), -NHC(O)(2-cloro-piridin-3-ilo), -NHC(O)$CH_2$(piridin-4-ilo), -NHC(O)$CH_2N(CH_3)(CH_2CH{=}CH_2)$, -NHC(O)$CH_2$NH(benz-ilo), -NHC(O)$CH_2OCH_3$, -NHC(O)[1-(C(O)$CH_2CH_3$)-azetidin-3-ilo], -NHC(O)(piridin-3-ilo), -NHC(O)$CH_2NHCH_2CH_2OCH_3$, -NHC(O)(1-[C(O)$CH_3$]piperidin-4-ilo), -NHC(O)$CH_2$(2-metil-pirrolidin-1-ilo), -NHC(O)(furan-3-ilo), -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)(2-cloro-piridin-5-ilo), -NHC(O)(2-clorofen-ilo), -NHC(O)$CH_2$(piridin-2-ilo), -NHC(O)$CH_2$(3-dimetilamino-azetidin-1-ilo), -NHC(O)$CH_2$(piridin-3-ilo), -NHC(O)$CH_2$(2-clorofen-ilo), -NHC(O)$CH_2N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)CH_2CH_2OH$, -NHC(O)$CH_2$(2-bencil-pirrolidin-1-ilo), -NHC(O)(furan-2-ilo, -NHC(O)(2-cloro-piridin-4-ilo), -NHC(O)$CH_2NHC(O)CH_3$, -NHC(O)$CH_2CH_2CH_3$, -NHC(O)(4-clorofen-ilo), -NHC(O)(4-metil-fen-ilo),

-NHC(O)$CH_2$NHC(O)O$(CH_3)_3$, -NHC(O)(benzo[d][1,3]dioxol-5-ilo), -NHC(O)$CH_2$NHO$CH_2$(2-metoxifen-ilo), -NHC(O)(piridin-4-ilo), -NHC(O)$CH_2$[4-(3,4-diclorofenil)-piperazin-1-il], -NHC(O)$CH_2CH_2$(piridin-3-ilo), -NHC(O)(tetrahidrofuran-3-ilo), -NHC(O)$CH_2$NH$CH_2$(2-metilfen-ilo), -NHC(O)CH$(CH_3)CH_2CH_3$, -NHC(O)$CH_2$(3-fluorofen-ilo), -NHC(O)$CH_2C(CH_3)_2$fenilo, -NHC(O)(2-metil-cicloprop-1-ilo), -NHC(O)(2-metil-4-metoxifen-ilo), -NHC(O)(2-metilpiridin-3-ilo), -NHC(O)(4-metoxifen-ilo), -NHC(O)$CH_2$(4-etilpiperazin-1-ilo), -NHC(O)(tien-2-ilo), -NHC(O)(3-fluoro-2-metilfen-ilo), -NHC(O)(2-bromo-tien-3-ilo), -NHC(O)(4-fluorofen-ilo), -NHC(O)$CH_2$(3-metilpiperidin-1-ilo), -NHC(O)CH$(CH_3)_2$, -NHC(O)$(CH_2)_3CH_3$, -NHC(O)$CH_2OCH_2CH_3$, -NHC(O)$CH_2$NH(2-fluorofen-ilo), -NHC(O)(3-dimetilaminofen-ilo), -NHC(O)$CH_2$(4-metilpiperidin-1-ilo), -NHC(O)$CH_2$NH(2-*n*-propilfen-ilo), -NHC(O)fenilo, -NHC(O)(pirazin2-ilo), -NHC(O)(3-fluoro-4-metoxifen-ilo), -NHC(O)$C(CH_3)_2CH_2CH_3$, -NHC(O)$CH_2O$(4-fluorofen-ilo), -NHC(O)(1-metilcarbonil-azetidin-3-ilo), -NHC(O)$CH_2$NH(4-metilfen-ilo), -NHC(O)$CH_2$NH(fen-ilo), -NHC(O)$CH_2$(4-alil-piperazin-1-ilo), -NHC(O)(2-metilfen-ilo), -NHC(O)$CH_2CH_2OCH_3$, -NHC(O)(3-metil-furan-2-ilo), -NHC(O)$C(CH_3)_3$, -NHC(O)$CH_2$NHObencilo, -NHC(O)$CH_2$NH(3-clorofen-ilo), -NHC(O)ciclobutilo, -NHC(O)$CH_2$(3-metoxifen-ilo), -NHC(O)(1-metilcicloprop-1-ilo), -NHC(O)(3-flurofen-ilo), -NHC(O)(4-dimetilaminofen-ilo), -NHC(O)(3,4-diclorofen-ilo), -NHC(O)$CH_2$NH$CH_2$(2-metiltiofen-ilo), -NHC(O)$CH_2$(2-fluorofen-ilo), -NHC(O)$CH_2N(CH_2CH_3)CH(CH_3)_2$, -NHC(O)(tiazol-4-ilo), -NHC(O)$CH_2N(CH_3)$bencilo, -NHC(O)$CH_2$NH$CH_2$(tien-2-ilo), -NHC(O)$CH_2$NH$CH_2$(piridin-2-ilo), -NHC(O)(3-metoxifen-ilo), -NHC(O)$CH_2$NH$CH_2$(3-cloro-

4-metilfen-ilo),
-NHC(O)CH($CH_3$)$CH_2CH_2CH_3$, -NHC(O)$CH_2$(4-clorofen-ilo), -NHC(O)(3-fluoro-4-metilfen-ilo), -NHC(O)$CH_2O$(2-metilfen-ilo), -NHC(O)$CH_2$(ciclohex-ilo), -NHC(O)(2-fenilo-ciclooprop-1-ilo), -NHC(O)(3-clorofen-ilo), -NHC(O)$CH_2$(2-metoxifen-ilo), -NHC(O)$CH_2CH_2$(3-metoxifen-ilo), -NHC(O)$CH_2NH$(2-fluoro-4-metil-fen-ilo), -NHC(O)$CH_2NHCH_2$(3-fluoro-fen-ilo), -NHC(O)$CH_2$(4-metoxi-fen-ilo), -NHC(O)bencilo, -NHC(O)(2,4-diclorofen-ilo), -NHC(O)(3-oxo-ciclohex-1-ilo), -NHC(O)$CH_2NH$(3-fluorofen-ilo), -NHC(O)$CH_2$(3-clorofen-ilo),
-NHC(O)$CH_2NHCH_2CH(CH_3)$fenilo, -NHC(O)$CH_2NHCH_2$(2,4-dimetilfen-ilo), -NHC(O)$CH_2$(2-metil-piperidin-1-ilo), -NHC(O)$CH_2NH$(2-metoxifen-ilo), -NHC(O)$CH_2$(1,2,3,4-tetrahidroisoquinolin-2-ilo), -NHC(O)$CH_2CH_2CH{=}CH_2$, -NHC(O)$CH_2NH$(2-metilfen-ilo), -NHC(O)$CH_2$(4-oxo-piperidin-1-ilo), -NHC(O)(2-fluorofen-ilo), -NHC(O)$CH_2NHCH(CH_3)$fenilo, -NHC(O)(2-fluoro-6-metoxifen-ilo), -NHC(O)$CH_2NH$(2-isopropilfen-ilo), -NHC(O)$CH_2CH_2$(2-metoxifen-ilo), -NHC(O)$CH_2CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(2-fenilo-morfolin-4-ilo), -NHC(O)$CH_2CH_2$(4-metoxifen-ilo), -NHC(O)$CH_2N$(alil)ciclopentilo,
-NHC(O)$CH_2N(CH_3)CH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2C$(O)ciclopropilo, -NHC(O)$CH_2NH$(3-*tert*-butilfen-ilo), -NHC(O)$CH_2N$(*n*-propil)(ciclopropilmet-ilo), -NHC(O)$CH_2$(2-oxo-ciclopent-ilo), -NHC(O)$CH_2NH$(4-clorofen-ilo), -NHC(O)$CH_2$(4-piperidin-1-ilpiperidin-1-ilo), -NHC(O)$CH_2$(4-ciclopentilpiperazin-1-ilo), -NHC(O)$CH_2$(2-metilfen-ilo), -NHC(O)$CH_2NHCH_2$(3-fluoro-6-metilfen-ilo),
-NHC(O)$CH_2C(CH_3)_3$, -NHC(O)$CH_2NH$(2-clorofen-ilo), -NHC(O)(3-fluoro-6-metilfen-ilo), -NHC(O)(4-fluoro-3-metilfen-ilo), -NHC(O)(2,3-diclorofen-ilo), -NHC(O)$CH_2$Ofenilo, -NHC(O)$CH_2NH$(2,3-dimetilfen-ilo),

-NHC(O)(2-fluoro-5-metilfen-ilo), -NHC(O)$CH_2$NHO$CH_2$(4-metilfen-ilo), -NHC(O)$CH_2$(4-isopropilpiperazin-1-ilo), -NHC(O)$CH_2$(4-fluorofen-ilo), -NHC(O)$CH_2CH(CH_3)_2$, -NHC(O)(2-metoxi-4-metilfen-ilo), -NHC(O)$CH_2$(4-*n*-propilpiperidin-1-ilo), -NHC(O)$CH_2$O(3-metilfen-ilo), -NHC(O)(tetrahidrofuran-2-ilo), -NHC(O)$CH_2$(3-hidroximetilpiperidin-1-ilo), -NHC(O)(1-*tert*-butoxicarbonilpiperidin-2-ilo), -NHC(O)$CH_2N(CH_3)CH_2$(piridin-3-ilo), -NHC(O)$CH_2N(CH_2CH_3)$fenilo, -NHC(O)$CH_2OCH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2$(ciclopent-ilo), -NHC(O)(2,5-diclorofen-ilo), -NHC(O)$CH_2$(4-metilcarbonilpiperazin-1-ilo), -NHC(O)(5-fluoro-2-metoxifen-ilo), -NHC(O)$CH_2N(CH_2CH_3)$ciclohexilo, -NHC(O)(5-metil-1,2-oxazol-3-ilo), -NHC(O)(3-metilpiridin-3-ilo), -NHC(O)(2-metoxipiridin-3-ilo), -NHC(O)(3,5-diclorofen-ilo), -NHC(O)$CH_2$(tiazolidin3-ilo), -NHC(O)$CH_2$(4-[C(O)H]-piperazin-1-ilo), -NHC(O)$CH_2$(2-piridin-4-ilpiperidin-1-ilo), -NHC(O)(2-metoxifen-ilo), -NHC(O)$CH_2N(CH_3)CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(4-[C(O)H]-homopiperazin-1-ilo), -NHC(O)(1-fenilciclоprop-1-ilo), -NHC(O)$CH_2$(2,6-dimetilmorfolin-4-ilo), NHC(O)$CH_2$(2-fenilpirrolidin-1-ilo), -NHC(O)$CH_2$(morfolin-4-ilo), -C(O)NHCH$(CH_3)CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2N(CH_3)_2$, -C(O)NH(pirrolidin-3-ilo), -C(O)$NHCH_2CH_2$(pirrolidin-1-ilo), -C(O)$NHCH_2CH_2NH_2$, -C(O)$N(CH_3)CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2$(piperidin-2-ilo), -C(O)NH(1-metilazetidin-3-ilo), -C(O)$NHCH_2CH_2$(piperidin-1-ilo), -C(O)$NHCH_2CH_2N(CH_2CH_3)_2$, -C(O)NH(1-metilpiperidin-3-ilo), -C(O)NH(piperidin-3-ilo), -C(O)$NHCH_2$(1-metilpiperidin-3-ilo), -C(O)$NHCH_2CH_2N(CH_2CH_2OH)_2$, -C(O)NH(1-etilpiperidin-3-ilo),

$-C(O)NH_2$, $-C(O)$(3-aminopirrolidin-1-ilo), $-C(O)$(3-metilaminopirrolidin-1-ilo), $-C(O)OH$, $-C(O)NHCH_2CH_2$(morfolin-4-ilo), $-C(O)NHCH_2$(1-etilpirrolidin-2-ilo), $-C(O)$(4-amino-3-oxo-pirazolidin-1-ilo), $-C(O)NHCH_3$, $-C(O)$(3-aminociclobut-1-ilo), $-C(O)NHCH_2$(piridin-3-ilo), $-C(O)NHCH_2CH_2OH$, $-C(O)NH$(3-oxo-pirazolidin-4-ilo), $-NHCH_2CH_2$(imidazol-4-ilo), $-C(O)$(3-dimetilaminopirrolidin-1-ilo), $-C(O)NHCH_2$(piridin-4-ilo), $-C(O)N(CH_3)$(1-metil-pirrolidin-3-ilo), $-C(O)$(3-dietilaminopirrolidin-1-ilo), $-C(O)NH$(pirrol-1-ilo), $-C(O)NHCH_2CH_2CH_2$(pirrolidin-1-ilo), $-C(O)N(CH_3)CH_2CH_2CN$, $-C(O)NHCH_2CH_2OCH_3$,
$-C(O)N(CH_2CH_3)CH_2CH_2CN$, $-C(O)$(3-aminopiperidin-1-ilo), $-C(O)NHCH_2CH_2CH_2N(CH_3)_2$, $-C(O)NH$(morfolin-4-ilo), $-C(O)NHN(CH_3)_2$,
$-C(O)NHCH_2CH_2CH_2$(imidazol-1-ilo), $-C(O)NHCH_2CH_2CH_2N(CH_2CH_3)_2$,
$-C(O)NHCH_2CH_2CN$, $-C(O)NHCH_2CH_2C(O)OCH_3$, $-C(O)NHCH_2CH_2SCH_3$, $-C(O)NHCH_2CH_2SCH_2CH_3$, $-C(O)N(CH_2CH_3)CH_2CH_2N(CH_3)_2$, $-C(O)NHCH_2CH_2CH_2$(2-oxo-pirrolidin-1-ilo),
$-C(O)NHCH_2CH_2$(piridin-4-ilo), $-C(O)NHCH_2CH_2CH_2OCH_2CH_3$, $-C(O)NHCH_2CH_2CH_2$(morfolin-4-ilo), $-C(O)NHCH_2CH_2CH_2OCH_3$, $-C(O)N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, $-C(O)NHCH_2CH_2CH_2OCH_2CH_2CH_3$, $-C(O)NHCH_2CH_2C(O)OCH_2CH_3$, $-C(O)NHCH_2CH_2CH_2OCH(CH_3)_2$, $-C(O)NHC(CH_3)_2CH_2$(piperidin-1-ilo), $-C(O)N(CH_3)CH_2CH_2CH_3$, $-C(O)NH$(piperidin-1-ilo), $-C(O)NHCH(CH_3)CH_2OCH_3$, $-C(O)NHC(CH_3)_2CH_2$(morfolin-4-ilo), $-C(O)$(2-dimetilaminometilpiperidin-1-ilo), $-C(O)NH(CH_2)_3O(CH_2)_3CH_3$, $C(O)NHCH(CH_3)(CH_2)_3N(CH_2CH_3)_2$, $-C(O)NHC(CH_3)_2C(O)$(piperidin-1-ilo), $-C(O)$(4-metilpiperazin-1-ilo), $-C(O)$(2-piperidin-1-ilmetil-piperidin-1-ilo), no, $-NHCH_3$, $-CH(CH_3)NHCH_2CH_2N(CH_3)_2$, $-C(O)CH_3$, $-S(O)_2NHCH_2CH_2N(CH_3)_2$, $-S(O)_2NH(CH_2)_3N(CH_3)_2$, 5-

(*N*,*N*-dimetilaminometil)-1,3,4-oxadiazol-2-o, $-NHCH_2CH_2N(CH_3)_2$, $-N(CH_3)_2$, $-OCH_2CH_2N(CH_3)_2$, $-NHC[N(CH_3)_2][=N(CH_3)_2]$, $-OCHF_2$, $-S(O)_2CH_3$, $-OCF_3$, o $-NHC(O)CH_2$(4-dimetilaminopiperidin-1-ilo).

**[00202]** En otra forma de realización (L), el compuesto de Fórmula I o IA es que donde $R^{3A}$ es hidroxiamino, $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$, $-NR^{11}C(O)NR^{11a}R^{11b}$, $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, $-NR^{13}C(O)OR^{13a}$, $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$, $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$, o $-N(R^{20})C(O)$-alquilen $C_1$-$C_6$-$C(O)R^{20a}$; donde cada uno de los alquilenos en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{3A}$ es $-NHC(O)CH_2NH(CH_3)$, $-NHC(O)CH(CH_3)NH_2$, $-NHC(O)C(CH_3)_2NH_2$, $-NHC(O)CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(NH_2)CH_2CH_3$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(CH_3)NH(CH_3)$, $-NHC(O)H$, $-NHC(O)CH_2$(azetidin-1-ilo), $-NHC(O)$(pirrolidin-2-ilo), $-NHC(O)CH(NH_2)CH_2OH$, $-NHC(O)$(azetidin-4-ilo), $-NHC(O)C(CH_3)_2NH(CH_3)$, $-NH_2$, $-NHC(O)CH_2NH(CH_2CH_2CH_3)$, $-NHC(O)CH_2CH_2NH_2$, $-NHOH$, o $-NHC(O)$(piperidin-3-ilo).

**[00203]** En otra forma de realización (M) el compuesto de Fórmula I o Ia y $R^{3a}$ $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$; y $R^7$ es hidrógeno o alquilo y $R^{7a}$ y $R^{7b}$ son de modo independiente hidrógeno, alquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{3A}$ es $-NHC(O)CH_2NH(CH_3)$, $-NHC(O)CH(CH_3)NH_2$, $-NHC(O)C(CH_3)_2NH_2$, -

$NHC(O)CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(NH_2)CH_2CH_3$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, o $-NHC(O)CH(CH_3)NH(CH_3)$.

**[00204]** La forma de realización (N) proporciona un compuesto de Fórmula I donde cada $R^3$ es de modo independiente halo; ciano; alquilo; alquenilo; alcoxi; hidroxiamino; carboxi; alquilsulfonilo, aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$; $-C(O)NR^8R^{8a}$; $-NR^9C(O)R^{9a}$; $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$; $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$; $-C(O)R^{12}$; $-NR^{13}C(O)OR^{13a}$; $-C(O)N(R^{14})N(R^{14a})(R^{14b})$; $-S(O)_2N(R^{15})$-alquilen $C_1$-$C_6$-$N(R^{15a})R^{15b}$; $-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$; heteroarilo opcionalmente sustituido con uno o dos aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$; $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$; $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$; -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$; o $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$; donde cada uno de los alquilenos en $R^3$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, amino, alquilamino, y dialquilamino; y los otros grupos son como se definieron en la Síntesis de la invención.

**[00205]** En otra forma de realización, cada $R^3$ es de modo independiente metilo, bromo, cloro, fluoro, $-NHC(O)CH_2NH(CH_3)$, $-NHC(O)CH_2NH(CH_2CH_3)$, $-NHC(O)CH(CH_3)NH_2$, $-NHC(O)C(CH_3)_2NH_2$, $-NHC(O)CH_2N(CH_3)_2$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(NH_2)CH_2CH_3$, $-NHC(O)CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, $-NHC(O)CH(CH_3)NH(CH_3)$, $-NHC(O)CH_2NH_2$, $-NHC(O)H$, $-NHC(O)CH_2$(azetidin-1-ilo), -NHC(O)(pirrolidin-2-ilo), $-NHC(O)CH(NH_2)CH_2OH$, -NHC(O)(azetidin-4-ilo), $-NHC(O)C(CH_3)_2NH(CH_3)$, $-NH_2$,

-NHC(O)$CH_2NH(CH_2CH_2CH_3)$, -NHC(O)$CH_2CH_2NH_2$, -NHOH, -NHC(O)(piperidin-3-ilo), -NHC(O)$CH_2$(4-metil-1,4-diazepan-1-ilo), -NHC(O)$CH(NH_2)(CH_2CH_3)$, -NHC(O)$CH_2NH(CH_2CH(OH)(CH_3))$, -NHC(O)$CH_2NHCH_2CH_2F$, -NHC(O)$CH_2NH(OCH_2CH(CH_3)_2)$, -NHC(O)(1-aminocicloprop-1-ilo), -NHC(O)$CH_2NH(CH_2$cicloprop-ilo), -NHC(O)$CH_2$(3-(dimetilamino)-azetidin-1-ilo), -NHC(O)(piperidin-2-ilo), -NHC(O)(morfolin-4-ilo), -NHC(O)$CH_2$(pirrolidin-1-ilo), -NHC(O)$CH(NH_2)CH_2CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)$CH_2$(imidazol-5-ilo), -NHC(O)(1-aminociclopent-1-ilo), -NHC(O)$CH_2NH(CH_2CH(CH_3)_2)$, -NHC(O)$CH_2N(CH_3)(CH_2CH_3)$, -NHC(O)(*N*-(imidazol-4-ilmetil)-azetidin-3-ilo), -NHC(O)(*N*-etil-azetidin-3-ilo), -NH$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)$(*N*-metil-pirrolidin-3-ilo), -NHC(O)$CH_2N(CH_3)(CH_2CH_2N(CH_3)_2)$, -NHC(O)$CH_2$(3-hidroxi-pirrolidin-1-ilo), -NHC(O)(1-amino-ciclobut-1-ilo), -NHC(O)$CH_2NH(CH_2)_3CH_3$, -NHC(O)$CH_2$(3-piperidin-1-ilazetidin-1-ilo), -NHC(O)$NH_2$, -NHC(O)(1-hidroxicicloprop-ilo), -NHC(O)$CH_2NHN(CH_3)_2$, -NHC(O)$NH(CH_2)_2N(CH_3)_2$, -NHC(O)$CH_2OH$, -NHC(O)(piridazin-4-ilo), -NHC(O)(N-metil-piperidin-4-ilo), -NHC(O)$CH_2NHCH(CH_3)_3$, -NHC(O)$CH_2$(3-dimetilamino-pirrolidin-1-ilo), -NHC(O)$CH_2NH(CH_2)_2N(CH_3)_2$, -NHC(O)(1-ciclopropilmetil-azetidin-3-ilo), -NHC(O)$CH_2NH(CH_3)_3$, -NHC(O)(imidazol-2-ilo), -NHC(O)(imidazol-4-ilo), -NHC(O)(1,2-oxazol-5-ilo), -NHC(O)$CH_2NHCH_2CF_3$, -NHC(O)$CH_2CH_2$(piperidin-1-ilo), -NHC(O)(3-oxo-ciclopent-1-ilo), -NHC(O)(2-hidroxi-piridin-6-ilo), -NHC(O)$CH_2NH$(3-fluoro-4-hidroxifen-ilo), -NHC(O)$(CH_2)_3N(CH_3)_2$, -NHC(O)(1-(furan-2-ilmetil)-azetidin-3-ilo), -NHC(O)(pirimidin-5-ilo), -NHC(O)(pirrol-2-ilo), -NHC(O)$CH_2N(CH_3)CH(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)_2$, -NHC(O)$CH_2$(3-metil-1,2-oxazol-5-ilo),

-NHC(O)$CH_2NHCH_2$(3-hidroxifen-ilo), -NHC(O)(*N*-metil-pirrol-2-ilo), -NHC(O)(2-amino-tetrahidropiran-2-ilo), -NHC(O)$CH_2$(4-metilamino-piperidin-1-ilo), -NHC(O)(piperidin-1-ilo), -NHC(O)(*N*-metil-pirrolidin-2-ilo), -NHC(O)(tien-3-ilo), -NHC(O)(*N*-(ciclopropilcarbonil)azetidin-3-ilo), -NHC(O)$CH_2$(4-metilpiperazin-1-ilo), -NHC(O)(*N*-bencilazetidin-3-ilo), -NHC(O)(2-cloro-piridin-3-ilo), -NHC(O)$CH_2$(piridin-4-ilo), -NHC(O)$CH_2N(CH_3)(CH_2CH{=}CH_2)$, -NHC(O)$CH_2$NH(benz-ilo), -NHC(O)$CH_2OCH_3$, -NHC(O)[1-(C(O)$CH_2CH_3$)-azetidin-3-il], -NHC(O)(piridin-3-ilo), -NHC(O)$CH_2NHCH_2CH_2OCH_3$, -NHC(O)(1-[C(O)$CH_3$]piperidin-4-ilo), -NHC(O)$CH_2$(2-metil-pirrolidin-1-ilo), -NHC(O)(furan-3-ilo), -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)(2-cloro-piridin-5-ilo), -NHC(O)(2-clorofen-ilo), -NHC(O)$CH_2$(piridin-2-ilo), -NHC(O)$CH_2$(3-dimetilamino-azetidin-1-ilo), -NHC(O)$CH_2$(piridin-3-ilo), -NHC(O)$CH_2$(2-clorofen-ilo), -NHC(O)$CH_2N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_2CH_3)CH_2CH_2OH$, -NHC(O)$CH_2$(2-bencil-pirrolidin-1-ilo), -NHC(O)(furan-2-ilo, -NHC(O)(2-cloro-piridin-4-ilo), -NHC(O)$CH_2NHC(O)CH_3$, -NHC(O)$CH_2CH_2CH_3$, -NHC(O)(4-clorofen-ilo), -NHC(O)(4-metil-fen-ilo), -NHC(O)$CH_2NHC(O)O(CH_3)_3$, -NHC(O)(benzo[d][1,3]dioxol-5-ilo), -NHC(O)$CH_2NHOCH_2$(2-metoxifen-ilo), -NHC(O)(piridin-4-ilo), -NHC(O)$CH_2$[4-(3,4-diclorofenil)-piperazin-1-ilo], -NHC(O)$CH_2CH_2$(piridin-3-ilo), -NHC(O)(tetrahidrofuran-3-ilo), -NHC(O)$CH_2NHCH_2$(2-metilfen-ilo), -NHC(O)$CH(CH_3)CH_2CH_3$, -NHC(O)$CH_2$(3-fluorofen-ilo), -NHC(O)$CH_2C(CH_3)_2$fenilo, -NHC(O)(2-metil-cicloprop-1-ilo), -NHC(O)(2-metil-4-metoxifen-ilo), -NHC(O)(2-metilpiridin-3-ilo), -NHC(O)(4-metoxifen-ilo), -NHC(O)$CH_2$(4-etilpiperazin-1-ilo), -NHC(O)(tien-2-ilo), -NHC(O)(3-

fluoro-2-metilfen-ilo), -NHC(O)(2-bromo-tien-3-ilo), -NHC(O)(4-fluorofen-ilo), -NHC(O)$CH_2$(3-metilpiperidin-1-ilo), -NHC(O)$CH(CH_3)_2$, -NHC(O)$(CH_2)_3CH_3$, -NHC(O)$CH_2OCH_2CH_3$, -NHC(O)$CH_2$NH(2-fluorofen-ilo), -NHC(O)(3-dimetilaminofen-ilo), -NHC(O)$CH_2$(4-metilpiperidin-1-ilo), -NHC(O)$CH_2$NH(2-*n*-propilfen-ilo), -NHC(O)fenilo, -NHC(O)(pirazin2-ilo), -NHC(O)(3-fluoro-4-metoxifen-ilo), -NHC(O)$C(CH_3)_2CH_2CH_3$, -NHC(O)$CH_2O$(4-fluorofen-ilo), -NHC(O)(1-metilcarbonil-azetidin-3-ilo), -NHC(O)$CH_2$NH(4-metilfen-ilo), -NHC(O)$CH_2$NH(fen-ilo), -NHC(O)$CH_2$(4-alil-piperazin-1-ilo), -NHC(O)(2-metilfen-ilo), -NHC(O)$CH_2CH_2OCH_3$, -NHC(O)(3-metil-furan-2-ilo), -NHC(O)$C(CH_3)_3$, -NHC(O)$CH_2$NHObencilo, -NHC(O)$CH_2$NH(3-clorofen-ilo), -NHC(O)ciclobutilo, -NHC(O)$CH_2$(3-metoxifen-ilo), -NHC(O)(1-metilcicloprop-1-ilo), -NHC(O)(3-flurofen-ilo), -NHC(O)(4-dimetilaminofen-ilo), -NHC(O)(3,4-diclorofen-ilo), -NHC(O)$CH_2NHCH_2$(2-metiltiofen-ilo), -NHC(O)$CH_2$(2-fluorofen-ilo), -NHC(O)$CH_2N(CH_2CH_3)CH(CH_3)_2$, -NHC(O)(tiazol-4-ilo), -NHC(O)$CH_2N(CH_3)$bencilo, -NHC(O)$CH_2NHCH_2$(tien-2-ilo), -NHC(O)$CH_2NHCH_2$(piridin-2-ilo), -NHC(O)(3-metoxifen-ilo), -NHC(O)$CH_2NHCH_2$(3-cloro-4-metilfen-ilo), -NHC(O)$CH(CH_3)CH_2CH_2CH_3$, -NHC(O)$CH_2$(4-clorofen-ilo), -NHC(O)(3-fluoro-4-metilfen-ilo), -NHC(O)$CH_2O$(2-metilfen-ilo), -NHC(O)$CH_2$(ciclohex-ilo), -NHC(O)(2-fenilo-cicloprop-1-ilo), -NHC(O)(3-clorofen-ilo), -NHC(O)$CH_2$(2-metoxifen-ilo), -NHC(O)$CH_2CH_2$(3-metoxifen-ilo), -NHC(O)$CH_2$NH(2-fluoro-4-metil-fen-ilo), -NHC(O)$CH_2NHCH_2$(3-fluoro-fen-ilo), -NHC(O)$CH_2$(4-metoxi-fen-ilo), -NHC(O)bencilo, -NHC(O)(2,4-diclorofen-ilo), -NHC(O)(3-oxo-ciclohex-1-ilo), -NHC(O)$CH_2$NH(3-fluorofen-ilo), -NHC(O)$CH_2$(3-clorofen-ilo), -NHC(O)$CH_2NHCH_2CH(CH_3)$fenilo, -NHC(O)$CH_2NHCH_2$(2,4-dimetilfen-ilo), -NHC(O)$CH_2$(2-metil-piperidin-1-ilo),

-NHC(O)$CH_2$NH(2-metoxifen-ilo), -NHC(O)$CH_2$(1,2,3,4-tetrahidroisoquinolin-2-ilo), -NHC(O)$CH_2CH_2CH=CH_2$, -NHC(O)$CH_2$NH(2-metilfen-ilo), -NHC(O)$CH_2$(4-oxo-piperidin-1-ilo), -NHC(O)(2-fluorofen-ilo), -NHC(O)$CH_2$NHCH($CH_3$)fenilo, -NHC(O)(2-fluoro-6-metoxifen-ilo), -NHC(O)$CH_2$NH(2-isopropilfen-ilo), -NHC(O)$CH_2CH_2$(2-metoxifen-ilo), -NHC(O)$CH_2CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(2-fenilo-morfolin-4-ilo), -NHC(O)$CH_2CH_2$(4-metoxifen-ilo), -NHC(O)$CH_2$N(alil)ciclopentilo, -NHC(O)$CH_2$N($CH_3$)$CH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2$C(O)ciclopropilo, -NHC(O)$CH_2$NH(3-*tert*-butilfen-ilo), -NHC(O)$CH_2$N(*n*-propil)(ciclopropilmet-ilo), -NHC(O)$CH_2$(2-oxo-ciclopent-ilo), -NHC(O)$CH_2$NH(4-clorofen-ilo), -NHC(O)$CH_2$(4-piperidin-1-ilpiperidin-1-ilo), -NHC(O)$CH_2$(4-ciclopentilpiperazin-1-ilo), -NHC(O)$CH_2$(2-metilfen-ilo), -NHC(O)$CH_2$NH$CH_2$(3-fluoro-6-metilfen-ilo), -NHC(O)$CH_2C(CH_3)_3$,
-NHC(O)$CH_2$NH(2-clorofen-ilo), -NHC(O)(3-fluoro-6-metilfen-ilo), -NHC(O)(4-fluoro-3-metilfen-ilo), -NHC(O)(2,3-diclorofen-ilo), -NHC(O)$CH_2$Ofenilo, -NHC(O)$CH_2$NH(2,3-dimetilfen-ilo), -NHC(O)(2-fluoro-5-metilfen-ilo), -NHC(O)$CH_2$NHO$CH_2$(4-metilfen-ilo), -NHC(O)$CH_2$(4-isopropilpiperazin-1-ilo), -NHC(O)$CH_2$(4-fluorofen-ilo), -NHC(O)$CH_2CH(CH_3)_2$, -NHC(O)(2-metoxi-4-metilfen-ilo), -NHC(O)$CH_2$(4-*n*-propilpiperidin-1-ilo), -NHC(O)$CH_2$O(3-metilfen-ilo), -NHC(O)(tetrahidrofuran-2-ilo), -NHC(O)$CH_2$(3-hidroximetilpiperidin-1-ilo), -NHC(O)(1-*tert*-butoxicarbonilpiperidin-2-ilo),
-NHC(O)$CH_2$N($CH_3$)$CH_2$(piridin-3-ilo), -NHC(O)$CH_2$N($CH_2CH_3$)fenilo, -NHC(O)$CH_2OCH_2CH_2OCH_3$, -NHC(O)$CH_2CH_2$(ciclopent-ilo), -NHC(O)(2,5-diclorofen-ilo), -NHC(O)$CH_2$(4-metilcarbonilpiperazin-1-ilo), -NHC(O)(5-fluoro-2-metoxifen-ilo),
-NHC(O)$CH_2$N($CH_2CH_3$)ciclohexilo, -NHC(O)(5-metil-1,2-

oxazol-3-ilo), -NHC(O)(3-metilpiridin-3-ilo), -NHC(O)(2-metoxipiridin-3-ilo), -NHC(O)(3,5-diclorofen-ilo), -NHC(O)$CH_2$(tiazolidin3-ilo), -NHC(O)$CH_2$(4-[C(O)H]-piperazin-1-ilo), -NHC(O)$CH_2$(2-piridin-4-ilpiperidin-1-ilo), -NHC(O)(2-metoxifen-ilo), -NHC(O)$CH_2N(CH_3)CH_2CH(CH_3)_2$, -NHC(O)$CH_2$(4-[C(O)H]-homopiperazin-1-ilo), -NHC(O)(1-fenilciclorop-1-ilo), -NHC(O)$CH_2$(2,6-dimetilmorfolin-4-ilo), NHC(O)$CH_2$(2-fenilpirrolidin-1-ilo), -NHC(O)$CH_2$(morfolin-4-ilo), -C(O)$NHCH(CH_3)CH_2N(CH_3)_2$, -C(O)$NHCH_2CH_2N(CH_3)_2$, -C(O)NH(pirrolidin-3-ilo), -C(O)$NHCH_2CH_2$(pirrolidin-1-ilo), -C(O)$NHCH_2CH_2NH_2$, -C(O)$N(CH_3)CH_2CH_2N(CH_3)_2$, -C(O)$NHCH_2$(piperidin-2-ilo), -C(O)NH(1-metilazetidin-3-ilo), -C(O)$NHCH_2CH_2$(piperidin-1-ilo), -C(O)$NHCH_2CH_2N(CH_2CH_3)_2$, -C(O)NH(1-metilpiperidin-3-ilo), -C(O)NH(piperidin-3-ilo), -C(O)$NHCH_2$(1-metilpiperidin-3-ilo), -C(O)$NHCH_2CH_2N(CH_2CH_2OH)_2$, -C(O)NH(1-etilpiperidin-3-ilo), -C(O)$NH_2$, -C(O)(3-aminopirrolidin-1-ilo), -C(O)(3-metilaminopirrolidin-1-ilo), -C(O)OH, -C(O)$NHCH_2CH_2$(morfolin-4-ilo), -C(O)$NHCH_2$(1-etilpirrolidin-2-ilo), -C(O)(4-amino-3-oxo-pirazolidin-1-ilo), -C(O)$NHCH_3$, -C(O)(3-aminociclobut-1-ilo), -C(O)$NHCH_2$(piridin-3-ilo), -C(O)$NHCH_2CH_2OH$, -C(O)NH(3-oxo-pirazolidin-4-ilo), -$NHCH_2CH_2$(imidazol-4-ilo), -C(O)(3-dimetilaminopirrolidin-1-ilo), -C(O)$NHCH_2$(piridin-4-ilo), -C(O)$N(CH_3)$(1-metil-pirrolidin-3-ilo), -C(O)(3-dietilaminopirrolidin-1-ilo), -C(O)NH(pirrol-1-ilo), -C(O)$NHCH_2CH_2CH_2$(pirrolidin-1-ilo), -C(O)$N(CH_3)CH_2CH_2CN$, -C(O)$NHCH_2CH_2OCH_3$, -C(O)$N(CH_2CH_3)CH_2CH_2CN$, -C(O)(3-aminopiperidin-1-ilo), -C(O)$NHCH_2CH_2CH_2N(CH_3)_2$, -C(O)NH(morfolin-4-ilo), -C(O)$NHN(CH_3)_2$, -C(O)$NHCH_2CH_2CH_2$(imidazol-1-ilo), -C(O)$NHCH_2CH_2CH_2N(CH_2CH_3)_2$, -C(O)$NHCH_2CH_2CN$, -C(O)$NHCH_2CH_2C(O)OCH_3$, -C(O)$NHCH_2CH_2SCH_3$,

$-C(O)NHCH_2CH_2SCH_2CH_3$, $-C(O)N(CH_2CH_3)CH_2CH_2N(CH_3)_2$, $-C(O)NHCH_2CH_2CH_2$(2-oxo-pirrolidin-1-ilo), $-C(O)NHCH_2CH_2$(piridin-4-ilo), $-C(O)NHCH_2CH_2CH_2OCH_2CH_3$, $-C(O)NHCH_2CH_2CH_2$(morfolin-4-ilo), $-C(O)NHCH_2CH_2CH_2OCH_3$, $-C(O)N(CH_3)CH_2CH_2CH_2N(CH_3)_2$, $-C(O)NHCH_2CH_2CH_2OCH_2CH_2CH_3$, $-C(O)NHCH_2CH_2C(O)OCH_2CH_3$, $-C(O)NHCH_2CH_2CH_2OCH(CH_3)_2$, $-C(O)NHC(CH_3)_2CH_2$(piperidin-1-ilo), $-C(O)N(CH_3)CH_2CH_2CH_3$, $-C(O)NH$(piperidin-1-ilo), $-C(O)NHCH(CH_3)CH_2OCH_3$, $-C(O)NHC(CH_3)_2CH_2$(morfolin-4-ilo), $-C(O)$(2-dimetilaminometilpiperidin-1-ilo), $-C(O)NH(CH_2)_3O(CH_2)_3CH_3$, $C(O)NHCH(CH_3)(CH_2)_3N(CH_2CH_3)_2$, $-C(O)NHC(CH_3)_2C(O)$(piperidin-1-ilo), $-C(O)$(4-metilpiperazin-1-ilo), $-C(O)$(2-piperidin-1-ilmetil-piperidin-1-ilo), ciano, $-NHCH_3$, $-CH(CH_3)NHCH_2CH_2N(CH_3)_2$, $-C(O)CH_3$, $-S(O)_2NHCH_2CH_2N(CH_3)_2$, $-S(O)_2NH(CH_2)_3N(CH_3)_2$, 5-(*N,N*-dimetilaminometil)-1,3,4-oxadiazol-2-ilo, $-NHCH_2CH_2N(CH_3)_2$, $-N(CH_3)_2$, $-OCH_2CH_2N(CH_3)_2$, $-NHC[N(CH_3)_2][=N(CH_3)_2]$, $-OCHF_2$, $-CF_3$, $-S(O)_2CH_3$, $-OCF_3$, $-NHC(O)CH_2$(4-dimetilaminopiperidin-1-ilo), o metoxi.

**[00206]** En otra forma de realización (P), el compuesto de Fórmula es aquel donde cada $R^3$ es de modo independiente halo, alquilo, hidroxiamino, $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$ , $-NR^9C(O)R^{9a}$, $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$-$NR^{11}C(O)NR^{11a}R^{11b}$, $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, $-NR^{13}C(O)OR^{13a}$, $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$ , $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$, o $-N(R^{20})C(O)$-alquilen $C_1$-$C_6$-$C(O)R^{20a}$; donde cada uno de los alquilenos en $R^3$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, cada $R^3$ es de modo independiente metilo, cloro, $-NHC(O)CH_2NH(CH_3)$,

-NHC(O)CH($CH_3$)$NH_2$, -NHC(O)C($CH_3$)$_2NH_2$, -NHC(O)$CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)CH($NH_2$)$CH_2CH_3$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)CH($CH_3$)NH($CH_3$), -NHC(O)H, -NHC(O)$CH_2$(azetidin-1-ilo), -NHC(O)(pirrolidin-2-ilo), -NHC(O)CH($NH_2$)$CH_2OH$, -NHC(O)(azetidin-4-ilo), -NHC(O)C($CH_3$)$_2$NH($CH_3$), -$NH_2$, -NHC(O)$CH_2$NH($CH_2CH_2CH_3$), -NHC(O)$CH_2CH_2NH_2$, -NHOH, o -NHC(O)(piperidin-3-ilo).

**[00207]** En otra forma de realización (Q), el compuesto de Fórmula es aquel donde $R^3$ es alquilo o -N($R^7$)C(O)-alquilen $C_1$-$C_6$-N($R^{7a}$)($R^{7b}$); y $R^7$ es hidrógeno o alquilo y $R^{7a}$ y $R^{7b}$ son de modo independiente hidrógeno, alquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, cada $R^3$ es de modo independiente metilo, -NHC(O)$CH_2$NH($CH_3$), -NHC(O)CH($CH_3$)$NH_2$, -NHC(O)C($CH_3$)$_2NH_2$, -NHC(O)-$CH_2N(CH_3)_2$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, -NHC(O)CH($NH_2$)$CH_2CH_3$, -NHC(O)$CH_2N(CH_3)CH_2CH_2N(CH_3)_2$, o -NHC(O)CH($CH_3$)NH($CH_3$).


**[00208]** En otra forma de realización (R), el compuesto de Fórmula es aquel donde B es fenilo, $R^3$ no está presente o $R^3$ es halo, alquilo, o alcoxi; $R^{3A}$ es -C(O)$NR^8R^{8a}$, -$NR^9$C(O)$R^{9a}$, -N($R^7$)C(O)-alquilen $C_1$-$C_6$-N($R^{7a}$)($R^{7b}$), o -C(O)N($R^{10}$)-alquilen $C_1$-$C_6$-N($R^{10a}$)$R^{10b}$ donde cada uno de los alquilenos en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino; y los otros grupos son como se definieron en la Síntesis de la invención.

**[00209]** En otra forma de realización (R1) de la forma de realización R, el compuesto es aquel donde $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es halo o alcoxi; $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es alcoxi; o $R^{50}$ y $R^{52}$ son hidrógeno y $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos

forman un heteroarilo de 6 miembros; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es halo o alcoxi; o $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es alcoxi.

**[00210]** En otra forma de realización de (R2) de la forma de realización R, el compuesto es aquel donde $R^{51}$ es metilo.

**[00211]** En otra forma de realización (S), el compuesto de Fórmula Ia:



**I(a)**

es aguel donde $R^3$ no está presente o $R^3$ es alquilo y $R^{3A}$ es $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, o $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$; donde cada uno de los alquilenos en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^3$ no está está presente o es metilo. En otra forma de realización, $R^3$ no está presente.

**[00212]** En otra forma de realización (S1) de la forma de realización S es aquel donde $R^7$ es hidrógeno o alquilo y $R^{7a}$, y $R^{7b}$ son de modo independiente hidrógeno, alquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; $R^8$ es hidrógeno o alquilo y $R^{8A}$ es

heterocicloalquilo o heterocicloalquilalquilo; $R^9$ es hidrógeno o alquilo y $R^{9a}$ es hidrógeno, heterocicloalquilo, o heterocicloalquilalquilo; y $R^{10}$, $R^{10a}$, y $R^{10b}$ son de modo independiente hidrógeno, alquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo.

**[00213]** En otra forma de realización (S2) de la forma de realización S es aquel donde $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es halo o alcoxi; o $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es alcoxi; o $R^{50}$ y $R^{52}$ son hidrógeno y $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 6 miembros. En otra forma de realización, $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es halo o alcoxi; o $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es alcoxi.


**[00214]** En otra forma de realización de (S3) de la forma de realización S, el compuesto es aquel donde $R^{51}$ es metilo.

**[00215]** En otra forma de realización (T), el compuesto de Fórmula es aquel donde B es heteroarilo, un $R^3$ es halo, alquilo, o alcoxi y un segundo $R^3$ es $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$, o $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$ donde cada uno de los alquilenos en $R^3$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino; y los otros grupos son como se definieron en la Síntesis de la invención.

**[00216]** En otra forma de realización (T1) de la forma de realización T, el compuesto es aquel donde $R^7$ es hidrógeno o alquilo y $R^{7a}$, y $R^{7b}$ son de modo independiente hidrógeno, alquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; $R^8$ es hidrógeno o alquilo y $R^{8A}$ es heterocicloalquilo o

heterocicloalquilalquilo; $R^9$ es hidrógeno o alquilo y $R^{9a}$ es hidrógeno, heterocicloalquilo, o heterocicloalquilalquilo; $R^{10}$, $R^{10a}$, y $R^{10b}$ son de modo independiente hidrógeno, alquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquil.

**[00217]** En otra forma de realización U, el compuesto de Fórmula es aquel donde B es




; cada $R^3$ (cuando $R^3$ está presente) es de modo independiente halo, alquilo, alcoxi, aminoalquiloxi, alquilaminoalquiloxi, dialquilaminoalquiloxi, alquilamino, dialquilamino, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$, o $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$; y los otros grupos son como se definieron en la Síntesis de la invención.

**[00218]** En otra forma de realización (U1) de la forma de realización U, el compuesto de Fórmula es aquel donde $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es halo o alcoxi; $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es alcoxi; o $R^{50}$ y $R^{52}$ son hidrógeno y $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 6 miembros; y los otros grupos son como se definieron en la Síntesis de la invención. En otra forma de realización, $R^{50}$, $R^{52}$, y $R^{53}$ son hidrógeno y $R^{54}$ es halo o alcoxi; o $R^{50}$, $R^{52}$, y $R^{54}$ son hidrógeno y $R^{53}$ es alcoxi.

**[00219]** En otra forma de realización (U2) de la forma de realización U1, el compuesto de Fórmula es aquel donde $R^{51}$ es metilo.

**[00220]** En otra forma de realización (U3) de la forma de realización U, el compuesto de Fórmula es aquel donde $R^7$

es hidrógeno o alquilo y $R^{7a}$, y $R^{7b}$ son de modo independiente hidrógeno, alquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; $R^8$ es hidrógeno o alquilo y $R^{8A}$ es heterocicloalquilo o heterocicloalquilalquilo; $R^9$ es hidrógeno o alquilo y $R^{9a}$ es hidrógeno, heterocicloalquilo, o heterocicloalquilalquilo; $R^{10}$, $R^{10a}$, y $R^{10b}$ son de modo independiente hidrógeno, alquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo

**[00221]** En otra forma de realización de la invención (V) el compuesto de Fórmula es aquel donde $W^1$, $W^2$, $W^3$, y $W^4$ son -C(H)=; o $W^2$ y $W^3$ son -C(H)= y uno de $W^1$ y $W^4$ es -N= y el otro es -C(H)=;

$R^{50}$ es hidrógeno;

$R^{51}$ es hidrógeno o alquilo;

$R^{52}$ es hidrógeno;

$R^{53}$ es hidrógeno, alcoxi, nitro, amino, o $-N(R^{55})C(O)-$alquilen $C_1-C_6-N(R^{55a})R^{55b}$; y $R^{54}$ es hidrógeno, alquilo, alcoxi, o halo; o $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 6 miembros;

B es fenilo sustituido con $R^{3a}$ y opcionalmente further sustituido con one $R^3$; o

B es heteroarilo opcionalmente sustituido con uno o dos $R^3$;

$R^{3A}$ es ciano; hidroxiamino; carboxi; alquilsulfonilo, aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; $-N(R^7)C(O)$-alquilen $C_1-C_6-N(R^{7a})(R^{7b})$; $-C(O)NR^8R^{8a}$; $-NR^9C(O)R^{9a}$; $-C(O)N(R^{10})$-alquilen $C_1-C_6-N(R^{10a})R^{10b}$; $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$; $-C(O)R^{12}$; $-NR^{13}C(O)OR^{13a}$;

$-C(O)N(R^{14})N(R^{14a})(R^{14b})$; $-S(O)_2N(R^{15})$-alquilen $C_1-C_6-N(R^{15a})R^{15b}$;

$-C(O)N(R^{16})$-alquilen $C_1-C_6-C(O)OR^{16a}$; heteroarilo opcionalmente sustituido con uno o dos aminoalquilo,

alquilaminoalquilo, o dialquilaminoalquilo; $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$; $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$; $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})-N(R^{22c})(R^{22a})$; -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$; o $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$; donde cada uno de los alquilenos en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino;

cada $R^3$ (cuando $R^3$ está presente) es de modo independiente halo; ciano; alquilo; alquenilo; alcoxi; hidroxiamino; carboxi; alquilsulfonilo, aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$; $-C(O)NR^8R^{8a}$; $-NR^9C(O)R^{9a}$; $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$; $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$; $-C(O)R^{12}$; $-NR^{13}C(O)OR^{13a}$; $-C(O)N(R^{14})N(R^{14a})(R^{14b})$; $-S(O)_2N(R^{15})$-alquilen $C_1$-$C_6$-$N(R^{15a})R^{15b}$;

$-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$; heteroarilo opcionalmente sustituido con uno o dos aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo; $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$; $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$; $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$; $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})-N(R^{22c})(R^{22a})$; -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$; o $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$; donde cada uno de los alquilenos en $R^3$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino;

con la condición de que cuando $R^{50}$ y $R^{52}$ son hidrógeno, $R^{51}$ es hidrógeno o metilo, $R^{53}$ es hidrógeno o metoxi, y $R^{54}$ es hidrógeno o metoxi, then B es not 2,3-dihidro-1,4-

benzodioxinilo, tien-2-ilo, o tien-2-il sustituido con one $R^3$ donde $R^3$ es halo.

**[00222]** Otra forma de realización (W) de la invención es un compuesto de Fórmula I donde $R^{50}$, $R^{53}$, y $R^{54}$ son de modo independiente hidrógeno, alquilo, alquenilo, halo, haloalquilo, haloalquenilo, hidroxi, alcoxi, alqueniloxi, haloalcoxi, nitro, amino, alquilamino, dialquilamino, $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-$N(R^{55a})R^{55b}$, alquilcarbonilo, alquenilcarbonilo, carboxi, alcoxicarbonilo, ciano, alquiltio, $-S(O)_2NR^{55}R^{55a}$, o alquilcarbonilamino y donde $R^{55}$ y $R^{55b}$ son de modo independiente hidrógeno, alquilo, o alquenilo y $R^{55a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi; o $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 5 o 6 miembros o heterocicloalquilo de 5 o 6 miembros.

**[00223]** Otra forma de realización (X) de la invención es un compuesto de Fórmula I donde $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 5 o 6 miembros o heterocicloalquilo de 5 o 6 miembros.

**Compuestos representativos**

**[00224]** Los compuestos representativos de Fórmula I y/o II se describen a continuación. Los ejemplos son solo ilustrativos y no limitan el alcance de la invención de ninguna manera. Los compuestos de la invención se nombran de acuerdo con la aplicación sistemática de las reglas de nomenclatura de acuerdo con la International Union de Pure y Applied Chemistry (IUPAC), International Union de Biochemistry y Molecular Biology (IUBMB), y el Chemical Abstracts Service (CAS). Los nombres de la Tabla 1 se generaron usando el programa de computación de denominación ACD/Labs 8,00, versión del producto 8,08 con

la excepción del Compuesto 374 que se nombró usando ChemDraw v. 9,0,1.





**Tabla 1**

**Inhibidores de PI3K-alfa representativos**

**[00225]** Los Compuestos de la Tabla 1 se pueden preparar como sus sales, solvatos, hidratos, y/o isómeros farmacéuticamente aceptables. Dichas sales, solvatos, hidratos y combinaciones de isómeros de los Compuestos de la Tabla 1 se pueden usar en la práctica de la invención. En particular, la invención se puede practicar con una o dos sales farmacéuticamente aceptables de un Compuesto de la Tabla 1, dichas sales se forman con uno o dos ácidos seleccionados de modo independiente de ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido nítrico, ácido fosfórico, ácido acético, ácido trifluoroacético, ácido propiónico, ácido hexanoico, ácido ciclopentanopropiónico, ácido glicólico, ácido pirúvico, ácido láctico, ácido oxálico, ácido maleico, ácido malónico, ácido succínico, ácido fumárico, ácido tartárico, ácido cítrico, ácido benzoico, ácido cinámico, ácido 3-(4-hidroxibenzoil)benzoico, ácido mandélico, ácido metansulfónico, ácido etansulfónico, ácido 1,2-etandisulfónico, ácido 2-hidroxietansulfónico, ácido bencensulfónico, ácido 4-clorobencensulfónico, ácido 2-naftalenosulfónico, ácido 4-toluensulfónico, ácido canforsulfónico, ácido glucoheptónico, ácido 4,4'-metilenbis-(3-hidroxi-2-ene-1-carboxílico), ácido 3-fenilpropiónico, ácido trimetilacético, ácido ter-butilacético, ácido lauril sulfúrico, ácido glucónico, ácido glutámico, ácido hidroxinaftoico, ácido salicílico, ácido esteárico, ácido mucónico ácido p-toluensulfónico y ácido salicílico. En particular, la invención se puede

practicar con una o dos sales farmacéuticamente aceptables de un Compuesto de la Tabla 1, dichas sales se forman con una o dos bases seleccionadas de modo independiente de sodio, potasio, litio, amonio, calcio, magnesio, hierro, zinc, cobre, manganeso, aluminio isopropilamina, trimetilamina, dietilamina, trietilamina, tripropilamina, etanolamina, 2-dimetilaminoetanol, 2-dietilaminoetanol, diciclohexilamina, lisina, arginina, histidina, cafeína, procaína, hidrabamina, colina, betaína, etilendiamina, glucosamina, metilglucamina, teobromina, purinas, piperazina, piperidina, N-etilpiperidina, trometamina, *N*-metilglucamina. Cualquier compuesto individual (y cualquiera de sus sales opcionales, solvatos opcionales e hidratos opcionales) de la Tabla 1 se puede usar en combinación con cualquiera de las formas de realización anteriores.

Tabla 1

| Comp. No. | Estructura | Nombre |
|---|---|---|
| |  | *N*-(4-{[(3-{[4-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil) acetamida |
| |  | 4-bromo-*N*-[3-(fenilamino)quinoxalin-2-il] bencensulfonamida |
| |  | 4-bromo-*N*-{3-[(2-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| |  | 4-bromo-*N*-(3-{[4-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |







| Tabla 1 | | |
|---|---|---|
| Comp. No. | Estructura | Nombre |
| |  | 4-cloro-*N*-{3-[(4-clorofenil)amino]-6-(metoxi)quinoxalin-2-il}bencensulfonamida |
| |  | *N*-(4-{[3-{[(4-clorofenil)sulfonil]amino}-7-(metoxi)quinoxalin-2-il]amino}fenil)acetamida |
| |  | 4-cloro-*N*-{6-(metoxi)-3-[(2-oxo-2,3-dihidro-1*H*-bencimidazol-5-il)amino]quinoxalin-2-il}bencensulfonamida |
| |  | *N*-{4-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]fenil}acetamida |
| |  | *N*-(3-{[4-(etiloxi)fenil]amino}quinoxalin-2-il)-4-metilbencensulfonamida |
| 0 |  | *N*-{3-[(3,4-dimetilfenil)amino]-6-metilquinoxalin-2-il}-4-metilbencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 11 |  | *N*-(3-{[3-(dimetilamino)fenil]amino}quinoxalin-2-il)-4-metilbencensulfonamida |
| 12 |  | 4-metil-*N*-{6-metil-3-[(4-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 13 |  | *N*-{3-[(4-hidroxifenil)amino]-6-metilquinoxalin-2-il}-4-metilbencensulfonamida |
| 14 |  | *N*-{3-[(2,5-dimetilfenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 15 |  | 4-cloro-*N*-[3-(naftalen-2-ilamino)quinoxalin-2-il]bencensulfonamida |
| 16 |  | *N*-{3-[(3-aminofenil)amino]quinoxalin-2-il}-4-clorobencensulfonamida |
| 17 |  | *N*-(3-{[4-(aminosulfonil)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |

Tabla 1









| Comp. No. | Estructura | Nombre |
|---|---|---|
| 18 |  | 4-cloro-*N*-{3-[(4-clorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 19 |  | 4-cloro-*N*-{3-[(4-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 20 |  | 4-cloro-*N*-{3-[(2-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 21 |  | 4-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]benzoato de metilo |
| 22 |  | 2-cloro-5-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]benzoato de metilo |
| 23 |  | *N*-{4-[(7-metil-3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]fenilo}acetamida |
| 24 |  | 4-metil-*N*-(6-metil-3-{[2-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 25 |  | *N*-{3-[(fenilmetil)amino]-quinoxalin-2-il}bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 26 |  | ácido 4-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)benzoico |
| 27 |  | 3-({3-[(fenilsulfonil)amino]-quinoxalin-2-il}amino)bencensulfonamida |
| 28 |  | *N*-{3-[(1,5-dimetil-3-oxo-2-fenilo-2,3-dihidro-1*H*-pirazol-4-il)amino]quinoxalin-2-il}bencensulfonamida |
| 29 |  | *N*-{3-[(4-hidroxifenil)amino]-quinoxalin-2-il}bencensulfonamida |
| 30 |  | *N*-{3-[(4-hidroxifenil)amino]-quinoxalin-2-il}-4-metilbencensulfonamida |
| 31 |  | *N*-(3-{[4-(aminosulfonil)fenil]amino}quinoxalin-2-il)-4-metilbencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 32 |  | Ácido 3-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 33 |  | *N*-[4-({[3-(fenilamino)-quinoxalin-2-il]amino}sulfonil)-fenil]acetamida |
| 34 |  | *N*-(4-{[(3-{[4-(aminosulfonil)fenil]amino}quinoxalin-2-il)amino]sulfonil}-fenil)acetamida |
| 35 |  | *N*-[4-({[3-(naftalen-1-ilamino)quinoxalin-2-il]amino}sulfonil)fenil]acetamida |
| 36 |  | *N*-{4-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]fenilo}acetamida |
| 37 |  | *N*-(3-{[3-(aminosulfonil)fenil]-amino}quinoxalin-2-il)-4-bromobencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 38 |  | *N*-{3-[(3-hidroxifenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 39 |  | Ácido 4-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]-2-hidroxibenzoico |
| 40 |  | *N*-(3-{[4-(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 41 |  | Ácido 3-[(3-{[(4-clorofenil)-sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 42 |  | *N*-(3-{[4-(aminosulfonil)fenil]-amino}quinoxalin-2-il)-4-clorobencensulfonamida |
| 43 |  | *N*-(3-{[3-(aminosulfonil)fenil]-amino}quinoxalin-2-il)-4-clorobencensulfonamida |
| 44 |  | *N*-[3-(naftalen-2-ilamino)quinoxalin-2-il]-4-nitrobencensulfonamida |

Tabla 1









| Comp. No. | Estructura | Nombre |
|---|---|---|
| 45 |  | *N*-(3-{[3-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 46 |  | 3-[(4-bromofenil)amino]-quinoxalin-2-il}-3-nitrobencensulfonamida |
| 47 |  | Ácido 3-[(3-{[(4-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 48 |  | 4-nitro-*N*-[3-(fenilamino)-quinoxalin-2-il]bencensulfonamida |
| 49 |  | 4-cloro-*N*-[3-(fenilamino)-quinoxalin-2-il]bencensulfonamida |
| 50 |  | 3-nitro-*N*-[3-(fenilamino)-quinoxalin-2-il]bencensulfonamida |
| 51 |  | Ácido 4-[(3-{[(4-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico acid |
| 52 |  | *N*-[3-(naftalen-2-ilamino)quinoxalin-2-il]-3-nitrobencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 53 |  | 4-metil-*N*-(3-{[3-(metoxi)fenil]-amino}quinoxalin-2-il)bencensulfonamida |
| 54 |  | *N*-(3-{[3-cloro-4-(metoxi)fenil]-amino}quinoxalin-2-il)bencensulfonamida |
| 55 |  | *N*-{3-[(3-cloro-4-fluorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 56 |  | metil 2-cloro-5-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)benzoate |
| 57 |  | 4-cloro-*N*-{3-[(3-hidroxifenil)amino]quinoxalin-2-il}bencensulfonamida |
| 58 |  | 4-metil-*N*-[6-metil-3-(fenilamino)-quinoxalin-2-il]bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 59 |  | *N*-{4-[({3-[(4-metilfenil)amino]-quinoxalin-2-il}amino)sulfonil]-fenil}acetamida |
| 60 |  | 4-[(3-{[(4-clorofenil)sulfonil]amino}-7-metilquinoxalin-2-il)amino]benzoato de 1-metiletilo |
| 61 |  | *N*-{3-[(4-metilfenil)amino]-quinoxalin-2-il}bencensulfonamida |
| 62 |  | *N*-{3-[(3-metilfenil)amino]-quinoxalin-2-il}bencensulfonamida |
| 63 |  | *N*-{3-[(4-bromofenil)amino]-quinoxalin-2-il}-4-metilbencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 64 |  | 4-metil-*N*-{3-[(3-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 65 |  | 4-metil-*N*-[3-(naftalen-1-ilamino)quinoxalin-2-il]bencensulfonamida |
| 66 |  | *N*-{4-[({3-[(4-clorofenil)amino]quinoxalin-2-il}amino)sulfonil]fenilo}acetamida |
| 67 |  | *N*-(4-{[(3-{[3-(aminosulfonil)fenil]amino}quinoxalin-2-il)amino]sulfonil}-fenil)acetamida |
| 68 |  | 4-metil-*N*-{3-[(fenilmetil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1









| Comp. No. | Estructura | Nombre |
|---|---|---|
| 69 |  | Ácido 4-[(3-{[(4-bromofenil)sulfonil]-amino}quinoxalin-2-il)amino]-2-hidroxibenzoico |
| 70 |  | 4-bromo-*N*-{3-[(4-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 71 |  | 4-bromo-*N*-{3-[(3-metilfenil)-amino]quinoxalin-2-il}bencensulfonamida |
| 72 |  | *N*-{4-[({3-[(2-hidroxietil)-amino]quinoxalin-2-il}amino)-sulfonil]fenilo}acetamida |
| 73 |  | Ácido 4-bromo-*N*-[3-(naftalen-1-ilamino)quinoxalin-2-il]bencensulfonamida |
| 74 |  | Ácido 4-[(3-{[(4-clorofenil)-sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 75 |  | Ácido 3-[(3-{[(3-nitrofenil)-sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 76 |  | *N*-{3-[(2-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 77 |  | 4-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)bencensulfonamida |
| 78 |  | *N*-[3-(naftalen-1-ilamino)quinoxalin-2-il]-3-nitrobencensulfonamida |
| 79 |  | *N*-(3-{[3-(aminosulfonil)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 80 |  | *N*-{3-[(4-bromofenil)amino]quinoxalin-2-il}-4-nitrobencensulfonamida |
| 81 |  | 4-cloro-*N*-[3-(naftalen-1-ilamino)quinoxalin-2-il]bencensulfonamida |
| 82 |  | *N*-{4-[({3-[(fenilmetil)amino]-quinoxalin-2-il}amino)sulfonil]-fenilo}acetamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 83 |  | *N*-[4-({[3-(butilamino)quinoxalin-2-il]amino}-sulfonil)fenil]acetamida |
| 84 |  | *N*-[3-(butilamino)quinoxalin-2-il]-4-metilbencensulfonamida |
| 85 |  | *N*-[3-(ciclohexilamino)quinoxalin-2-il]bencensulfonamida |
| 86 |  | 1-(fenilsulfonil)-3-[4-(pirrolidin-1-ilsulfonil)fenil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |
| 87 |  | 1-(fenilsulfonil)-3-[4-(piperidin-1-ilsulfonil)fenil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |
| 88 |  | 2,5-dicloro-*N*-[3-(3,4-dihidroquinolin-1(2*H*)-il)quinoxalin-2-il]bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 89 |  | 2-[(3-{[(4-metilfenil)sulfonil]-amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3-carboxilato de etilo |
| 90 |  | 2,5-dicloro-*N*-{3-[(2-morfolin-4-ilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 91 |  | *N*-{4-[({3-[(3-metilfenil)amino]-quinoxalin-2-il}amino)sulfonil]-fenilo}acetamida |
| 92 |  | 4-cloro-*N*-{3-[(3-cloro-4-piperidin-1-ilfenil)amino]-6-metilquinoxalin-2-il}bencensulfonamida |
| 93 |  | 3-nitro-*N*-[3-(quinolin-6-ilamino)quinoxalin-2-il]bencensulfonamida |
| 94 |  | *N*-{[4-({3-[(fenilsulfonil)-amino]quinoxalin-2-il}amino)-fenil]carbonil}glicinato de butilo |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 95 |  | 4-nitro-*N*-(3-{[3-(trifluorometil)-fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 96 |  | *N*-[4-({3-[(fenilsulfonil)-amino]quinoxalin-2-il}amino)fenil]acetamida |
| 97 |  | *N*-{3-[(3-{[(4-metilfenil)sulfonil]-amino}quinoxalin-2-il)amino]fenilo}acetamida |
| 98 |  | 3,3,3-trifluoro-2-hidroxi-2-{4-[(3-{[(4-metilfenil)sulfonil]-amino}quinoxalin-2-il)amino]fenilo}propanoato de etilo |
| 99 |  | *N*-{3-[(4-{[(2,6-dimetilpirimidin-4-il)amino]-sulfonil}fenil)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 100 |  | 4-cloro-*N*-{3-[(3,4-dimetilfenil)amino]-6-metilquinoxalin-2-il}bencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 101 |  | 4-cloro-*N*-(6-metil-3-{[3-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 102 |  | 4-[(3-{[(4-clorofenil)sulfonil]-amino}-7-metilquinoxalin-2-il)amino]benzoato de butilo |
| 103 |  | 4-cloro-*N*-{3-[(3-cloro-4-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 104 |  | 4-[(3-{[(4-clorofenil)sulfonil]-amino}quinoxalin-2-il)amino]-benzoato de 1-metiletilo |
| 105 |  | *N*-{3-[(2,5-dimetilfenil)amino]-6-nitroquinoxalin-2-il}-4-metilbencensulfonamida |
| 106 |  | *N*-[3-(ciclohexilamino)-6-nitroquinoxalin-2-il]-4-metilbencensulfonamida |
| 107 |  | *N*-{3-[(2,4-dimetilfenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 108 |  | *N*-(3-{[4-(etiloxi)fenil]amino}-6-metilquinoxalin-2-il)-4-metilbencensulfonamida |
| 109 |  | Ácido 3-({3-[({4-[hidroxi(oxido)amino]-fenil}-sulfonil)amino]quinoxalin-2-il}amino)benzoico |
| 110 |  | {[4-({3-fenilsulfonil)amino]quinoxalin-2-}amino)fenil]-carbonil}glicina |
| 111 |  | *N*-{3-[(3-{[(4-clorofenil)sulfonil]amino}-7-metilquinoxalin-2-il)amino]fenilo}acetamida |
| 112 |  | 4-cloro-*N*-{3-[(3,5-dimetil-1*H*-pirazol-4-il)amino]-6-metilquinoxalin-2-il}bencensulfonamida |
| 113 |  | 4-bromo-*N*-{3-[(4'-nitrobifenil-3-il)amino]quinoxalin-2-il}bencensulfonamida |
| 114 |  | 4-bromo-*N*-{3-[(2-clorofenil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 115 |  | *N*-{3-[(4-butilfenil)amino]-6-metilquinoxalin-2-il}-4-clorobencensulfonamida |
| 116 |  | *N*-{4-[(3-{[(4-clorofenil)sulfonil]amino}-7-metilquinoxalin-2-il)amino]fenilo}acetamida |
| 117 |  | 4-cloro-*N*-{6-metil-3-[(2-oxo-2,3-dihidro-1*H*-bencimidazol-5-il)amino]quinoxalin-2-il}bencensulfonamida |
| 118 |  | 4-[(3-{[(4-clorofenil)sulfonil]-amino}-7-metilquinoxalin-2-il)amino]benzoato de propilo |
| 119 |  | 4-cloro-*N*-{3-[(4-fluorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 120 |  | *N*-[4-({[3-(naftalen-2-ilamino)quinoxalin-2-il]amino}-sulfonil)fenil]acetamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 121 |  | 4-bromo-*N*-(3-{[4-(fenilamino)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 122 |  | Ácido 2-hidroxi-4-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)benzoico |
| 123 |  | *N*-(3-{[3-(aminosulfonil)fenil]-amino}quinoxalin-2-il)-4-metilbencensulfonamida |
| 124 |  | Ácido 4-[(3-{[(3-nitrofenil)-sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 125 |  | *N*-(3-{[3-(butiloxi)fenil]amino}quinoxalin-2-il)-4-metilbencensulfonamida |
| 126 |  | *N*-{3-[(4-fluorofenil)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 127 |  | Ácido 4-{[3-({[4-(acetilamino)fenil]sulfonil}amino)quinoxalin-2-il]amino}-2-hidroxibenzoico |
| 128 |  | *N*-[3-(naftalen-1-ilamino)quinoxalin-2-il]-4-nitrobencensulfonamida |
| 129 |  | Ácido 4-[(3-{[(4-bromofenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 130 |  | *N*-{4-[({3-[(3-hidroxifenil)-amino]quinoxalin-2-il}amino)-sulfonil]fenilo}acetamida |
| 131 |  | Ácido 3-[(3-{[(4-bromofenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 132 |  | 4-bromo-*N*-(3-{[3-(butiloxi)-fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 133 |  | 4-bromo-*N*-(3-{[3-(trifluorometil)-fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 134 |  | 4-metil-*N*-{3-[(4'-nitrobifenil-3-il)amino]quinoxalin-2-il}bencensulfonamida |
| 135 |  | 4-cloro-*N*-{3-[(3-fluorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 136 |  | *N*-{3-[(2-clorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 137 |  | 4-bromo-*N*-[3-(quinolin-5-ilamino)quinoxalin-2-il]bencensulfonamida |
| 138 |  | *N*-{3-[(3-fluorofenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 139 |  | *N*-{3-[(4-fluorofenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 140 |  | 3-nitro-*N*-(3-{[3-(trifluorometil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 141 |  | Ácido 2-hidroxi-4-[(3-{[(3-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 142 |  | *N*-{3-[(3-clorofenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 143 |  | *N*-[3-(1,3-benzodioxol-5-ilamino)quinoxalin-2-il]-4-bromobencensulfonamida |
| 144 |  | *N*-{3-[(3-acetilfenil)amino]quinoxalin-2-il}-4-clorobencensulfonamida |
| 145 |  | 3-nitro-*N*-(3-{[4-(9*H*-xanten-9-il)fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 146 |  | 4-cloro-*N*-{3-[(4'-nitrobifenil-3-il)amino]quinoxalin-2-il}bencensulfonamida |
| 147 |  | *N*-[3-(2,1,3-benzotiadiazol-5-ilamino)quinoxalin-2-il]-4-tolilsulfonamida |
| 148 |  | *N*-{3-[(2-metil-1,3-dioxo-2,3-dihidro-1*H*-isoindol-5-il)amino]quinoxalin-2-il}bencensulfonamida |
| 149 |  | 4-metil-*N*-[3-(quinolin-5-ilamino)quinoxalin-2-il]bencensulfonamida |
| 150 |  | 4-metil-*N*-{3-[(1-oxo-1,3-dihidro-2-benzofuran-5-il)amino]quinoxalin-2-il}bencensulfonamida |
| 151 |  | 4-cloro-*N*-{3-[(2-clorofenil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 152 |  | Ácido 2-hidroxi-5-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 153 |  | *N*-(3-{[3,5-bis(1,1-dimetiletil)-4-hidroxifenil]amino}quinoxalin-2-il)bencensulfonamida |
| 154 |  | *N*-[3-({2-[(trifluorometil)-tio]fenilo}amino)quinoxalin-2-il]bencensulfonamida |
| 155 |  | *N*-{4-[({3-[(4-hidroxifenil)amino]-quinoxalin-2-il}amino)sulfonil]-fenil}acetamida |
| 156 |  | *N*-[3-(1,3-benzodioxol-5-ilamino)quinoxalin-2-il]-4-metilbencensulfonamida |
| 157 |  | *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 158 |  | *N*-{3-[(2,4-diclorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 159 |  | *N*-[4-({[3-(2,3-dihidro-1,4-benzodioxin-6-ilamino)-quinoxalin-2-il]amino}sulfonil)-fenil]acetamida |
| 160 |  | 4-cloro-*N*-{3-[(3,4-dimetilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 161 |  | *N*-(3-{[2,5-bis(metoxi)fenil]-amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 162 |  | 4-bromo-*N*-{3-[(3,4-dimetilfenil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 163 |  | Ácido 5-{[3-({[4-(acetilamino)fenil]sulfonil}amino)quinoxalin-2-il]amino}-2-hidroxibenzoico |
| 164 |  | *N*-(3-{[2,5-bis(metoxi)fenil]-amino}quinoxalin-2-il)-4-clorobencensulfonamida |
| 165 |  | *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-metilbencensulfonamida |
| 166 |  | *N*-{3-[(2,4-diclorofenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 167 |  | 4-bromo-*N*-{3-[(3-fluorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 168 |  | Ácido 4-{[3-({[4-(acetilamino)fenil]sulfonil}amino)quinoxalin-2-il]amino}benzoico |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 169 |  | *N*-{3-[(2-fluorofenil)amino]-quinoxalin-2-il}-4-metilbencensulfonamida |
| 170 |  | *N*-[3-(2,3-dihidro-1,4-benzodioxin-6-ilamino)-quinoxalin-2-il]-4-metilbencensulfonamida |
| 171 |  | *N*-{3-[(3,4-dimetilfenil)amino]-quinoxalin-2-il}bencensulfonamida |
| 172 |  | 4-metil-*N*-(3-{[3-(trifluorometil)-fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 173 |  | Ácido 5-[(3-{[(4-clorofenil)-sulfonil]amino}quinoxalin-2-il)amino]-2-hidroxibenzoico |
| 174 |  | 3-nitro-*N*-{3-[(1-oxo-1,3-dihidro-2-benzofuran-5-il)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 175 |  | *N*-{4-[({3-[(2-bromo-4-metilfenil)amino]quinoxalin-2-il}amino)sulfonil]fenil}acetamida |
| 176 |  | *N*-{3-[(2-fluorofenil)-amino]quinoxalin-2-il}-4-nitrobencensulfonamida |
| 177 |  | *N*-{3-[(2-metil-1,3-dioxo-2,3-dihidro-1*H*-isoindol-5-il)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 178 |  | 4-cloro-*N*-{3-[(1-oxo-1,3-dihidro-2-benzofuran-5-il)amino]quinoxalin-2-il}bencensulfonamida |
| 179 |  | *N*-{3-[(1-oxo-1,3-dihidro-2-benzofuran-5-il)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 180 |  | *N*-{3-[(2-fluorofenil)amino]-quinoxalin-2-il}-3-nitrobencensulfonamida |
| 181 |  | *N*-[2-(butiloxi)-2-hidroxietil]-4-({3-[(fenilsulfonil)amino]-quinoxalin-2-il}amino)benzamida |
| 182 |  | 3-nitro-*N*-(3-{[4-(fenilamino)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 183 |  | 4-bromo-*N*-{3-[(4-fluorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 184 |  | 4-metil-*N*-[3-({2-[(trifluorometil)tio]fenil}amino)quinoxalin-2-il]bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 185 |  | *N*-[4-({3-[2-(metoxi)fenil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalin-1-il}sulfonil)fenil]acetamida |
| 186 |  | Ácido 4-(3-{[4-(acetilamino)fenil]sulfonil}-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalin-1-il)benzoico |
| 187 |  | 1-naftalen-2-il-3-[(3-nitrofenil)sulfonil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |
| 188 |  | *N*-[4-({3-[4-(metoxi)fenil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalin-1-il}sulfonil)-fenil]acetamida |
| 189 |  | 1-(3-metilfenil)-3-[(4-metilfenil)sulfonil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 190 |  | *N*-(4-{[3-(4-metilfenil)-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalin-1-il]sulfonil}-fenil)acetamida |
| 191 |  | *N*-{4-[(3-fenilo-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalin-1-il)sulfonil]fenil}acetamida |
| 192 |  | *N*-(4-{[3-(3-metilfenil)-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalin-1-il]sulfonil}fenil)acetamida |
| 193 |  | 1-[4-(metoxi)fenil]-3-[(4-metilfenil)sulfonil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |
| 194 |  | *N*-(4-{[3-(2-metilfenil)-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalin-1-il]sulfonil}-fenil)acetamida |
| 195 |  | 1-(3-metilfenil)-3-[(3-nitrofenil)sulfonil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 196 |  | 1-(4-metilfenil)-3-[(3-nitrofenil)sulfonil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |
| 197 |  | *N*-{3-[(4-metilfenil)amino]-quinoxalin-2-il}-3-(1*H*-tetrazol-1-il)bencensulfonamida |
| 198 |  | *N*-(3-{[2-(etiloxi)fenil]amino}-quinoxalin-2-il)-4-metilbencensulfonamida |
| 199 |  | *N*-{4-[({3-[(4-etilfenil)amino]-quinoxalin-2-il}amino)sulfonil]fenil}-acetamida |
| 200 |  | 4-bromo-*N*-(3-{[3-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 201 |  | *N*-(4-{[(3-{[4-(etiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 202 |  | *N*-{4-[({3-[(2-etilfenil)amino]-quinoxalin-2-il}amino)sulfonil]-fenil}acetamida |
| 203 |  | *N*-(4-{[(3-{[2-(etiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-acetamida |
| 204 |  | *N*-{3-[(4-nitrofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 205 |  | 4-(etiloxi)-*N*-(3-{[4-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 206 |  | *N*-acetil-*N*-[4-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)fenil]-beta-alaninato de metilo |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 207 |  | *N*-acetil-*N*-{4-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]fenil}-beta- alaninato de metilo |
| 208 |  | *N*-{3-[(3-cloro-5-metilfenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 209 |  | *N*-{3-[(3-acetilfenil)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 210 |  | 4-{[3-({[4-(acetilamino)fenil]sulfonil}amino)quinoxalin-2-il]amino}-*N*-[4-(metoxi)fenil]benzamida |
| 211 |  | Ácido 2-hidroxi-5-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)benzoico |
| 212 |  | *N*-{3-(2,3-dihidro-1,4-benzodioxin-6-ilamino)-quinoxalin-2-il]-3-nitrobencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 213 |  | *N*-[4-(metoxi)fenil]-4-[(3-{[(4-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]benzamida |
| 214 |  | 4-cloro-*N*-{3-[(2-oxo-2,3-dihidro-1*H*-bencimidazol-5-il)amino]quinoxalin-2-il}bencensulfonamida |
| 215 |  | 4-metil-*N*-{3-[metil(fenilmetil)amino]quinoxalin-2-il}bencensulfonamida |
| 216 |  | *N*-[3-(3,4-dihidroisoquinolin-2(1*H*)-il)quinoxalin-2-il]-2-metilbencensulfonamida |
| 217 |  | *N*-[4-({[3-(2,1,3-benzotiadiazol-5-ilamino)quinoxalin-2-il]amino}sulfonil)fenil]-acetamida |

Tabla 1












| Comp. No. | Estructura | Nombre |
|---|---|---|
| 218 |  | 4-bromo-*N*-{3-[(4-fenilquinolin-8-il)amino]quinoxalin-2-il}bencensulfonamida |
| 219 |  | 4-metil-*N*-{3-[(4-fenilquinolin-8-il)amino]quinoxalin-2-il}bencensulfonamida |
| 220 |  | 1-[(4-clorofenil)sulfonil]-3-[4-(pirrolidin-1-ilsulfonil)fenil]-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |
| 221 |  | 1-(4-morfolin-4-ilfenil)-3-(fenilsulfonil)-2,3-dihidro-1*H*-imidazo[4,5-b]quinoxalina |
| 222 |  | 4,5-dimetil-2-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)tiofeno-3-carboxilato de metilo |

Tabla 1

| Comp. No. | Estructura | Nombre |
|---|---|---|
| 223 |  | 6-metil-2-[(3-{[(2-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3-carboxilato de etilo |
| 224 |  | 2-{[3-({[4-(acetilamino)fenil]sulfonil}amino)quinoxalin-2-il]amino}-6-fenilo-4,5,6,7-tetrahidro-1-benzotiofeno-3-carboxilato de etilo |
| 225 |  | 6-metil-2-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3-carboxilato de etilo |
| 226 |  | 4-[(3-{[(4-clorofenil)sulfonil]-amino}quinoxalin-2-il)amino]benzoato de propilo |
| 227 |  | *N*-{3-[(4-butilfenil)amino]quinoxalin-2-il}-4-clorobencensulfonamida |
| 228 |  | *N*-{3-[(2-clorofenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |







| Tabla 1 | | |
|---|---|---|
| Comp. No. | Estructura | Nombre |
| 229 |  | *N*-{3-[(2,3-dimetilfenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 230 |  | *N*-{3-[(3,4-dimetilfenil)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 231 |  | *N*-{4-[({3-[(2,3-dimetilfenil)-amino]quinoxalin-2-il}amino-)sulfonil]fenil}acetamida |
| 232 |  | 4-cloro-*N*-{3-[(2,3-dimetilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 233 |  | 3-nitro-*N*-(3-{[3,4,5-tris(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 234 |  | 4-cloro-*N*-{3-[(2,4-diclorofenil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1




















| Comp. No. | Estructura | Nombre |
|---|---|---|
| 235 |  | *N*-{3-[(2,3-dimetilfenil)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 236 |  | *N*-{4-[({3-[(3,4-dimetilfenil)-amino]quinoxalin-2-il}amino)-sulfonil]fenil}acetamida |
| 237 |  | 2-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]-5,6-dihidro-4*H*-ciclopenta[b]tiofeno-3-carboxilato de etilo |
| 238 |  | 4-cloro-*N*-(3-{[4-cloro-3-(morfolin-4-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 239 |  | etil 2-[(3-{[(2-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3-carboxilate |
| 240 |  | 4-bromo-*N*-{3-[(2,4-diclorofenil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1

| Comp. No. | Estructura | Nombre |
|---|---|---|
| 241 |  | 5-etil-2-[(3-{[(3-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]tiofeno-3-carboxilato de etilo |
| 242 |  | *N*-(3-{[3-(morfolin-4-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| |  | 2-[(3-{[(4-bromofenil)sulfonil]amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3- carboxilato de etilo |
| 244 |  | 4-metil-*N*-(3-{[3-(piperidin-1-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 245 |  | 4-cloro-*N*-(3-{[4-(morfolin-4-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 246 |  | 4-cloro-*N*-(3-{[3-(morfolin-4-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 247 |  | 4-metil-*N*-[3-(quinolin-6-ilamino)quinoxalin-2-il]bencensulfonamida |

| Tabla 1 | | |
|---|---|---|
| Comp. No. | Estructura | Nombre |
| 248 |  | *N*-(3-{[3-(piperidin-1-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 249 |  | *N*-(3-{[4-(fenilamino)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 250 |  | *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-bromobencensulfonamida |
| 251 |  | 2-[(3-{[(3-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]-5,6-dihidro-4*H*-ciclopenta[b]tiofeno-3- carboxilato de etilo |
| 252 |  | *N*-{3-[(4'-nitrobifenil-4-il)amino]quinoxalin-2-il}bencensulfonamida |
| 253 |  | 2-[(3-{[(3-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3- carboxilato de etilo |







| Tabla 1 | | |
|---|---|---|
| Comp. No. | Estructura | Nombre |
| 254 |  | *N*-(3-{[4-cloro-3-(morfolin-4-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 255 |  | 5-etil-2-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)tiofeno-3- carboxilato de etilo |
| 256 |  | *N*-[4-({[3-(quinolin-6-ilamino)quinoxalin-2-il]amino}sulfonil)fenil]acetamida |
| 257 |  | 2-[(3-{[(2-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]-5,6-dihidro-4*H*-ciclopenta[b]tiofeno-3- carboxilato de etilo |
| 258 |  | 3,4-dicloro-*N*-[3-(naftalen-1-ilamino)quinoxalin-2-il]bencensulfonamida |
| 259 |  | 2-{[3-({[4-(acetilamino)-3,5-dibromofenil]sulfonil}amino)quinoxalin-2-il]amino}-4,5,6,7-tetrahidro-1-benzotiofeno-3- carboxilato de etilo |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 260 |  | 2-[(3-{[(2-cloro-5-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3- carboxilato de etilo |
| 261 |  | *N*-{3-[(3-fluorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 262 |  | *N*-(3-{[4-(morfolin-4-ilsulfonil)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 263 |  | 2-{[3-({[4-(acetilamino)fenil]sulfonil}amino)quinoxalin-2-il]amino}-4,5,6,7-tetrahidro-1-benzotiofeno-3- carboxilato de etilo |
| 264 |  | 2-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]-5-etiltiofeno-3- carboxilato de etilo |
| 265 |  | *N*,*N*-dietil-4-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]bencensulfonamida |
| 266 |  | 2-{[3-({[4-(acetilamino)fenil]sulfonil}amino)quinoxalin-2-il]amino}-5-etiltiofeno-3-carboxilato de etilo |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 267 |  | 2-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3- carboxilato de etilo |
| 268 |  | 2-({3-[(fenilsulfonil)amino]quinoxalin-2-il}amino)-4,5,6,7-tetrahidro-1-benzotiofeno-3- carboxilato de etilo |
| 269 |  | *N*-[4-(metoxi)fenil]-4-[(3-{[(3-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]benzamida |
| 270 |  | *N*-[3-({4-[(4-aminofenil)oxi]fenil}amino)quinoxalin-2-il]-4-clorobencensulfonamida |
| 271 |  | *N*-[4-({[3-({4-[(4-aminofenil)oxi]fenil}amino)quinoxalin-2-il]amino}sulfonil)fenil]acetamida |
| 272 |  | ácido (2E)-3-{3-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]fenil}prop-2-enoico |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 273 |  | *N*-{3-[(9-etil-9*H*-carbazol-3-il)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 274 |  | *N*-[3-({4-[(4-aminofenil)oxi]fenil}amino)quinoxalin-2-il]bencensulfonamida |
| 275 |  | 4-bromo-*N*-{3-[(9-etil-9*H*-carbazol-3-il)amino]quinoxalin-2-il}bencensulfonamida |
| 276 |  | *N*-{3-[(9-etil-9*H*-carbazol-3-il)amino]quinoxalin-2-il}bencensulfonamida |
| 277 |  | *N*-{3-[(2-yodofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 278 |  | *N*-{3-[(1-feniletil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 279 |  | 4-bromo-*N*-{3-[(4-bromofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 280 |  | 4-bromo-*N*-{3-[(4-clorofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 281 |  | 4-bromo-*N*-[3-(naftalen-2-ilamino)quinoxalin-2-il]bencensulfonamida |
| 282 |  | *N*-{3-[(2,3-dimetilfenil)amino]-6-metilquinoxalin-2-il}-4-metilbencensulfonamida |
| 283 |  | 4-cloro-*N*-{3-[(2-yodofenil)amino]quinoxalin-2-il}bencensulfonamida |
| 284 |  | *N*-(3-{[4-(octiloxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 285 |  | *N*-[3-(2,1,3-benzotiadiazol-5-ilamino)quinoxalin-2-il]-3-nitrobencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 286 |  | *N*-{3-[(2-bromo-4-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 287 |  | *N*-[3-({4-[(3-aminofenil)sulfonil]-fenil}amino)quinoxalin-2-il]-4-clorobencensulfonamida |
| 288 |  | *N*-[3-({2-[(difluorometil)oxi]fenil}amino)quinoxalin-2-il]-3-nitrobencensulfonamida |
| 289 |  | Ácido 8-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]quinoline-2-carboxílico |
| 290 |  | 3,3,3-trifluoro-2-hidroxi-2-{4-[(3-{[(3-nitrofenil)sulfonil]amino}quinoxalin-2-il)amino]fenil}propanoato de etilo |
| 291 |  | *N*-[3-(quinolin-6-ilamino)quinoxalin-2-il]bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 292 |  | Tiocinato de 4-{[3-({[4-(acetilamino)-fenil]sulfonil}amino)quinoxalin-2-il]amino}fenilo |
| 293 |  | 1-[3-({[4-(acetilamino)fenil]-sulfonil}amino)quinoxalin-2-il]-4-metilpiridiniio |
| 294 |  | *N*-{3-[(2-clorofenil)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 295 |  | 4-metil-*N*-[3-(fenilamino)quinoxalin-2-il]bencensulfonamida |
| 296 |  | 4-metil-*N*-{3-[(2-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 297 |  | 4-metil-*N*-{3-[(4-metilfenil)amino]quinoxalin-2-il}bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 298 |  | *N*-{3-[(4-clorofenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 299 |  | 4-metil-*N*-[3-(naftalen-2-ilamino)quinoxalin-2-il]bencensulfonamida |
| 300 |  | *N*-{4-[({3-[(4-bromofenil)amino]quinoxalin-2-il}amino)sulfonil]fenil}acetamida |
| 301 |  | *N*-{4-[({3-[(2-metilfenil)amino]quinoxalin-2-il}amino)sulfonil]fenil}acetamida |
| 302 |  | *N*-{3-[bis(fenilmetil)amino]quinoxalin-2-il}bencensulfonamida |
| 303 |  | Ácido 4-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |

Tabla 1









| Comp. No. | Estructura | Nombre |
|---|---|---|
| 304 |  | Ácido 2-hidroxi-4-[(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)amino]benzoico |
| 305 |  | 4-bromo-*N*-(3-{[2-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 306 |  | *N*-{3-[(3-hidroxifenil)amino]quinoxalin-2-il}bencensulfonamida |
| 307 |  | *N*-[3-(naftalen-1-ilamino)quinoxalin-2-il]bencensulfonamida |
| 308 |  | 3-metil-1-(3-{[(4-metilfenil)sulfonil]amino}quinoxalin-2-il)piridinio |
| 309 |  | *N*-(3-{[3-{[(4-clorofenil)sulfonil]amino}-7-(metoxi)quinoxalin-2-il]amino}fenil)acetamida |
| 310 |  | *N*-{3-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]fenil}acetamida |
| 311 |  | *N*-{3-[(4-bromofenil)amino]quinoxalin-2-il}-4-clorobencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 312 |  | *N*-{3-[(2,4-dimetilfenil)amino]-6-metilquinoxalin-2-il}-4-metilbencensulfonamida |
| 313 |  | *N*-{3-[(3,4-dimetilfenil)amino]quinoxalin-2-il}-4-metilbencensulfonamida |
| 314 |  | *N*-{3-[(2,5-dimetilfenil)amino]-6-metilquinoxalin-2-il}-4-metilbencensulfonamida |
| 315 |  | 4-[(3-{[(4-clorofenil)sulfonil]amino}quinoxalin-2-il)amino]benzoato de etilo |
| 316 |  | 4-cloro-*N*-{3-[(4-etilfenil)amino]quinoxalin-2-il}bencensulfonamida |
| 317 |  | 4-cloro-*N*-(6-metil-3-{[4-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 318 |  | 4-cloro-*N*-{3-[(4-clorofenil)amino]-6-metilquinoxalin-2-il}bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 319 |  | *N*-(3-{[4-cloro-2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 320 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 321 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-metilbencensulfonamida |
| 322 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 323 |  | *N*-(3-{[2-metil-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 324 |  | *N*-[3-(2-Cloro-5-metoxi-fenilamino)-quinoxalin-2-il]-benzensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 325 |  | 3-amino-*N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 326 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-clorobencensulfonamida |
| 327 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida |
| 328 |  | *N*-(3-{[4-cloro-3-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 329 |  | *N*-(3-{[4-fluoro-3-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 330 |  | 3-amino-*N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1









| Comp. No. | Estructura | Nombre |
|---|---|---|
| 331 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-bromobencensulfonamida |
| 332 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 333 |  | 3-amino-*N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 334 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 335 |  | *N*-(3-{[2,5-bis(metoxi)fenil]amino}-7-metilquinoxalin-2-il)bencensulfonamida |
| 336 |  | *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-(metoxi)bencensulfonamida |
| 337 |  | *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-bromobencensulfonamida |
| 338 |  | *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-fluorobencensulfonamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 339 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-2-fluorobencensulfonamida |
| 340 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-(metoxi)bencensulfonamida |
| 341 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-bromobencensulfonamida |
| 342 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metilpiperidino-4-carboxamida |
| 343 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-piperidin-1-ilpropanamida |
| 344 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-(dimetilamino)butanamida |
| 345 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(hidroxiamino)bencensulfonamida |

Tabla 1













| Comp. No. | Estructura | Nombre |
|---|---|---|
| 346 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-morfolin-4-ilacetamida |
| 347 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-*N*-2-metilglicinamida |
| 348 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-L-alaninamida |
| 349 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-2-metilalaninamida |
| 350 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 351 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-alaninamida |

Tabla 1

| Comp. No. | Estructura | Nombre |
|---|---|---|
| 352 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metilglicinamida |
| 353 |  Abs | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-D-alaninamida |
| 354 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metilglicinamida |
| 355 |  Abs | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-alaninamida |
| 356 |  Abs | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-alaninamida |
| 357 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida |








| Tabla 1 | | |
|---|---|---|
| Comp. No. | Estructura | Nombre |
| 358 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida |
| 359 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 360 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[2-(dimetilamino)etil]-*N*-2-metilglicinamida |
| 361 |  | (2S)-2-amino-*N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)butanamida |
| 362 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[2-(dimetilamino)etil]-*N*-2-metilglicinamida |
| 363 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 364 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-L-alaninamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 365 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida |
| 366 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida |
| 367 |  | *N*-(2-cloro-5-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metilglicinamida |
| 368 |  | 2-(dimetilamino)-*N*-(3-(*N*-(3-(3-(2-(dimetilamino)acetamido)-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida |
| 369 |  | *N*-(3-{[(3-{[2-acetil-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 370 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-(formilamino)bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 371 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-etilglicinamida |
| 372 |  | *N*-(5-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-2-metilfenil)glicinamida |
| 373 |  | 2-azetidin-1-il-*N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida |
| 374 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-prolinamida |
| 375 |  | *N*-(3-{[(3-{[2-bromo-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metilglicinamida |
| 376 |  | *N*-2-,*N*-2-dimetil-*N*-(3-{[(3-{[6-(metoxi)quinolin-8-il]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 377 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-alaninamida |
| 378 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-D-alaninamida |
| 379 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-prolinamida |
| 380 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-serinamida |
| 381 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)azetidin-3-carboxamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 382 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,2-dimetilalaninamida |
| 383 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-D-alaninamida |
| 384 |  | *N*-(3-{[(3-{[2-bromo-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 385 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-propilglicinamida |
| 386 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-L-alaninamida |
| 387 |  | *N*-(5-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-2-metilfenil)-beta-alaninamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 388 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piperidino-3-carboxamida |
| 389 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-metil-1,4-diazepan-1-il)acetamida |
| 390 |  | (2S)-2-amino-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)butanamida |
| 391 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-hidroxipropil)glicinamida |
| 392 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-fluoroetil)glicinamida |
| 393 |  | 3-amino-*N*-(2-{[3,5-bis(metoxi)fenil]amino}pirido[2,3-b]pirazin-3-il)bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 394 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(2-metilpropil)oxi]glicinamida |
| 395 |  | 1-amino-*N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-ciclopropanocarboxamida |
| 396 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(formilamino)bencensulfonamida |
| 397 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(ciclopropilmetil)glicinamida |
| 398 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-prolinamida |
| 399 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(dimetilamino)azetidin-1-il]acetamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 400 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-prolinamida |
| 401 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piperidino-2-carboxamida |
| 402 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)morfolino-4-carboxamida |
| 403 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-pirrolidin-1-ilacetamida |
| 404 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-6-,*N*-6-dimetil-L-lisinamida |
| 405 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-etil-*N*-2-metilglicinamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 406 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(1*H*-imidazol-4-il)acetamida |
| 407 |  | 1-amino-*N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-ciclopentanocarboxamida |
| 408 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-metilpropil)glicinamida |
| 409 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-etil-*N*-2-metilglicinamida |
| 410 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(1*H*-imidazol-4-ilmetil)azetidin-3-carboxamida |
| 411 |  | *N*-(5-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-2-metilfenil)-*N*-2-,*N*-2-dimetilglicinamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 412 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-etilazetidin-3-carboxamida |
| 413 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-*N*-2-(1-metilpirrolidin-3-il)glicinamida |
| 414 |  | *N*-(3-{[(2-{[3,5-bis(metoxi)fenil]amino}pirido[2,3-b]pirazin-3-il)amino]sulfonil}fenil)-*N*-2-[2-(dimetilamino)etil]-*N*-2-metilglicinamida |
| 415 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(3S)-3-hidroxipirrolidin-1-il]acetamida |
| 416 |  | 1-amino-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-ciclobutanocarboxamida |
| 417 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-butilglicinamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 418 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-piperidin-1-ilazetidin-1-il)acetamida |
| 419 |  | 3-[(aminocarbonil)amino]-*N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 420 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-hidroxiciclopropanocarboxamida |
| 421 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2,2-dimetilhidrazino)acetamida |
| 422 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-[({[2-(dimetilamino)etil]amino}carbonil)-amino]bencensulfonamida |
| 423 |  | *N*-(3-{[(3-{[3-fluoro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metilglicinamida |
| 424 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-hidroxiacetamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 425 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piridazino-4-carboxamida |
| 426 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(1-metiletil)glicinamida |
| 427 |  | 1-amino-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-ciclopentanocarboxamida |
| 428 |  | 1-amino-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-ciclopropanocarboxamida |
| 429 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(dimetilamino)pirrolidin-1-il]acetamida |
| 430 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[2-(dimetilamino)etil]glicinamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 431 |  | 2-(dimetilamino)etil(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)carbamato |
| 432 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(ciclopropilmetil)azetidin-3-carboxamida |
| 433 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(1,1-dimetiletil)glicinamida |
| 434 |  | *N*-2-metil-*N*-(3-{[(3-{[3-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida |
| 435 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1*H*-imidazol-2-carboxamida |
| 436 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)isoxazol-5-carboxamida |
| 437 |  | *N*-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2,2,2-trifluoroetil)glicinamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 438 |  | 3-amino-*N*-(3-{[2-metil-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 439 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-oxociclopentanocarboxamida |
| 440 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-6-hidroxipiridino-2-carboxamida |
| 441 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(3-fluoro-4-hidroxifenil)glicinamida |
| 442 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(furan-2-ilmetil)azetidin-3-carboxamida |
| 443 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pirimidino-5-carboxamida |
| 444 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1*H*-pirrol-2-carboxamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 445 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-*N*-2-(1-metiletil)glicinamida |
| 446 |  | *N*-(3-{[(3-{[3-fluoro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 447 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1*H*-imidazol-4-carboxamida |
| 448 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dietilglicinamida |
| 449 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-metilisoxazol-5-il)acetamida |
| 450 |  | *N*-2-,*N*-2-dimetil-*N*-(3-{[(3-{[2-metil-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 451 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(3-hidroxifenil)metil]glicinamida |
| 452 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metil-1*H*-pirrol-2-carboxamida |
| 453 |  | 4-amino-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tetrahidro-2*H*-piran-4-carboxamida |
| 454 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(metilamino)piperidin-1-il]acetamida |
| 455 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piperidin-1-ilacetamida |
| 456 |  | *N*-(4-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dimetilglicinamida |

Tabla 1








| Comp. No. | Estructura | Nombre |
|---|---|---|
| 457 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metil-L-prolinamida |
| 458 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tiofeno-3-carboxamida |
| 459 |  | 3-amino-*N*-{3-[(2-cloro-5-hidroxifenil)amino]quinoxalin-2-il}bencensulfonamida |
| 460 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(ciclopropilcarbonil)azetidin-3-carboxamida |
| 461 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-metilpiperazin-1-il)acetamida |
| 462 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(fenilmetil)azetidin-3-carboxamida |
| 463 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-cloropiridino-3-carboxamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 464 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piridin-4-ilacetamida |
| 465 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-*N*-2-prop-2-en-1-ilglicinamida |
| 466 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(fenilmetil)glicinamida |
| 467 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(metoxi)acetamida |
| 468 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-propanoilazetidin-3-carboxamida |
| 469 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piridino-3-carboxamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 470 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[2-(metoxi)etil]glicinamida |
| 471 |  | 1-acetil-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piperidino-4-carboxamida |
| 472 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-metilpirrolidin-1-il)acetamida |
| 473 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)furan-3-carboxamida |
| 474 |  | *N*-2-,*N*-2-dimetil-*N*-(3-{[(3-{[3-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 475 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-6-cloropiridino-3-carboxamida |
| 476 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-clorobenzamida |
| 477 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piridin-2-ilacetamida |
| 478 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(dimetilamino)azetidin-1-il]acetamida |
| 479 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piridin-3-ilacetamida |
| 480 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-clorofenil)acetamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 481 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[3-(dimetilamino)propil]-*N*-2-metilglicinamida |
| 482 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-etil-*N*-2-(2-hidroxietil)glicinamida |
| 483 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[2-(fenilmetil)pirrolidin-1-il]acetamida |
| 484 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)propanamida |
| 485 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)furan-2-carboxamida |
| 486 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-cloropiridino-4-carboxamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 487 |  | *N*-2-acetil-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida |
| 488 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)butanamida |
| 489 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-clorobenzamida |
| 490 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metilbenzamida |
| 491 |  | 1,1-dimetiletil{2-[(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)amino]-2-oxoetil}carbamato |
| 492 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1,3-benzodioxol-5-carboxamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 493 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-({[2-(metoxi)fenil]metil}oxi)glicinamida |
| 494 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piridino-4-carboxamida |
| 495 |  | *N*-(3-{[(3-{[4-fluoro-3-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-,*N*-2-dimetilglicinamida |
| 496 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(3,4-diclorofenil)piperazin-1-il]acetamida |
| 497 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-piridin-3-ilpropanamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 498 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tetrahidrofuran-3-carboxamida |
| 499 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(2-metilfenil)metil]glicinamida |
| 500 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilbutanamida |
| 501 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-fluorofenil)acetamida |
| 502 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(1-metil-1-feniletil)glicinamida |
| 503 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilciclopropanocarboxamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 504 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metil-4-(metoxi)benzamida |
| 505 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilpiridino-3-carboxamida |
| 506 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-(metoxi)benzamida |
| 507 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-etilpiperazin-1-il)acetamida |
| 508 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tiofeno-2-carboxamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 509 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluoro-2-metilbenzamida |
| 510 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-bromotiofeno-3-carboxamida |
| 511 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-fluorobenzamida |
| 512 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-metilpiperidin-1-il)acetamida |
| 513 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilpropanamida |
| 514 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pentanamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 515 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(etiloxi)acetamida |
| 516 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-fluorofenil)glicinamida |
| 517 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-(dimetilamino)benzamida |
| 518 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-metilpiperidin-1-il)acetamida |
| 519 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-propilfenil)glicinamida |
| 520 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)benzamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 521 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pirazino-2-carboxamida |
| 522 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluoro-4-(metoxi)benzamida |
| 523 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,2-dimetilbutanamida |
| 524 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(4-fluorofenil)oxi]acetamida |
| 525 |  | 1-acetil-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)azetidin-3-carboxamida |
| 526 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(4-metilfenil)glicinamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 527 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-fenilglicinamida |
| 528 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-prop-2-en-1-ilpiperazin-1-il)acetamida |
| 529 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilbenzamida |
| 530 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-(metoxi)propanamida |
| 531 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-metilfuran-2-carboxamida |
| 532 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,2-dimetilpropanamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 533 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(fenilmetil)oxi]glicinamida |
| 534 |  | *N*-{3-[({3-[(2-cloro-5-hidroxifenil)amino]quinoxalin-2-il}amino)sulfonil]fenil}-*N*-2-,*N*-2-dimetilglicinamida |
| 535 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(3-clorofenil)glicinamida |
| 536 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-ciclobutanocarboxamida |
| 537 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(metoxi)fenil]acetamida |
| 538 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metilciclopropanocarboxamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 539 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluorobenzamida |
| 540 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-(dimetilamino)benzamida |
| 541 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3,4-diclorobenzamida |
| 542 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-{[2-(metiltio)fenil]metil}glicinamida |
| 543 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-fluorofenil)acetamida |

Tabla 1





| Comp. No. | Estructura | Nombre |
|---|---|---|
| 544 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-etil-*N*-2-(1-metiletil)glicinamida |
| 545 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1,3-tiazol-4-carboxamida |
| 546 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-*N*-2-(fenilmetil)glicinamida |
| 547 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-tienilmetil)glicinamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 548 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(piridin-2-ilmetil)glicinamida |
| 549 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-(metoxi)benzamida |
| 550 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(3-cloro-4-metilfenil)metil]glicinamida |
| 551 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilpentanamida |
| 552 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-clorofenil)acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 553 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluoro-4-metilbenzamida |
| 554 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(2-metilfenil)oxi]acetamida |
| 555 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-ciclohexilacetamida |
| 556 |  | (1R,2R)-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fenilciclopropanocarboxamida |
| 557 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-clorobenzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 558 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[2-(metoxi)fenil]acetamida |
| 559 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-[3-(metoxi)fenil]propanamida |
| 560 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-fluoro-4-metilfenil)glicinamida |
| 561 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(3-fluorofenil)metil]glicinamida |
| 562 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(metoxi)fenil]acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 563 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fenilacetamida |
| 564 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,4-diclorobenzamida |
| 565 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-oxociclohexanocarboxamida |
| 566 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(3-fluorofenil)glicinamida |
| 567 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-clorofenil)acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 568 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-fenilpropil)glicinamida |
| 569 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(2,4-dimetilfenil)metil]glicinamida |
| 570 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-metilpiperidin-1-il)acetamida |
| 571 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[2-(metoxi)fenil]glicinamida |
| 572 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3,4-dihidroisoquinolin-2(1*H*)-il)acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 573 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pent-4-enamida |
| 574 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2-metilfenil)glicinamida |
| 575 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-oxopiperidin-1-il)acetamida |
| 576 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fluorobenzamida |
| 577 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(1-feniletil)glicinamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 578 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fluoro-6-(metoxi)benzamida |
| 579 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[2-(1-metiletil)fenil]glicinamida |
| 580 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-[2-(metoxi)fenil]propanamida |
| 581 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metilpentanamida |
| 582 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-fenilmorfolin-4-il)acetamida |

Tabla 1





| Comp. No. | Estructura | Nombre |
|---|---|---|
| 583 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-[4-(metoxi)fenil]propanamida |
| 584 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-ciclopentil-*N*-2-prop-2-en-1-ilglicinamida |
| 585 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-*N*-2-[2-(metoxi)etil]glicinamida |
| 586 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-ciclopropil-4-oxobutanamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 587 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[3-(1,1-dimetiletil)fenil]glicinamida |
| 588 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(ciclopropilmetil)-*N*-2-propilglicinamida |
| 589 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-oxociclopentil)acetamida |
| 590 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(4-clorofenil)glicinamida |
| 591 |  | 2-(1,4'-bipiperidin-1'-il)-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 592 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-ciclopentilpiperazin-1-il)acetamida |
| 593 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-metilfenil)acetamida |
| 594 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-[(5-fluoro-2-metilfenil)metil]glicinamida |
| 595 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3,3-dimetilbutanamida |
| 596 |  | *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-clorofenil)glicinamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 597 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-5-fluoro-2-metilbenzamida |
| 598 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-fluoro-3-metilbenzamida |
| 599 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,3-diclorobenzamida |
| 600 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(feniloxi)acetamida |
| 601 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-(2,3-dimetilfenil)glicinamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 602 |  | 3-amino-*N*-(3-{[3,5-bis(metoxi)fenil]amino}pirido[2,3-b]pirazin-2-il)bencensulfonamida |
| 603 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fluoro-5-metilbenzamida |
| 604 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-{[(4-metilfenil)metil]oxi}glicinamida |
| 605 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(1-metiletil)piperazin-1-il]acetamida |
| 606 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-fluorofenil)acetamida |
| 607 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-metilbutanamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 608 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metil-2-(metoxi)benzamida |
| 609 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-propilpiperidin-1-il)acetamida |
| 610 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(3-metilfenil)oxi]acetamida |
| 611 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tetrahidrofuran-2-carboxamida |
| 612 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(hidroximetil)piperidin-1-il]acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 613 |  | 1,1-dimetiletil2-{[(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)amino]carbonil}piperidino-1-carboxilate |
| 614 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-*N*-2-(piridin-3-ilmetil)glicinamida |
| 615 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-etil-*N*-2-fenilglicinamida |
| 616 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-{[2-(metoxi)etil]oxi}acetamida |
| 617 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-ciclopentilpropanamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 618 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,5-diclorobenzamida |
| 619 |  | 2-(4-acetilpiperazin-1-il)-*N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida |
| 620 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-5-fluoro-2-(metoxi)benzamida |
| 621 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-ciclohexil-*N*-2-etilglicinamida |
| 622 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-5-metilisoxazol-3-carboxamida |
| 623 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-metilpiridino-2-carboxamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 624 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(metoxi)piridino-3-carboxamida |
| 625 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3,5-diclorobenzamida |
| 626 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(1,3-tiazolidin-3-il)acetamida |
| 627 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-formilpiperazin-1-il)acetamida |
| 628 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-piridin-4-ilpiperidin-1-il)acetamida |
| 629 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(metoxi)benzamida |

Tabla 1











| Comp. No. | Estructura | Nombre |
|---|---|---|
| 630 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-*N*-2-metil-*N*-2-(2-metilpropil)glicinamida |
| 631 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-formil-1,4-diazepan-1-il)acetamida |
| 632 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-fenilciclopropanocarboxamida |
| 633 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2,6-dimetilmorfolin-4-il)acetamida |
| 634 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-fenilpirrolidin-1-il)acetamida |

Tabla 1

| Comp. No. | Estructura | Nombre |
|---|---|---|
| 635 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)-1-metiletil]benzamida |
| 636 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]benzamida |
| 637 |  | 5-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-2-fluorobenzamida |
| 638 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-pirrolidin-3-ilbenzamida |
| 639 |  | 3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]benzamida |

Organizacion y
Digitalizacion CSA Ltda

DVN
OK

5/7

# PATENTE DE INVENCION

09-126923






| Tabla 1 | | |
|---|---|---|
| Comp. No. | Estructura | Nombre |
| 640 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-pirrolidin-1-iletil)benzamida |
| 641 |  | *N*-(2-aminoetil)-3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida |
| 642 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-*N*-metilbenzamida |
| 643 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(piperidin-2-ilmetil)benzamida |
| 644 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1-metilazetidin-3-il)benzamida |

Tabla 1





| Comp. No. | Estructura | Nombre |
|---|---|---|
| 645 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-piperidin-1-iletil)benzamida |
| 646 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dietilamino)etil]benzamida |
| 647 |  | 3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-*N*-metilbenzamida |
| 648 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1-metilpiperidin-3-il)benzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 649 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-piperidin-3-ilbenzamida |
| 650 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[(1-metilpiperidin-2-il)metil]benzamida |
| 651 |  | *N*-{2-[bis(2-hidroxietil)amino]etil}-3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida |
| 652 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1-etilpiperidin-3-il)benzamida |
| 653 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 654 |  | 3-[(3-aminopirrolidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 655 |  | 5-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-2-(metoxi)benzamida |
| 656 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-{[3-(metilamino)pirrolidin-1-il]carbonil}bencensulfonamida |
| 657 |  | Ácido 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzoico |
| 658 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-morfolin-4-iletil)benzamida |

Tabla 1





| Comp. No. | Estructura | Nombre |
|---|---|---|
| 659 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[(1-etilpirrolidin-2-il)metil]benzamida |
| 660 |  | 3-[(4-amino-3-oxopirazolidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 661 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-metilbenzamida |
| 662 |  | 3-[(3-aminoazetidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 663 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(piridin-3-ilmetil)benzamida |
| 664 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(piridin-2-ilmetil)benzamida |
| 665 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-hidroxietil)benzamida |
| 666 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(3-oxopirazolidin-4-il)benzamida |
| 667 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(1*H*-imidazol-4-il)etil]benzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 668 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-{[3-(dimetilamino)pirrolidin-1-il]carbonil}bencensulfonamida |
| 669 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(piridin-4-ilmetil)benzamida |
| 670 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-metil-*N*-(1-metilpirrolidin-3-il)benzamida |
| 671 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-{[3-(dietilamino)pirrolidin-1-il]carbonil}bencensulfonamida |
| 672 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-1*H*-pirrol-1-ilbenzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 673 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(3-pirrolidin-1-ilpropil)benzamida |
| 674 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-cianoetil)-*N*-metilbenzamida |
| 675 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(metoxi)etil]benzamida |
| 676 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-cianoetil)-*N*-etilbenzamida |
| 677 |  | 3-[(3-aminopiperidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 678 |  | Ácido 3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzoico |
| 679 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(dimetilamino)propil]benzamida |
| 680 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-morfolin-4-ilbenzamida |
| 681 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-[(2,2-dimetilhidrazino)carbonil]-bencensulfonamida |
| 682 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(1*H*-imidazol-1-il)propil]benzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 683 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(dietilamino)propil]benzamida |
| 684 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-cianoetil)benzamida |
| 685 |  | *N*-[(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)carbonil]-beta-alaninato de metilo |
| 686 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(metiltio)etil]benzamida |
| 687 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(etiltio)etil]benzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 688 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-*N*-etilbenzamida |
| 689 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(2-oxopirrolidin-1-il)propil]benzamida |
| 690 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-piridin-4-iletil)benzamida |
| 691 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(etiloxi)propil]benzamida |
| 692 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(3-morfolin-4-ilpropil)benzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 693 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(metoxi)propil]benzamida |
| 694 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(dimetilamino)propil]-*N*-metilbenzamida |
| 695 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(propiloxi)propil]benzamida |
| 696 |  | etil*N*-[(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)carbonil]-beta-alaninate |
| 697 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-{3-[(1-metiletil)oxi]propil}benzamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 698 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1,1-dimetil-2-piperidin-1-iletil)benzamida |
| 699 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-metil-*N*-propilbenzamida |
| 700 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-piperidin-1-ilbenzamida |
| 701 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[1-metil-2-(metoxi)etil]benzamida |
| 702 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1,1-dimetil-2-morfolin-4-iletil)benzamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 703 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-({2-[(dimetilamino)metil]piperidin-1-il}carbonil)bencensulfonamida |
| 704 |  | *N*-[3-(butiloxi)propil]-3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida |
| 705 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[4-(dietilamino)-1-metilbutil]benzamida |
| 706 |  | 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1,1-dimetil-2-oxo-2-piperidin-1-iletil)benzamida |
| 707 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-[(4-metilpiperazin-1-il)carbonil]bencensulfonamida |
| 708 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-{[2-(piperidin-1-ilmetil)piperidin-1-il]carbonil}bencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 709 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-6-oxo-1,6-dihidropiridino-3-sulfonamida |
| 710 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-6-oxo-1,6-dihidropiridino-3-sulfonamida |
| 711 |  | 3-amino-*N*-(3-{[6-(metoxi)quinolin-8-il]amino}quinoxalin-2-il)bencensulfonamida |
| 712 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)tiofeno-2-sulfonamida |
| 713 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-cianobencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 714 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(metilamino)bencensulfonamida |
| 715 |  | *N*-(2-{[3,5-bis(metoxi)fenil]amino}pirido[2,3-b]pirazin-3-il)-3-nitrobencensulfonamida |
| 716 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-(1-{[2-(dimetilamino)etil]amino}etil)-bencensulfonamida |
| 717 |  | 3-amino-*N*-(3-{[3-(metoxi)-5-nitrofenil]amino}quinoxalin-2-il)bencensulfonamida |
| 718 |  | 3-acetil-*N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |
| 719 |  | 3-amino-*N*-(3-{[3-fluoro-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 720 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-*N*'-[2-(dimetilamino)etil]benceno-1,3-disulfonamida |
| 721 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-*N*'-[3-(dimetilamino)propil]benceno-1,3-disulfonamida |
| 722 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-6-cloropiridino-3-sulfonamida |
| 723 |  | *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-{5-[(dimetilamino)metil]-1,3,4-oxadiazol-2-il}bencensulfonamida |
| 724 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-6-{[2-(dimetilamino)etil]amino}piridino-3-sulfonamida |
| 725 |  | 3-amino-*N*-(3-{[3-amino-5-(metoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 726 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(dimetilamino)bencensulfonamida |
| 727 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-6-{[2-(dimetilamino)etil]oxi}piridino-3-sulfonamida |
| 728 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-6-(dimetilamino)piridino-3-sulfonamida |
| 729 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-cianobencensulfonamida |
| 730 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-fluorobencensulfonamida |
| 731 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-fluoro-2-metilbencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 732 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-2-metilbencensulfonamida |
| 733 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-cianobencensulfonamida |
| 734 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3,5-difluorobencensulfonamida |
| 735 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-2-clorobencensulfonamida |
| 736 |  | *N*-(4-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 737 |  | *N*-(3-{[6-(metoxi)quinolin-8-il]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 738 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(2*H*-tetrazol-5-il)bencensulfonamida |
| 739 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)naftaleno-1-sulfonamida |
| 740 |  | *N*-{[(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)amino](dimetilamino)metilideno}-*N*-metilmetanaminio |
| 741 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-fluorobencensulfonamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 742 |  | *N*-(3-{[2-bromo-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 743 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-[(difluorometil)oxi]bencensulfonamida |
| 744 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-2-(trifluorometil)bencensulfonamida |
| 745 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-cloro-4-fluorobencensulfonamida |
| 746 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-(trifluorometil)bencensulfonamida |

Tabla 1







| Comp. No. | Estructura | Nombre |
|---|---|---|
| 747 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(metilsulfonil)bencensulfonamida |
| 748 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-2,5-diclorotiofeno-3-sulfonamida |
| 749 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3,5-diclorobencensulfonamida |
| 750 |  | *N*-(3-{[2-metil-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 751 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-[(trifluorometil)oxi]bencensulfonamida |
| 752 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(dimetilamino)piperidin-1-il]acetamida |

Tabla 1






| Comp. No. | Estructura | Nombre |
|---|---|---|
| 753 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-5-cloro-2-(metoxi)bencensulfonamida |
| 754 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(trifluorometil)bencensulfonamida |
| 755 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-2,5-bis(metoxi)bencensulfonamida |
| 756 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3,5-dimetilisoxazol-4-sulfonamida |
| 757 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-5-bromo-2-(metoxi)bencensulfonamida |

Tabla 1













| Comp. No. | Estructura | Nombre |
|---|---|---|
| 758 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-fluoro-3-(trifluorometil)bencensulfonamida |
| 759 |  | *N*-(3-{[3-fluoro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 760 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-fluoro-4-metilbencensulfonamida |
| 761 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-cloro-4-metilbencensulfonamida |
| 762 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-2,5-dimetiltiofeno-3-sulfonamida |
| 763 |  | *N*-(3-{[3-(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |

Tabla 1

| Comp. No. | Estructura | Nombre |
|---|---|---|
| 764 |  | *N*-{3-[(2-cloro-5-hidroxifenil)amino]quinoxalin-2-il}-3-nitrobencensulfonamida |
| 765 |  | *N*-(3-{[(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metil-3-(metoxi)benzamida |
| 766 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-1-fenilmetansulfonamida |
| 767 |  | *N*-(3-{[3-(metoxi)-5-nitrofenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida |
| 768 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-1-(3-clorofenil)metansulfonamida |
| 769 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4,5-diclorotiofeno-2-sulfonamida |



| Tabla 1 | | |
|---|---|---|
| Comp. No. | Estructura | Nombre |
| 770 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-5-cloro-1,3-dimetil-1*H*-pirazol-4-sulfonamida |
| 771 |  | *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3,5-bis(trifluorometil)bencensulfonamida |

**Tabla 2a.**

**Inhibidores de AKT representativos**

**[00226]** Los Compuestos de la Tabla 2a se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas estas combinaciones de sal, solvato, hidrato e isómero de los Compuestos de la Tabla 2a se pueden usar para practicar la invención.

| Comp No. | *Nombre* |
|---|---|
| 1 | 3-(azetidin-3-ilidenmetil)-4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 2 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(3-fluoropiridin-4-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 3 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(3-cloropiridin-4-il)-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 4 | 2-({5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}oxi)-*N*,*N*-dimetiletanamina |
| 5 | 2-({5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}oxi)-*N*,*N*-dietiletanamina |
| 6 | 4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 7 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-piperazin-1-il-1*H*-pirazolo[3,4-d]pirimidina |
| 8 | *N*-(3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}prop-2-in-1-il)acetamida |
| 9 | *N*,*N*-dietil-2-({3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]fenil}oxi)etanamina |
| 10 | 3-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-2-metilfenil}-*N*,*N*-dietilpropan-1-amina |
| 11 | 3-bromo-4-{4-[5-cloro-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 12 | 3-bromo-4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 13 | 2-({3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-2-metilfenil}oxi)-*N*,*N*-dietiletanamina |
| 14 | 4-[4-(5-cloro-2-metil-3-{[2-(1-metilpiperidin-4-il)etil]oxi}fenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 15 | 5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 16 | 4-(4-{5-cloro-2-metil-3-[(2-morfolin-4-iletil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 17 | 4-(4-{5-cloro-2-metil-3-[(2-piperidin-1-iletil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 18 | 3-bromo-4-{4-[5-cloro-2-metil-3-(3-morfolin-4-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 19 | 3-bromo-4-(4-{5-cloro-2-metil-3-[3-(4-metilpiperazin-1-il)propil]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 20 | 3-bromo-4-(4-{5-cloro-2-metil-3-[(2-piperidin-1-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 21 | 3-bromo-4-(4-{5-cloro-2-metil-3-[(2-morfolin-4-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 22 | 4-{4-[5-cloro-2-metil-3-(3-morfolin-4-ilpropil)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 23 | *N*'-{5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}-*N*,*N*-dietiletano-1,2-diamine |
| 24 | 4-{4-[5-cloro-2-metil-3-(3-piperidin-1-ilpropil)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 25 | 4-[4-(5-cloro-3-{[2-(4-etilpiperazin-1-il)etil]oxi}-2-metilfenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 26 | 4-(4-{5-cloro-2-metil-3-[(3-morfolin-4-ilpropil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 27 | 3-bromo-4-{4-[5-cloro-2-metil-3-(3-piperidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 28 | *N*'-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-2-metilfenil}-*N*,*N*-dietiletano-1,2-diamine |
| 29 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 30 | 4-[4-(5-cloro-2-metil-3-{[2-(4-metilpiperazin-1-il)etil]oxi}fenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 31 | 4-[4-(5-cloro-2-metil-3-{[(1-metilpiperidin-4-il)metil]oxi}fenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 32 | *N*,*N*-dietil-2-({3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}oxi)etanamina |
| 33 | 2-[(5-cloro-3-{4-[1-(1,1-dimetiletil)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}-2-metilfenil)oxi]-*N*,*N*-dietiletanamina |
| 34 | 2-[(5-cloro-2-metil-3-{4-[3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}fenil)oxi]-*N*,*N*-dietiletanamina |

| Comp No. | *Nombre* |
|---|---|
| 35 | 4-(4-{5-cloro-2-metil-3-[(3-pirrolidin-1-ilpropil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 36 | 4-[4-(5-cloro-2-metil-3-{[3-(4-metilpiperazin-1-il)propil]oxi}fenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 37 | 3-bromo-4-(4-{5-cloro-2-metil-3-[(3-piperidin-1-ilpropil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 38 | 3-bromo-4-(4-{5-cloro-2-metil-3-[(3-morfolin-4-ilpropil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 39 | 4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 40 | 4-(4-{5-cloro-2-metil-3-[(3-morfolin-4-ilpropil)oxi]fenil}piperazin-1-il)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 41 | 4-(4-{5-cloro-2-metil-3-[(2-morfolin-4-iletil)oxi]fenil}piperazin-1-il)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 42 | 4-(4-{5-cloro-2-metil-3-[(3-piperidin-1-ilpropil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 43 | 4-[4-(5-cloro-3-{[3-(4-etilpiperazin-1-il)propil]oxi}-2-metilfenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 44 | 5-cloro-2-metil-3-[4-(1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-(2-pirrolidin-1-iletil)anilina |

| Comp No. | *Nombre* |
|---|---|
| 45 | 5-cloro-2-metil-3-[4-(3-metil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-(2-pirrolidin-1-iletil)anilina |
| 46 | *N*'-(5-cloro-2-metil-3-{4-[3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}fenil)-*N*,*N*-dimetiletano-1,2-diamina |
| 47 | 3-({5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}oxi)-*N*,*N*-dietilpropan-1-amina |
| 48 | *N*'-(5-cloro-2-metil-3-{4-[3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}fenil)-*N*,*N*-dietiletano-1,2-diamina |
| 49 | 5-cloro-2-metil-*N*-(2-pirrolidin-1-iletil)-3-{4-[3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}anilina |
| 50 | 3-bromo-4-(4-{4-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 51 | 4-(4-{4-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 52 | 3-metil-4-(4-{4-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 53 | 4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 54 | 4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-3-metil-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 55 | 4-(4-{5-cloro-2-metil-3-[(2-piperidin-1-iletil)oxi]fenil}piperazin-1-il)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 56 | 3-[(5-cloro-2-metil-3-{4-[3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}fenil)oxi]-*N*,*N*-dietilpropan-1-amina |
| 57 | 5-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 58 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-fluoro-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 59 | 4-{4-[5-cloro-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 60 | 3-bromo-4-{4-[5-fluoro-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 61 | 4-{4-[5-cloro-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 62 | 4-(4-{5-cloro-2-metil-3-[3-(4-metilpiperazin-1-il)propil]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 63 | 3-bromo-4-(4-piridin-2-ilpiperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 64 | 3-bromo-4-[4-(2,4-dimetilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 65 | 3-bromo-4-{4-[3-(metiloxi)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 66 | 3-bromo-4-{4-[2-(metiloxi)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 67 | 3-bromo-4-{4-[4-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 68 | 4-(4-{5-cloro-2-metil-3-[(3-pirrolidin-1-ilpropil)oxi]fenil}piperazin-1-il)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 69 | 4-(4-{5-cloro-2-metil-3-[(3-piperidin-1-ilpropil)oxi]fenil}piperazin-1-il)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 70 | 4-[4-(5-cloro-2-metil-3-{[3-(4-metilpiperazin-1-il)propil]oxi}fenil)piperazin-1-il]-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 71 | 4-[4-(5-cloro-3-{[3-(4-etilpiperazin-1-il)propil]oxi}-2-metilfenil)piperazin-1-il]-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 72 | 3-bromo-4-[4-(5-cloro-2-metil-3-{[2-(4-metilpiperazin-1-il)etil]oxi}fenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 73 | 4-[4-(5-cloro-2-metil-3-{[2-(4-metilpiperazin-1-il)etil]oxi}fenil)piperazin-1-il]-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 74 | 3-bromo-4-[4-(5-cloro-3-{[2-(4-etilpiperazin-1-il)etil]oxi}-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 75 | 3-bromo-4-[4-(3,4-diclorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 76 | 3-bromo-4-[4-(3,4-difluorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 77 | 3-bromo-4-[4-(2,4-diclorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 78 | 3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-fluoro-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 79 | 5-fluoro-2-metil-*N*-(2-pirrolidin-1-iletil)-3-{4-[3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}anilina |
| 80 | 4-{4-[3,5-bis(metiloxi)fenil]piperazin-1-il}-3-bromo-1*H*-pirazolo[3,4-d]pirimidina |
| 81 | 4-[4-(5-cloro-3-{[2-(4-etilpiperazin-1-il)etil]oxi}-2-metilfenil)piperazin-1-il]-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 82 | *N*-{5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}-*N*,*N*',*N*'-trimetiletano-1,2-diamina |
| 83 | 3-({3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-2-metilfenil}oxi)-*N*,*N*-dietilpropan-1-amina |
| 84 | 3-bromo-4-(4-{5-cloro-2-metil-3-[(3-pirrolidin-1-ilpropil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 85 | 3-bromo-4-[4-(5-cloro-2-metil-3-{[3-(4-metilpiperazin-1-il)propil]oxi}fenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 86 | 3-bromo-4-[4-(5-cloro-3-{[3-(4-etilpiperazin-1-il)propil]oxi}-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 87 | 3-(5-cloro-2-metil-3-{4-[3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}fenil)-*N*,*N*-dietilpropan-1-amina |

| Comp No. | *Nombre* |
|---|---|
| 88 | 3-bromo-4-[4-(5-cloro-2-metil-3-{[(1-metilpiperidin-4-il)metil]oxi}fenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 89 | 3-bromo-4-[4-(5-cloro-2-metil-3-{[2-(1-metilpiperidin-4-il)etil]oxi}fenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 90 | 4-[4-(5-cloro-2-metil-3-{[(1-metilpiperidin-4-il)metil]oxi}fenil)piperazin-1-il]-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 91 | 4-[4-(5-cloro-2-metil-3-{[2-(1-metilpiperidin-4-il)etil]oxi}fenil)piperazin-1-il]-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 92 | 4-(4-{5-cloro-2-metil-3-[3-(4-metilpiperazin-1-il)propil]fenil}piperazin-1-il)-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 93 | 3-bromo-4-[4-(3-cloro-4-fluorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 94 | 1-{4-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]fenil}etanona |
| 95 | 3-bromo-4-[4-(2,5-diclorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 96 | 3-bromo-4-[4-(3,4-dimetilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 97 | 3-bromo-4-[4-(4-nitrofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 98 | 3-etil-4-(4-fenilpiperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 99 | 3-etil-4-{4-[3-(metiloxi)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 100 | 4-{4-[5-cloro-2-metil-3-(3-piperidin-1-ilpropil)fenil]piperazin-1-il}-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 101 | 4-[4-(3,6-dimetilpirazin-2-il)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 102 | 1-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]isoquinolina |
| 103 | 3-bromo-4-[4-(2,6-dimetilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 104 | 3-bromo-4-{4-[4-(etiloxi)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 105 | 3-bromo-4-[4-(2-etilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 106 | 4-{4-[2,4-bis(metiloxi)fenil]piperazin-1-il}-3-bromo-1*H*-pirazolo[3,4-d]pirimidina |
| 107 | 3-bromo-4-(4-pirazin-2-ilpiperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 108 | 3-bromo-4-(4-pirimidin-2-ilpiperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 109 | 4-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(trifluorometil)quinolina |
| 110 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]pirazino-2-carbonitrilo |
| 111 | 4-[4-(4,6-dimetilpirimidin-2-il)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 112 | 4-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(trifluorometil)pirimidino-5-carboxilato de etilo |
| 113 | 4-{4-[3-cloro-5-(metiloxi)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 114 | 4-[4-(3-bromo-2-cloro-5-fluorofenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 115 | 2-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]piridino-3-carboxamida |
| 116 | 3-etil-4-{4-[4-(trifluorometil)piridin-2-il]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 117 | 3-bromo-4-{4-[4-(trifluorometil)piridin-2-il]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 118 | 3-bromo-4-{4-[4-(trifluorometil)pirimidin-2-il]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 119 | 2-({3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]pirazin-2-il}oxi)-*N*,*N*-dimetiletanamina |
| 120 | 4-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilquinolina |
| 121 | 3-bromo-4-[4-(2-nitrofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 122 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]benzonitrilo |
| 123 | 4-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]benzonitrilo |
| 124 | 3-bromo-4-{4-[4-(trifluorometil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 125 | 3-bromo-4-(4-{4-[(fenilmetil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 126 | 4-{4-[5-cloro-2-metil-3-(metiloxi)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 127 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]piridino-3-carbonitrilo |

| Comp No. | *Nombre* |
|---|---|
| 128 | 3-bromo-4-[4-(3,5-diclorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 129 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-cloro-5-fluoro-*N*-(2-pirrolidin-1-iletil)anilina |
| 130 | 2-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-fluoro-*N*-(2-pirrolidin-1-iletil)anilina |
| 131 | 3-bromo-4-[4-(2,5-difluorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 132 | 4-[4-(2,5-difluorofenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 133 | 3-bromo-4-{4-[3-(metiloxi)pirazin-2-il]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 134 | 3-bromo-4-[4-(3-clorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 135 | 3-bromo-4-{4-[3-(trifluorometil)piridin-2-il]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 136 | 3-bromo-4-{4-[3-cloro-5-(trifluorometil)piridin-2-il]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 137 | 4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-3-(1-metiletil)-1*H*-pirazolo[3,4-d]pirimidina |
| 138 | 5-cloro-2-metil-3-{4-[3-(1-metiletil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}-*N*-(2-pirrolidin-1-iletil)anilina |
| 139 | 2-({3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]fenil}oxi)-*N*-etilacetamida |
| 140 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,*N*-dietilpirimidin-4-amina |

| Comp No. | *Nombre* |
|---|---|
| 141 | 3-bromo-4-[4-(3-{[(3-metilfenil)metil]oxi}fenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 142 | 3-bromo-4-(4-{3-[(2-piperidin-1-iletil)oxi]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 143 | 3-bromo-4-[4-(4-furan-2-ilpirimidin-2-il)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 144 | 6-{2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]pirimidin-4-il}-2*H*-1,4-benzoxazin-3(4*H*)-one |
| 145 | 3-etil-4-{4-[2-metil-3-(metiloxi)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 146 | *N*'-{5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}-*N*-metil-*N*-(1-metiletil)etano-1,2-diamina |
| 147 | *N*'-{5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}-*N*-etil-*N*-metiletano-1,2-diamina |
| 148 | *N*'-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-2-metilfenil}-*N*,*N*-dimetiletano-1,2-diamina |
| 149 | 3-({6-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-cloro-5-metilpirimidin-4-il}oxi)-*N*,*N*-dietilpropan-1-amina |
| 150 | 3-bromo-4-[4-(2,3-diclorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 151 | 3-bromo-4-{4-[2-(trifluorometil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 152 | 3-bromo-4-(4-fenilpiperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 153 | 3-bromo-4-[4-(4-fluorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 154 | 3-bromo-4-[4-(4-clorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 155 | 3-bromo-4-{4-[3-(trifluorometil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 156 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-6-amina |
| 157 | 3-bromo-4-[4-(4-bromofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 158 | 3-bromo-4-[3-metil-4-(3-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 159 | 4-[4-(3-bromo-5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-6-amina |
| 160 | 4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-3-ciclopropil-1*H*-pirazolo[3,4-d]pirimidina |
| 161 | 5-cloro-3-[4-(3-ciclopropil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 162 | 5-cloro-2-metil-3-{4-[3-(2-metilpropil)-1*H*-pirazolo[3,4-d]pirimidin-4-il]piperazin-1-il}-*N*-(2-pirrolidin-1-iletil)anilina |
| 163 | 4-(4-{5-cloro-2-metil-3-[(2-pirrolidin-1-iletil)oxi]fenil}piperazin-1-il)-3-(2-metilpropil)-1*H*-pirazolo[3,4-d]pirimidina |
| 164 | 3-bromo-4-[(3S)-4-(5-cloro-2-metilfenil)-3-metilpiperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 165 | 5-bromo-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilanilina |

| Comp No. | *Nombre* |
|---|---|
| 166 | 2-({3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]fenil}oxi)-*N*-ciclopropilacetamida |
| 167 | 3-bromo-4-(4-{3-[(2-piperidin-1-iletil)oxi]pirazin-2-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 168 | 4-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-6,7-bis(metiloxi)quinazoline |
| 169 | 2-({3-cloro-5-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]fenil}oxi)-*N*,*N*-dietiletanamina |
| 170 | 4-{4-[2-cloro-5-(trifluorometil)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 171 | 3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-[(2-metilpropil)oxi]-*N*-(2-pirrolidin-1-iletil)anilina |
| 172 | 3-({4-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-6-cloro-5-metilpirimidin-2-il}oxi)-*N*,*N*-dietilpropan-1-amina |
| 173 | 3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-[(fenilmetil)oxi]-*N*-(2-pirrolidin-1-iletil)anilina |
| 174 | 3-bromo-4-[(3R)-4-(5-cloro-2-metilfenil)-3-metilpiperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 175 | 3-[(2S)-4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-2-metilpiperazin-1-il]-4-metil-*N*-fenilbenzamida |
| 176 | 3-[(2S)-4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-2-metilpiperazin-1-il]-4-metil-*N*-(fenilmetil)benzamida |
| 177 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metilbenzoato de metilo |
| 178 | Ácido 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metilbenzoico |

| Comp No. | *Nombre* |
|---|---|
| 179 | Ácido (2E)-3-(4-{4-[5-cloro-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidin-3-il)prop-2-enoico |
| 180 | 3-(4-{4-[5-cloro-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidin-3-il)prop-2-in-1-ol |
| 181 | 4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-1-(5-cloro-2-metilfenil)piperazin-2-ona |
| 182 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-[(2-metilpropil)oxi]-*N*-(2-pirrolidin-1-iletil)anilina |
| 183 | *N*'-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-[(2-metilpropil)oxi]fenil}-*N*,*N*-dietiletano-1,2-diamina |
| 184 | 3-bromo-5-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metilbenzoato de metilo |
| 185 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-fenilbenzamida |
| 186 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,4-dimetilbenzamida |
| 187 | 2-({3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]fenil}oxi)-*N*,*N*-dietiletanamina |
| 188 | metil 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]benzoate |
| 189 | 3-bromo-5-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-fenilbenzamida |
| 190 | 3-bromo-5-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-fenilbenzamida |

| Comp No. | *Nombre* |
|---|---|
| 191 | *N*'-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-2-metilfenil}-*N*-metil-*N*-(1-metiletil)etano-1,2-diamina |
| 192 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-fenilo-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 193 | *N*'-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-[(2-metilpropil)oxi]fenil}-*N*,*N*-dimetiletano-1,2-diamina |
| 194 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,*N*,4-trimetilbenzamida |
| 195 | 3-[4-(3-cloro-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-(2-metilpropil)benzamida |
| 196 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,*N*,4-trimetil-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 197 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-2-oxopiperazin-1-il]-4-metil-*N*-fenilbenzamida |
| 198 | 3-[(2R)-4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-2-(hidroximetil)piperazin-1-il]-4-metil-*N*-fenilbenzamida |
| 199 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(pirrolidin-1-ilcarbonil)-*N*-(2-pirrolidin-1-iletil)anilina |
| 200 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,4-dimetil-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 201 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-(4-clorofenil)-4-metil-5-[(2-pirrolidin-1-iletil)amino]benzamida |

| Comp No. | *Nombre* |
|---|---|
| 202 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-(2-clorofenil)-4-metil-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 203 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(ciclopropilmetil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 204 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-[(3-metilbutil)oxi]-*N*-(2-pirrolidin-1-iletil)anilina |
| 205 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(2-etilbutil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 206 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-(butiloxi)-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 207 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-(1-metiletil)-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 208 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,4-dimetil-*N*-(1-metiletil)-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 209 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(ciclobutilmetil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 210 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-(etiloxi)-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 211 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-[2-(dimetilamino)etil]-4-metilbenzamida |

| Comp No. | *Nombre* |
|---|---|
| 212 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-(1,1-dimetiletil)-4-metil-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 213 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-piridin-3-il-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 214 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(2-fluoro-2-metilpropil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 215 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(ciclohexilmetil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 216 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(ciclopentilmetil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 217 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-etil-4-metil-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 218 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-[(1-metiletil)oxi]-*N*-(2-pirrolidin-1-iletil)anilina |
| 219 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(2,2-dimetilpropil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 220 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)-5-[(tetrahidrofuran-2-ilmetil)oxi]anilina |
| 221 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-{[2-(metiloxi)etil]oxi}-*N*-(2-pirrolidin-1-iletil)anilina |

| Comp No. | *Nombre* |
|---|---|
| 222 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(propiloxi)-*N*-(2-pirrolidin-1-iletil)anilina |
| 223 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-{[2-(dimetilamino)etil]amino}-4-metil-*N*-fenilbenzamida |
| 224 | *N*'-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(2-fluoro-2-metilpropil)oxi]-2-metilfenil}-*N*,*N*-dimetiletano-1,2-diamina |
| 225 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-{[2-(dimetilamino)etil]amino}-4-metil-*N*-(1-metiletil)benzamida |
| 226 | 1-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}pentan-1-ona |
| 227 | *N*'-(3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metilfenil)-*N*,*N*-dimetiletano-1,2-diamina |
| 228 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 229 | 5-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-*N*-(2-pirrolidin-1-iletil)bifenil-3-amina |
| 230 | 1-(3-{5-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metilbifenil-3-il}propil)piridinio |
| 231 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)-5-(1,3-tiazol-2-il)anilina |

| Comp No. | *Nombre* |
|---|---|
| 232 | Ácido 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]benzoico |
| 233 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(feniletinil)-*N*-(2-pirrolidin-1-iletil)anilina |
| 234 | {3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}(fenil)metanona |
| 235 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-etinil-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 236 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-(3,3-dimetilbut-1-in-1-il)-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 237 | 3-bromo-4-{4-[5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 238 | 3-bromo-4-{4-[2-metil-5-[(2-metilpropil)oxi]-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 239 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(3-fenilo-1,2,4-oxadiazol-5-il)-*N*-(2-pirrolidin-1-iletil)anilina |
| 240 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(3-metil-1,2,4-oxadiazol-5-il)-*N*-(2-pirrolidin-1-iletil)anilina |
| 241 | 1-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}propan-1-ona |

| Comp No. | *Nombre* |
|---|---|
| 242 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-(3,3-dimetilbutil)-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 243 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-etil-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 244 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)-5-[2-(trimetilsilil)etil]anilina |
| 245 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(2-feniletil)-*N*-(2-pirrolidin-1-iletil)anilina |
| 246 | 1-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}butan-1-ona |
| 247 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,4-dimetil-*N*-(metiloxi)-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 248 | 3-bromo-4-[4-(3-bromo-5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 249 | 4-[4-(3-bromo-5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metilfenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 250 | 1-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}etanona |
| 251 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(difluorometil)oxi]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |

| Comp No. | *Nombre* |
|---|---|
| 252 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-{[(difluorometil)oxi]metil}-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 253 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(metiloxi)-*N*-(2-pirrolidin-1-iletil)anilina |
| 254 | 5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 255 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-3,5,6-trifluoro-*N*-(3-metilbutil)piridin-4-amina |
| 256 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-[(ciclopropilmetil)oxi]-4-metil-5-[(2-pirrolidin-1-iletil)amino]benzamida |
| 257 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(5-metil-1,2,4-oxadiazol-3-il)-*N*-(2-pirrolidin-1-iletil)anilina |
| 258 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-(etilsulfonil)-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 259 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-5-(metilsulfonil)-*N*-(2-pirrolidin-1-iletil)anilina |
| 260 | 1-{3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}pentan-1-ona |
| 261 | 3-bromo-4-[4-(5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 262 | 6-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-3,5-difluoro-*N*~4~-(3-metilbutil)-*N*~2~-(2-pirrolidin-1-iletil)piridino-2,4-diamina |
| 263 | 3-bromo-5-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-(2-pirrolidin-1-iletil)anilina |
| 264 | 3-bromo-4-[4-(3',4',6-trifluoro-4-metilbifenil-3-il)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 265 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-cloro-*N*-(2-pirrolidin-1-iletil)anilina |
| 266 | {3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}metanol |
| 267 | 3-bromo-4-(4-{4-metil-2'-[(2-pirrolidin-1-iletil)oxi]bifenil-3-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 268 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-{[(2,2-difluorociclopropil)metil]oxi}-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 269 | 5-bromo-3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 270 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(etiloxi)metil]-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 271 | 3-[4-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-1-metil-6-(trifluorometil)-1*H*-bencimidazol-2-il]propan-1-ol |

| Comp No. | *Nombre* |
|---|---|
| 272 | 1-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}-4,4,4-trifluorobutan-1-ona |
| 273 | {3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}(ciclopropil)metanona |
| 274 | 3-({3'-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4'-metilbifenil-2-il}oxi)-*N*,*N*-dimetilpropan-1-amina |
| 275 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-(1,1-difluorobutil)-2-metil-*N*-(2-pirrolidin-1-iletil)anilina |
| 276 | 3-bromo-4-(4-{4-metil-2'-[(3-morfolin-4-ilpropil)oxi]bifenil-3-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 277 | 3-bromo-4-(4-{4-metil-2'-[(2-morfolin-4-iletil)oxi]bifenil-3-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 278 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)-5-{[(2,2,2-trifluoroetil)oxi]metil}anilina |
| 279 | 1-[2-({3'-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4'-metilbifenil-2-il}oxi)etil]pirrolidine-2,5-diona |
| 280 | 3-bromo-4-(4-{3'-fluoro-4-metil-2'-[(2-pirrolidin-1-iletil)oxi]bifenil-3-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 281 | 1-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-[(2-pirrolidin-1-iletil)amino]fenil}butan-1-ona |

| Comp No. | *Nombre* |
|---|---|
| 282 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)-5-[(3,3,3-trifluoropropil)oxi]anilina |
| 283 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)-5-[(2,2,2-trifluoroetil)oxi]anilina |
| 284 | 1-{3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-4-metil-5-[(2-pirrolidin-1-iletil)amino]fenil}butan-1-ol |
| 285 | 3-bromo-4-(4-{4-cloro-2'-[(2-pirrolidin-1-iletil)oxi]bifenil-3-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 286 | 3-[4-(4-{5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metil-3-[(2-pirrolidin-1-iletil)amino]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidin-3-il]prop-2-in-1-ol |
| 287 | 3-bromo-4-(4-{4-cloro-4'-fluoro-2'-[(2-pirrolidin-1-iletil)oxi]bifenil-3-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 288 | 3-bromo-4-(4-{4-metil-3'-[(2-pirrolidin-1-iletil)oxi]bifenil-3-il}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 289 | Ácido (2E)-3-[4-(4-{5-{[2,3-difluoro-2-(fluorometil)propil]oxi}-2-metil-3-[(2-pirrolidin-1-iletil)amino]fenil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidin-3-il]prop-2-enoico |
| 290 | 3-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metil-*N*-(2-pirrolidin-1-iletil)-5-[4,4,4-trifluoro-1,1-bis(metiloxi)butil]anilina |
| 291 | 6-(4-fenilpiperazin-1-il)-9*H*-purina |
| 292 | 6-[4-(3-clorofenil)piperazin-1-il]-9*H*-purina |
| 293 | 4-(4-fenilpiperazin-1-il)-7*H*-pirrolo[2,3-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 294 | 4-[4-(3-clorofenil)piperazin-1-il]-7*H*-pirrolo[2,3-d]pirimidina |
| 295 | 4-(4-fenilpiperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 296 | 4-[4-(3-clorofenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 297 | 6-[4-(2-clorofenil)piperazin-1-il]-9*H*-purina |
| 298 | 6-[4-(2-fluorofenil)piperazin-1-il]-9*H*-purina |
| 299 | 4-[4-(2-metilfenil)piperazin-1-il]-7*H*-pirrolo[2,3-d]pirimidina |
| 300 | 4-{4-[2-(metiloxi)fenil]piperazin-1-il}-7*H*-pirrolo[2,3-d]pirimidina |
| 301 | 4-{4-[3-(metiloxi)fenil]piperazin-1-il}-7*H*-pirrolo[2,3-d]pirimidina |
| 302 | 4-{4-[4-(metiloxi)fenil]piperazin-1-il}-7*H*-pirrolo[2,3-d]pirimidina |
| 303 | 4-{4-[3-(trifluorometil)fenil]piperazin-1-il}-7*H*-pirrolo[2,3-d]pirimidina |
| 304 | 6-{4-[4-(metiloxi)fenil]piperazin-1-il}-9*H*-purina |
| 305 | 6-{4-[2-(metiloxi)fenil]piperazin-1-il}-9*H*-purina |
| 306 | 6-[4-(4-clorofenil)piperazin-1-il]-9*H*-purina |
| 307 | 6-[4-(4-fluorofenil)piperazin-1-il]-9*H*-purina |
| 308 | 4-[4-(4-clorofenil)piperazin-1-il]-7*H*-pirrolo[2,3-d]pirimidina |
| 309 | 4-[4-(2-clorofenil)piperazin-1-il]-7*H*-pirrolo[2,3-d]pirimidina |
| 310 | 4-[4-(4-fluorofenil)piperazin-1-il]-7*H*-pirrolo[2,3-d]pirimidina |
| 311 | 4-[4-(2-fluorofenil)piperazin-1-il]-7*H*-pirrolo[2,3-d]pirimidina |
| 312 | 6-{4-[3-(trifluorometil)fenil]piperazin-1-il}-9*H*-purina |

| Comp No. | *Nombre* |
|---|---|
| 313 | 6-[4-(2-metilfenil)piperazin-1-il]-9*H*-purina |
| 314 | 4-{4-[3-(trifluorometil)fenil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 315 | 4-[4-(2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 316 | 4-[4-(3-clorofenil)piperazin-1-il]-3-metil-1*H*-pirazolo[3,4-d]pirimidina |
| 317 | 3-metil-4-[4-(2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 318 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 319 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-metil-1*H*-pirazolo[3,4-d]pirimidina |
| 320 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-metil-6-fenilo-1*H*-pirazolo[3,4-d]pirimidina |
| 321 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 322 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-6-metil-1*H*-pirazolo[3,4-d]pirimidina |
| 323 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-6-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 324 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-6-(1-metiletil)-1*H*-pirazolo[3,4-d]pirimidina |
| 325 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-fenilo-1*H*-pirazolo[3,4-d]pirimidina |
| 326 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-({[2-(metiloxi)etil]oxi}metil)-1*H*-pirazolo[3,4-d]pirimidina |
| 327 | 3-bromo-4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 328 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-propil-1*H*-pirazolo[3,4-d]pirimidina |
| 329 | 4-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}fenol |
| 330 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-*N*-fenilo-1*H*-pirazolo[3,4-d]pirimidin-3-amina |
| 331 | 4-[4-(3-clorofenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 332 | 4-{4-[5-cloro-2-(metiloxi)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 333 | 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}fenol |
| 334 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-{3-[(fenilmetil)oxi]fenil}-1*H*-pirazolo[3,4-d]pirimidina |
| 335 | 3-(1,3-benzodioxol-5-il)-4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 336 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(2-tienil)-1*H*-pirazolo[3,4-d]pirimidina |
| 337 | 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}anilina |
| 338 | Ácido 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}benzoico |
| 339 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(4-metilfenil)-1*H*-pirazolo[3,4-d]pirimidina |
| 340 | *N*-(4-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}fenil)acetamida |
| 341 | 4-[4-(3-clorofenil)-1,4-diazepan-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 342 | 4-[5-(3-clorofenil)-2,5-diazabiciclo[2,2,1]hept-2-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 343 | 4-(4-{3-cloro-4-[(2-morfolin-4-iletil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 344 | 1-(3-clorofenil)-4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazine-2-carboxilato de metilo |
| 345 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(3-metilbut-2-en-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 346 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(trifluorometil)-1*H*-pirazolo[3,4-d]pirimidina |
| 347 | 4-(3-clorofenil)-1-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazino-2- carboxilato de metilo |
| 348 | 4-(4-{3-cloro-4-[(2-piperidin-1-iletil)oxi]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 349 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(1-metiletil)-1*H*-pirazolo[3,4-d]pirimidina |
| 350 | Ácido 1-(3-clorofenil)-4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazino-2-carboxílico |
| 351 | 1-(3-clorofenil)-4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)-*N*-metilpiperazino-2-carboxamida |
| 352 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(fenilmetil)-1*H*-pirazolo[3,4-d]pirimidina |
| 353 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(2-metilpropil)-1*H*-pirazolo[3,4-d]pirimidina |
| 354 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-[4-(metiloxi)fenil]-1*H*-pirazolo[3,4-d]pirimidina |
| 355 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(4-fluorofenil)-1*H*-pirazolo[3,4-d]pirimidina |
| 356 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-[4-(feniloxi)fenil]-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 357 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-{4-[(piperidin-4-ilmetil)oxi]fenil}-1*H*-pirazolo[3,4-d]pirimidina |
| 358 | 1-(3-clorofenil)-*N*-[2-(dimetilamino)etil]-4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazino-2-carboxamida |
| 359 | 4-[4-(5-cloro-2-metil-3-morfolin-4-ilfenil)piperazin-1-il]-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 360 | 4-(3-clorofenil)-1-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)-*N*-metilpiperazino-2-carboxamida |
| 361 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-[2-(metiloxi)fenil]-1*H*-pirazolo[3,4-d]pirimidina |
| 362 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-piridin-4-il-1*H*-pirazolo[3,4-d]pirimidina |
| 363 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-[3-(metiloxi)fenil]-1*H*-pirazolo[3,4-d]pirimidina |
| 364 | 4-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}benzonitrilo |
| 365 | [5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(metiloxi)fenil]metanol |
| 366 | 5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(metiloxi)benzoato de metilo |
| 367 | Ácido (2E)-3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}prop-2-enoico |
| 368 | Ácido 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}propanoico |
| 369 | 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}propan-1-ol |
| 370 | metil (2E)-3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}prop-2-enoate |

| Comp No. | *Nombre* |
|---|---|
| 371 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-{4-[(2-morfolin-4-iletil)oxi]fenil}-1*H*-pirazolo[3,4-d]pirimidina |
| 372 | 5-cloro-*N*-[2-(dimetilamino)etil]-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(metiloxi)benzamida |
| 373 | 4-(4-{5-cloro-2-(metiloxi)-3-[(4-metilpiperazin-1-il)carbonil]fenil}piperazin-1-il)-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 374 | 5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(metiloxi)benzoato de 2-(dimetilamino)etilo |
| 375 | 1-[5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(metiloxi)fenil]-*N*,*N*-dimetilmetanamina |
| 376 | *N*'-{[5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(metiloxi)fenil]metil}-*N*,*N*-dimetiletano-1,2-diamina |
| 377 | [1-(3-clorofenil)-4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-2-il]metanol |
| 378 | 3-[(4-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}fenil)oxi]-*N*,*N*-dimetilpropan-1-amina |
| 379 | 2-cloro-4-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-metilfenol |
| 380 | 1-(3-clorofenil)-4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)-*N*-(1-metilpiperidin-4-il)piperazino-2-carboxamida |
| 381 | 1-(3-clorofenil)-4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)-*N*-(2-morfolin-4-iletil)piperazino-2-carboxamida |

| Comp No. | *Nombre* |
|---|---|
| 382 | 2-{[5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(metiloxi)fenil]oxi}-*N*,*N*-dimetiletanamina |
| 383 | 3-{5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}-*N*,*N*-dimetilprop-2-in-1-amina |
| 384 | *N*'-{5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}-*N*,*N*-dimetiletano-1,2-diamina |
| 385 | (2E)-3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}prop-2-enoato de 1,1-dimetiletilo |
| 386 | 3-({2-cloro-4-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-metilfenil}oxi)-*N*,*N*-dimetilpropan-1-amina |
| 387 | 2-({2-cloro-4-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-5-metilfenil}oxi)-*N*,*N*-dimetiletanamina |
| 388 | 4-{4-[5-cloro-2-metil-4-(metiloxi)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |
| 389 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(4-metilpiperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 390 | 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}-*N*,*N*-dietilprop-2-in-1-amina |
| 391 | 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}prop-2-in-1-ol |
| 392 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(piperidin-4-ilmetil)-1*H*-pirazolo[3,4-d]pirimidina |

| Comp No. | *Nombre* |
|---|---|
| 393 | (3aR,6aS)-5-({4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}metiliden)hexahidrociclopenta[c]pirrol-2(1*H*)-carboxilato de fenilmetilo |
| 394 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-[(E)-(3aR,6aS)-hexahidrociclopenta[c]pirrol-5(1*H*)-ilidenmetil]-1*H*-pirazolo[3,4-d]pirimidina |
| 395 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(3-pirrolidin-1-ilprop-1-in-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 396 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-[3-(4-metilpiperazin-1-il)prop-1-in-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 397 | 3-{4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidin-3-il}-*N*,*N*-dietilpropan-1-amina |
| 398 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(3-pirrolidin-1-ilpropil)-1*H*-pirazolo[3,4-d]pirimidina |
| 399 | 4-[4-(5-cloro-2-metilfenil)piperazin-1-il]-3-(1,2,3,6-tetrahidropiridin-4-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 400 | 3-{5-cloro-3-[4-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-metilfenil}-*N*,*N*-dietilpropan-1-amina |
| 401 | 4-{4-[5-cloro-2-metil-3-(3-pirrolidin-1-ilpropil)fenil]piperazin-1-il}-3-etil-1*H*-pirazolo[3,4-d]pirimidina |

**Tabla 2b.**

**Inhibidores representativos de AKT adicionales**

**[00227]** Los Compuestos de la Tabla 2b se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las

combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 2b se pueden usar para practicar la la invención.

| Entrada | Nombre |
|---|---|
| 1 | [1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metanol |
| 2 | 2-{[[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]oxi}-*N*,*N*-dimetiletanamina |
| 3 | 3-{[[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]oxi}-*N*,*N*-dimetilpropan-1-amina |
| 4 | 3-bromo-4-{4-[(4-bromofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 5 | {4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-1-[(4-clorofenil)metil]piperazin-2-il}metanol |
| 6 | *N*'-[[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]-*N*,*N*-dietiletano-1,2-diamina |
| 7 | 3-bromo-4-(4-{[4-(1,1-dimetiletil)fenil]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 8 | 4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-1-[(4-clorofenil)metil]piperazin-2-ona |
| 9 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-2-(4-clorofenil)-*N*-[2-(dimetilamino)etil]acetamida |
| 10 | *N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*-(4-clorofenil)-*N*',*N*'-dietilpropane-1,3-diamina |
| 11 | 3-bromo-4-(4-{[4-(trifluorometil)fenil]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |

| Entrada | Nombre |
|---|---|
| 12 | *N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*-(4-clorofenil)-*N*'-[2-(dimetilamino)etil]urea |
| 13 | *N*-[[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]-*N*'-[2-(dimetilamino)etil]urea |
| 14 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-2-oxopiperazin-1-il]-2-(4-clorofenil)-*N*-[2-(dimetilamino)etil]acetamida |
| 15 | 2-(dimetilamino)etil [1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)carbamate |
| 16 | 3-bromo-4-{4-[(4-cloro-3-fluorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 17 | 3-bromo-4-{4-[(4-cloro-2-fluorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 18 | *N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*-(4-clorofenil)-*N*',*N*'-dietiletano-1,2-diamina |
| 19 | 3-bromo-4-{4-[(4-clorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 20 | [1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-fluorofenil)metanona |
| 21 | *N*-[[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]-*N*',*N*'-dietil-*N*-metiletano-1,2-diamina |
| 22 | [1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-fluorofenil)metanol |
| 23 | 3-bromo-4-(4-{[2-fluoro-4-(trifluorometil)fenil]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |

| Entrada | Nombre |
|---|---|
| 24 | *N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*-(4-clorofenil)-*N*~3~,*N*~3~-dietil-beta-alaninamida |
| 25 | 2-{[[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-fluorofenil)metil]oxi}-*N*,*N*-dimetiletanamina |
| 26 | *N*-[[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]-*N*~3~,*N*~3~-dietil-beta-alaninamida |
| 27 | 3-bromo-4-{4-[(3,4-diclorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 28 | *N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*-(4-clorofenil)-*N*'-[2-(dimetilamino)etil]etandiamida |
| 29 | *N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*-(4-clorofenil)-2-(dietilamino)etansulfonamida |
| 30 | 4-[4-(bifenil-4-ilmetil)piperazin-1-il]-3-bromo-1*H*-pirazolo[3,4-d]pirimidina |
| 31 | 3-bromo-4-{(3S)-4-[(4-clorofenil)metil]-3-metilpiperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 32 | 3-bromo-4-(4-{[4-(metiloxi)fenil]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 33 | 4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-*N*-[3-(trifluorometil)fenil]piperazino-1-carboxamida |
| 34 | 3-bromo-4-{4-[(4-fluorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 35 | *N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*-(4-clorofenil)pent-4-enamida |
| 36 | 3-bromo-4-[4-(2,3-dihidro-1,4-benzodioxin-6-ilmetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 37 | 4-[4-(1,3-benzodioxol-5-ilmetil)piperazin-1-il]-3-bromo-1*H*-pirazolo[3,4-d]pirimidina |

| Entrada | Nombre |
|---|---|
| 38 | [1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metanona |
| 39 | 3-bromo-4-(4-{[4-(feniloxi)fenil]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 40 | 3-bromo-4-{4-[(3,4-diclorofenil)metil]piperidin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 41 | 4-{[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]metil}-*N*,*N*-dimetilanilina |
| 42 | 4-{[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]metil}benzoato de metilo |
| 43 | 3-bromo-4-{4-[(2E)-3-fenilprop-2-enoil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 44 | 1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-4-[(4-clorofenil)metil]-*N*-[3-(dietilamino)propil]piperidino-4-carboxamida |
| 45 | 3-bromo-4-{4-[(2-bromofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 46 | 3-bromo-4-{4-[(2-clorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 47 | 3-bromo-4-{4-[(2,4-diclorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 48 | 3-bromo-4-{4-[(2-cloro-4-fluorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 49 | 1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-4-(4-clorofenil)-*N*-[3-(dietilamino)propil]piperidino-4-carboxamida |
| 50 | 3-bromo-4-[4-(fenilmetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 51 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*-piridin-2-ilacetamida |
| 52 | 3-bromo-4-[4-(1*H*-imidazol-2-ilmetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 53 | 3-bromo-4-(4-{[3-(feniloxi)fenil]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |

| Entrada | Nombre |
|---|---|
| 54 | 3-bromo-4-{4-[(3-metilfenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 55 | 3-{[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]metil}benzonitrilo |
| 56 | 3-bromo-4-{4-[(2-cloro-6-fluorofenil)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 57 | 3-bromo-4-[4-(1-feniletil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 58 | 3-bromo-4-[4-(piridin-4-ilmetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 59 | 1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-*N*-(4-clorofenil)piperidin-4-amina |
| 60 | 3-bromo-4-[4-(piridin-3-ilmetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 61 | 3-bromo-4-(4-{[2,3,4-tris(metiloxi)fenil]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 62 | 3-bromo-4-[4-({3-[(fenilmetil)oxi]fenil}metil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 63 | 3-bromo-4-[4-(naftalen-1-ilmetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 64 | 3-bromo-4-(4-{[5-(4-clorofenil)furan-2-il]metil}piperazin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 65 | 3-bromo-4-[4-({4-[(4-fluorofenil)oxi]-3-nitrofenil}metil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 66 | 3-bromo-4-[4-(furan-2-ilcarbonil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 67 | 3-bromo-4-[4-(1*H*-indol-6-ilcarbonil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 68 | 3-bromo-4-{4-[2-(2-tienil)etil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |

| Entrada | Nombre |
|---|---|
| 69 | 3-bromo-4-[4-(3-pirrolidin-1-ilpropil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 70 | 3-bromo-4-[4-(ciclohexilmetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 71 | 3-bromo-4-{4-[(10-cloroanthracen-9-il)metil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 72 | 3-bromo-4-[4-(1-metilpropil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 73 | 4-(4-{[4,6-bis(metiloxi)pirimidin-2-il]metil}piperazin-1-il)-3-bromo-1*H*-pirazolo[3,4-d]pirimidina |
| 74 | 3-bromo-4-{4-[2-(metiloxi)etil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 75 | 3-bromo-4-[4-(2-morfolin-4-il-2-oxoetil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 76 | 3-bromo-4-{4-[3-(metiloxi)propil]piperazin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 77 | 4-{4-[[4,6-bis(metiloxi)pirimidin-2-il](fenil)metil]piperazin-1-il}-3-bromo-1*H*-pirazolo[3,4-d]pirimidina |
| 78 | 3-bromo-4-[4-(6,7,8,9-tetrahidro-5*H*-benzociclohepten-5-il)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 79 | 3-bromo-4-[4-({4-[(fenilmetil)oxi]fenil}metil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 80 | 3-bromo-4-[4-({3-cloro-4-[(fenilmetil)oxi]fenil}metil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 81 | 4-{[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]metil}-*N*-(3-morfolin-4-ilpropil)benzamida |
| 82 | 4-{[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]metil}-*N*-[3-(metiloxi)propil]benzamida |

| Entrada | Nombre |
|---|---|
| 83 | 2-[({4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)-1-[(4-clorofenil)metil]piperazin-2-il}metil)oxi]-*N*,*N*-dimetiletanamina |
| 84 | 3-bromo-4-[4-({4-[(4-clorofenil)oxi]-3-nitrofenil}metil)piperazin-1-il]-1*H*-pirazolo[3,4-d]pirimidina |
| 85 | 2-[4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il]-*N*,*N*-dimetilacetamida |
| 86 | 2-{[(R)-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]oxi}-*N*,*N*-dimetiletanamina |
| 87 | *N*-(4-bromo-3-fluorofenil)-*N*-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-*N*'-[2-(dimetilamino)etil]urea |
| 88 | 2-({(R)-(4-clorofenil)[1-(3-etil-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]metil}oxi)-*N*,*N*-dimetiletanamina |
| 89 | 2-{[(S)-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]oxi}-*N*,*N*-dimetiletanamina |
| 90 | 3-bromo-4-(4-{(R)-(4-clorofenil)[(2-pirrolidin-1-iletil)oxi]metil}piperidin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 91 | 1-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-1-(4-clorofenil)-4-(dimetilamino)butan-1-ol |
| 92 | 2-{[(R)-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-cloro-3-fluorofenil)metil]oxi}-*N*,*N*-dimetiletanamina |
| 93 | 3-bromo-4-(4-{(R)-(4-clorofenil)[(2-piperidin-1-iletil)oxi]metil}piperidin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |

| Entrada | Nombre |
|---|---|
| 94 | 4-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-4-(4-clorofenil)-*N*,*N*-dimetilbutan-1-amina |
| 95 | 3-bromo-4-(4-{(R)-(4-clorofenil)[(2-morfolin-4-iletil)oxi]metil}piperidin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 96 | 1-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-1-(4-fluorofenil)-*N*-(furan-2-ilmetil)-*N*-metilmetanamina |
| 97 | 1-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]-1-(4-fluorofenil)-*N*-metil-*N*-(piridin-2-ilmetil)metanamina |
| 98 | 4-{[{[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-fluorofenil)metil}(metil)amino]metil}-*N*,*N*-dimetilanilina |
| 99 | [4-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperazin-1-il](1*H*-indol-6-il)metanol |
| 100 | 3-bromo-4-(4-{(R)-(4-cloro-3-fluorofenil)[(2-pirrolidin-1-iletil)oxi]metil}piperidin-1-il)-1*H*-pirazolo[3,4-d]pirimidina |
| 101 | 3-bromo-4-{4-[(4-clorofenil)oxi]piperidin-1-il}-1*H*-pirazolo[3,4-d]pirimidina |
| 102 | 2-{[(R)-[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il](4-clorofenil)metil]oxi}-*N*,*N*-dietiletanamina |
| 103 | 2-{[1-(3-bromo-1*H*-pirazolo[3,4-d]pirimidin-4-il)piperidin-4-il]oxi}-5-cloro-*N*-(2-pirrolidin-1-iletil)anilina |

**Tabla 3a.**

**Inhibidores representativos de c-MET y/o Flt-3**

**[00228]** Los Compuestos de la Tabla 3a se pueden preparar como sales, solvatos, hidratos y/o isómeros

farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 3a se pueden usar para practicar la la invención.

| Comp No. | Nombre |
|---|---|
| 1 | *N*-(4-fluorofenil)-*N*'-[3-fluoro-4-(7*H*-pirrolo[2,3-d]pirimidin-4-iloxi)fenil]propandiamida |
| 2 | *N*-(4-fluorofenil)-*N*'-[3-fluoro-4-(7*H*-pirrolo[2,3-d]pirimidin-4-iloxi)fenil]ciclopropano-1,1-dicarboxamida |
| 3 | *N*-({[3-fluoro-4-(7*H*-pirrolo[2,3-d]pirimidin-4-iloxi)fenil]amino}carbonotioil)-2-fenilacetamida |
| 4 | *N*-(4-fluorofenil)-*N*'-(4-{[1-(tetrahidro-2*H*-piran-2-il)-1*H*-pirazolo[3,4-d]pirimidin-4-il]oxi}fenil)ciclopropano-1,1-dicarboxamida |
| 5 | 2-fenilo-*N*-{[(4-{[1-(tetrahidro-2*H*-piran-2-il)-1*H*-pirazolo[3,4-d]pirimidin-4-il]oxi}fenil)amino]carbonotioil}acetamida |
| 6 | *N*-(4-fluorofenil)-*N*'-[4-(1*H*-pirazolo[3,4-d]pirimidin-4-iloxi)fenil]ciclopropano-1,1-dicarboxamida |
| 7 | 2-fenilo-*N*-({[4-(1*H*-pirazolo[3,4-d]pirimidin-4-iloxi)fenil]amino}carbonotioil)acetamida |
| 8 | *N*-(4-fluorofenil)-*N*'-(4-{[9-(tetrahidro-2*H*-piran-2-il)-9*H*-purin-6-il]oxi}fenil)ciclopropano-1,1-dicarboxamida |
| 9 | 2-fenilo-*N*-{[(4-{[9-(tetrahidro-2*H*-piran-2-il)-9*H*-purin-6-il]oxi}fenil)amino]carbonotioil}acetamida |
| 10 | *N*-(4-fluorofenil)-*N*'-[4-(9*H*-purin-6-iloxi)fenil]ciclopropano-1,1-dicarboxamida |

| Comp No. | Nombre |
|---|---|
| 11 | 2-fenilo-*N*-({[4-(9*H*-purin-6-iloxi)fenil]amino}carbonotioil)acetamida |
| 12 | *N*-{3-fluoro-4-[(6-{[(2-morfolin-4-iletil)amino]carbonil}-7*H*-pirrolo[2,3-d]pirimidin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |

Tabla 3b.

Inhibidores representativos adicionales de c-MET, c-KIT, y/o Flt-3

**[00229]** Los Compuestos de la Tabla 3b se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 3b se pueden usar para practicar la invención.

| Entrada | Nombre |
|---|---|
| 1 | *N*-[({3-fluoro-4-[(6-(metiloxi)-7-{[(3aR,6aS)-octahidrociclopenta[c]pirrol-5-ilmetil]oxi}quinazolin-4-il)oxi]fenil}amino)carbonotioil]-2-fenilacetamida |
| 2 | *N*-{[(3-fluoro-4-{[7-({[(3aR,6aS)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-il]oxi}fenil)amino]carbonotioil}-2-fenilacetamida |
| 3 | *N*-{[(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)(metil)amino]carbonotioil}-2-fenilacetamida |
| 4 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)imidazolidin-2-ona |

| Entrada | Nombre |
|---|---|
| 5 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-3-(fenilmetil)imidazolidin-2-ona |
| 6 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-3-(fenilacetil)imidazolidin-2-ona |
| 7 | [(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)amino](oxo)acetato de etilo |
| 8 | *N*-{[(4-{[6,7-bis(metiloxi)quinazolin-4-il]amino}-3-fluorofenil)amino]carbonotioil}-2-fenilacetamida |
| 9 | *N'*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*-metil-*N*-(2-feniletil)sulfamida |
| 10 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-3-(fenilmetil)-1,2,4-oxadiazol-5-amina |
| 11 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)piperidin-2-ona |
| 12 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N'*-(fenilmetil)etandiamida |
| 13 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-4-fenilo-1,3-tiazol-2-amina |
| 14 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N'*-(2-feniletil)etandiamida |
| 15 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-1-fenilmetansulfonamida |
| 16 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-2-feniletansulfonamida |
| 17 | 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluoro-*N*-(fenilmetil)bencensulfonamida |
| 18 | 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluoro-*N*-metil-*N*-(fenilmetil)bencensulfonamida |
| 19 | 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluoro-*N*-(2-feniletil)bencensulfonamida |

| Entrada | Nombre |
|---|---|
| 20 | 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluoro-*N*-metil-*N*-(2-feniletil)bencensulfonamida |
| 21 | 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluoro-*N*-(3-fenilpropil)bencensulfonamida |
| 22 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)pirrolidin-2-ona |
| 23 | (fenilmetil)carbamato de 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenilo |
| 24 | (2-feniletil)carbamato de 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenilo |
| 25 | 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluoro-*N*-metil-*N*-(3-fenilpropil)bencensulfonamida |
| 26 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N'*-feniletandiamida |
| 27 | *N*-{[(3-fluoro-4-{[7-{[(2-metiloctahidrociclopenta[c]pirrol-5-il)metil]oxi}-6-(metiloxi)quinolin-4-il]oxi}fenil)amino]carbonotioil}-2-fenilacetamida |
| 28 | *N*-[(Z)-[(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)amino](imino)metil]-2-fenilacetamida |
| 29 | 4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluoro-*N*-[2-(feniloxi)etil]bencensulfonamida |
| 30 | *N,N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-bis-(3-fenilpropano-1-sulfonamida) |
| 31 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-3-fenilpropano-1-sulfonamida |
| 32 | *N*2-[(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)sulfonil]-*N*1-fenilglicinamida |
| 33 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}piridin-3-il)-2-fenilacetamida |
| 34 | *N*-{[(6-{[6,7-bis(metiloxi)quinolin-4- |

| Entrada | Nombre |
|---|---|
| | il]oxi}piridin-3-il)amino]carbonotioil}-2-fenilacetamida |
| 35 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-1,3-benzotiazol-2-amina |
| 36 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-1,3-benzotiazol-2-amina |
| 37 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-1,3-benzotiazol-2-il)-2-fenilacetamida |
| 38 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(2-morfolin-4-iletil)etandiamida |
| 39 | ter-butil éster del ácido bencil-{[4-(6,7-dimetoxi-quinolin-4-iloxi)-3-fluoro-fenilcarbamoil]-metil}-carbámico |
| 40 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-(fenilmetil)glicinamida |
| 41 | *N*2-acetil-*N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-(fenilmetil)glicinamida |
| 42 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-1,3-benzotiazol-2-il)-2-fenilacetamida |
| 43 | ter-butil éster del ácido bencil-{[6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-ilcarbamoil]-metil}-carbámico |
| 44 | *N*1-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}piridin-3-il)-*N*2-(fenilmetil)glicinamida |
| 45 | *N*2-acetil-*N*1-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}piridin-3-il)-*N*2-(fenilmetil)glicinamida |
| 46 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}piridin-3-il)-3-fenilpropanamida |
| 47 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}piridin-3-il)-4-fenilbutanamida |
| 48 | *N*1-(6-{[6,7-bis(metiloxi)quinolin-4- |

| Entrada | Nombre |
|---|---|
| | il]oxi}piridin-3-il)-*N*2-metil-*N*2-(fenilmetil)glicinamida |
| 49 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-{2-[4-(metiloxi)fenil]etil}etandiamida |
| 50 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-metil-*N*2-(fenilmetil)glicinamida |
| 51 | 4-[(2-amino-1,3-benzotiazol-6-il)oxi]-6,7-bis(metiloxi)-1-(2-oxo-2-feniletil)quinolinio |
| 52 | *N*-{[(4-{[6,7-bis(metiloxi)quinolin-4-il]amino}fenil)amino]carbonotioil}-2-fenilacetamida |
| 53 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-1,3-benzotiazol-2-il)-3-fenilpropanamida |
| 54 | *N*-{[(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)amino]carbonotioil}-2-fenilacetamida |
| 55 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(2,3-dihidro-1*H*-inden-1-il)etandiamida |
| 56 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(2,3-dihidro-1*H*-inden-2-il)etandiamida |
| 57 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(1,2,3,4-tetrahidronaftalen-1-il)etandiamida |
| 58 | *N*'-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*-(2-feniletil)-*N*-(fenilmetil)sulfamida |
| 59 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-(trifluoroacetil)glicinamida |

| Entrada | Nombre |
|---|---|
| 60 | *N*-{[4-(6,7-dimetoxi-quinolin-4-iloxi)-3-fluoro-fenilcarbamoil]-metil}-benzamida |
| 61 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}piridin-3-il)-*N*'-(4-fluorofenil)propandiamida |
| 62 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-[(2S)-1,2,3,4-tetrahidronaftalen-2-il]etandiamida |
| 63 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-[2-(4-metilfenil)etil]etandiamida |
| 64 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(2-fenilpropil)etandiamida |
| 65 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-[2-(4-clorofenil)etil]etandiamida |
| 66 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*,*N*'-bis(fenilmetil)sulfamida |
| 67 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*,*N*'-bis(2-feniletil)sulfamida |
| 68 | [(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)amino](oxo)acetato de etilo |
| 69 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(2-feniletil)etandiamida |
| 70 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(4-fluorofenil)propandiamida |
| 71 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(1,2,3,4-tetrahidronaftalen-2-il)etandiamida |
| 72 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-[2-(1-metilpirrolidin-2-il)etil]etandiamida |
| 73 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-[2-(feniloxi)etil]etandiamida |

| Entrada | Nombre |
|---|---|
| 74 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-[2-hidroxi-1-(fenilmetil)etil]urea |
| 75 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-3-[(4-metilfenil)sulfonil]-4-(fenilmetil)imidazolidin-2-ona |
| 76 | *N*'-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*-metil-*N*-(2-feniletil)etandiamida |
| 77 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-{[3-(trifluorometil)fenil]metil}etandiamida |
| 78 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-{2-[3-(trifluorometil)fenil]etil}etandiamida |
| 79 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-3-oxo-4-fenilbutanamida |
| 80 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-2-[3-(trifluorometil)fenil]acetamida |
| 81 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-*N*-[2-(feniloxi)etil]-1,3-benzotiazol-2-amina |
| 82 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-*N*-(2-piperidin-1-iletil)-1,3-benzotiazol-2-amina |
| 83 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-*N*-metil-*N*-(2-feniletil)-1,3-benzotiazol-2-amina |
| 84 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-*N*-(2-pirrolidin-1-iletil)-1,3-benzotiazol-2-amina |
| 85 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-*N*-{[3-(trifluorometil)fenil]metil}-1,3-benzotiazol-2-amina |
| 86 | 6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-*N*-{2-[3-(trifluorometil)fenil]etil}-1,3- |

| Entrada | Nombre |
|---|---|
| | benzotiazol-2-amina |
| 87 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N'*-[3-(trifluorometil)fenil]propandiamida |
| 88 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-1,3-benzotiazol-2-il)-2-[3-(trifluorometil)fenil]acetamida |
| 89 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-{[3-(trifluorometil)fenil]metil}glicinamida |
| 90 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-(2-feniletil)glicinamida |
| 91 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-{2-[3-(trifluorometil)fenil]etil}glicinamida |
| 92 | ter-butil éster del ácido bencil-{[5-cloro-6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-ilcarbamoil]-metil}-carbámico |
| 93 | *N*1-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*2-(fenilmetil)glicinamida |
| 94 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-1,3-benzotiazol-2-il)-2-[3,5-bis(trifluorometil)fenil]acetamida |
| 95 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-1,3-benzotiazol-2-il)-2-[2-cloro-5-(trifluorometil)fenil]acetamida |
| 96 | *N*-{3-fluoro-4-[(6-(metiloxi)-7-{[(1-metilpiperidin-4-il)metil]oxi}quinolin-4-il)oxi]fenil}-*N'*-(2-feniletil)etandiamida |
| 97 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N'*-(1,2,3,4-tetrahidroisoquinolin-1- |

| Entrada | Nombre |
|---|---|
| | ilmetil)etandiamida |
| 98 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-[(2-metil-1,2,3,4-tetrahidroisoquinolin-1-il)metil]etandiamida |
| 99 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-metil-*N*2-{[3-(trifluorometil)fenil]metil}glicinamida |
| 100 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-metil-*N*2-{2-[3-(trifluorometil)fenil]etil}glicinamida |
| 101 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*2-metil-*N*2-(2-feniletil)glicinamida |
| 102 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-4-(fenilmetil)imidazolidin-2-ona |
| 103 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}piridazin-3-il)-*N*'-(4-fluorofenil)propandiamida |
| 104 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(2-clorofenil)propandiamida |
| 105 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(3-clorofenil)propandiamida |
| 106 | *N*1-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*2-metil-*N*2-(fenilmetil)glicinamida |
| 107 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(4-clorofenil)propandiamida |
| 108 | (2E)-*N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-2-[(metiloxi)imino]propanamida |
| 109 | (2E)-*N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-2-[(etiloxi)imino]propanamida |
| 110 | (2E)-*N*-(4-{[6,7-bis(metiloxi)quinolin-4- |

| Entrada | Nombre |
|---|---|
| | il]oxi}fenil)-2-{[(fenilmetil)oxi]imino}propanamida |
| 111 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-1-(fenilmetil)prolinamida |
| 112 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-3-[(4-metilfenil)sulfonil]-4-(fenilmetil)imidazolidin-2-ona |
| 113 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-4-(fenilmetil)imidazolidin-2-ona |
| 114 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-4-(fenilmetil)-4,5-dihidro-1,3-oxazol-2-amina |
| 115 | 6,7-bis(metiloxi)-4-({4-[4-(fenilmetil)piperazin-1-il]fenil}oxi)quinolina |
| 116 | 1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-4-(fenilmetil)piperazin-2-ona |
| 117 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*2-(fenilmetil)alaninamida |
| 118 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*2-metil-*N*2-(fenilmetil)alaninamida |
| 119 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*2-(fenilmetil)leucinamida |
| 120 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*2-metil-*N*2-(fenilmetil)leucinamida |
| 121 | *N*1-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*2-(fenilmetil)valinamida |
| 122 | 4-(6,7-dimetoxi-quinolin-4-ilamino)-*N*-(3-fenilo-propil)-benzamida |
| 123 | 4-bencil-1-[4-(6,7-dimetoxi-quinolin-4-iloxi)-fenil]-tetrahidro-pirimidin-2-ona |
| 124 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-phenetil-oxalamida |

| Entrada | Nombre |
|---|---|
| 125 | 2-(Bencil-metil-amino)-*N*-[4-(6,7-dimetoxi-quinolin-4-iloxi)-fenil]-3-metil-butiramida (nota: Orden alfabético de prefijos ignorado mientras se selecciona la cadena original) |
| 126 | *N*-[4-(6,7-Dimetoxi-quinolin-4-iloxi)-fenil]-2-fenoxiimino-propionamida |
| 127 | 2-Benciloxiimino-*N*-[4-(6,7-dimetoxi-quinolin-4-iloxi)-fenil]-2-fenilo-acetamida |
| 128 | 4-[4-(4-Bencil-piperidin-1-il)-fenoxi]-6,7-dimetoxi-quinolina |
| 129 | *N*-[4-(6,7-Dimetoxi-quinolin-4-iloxi)-3-fluoro-fenil]-*N*'-(2-isopropil-1,2,3,4-tetrahidro-isoquinolin-1-ilmetil)-oxalamida |
| 130 | *N*-[4-(6,7-Dimetoxi-quinolin-4-iloxi)-3-fluoro-fenil]-*N*'-(2-etil-1,2,3,4-tetrahidro-isoquinolin-1-ilmetil)-oxalamida |
| 131 | ter-butil éster del ácido 4-(4-{3-cloro-5-[2-(4-fluoro-fenilcarbamoil)-acetilamino]-piridin-2-iloxi}-6-metoxi-quinolin-7-iloximetil)-piperidino-1-carboxílico |
| 132 | *N*-{5-cloro-6-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-piridin-3-il}-*N*'-(4-fluoro-fenil)-malonamida |
| 133 | *N*-{5-Cloro-6-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-piridin-3-il}-*N*'-(4-fluoro-fenil)-malonamida |
| 134 | *N*-{4-[7-(3-Dietilamino-propoxi)-6-metoxi-quinolin-4-iloxi]-3-fluoro-fenil}-*N*'-phenetil-oxalamida |
| 135 | *N*-{3-Fluoro-4-[6-metoxi-7-(3-morfolin-4-il-propoxi)-quinolin-4-iloxi]-fenil}-*N*'-fenetil-oxalamida |

| Entrada | Nombre |
|---|---|
| 136 | *N*-{3-Fluoro-4-[6-metoxi-7-(3-piperidin-1-il-propoxi)-quinolin-4-iloxi]-fenil}-*N*'-fenetil-oxalamida |
| 137 | *N*-{4-[7-(2-Dietilamino-etoxi)-6-metoxi-quinolin-4-iloxi]-3-fluoro-fenil}-*N*'-fenetil-oxalamida |
| 138 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-metil-*N*'-fenetil-oxalamida |
| 139 | *N*-{3-Fluoro-4-[6-metoxi-7-(2-metil-octahidro-ciclopenta[c]pirrol-5-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-fenetil-oxalamida |
| 140 | *N*-{3-Fluoro-4-[6-metoxi-7-(2-metil-octahidro-ciclopenta[c]pirrol-5-ilmetoxi)-quinazolin-4-iloxi]-fenil}-*N*'-fenetil-oxalamida |
| 141 | 2-(3,4-Dihidro-1*H*-isoquinolin-2-il)-*N*-{3-fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-2-oxo-acetamida |
| 142 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-2-oxo-2-(3-fenilo-pirrolidin-1-il)-acetamida |
| 143 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-2-oxo-2-(2-fenilo-morfolin-4-il)-acetamida |
| 144 | *N*-(2-Dimetilamino-2-fenilo-etil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 145 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-oxo-2-fenilo-etil)-oxalamida |
| 146 | *N*-[5-Cloro-6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-il]-2,2-difluoro-*N*'-(4-fluoro-fenil)- |

| Entrada | Nombre |
|---|---|
| | malonamida |
| 147 | *N*-Bencil-*N'*-{3-fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 148 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-[2-(2-fluoro-fenil)-etil]-oxalamida |
| 149 | *N*-[2-(3-Cloro-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 150 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-[2-(2-metoxi-fenil)-etil]-oxalamida |
| 151 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(2-piridin-3-il-etil)-oxalamida |
| 152 | *N*-Bencil-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 153 | *N*-[2-(2,5-Dimetoxi-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 154 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-[2-(2-trifluorometil-fenil)-etil]-oxalamida |
| 155 | *N*-[2-(2-Etoxi-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 156 | *N*-[2-(2,4-Dimetil-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 157 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)- |

| Entrada | Nombre |
|---|---|
| | quinolin-4-iloxi]-fenil}-*N*'-(1*S* -fenilo-2-p-tolil-etil)-oxalamida |
| 158 | *N*-[2-(4-Cloro-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 159 | Ácido *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalámico |
| 160 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[2-(3-fluoro-fenil)-etil]-oxalamida |
| 161 | *N*-[2-(2-Cloro-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 162 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[2-(3-metoxi-fenil)-etil]-oxalamida |
| 163 | *N*-(1,2-Difenil-etil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 164 | *N*-[2-(2,4-Dicloro-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 165 | *N*-[2-(3,4-Dimetoxi-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 166 | *N*-[2-(4-Etil-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 167 | *N*-[2-(4-Etoxi-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]- |

| Entrada | Nombre |
|---|---|
| | fenil}-oxalamida |
| 168 | *N*-[2-(4-Etoxi-3-metoxi-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 169 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-[2-(4-fenoxi-fenil)-etil]-oxalamida |
| 170 | *N*-[2-(3-Etoxi-4-metoxi-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 171 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(2-piridin-2-il-etil)-oxalamida |
| 172 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(2-piridin-4-il-etil)-oxalamida |
| 173 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-[2-(4-fluoro-fenil)-etil]-oxalamida |
| 174 | *N*-[2-(2-Bromo-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 175 | *N*-[2-(2-Cloro-6-fluoro-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 176 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(2*R*-fenilo-propil)-oxalamida |
| 177 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-indan-1-il-oxalamida |
| 178 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4- |

| Entrada | Nombre |
|---|---|
| | ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-isobutil-oxalamida |
| 179 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(3-metil-butil)-oxalamida |
| 180 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2*R*-fenilo-propil)-oxalamida |
| 181 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-fenilo-propil)-oxalamida |
| 182 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-indan-2-il-oxalamida |
| 183 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1*R*-fenilo-etil)-oxalamida |
| 184 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1*S*-fenilo-etil)-oxalamida |
| 185 | *N*-[2-(3-Bromo-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 186 | *N*-[2-(2,6-Dicloro-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 187 | *N*-[2-(2,4-Dicloro-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 188 | *N*-(2-Benzo[1,3]dioxol-5-il-etil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4- |

| Entrada | Nombre |
|---|---|
| | iloxi]-fenil}-oxalamida |
| 189 | *N*-[2-(3-Bromo-4-metoxi-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 190 | *N*-[2-(3,5-Dimetoxi-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 191 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-o-tolil-etil)-oxalamida |
| 192 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-m-tolil-etil)-oxalamida |
| 193 | *N*-[2-(3-Etoxi-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 194 | *N*-[2-(3,4-Dimetil-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 195 | *N*-[2-(2,5-Dimetil-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 196 | *N*-[2-(3-Cloro-4-propoxi-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 197 | *N*-[2-(4-Butoxi-3-cloro-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 198 | *N*-[2-(4-tert-Butil-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |

| Entrada | Nombre |
|---|---|
| 199 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[2-(4-sulfamoil-fenil)-etil]-oxalamida |
| 200 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[2-(4-hidroxi-3-metoxi-fenil)-etil]-oxalamida |
| 201 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[2-(3-hidroxi-4-metoxi-fenil)-etil]-oxalamida |
| 202 | *N*-(2,4-Dicloro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 203 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(4-fluoro-2-trifluorometil-bencil)-oxalamida |
| 204 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1-p-tolil-etil)-oxalamida |
| 205 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(3-fluoro-4-trifluorometil-bencil)-oxalamida |
| 206 | *N*-(3-Cloro-4-fluoro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 207 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[1-(3-metoxi-fenil)-etil]-oxalamida |
| 208 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1-naftalen-2-il-etil)-oxalamida |
| 209 | *N*-(4-Cloro-3-trifluorometil-bencil)-*N*'-{3-fluoro- |

| Entrada | Nombre |
|---|---|
| | 4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 210 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1-p-tolil-etil)-oxalamida |
| 211 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(6-trifluorometil-piridin-3-ilmetil)-oxalamida |
| 212 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-metil-bencil)-oxalamida |
| 213 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(3-metil-bencil)-oxalamida |
| 214 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(4-fluoro-3-trifluorometil-bencil)-oxalamida |
| 215 | *N*-(3,5-Dicloro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 216 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1R,2,3,4-tetrahidro-naftalen-1-il)-oxalamida |
| 217 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1S,2,3,4-tetrahidro-naftalen-1-il)-oxalamida |
| 218 | *N*-Ciclopentil-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 219 | *N*-[1-(4-Bromo-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]- |

| Entrada | Nombre |
|---|---|
| | fenil}-oxalamida |
| 220 | *N*-(2-Fluoro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 221 | *N*-[2-(3,4-Dicloro-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 222 | *N*-(4-Fluoro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 223 | *N*-(2,3-Difluoro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 224 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-fenoxi-etil)-oxalamida |
| 225 | *N*-(2,2-Difenil-etil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 226 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[2-(4-metoxi-fenil)-etil]-oxalamida |
| 227 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-fenilo-propil)-oxalamida |
| 228 | *N*-[2-(4-Bromo-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 229 | *N*-{4-[7-(1-Etil-piperidin-4-ilmetoxi)-6-metoxi-quinolin-4-iloxi]-3-fluoro-fenil}-2-oxo-2-(2-fenilo-morfolin-4-il)-acetamida |

| Entrada | Nombre |
|---|---|
| 230 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(3-fluoro-5-trifluorometil-bencil)-oxalamida |
| 231 | *N*-(3,5-Difluoro-bencil)-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 232 | *N*-(2-Cloro-5-trifluorometil-bencil)-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 233 | *N*-[4-(6,7-Dimetoxi-quinolin-4-iloxi)-3-fluoro-fenil]-*N'*-(2-dimetilamino-2-fenilo-etil)-oxalamida |
| 234 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(4-metoxi-bencil)-oxalamida |
| 235 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(4-trifluorometil-bencil)-oxalamida |
| 236 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(3-metoxi-bencil)-oxalamida |
| 237 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(3-trifluorometil-bencil)-oxalamida |
| 238 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(3-trifluorometoxi-bencil)-oxalamida |
| 239 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(2-metoxi-bencil)-oxalamida |

| Entrada | Nombre |
|---|---|
| 240 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-trifluorometil-bencil)-oxalamida |
| 241 | *N*-(3-Cloro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 242 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-trifluorometoxi-bencil)-oxalamida |
| 243 | *N*-(2-Cloro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 244 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(4-trifluorometoxi-bencil)-oxalamida |
| 245 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(4-metoxi-bencil)-oxalamida |
| 246 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(4-trifluorometil-bencil)-oxalamida |
| 247 | *N*-{4-[7-(Azetidin-3-ilmetoxi)-6-metoxi-quinolin-4-iloxi]-3-fluoro-fenil}-*N*'-fenetil-oxalamida |
| 248 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-azetidin-3-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-fenetil-oxalamida |
| 249 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-hidroxi-2-fenilo-etil)-oxalamida |
| 250 | *N*-[5-Cloro-6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-il]-*N*'-(2,4-difluoro-fenil)-malonamida |

| Entrada | Nombre |
|---|---|
| 251 | *N*-[5-Cloro-6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-il]-*N*'-(4-fluoro-fenil)-*N*'-metil-malonamida |
| 252 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1R-fenilo-propil)-oxalamida |
| 253 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(1R-fenilo-propil)-oxalamida |
| 254 | *N*-(3,4-Difluoro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 255 | *N*-(2,6-Difluoro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 256 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-[2-(4-fluoro-fenil)-etil]-oxalamida |
| 257 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-fenil-oxalamida |
| 258 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(3-fluoro-fenil)-oxalamida |
| 259 | *N*-(4-Cloro-3-fluoro-fenil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 260 | *N*-(3,4-Dimetoxi-fenil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 261 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)- |

| Entrada | Nombre |
|---|---|
| | quinolin-4-iloxi]-fenil}-*N*'-(3-metil-butil)-oxalamida |
| 262 | *N*-(3,3-Dimetil-butil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 263 | *N*-{5-Cloro-6-[6-metoxi-7-(3-piperidin-1-il-propoxi)-quinolin-4-iloxi]-piridin-3-il}-*N*'-(4-fluoro-fenil)-malonamida |
| 264 | *N*-{5-Cloro-6-[6-metoxi-7-(3-morfolin-4-il-propoxi)-quinolin-4-iloxi]-piridin-3-il}-*N*'-(4-fluoro-fenil)-malonamida |
| 265 | *N*-{5-Cloro-6-[7-(3-dietilamino-propoxi)-6-metoxi-quinolin-4-iloxi]-piridin-3-il}-*N*'-(4-fluoro-fenil)-malonamida |
| 266 | *N*-(4-Cloro-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 267 | *N*-(3,5-Dimetoxi-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 268 | *N*-(4-Butil-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 269 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-p-tolil-etil)-oxalamida |
| 270 | *N*-(3,5-Bis-trifluorometil-bencil)-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 271 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-pirazin-2-ilmetil- |

| Entrada | Nombre |
|---|---|
| | oxalamida |
| 272 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-piridin-2-ilmetil-oxalamida |
| 273 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinazolin-4-iloxi]-fenil}-*N'*-fenetil-oxalamida |
| 274 | *N*-{3-Fluoro-4-[6-metoxi-7-(1-metil-piperidin-4-ilmetoxi)-quinazolin-4-iloxi]-fenil}-*N'*-fenetil-oxalamida |
| 275 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(2-fluoro-3-trifluorometil-bencil)-oxalamida |
| 276 | *N*-[2-(2-Bromo-6-metoxi-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 277 | *N*-[2-(3,4-Dimetoxi-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*-metil-oxalamida |
| 278 | *N*-[2-(5-Bromo-2-metoxi-fenil)-etil]-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 279 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-(2-fluoro-5-trifluorometil-bencil)-oxalamida |
| 280 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N'*-[1-(4-fluoro-fenil)-etil]-oxalamida |
| 281 | *N*-(1S-Bencil-2-oxo-2-pirrolidin-1-il-etil)-*N'*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 282 | *N*-{3-Fluoro-4-[6-metoxi-7-(octahidro- |

| Entrada | Nombre |
|---|---|
| | ciclopenta[c]pirrol-5-ilmetoxi)-quinazolin-4-iloxi]-fenil}-*N*'-fenetil-oxalamida |
| 283 | *N*-[2-(4-Amino-fenil)-etil]-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 284 | 2-(4-Bencil-piperidin-1-il)-*N*-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-2-oxo-acetamida |
| 285 | *N*-[4-(6,7-Dimetoxi-quinolin-4-iloxi)-fenil]-*N*'-(4-fluoro-fenil)-malonamida |
| 286 | *N*-[5-Cloro-6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-il]-*N*'-(3-fluoro-fenil)-malonamida |
| 287 | *N*-[5-Cloro-6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-il]-*N*'-fenilo-malonamida |
| 288 | *N*-[5-Cloro-6-(6,7-dimetoxi-quinolin-4-iloxi)-piridin-3-il]-*N*'-(4-fluoro-fenil)-2,2-dimetil-malonamida |
| 289 | *N*-Etil-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 290 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-isopropil-oxalamida |
| 291 | *N*-Butil-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 292 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-metoxi-etil)-oxalamida |
| 293 | *N*-Ciclopropilmetil-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-oxalamida |
| 294 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*'-(2-morfolin-4-il- |

| Entrada | Nombre |
|---|---|
| | etil)-oxalamida |
| 295 | *N*-{3-Fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-2-oxo-2-pirrolidin-1-il-acetamida |
| 296 | *N*-Etil-*N*'-{3-fluoro-4-[6-metoxi-7-(piperidin-4-ilmetoxi)-quinolin-4-iloxi]-fenil}-*N*-metil-oxalamida |

**Tabla 3c.**

**Inhibidores representativos adicionales de c-MET, c-KIT, y/o Flt-3**

**[00230]** Los Compuestos de la Tabla 3c se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 3c se pueden usar para practicar la la invención.

| Entrada | Nombre |
|---|---|
| 1 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 2 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 3 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(fenilmetil)ciclopropano-1,1-dicarboxamida |
| 4 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-fenilciclopropano-1,1-dicarboxamida |

| Entrada | Nombre |
|---|---|
| 5 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 6 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-piperidin-1-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 7 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-piperidin-1-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 8 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloropiridin-3-il)-*N*'-(2-feniletil)ciclopropano-1,1-dicarboxamida |
| 9 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-2-metilpiridin-3-il)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 10 | *N*-{4-[(7-cloroquinolin-4-il)oxi]-3-fluorofenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 11 | *N*-{4-[(7-cloroquinolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 12 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 13 | *N*-(4-{[6,7-bis(metiloxi)quinazolin-4-il]oxi}fenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 14 | *N*-(4-{[6,7-bis(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 15 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 16 | *N*-{5-cloro-6-[(6-(metiloxi)-7-{[(1-metilpiperidin-4- |

| Entrada | Nombre |
|---|---|
| | il)metil]oxi}quinolin-4-il)oxi]piridin-3-il}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 17 | *N*-[5-cloro-6-({6-(metiloxi)-7-[(piperidin-4-ilmetil)oxi]quinolin-4-il}oxi)piridin-3-il]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 18 | *N*-[5-cloro-6-({6-(metiloxi)-7-[(fenilmetil)oxi]quinolin-4-il}oxi)piridin-3-il]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 19 | *N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 20 | *N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 21 | *N*-{3-fluoro-4-[(6-(metiloxi)-7-{[(1-metilpiperidin-4-il)metil]oxi}quinazolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 22 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-2-metilfenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 23 | *N*-(4-fluorofenil)-*N*'-[2-metil-6-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)piridin-3-il]ciclopropano-1,1-dicarboxamida |
| 24 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 25 | *N*-(6-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-cloro-2-metilpiridin-3-il)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 26 | *N*-[3-fluoro-4-({7-(metiloxi)-6-[(3-morfolin-4- |

| Entrada | Nombre |
|---|---|
| | ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 27 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-3,5-difluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 28 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-2,5-difluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 29 | *N*-[3-fluoro-4-({7-(metiloxi)-6-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 30 | *N*-{3-fluoro-4-[(6-(metiloxi)-7-(2-metil octahidrociclo-penta[c]pirrol-5-ilmetoxi)quinazolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 31 | *N*-{3-fluoro-4-[(7-(metiloxi)-6-{[(1-metilpiperidin-4-il)metil]oxi}quinazolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 32 | *N*-[5-fluoro-2-metil-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 33 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-2,3,5-trifluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 34 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-5-fluoro-2-metilfenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 35 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-2-cloro-5-metilfenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |

| Entrada | Nombre |
|---|---|
| 36 | *N*-(3-fluoro-4-{[6-hidroxi-7-(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 37 | *N*-(4-fluorofenil)-*N*'-[2-metil-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]ciclopropano-1,1-dicarboxamida |
| 38 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-piperazin-1-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 39 | *N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 40 | *N*-{3-fluoro-4-[(6-(metiloxi)-7-{[(1-metilpiperidin-4-il)metil]oxi}quinolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 41 | *N*-(4-fluorofenil)-*N*'-[4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]ciclopropano-1,1-dicarboxamida |
| 42 | *N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 43 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}-2-cloro-5-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 44 | *N*-(4-{[6,7-bis(metiloxi)-2-(metiltio)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 45 | *N*-(4-fluorofenil)-*N*'-(4-{[2-metil-6,7-bis(metiloxi)quinazolin-4-il]oxi}fenil)ciclopropano-1,1-dicarboxamida |

| Entrada | Nombre |
|---|---|
| 46 | *N*-(4-{[2-amino-6,7-bis(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 47 | *N*-(3-fluoro-4-{[2-(metilamino)-6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 48 | (1S,2R)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 49 | (1R,2R)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 50 | *N*-(4-{[6-{[3-(dietilamino)propil]oxi}-7-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 51 | *N*-(4-{[6-{[2-(dietilamino)etil]oxi}-7-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 52 | 4-(3-{[4-[(2-fluoro-4-{[(1-{[(4-fluorofenil)amino]carbonil}ciclopropil)carbonil]amino}fenil)oxi]-6-(metiloxi)quinolin-7-il]oxi}propil)piperazino-1-carboxilato de 1,1-dimetiletilo |
| 53 | (1R,2R)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 54 | (1R,2R)-*N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 55 | *N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6- |

| Entrada | Nombre |
|---|---|
| | (metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 56 | *N*-(4-{[7-{[3-(4-acetilpiperazin-1-il)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 57 | 4-(3-{[4-[(2-fluoro-4-{[((1R,2R)-1-{[(4-fluorofenil)amino]carbonil}-2-metilciclopropil)carbonil]amino}fenil)oxi]-6-(metiloxi)quinolin-7-il]oxi}propil)piperazino-1-carboxilato de 1,1-dimetiletilo |
| 58 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-(4-fluorofenil)-1-(fenilmetil)azetidin-3,3-dicarboxamida |
| 59 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-(4-fluorofenil)azetidin-3,3-dicarboxamida |
| 60 | (1R,2S)-*N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 61 | (1R,2R)-*N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 62 | (1R,2R)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-piperazin-1-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 63 | *N*-(3-fluoro-4-{[7-({3-[4-(1-metiletil)piperazin-1-il]propil}oxi)-6-(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 64 | *N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6- |

| Entrada | Nombre |
|---|---|
| | (metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida |
| 65 | (1R,2R)-*N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 66 | (1R,2R)-*N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 67 | (1R,2S)-*N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 68 | (1R,2S)-*N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 69 | *N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 70 | (1R,2S)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-piperazin-1-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 71 | (1R,2R,3S)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 72 | (1R,2R,3S)-*N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 73 | (1R,2R,3S)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinazolin-4-il}oxi)fenil]- |

| Entrada | Nombre |
|---|---|
| | *N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 74 | (1R,2R,3S)-*N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinazolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 75 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 76 | (2R,3R)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 77 | (2R,3R)-*N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 78 | *N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,2-dimetilciclopropano-1,1-dicarboxamida |
| 79 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2,2-dimetilciclopropano-1,1-dicarboxamida |
| 80 | (1R,2R,3S)-*N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |

| Entrada | Nombre |
|---|---|
| 81 | *N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,2-dimetilciclopropano-1,1-dicarboxamida |
| 82 | (1R,2R,3S)-*N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 83 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2,2-dimetilciclopropano-1,1-dicarboxamida |
| 84 | *N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,2-dimetilciclopropano-1,1-dicarboxamida |
| 85 | *N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,2-dimetilciclopropano-1,1-dicarboxamida |
| 86 | *N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 87 | *N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinazolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 88 | *N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-piperazin-1-ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 89 | (2R,3R)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin- |

| Entrada | Nombre |
|---|---|
| | 4-ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 90 | *N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 91 | *N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)ciclobutano-1,1-dicarboxamida |
| 92 | (1R,2R)-*N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 93 | (1R,2R)-*N*-{3-fluoro-4-[(6-(metiloxi)-7-{[3-(4-metilpiperazin-1-il)propil]oxi}quinazolin-4-il)oxi]fenil}-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 94 | (2R,3R)-*N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 95 | (2R,3R)-*N*-(4-{[7-{[3-(dietilamino)propil]oxi}-6-(metiloxi)quinazolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1-dicarboxamida |
| 96 | (1R,2R)-*N*-[3-fluoro-4-({6-(metiloxi)-7-[(3-piperazin-1-ilpropil)oxi]quinazolin-4-il}oxi)fenil]-*N*'-(4-fluorofenil)-2-metilciclopropano-1,1-dicarboxamida |
| 97 | (2R,3R)-*N*-(4-{[7-{[2-(dietilamino)etil]oxi}-6-(metiloxi)quinolin-4-il]oxi}-3-fluorofenil)-*N*'-(4-fluorofenil)-2,3-dimetilciclopropano-1,1- |

| Entrada | Nombre |
|---|---|
| | dicarboxamida |
| 98 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-[(4-fluorofenil)metil]ciclopropano-1,1-dicarboxamida |
| 99 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-(2-morfolin-4-iletil)ciclopropano-1,1-dicarboxamida |
| 100 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-[2-(piperidin-1-ilmetil)fenil]ciclopropano-1,1-dicarboxamida |
| 101 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-[2-(pirrolidin-1-ilmetil)fenil]ciclopropano-1,1-dicarboxamida |
| 102 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-[3-(morfolin-4-ilmetil)fenil]ciclopropano-1,1-dicarboxamida |
| 103 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-[2-(morfolin-4-ilmetil)fenil]ciclopropano-1,1-dicarboxamida |
| 104 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-fenilciclopropano-1,1-dicarboxamida |
| 105 | *N*-[3-(aminometil)fenil]-*N*'-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)ciclopropano-1,1-dicarboxamida |
| 106 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-[3-(piperidin-1-ilmetil)fenil]ciclopropano-1,1-dicarboxamida |
| 107 | *N*-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-*N*'-[3-(pirrolidin-1-ilmetil)fenil]ciclopropano-1,1-dicarboxamida |

**Tabla 4.**

**Inhibidores representativos de EGFR, ErbB2 y/o VEGFR**

**[00231]** Los Compuestos de la Tabla 4 se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 4 se pueden usar para practicar la invención. En particular, la invención se puede practicar con una o dos sales farmacéuticamente aceptables de un Compuesto de Tabla 4, dichas sales se forman con uno o dos ácidos seleccionados de modo independiente de ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido nítrico, ácido fosfórico, ácido acético, ácido trifluoroacético, ácido propiónico, ácido hexanoico, ácido ciclopentanopropiónico, ácido glicólico, ácido pirúvico, ácido láctico, ácido oxálico, ácido maleico, ácido malónico, ácido succínico, ácido fumárico, ácido tartárico, ácido cítrico, ácido benzoico, ácido cinámico, ácido 3-(4-hidroxibenzoil)benzoico, ácido mandélico, ácido metansulfónico, ácido etansulfónico, ácido 1,2-etandisulfónico, ácido 2-hidroxietansulfónico, ácido bencensulfónico, ácido 4-clorobencensulfónico, ácido 2-naftalenosulfónico, ácido 4-toluensulfónico, ácido canforsulfónico, ácido glucoheptónico, ácido 4,4'-metilenbis-(3-hidroxi-2-ene-1-carboxílico), ácido 3-fenilpropiónico, ácido trimetilacético, ácido ter-butilacético, ácido lauril sulfúrico, ácido glucónico, ácido glutámico, ácido hidroxinaftoico, ácido salicílico, ácido esteárico, ácido mucónico ácido p-toluensulfónico y ácido salicílico.

| Entrada | Nombre |
|---|---|
| 1 | *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-(1-metiletil)octahidrociclopenta[c]pirrol-5-il]metil}oxi)- |

| Entrada | Nombre |
|---|---|
| | 6-(metiloxi)quinazolin-4-amina |
| 2 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-(1-metiletil)octahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 3 | 7-({[(3a*R*,5r,6a*S*)-2-acetiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-*N*-(4-bromo-3-cloro-2-fluorofenil)-6-(metiloxi)quinazolin-4-amina |
| 4 | *N*-(4-bromo-3-cloro-2-fluorofenil)-6-(metiloxi)-7-{[(3a*R*,5r,6a*S*)-octahidrociclopenta[c]pirrol-5-ilmetil]oxi}quinazolin-4-amina |
| 5 | (3a*R*,6a*S*)-5-({[4-[(4-bromo-3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)hexahidrociclopenta[c]pirrol-2(1*H*)-carboxilato de etilo |
| 6 | *N*-(4-bromo-3-cloro-2-fluorofenil)-6-(metiloxi)-7-({[(3a*R*,5r,6a*S*)-2-(metilsulfonil)octahidrociclopenta[c]pirrol-5-il]metil}oxi)quinazolin-4-amina |
| 7 | *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-etiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 8 | *N*-(3,4-dicloro-2-fluorofenil)-6-(metiloxi)-7-({[(3a*R*,5r,6a*S*)-2-(2-metilpropil)octahidrociclopenta[c]pirrol-5-il]metil}oxi)quinazolin-4-amina |
| 9 | *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 10 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 11 | *N*-(3-cloro-2,4-difluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6- |

| Entrada | Nombre |
|---|---|
| | (metiloxi)quinazolin-4-amina |
| 12 | *N*-(4,5-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 13 | *N*-(4-bromo-5-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 14 | *N*-(4-bromo-2,3-diclorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 15 | *N*-(3,4-diclorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 16 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-etiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 17 | *N*-(4-bromo-3-cloro-2-fluorofenil)-6-(metiloxi)-7-({[(3a*R*,5r,6a*S*)-2-(2-metilpropil)octahidrociclopenta[c]pirrol-5-il]metil}oxi)quinazolin-4-amina |
| 18 | *N*-(4-bromo-2,3-diclorofenil)-7-{[(3*R*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 19 | *N*-(4,5-dicloro-2-fluorofenil)-7-{[(3*R*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 20 | *N*-(4-bromo-5-cloro-2-fluorofenil)-7-{[(3*R*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 21 | *N*-(3-cloro-2,4-difluorofenil)-7-{[(3*R*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 22 | *N*-(3,4-dicloro-2-fluorofenil)-7-{[(3*S*,9a*S*)-hexahidro- |

| Entrada | Nombre |
|---|---|
| | 1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 23 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-{[(3*S*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 24 | *N*-(3-cloro-2,4-difluorofenil)-7-{[(3*S*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 25 | *N*-(3,4-diclorofenil)-7-[(hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 26 | *N*-(4,5-dicloro-2-fluorofenil)-7-{[(3*S*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 27 | *N*-(4-bromo-2,3-diclorofenil)-7-{[(3*S*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 28 | *N*-(4-bromo-5-cloro-2-fluorofenil)-7-{[(3*S*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 29 | *N*-(3,4-dicloro-2-fluorofenil)-7-{[(3*R*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 30 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-{[(3*R*,9a*S*)-hexahidro-1*H*-[1,4]oxazino[3,4-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 31 | *N*-(3,4-diclorofenil)-7-{[(3*R*,8a*R*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 32 | *N*-(4-bromo-5-cloro-2-fluorofenil)-7-{[(3*S*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 33 | *N*-(3,4-diclorofenil)-7-{[(3*S*,8a*R*)-hexahidro-1*H*- |

| Entrada | Nombre |
|---|---|
| | pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 34 | *N*-(3,4-diclorofenil)-7-{[(3*S*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 35 | *N*-(3,4-diclorofenil)-7-{[(3*R*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 36 | *N*-(3,4-dicloro-2-fluorofenil)-7-{[(3*S*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 37 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-{[(3*S*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 38 | *N*-(3-cloro-2,4-difluorofenil)-7-{[(3*S*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 39 | *N*-(4-bromo-2,3-diclorofenil)-7-{[(3*S*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 40 | *N*-(4,5-dicloro-2-fluorofenil)-7-{[(3*S*,8a*S*)-hexahidro-1*H*-pirrolo[2,1-c][1,4]oxazin-3-ilmetil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 41 | 1,4:3,6-dianhidro-5-({[4-[(4-bromo-5-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-5-deoxi-2-O-metil-D-xilo-hexitol |
| 42 | 1,4:3,6-dianhidro-5-deoxi-5-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-2-O-metil-D-glucitol |
| 43 | 1,4:3,6-dianhidro-5-deoxi-5-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-2-O-metil-D-xilo-hexitol |

| Entrada | Nombre |
|---|---|
| 44 | 1,4:3,6-dianhidro-5-({[4-[(4-bromo-3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-5-deoxi-2-O-metil-D-xilo-hexitol |
| 45 | 1,4:3,6-dianhidro-5-({[4-[(3-cloro-2,4-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-5-deoxi-2-O-metil-D-xilo-hexitol |
| 46 | 1,4:3,6-dianhidro-5-({[4-[(4-bromo-2,3-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-5-deoxi-2-O-metil-D-glucitol |
| 47 | 1,4:3,6-dianhidro-2-deoxi-2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-5-O-metil-D-treo-hexitol |
| 48 | 1,4:3,6-dianhidro-5-deoxi-5-({[4-[(4,5-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-2-O-metil-D-glucitol |
| 49 | (3*S*,9a*S*)-3-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)hexahidro-2*H*-pirido[1,2-a]pirazin-1(6*H*)-ona |
| 50 | (3*S*,9a*R*)-3-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)hexahidro-2*H*-pirido[1,2-a]pirazin-1(6*H*)-ona |
| 51 | (3*S*,8a*S*)-3-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)hexahidropirrolo[1,2-a]pirazin-1(2*H*)-ona |
| 52 | (3*S*,8a*R*)-3-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)hexahidropirrolo[1,2-a]pirazin-1(2*H*)-ona |
| 53 | (3*S*,8a*S*)-3-({[4-[(4-bromo-3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)hexahidropirrolo[1,2-a]pirazin-1(2*H*)-ona |
| 54 | (3*S*,8a*S*)-3-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-2-metilhexahidropirrolo[1,2-a]pirazin-1(2*H*)-ona |

| Entrada | Nombre |
|---|---|
| 55 | *N*-(3,4-diclorofenil)-7-({2-[(8-metil-8-azabiciclo[3,2,1]oct-3-il)amino]etil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 56 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(8a*R*)-tetrahidro-1*H*-[1,3]tiazolo[4,3-c][1,4]oxazin-6-ilmetil]oxi}quinazolin-4-amina |
| 57 | *N*-(3,4-diclorofenil)-7-{[2-(8-metil-8-azabiciclo[3,2,1]oct-3-il)etil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 58 | *N*-(3,4-diclorofenil)-7-{[(8-metil-8-azabiciclo[3,2,1]oct-3-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 59 | *N*-(3,4-diclorofenil)-7-{[(3a*R*,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]oxi}-6-(metiloxi)quinazolin-4-amina |
| 60 | *N*-(3,4-diclorofenil)-7-[(8-metil-8-azabiciclo[3,2,1]oct-3-il)oxi]-6-(metiloxi)quinazolin-4-amina |
| 61 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-5-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 62 | 1,4:3,6-dianhidro-2-O-[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 63 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 64 | 1,4:3,6-dianhidro-2-O-metil-5-O-{6-(metiloxi)-4-[(2,3,4-triclorofenil)amino]quinazolin-7-il}-L-iditol |
| 65 | 1,4:3,6-dianhidro-5-O-[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-O-metil-D-xilo-hexitol |
| 66 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-2,3-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O- |

| Entrada | Nombre |
|---|---|
| | metil-L-iditol |
| 67 | 1,4:3,6-dianhidro-5-*O*-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-L-sorbose etilene glicol acetal |
| 68 | 1,4:3,6-dianhidro-2-O-[4-[(3-cloro-2,4-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 69 | 1,4:3,6-dianhidro-2-O-[4-[(4,5-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 70 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-(difluorometil)-L-iditol |
| 71 | 1,4:3,6-dianhidro-2-O-[4-[(3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 72 | 1,4:3,6-dianhidro-2-O-[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 73 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 74 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-etil-L-iditol |
| 75 | 1,4:3,6-dianhidro-2-O-[4-[(3-bromo-2-metilfenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 76 | 1,4:3,6-dianhidro-2-O-[4-[(3-cloro-2-metilfenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-L-iditol |
| 77 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-deoxi-D-xilo-hexitol |
| 78 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-D-glucitol |
| 79 | metil 3,6-anhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-O-metil-alfa-L-idofuranoside |

| Entrada | Nombre |
|---|---|
| 80 | 3,6-anhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-1,2-O-(1-metiletiliden)-beta-L-xilo-hexofuranose |
| 81 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-deoxi-5-metiliden-D-xilo-hexitol |
| 82 | metil 3,6-anhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-O-metil-beta-L-idofuranósido |
| 83 | *N*-(3,4-dicloro-2-fluorofenil)-6-(metiloxi)-7-[(octahidro-2*H*-quinolizin-3-ilmetil)oxi]quinazolin-4-amina |
| 84 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-{6-(metiloxi)-4-[(2,3,4-trifluorofenil)amino]quinazolin-7-il}-D-iditol |
| 85 | 1,4:3,6-dianhidro-5-O-[4-[(2-cloro-4-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 86 | 1,4:3,6-dianhidro-5-O-[4-[(2-bromo-4-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 87 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(2,6-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 88 | 1,4:3,6-dianhidro-5-O-[4-[(3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 89 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-[4-{[4-fluoro-3-(trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-D-iditol |
| 90 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(2,4-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 91 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(2,5- |

| Entrada | Nombre |
|---|---|
| | diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 104 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-cloro-5-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 105 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(4,5-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 106 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-{6-(metiloxi)-4-[(2,3,4-triclorofenil)amino]quinazolin-7-il}-D-iditol |
| 107 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-{6-(metiloxi)-4-[(3,4,5-triclorofenil)amino]quinazolin-7-il}-D-iditol |
| 108 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 109 | 1,4:3,6-dianhidro-5-O-[4-[(4-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 110 | 1,4:3,6-dianhidro-5-O-[4-[(3-cloro-2-metilfenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 111 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(3,4-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 112 | 1,4:3,6-dianhidro-5-O-[4-[(2-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 113 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-[4-[(2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-D-iditol |
| 114 | 1,4:3,6-dianhidro-5-O-[4-[(3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 115 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-[4-[(4-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-D-iditol |

| Entrada | Nombre |
|---|---|
| | difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 92 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(2,3-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 93 | 1,4:3,6-dianhidro-5-O-[4-[(5-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 94 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(3,5-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 95 | 1,4:3,6-dianhidro-5-O-[4-[(3-cloro-4-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 96 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-2-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 97 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 98 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-5-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 99 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-{6-(metiloxi)-4-[(2,4,5-trifluorofenil)amino]quinazolin-7-il}-D-iditol |
| 100 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-{6-(metiloxi)-4-[(2,4,6-trifluorofenil)amino]quinazolin-7-il}-D-iditol |
| 101 | 1,4:3,6-dianhidro-5-O-[4-({4-[(4-clorofenil)oxi]-3,5-difluorofenil}amino)-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 102 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 103 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-2,3- |

| Entrada | Nombre |
|---|---|
| 116 | 1,4:3,6-dianhidro-5-O-[4-[(4-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 117 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(2,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 118 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(2,5-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 119 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 120 | 1,4:3,6-dianhidro-5-O-[4-[(2-bromo-4,6-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 121 | 1,4:3,6-dianhidro-5-O-[4-{[4-cloro-3-(trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 122 | 1,4:3,6-dianhidro-5-O-[4-{[2-cloro-5-(trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 123 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-[4-{[2-fluoro-3-(trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-D-iditol |
| 124 | 1,4:3,6-dianhidro-5-O-[4-{[2-bromo-5-(trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 125 | 1,4:3,6-dianhidro-5-O-[4-{[2-bromo-4-(trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 126 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-[4-{[4-fluoro-2-(trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-D-iditol |
| 127 | 1,4:3,6-dianhidro-5-O-[4-{[3-bromo-5- |

| Entrada | Nombre |
|---|---|
| | (trifluorometil)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 128 | 1,4:3,6-dianhidro-5-O-[4-[(2-bromofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 129 | 1,4:3,6-dianhidro-5-O-[4-[(3-bromofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 130 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 131 | 1,4:3,6-dianhidro-5-O-[4-[(3-bromo-4-metilfenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 132 | 1,4:3,6-dianhidro-5-O-[4-[(5-cloro-2-metilfenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 133 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-[(3,5-dimetilfenil)amino]-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 134 | 1,4:3,6-dianhidro-5-O-[4-{[2,5-bis(metiloxi)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 135 | 1,4:3,6-dianhidro-5-O-[4-{[5-cloro-2,4-bis(metiloxi)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 136 | 1,4:3,6-dianhidro-5-O-[4-{[4-cloro-2,5-bis(metiloxi)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 137 | 1,4:3,6-dianhidro-5-O-[4-[(3-cloro-2,4-difluorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-fluoro-D-iditol |
| 138 | *N*-(3,4-diclorofenil)-7-[({5-[(dimetilamino)metil]-1,2,4-oxadiazol-3-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 139 | *N*-(3,4-diclorofenil)-7-[({3-[(dimetilamino)metil]-1,2,4-oxadiazol-5-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 140 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({3-[(4-metilpiperazin-1-il)metil]-1,2,4-oxadiazol-5-il}metil)oxi]quinazolin-4-amina |
| 141 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5-piperidin-4-il-1,2,4-oxadiazol-3-il)metil]oxi}quinazolin-4-amina |
| 142 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[5-(1-metilpiperidin-4-il)-1,2,4-oxadiazol-3-il]metil}oxi)quinazolin-4-amina |
| 143 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[3-(morfolin-4-ilmetil)-1,2,4-oxadiazol-5-il]metil}oxi)quinazolin-4-amina |
| 144 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(morfolin-2-ilmetil)oxi]quinazolin-4-amina |
| 145 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5-piperidin-2-il-1,2,4-oxadiazol-3-il)metil]oxi}quinazolin-4-amina |
| 146 | *N*-(3,4-diclorofenil)-7-[({2-[(dimetilamino)metil]-1,3-tiazol-4-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 147 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(fenilmetil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 148 | 1,1-dimetiletil 2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolino-4-carboxilate |
| 149 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[2-(morfolin-4-ilmetil)-1,3-tiazol-4-il]metil}oxi)quinazolin-4-amina |
| 150 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({2-[(4-metilpiperazin-1-il)metil]-1,3-tiazol-4-il}metil)oxi]quinazolin-4-amina |
| 151 | *N*-(3,4-diclorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 152 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(1,4-oxazepan-2-ilmetil)oxi]quinazolin-4-amina |
| 153 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5-piperidin-3-il-1,2,4-oxadiazol-3-il)metil]oxi}quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 154 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[5-(1-metilpiperidin-2-il)-1,2,4-oxadiazol-3-il]metil}oxi)quinazolin-4-amina |
| 155 | *N*-(3,4-diclorofenil)-7-{[(4-metil-1,4-oxazepan-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 156 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[5-(1-metilpiperidin-3-il)-1,2,4-oxadiazol-3-il]metil}oxi)quinazolin-4-amina |
| 157 | *N*-(3,4-diclorofenil)-7-({[5-(1,1-dimetiletil)-1,2,4-oxadiazol-3-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 158 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2-fenilo-1,3-tiazol-4-il)metil]oxi}quinazolin-4-amina |
| 159 | 7-[(2,1,3-benzotiadiazol-4-ilmetil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 160 | *N*-(3,4-diclorofenil)-7-{[(5-metilisoxazol-3-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 161 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5-metil-4-fenilisoxazol-3-il)metil]oxi}quinazolin-4-amina |
| 162 | 7-[(1,3-benzotiazol-2-ilmetil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 163 | 7-[(2,1,3-benzoxadiazol-5-ilmetil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 164 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[2-(2-tienil)-1,3-tiazol-4-il]metil}oxi)quinazolin-4-amina |
| 165 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(1-fenilo-1*H*-pirazol-4-il)metil]oxi}quinazolin-4-amina |
| 166 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({5-[3-(trifluorometil)fenil]-1,2,4-oxadiazol-3-il}metil)oxi]quinazolin-4-amina |
| 167 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({5-[4-(trifluorometil)fenil]-1,2,4-oxadiazol-3-il}metil)oxi]quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 168 | 7-({[3-(4-clorofenil)-1,2,4-oxadiazol-5-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 169 | 7-({[6-bromo-2-(metiloxi)naftalen-1-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 170 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(1,3-tiazol-4-ilmetil)oxi]quinazolin-4-amina |
| 171 | 7-{[(6-cloropiridin-3-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 172 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(piridin-4-ilmetil)oxi]quinazolin-4-amina |
| 173 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2-metil-1,3-tiazol-4-il)metil]oxi}quinazolin-4-amina |
| 174 | 7-{[(6-cloro-4*H*-1,3-benzodioxin-8-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 175 | 7-{[(5-cloro-1-metil-3-fenilo-1*H*-pirazol-4-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 176 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[1-metil-3-(trifluorometil)-1*H*-tieno[2,3-c]pirazol-5-il]metil}oxi)quinazolin-4-amina |
| 177 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(3-fenilisoxazol-5-il)metil]oxi}quinazolin-4-amina |
| 178 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2,4,6-trimetilfenil)metil]oxi}quinazolin-4-amina |
| 179 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(piridin-3-ilmetil)oxi]quinazolin-4-amina |
| 180 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({3-[4-(metiloxi)fenil]isoxazol-5-il}metil)oxi]quinazolin-4-amina |
| 181 | *N*-(3,4-diclorofenil)-7-({[5-[(2,4-diclorofenil)oxi]-1-metil-3-(trifluorometil)-1*H*-pirazol-4-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 182 | 7-[(ciclopropilmetil)oxi]-*N*-(3,4-diclorofenil)-6- |

| Entrada | Nombre |
|---|---|
| | (metiloxi)quinazolin-4-amina |
| 183 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(tetrahidrofuran-2-ilmetil)oxi]quinazolin-4-amina |
| 184 | 7-(ciclopentiloxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 185 | 7-[(2-ciclohexiletil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 186 | 7-[(ciclohexilmetil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 187 | 7-[(ciclobutilmetil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 188 | *N*-(3,4-diclorofenil)-7-{[2-(1,3-dioxolan-2-il)etil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 189 | *N*-(3,4-diclorofenil)-7-{[2-(1,3-dioxan-2-il)etil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 190 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(2-morfolin-4-iletil)oxi]quinazolin-4-amina |
| 191 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(2-pirrolidin-1-iletil)oxi]quinazolin-4-amina |
| 192 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(2-piperidin-1-iletil)oxi]quinazolin-4-amina |
| 193 | 2-(2-{[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}etil)-1*H*-isoindole-1,3(2*H*)-diona |
| 194 | metil 6-O-[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-alfa-D-glucopiranósido |
| 195 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(2-morfolin-4-il-2-oxoetil)oxi]quinazolin-4-amina |
| 196 | 2-[3-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,2,4-oxadiazol-5-il]piperidino-1-carboxilato de 1,1-dimetiletilo |
| 197 | 4-[3-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,2,4-oxadiazol-5- |

| Entrada | Nombre |
|---|---|
| | il]piperidino-1-carboxilato de 1,1-dimetiletilo |
| 198 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(4-pirrolidin-1-ilfenil)-1,3-tiazol-2-il]metil}oxi)quinazolin-4-amina |
| 199 | *N*-(3,4-diclorofenil)-7-[({4-[4-(dietilamino)fenil]-1,3-tiazol-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 200 | 5-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,3-tiazol-4-il]-2-hidroxibenzamida |
| 201 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-piridin-3-il-1,3-tiazol-2-il)metil]oxi}quinazolin-4-amina |
| 202 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-piridin-2-il-1,3-tiazol-2-il)metil]oxi}quinazolin-4-amina |
| 203 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-piridin-4-il-1,3-tiazol-2-il)metil]oxi}quinazolin-4-amina |
| 204 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2-morfolin-4-il-1,3-tiazol-4-il)metil]oxi}quinazolin-4-amina |
| 205 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(3-morfolin-4-il-1,2,4-oxadiazol-5-il)metil]oxi}quinazolin-4-amina |
| 206 | *N*-(3,4-diclorofenil)-7-({[3-(dimetilamino)-1,2,4-oxadiazol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 207 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({4-[(4-metilpiperazin-1-il)metil]-1,3-tiazol-2-il}metil)oxi]quinazolin-4-amina |
| 208 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[(4,5,6,7-tetrahidro[1,3]tiazolo[5,4-c]piridin-2-ilmetil)oxi]quinazolin-4-amina |
| 209 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(morfolin-4-ilmetil)-1,3-tiazol-2-il]metil}oxi)quinazolin-4-amina |
| 210 | *N*-(3,4-diclorofenil)-7-[({4-[(4-metil-1,4-diazepan-1-il)metil]-1,3-tiazol-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 211 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5- |

| Entrada | Nombre |
|---|---|
| | {[(fenilmetil)oxi]metil}-1,2,4-oxadiazol-3-il)metil]oxi}quinazolin-4-amina |
| 212 | *N*-(3,4-diclorofenil)-7-{[(4-etilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 213 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2-piperidin-4-il-1,3-tiazol-4-il)metil]oxi}quinazolin-4-amina |
| 214 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[2-(1-metilpiperidin-4-il)-1,3-tiazol-4-il]metil}oxi)quinazolin-4-amina |
| 215 | 4-[5-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,2,4-oxadiazol-3-il]piperazino-1-carboxilato de 1,1-dimetiletilo |
| 217 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(3-piperazin-1-il-1,2,4-oxadiazol-5-il)metil]oxi}quinazolin-4-amina |
| 218 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[3-(4-metilpiperazin-1-il)-1,2,4-oxadiazol-5-il]metil}oxi)quinazolin-4-amina |
| 219 | *N*-(3,4-diclorofenil)-7-({[5-(1-etilpiperidin-2-il)-1,2,4-oxadiazol-3-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 220 | *N*-(3,4-diclorofenil)-7-({[3-(4-etilpiperazin-1-il)-1,2,4-oxadiazol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 221 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({5-[4-(metiloxi)fenil]-1,2,4-oxadiazol-3-il}metil)oxi]quinazolin-4-amina |
| 222 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({2-[4-(trifluorometil)fenil]-1,3-tiazol-4-il}metil)oxi]quinazolin-4-amina |
| 223 | 7-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 224 | *N*-(3,4-diclorofenil)-7-({[5-(3,5-dimetilisoxazol-4-il)-1,2,4-oxadiazol-3-il]metil}oxi)-6-(metiloxi)quinazolin- |

| Entrada | Nombre |
|---|---|
| | 4-amina |
| 225 | 7-{[(5-cloro-1-benzotien-3-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 226 | *N*-(3,4-diclorofenil)-7-[({3-[4-(1,1-dimetiletil)fenil]-1,2,4-oxadiazol-5-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 227 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({5-[2-(metiloxi)fenil]-1,2,4-oxadiazol-3-il}metil)oxi]quinazolin-4-amina |
| 228 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[5-(4-metilfenil)-1,3,4-oxadiazol-2-il]metil}oxi)quinazolin-4-amina |
| 229 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[1-(fenilmetil)-1*H*-imidazol-2-il]metil}oxi)quinazolin-4-amina |
| 230 | *N*-(3,4-diclorofenil)-7-({[3-(2,6-diclorofenil)-5-metilisoxazol-4-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 231 | *N*-(3,4-diclorofenil)-7-{[(6-fluoro-4*H*-1,3-benzodioxin-8-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 232 | 7-{[(3,5-dibromofenil)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 233 | *N*-(3,4-diclorofenil)-7-{[(2,6-difluorofenil)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 234 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({3-[(piridin-2-ilsulfonil)metil]-1,2,4-oxadiazol-5-il}metil)oxi]quinazolin-4-amina |
| 235 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5-fenilo-1,2,4-oxadiazol-3-il)metil]oxi}quinazolin-4-amina |
| 236 | 7-({[4-cloro-2-(trifluorometil)quinolin-6-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 237 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[2-(1-metilpirrolidin-2-il)etil]oxi}quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 238 | *N*-(3,4-diclorofenil)-7-({[5-(1-etilpiperidin-4-il)-1,2,4-oxadiazol-3-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 239 | *N*-(3,4-diclorofenil)-7-({[5-(1-etilpiperidin-3-il)-1,2,4-oxadiazol-3-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 240 | *N*-(3,4-diclorofenil)-7-({[2-(dimetilamino)-1,3-tiazol-4-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 241 | *N*-(3,4-diclorofenil)-7-{[(4-etil-1,4-oxazepan-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 242 | *N*-(3,4-diclorofenil)-7-({[2-(1-etilpiperidin-4-il)-1,3-tiazol-4-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 243 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({3-[(2*S*)-pirrolidin-2-il]-1,2,4-oxadiazol-5-il}metil)oxi]quinazolin-4-amina |
| 244 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({2-[(2*S*)-pirrolidin-2-il]-1,3-tiazol-4-il}metil)oxi]quinazolin-4-amina |
| 245 | Benzoato de [4-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,3-tiazol-2-il]metilo |
| 246 | [4-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,3-tiazol-2-il]metanol |
| 247 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5-metil-4,5,6,7-tetrahidro[1,3]tiazolo[5,4-c]piridin-2-il)metil]oxi}quinazolin-4-amina |
| 248 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({2-[(4*S*)-1,3-tiazolidin-4-il]-1,3-tiazol-4-il}metil)oxi]quinazolin-4-amina |
| 249 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2-piperidin-2-il-1,3-tiazol-4-il)metil]oxi}quinazolin-4-amina |
| 250 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[2-(1- |

| Entrada | Nombre |
|---|---|
| | metilpiperidin-2-il)-1,3-tiazol-4-il]metil}oxi)quinazolin-4-amina |
| 251 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2-piperidin-3-il-1,3-tiazol-4-il)metil]oxi}quinazolin-4-amina |
| 252 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[2-(1-metilpiperidin-3-il)-1,3-tiazol-4-il]metil}oxi)quinazolin-4-amina |
| 253 | *N*-(3,4-diclorofenil)-7-({[2-(1-etilpiperidin-2-il)-1,3-tiazol-4-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 254 | *N*-(3,4-diclorofenil)-7-({[2-(1-etilpiperidin-3-il)-1,3-tiazol-4-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 255 | *N*-(3,4-diclorofenil)-7-[({3-[(2*S*)-1-etilpirrolidin-2-il]-1,2,4-oxadiazol-5-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 256 | *N*-(3,4-diclorofenil)-7-[({2-[(2*S*)-1-etilpirrolidin-2-il]-1,3-tiazol-4-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 257 | *N*-(3,4-diclorofenil)-7-{[(5-etil-4,5,6,7-tetrahidro[1,3]tiazolo[5,4-c]piridin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 258 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-propil-1,4-oxazepan-2-il)metil]oxi}quinazolin-4-amina |
| 259 | 7-({[4-(ciclopropilmetil)-1,4-oxazepan-2-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 260 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({4-[2-(metiloxi)etil]-1,4-oxazepan-2-il}metil)oxi]quinazolin-4-amina |
| 261 | *N*-(3,4-diclorofenil)-7-({[4-(1-metiletil)-1,4-oxazepan-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 262 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(2-piperazin-1-il-1,3-tiazol-4-il)metil]oxi}quinazolin-4-amina |
| 263 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(5-pirrolidin-2-il-1,2,4-oxadiazol-3-il)metil]oxi}quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 264 | *N*-(3,4-diclorofenil)-7-({[5-(1-etilpirrolidin-2-il)-1,2,4-oxadiazol-3-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 265 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({3-[(2*S*)-1-metilpirrolidin-2-il]-1,2,4-oxadiazol-5-il}metil)oxi]quinazolin-4-amina |
| 266 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({2-[(2*S*)-1-metilpirrolidin-2-il]-1,3-tiazol-4-il}metil)oxi]quinazolin-4-amina |
| 267 | *N*-(3,4-diclorofenil)-7-({[2-(4-etilpiperazin-1-il)-1,3-tiazol-4-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 268 | *N*-(3,4-diclorofenil)-7-{[(1,4-dimetilpiperazin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 269 | 7-{[(4-ciclopentilmorfolin-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 270 | *N*-(3,4-diclorofenil)-7-({[4-(1-metiletil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 271 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(3-fenilpropil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 272 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({4-[2-(metiloxi)etil]morfolin-2-il}metil)oxi]quinazolin-4-amina |
| 273 | 2-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]propanoato de etilo |
| 274 | *N*-(3,4-diclorofenil)-7-{[(4-hex-5-en-1-ilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 275 | 2-({2-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]etil}oxi)etanol |
| 276 | 3-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]propanoato de metilo |

| Entrada | Nombre |
|---|---|
| 277 | 6-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]hexanonitrilo |
| 278 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(tetrahidro-2*H*-piran-2-ilmetil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 279 | 4-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]butanenitrilo |
| 280 | *N*-(3,4-diclorofenil)-7-[({4-[(4-fluorofenil)metil]morfolin-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 281 | 5-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]pentanoato de metilo |
| 282 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-oct-7-en-1-ilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 283 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-propilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 284 | 6-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]hexan-1-ol |
| 285 | 7-{[(4-acetilmorfolin-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 286 | 7-({[4-(ciclopropilmetil)morfolin-2-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 287 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-prop-2-in-1-ilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 288 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-piridin-4-ilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 289 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(piridin-2-ilmetil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 290 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-pent-2-in-1- |

| Entrada | Nombre |
|---|---|
| | ilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 291 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[2-(4-metilpiperazin-1-il)-1,3-tiazol-4-il]metil}oxi)quinazolin-4-amina |
| 292 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[5-(1-metilpirrolidin-2-il)-1,2,4-oxadiazol-3-il]metil}oxi)quinazolin-4-amina |
| 293 | *N*-(3-cloro-4-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 294 | 7-{[(4-butil-1,4-oxazepan-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi) quinazolin-4-amina |
| 295 | (3,4-diclorofenil)[7-(metiloxi)-6-({[4-(2-metilpropil)-1,4-oxazepan-2-il]metil}oxi) quinazolin-4-amina |
| 296 | 7-{[(4-acetil-1-etilpiperazin-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 297 | (3,4-diclorofenil)(6-(metiloxi)-7-{[(4-pentil-1,4-oxazepan-2-il)metil]oxi} quinazolin-4-amina |
| 298 | (3,4-diclorofenil)[6-(metiloxi)-7-({[4-(tetrahidro-2*H*-piran-2-ilmetil)-1,4-oxazepan-2-il]metil}oxi)quinazolin-4-amina |
| 299 | (3,4-diclorofenil)[6-(metiloxi)-7-({[4-(3-tienilmetil)-1,4-oxazepan-2-il]metil}oxi) quinazolin-4-amina |
| 300 | *N*-[4-cloro-2,5-bis(metiloxi)fenil]-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 301 | *N*-(3-bromo-2-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 302 | 7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)-*N*-(3,4,5-triclorofenil)quinazolin-4-amina |
| 303 | *N*-(3-cloro-2-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 304 | *N*-(3,4-diclorofenil)-7-{[(4-etanimidoil-1,4-oxazepan-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 305 | *N*-(4-bromo-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 306 | *N*-(5-cloro-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 307 | *N*-(4-cloro-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 308 | *N*-(2,4-diclorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 309 | *N*-(2,4-dibromofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 310 | 7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)-*N*-(2,3,4-triclorofenil)quinazolin-4-amina |
| 311 | *N*-(3,4-diclorofenil)-7-{[(1-etil-4-metilpiperazin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 312 | *N*'-ciano-2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolino-4-carboximidamida |
| 313 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[2-(pirrolidin-1-ilmetil)-1,3-tiazol-4-il]metil}oxi)quinazolin-4-amina |
| 314 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(tetrahidro-2*H*-piran-4-il)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 315 | *N*-(3,4-diclorofenil)-7-({[4-(2-etilbutil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 316 | 7-({[4-(ciclohexilmetil)morfolin-2-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 317 | 2-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]etanol |
| 318 | 7-{[(4-but-2-in-1-ilmorfolin-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 319 | 7-{[(4-ciclobutilmorfolin-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 320 | *N*-(3,4-diclorofenil)-7-[({4-[2-(1,3-dioxolan-2-il)etil]morfolin-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 321 | 7-({[4-(2-ciclohexiletil)morfolin-2-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 322 | *N*-(3,4-diclorofenil)-7-[({4-[2-(1,3-dioxan-2-il)etil]morfolin-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 323 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-pent-4-en-1-ilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 324 | *N*-(3,4-diclorofenil)-7-[({4-[(2*R*)-2-metilbutil]morfolin-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 325 | *N*-(3,4-diclorofenil)-7-({[4-(4-fluorobutil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 326 | 3-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]butan-2-ona |
| 327 | 1-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]butan-2-ona |
| 328 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-pentilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 329 | *N*-(3,4-diclorofenil)-7-{[(4-hexilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 330 | *N*-(3,4-diclorofenil)-7-{[(4-heptilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 331 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-octilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 332 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(2-feniletil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 333 | 7-{[(4-butilmorfolin-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 334 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-prop-2-en-1-ilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 335 | 2-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]-1-feniletanona |
| 336 | *N*-(3,4-diclorofenil)-7-({[4-(2-fluoroetil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 337 | *N*-(3,4-diclorofenil)-7-({[4-(3-metilbut-2-en-1-il)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 338 | 7-[({4-[(2E)-3-bromoprop-2-en-1-il]morfolin-2-il}metil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 339 | 2-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]acetamida |
| 340 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({4-[3-(tetrahidro-2*H*-piran-2-iloxi)propil]-1,4-oxazepan-2-il}metil)oxi]quinazolin-4-amina |
| 341 | *N*-(3,4-diclorofenil)-7-({[4-(3-metilbutil)-1,4-oxazepan-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 342 | 7-({[4-(ciclohexilmetil)-1,4-oxazepan-2-il]metil}oxi)-4-[(3,4-diclorofenil)metil]-6-(metiloxi)quinazoline |
| 343 | 7-({[4-(2-ciclohexiletil)-1,4-oxazepan-2-il]metil}oxi)-4-[(3,4-diclorofenil)metil]-6-(metiloxi)quinazoline |
| 345 | *N*-(3,4-diclorofenil)-7-({[4-(2-etilbutil)-1,4-oxazepan-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 346 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(metilsulfonil)-1,4-oxazepan-2-il]metil}oxi)quinazolin-4-amina |
| 347 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(1-metilpiperidin-4-il)morfolin-2-il]metil}oxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 348 | *N*-(3-cloro-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 349 | *N*'-ciano-2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,4-oxazepano-4-carboximidamida |
| 350 | *N*-(3-bromo-4-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 351 | *N*-(3,4-diclorofenil)-7-{[(1,4-dietilpiperazin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 352 | 4-({[4-[(4-bromo-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-*N*'-cianopiperidino-1-carboximidamida |
| 353 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(metilsulfonil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 354 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({4-[(fenilmetil)sulfonil]morfolin-2-il}metil)oxi]quinazolin-4-amina |
| 355 | *N*-(3,4-diclorofenil)-7-[({4-[(4-fluorofenil)sulfonil]morfolin-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 356 | *N*-(3,4-diclorofenil)-7-({[4-(etilsulfonil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 357 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(fenilsulfonil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 358 | 7-[({4-[(3-cloropropil)sulfonil]morfolin-2-il}metil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 359 | 7-({[4-(butilsulfonil)morfolin-2-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 360 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({4-[(4-metilfenil)sulfonil]morfolin-2-il}metil)oxi]quinazolin- |

| Entrada | Nombre |
|---|---|
| | 4-amina |
| 361 | *N*-(3,4-diclorofenil)-7-[({4-[(3,5-dimetilisoxazol-4-il)carbonil]morfolin-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 362 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-{[3-(metiloxi)fenil]acetil}morfolin-2-il)metil]oxi}quinazolin-4-amina |
| 363 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(2-metilpentanoil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 364 | 7-[({4-[(4-butilfenil)carbonil]morfolin-2-il}metil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 365 | 7-[({4-[(4-clorofenil)acetil]morfolin-2-il}metil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 366 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(2-propilpentanoil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 367 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(4-metilpentanoil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 368 | *N*-(3,4-diclorofenil)-7-[({4-[(2,5-difluorofenil)carbonil]morfolin-2-il}metil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 369 | 7-({[4-(ciclopentilcarbonil)morfolin-2-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 370 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(2-fenilbutanoil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 371 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-[({4-[(2,3,6-trifluorofenil)carbonil]morfolin-2-il}metil)oxi]quinazolin-4-amina |
| 372 | *N*-(3,4-diclorofenil)-7-({[4-(furan-3- |

| Entrada | Nombre |
|---|---|
| | ilcarbonil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 373 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4-propanoilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 374 | *N*-(3,4-diclorofenil)-7-{[(4-hexanoilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 375 | *N*-(3,4-diclorofenil)-7-({[4-(2-etilhexanoil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 376 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(3-fenilpropanoil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 377 | *N*-(3,4-diclorofenil)-7-({[4-(2,2-dimetilpropanoil)morfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 378 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[4-(naftalen-1-ilcarbonil)morfolin-2-il]metil}oxi)quinazolin-4-amina |
| 379 | 7-[({4-[(2-cloropiridin-3-il)carbonil]morfolin-2-il}metil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 380 | 7-[({4-[(6-cloropiridin-3-il)carbonil]morfolin-2-il}metil)oxi]-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 381 | 7-({[4-(1,3-benzodioxol-5-ilcarbonil)morfolin-2-il]metil}oxi)-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 382 | *N*-(3,4-diclorofenil)-6-[(1-metiletil)oxi]-7-[(morfolin-2-ilmetil)oxi]quinazolin-4-amina |
| 383 | *N*-(3,4-diclorofenil)-6-{[2-(metiloxi)etil]oxi}-7-[(morfolin-2-ilmetil)oxi]quinazolin-4-amina |
| 384 | *N*-(3,4-diclorofenil)-6-(etiloxi)-7-[(morfolin-2-ilmetil)oxi]quinazolin-4-amina |
| 385 | *N*-(3,4-diclorofenil)-6-(etiloxi)-7-{[(4-metilmorfolin-2-il)metil]oxi}quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 386 | *N*-(4-bromo-2-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 387 | *N*-(4-cloro-3-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 388 | *N'*-ciano-2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-*N*-metilmorfolino-4-carboximidamida |
| 389 | *N*-(4-bromo-3-clorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 390 | *N*-(3,4-diclorofenil)-6-[(1-metiletil)oxi]-7-{[(4-metilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 391 | *N*-(3,4-diclorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-{[2-(metiloxi)etil]oxi}quinazolin-4-amina |
| 392 | *N*-(4-bromo-2-clorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 393 | 7-{[(4-acetil-1,4-oxazepan-2-il)metil]oxi}-*N*-(3,4-diclorofenil)-6-(metiloxi)quinazolin-4-amina |
| 394 | 4-[(3,4-diclorofenil)amino]-7-{[(4-metilmorfolin-2-il)metil]oxi}quinazolin-6-ol |
| 395 | *N*-(3-bromo-4-clorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 396 | Ácido 3-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]-3-oxopropanoico |
| 397 | 4-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il]-4-oxobutanoato de metilo |
| 398 | *N*-(3,4-diclorofenil)-7-{[(4-metilmorfolin-3-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 399 | *N*-(3-bromo-2-clorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 400 | *N'*-ciano-2-({[4-[(3,4-diclorofenil)amino]-6- |

| Entrada | Nombre |
|---|---|
| | (metiloxi)quinazolin-7-il]oxi}metil)-*N*-[2-(metiloxi)etil]morfolino-4-carboximidamida |
| 401 | *N*'-ciano-2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-*N*-etilmorfolino-4-carboximidamida |
| 402 | [(1E)-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il](piperidin-1-il)metiliden]cianamida |
| 403 | [(1E)-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il](pirrolidin-1-il)metiliden]cianamida |
| 404 | [(1E)-[2-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)morfolin-4-il](4-metilpiperazin-1-il)metiliden]cianamida |
| 405 | *N*-(3,4-diclorofenil)-7-{[(6-etil-4,6-dimetilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 406 | *N*-(4-bromo-3-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 407 | *N*-(3,4-diclorofenil)-7-{[(6,6-dimetilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 408 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4,6,6-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 409 | *N*-(3,4-diclorofenil)-7-{[2-(5,5-dimetilmorfolin-2-il)etil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 410 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[2-(4,5,5-trimetilmorfolin-2-il)etil]oxi}quinazolin-4-amina |
| 411 | 2-(2-{[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}etil)-5,5-dimetilmorfolino-4-carboxilato de 1,1-dimetiletilo |
| 412 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[(4,5,5-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 413 | *N*-(4-bromo-2,3-diclorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 414 | *N*-(4,5-dicloro-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 415 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-{[2-(4,6,6-trimetilmorfolin-2-il)etil]oxi}quinazolin-4-amina |
| 416 | *N*-(4-bromo-2,3-difluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 417 | *N*-(4-bromo-2,5-difluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 418 | *N*-(4-bromo-3,5-difluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 419 | *N*-(3,4-dicloro-2-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 420 | *N*-(3,4-diclorofenil)-7-({[(2*R*,5*S*,6*S*)-5,6-dimetilmorfolin-2-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 421 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[(2*R*,5*S*,6*S*)-4,5,6-trimetilmorfolin-2-il]metil}oxi)quinazolin-4-amina |
| 422 | *N*-(3,4-diclorofenil)-6-(metiloxi)-7-({[(2*S*,5*S*,6*S*)-4,5,6-trimetilmorfolin-2-il]metil}oxi)quinazolin-4-amina |
| 423 | *N*-(4-bromo-3-cloro-2-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 424 | *N*-(4-bromo-5-cloro-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 425 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 426 | *N*-(3,4-dicloro-2-fluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 427 | *N*-(3-cloro-2,4-difluorofenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |
| 428 | *N*-(2,3-dicloro-4-metilfenil)-7-{[(4-metilmorfolin-2-il)metil]oxi}-6-(metiloxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 429 | 6-({[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-3,3,4-trimetilmorfolin-2-ona |
| 430 | *N*-(4-bromo-2,3-diclorofenil)-6-(metiloxi)-7-{[(4,5,5-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 431 | *N*-(4-bromo-5-cloro-2-fluorofenil)-6-(metiloxi)-7-{[(4,5,5-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 432 | *N*-(4,5-dicloro-2-fluorofenil)-6-(metiloxi)-7-{[(4,5,5-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 433 | *N*-(3,4-dicloro-2-fluorofenil)-6-(metiloxi)-7-{[(4,5,5-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 434 | *N*-(4-bromo-3-cloro-2-fluorofenil)-6-(metiloxi)-7-{[(4,5,5-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 435 | *N*-(3-cloro-2,4-difluorofenil)-6-(metiloxi)-7-{[(4,5,5-trimetilmorfolin-2-il)metil]oxi}quinazolin-4-amina |
| 436 | (6*S*)-6-({[4-[(4-bromo-3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-4-metilpiperazin-2-ona |
| 437 | (6*S*)-6-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-4-metilpiperazin-2-ona |
| 438 | (6*S*)-6-({[4-[(4-bromo-3-cloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,4-dimetilpiperazin-2-ona |
| 439 | (6*S*)-6-({[4-[(3,4-dicloro-2-fluorofenil)amino]-6-(metiloxi)quinazolin-7-il]oxi}metil)-1,4-dimetilpiperazin-2-ona |
| 440 | *N*-(4-bromo-3-clorofenil)-7-{[(3a'*S*,4*R*,6'*S*,6a'*R*)-2,2-dimetiltetrahidrospiro[1,3-dioxolane-4,3'-furo[3,2-b]furan]-6'-il]oxi}-6-(metiloxi)quinazolin-4-amina |

| Entrada | Nombre |
|---|---|
| 441 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-5-C-[(metiloxi)metil]-L-glucitol |
| 442 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-(metilsulfonil)-L-glucitol |
| 443 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-L-glucitol |
| 444 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-*S*-metil-5-tio-D-iditol |
| 445 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-morfolin-4-il-D-iditol |
| 446 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(4-metilpiperazin-1-il)-D-iditol |
| 447 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-pirrolidin-1-il-D-iditol |
| 448 | 2-O-acetil-1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-D-iditol |
| 449 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-D-iditol |
| 450 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(metilsulfonil)-D-iditol |
| 451 | 2-amino-1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-D-iditol |
| 452 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(dimetilamino)-D-iditol |
| 453 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]- |

| Entrada | Nombre |
|---|---|
| | 6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(dietilamino)-D-iditol |
| 454 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-piperidin-1-il-D-iditol |
| 455 | 2-(acetilamino)-1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-D-iditol |
| 456 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-5-C-(trifluorometil)-L-glucitol |
| 457 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-[(metilsulfonil)amino]-D-iditol |
| 458 | *N*-(4-bromo-3-clorofenil)-6-(metiloxi)-7-[(1-metilpirrolidin-3-il)oxi]quinazolin-4-amina |
| 459 | *N*-(4-bromo-3-clorofenil)-6-(metiloxi)-7-[(3*R*)-tetrahidrofuran-3-iloxi]quinazolin-4-amina |
| 460 | *N*-(4-bromo-3-clorofenil)-6-(metiloxi)-7-{[(3*S*,4*R*)-4-(metiloxi)tetrahidrofuran-3-il]oxi}quinazolin-4-amina |
| 461 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-(6-(metiloxi)-4-{[4-(4-metilpiperazin-1-il)fenil]amino}quinazolin-7-il)-D-iditol |
| 462 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-[4-{[3-fluoro-4-(4-metilpiperazin-1-il)fenil]amino}-6-(metiloxi)quinazolin-7-il]-D-iditol |
| 463 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-{[2,3-dicloro-4-(4-metilpiperazin-1-il)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 464 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-{[3,4-dicloro-2-(4-metilpiperazin-1-il)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-fluoro-D-iditol |
| 465 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]- |

| Entrada | Nombre |
|---|---|
| | 6-(metiloxi)quinazolin-7-il]-5-C-(trifluorometil)-D-glucitol |
| 466 | (3,4-diclorofenil)[6-(metiloxi)-7-({[4-(tetrahidrofuran-2-ilmetil)-1,4-oxazepan-2-il]metil}oxi)quinazolin -4-amina |
| 467 | *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 468 | *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclo-penta[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 469 | *N*-(3-cloro-2,4-difluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 470 | *N*-(4,5-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclo-penta[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 471 | *N*-(4-bromo-5-cloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclo-penta[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 472 | *N*-(4-bromo-2,3-diclorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclo-penta[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 473 | *N*-(3,4-diclorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 474 | *N*-(3,4-diclorofenil)-7-[(2-{[(3-*endo*)-8-metil-8-azabiciclo[3,2,1]oct-3-il]amino}etil)oxi]-6-(metiloxi)quinazolin-4-amina |
| 475 | *N*-(3,4-diclorofenil)-7-({2-[(3-*endo*)-8-metil-8-azabiciclo[3,2,1]oct-3-il]etil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 476 | *N*-(3,4-diclorofenil)-7-({[(3-*endo*)-8-metil-8- |

| Entrada | Nombre |
|---|---|
| | azabiciclo[3,2,1]oct-3-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina |
| 477 | *N*-(3,4-diclorofenil)-7-{[(3-*exo*)-8-metil-8-azabiciclo[3,2,1]oct-3-il]oxi}-6-(metiloxi)quinazolin-4-amina |
| 478 | 1,4:3,6-Dianhidro-5-*O*-[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-*O*-metil-D-glucitol |
| 479 | 1,4:3,6-dianhidro-5-*O*-{4-[(3-cloro-2-fluorofenil)amino]-6-(metiloxi)quin-azolin-7-il}-2-deoxi-2-fluoro-L-iditol |
| 480 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-(metilsulfonil)-D-glucitol |
| 481 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-D-glucitol |
| 482 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-S-metil-5-tio-L-iditol |
| 483 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-morfolin-4-il-L-iditol |
| 484 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(4-metilpiperazin-1-il)-L-iditol |
| 485 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-pirrolidin-1-il-L-iditol |
| 486 | 2-O-acetil-1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-L-iditol |
| 487 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-L-iditol |
| 488 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(metilsulfonil)-L-iditol |







| Entrada | Nombre |
|---|---|
| 489 | 2-amino-1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-L-iditol |
| 490 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(dimetilamino)-L-iditol |
| 491 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-(dietilamino)-L-iditol |
| 492 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-piperidin-1-il-L-iditol |
| 493 | 2-(acetilamino)-1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-L-iditol |
| 494 | 1,4:3,6-dianhidro-2-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-O-metil-5-C-(trifluorometil)-D-glucitol |
| 495 | 1,4:3,6-dianhidro-5-O-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-deoxi-2-[(metilsulfonil)amino]-L-iditol |
| 496 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-(6-(metiloxi)-4-{[4-(4-metilpiperazin-1-il)fenil]amino}quinazolin-7-il)-L-iditol |
| 497 | 1,4:3,6-dianhidro-2-deoxi-2-fluoro-5-O-[4-{[3-fluoro-4-(4-metilpiperazin-1-il)fenil]amino}-6-(metiloxi)quinazolin-7-il]-L-iditol |
| 498 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-{[2,3-dicloro-4-(4-metilpiperazin-1-il)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-fluoro-L-iditol |
| 499 | 1,4:3,6-dianhidro-2-deoxi-5-O-[4-{[3,4-dicloro-2-(4-metilpiperazin-1-il)fenil]amino}-6-(metiloxi)quinazolin-7-il]-2-fluoro-L-iditol |






| Entrada | Nombre |
|---|---|
| 500 | 1,4:3,6-Dianhidro-5-*O*-[4-[(3,4-diclorofenil)amino]-6-(metiloxi)quinazolin-7-il]-2-*O*-metil-D-glucitol |
| 501 | 1,4:3,6-Dianhidro-2-*O*-[4-[(4-bromo-3-clorofenil)amino]-6-(metiloxi)quinazolin-7-il]-5-*O*-metil-L-glucitol |







**Tabla 5a.**







**Inhibidores representativos de IGF-1R**








**[00232]** Los Compuestos de la Tabla 5a se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 5a se pueden usar para practicar la invención.








| Entrada | Estructura |
|---|---|
| 1 |  |
| 2 |  |
| 3 |  |
| 4 |  |
| 5 |  |
| 6 |  |









| Entrada | Estructura |
|---|---|
| 7 |  |
| 8 |  |
| 9 |  |
| 10 |  |
| 11 |  |









| Entrada | Estructura |
|---|---|
| 12 |  |
| 13 |  |
| 14 |  |
| 15 |  |
| 16 |  |
| 17 |  |







| Entrada | Estructura |
|---|---|
| 18 |  |
| 19 |  |
| 20 |  |
| 21 |  |
| 22 |  |
| 23 |  |








| Entrada | Estructura |
|---|---|
| 24 |  |
| 25 |  |
| 26 |  |
| 27 |  |
| 28 |  |
| 29 |  |
| 30 |  |









| Entrada | Estructura |
|---|---|
| 31 |  |
| 32 |  |
| 33 |  |
| 34 |  |
| 35 |  |
| 36 |  |
| 37 |  |








| Entrada | Estructura |
|---|---|
| 38 |  |
| 39 |  |
| 40 |  |
| 41 |  |
| 42 |  |
| 43 |  |
| 44 |  |
| 45 |  |








| Entrada | Estructura |
|---|---|
| 46 |  |
| 47 |  |
| 48 |  |
| 49 |  |
| 50 |  |
| 51 |  |
| 52 |  |
| 53 |  |








| Entrada | Estructura |
|---|---|
| 54 |  |
| 55 |  |
| 56 |  |
| 57 |  |
| 58 |  |
| 59 |  |








| Entrada | Estructura |
|---|---|
| 60 |  |
| 61 |  |
| 62 |  |
| 63 |  |
| 64 |  |
| 65 |  |
| 66 |  |









| Entrada | Estructura |
|---|---|
| 67 |  |
| 68 |  |
| 69 |  |
| 70 |  |
| 71 |  |
| 72 |  |
| 73 |  |
| 74 |  |








| Entrada | Estructura |
|---|---|
| 75 |  |
| 76 |  |
| 77 |  |
| 78 |  |
| 79 |  |
| 80 |  |
| 81 |  |








| Entrada | Estructura |
|---|---|
| 82 |  |
| 83 |  |
| 84 |  |
| 85 |  |
| 86 |  |
| 87 |  |
| 88 |  |








| Entrada | Estructura |
|---|---|
| 89 |  |
| 90 |  |
| 91 |  |
| 92 |  |
| 93 |  |
| 94 |  |
| 95 |  |








| Entrada | Estructura |
|---|---|
| 96 |  |
| 97 |  |
| 98 |  |
| 99 |  |
| 100 |  |
| 101 |  |
| 102 |  |









| Entrada | Estructura |
|---|---|
| 103 |  |
| 104 |  |
| 105 |  |
| 106 |  |
| 107 |  |
| 108 |  Abs |
| 109 |  |
| 110 |  |








| Entrada | Estructura |
|---|---|
| 111 |  |
| 112 |  |
| 113 |  |
| 114 |  |
| 115 |  |
| 116 |  |
| 117 |  |








| Entrada | Estructura |
|---|---|
| 118 |  |
| 119 |  |
| 120 |  |
| 121 |  |
| 122 |  |
| 123 |  |
| 124 |  |









| Entrada | Estructura |
|---|---|
| 125 |  |
| 126 |  |
| 127 |  |
| 128 |  |
| 129 |  |
| 130 |  |
| 131 |  |








| Entrada | Estructura |
|---|---|
| 132 |  |
| 133 |  |
| 134 |  |
| 135 |  |
| 136 |  |
| 137 |  |
| 138 |  |







| Entrada | Estructura |
|---|---|
| 139 |  |
| 140 |  |
| 141 |  Abs |
| 142 |  |
| 143 |  |
| 144 |  |
| 145 |  Abs |
| 146 |  |







| Entrada | Estructura |
|---|---|
| 147 |  |
| 148 |  |
| 149 |  |
| 150 |  |
| 151 |  |
| 152 |  |
| 153 |  |







| Entrada | Estructura |
|---|---|
| 154 |  |
| 155 |  |
| 156 |  |
| 157 |  |
| 158 |  |
| 159 |  |
| 160 |  |








| Entrada | Estructura |
|---|---|
| 161 |  |
| 162 |  |
| 163 |  |
| 164 |  |
| 165 |  |
| 166 |  |
| 167 |  |
| 168 |  |







| Entrada | Estructura |
|---|---|
| 169 |  |
| 170 |  |
| 171 |  |
| 172 |  |
| 173 |  |
| 174 |  |
| 175 |  |









| Entrada | Estructura |
|---|---|
| 176 |  |
| 177 |  |
| 178 |  |
| 179 |  |
| 180 |  |
| 181 |  |








| Entrada | Estructura |
|---|---|
| 182 |  |
| 183 |  |
| 184 |  |
| 185 |  |
| 186 |  |
| 187 |  |








| Entrada | Estructura |
|---|---|
| 188 |  |
| 189 |  |
| 190 |  |
| 191 |  |
| 192 |  |
| 193 |  |







| Entrada | Estructura |
|---|---|
| 194 |  |
| 195 |  |
| 196 |  |
| 197 |  |
| 198 |  |
| 199 |  |
| 200 |  |







| Entrada | Estructura |
|---|---|
| 201 |  |
| 202 |  |
| 203 |  |
| 204 |  |
| 205 |  |
| 206 |  |

| Entrada | Estructura |
|---|---|
| 207 |  |
| 208 |  |
| 209 |  |
| 210 |  |
| 211 |  |
| 212 |  |
| 213 |  |
| 214 |  |

| Entrada | Estructura |
|---|---|
| 215 |  |
| 216 |  |
| 217 |  |
| 218 |  |
| 219 |  |
| 220 |  |
| 221 |  |

| Entrada | Estructura |
|---|---|
| 222 |  |
| 223 |  |
| 224 |  |
| 225 |  |
| 226 |  |
| 227 |  |
| 228 |  |

| Entrada | Estructura |
|---|---|
| 229 |  |
| 230 |  |
| 231 |  |
| 232 |  |
| 233 |  |
| 234 |  |

| Entrada | Estructura |
|---|---|
| 235 |  |
| 236 |  |
| 237 |  |
| 238 |  |
| 239 |  |
| 240 |  |

Organizacion y







DVA








OK







6/7







# PATENTE DE INVENCIÓN







09-126923






| Entrada | Estructura |
|---|---|
| 241 |  |
| 242 |  |
| 243 |  |
| 244 |  |
| 245 |  |
| 246 |  |







| Entrada | Estructura |
|---|---|
| 247 |  |
| 248 |  |
| 249 |  |
| 250 |  Abs |
| 251 |  |
| 252 |  |
| 253 |  |








| Entrada | Estructura |
|---|---|
| 254 |  |
| 255 |  |
| 256 |  |
| 257 |  |
| 258 |  |
| 259 |  |








| Entrada | Estructura |
|---|---|
| 260 |  |
| 261 |  |
| 262 |  |
| 263 |  |
| 264 |  |
| 265 |  |






| Entrada | Estructura |
|---|---|
| 266 |  |
| 267 |  |
| 268 |  |
| 269 |  |
| 270 |  |
| 271 |  |






| Entrada | Estructura |
|---|---|
| 272 |  |
| 273 |  |
| 274 |  |
| 275 |  |
| 276 |  |








| Entrada | Estructura |
|---|---|
| 277 |  |
| 278 |  |
| 279 |  |
| 280 |  |
| 281 |  |
| 282 |  |








| Entrada | Estructura |
|---|---|
| 283 |  |
| 284 |  |
| 285 |  |
| 286 |  |
| 287 |  |
| 288 |  |
| 289 |  |








| Entrada | Estructura |
|---|---|
| 290 |  |
| 291 |  |
| 292 |  |
| 293 |  |
| 294 |  |
| 295 |  |
| 296 |  |







| Entrada | Estructura |
|---|---|
| 297 |  |
| 298 |  |
| 299 |  |
| 300 |  |
| 301 |  |






| Entrada | Estructura |
|---|---|
| 302 |  |
| 303 |  |
| 304 |  |
| 305 |  |
| 306 |  |





| Entrada | Estructura |
|---|---|
| 307 |  |
| 308 |  |
| 309 |  |
| 310 |  |
| 311 |  |
| 312 |  |
| 313 |  |





| Entrada | Estructura |
|---|---|
| 314 |  |
| 315 |  |
| 316 |  |
| 317 |  |
| 318 |  |
| 319 |  |
| 320 |  |






| Entrada | Estructura |
|---|---|
| 321 |  |
| 322 |  |
| 323 |  |
| 324 |  |
| 325 |  |
| 326 |  |
| 327 |  |





| Entrada | Estructura |
|---|---|
| 328 |  |
| 329 |  |
| 330 |  |
| 331 |  |
| 332 |  |
| 333 |  |






| Entrada | Estructura |
|---|---|
| 334 |  |
| 335 |  |
| 336 |  |
| 337 |  |
| 338 |  |







| Entrada | Estructura |
|---|---|
| 339 |  |
| 340 |  |
| 341 |  |
| 342 |  |








| Entrada | Estructura |
|---|---|
| 343 |  |
| 344 |  |
| 345 |  |
| 346 |  |








| Entrada | Estructura |
|---|---|
| 347 |  |
| 348 |  |
| 349 |  |
| 350 |  |
| 351 |  |







| Entrada | Estructura |
|---|---|
| 352 |  |
| 353 |  |
| 354 |  |
| 355 |  |







| Entrada | Estructura |
|---|---|
| 356 |  |
| 357 |  |
| 358 |  |
| 495 |  |
| 496 |  |







| Entrada | Estructura |
|---|---|
| 497 |  |
| 498 |  |
| 499 |  |
| 500 |  |
| 501 |  |
| 502 | Chiral  |








| Entrada | Estructura |
|---|---|
| 503 |   |
| 504 |  |
| 505 |  |
| 506 |  |
| 507 |  |
| 508 |  |
| 509 |  |








| Entrada | Estructura |
|---|---|
| 510 |  |
| 511 |   |
| 512 |  |
| 513 |  |
| 514 |  |
| 515 |  |
| 516 |  |









| Entrada | Estructura |
|---|---|
| 517 |  |
| 518 |  |
| 519 |  |
| 520 |  |
| 521 |  |
| 522 |  |








| Entrada | Estructura |
|---|---|
| 523 |  |
| 524 |  |
| 525 |  |
| 526 |  |
| 527 |  |
| 528 |  |









| Entrada | Estructura |
|---|---|
| 529 |  |
| 530 |  |
| 531 |  |
| 532 |  |
| 533 |  |
| 534 |  |

| Entrada | Estructura |
|---|---|
| 535 |  |
| 536 |  |
| 537 |  |
| 538 |  |
| 539 |  |
| 540 |  |
| 541 |  |

| Entrada | Estructura |
|---|---|
| 542 |  |
| 543 |  |
| 544 |  |
| 545 |  |
| 546 |  |
| 547 |  |
| 548 |  |

| Entrada | Estructura |
|---|---|
| 549 |  |
| 550 |  |
| 551 |  |
| 552 |  |
| 553 |  |
| 554 |  |
| 555 |  |
| 556 |  |

| Entrada | Estructura |
|---|---|
| 557 |   |
| 558 |  |
| 559 |  |
| 560 |  |
| 561 |  |
| 562 |  |
| 563 |  |

| Entrada | Estructura |
|---|---|
| 564 |  |
| 565 |  |
| 566 |  |
| 567 |  |
| 568 |  |
| 569 |  |
| 570 |  |
| 571 |  |












| Entrada | Estructura |
|---|---|
| 572 |  |






**Tabla 5b.**






**Inhibidores representativos adicionales de IGF1R**







**[00233]** Los Compuestos de la Tabla 5b se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 5b se pueden usar para practicar la invención.







| Entrada | Estructura | Nombre |
|---|---|---|
| 573 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^6$-[3-(dietilamino)propil]-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4,6-triamina |
| 574 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^6$-[2-(dietilamino)etil]-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4,6-triamina |
| 575 |  Chiral | $N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]-6-[(3S)-3-metilpiperazin-1-il]pirimidino-2,4-diamina |
| 576 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-{[2-(dimetilamino)etil]oxi}-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4-diamina |






| Entrada | Estructura | Nombre |
|---|---|---|
| 577 |  | $N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-6-[(1-metilpirrolidin-3-il)oxi]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 578 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[(1-metilpirrolidin-3-il)oxi]pirimidino-2,4-diamina |
| 579 |  | $N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-6-[(1-metilpirrolidin-3-il)oxi]pirimidino-2,4-diamina |
| 580 |  | $N^4$-[2-(dietilamino)etil]-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^6$-[5-(1-metiletil)-1*H*-pirazol-3-il]pirimidino-2,4,6-triamina |
| 581 |  | $N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]pirimidino-2,4-diamina |
| 582 |  | $N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]-6-[(1-metilpiperidin-3-il)oxi]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |







| Entrada | Estructura | Nombre |
|---|---|---|
| 583 |  | $N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]-6-[(1-metilpiperidin-3-il)oxi]pirimidino-2,4-diamina |
| 584 |  | *N*-(5-ciclopropil-1*H*-pirazol-3-il)-6-metil-2-{[(3-fenilisoxazol-5-il)metil]oxi}pirimidin-4-amina |
| 585 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-metil-$N^2$-[(4-fenilo-1*H*-imidazol-2-il)metil]pirimidino-2,4-diamina |
| 586 |  | 6-{[2-(dimetilamino)etil]oxi}-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]pirimidino-2,4-diamina |
| 587 |  | $N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]-6-[(2-morfolin-4-iletil)oxi]pirimidino-2,4-diamina |






| Entrada | Estructura | Nombre |
|---|---|---|
| 588 |  | $N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]-6-[(2-morfolin-4-iletil)oxi]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 589 |  | $N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-$N^2$-[(3-fenilisoxazol-5-il)metil]-6-[(2-piperidin-1-iletil)oxi]pirimidino-2,4-diamina |
| 590 |  | $N^4$-[3-(dietilamino)propil]-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^6$-[5-(1-metiletil)-1*H*-pirazol-3-il]pirimidino-2,4,6-triamina |
| 591 |  Chiral | $N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]-6-[(3S)-3-metilpiperazin-1-il]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 592 |  | $N^4$-[2-(dietilamino)etil]-$N^6$-[5-(1-metiletil)-1*H*-pirazol-3-il]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4,6-triamina |






| Entrada | Estructura | Nombre |
|---|---|---|
| 593 |  | $N^4$-[5-(1-metiletil)-1*H*-pirazol-3-il]-6-[(1-metilpiperidin-4-il)oxi]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 594 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[(2-morfolin-4-iletil)oxi]pirimidino-2,4-diamina |
| 595 |  | $N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-6-[(2-piperidin-1-iletil)oxi]pirimidino-2,4-diamina |
| 596 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-[3-(dietilamino)propil]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 597 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[(2-piperidin-1-iletil)oxi]pirimidino-2,4-diamina |
| 598 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[(1-metilpiperidin-3-il)oxi]pirimidino-2,4-diamina |







| Entrada | Estructura | Nombre |
|---|---|---|
| 599 |  | $N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-$N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-6-[(1-metilpiperidin-4-il)oxi]pirimidino-2,4-diamina |
| 600 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-metil-$N^2$-[(3-metilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 601 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-[(3-metilisoxazol-5-il)metil]-6-morfolin-4-ilpirimidino-2,4-diamina |
| 602 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-[(3-metilisoxazol-5-il)metil]-6-(4-metilpiperazin-1-il)pirimidino-2,4-diamina |
| 603 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[(1-metilpiperidin-4-il)oxi]pirimidino-2,4-diamina |
| 604 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-{[3-(4-fluorofenil)isoxazol-5-il]metil}-6-morfolin-4-ilpirimidino-2,4-diamina |






| Entrada | Estructura | Nombre |
|---|---|---|
| 605 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-{[3-(4-fluorofenil)isoxazol-5-il]metil}-6-(4-metilpiperazin-1-il)pirimidino-2,4-diamina |
| 606 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-{[3-(4-fluorofenil)isoxazol-5-il]metil}-6-[(2-morfolin-4-iletil)oxi]pirimidino-2,4-diamina |
| 607 |  | $N^2$-{[3-(4-fluorofenil)isoxazol-5-il]metil}-$N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-6-morfolin-4-ilpirimidino-2,4-diamina |
| 608 |  | $N^2$-{[3-(4-fluorofenil)isoxazol-5-il]metil}-$N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-6-(4-metilpiperazin-1-il)pirimidino-2,4-diamina |
| 609 |  | $N^2$-{[3-(4-fluorofenil)isoxazol-5-il]metil}-$N^4$-[3-(1-metiletil)-1*H*-pirazol-5-il]-6-[(2-morfolin-4-iletil)oxi]pirimidino-2,4-diamina |







| Entrada | Estructura | Nombre |
|---|---|---|
| 610 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-metil-$N^2$-[(3-piridin-3-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 611 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-(4-metilpiperazin-1-il)-$N^2$-[(3-piridin-2-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 612 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-morfolin-4-il-$N^2$-[(3-piridin-2-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 613 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-piperazin-1-ilpirimidino-2,4-diamina |
| 614 |  | 6-(4-acetilpiperazin-1-il)-$N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4-diamina |
| 615 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[4-(metilsulfonil)piperazin-1-il]pirimidino-2,4-diamina |






| Entrada | Estructura | Nombre |
|---|---|---|
| 616 |  | 4-{6-[(5-ciclopropil-1*H*-pirazol-3-il)amino]-2-({[3-(1-metiletil)isoxazol-5-il]metil}amino)pirimidin-4-il}piperazino-1-carbaldehído |
| 617 |  | $N^4$-(3-metil-1*H*-pirazol-5-il)-6-morfolin-4-il-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 618 |  | 6-(4-metilpiperazin-1-il)-$N^4$-(3-metil-1*H*-pirazol-5-il)-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 619 |  | $N^4$-(3-metil-1*H*-pirazol-5-il)-6-[(2-morfolin-4-iletil)oxi]-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 620 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-metil-$N^2$-[(3-piridin-4-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |







| Entrada | Estructura | Nombre |
|---|---|---|
| 621 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(3,4-difluorofenil)isoxazol-5-il]metil}-6-metilpirimidino-2,4-diamina |
| 622 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(2,4-difluorofenil)isoxazol-5-il]metil}-6-metilpirimidino-2,4-diamina |
| 623 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-metil-$N^2$-[(3-pirazin-2-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 624 |  | 5-cloro-$N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-morfolin-4-il-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 625 |  | 5-cloro-$N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-(4-metilpiperazin-1-il)-$N^2$-[(3-fenilisoxazol-5-il)metil]pirimidino-2,4-diamina |






| Entrada | Estructura | Nombre |
|---|---|---|
| 626 |  | $N^2$-[(3-metilisoxazol-5-il)metil]-6-(4-metilpiperazin-1-il)-$N^4$-(3-metil-1*H*-pirazol-5-il)pirimidino-2,4-diamina |
| 627 |  | $N^2$-[(3-metilisoxazol-5-il)metil]-$N^4$-(3-metil-1*H*-pirazol-5-il)-6-morfolin-4-ilpirimidino-2,4-diamina |
| 628 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-(4-metilpiperazin-1-il)-$N^2$-[(3-pirimidin-4-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 629 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-[(3-furan-3-ilisoxazol-5-il)metil]-6-(4-metilpiperazin-1-il)pirimidino-2,4-diamina |
| 630 |  Chiral | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^6$-(8-metil-8-azabiciclo[3,2,1]oct-3-il)-$N^2$-[(3-metilisoxazol-5-il)metil]pirimidino-2,4,6-triamina |
| 631 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-(5-metil-2,5-diazabiciclo[2,2,1]hept-2-il)-$N^2$-[(3-metilisoxazol-5-il)metil]pirimidino-2,4-diamina |

| Entrada | Estructura | Nombre |
|---|---|---|
| 632 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-(5-metil-2,5-diazabiciclo[2,2,1]hept-2-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4-diamina |
| 633 |  | $N^4$-biciclo[2,2,1]hept-2-il-$N^6$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4,6-triamina |
| 634 |  | $N^4$-biciclo[2,2,1]hept-2-il-$N^6$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-[(3-metilisoxazol-5-il)metil]pirimidino-2,4,6-triamina |
| 635 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-[(3-metilisoxazol-5-il)metil]-6-[(1R,4R)-5-(fenilmetil)-2,5-diazabiciclo[2,2,1]hept-2-il]pirimidino-2,4-diamina |
| 636 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[(1R,4R)-5-(fenilmetil)-2,5-diazabiciclo[2,2,1]hept-2-il]pirimidino-2,4-diamina |

| Entrada | Estructura | Nombre |
|---|---|---|
| 637 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-morfolin-4-il-$N^2$-[(3-pirimidin-4-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 638 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-{[2-(dimetilamino)etil]oxi}-$N^2$-[(3-pirimidin-4-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 639 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(5-fluoropiridin-2-il)isoxazol-5-il]metil}-6-metilpirimidino-2,4-diamina |
| 640 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-(4-metilpiperazin-1-il)-$N^2$-{[3-(2-tienil)isoxazol-5-il]metil}pirimidino-2,4-diamina |
| 641 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-{[2-(dimetilamino)etil]oxi}-$N^2$-[(3-piridin-2-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 642 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-(4-metilpiperazin-1-il)-$N^2$-[(3-pirimidin-5-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |

| Entrada | Estructura | Nombre |
|---|---|---|
| 643 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-morfolin-4-il-$N^2$-[(3-pirimidin-5-ilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 644 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-{[2-(dietilamino)etil]oxi}-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4-diamina |
| 645 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}-6-[(2-pirrolidin-1-iletil)oxi]pirimidino-2,4-diamina |
| 646 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-{[2-(dietilamino)etil]oxi}-$N^2$-[(3-metilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 647 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-$N^2$-[(3-metilisoxazol-5-il)metil]-6-[(2-pirrolidin-1-iletil)oxi]pirimidino-2,4-diamina |

| Entrada | Estructura | Nombre |
|---|---|---|
| 648 |  | $N^4$-(5-ciclopropil-1*H*-pirazol-3-il)-6-(4-metilpiperazin-1-il)-$N^2$-{[3-(1,3-tiazol-2-il)isoxazol-5-il]metil}pirimidino-2,4-diamina |
| 649 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-[2-(dimetilamino)etoxi]-$N^2$-[(3-metilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 650 |  | 6-{[2-(dimetilamino)etil]oxi}-$N^2$-[(3-metilisoxazol-5-il)metil]-$N^4$-(3-metil-1*H*-pirazol-5-il)pirimidino-2,4-diamina |
| 651 |  | 6-{[2-(dietilamino)etil]oxi}-$N^2$-[(3-metilisoxazol-5-il)metil]-$N^4$-(3-metil-1*H*-pirazol-5-il)pirimidino-2,4-diamina |
| 652 |  | $N^2$-[(3-metilisoxazol-5-il)metil]-$N^4$-(3-metil-1*H*-pirazol-5-il)-6-[(2-pirrolidin-1-iletil)oxi]pirimidino-2,4-diamina |
| 653 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-metil-$N^2$-[2-(3-fenilisoxazol-5-il)etil]pirimidino-2,4-diamina |

| Entrada | Estructura | Nombre |
|---|---|---|
| 654 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-metil-$N^2$-[1-(3-fenilisoxazol-5-il)etil]pirimidino-2,4-diamina |
| 655 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-[(3-etilisoxazol-5-il)metil]-6-(4-metilpiperazin-1-il)pirimidino-2,4-diamina |
| 656 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-[(3-etilisoxazol-5-il)metil]-6-morfolin-4-ilpirimidino-2,4-diamina |
| 657 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-{[2-(dimetilamino)etil]oxi}-$N^2$-[(3-etilisoxazol-5-il)metil]pirimidino-2,4-diamina |
| 658 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-{[2-(dietilamino)etil]oxi}-$N^2$-[(3-etilisoxazol-5-il)metil]pirimidino-2,4-diamina |






| Entrada | Estructura | Nombre |
|---|---|---|
| 659 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-$N^2$-[(3-etilisoxazol-5-il)metil]-6-[(2-pirrolidin-1-iletil)oxi]pirimidino-2,4-diamina |
| 660 |  | $N^2$-{[3-(2-aminopirimidin-4-il)isoxazol-5-il]metil}-$N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-(4-metilpiperazin-1-il)pirimidino-2,4-diamina |
| 661 |  | $N^4$-(3-ciclopropil-1*H*-pirazol-5-il)-6-(4-etilpiperazin-1-il)-$N^2$-{[3-(1-metiletil)isoxazol-5-il]metil}pirimidino-2,4-diamina |
| 662 |  | 2-(1-{6-[(3-ciclopropil-1*H*-pirazol-5-il)amino]-2-({[3-(1-metiletil)isoxazol-5-il]metil}amino)pirimidin-4-il}piperidin-4-il)etanol |
| 663 |  | 2-(4-{6-[(3-ciclopropil-1*H*-pirazol-5-il)amino]-2-({[3-(1-metiletil)isoxazol-5-il]metil}amino)pirimidin-4-il}piperazin-1-il)etanol |

**Tabla 6.**

**Inhibidores representativos de Raf**

**[00234]** Los Compuestos de la Tabla 6 se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 6 se pueden usar para practicar la invención.

| Entrada | Nombre |
|---|---|
| 1 | 6-(2-butil-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 2 | 6-[1-hidroxi-3-oxo-2-(2-feniletil)-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 3 | 6-(1-hidroxi-2-{[4-(metiloxi)fenil]metil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 4 | 6-(1-hidroxi-2-{[3-(metiloxi)fenil]metil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 5 | 6-{2-[(4-fluorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 6 | 6-(1-hidroxi-3-oxo-2-fenilo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 7 | 6-{2-[(3-bromofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 8 | 6-{2-[(4-bromofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 9 | 6-[1-hidroxi-3-oxo-2-(3-fenilpropil)-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |

| Entrada | Nombre |
|---|---|
| 10 | 6-{2-[(3,4-diclorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 11 | 6-{1-hidroxi-2-[(4-metilfenil)metil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 12 | 6-{2-[(4-clorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 13 | 6-[1-hidroxi-2-(1-metiletil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 14 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 15 | 6-{2-[(3,4-dimetilfenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 16 | 6-(2-{[4-cloro-3-(trifluorometil)fenil]metil}-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 17 | 6-(2-{[4-(dimetilamino)fenil]metil}-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 18 | 6-[2-(3-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 19 | 6-[2-(4-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 20 | 6-[2-(3,4-diclorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 21 | 6-[1-hidroxi-2-(4-metilfenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |

| Entrada | Nombre |
|---|---|
| 22 | 3-(2-{[3,5-bis(metiloxi)fenil]amino}-1*H*-bencimidazol-5-il)-3-(metiloxi)-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 23 | 3-(2-{[3,5-bis(metiloxi)fenil]amino}-1*H*-bencimidazol-5-il)-2-(1-metiletil)-3-(metiloxi)-2,3-dihidro-1*H*-isoindol-1-ona |
| 24 | 3-(2-{[3,5-bis(metiloxi)fenil]amino}-1*H*-bencimidazol-5-il)-3-hidroxi-2-fenilo-2,3-dihidro-1*H*-isoindol-1-ona |
| 25 | 3-(2-{[3,5-bis(metiloxi)fenil]amino}-1*H*-bencimidazol-5-il)-3-hidroxi-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 26 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1-metil-1*H*-bencimidazol-2-il}carbamate |
| 27 | 3-(1*H*-bencimidazol-5-il)-3-hidroxi-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 28 | 5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-*N*-metil-1*H*-bencimidazol-2-carboxamida |
| 29 | 3-hidroxi-3-(2-metil-1*H*-bencimidazol-5-il)-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 30 | 7-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-3,4-dihidroquinoxalin-2(1*H*)-ona |
| 31 | 7-[2-(3-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-3,4-dihidroquinoxalin-2(1*H*)-ona |
| 32 | 1,1-dimetiletil 4-{[1-hidroxi-3-oxo-1-(3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-6-il)-1,3-dihidro-2*H*-isoindol-2-il]metil}piperidino-1-carboxilate |
| 33 | 6-(1-hidroxi-2-{[2-(metiloxi)fenil]metil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |

| Entrada | Nombre |
|---|---|
| 34 | 6-{2-[(3-clorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 35 | 6-{2-[(2-clorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 36 | 6-{2-[(3-fluorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 37 | 6-{2-[(2-bromofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 38 | 6-{2-[(2-fluorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 39 | 6-[2-(3-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 40 | 6-[1-hidroxi-2-(3-yodofenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 41 | 6-[2-(3-bromofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 42 | 6-[1-hidroxi-2-(3-nitrofenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 43 | 6-{1-hidroxi-2-[3-(metiloxi)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 44 | 6-[1-hidroxi-2-(3-metilfenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 45 | 3-hidroxi-3-(1*H*-indol-5-il)-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 46 | [6-(1-hidroxi-3-oxo-2-fenilo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamate |

| Entrada | Nombre |
|---|---|
| 47 | 6-[2-(2-aminofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 48 | 6-{[2-(3-fenilo-1,2,4-oxadiazol-5-il)fenil]carbonil}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 49 | 6-{[2-(1*H*-bencimidazol-2-il)fenil]carbonil}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 50 | 6-(1-hidroxi-3-oxo-2-{[2-(trifluorometil)fenil]metil}-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 51 | 6-{2-[(5-bromo-2-fluorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 52 | 6-{1-hidroxi-2-[(3-nitrofenil)metil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 53 | 6-(1-hidroxi-3-oxo-2-{[3-(trifluorometil)fenil]metil}-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 54 | 6-(2-{[2,3-bis(metiloxi)fenil]metil}-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 55 | 6-{1-hidroxi-2-[(3-yodofenil)metil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 56 | 6-[1-hidroxi-3-oxo-2-({3-[(trifluorometil)oxi]fenil}metil)-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 57 | 6-(1-hidroxi-2-{[2-(metiltio)fenil]metil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |

| Entrada | Nombre |
|---|---|
| 58 | 6-[2-(3,4-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 59 | 6-{1-hidroxi-2-[3-(1-metiletil)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 60 | 6-(1-hidroxi-3-oxo-2-{3-[(trifluorometil)oxi]fenil}-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 61 | 6-{1-hidroxi-3-oxo-2-[3-(trifluorometil)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 62 | 3-[1-hidroxi-3-oxo-1-(3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-6-il)-1,3-dihidro-2*H*-isoindol-2-il]bencensulfonamida |
| 63 | 6-{2-[5-cloro-2-(metiloxi)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 64 | 6-{2-[4-fluoro-3-(trifluorometil)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 65 | 3-hidroxi-3-(1*H*-indol-6-il)-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 66 | 6-[2-(3-fluoro-5-yodofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 67 | 6-[2-(3-aminofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 68 | 6-[2-(3,5-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |

| Entrada | Nombre |
|---|---|
| 69 | 6-{1-hidroxi-2-[3-(metilsulfonil)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 70 | etil 3-[1-hidroxi-3-oxo-1-(3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-6-il)-1,3-dihidro-2*H*-isoindol-2-il]benzoate |
| 71 | 3-[1-hidroxi-3-oxo-1-(3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-6-il)-1,3-dihidro-2*H*-isoindol-2-il]benzonitrilo |
| 72 | 6-[2-(2-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 73 | 6-[2-(3-amino-5-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 74 | 6-[2-(5-cloro-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 75 | 6-[2-(3-cloro-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 76 | 6-[2-(3-etilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 77 | 6-[2-(3-etinilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 78 | 6-[1-hidroxi-2-(3-hidroxifenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 79 | 6-{1-hidroxi-3-oxo-2-[3-(feniloxi)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 80 | 6-(1-hidroxi-3-oxo-2-{3-[(fenilmetil)oxi]fenil}-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |

| Entrada | Nombre |
|---|---|
| 81 | 3-[1-hidroxi-3-oxo-1-(3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-6-il)-1,3-dihidro-2*H*-isoindol-2-il]benzamida |
| 82 | 6-{1-hidroxi-2-[3-(hidroximetil)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 83 | 6-[2-(2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 84 | 3-hidroxi-3-[2-(metilamino)-1*H*-bencimidazol-5-il]-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 85 | 6-(2-bifenil-3-il-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 86 | 6-(2-{3-[(dimetilamino)metil]fenil}-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 87 | 6-[2-(3,5-diclorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 88 | 6-(1-hidroxi-3-oxo-2-piperidin-4-il-2,3-dihidro-1*H*-isoindol-1-il)-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 89 | 6-[2-(3-{[2-(dimetilamino)etil]oxi}fenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 90 | 6-[1-hidroxi-2-(2-metilfenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-2*H*-1,4-benzoxazin-3(4*H*)-ona |
| 91 | *N*-metil-2-[(3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-6-il)carbonil]-*N*-fenilbenzamida |
| 92 | {5-[1-(etiloxi)-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 93 | fenilmetil 2-[(2-{[(metiloxi)carbonil]amino}-1*H*-bencimidazol-5-il)carbonil]benzoate |

| Entrada | Nombre |
|---|---|
| 94 | 3-hidroxi-3-(1*H*-indazol-5-il)-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 95 | 3-hidroxi-3-(1*H*-indazol-6-il)-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 96 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de etilo |
| 97 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-metilpropilo |
| 98 | {5-[1-hidroxi-3-oxo-2-(2-tienilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 99 | {5-[1-hidroxi-3-oxo-2-(2-feniletil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il} carbamato de metilo |
| 100 | 3-[2-amino-1-(1,1-dimetiletil)-1*H*-bencimidazol-5-il]-3-hidroxi-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 101 | 3-(2-amino-1*H*-bencimidazol-5-il)-3-hidroxi-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-ona |
| 102 | [5-(1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 103 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 3-(metiloxi)butilo |
| 104 | (5-{1-hidroxi-3-oxo-2-[(1*R*)-1-feniletil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 105 | (5-{1-hidroxi-3-oxo-2-[(1*S*)-1-feniletil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 106 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-(metiloxi)etilo |
| 107 | {6-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1-metil-1*H*-bencimidazol-2-il} carbamato de metilo |
| 108 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de prop-2-in-1-ilo |
| 109 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de but-2-in-1-ilo |
| 110 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 1-metiletilo |
| 111 | {5-[2-(2,3-dihidro-1*H*-inden-2-il)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 112 | {5-[1-hidroxi-3-oxo-2-(piridin-4-ilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il} carbamato de metilo |
| 113 | {5-[1-hidroxi-3-oxo-2-(piridin-3-ilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il} carbamato de metilo |
| 114 | (6-{2-[(3-fluorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 115 | {5-[1-hidroxi-2-(3-metilfenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 116 | [5-(1-hidroxi-2-{[2-(metiloxi)fenil]metil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 117 | [5-(1-hidroxi-2-{[3-(metiloxi)fenil]metil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 118 | [5-(1-hidroxi-2-{[4-(metiloxi)fenil]metil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 119 | (6-{2-[(4-fluorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 120 | (6-{2-[(3-bromofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 121 | (5-{1-hidroxi-2-[(3-yodofenil)metil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 122 | (5-{2-[(3-clorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 123 | (5-{2-[(2-fluorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 124 | {5-[1-hidroxi-3-oxo-2-(piridin-2-ilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 125 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de fenilmetilo |
| 126 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-fluoroetilo |
| 127 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de propilo |

| Entrada | Nombre |
|---|---|
| 128 | (5-{1-hidroxi-2-[4-(metiloxi)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 129 | (5-{2-[(2-clorofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 130 | (5-{2-[(2-bromofenil)metil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 131 | (5-{1-hidroxi-2-[(3-metilfenil)metil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 132 | (5-{1-hidroxi-2-[(4-metilfenil)metil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 133 | (5-{1-hidroxi-2-[(2-metilfenil)metil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il) carbamato de metilo |
| 134 | {5-[2-(3-bromofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 135 | {5-[2-(3-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 136 | {5-[2-(3-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 137 | (5-{1-hidroxi-2-[3-(metiloxi)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 138 | {5-[2-(4-bromofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 139 | {5-[2-(4-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 140 | {5-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 141 | {5-[2-(3,5-dimetilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 142 | {5-[2-(2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 143 | {5-[2-(2-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 144 | {5-[1-hidroxi-2-(2-metilfenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 145 | (5-{1-hidroxi-2-[2-(metiloxi)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 146 | {5-[1-hidroxi-2-(4-metilfenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 147 | (5-{1-hidroxi-3-oxo-2-[3-(trifluorometil)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 148 | (5-{1-hidroxi-3-oxo-2-[(1*R*)-1-feniletil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de but-2-in-1-ilo |
| 149 | *N*-etil-*N*'-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}urea |

| Entrada | Nombre |
|---|---|
| 150 | (5-{1-hidroxi-3-oxo-2-[(1*R*)-1-feniletil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de fenilmetilo |
| 151 | {6-[2-(3-amino-5-clorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 152 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de piperidin-4-ilmetilo |
| 153 | {5-[2-(ciclopropilmetil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 154 | {5-[2-(2,2-dimetilpropil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 155 | {5-[2-(3,5-diclorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 156 | {5-[2-(3,5-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 157 | *N*-etil-*N*'-(5-{1-hidroxi-3-oxo-2-[(1*R*)-1-feniletil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)urea |
| 158 | *N*'-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-*N*,*N*-dimetilurea |
| 159 | {5-[2-(3-{[2-(dimetilamino)etil]oxi}fenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 160 | {6-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 3-(4-metilpiperazin-1-il)propilo |

| Entrada | Nombre |
|---|---|
| 161 | {5-[2-(ciclohexilmetil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 162 | {5-[1-hidroxi-2-(2-metilpropil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 163 | {5-[1-hidroxi-3-oxo-2-(1,3-tiazol-2-ilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 164 | {5-[2-(3,4-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 165 | (5-{2-[1-(3,5-difluorofenil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 166 | (5-{2-[1-(3-fluorofenil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 167 | [5-(2-ciclohexil-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 168 | {5-[2-(2,5-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 169 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-*N*'-(fenilmetil)urea |
| 170 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de piperidin-4-ilo |
| 171 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-*N*'-metilurea |

| Entrada | Nombre |
|---|---|
| 172 | (5-{2-[1-(2-fluorofenil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 173 | (5-{1-hidroxi-3-oxo-2-[1-(2-tienil)etil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 174 | (5-{2-[1-(3-clorofenil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 175 | (5-{1-hidroxi-2-[3-metil-5-(trifluorometil)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 176 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}propanamida |
| 177 | {5-[2-(3,4-diclorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 178 | {5-[2-(3-etilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 179 | {5-[2-(3-etinilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 180 | {5-[2-(4-cloro-3-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 181 | [5-(1-hidroxi-3-oxo-2-{1-[3-(trifluorometil)fenil]etil}-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 182 | (5-{1-hidroxi-3-oxo-2-[(1*R*)-1-fenilpropil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 183 | [5-(1-hidroxi-3-oxo-2-{2-[(trifluorometil)oxi]fenil}-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 184 | {5-[2-(2,3-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 185 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de ciclohexilo |
| 186 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de tetrahidrofuran-2-ilmetilo |
| 187 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de m ciclopropilmetilo |
| 188 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}morfolino-4-carboxamida |
| 189 | {5-[2-(ciclopentilmetil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 190 | {5-[2-(2,3-dimetilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 191 | {5-[2-(2,3-dihidro-1*H*-inden-1-il)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 192 | (2*S*)-ciclohexil[1-hidroxi-1-(2-{[(metiloxi)carbonil]amino}-1*H*-bencimidazol-5-il)-3-oxo-1,3-dihidro-2*H*-isoindol-2-il]etanoato de metilo |

| Entrada | Nombre |
|---|---|
| 193 | {5-[2-(2,6-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 194 | {5-[2-(3-cloro-4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 195 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de but-3-en-1-ilo |
| 196 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2,2,2-trifluoroetilo |
| 197 | {5-[2-(5-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 198 | (5-{2-[1-(5-cloro-2-metilfenil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 199 | (5-{1-hidroxi-3-oxo-2-[(1*S*)-1-fenilpropil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 200 | (5-{2-[1-(3-cloro-2-metilfenil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 201 | (5-{1-hidroxi-2-[1-(5-metil-2-tienil)etil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 202 | (5-{2-[1-(5-cloro-2-tienil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 203 | {5-[1-hidroxi-2-(3-yodofenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 204 | (5-{1-hidroxi-2-[3-(1-metiletil)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 205 | {5-[2-(furan-2-ilmetil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 206 | {5-[1-hidroxi-3-oxo-2-(3-tienilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 207 | {5-[2-(ciclobutilmetil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 208 | 3,3,3-trifluoro-2-hidroxi-*N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-2-(trifluorometil)propanamida |
| 209 | (5-{1-hidroxi-2-[1-(4-metil-2-tienil)etil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 210 | (5-{2-[1-(4-bromo-2-tienil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 211 | {5-[1-hidroxi-2-(3-{[2-(metiloxi)etil]oxi}fenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 212 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de tetrahidrofuran-3-ilmetilo |
| 213 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}piperidino-1-carboxamida |
| 214 | {5-[2-(3-bromo-4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 215 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2,3-dihidroxipropilo |
| 216 | {5-[1-hidroxi-3-oxo-2-(tetrahidrofuran-2-ilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 217 | (5-{2-[3-(aminocarbonil)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 218 | 4,4,4-trifluoro-3-hidroxi-*N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-3-(trifluorometil)butanamida |
| 219 | (5-{1-hidroxi-2-[3-(metilsulfonil)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 220 | (5-{1-hidroxi-3-oxo-2-[3-(feniloxi)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 221 | [5-(1-hidroxi-3-oxo-2-{3-[(fenilmetil)oxi]fenil}-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 222 | [5-(2-bifenil-3-il-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 223 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2,2-dimetil-3-[(fenilmetil)oxi]propilo |
| 224 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 225 | {5-[2-(3-cianofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 226 | {5-[2-(3-etinil-4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 227 | {5-[2-(4-fluoro-3-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 228 | {6-[2-(3,4-dicloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 229 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de [(4*S*)-2,2-dimetil-1,3-dioxolan-4-il]metilo |
| 230 | {5-[2-(5-bromo-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 231 | (5-{2-[3-(acetilamino)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 232 | (5-{1-hidroxi-3-oxo-2-[3-(fenilmetil)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 233 | (5-{2-[1-(4-cloro-2-tienil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 234 | (5-{1-hidroxi-3-oxo-2-[3-(fenilcarbonil)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 235 | [5-(2-{3-[(dimetilamino)metil]fenil}-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 236 | (5-{2-[3-(aminosulfonil)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 237 | {5-[2-(3-acetilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 238 | {5-[2-(3-etil-4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 239 | {5-[2-(3-cloro-5-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 240 | *N*-{6-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-2-metilpropanamida |
| 241 | (5-{2-[1-(3-cloro-2-tienil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 242 | [5-(1-hidroxi-3-oxo-2-piridin-3-il-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 243 | (5-{1-hidroxi-3-oxo-2-[3-(fenilamino)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 244 | {5-[2-(5-bromo-2,4-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 245 | {5-[2-(5-cloro-2,4-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 246 | {5-[2-(3,5-dicloro-4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 247 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2,2-dimetil-3-(metiloxi)propilo |

| Entrada | Nombre |
|---|---|
| 248 | 3-hidroxi-2,2-dimetilpropil {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 249 | (5-{2-[1-(5-bromo-2-tienil)etil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 250 | {5-[2-(4,5-dicloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 251 | {5-[2-(3-bromo-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 252 | {5-[2-(3-cloro-2,4-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 253 | *N*-{6-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}pent-4-ynamida |
| 254 | (6-{1-metil-3-oxo-2-[3-(trifluorometil)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 255 | [5-(1-hidroxi-3-oxo-2-{3-[(1,1,2,2-tetrafluoroetil)oxi]fenil}-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 256 | {5-[1-hidroxi-3-oxo-2-(3-piperidin-4-ilfenil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 257 | {5-[2-(3-etenilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 258 | (5-{2-[3-(dimetilamino)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 259 | 2,2-difluoro-*N*-{6-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}ciclopropanocarboxamida |
| 260 | *N*-etil-*N*'-{6-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}urea |
| 261 | {5-[2-(3-aminofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 262 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-4-[(fenilmetil)oxi]butanamida |
| 263 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-4-piperidin-1-ilbutanamida |
| 264 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-4-(4-metilpiperazin-1-il)butanamida |
| 265 | *N*-{6-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}butanamida |
| 266 | {6-[2-(3-bromofenil)-5,6-dicloro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 267 | [5-(1-hidroxi-2-{3-[metil(fenil)amino]fenil}-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 268 | {5-[1-hidroxi-3-oxo-2-(fenilsulfonil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 269 | {5-[(2-{[(fenilamino)carbonil]amino}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 270 | (5-{[2-({[(fenilmetil)oxi]carbonil}amino)fenil]carbonil}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 271 | [5-({2-[(2-fenilhidrazino)carbonil]fenil}carbonil)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 272 | {5-[(2-{[(feniloxi)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 273 | {5-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de but-2-in-1-ilo |
| 274 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-3-piperidin-1-ilpropanamida |
| 275 | *N*-{6-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}propanamida |
| 276 | *N*-(4-fluorofenil)-2-{[2-(pent-4-ynoilamino)-1*H*-bencimidazol-6-il]carbonil}benzamida |
| 277 | 4-(dietilamino)-*N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}butanamida |
| 278 | *N*-{5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-4-pirrolidin-1-ilbutanamida |
| 279 | {6-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 3-piperidin-1-ilpropilo |
| 280 | {6-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de -(4-metilpiperazin-1-il)propilo |
| 281 | {5-[2-(3-bromofenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 282 | {5-[2-(3-etinil-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 283 | {5-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-piperidin-1-iletilo |
| 284 | {5-[2-(3-cloro-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 285 | {5-[2-(5-cloro-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 286 | *N*-{6-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-2,2-dimetil-3-piperidin-1-ilpropanamida |
| 287 | *N*-{5-[2-(4-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-4-piperidin-1-ilbutanamida |
| 288 | *N*-{5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-4-piperidin-1-ilbutanamida |
| 289 | [6-({2-[(fenilcarbonil)amino]fenil}carbonil)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 290 | {5-[1-hidroxi-2-(3-morfolin-4-ilfenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 291 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-(dimetilamino)etilo |
| 292 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-(dietilamino)etilo |

| Entrada | Nombre |
|---|---|
| 293 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-piperidin-1-iletilo |
| 294 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 3-piperidin-1-ilpropilo |
| 295 | {6-[2-(3-bromofenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 296 | {6-[2-(3-bromofenil)-4,7-difluoro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-piperidin-1-iletilo |
| 297 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-[metil(fenilmetil)amino]etilo |
| 298 | {5-[1-hidroxi-3-oxo-2-(3-pirrolidin-1-ilfenil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 299 | {5-[2-(5-cloro-2,3-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 300 | {5-[1-hidroxi-3-oxo-2-(pirrolidin-2-ilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 301 | {5-[1-hidroxi-3-oxo-2-(pirrolidin-3-ilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 302 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de (1-metilpiperidin-2-il)metilo |
| 303 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de [(2*S*)-1-metilpirrolidin-2-il]metilo |

| Entrada | Nombre |
|---|---|
| 304 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de octahidro-2*H*-quinolizin-1-ilmetilo |
| 305 | {5-[2-(5-bromo-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 306 | 5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1,3-dihidro-2*H*-bencimidazol-2-ona |
| 307 | {5-[2-(3-bromo-2,5-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 308 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-morfolin-4-iletilo |
| 309 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de (1-metilpiperidin-3-il)metilo |
| 310 | (5-{2-[5-cloro-2-(metiloxi)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 311 | [5-(2-{3-[ciclohexil(metil)amino]fenil}-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 312 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 8-azabiciclo[3,2,1]oct-3-ilmetilo |
| 313 | {6-[1-(3-bromofenil)-5-oxopirrolidin-2-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 314 | {5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de (1-metilpiperidin-4-il)metilo |

| Entrada | Nombre |
|---|---|
| 315 | 4-({[({5-[1-hidroxi-3-oxo-2-(fenilmetil)-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}amino)carbonil]oxi}metil)piperidino-1-carboxilato de 1,1-dimetiletilo |
| 316 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de (1-metilpiperidin-4-il)metilo |
| 317 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-(1-metilpiperidin-4-il)etilo |
| 318 | ({6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}amino)(oxo)acetato de metilo |
| 319 | *N*-(5-{1-hidroxi-3-oxo-2-[3-(feniloxi)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)-4-piperidin-1-ilbutanamida |
| 320 | {6-[2-(3-bromofenil)-1-metil-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 321 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 4-(dietilamino)but-2-in-1-ilo |
| 322 | {5-[2-(3-cloro-2,6-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 323 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-(2-oxopirrolidin-1-il)etilo |
| 324 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-(2,5-dioxopirrolidin-1-il)etilo |

| Entrada | Nombre |
|---|---|
| 325 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2,2,3,3-tetrafluorociclobutilo |
| 326 | 1-acetil-*N*-{5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}piperidino-4-carboxamida |
| 327 | *N*-{5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}ciclobutanocarboxamida |
| 328 | [5-(2-{3-[etil(fenil)amino]fenil}-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il)-1*H*-bencimidazol-2-il]carbamato de metilo |
| 329 | *N*-{6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-2,2-difluorociclopropanocarboxamida |
| 330 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de ciclobutilo |
| 331 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2,2-difluoroetilo |
| 332 | 2-(3-cloro-2-fluorofenil)-3-hidroxi-3-[2-(piridin-2-ilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 333 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 1-metiletilo |
| 334 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de ciclopropilmetilo |
| 335 | *N*-{5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}ciclopropanocarboxamida |

| Entrada | Nombre |
|---|---|
| 336 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-(metiloxi)etilo |
| 337 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de tetrahidrofuran-2-ilmetilo |
| 338 | *N*-{5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-2-(2-tienil)acetamida |
| 339 | {6-[2-(3-cloro-2-fluorofenil)-4,7-difluoro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 340 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de etilo |
| 341 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2-fluoroetilo |
| 342 | (5-{1-hidroxi-3-oxo-2-[2-(feniloxi)fenil]-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 343 | *N'*-{5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}-*N*,*N*-dietilpentanediamida |
| 344 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de ciclobutilmetilo |
| 345 | {6-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de 2,2,2-trifluoroetilo |
| 346 | (5-{2-[3-(1,1-dimetiletil)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 347 | {6-[2-(3-cloro-2-fluorofenil)-7-fluoro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 348 | 2-(3-cloro-2-fluorofenil)-3-hidroxi-3-[2-(fenilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 349 | {6-[4,7-dicloro-2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 350 | 2-[(2-{[(etiloxi)carbonil]amino}-1,3-benzoxazol-5-il)carbonil]benzoato de fenilmetilo |
| 351 | {5-[2-(5-cloro-3-etinil-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 352 | {5-[2-(5-etinil-2,4-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 353 | {5-[2-(3-etinil-2,4-difluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 354 | 2-(3-cloro-2-fluorofenil)-3-hidroxi-3-[2-(pirimidin-2-ilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 355 | {5-[2-(3-etinil-2-fluorofenil)-4,7-difluoro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 356 | 2-(3-cloro-2-fluorofenil)-3-hidroxi-3-[2-(1,3-tiazol-2-ilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 357 | {5-[2-(3-cloro-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1,3-benzoxazol-2-il}carbamato de etilo |

| Entrada | Nombre |
|---|---|
| 358 | {5-[2-(5-cloro-3-yodo-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 359 | {5-[2-(3-etil-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 360 | {5-[2-(5-etinil-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 361 | 2-(3-cloro-2-fluorofenil)-3-hidroxi-3-[2-(pirazin-2-ilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 362 | {5-[2-(2-fluoro-3-yodofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 363 | {6-[2-(5-etinil-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 364 | 2-(3-etinil-2-fluorofenil)-3-hidroxi-3-[2-(pirimidin-2-ilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 365 | {5-[2-(2,5-dimetilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 366 | {5-[2-(3-etenil-2-fluorofenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 367 | (6-{2-[2-fluoro-3-(metiloxi)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 368 | (5-{1-hidroxi-2-[2-metil-5-(metiloxi)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 369 | {5-[2-(3-etinil-2-fluorofenil)-7-fluoro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 370 | {5-[2-(2-fluoro-3-prop-1-in-1-ilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 371 | {5-[2-(5-cloro-2-metilfenil)-7-fluoro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 372 | {5-[2-(3-etinil-2-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 373 | 3-hidroxi-2-[3-(metiloxi)fenil]-3-[2-(pirimidin-2-ilamino)-1*H*-bencimidazol-6-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 374 | 3-hidroxi-2-(3-metilfenil)-3-[2-(pirimidin-2-ilamino)-1*H*-bencimidazol-6-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 375 | 2-(5-cloro-2-metilfenil)-3-hidroxi-3-[2-(pirimidin-2-ilamino)-1*H*-bencimidazol-6-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 376 | {6-[2-(5-cloro-2-metilfenil)-4,7-difluoro-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 377 | {5-[2-(3-etinil-2-fluorofenil)-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 378 | 2-(3-cloro-2-fluorofenil)-3-{2-[(6-cloropiridazin-3-il)amino]-1*H*-bencimidazol-5-il}-3-hidroxi-2,3-dihidro-1*H*-isoindol-1-ona |
| 379 | 2-(3-cloro-2-fluorofenil)-4,7-difluoro-3-hidroxi-3-[2-(pirimidin-2-ilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |

| Entrada | Nombre |
|---|---|
| 380 | {5-[2-(2-fluoro-5-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 381 | (5-{2-[2-fluoro-5-(metiloxi)fenil]-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 382 | (5-{1-hidroxi-2-[5-metil-2-(metiloxi)fenil]-3-oxo-2,3-dihidro-1*H*-isoindol-1-il}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 383 | {5-[2-(3-etinil-5-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 384 | 2-(3-cloro-2-fluorofenil)-3-{2-[(5-cloropirimidin-2-il)amino]-1*H*-bencimidazol-5-il}-3-hidroxi-2,3-dihidro-1*H*-isoindol-1-ona |
| 385 | 2-(3-cloro-2-fluorofenil)-3-hidroxi-3-{2-[(4-metilpirimidin-2-il)amino]-1*H*-bencimidazol-5-il}-2,3-dihidro-1*H*-isoindol-1-ona |
| 386 | 3-(2-{[4,6-bis(metiloxi)pirimidin-2-il]amino}-1*H*-bencimidazol-5-il)-2-(3-cloro-2-fluorofenil)-3-hidroxi-2,3-dihidro-1*H*-isoindol-1-ona |
| 387 | 2-(3-cloro-2-fluorofenil)-3-hidroxi-3-(2-{[4-metil-6-(metiloxi)pirimidin-2-il]amino}-1*H*-bencimidazol-5-il)-2,3-dihidro-1*H*-isoindol-1-ona |
| 388 | 3-hidroxi-2-(3-metilfenil)-3-[2-(pirazin-2-ilamino)-1*H*-bencimidazol-6-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 389 | 2-(5-cloro-2-metilfenil)-3-hidroxi-3-[2-(pirazin-2-ilamino)-1*H*-bencimidazol-6-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 390 | {6-[2-(2-fluoro-3-metilfenil)-1-hidroxi-3-oxo-2,3-dihidro-1*H*-isoindol-1-il]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 391 | 3-hidroxi-2-[3-(metiloxi)fenil]-3-[2-(pirazin-2-ilamino)-1*H*-bencimidazol-5-il]-2,3-dihidro-1*H*-isoindol-1-ona |
| 392 | {6-[(2-{[(2-tienilmetil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 393 | {6-[(2-{[(3-metilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 394 | {6-[(2-{[(3-bromofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 395 | {6-[(2-{[(3-clorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 396 | {6-[(2-{[(3-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 397 | (6-{[2-({[3-(metiloxi)fenil]amino}carbonil)fenil]carbonil}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 398 | (6-{[2-({[3-(trifluorometil)fenil]amino}carbonil)fenil]carbonil}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 399 | {6-[(2-{[(3-etilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 400 | {6-[(2-{[(3-etinilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 401 | {6-[(2-{[(3-cloro-4-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 402 | {6-[(2-{[(5-cloro-2-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 403 | {6-[(2-{[(3-yodofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 404 | (6-{[2-({[3-(1-metiletil)fenil]amino}carbonil)fenil]carbonil}-1*H*-bencimidazol-2-il)carbamato de metilo |
| 405 | {6-[(2-{[(3-tienilmetil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 406 | {6-[(2-{[(3-bromo-4-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 407 | {6-[(2-{[(3-cloro-2-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 408 | {6-[(2-{[(4-fluoro-3-metilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 409 | {6-[(2-{[(5-bromo-2-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 410 | {6-[(2-{[(5-bromo-2,4-difluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 411 | {6-[(2-{[(5-cloro-2,4-difluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 412 | {6-[(2-{[(3-bromo-2-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |

| Entrada | Nombre |
|---|---|
| 413 | {6-[(2-{[(3-etenilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 414 | {6-[(2-{[(3-etinil-2-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 415 | {6-[(2-{[(5-cloro-2-metilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 416 | {6-[(2-{[(5-bromo-2-metilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 417 | {6-[(2-{[(2-fluoro-3-yodofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 418 | {6-[(2-{[(3-etenil-2-fluorofenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |
| 419 | {6-[(2-{[(2-fluoro-5-metilfenil)amino]carbonil}fenil)carbonil]-1*H*-bencimidazol-2-il}carbamato de metilo |

**Tabla 7.**

**Inhibidores representativos de EGFR y/o VEGFR**

**[00235]** Los Compuestos de la Tabla 7 se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 7 se pueden usar para practicar la invención.

| Entrada | Nombre |
|---|---|
| 1 | (3*Z*)-3-[[5-(metiloxi)-1*H*-bencimidazol-2-il](fenil)metiliden]-5-{[1-(fenilmetil)pirrolidin-3- |

| Entrada | Nombre |
|---|---|
| | il]amino}-1,3-dihidro-2*H*-indol-2-ona |
| 2 | (3*Z*)-5-[(1-etilpiperidin-3-il)amino]-3-[[5-(metiloxi)-1*H*-bencimidazol-2-il](fenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 3 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[[5-(metiloxi)-1*H*-bencimidazol-2-il](fenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 4 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[1*H*-imidazol-2-il(fenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 5 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-{[5-(metiloxi)-1*H*-bencimidazol-2-il][4-(metiloxi)fenil]metiliden}-1,3-dihidro-2*H*-indol-2-ona |
| 6 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[[5-(metiloxi)-1*H*-bencimidazol-2-il](4-metilfenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 7 | (3*Z*)-3-[1*H*-bencimidazol-2-il(4-nitrofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 8 | (3*Z*)-3-{1*H*-bencimidazol-2-il[4-(metiloxi)fenil]metiliden}-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 9 | (3*Z*)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 10 | (3*Z*)-3-[[5-(metiloxi)-1*H*-bencimidazol-2-il](fenil)metiliden]-5-[(2,2,6,6-tetrametilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 11 | (3*Z*)-3-[(4-aminofenil)(1*H*-bencimidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 12 | (3*Z*)-3-[1*H*-bencimidazol-2-il(4-metilfenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 13 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[1*H*-imidazol-2-il(4-metilfenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 14 | (3*Z*)-5-[(1-etilpiperidin-4-il)oxi]-3-[[5-(metiloxi)-1*H*-bencimidazol-2-il](fenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 15 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-{1*H*-imidazol-2-il[4-(metiloxi)fenil]metiliden}-1,3-dihidro-2*H*-indol-2-ona |

| Entrada | Nombre |
|---|---|
| 16 | (3*Z*)-3-[1*H*-bencimidazol-2-il(4-fluorofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 17 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3,5-difluorofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 18 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-fluorofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 19 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-nitrofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 20 | 3-((*Z*)-1*H*-bencimidazol-2-il{5-[(1-etilpiperidin-4-il)amino]-2-oxo-1,2-dihidro-3*H*-indol-3-iliden}metil)benzonitrilo |
| 21 | (3*Z*)-3-[(3-aminofenil)(1*H*-bencimidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 22 | (3*Z*)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-5-(piperidin-4-ilamino)-1,3-dihidro-2*H*-indol-2-ona |
| 23 | 3-((*Z*)-1*H*-bencimidazol-2-il{5-[(1-etilpiperidin-4-il)amino]-2-oxo-1,2-dihidro-3*H*-indol-3-iliden}metil)bencenocarboximidamida |
| 24 | (3*Z*)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 25 | (3*Z*)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-5-[(2,2,6,6-tetrametilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 26 | (3*Z*)-3-{1*H*-bencimidazol-2-il[3-(metiloxi)fenil]metiliden}-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 27 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-clorofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 28 | 2-(2-{2-[(*Z*)-{5-[(1-etilpiperidin-4-il)amino]-2-oxo-1,2-dihidro-3*H*-indol-3-iliden}(fenil)metil]-1*H*-imidazol-4-il}etil)-1*H*-isoindole-1,3(2*H*)-diona |
| 29 | (3*Z*)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-5-({1-[2-(dimetilamino)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 30 | (3*Z*)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-5-{[1-(metilsulfonil)piperidin-4-il]amino}-1,3-dihidro-2*H*-indol- |

| Entrada | Nombre |
|---|---|
| | 2-ona |
| 31 | (3*Z*)-5-(8-azabiciclo[3,2,1]oct-3-ilamino)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 32 | (3*Z*)-3-{1*H*-bencimidazol-2-il[3-(metiloxi)fenil]metiliden}-5-[(1-etilpiperidin-4-il)oxi]-1,3-dihidro-2*H*-indol-2-ona |
| 33 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3,5-difluorofenil)metiliden]-5-[(1-etilpiperidin-4-il)oxi]-1,3-dihidro-2*H*-indol-2-ona |
| 34 | (3*Z*)-3-[1*H*-bencimidazol-2-il(fenil)metiliden]-5-{[1-(fenilmetil)piperidin-4-il]oxi}-1,3-dihidro-2*H*-indol-2-ona |
| 35 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-clorofenil)metiliden]-5-[(1-etilpiperidin-4-il)oxi]-1,3-dihidro-2*H*-indol-2-ona |
| 36 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3,5-difluorofenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}oxi)-1,3-dihidro-2*H*-indol-2-ona |
| 37 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-clorofenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}oxi)-1,3-dihidro-2*H*-indol-2-ona |
| 38 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-clorofenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 39 | (3*Z*)-3-{1*H*-bencimidazol-2-il[3-(metiloxi)fenil]metiliden}-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 40 | (3*Z*)-3-[(3-clorofenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 41 | (3*Z*)-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 42 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3,5-difluorofenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 43 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-clorofenil)metiliden]-5-[(1-etilpiperidin-4-il)(metil)amino]-1,3-dihidro-2*H*-indol- |

| Entrada | Nombre |
|---|---|
| | 2-ona |
| 44 | (3*Z*)-3-[(3-clorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)oxi]-1,3-dihidro-2*H*-indol-2-ona |
| 45 | (3*Z*)-3-[1*H*-bencimidazol-2-il(4-clorofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 46 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-fluorofenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 47 | (3*Z*)-3-[1*H*-bencimidazol-2-il(4-fluorofenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 48 | (3*Z*)-3-[(3-clorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 49 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 50 | (3*Z*)-3-[1*H*-bencimidazol-2-il(3-fluoro-4-metilfenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 51 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(3-fluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 52 | (3*Z*)-3-[1*H*-bencimidazol-2-il(4-fluoro-3-metilfenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 53 | (3*Z*)-3-[(3-cloro-4-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 54 | (3*Z*)-3-[(3,4-difluorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 55 | (3*Z*)-3-[(5-cloro-1*H*-bencimidazol-2-il)(fenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 56 | (3*Z*)-3-[(5-cloro-1*H*-bencimidazol-2-il)(3,5-difluorofenil)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |

| Entrada | Nombre |
|---|---|
| 57 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(3-fluoro-4-metilfenil)(1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 58 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(4-fluorofenil)(1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 59 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[1*H*-imidazol-2-il(4-propilfenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 60 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-{1*H*-imidazol-2-il[4-(trifluorometil)fenil]metiliden}-1,3-dihidro-2*H*-indol-2-ona |
| 61 | (3*E*)-3-[(3,5-difluorofenil)(5-fluoro-1*H*-bencimidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 62 | (3*Z*)-3-[(3,5-difluorofenil)(5-fluoro-1*H*-bencimidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 63 | (3*Z*)-3-[(3-fluoro-4-metilfenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 64 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(4-metil-1*H*-imidazol-2-il)(4-metilfenil)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 65 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[[3-fluoro-4-(trifluorometil)fenil](1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 66 | (3*Z*)-3-[(4-clorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 67 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(3-fluoro-4-metilfenil)(4-metil-1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 68 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-{1*H*-imidazol-2-il[6-(trifluorometil)piridin-3-il]metiliden}-1,3-dihidro-2*H*-indol-2-ona |
| 69 | (3*Z*)-3-[1*H*-imidazol-2-il(4-metilfenil)metiliden]-5-({1-[2- |

| Entrada | Nombre |
|---|---|
| | (metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 70 | (3*Z*)-3-[(3-fluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 71 | (3*Z*)-3-{1*H*-imidazol-2-il[4-(trifluorometil)fenil]metiliden}-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 72 | (3*Z*)-3-[(5-cloro-1*H*-bencimidazol-2-il)(fenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 73 | (3*Z*)-3-[(3,5-difluorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 74 | (3*Z*)-3-[(3,5-difluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 75 | (3*Z*)-3-[(3,5-difluorofenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 76 | (3*Z*)-3-[(3,5-difluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 77 | (3*Z*)-3-[(4-metil-1*H*-imidazol-2-il)(4-metilfenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 78 | (3*Z*)-3-[(4-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 79 | (3*Z*)-3-[(3,4-difluorofenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 80 | (3*Z*)-3-[(3-cloro-4-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |

| Entrada | Nombre |
|---|---|
| 81 | (3*Z*)-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-(piperidin-4-ilamino)-1,3-dihidro-2*H*-indol-2-ona |
| 82 | (3*Z*)-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-{[1-(2-piperidin-1-iletil)piperidin-4-il]amino}-1,3-dihidro-2*H*-indol-2-ona |
| 83 | (3*Z*)-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-{[1-(2-morfolin-4-iletil)piperidin-4-il]amino}-1,3-dihidro-2*H*-indol-2-ona |
| 84 | (3*Z*)-5-({1-[2-(dietilamino)etil]piperidin-4-il}amino)-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 85 | (3*Z*)-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-{[1-(2-pirrolidin-1-iletil)piperidin-4-il]amino}-1,3-dihidro-2*H*-indol-2-ona |
| 86 | (3*Z*)-3-[1*H*-imidazol-2-il(4-metilfenil)metiliden]-5-[(1-metilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 87 | (3*Z*)-3-[(3-fluorofenil)(1*H*-1,2,4-triazol-5-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 88 | 2-{(*Z*)-(3-fluorofenil)[5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-2-oxo-1,2-dihidro-3*H*-indol-3-iliden]metil}-4-metil-1*H*-imidazol-5-carboxilato de etilo |
| 89 | (3*Z*)-3-[1*H*-imidazol-2-il(fenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 90 | (3*Z*)-3-{1*H*-imidazol-2-il[4-(metiloxi)fenil]metiliden}-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 91 | (3*Z*)-3-[(4-clorofenil)(1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 92 | (3*Z*)-3-[[3-fluoro-4-(trifluorometil)fenil](1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 93 | (3*Z*)-3-[(3-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-{[1- |

| Entrada | Nombre |
|---|---|
| | (metilsulfonil)piperidin-4-il]amino}-1,3-dihidro-2*H*-indol-2-ona |
| 94 | (3*Z*)-3-[1*H*-imidazol-2-il(4-propilfenil)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 95 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(3-fluorofenil)(4-fenilo-1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 96 | (3*Z*)-3-[(3-fluorofenil)(4-fenilo-1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 97 | (3*Z*)-3-[(3-fluoro-4-metilfenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 98 | (3*Z*)-3-{1*H*-imidazol-2-il[6-(trifluorometil)piridin-3-il]metiliden}-5-({1-[2-(metiloxi)etil]piperidin-4-il}amino)-1,3-dihidro-2*H*-indol-2-ona |
| 99 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(3-fluorofenil)(1*H*-1,2,4-triazol-5-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 100 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[[2-fluoro-4-(trifluorometil)fenil](1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 101 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-{(4-metil-1*H*-imidazol-2-il)[4-(trifluorometil)fenil]metiliden}-1,3-dihidro-2*H*-indol-2-ona |
| 102 | (3*Z*)-3-[(4-clorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 103 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[[3-fluoro-4-(trifluorometil)fenil](4-metil-1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 104 | (3*Z*)-3-[(3,4-difluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |

| Entrada | Nombre |
|---|---|
| 105 | (3*Z*)-3-[(3-cloro-4-fluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 106 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(4-fluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 107 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[(2-fluorofenil)(1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 108 | (3*Z*)-5-[(1-etilpiperidin-4-il)amino]-3-[[2-fluoro-4-(trifluorometil)fenil](4-metil-1*H*-imidazol-2-il)metiliden]-1,3-dihidro-2*H*-indol-2-ona |
| 109 | (3*Z*)-3-[(2,3-difluorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 110 | (3*Z*)-3-[(2,3-difluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 111 | (3*Z*)-3-[(2,4-difluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 112 | (3*Z*)-3-[(2,4-difluorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 113 | (3*Z*)-3-[(2-fluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 114 | (3*Z*)-3-[(3-trifluorometilfenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 115 | (3*Z*)-3-[(3-trifluorometilfenil)( 4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 116 | (3*Z*)-3-[(2,4-dicloro-5-fluorofenil)(1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 117 | (3*Z*)-3-[(2,4-dicloro-5-fluorofenil)(4-metil-1*H*-imidazol-2- |

| Entrada | Nombre |
|---|---|
| | il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |
| 118 | (3*Z*)-3-[(4-cloro-2-fluorofenil)(4-metil-1*H*-imidazol-2-il)metiliden]-5-[(1-etilpiperidin-4-il)amino]-1,3-dihidro-2*H*-indol-2-ona |

**Tabla 8. Inhibidores de c-KIT**

**[00236]** Los Compuestos de la Tabla 8 se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 8 se pueden usar para practicar la invención.

| Entrada | Nombre |
|---|---|
| 1 | *N*-[5-cloro-2-(metiloxi)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 2 | *N*-fenilo-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 3 | *N*-(2-metilfenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 4 | *N*-(2-clorofenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 5 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 6 | 2-[({[3-(1*H*-tetrazol-1-il)fenil]oxi}acetil)amino]-4,5,6,7-tetrahidro-1-benzotiofeno-3-carboxilato de etilo |
| 7 | *N*-(3-cloro-2-metilfenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 8 | *N*-(3-fluorofenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 9 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(2*H*-tetrazol-5-il)fenil]oxi}acetamida |

| Entrada | Nombre |
|---|---|
| 10 | *N*-(4-cloro-2-fluorofenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 11 | *N*-(4-bromo-3-metilfenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 12 | *N*-(4-morfolin-4-ilfenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 13 | *N*-[4-fluoro-3-(trifluorometil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 14 | *N*-[4-bromo-3-(trifluorometil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 15 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 16 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}propanamida |
| 17 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(5-metil-1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 18 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[2-metil-5-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 19 | *N*-(4-clorofenil)-*N*-metil-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 20 | *N*-[4-cloro-2-(trifluorometil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 21 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(2,5-dioxopirrolidin-1-il)fenil]oxi}acetamida |
| 22 | (2E)-*N*-[4-cloro-3-(trifluorometil)fenil]-3-[3-(1*H*-tetrazol-1-il)fenil]prop-2-enamida |
| 23 | *N*-[4-fluoro-3-(trifluorometil)fenil]-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 24 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(2-metil-2*H*-tetrazol-5-il)fenil]oxi}acetamida |
| 25 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[2,4-dicloro-5-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |

| Entrada | Nombre |
|---|---|
| 26 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]tio}acetamida |
| 27 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*~2~-[3-(1*H*-tetrazol-1-il)fenil]glicinamida |
| 28 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[2-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 29 | 1-{3-[(2-{[4-cloro-3-(trifluorometil)fenil]amino}-2-oxoetil)oxi]fenil}-1*H*-1,2,3-triazol-4-carboxilato de metilo |
| 30 | {4-[({[3-(1*H*-tetrazol-1-il)fenil]oxi}acetil)amino]fenil}carbamato de 1,1-dimetiletilo |
| 31 | {4-[({[4-(1*H*-tetrazol-1-il)fenil]oxi}acetil)amino]fenil}carbamato de 1,1-dimetiletilo |
| 32 | *N*-{4-[(1-etilpiperidin-4-il)amino]fenil}-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 33 | *N*-{4-[(1-etilpiperidin-3-il)amino]fenil}-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 34 | *N*-(4-aminofenil)-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 35 | *N*-{4-[(1-etilpiperidin-4-il)amino]fenil}-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 36 | *N*-{4-[(1-etilpiperidin-3-il)amino]fenil}-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 37 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(3-piridin-4-ilfenil)oxi]acetamida |
| 38 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*~2~-metil-*N*~2~-[3-(1*H*-tetrazol-1-il)fenil]glicinamida |
| 39 | *N*-1,3-benzotiazol-2-il-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |

| Entrada | Nombre |
|---|---|
| 40 | *N*-quinolin-8-il-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 41 | *N*-(2,3-dihidro-1,4-benzodioxin-6-il)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 42 | *N*-isoquinolin-5-il-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 43 | *N*-{3-[(fenilmetil)oxi]fenil}-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 44 | *N*-[5-metil-2-(metiloxi)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 45 | *N*-[2,5-bis(metiloxi)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 46 | *N*-(6-fluoro-1,3-benzotiazol-2-il)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 47 | 3-[({[3-(1*H*-tetrazol-1-il)fenil]oxi}acetil)amino]benzoato de metilo |
| 48 | 5-cloro-2-[({[3-(1*H*-tetrazol-1-il)fenil]oxi}acetil)amino]benzamida |
| 49 | *N*-[5-cloro-2,4-bis(metiloxi)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 50 | *N*-[2-(feniloxi)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 51 | *N*-[3-(aminosulfonil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 52 | *N*-[2-(metiloxi)-5-(trifluorometil)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 53 | *N*-(4-{[(4-metilfenil)sulfonil]amino}fenil)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 54 | *N*-(5-fenilo-1*H*-pirazol-3-il)-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 55 | *N*-1,3-benzotiazol-2-il-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |

| Entrada | Nombre |
|---|---|
| 56 | *N*-quinolin-8-il-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 57 | 2-{3-[(2-{[4-cloro-3-(trifluorometil)fenil]amino}-2-oxoetil)oxi]fenil}-1*H*-pirrol-1-carboxilato de 1,1-dimetiletilo |
| 58 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(1*H*-pirrol-2-il)fenil]oxi}acetamida |
| 59 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(3-pirimidin-5-ilfenil)oxi]acetamida |
| 60 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(1*H*-1,2,3-triazol-1-il)fenil]oxi}acetamida |
| 61 | 4-cloro-*N*-(2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}etil)-3-(trifluorometil)anilina |
| 62 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*-(2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}etil)formamida |
| 63 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(3-piridin-3-ilfenil)oxi]acetamida |
| 64 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(3-furan-3-ilfenil)oxi]acetamida |
| 65 | (2E)-*N*-[4-fluoro-3-(trifluorometil)fenil]-3-[3-(1*H*-tetrazol-1-il)fenil]prop-2-enamida |
| 66 | *N*-[4-fluoro-3-(trifluorometil)fenil]-3-[3-(1*H*-tetrazol-1-il)fenil]propanamida |
| 67 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[6-(1*H*-tetrazol-1-il)pirimidin-4-il]oxi}acetamida |
| 68 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-(3,5-dimetilisoxazol-4-il)fenil]oxi}acetamida |
| 69 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(3-quinolin-7-ilfenil)oxi]acetamida |
| 70 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(3-furan-2-ilfenil)oxi]acetamida |

| Entrada | Nombre |
|---|---|
| 71 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[3-(1*H*-tetrazol-1-il)fenil]hidrazinocarboxamida |
| 72 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(3-dibenzo[b,d]furan-4-ilfenil)oxi]acetamida |
| 73 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(4-pirimidin-5-ilfenil)oxi]acetamida |
| 74 | *N*-metil-*N*-[4-(metiloxi)fenil]-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 75 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N'*-{[3-(1*H*-tetrazol-1-il)fenil]metil}urea |
| 76 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*-metil-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 77 | *N*-[4-fluoro-3-(trifluorometil)fenil]-*N*~2~-[3-(1*H*-tetrazol-1-il)fenil]glicinamida |
| 78 | *N*-[4-fluoro-3-(trifluorometil)fenil]-2-{[3-(piridin-2-ilamino)fenil]oxi}acetamida |
| 79 | *N*-[2-fluoro-5-(trifluorometil)fenil]-2-[3-(1*H*-tetrazol-1-il)fenil]hidrazinocarboxamida |
| 80 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(4-piridin-3-ilfenil)oxi]acetamida |
| 81 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N'*-[(3-pirimidin-5-ilfenil)metil]urea |
| 82 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N'*-[(4-pirimidin-5-ilfenil)metil]urea |
| 83 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N'*-[(4-piridin-3-ilfenil)metil]urea |
| 84 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(1*H*-tetrazol-1-il)fenil]metilo |
| 85 | *N*-[4-fluoro-3-(trifluorometil)fenil]-2-[(4-pirimidin-5-ilfenil)oxi]acetamida |
| 86 | *N*~2~-[4-cloro-3-(trifluorometil)fenil]-*N*-[3-(1*H*-tetrazol-1-il)fenil]glicinamida |

| Entrada | Nombre |
|---|---|
| 87 | 2-{[4-cloro-3-(trifluorometil)fenil]oxi}-*N*-[3-(1*H*-tetrazol-1-il)fenil]acetamida |
| 88 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-metil-4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 89 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[4-(1*H*-1,2,3-triazol-1-il)fenil]oxi}acetamida |
| 90 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[3-fluoro-4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 91 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[2-fluoro-4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 92 | *N*-({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)-3-(1*H*-tetrazol-1-il)bencensulfonamida |
| 93 | *N*-({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)-*N*-metil-3-(1*H*-tetrazol-1-il)bencensulfonamida |
| 94 | *N*-[4-fluoro-3-(trifluorometil)fenil]-2-[(4-piridin-3-ilfenil)oxi]acetamida |
| 95 | 2-({4-[2,4-bis(metiloxi)pirimidin-5-il]fenil}oxi)-*N*-[4-fluoro-3-(trifluorometil)fenil]acetamida |
| 96 | 2-({4-[2,4-bis(metiloxi)pirimidin-5-il]fenil}oxi)-*N*-[4-cloro-3-(trifluorometil)fenil]acetamida |
| 97 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[(4-piridin-4-ilfenil)oxi]acetamida |
| 98 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*~2~-[3-(metiloxi)-4-(1*H*-tetrazol-1-il)fenil]glicinamida |
| 99 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*~2~-[4-(metiloxi)-3-(1*H*-tetrazol-1-il)fenil]glicinamida |

| Entrada | Nombre |
|---|---|
| 100 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*~2~-[4-(1*H*-tetrazol-1-il)fenil]glicinamida |
| 101 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(2,3,5,6-tetrafluoro-4-pirimidin-5-ilfenil)hidrazinocarboxamida |
| 102 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[4-(1*H*-tetrazol-1-il)fenil]metil}urea |
| 103 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(4-pirimidin-5-ilfenil)hidrazinocarboxamida |
| 104 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[(3-piridin-3-ilfenil)metil]urea |
| 105 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-metil-2-{[3-(1*H*-tetrazol-1-il)fenil]oxi}propanamida |
| 106 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[4-(1*H*-tetrazol-1-il)fenil]oxi}propanamida |
| 107 | *N*-({4-[2,4-bis(metiloxi)pirimidin-5-il]fenil}metil)-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 108 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({3-[2-(metiloxi)pirimidin-5-il]fenil}metil)urea |
| 109 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({3-[6-(metiloxi)piridin-3-il]fenil}metil)urea |
| 110 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({4-[2-(metiloxi)pirimidin-5-il]fenil}metil)urea |
| 111 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({4-[6-(metiloxi)piridin-3-il]fenil}metil)urea |
| 112 | 2-{4-[(2-{[4-cloro-3-(trifluorometil)fenil]amino}-2-oxoetil)oxi]fenil}-1*H*-indole-1-carboxilato de 1,1-dimetiletilo |

| Entrada | Nombre |
|---|---|
| 113 | *N*-({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)-4-(1*H*-tetrazol-1-il)bencensulfonamida |
| 114 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*~2~-[3-(2*H*-tetrazol-5-il)fenil]glicinamida |
| 115 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[2,6-difluoro-4-(1*H*-tetrazol-1-il)fenil]oxi}acetamida |
| 116 | [4-cloro-3-(trifluorometil)fenil]carbamato de (3-piridin-3-ilfenil)metilo |
| 117 | [4-cloro-3-(trifluorometil)fenil]carbamato de (3-pirimidin-5-ilfenil)metilo |
| 118 | [4-cloro-3-(trifluorometil)fenil]carbamato de (3-piridin-4-ilfenil)metil |
| 119 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-[4-(1*H*-tetrazol-1-il)fenil]hidrazinocarboxamida |
| 120 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(4-piridin-3-ilfenil)hidrazinocarboxamida |
| 121 | [4-cloro-3-(trifluorometil)fenil]carbamato de (4-piridin-3-ilfenil)metilo |
| 122 | ([4-cloro-3-(trifluorometil)fenil]carbamato de 4-piridin-4-ilfenil)metilo |
| 123 | [4-cloro-3-(trifluorometil)fenil]carbamato de (4-pirimidin-5-ilfenil)metilo |
| 124 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[(4-piridin-4-ilfenil)metil]urea |
| 125 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(3-piridin-3-ilfenil)hidrazinocarboxamida |
| 126 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(3-pirimidin-5-ilfenil)hidrazinocarboxamida |
| 127 | *N*-[5-cloro-2,4-bis(metiloxi)fenil]-*N*'-[(4-pirimidin-5-ilfenil)metil]urea |

| Entrada | Nombre |
|---|---|
| 128 | *N*-[5-cloro-2,4-bis(metiloxi)fenil]-*N*'-[(4-piridin-3-ilfenil)metil]urea |
| 129 | [5-cloro-2,4-bis(metiloxi)fenil]carbamato de (4-pirimidin-5-ilfenilo) |
| 130 | [5-cloro-2,4-bis(metiloxi)fenil]carbamato de (4-piridin-3-ilfenilo) |
| 131 | [4-cloro-3-(trifluorometil)fenil]carbamato de 1-(4-piridin-3-ilfenil)etilo |
| 132 | [4-cloro-3-(trifluorometil)fenil]carbamato de 1-(4-pirimidin-5-ilfenil)etilo |
| 133 | *N*-[5-cloro-2,4-bis(metiloxi)fenil]-*N*'-[(3-piridin-3-ilfenil)metil]urea |
| 134 | *N*-[5-cloro-2,4-bis(metiloxi)fenil]-*N*'-[(3-pirimidin-5-ilfenil)metil]urea |
| 135 | [5-cloro-2,4-bis(metiloxi)fenil]carbamato de (3-piridin-3-ilfenilo) |
| 136 | [5-cloro-2,4-bis(metiloxi)fenil]carbamato de (3-pirimidin-5-ilfenilo) |
| 137 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-metil-2-(3-pirimidin-5-ilfenil)hidrazinocarboxamida |
| 138 | *N*-[4-fluoro-3-(trifluorometil)fenil]-*N*'-[(4-piridin-3-ilfenil)metil]urea |
| 139 | *N*-{[3-(6-aminopiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 140 | *N*-{[4-(6-aminopiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 141 | *N*-{[3-(2-aminopirimidin-5-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 142 | *N*-{[4-(2-aminopirimidin-5-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 143 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[1-(4-piridin-3-ilfenil)etil]urea |

| Entrada | Nombre |
|---|---|
| 144 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[1-(4-pirimidin-5-ilfenil)etil]urea |
| 145 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[4-(1*H*-indol-2-il)fenil]oxi}acetamida |
| 146 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(isoquinolin-7-iloxi)acetamida |
| 147 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(4-piridin-4-ilfenil)hidrazinocarboxamida |
| 148 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-(3-piridin-4-ilfenil)hidrazinocarboxamida |
| 149 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[(3-piridin-4-ilfenil)metil]urea |
| 150 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[(3-quinoxalin-6-ilfenil)metil]urea |
| 151 | 3-amino-6-(3-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazino-2-carboxilato de metilo |
| 152 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[(4-quinoxalin-6-ilfenil)metil]urea |
| 153 | *N*-{[3-(2-amino-5-metilpiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 154 | 3-amino-6-(4-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazino-2-carboxilato de metilo |
| 155 | [3-cloro-4-(metiloxi)fenil]carbamato de [3-(1*H*-tetrazol-1-il)fenil]metilo |
| 156 | *N*-[3-cloro-4-(metiloxi)fenil]-*N*'-{[3-(1*H*-tetrazol-1-il)fenil]metil}urea |
| 157 | *N*-[4-cloro-3-(trifluorometil)fenil]-2-{[4-(5-hidroxi-1*H*-tetrazol-1-il)fenil]oxi}acetamida |

| Entrada | Nombre |
|---|---|
| 158 | *N*-{[3-(2-amino-5-cloropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 159 | *N*-{[4-(2-amino-5-cloropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 160 | *N*-{[3-(6-cloropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 161 | *N*-{[4-(6-cloropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 162 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[4-(pirimidin-2-iloxi)fenil]metil}urea |
| 163 | *N*-({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)-3-(1*H*-tetrazol-1-il)benzamida |
| 164 | 3-amino-6-(3-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)-*N*-[2-(dimetilamino)etil]pirazino-2-carboxamida |
| 165 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[3-(6-fluoropiridin-3-il)fenil]metil}urea |
| 166 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({3-[2-(metiloxi)piridin-3-il]fenil}metil)urea |
| 167 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[4-(6-fluoropiridin-3-il)fenil]metil}urea |
| 168 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({4-[2-(metiloxi)piridin-3-il]fenil}metil)urea |
| 169 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[4-(6-metilpiridin-3-il)fenil]metil}urea |
| 170 | *N*-{[4-(2-amino-5-fluoropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |

| Entrada | Nombre |
|---|---|
| 171 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[3-(6-metilpiridin-3-il)fenil]metil}urea |
| 172 | *N*-{[4-(2-aminopiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 173 | *N*-{[3-(2-aminopiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 174 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(6-metilpiridin-3-il)fenil]metilo |
| 175 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(2-amino-5-fluoropiridin-3-il)fenil]metilo |
| 176 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(2-aminopiridin-3-il)fenil]metilo |
| 177 | [4-cloro-3-(trifluorometil)fenil]carbamato de (3-pirazin-2-ilfenil)metilo |
| 178 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({3-[6-(hidroximetil)piridin-3-il]fenil}metil)urea |
| 179 | *N*-{[3-(6-acetilpiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 180 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[3-(6-cianopiridin-3-il)fenil]metil}urea |
| 181 | (3S)-3-({[3-amino-6-(3-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazin-2-il]carbonil}amino)piperidino-1-carboxilato de 1,1-dimetiletilo |
| 182 | 3-amino-6-(3-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)-*N*-[(3S)-piperidin-3-il]pirazino-2-carboxamida |
| 183 | (3S)-3-({[3-amino-6-(4-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazin-2-il]carbonil}amino)piperidino-1-carboxilato de 1,1-dimetiletilo |

| Entrada | Nombre |
|---|---|
| 184 | 3-amino-6-(4-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)-*N*-[(3S)-piperidin-3-il]pirazino-2-carboxamida |
| 185 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(7*H*-pirrolo[2,3-d]pirimidin-4-il)fenil]metilo |
| 186 | *N*-{[3-(2-amino-5-fluoropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 187 | [4-cloro-3-(trifluorometil)fenil]carbamato de [6-(1*H*-tetrazol-1-il)piridin-2-il]metilo |
| 188 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(1*H*-bencimidazol-2-il)fenil]metilo |
| 189 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(6-amino-2-metilpiridin-3-il)fenil]metilo |
| 190 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({3-[5-(metiltio)piridin-3-il]fenil}metil)urea |
| 191 | [4-(6-metilpiridin-3-il)fenil]metil [4-cloro-3-(trifluorometil)fenil]carbamato de metilo |
| 192 | [4-cloro-3-(trifluorometil)fenil]carbamato de [4-(2-amino-5-fluoropiridin-3-il)fenil]metilo |
| 193 | [4-cloro-3-(trifluorometil)fenil]carbamato de [4-(2-aminopiridin-3-il)fenil]metilo |
| 194 | [4-cloro-3-(trifluorometil)fenil]carbamato de (4-pirazin-2-ilfenil)metilo |
| 195 | [4-cloro-3-(trifluorometil)fenil]carbamato de [4-(7*H*-pirrolo[2,3-d]pirimidin-4-il)fenil]metilo |
| 196 | [4-cloro-3-(trifluorometil)fenil]carbamato de [4-(6-amino-2-metilpiridin-3-il)fenil]metilo |

| Entrada | Nombre |
|---|---|
| 197 | 1,3-benzotiazol-2-ilcarbamato de [3-(1*H*-tetrazol-1-il)fenil]metilo |
| 198 | (5-bromopiridin-2-il)carbamato de [3-(1*H*-tetrazol-1-il)fenilo] |
| 199 | (3,5-dimetilfenil)carbamato de (3-piridin-3-ilfenil)metilo |
| 200 | [5-cloro-2-(metiloxi)fenil]carbamato de (3-piridin-3-ilfenilo) |
| 201 | [4-cloro-3-(trifluorometil)fenil]carbamato de [4-(1*H*-tetrazol-1-il)fenil]metilo |
| 202 | [5-cloro-2-(metiloxi)fenil]carbamato de (3-pirimidin-5-ilfenilo) |
| 203 | (3,4-dimetilfenil)carbamato de (4-pirimidin-5-ilfenil)metilo |
| 204 | (3,4-dimetilfenil)carbamato de (3-piridin-3-ilfenil)metilo |
| 205 | 3-({[3-amino-6-(3-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazin-2-il]carbonil}amino)piperidino-1-carboxilato de 1,1-dimetiletilo |
| 206 | 3-({[3-amino-6-(4-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazin-2-il]carbonil}amino)piperidino-1-carboxilato de 1,1-dimetiletilo |
| 207 | 3-amino-6-(3-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)-*N*-piperidin-3-ilpirazino-2-carboxamida |
| 208 | 3-amino-6-(4-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)-*N*-piperidin-3-ilpirazino-2-carboxamida |

| Entrada | Nombre |
|---|---|
| 209 | 4-{[3-amino-6-(3-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazin-2-il]carbonil}piperazino-1-carboxilato de 1,1-dimetiletilo |
| 210 | 4-{[3-amino-6-(4-{[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]metil}fenil)pirazin-2-il]carbonil}piperazino-1-carboxilato de 1,1-dimetiletilo |
| 211 | *N*-({3-[5-amino-6-(piperazin-1-ilcarbonil)pirazin-2-il]fenil}metil)-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 212 | *N*-({4-[5-amino-6-(piperazin-1-ilcarbonil)pirazin-2-il]fenil}metil)-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 213 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[3-(1*H*-pirazol-4-il)fenil]metil}urea |
| 214 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[4-(1*H*-pirazol-4-il)fenil]metil}urea |
| 215 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(2-piperazin-1-ilpirimidin-5-il)fenil]metilo |
| 216 | [4-cloro-3-(trifluorometil)fenil]carbamato de [4-(2-piperazin-1-ilpirimidin-5-il)fenil]metilo |
| 217 | *N*-{[3-(2-cloropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 218 | *N*-{[4-(2-cloropiridin-3-il)fenil]metil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 219 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[3-(2-fluoropiridin-3-il)fenil]metil}urea |
| 220 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-{[4-(2-fluoropiridin-3-il)fenil]metil}urea |
| 221 | [3-(trifluorometil)fenil]carbamato de [3-(1*H*-tetrazol-1-il)fenil]metilo |

| Entrada | Nombre |
|---|---|
| 222 | [6-(trifluorometil)piridin-2-il]carbamato de [3-(1*H*-tetrazol-1-il)fenilo] |
| 223 | [4-(trifluorometil)piridin-2-il]carbamato de [3-(1*H*-tetrazol-1-il)fenil]metilo |
| 224 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-({3-[5-(metiltio)piridin-2-il]fenil}metil)urea |
| 225 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(2,6-dimetilpiridin-3-il)fenil]metilo |
| 226 | [4-cloro-3-(trifluorometil)fenil]carbamato de {3-[5-(metiloxi)piridin-3-il]fenil}metilo |
| 227 | [4-cloro-3-(trifluorometil)fenil]carbamato de 2,3'-bipiridin-6-ilmetilo |
| 228 | [4-cloro-3-(trifluorometil)fenil]carbamato de (6-pirimidin-5-ilpiridin-2-il)metilo |
| 229 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[(3-isoquinolin-4-ilfenil)metil]urea |
| 230 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[(4-isoquinolin-4-ilfenil)metil]urea |
| 231 | [4-(trifluorometil)piridin-2-il]carbamato de [6-(1*H*-tetrazol-1-il)piridin-2-il]metilo |
| 232 | [4-cloro-3-(trifluorometil)fenil]carbamato de [3-(1*H*-pirazol-4-il)fenil]metilo |
| 233 | [4-cloro-3-(trifluorometil)fenil]carbamato de [4-(1*H*-pirazol-4-il)fenil]metilo |

**Tabla 9. Inhibidores de c-KIT y/o Flt-3**

**[00237]** Los Compuestos de la Tabla 9 se pueden preparar como sales, solvatos, hidratos y/o isómeros farmacéuticamente aceptables de estos. Todas las combinaciones de sales, solvatos, hidratos e isómeros de los Compuestos de la Tabla 9 se pueden usar para practicar la invención.

| Entrada | Nombre |
|---|---|
| 1 | 4-((*E*)-2-{3-[6-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}etenil)fenol |
| 2 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-(4-{3-[5-(4-etilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 3 | *N*-(3-etilfenil)-*N*'-(4-{3-[5-(4-etilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 4 | *N*-(4-{3-[5-(4-etilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)-*N*'-[3-(trifluorometil)fenil]urea |
| 5 | *N*-(3-acetilfenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 6 | *N*-(3,4-diclorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 7 | *N*-(3-bromofenil)-*N*'-(4-{3-[6-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 8 | *N*-[4-fluoro-3-(trifluorometil)fenil]-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 9 | *N*-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)-*N*'-[4-(feniloxi)fenil]urea |
| 10 | *N*-(3-clorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 11 | *N*-[3,5-bis(metiloxi)fenil]-*N*'-(4-{3-[6-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 12 | *N*-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)-*N*'-{4-[(trifluorometil)oxi]fenil}urea |
| 13 | *N*-(4-{3-[6-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)-*N*'-[4-(trifluorometil)fenil]urea |

| Entrada | Nombre |
|---|---|
| 14 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 15 | *N*-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)-*N*'-[3-(trifluorometil)fenil]urea |
| 16 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-(4-{3-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-5-il}fenil)urea |
| 17 | *N*-(3,4-dimetilfenil)-*N*'-(4-{5-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-3-il}fenil)urea |
| 18 | *N*-(4-clorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 19 | *N*-(3,5-difluorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 20 | *N*-[3-(metiloxi)fenil]-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 21 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-(4-{3-[4-(4-etilpiperazin-1-il)fenil]-1*H*-pirazol-5-il}fenil)urea |
| 22 | *N*-(3-fluorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 23 | *N*-(4-fluorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 24 | *N*-(3-cianofenil)-*N*'-(4-{3-[6-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 25 | *N*-(3,4-difluorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 26 | *N*-[3,4-bis(metiloxi)fenil]-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 27 | *N*-[5-cloro-2-(metiloxi)fenil]-*N*'-(4-{5-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-3-il}fenil)urea |

| Entrada | Nombre |
|---|---|
| 28 | *N*-(4-{5-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-3-il}fenil)-*N*'-[4-(feniloxi)fenil]urea |
| 29 | *N*-(2,4-difluorofenil)-*N*'-(4-{3-[6-(4-etilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 30 | *N*-{4-[3-(1*H*-bencimidazol-2-il)-1*H*-pirazol-5-il]fenil}-*N*'-[4-cloro-3-(trifluorometil)fenil]urea |
| 31 | *N*-{4-[3-(1*H*-bencimidazol-2-il)-1*H*-pirazol-5-il]fenil}-*N*'-[2-fluoro-5-(trifluorometil)fenil]urea |
| 32 | *N*-(2,4-difluorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 33 | *N*-{4-[3-(1*H*-bencimidazol-2-il)-1*H*-pirazol-5-il]fenil}-*N*'-fenilurea |
| 34 | *N*-[3,5-bis(trifluorometil)fenil]-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 35 | *N*-(2-fluorofenil)-*N*'-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 36 | 4-((*E*)-2-{5-[(*E*)-2-feniletenil]-1*H*-pirazol-3-il}etenil)fenol |
| 37 | 2-(metiloxi)-4-((*E*)-2-{5-[(*E*)-2-feniletenil]-1*H*-pirazol-3-il}etenil)fenol |
| 38 | *N*-(5-fluoro-2-metilfenil)-*N*'-(4-{3-[6-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 39 | *N*-(4-{3-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)-*N*'-fenilurea |
| 40 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-(4-{3-[3-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-5-il}fenil)urea |
| 41 | *N*-(2,4-difluorofenil)-*N*'-(4-{3-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-5-il}fenil)urea |
| 42 | *N*-(2,3-dihidro-1,4-benzodioxin-6-il)-*N*'-(4-{5-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-3-il}fenil)urea |

| Entrada | Nombre |
|---|---|
| 43 | *N*-[2,4-bis(metiloxi)fenil]-*N*'-(4-{5-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-3-il}fenil)urea |
| 44 | 4-((*E*)-2-{3-[(*E*)-2-(4-fluorofenil)etenil]-1*H*-pirazol-5-il}etenil)-2-(metiloxi)fenol |
| 45 | 4-{(*E*)-2-[3-(1-benzofuran-2-il)-1*H*-pirazol-5-il]etenil}fenol |
| 46 | *N*-(4-{3-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-5-il}fenil)-*N*'-(2-feniletil)etandiamida |
| 47 | 4-{(*E*)-2-[3-(1*H*-bencimidazol-2-il)-1*H*-pirazol-5-il]etenil}fenol |
| 48 | 4-((*E*)-2-{3-[(*E*)-2-(4-clorofenil)etenil]-1*H*-pirazol-5-il}etenil)-2-(metiloxi)fenol |
| 49 | 4-{(*E*)-2-[3-(1-benzotien-2-il)-1*H*-pirazol-5-il]etenil}fenol |
| 50 | *N*-[4-cloro-3-(trifluorometil)fenil]-*N*'-[4-(3-fenilo-1*H*-pirazol-5-il)fenil]urea |
| 51 | 4-((*E*)-2-{3-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-5-il}etenil)fenol |
| 52 | {4-[3-(1*H*-bencimidazol-2-il)-1*H*-pirazol-5-il]fenil}carbamato de 1,1-dimetiletilo |
| 53 | *N*-(5-fluoro-2-metilfenil)-*N*'-(4-{5-[4-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-3-il}fenil)urea |
| 54 | 4-[(*E*)-2-(3-fenilo-1*H*-pirazol-5-il)etenil]fenol |
| 55 | 2-(metiloxi)-4-[(*E*)-2-(5-fenilo-1*H*-pirazol-3-il)etenil]fenol |
| 56 | 4-[(*E*)-2-(5-naftalen-2-il-1*H*-pirazol-3-il)etenil]fenol |
| 57 | 4-{(*E*)-2-[5-(2-fluorofenil)-1*H*-pirazol-3-il]etenil}fenol |
| 58 | 4-((*E*)-2-{3-[3-(4-metilpiperazin-1-il)fenil]-1*H*-pirazol-5-il}etenil)fenol |
| 59 | 4-((*E*)-2-{3-[(*E*)-2-(2,4-difluorofenil)etenil]-1*H*-pirazol-5-il}etenil)-2-(metiloxi)fenol |

| Entrada | Nombre |
|---|---|
| 60 | 4-{(*E*)-2-[5-(4-fluorofenil)-1*H*-pirazol-3-il]etenil}fenol |
| 61 | 4-{(*E*)-2-[3-(4-clorofenil)-1*H*-pirazol-5-il]etenil}fenol |
| 62 | 4-[(*E*)-2-(5-piridin-2-il-1*H*-pirazol-3-il)etenil]fenol |
| 63 | 4-{(*E*)-2-[3-(5-cloro-1-benzofuran-2-il)-1*H*-pirazol-5-il]etenil}fenol |
| 64 | *N*-(1,1-dimetiletil)-*N*'-(4-{3-[5-(4-etilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-5-il}fenil)urea |
| 65 | 4-[(*E*)-2-(3-piridin-4-il-1*H*-pirazol-5-il)etenil]fenol |
| 66 | 4-{(*E*)-2-[3-(3-clorofenil)-1*H*-pirazol-5-il]etenil}fenol |
| 67 | 4-((*E*)-2-{5-[2-(metiloxi)fenil]-1*H*-pirazol-3-il}etenil)fenol |
| 68 | 4-{(*E*)-2-[3-(2-clorofenil)-1*H*-pirazol-5-il]etenil}fenol |
| 69 | 4-[(*E*)-2-(3-piridin-3-il-1*H*-pirazol-5-il)etenil]fenol |
| 70 | 4-((*E*)-2-{5-[3-(metiloxi)fenil]-1*H*-pirazol-3-il}etenil)fenol |
| 71 | (4-{3-[(*E*)-2-feniletenil]-1*H*-pirazol-5-il}fenil)carbamato de 1,1-dimetiletil |
| 72 | 4-{(*E*)-2-[3-(3,4-diclorofenil)-1*H*-pirazol-5-il]etenil}fenol |
| 73 | 2-{5-[(*E*)-2-feniletenil]-1*H*-pirazol-3-il}-1-benzofuran-6-ol |
| 74 | 4-{(*E*)-2-[5-(3-fluorofenil)-1*H*-pirazol-3-il]etenil}fenol |
| 75 | 2-(5-fenilo-1*H*-pirazol-3-il)-1*H*-bencimidazol |
| 76 | *N*-fenilo-*N*'-[4-(3-fenilo-1*H*-pirazol-5-il)fenil]urea |
| 77 | 4-[3-(1*H*-bencimidazol-2-il)-1*H*-pirazol-5-il]anilina |
| 78 | 4-[(*E*)-2-(5-bifenil-3-il-1*H*-pirazol-3-il)etenil]fenol |

| Entrada | Nombre |
|---|---|
| 79 | 4-((*E*)-2-{5-[5-(4-metilpiperazin-1-il)-1*H*-bencimidazol-2-il]-1*H*-pirazol-3-il}etenil)fenol |

**Administracion general**

[00238] En un aspecto, la invención proporciona composiciones farmacéuticas que comprende un inhibidor de PI3K de acuerdo con la invención y un portador, excipiente o diluyente farmacéuticamente aceptable. En otras formas de realización específicas, la administración puede ser específicamente por vía oral. La administración de los compuestos de la invención, o sus sales farmacéuticamente aceptables, en forma pura o en una composición farmacéutica apropiada, se puede llevar a cabo por cualquiera de los modos aceptados de administración o agentes para cumplir utilidades similares. En consecuencia, la administración puede ser, por ejemplo, oral, nasal, parenteral (intravenosa, intramuscular, o subcutánea), tópica, transdérmica, intravaginal, intravesical, intracisternal, o rectal, en formas de dosificación en forma sólida, semisólida, polvo liofilizado o líquido, tal como por ejemplo, comprimidos, supositorios, pastillas, cápsulas de gelatina elástica blanda y dura, polvos, soluciones, suspensiones, o aerosoles, o similares, con preferencia en formas de dosificación unitaria adecuadas para la administración simple de dosis exactas. Cuando se tratan cánceres cerebrales, que incluyen los glioblastomas, la administración puede ser específicamente por la colocación de un gliadel, una material disolvible que contiene el fármaco quimioterapéutico (en particular BCNU), directamente en los tumores cerebrales durante una operación.

**[00239]** Las composiciones incluirán un compuesto de Fórmula I o II como el/un agente activo y puede incluir un

incluirán un portador o excipiente farmacéutico convencional y además puede incluir otros agentes medicinales y agentes farmacéuticos que se administran generalmente a un paciente tratado para la cáncer.

**[00240]** Los adyuvantes incluyen agentes conservantes, humectantes, de suspensión, edulcorantes, saborizantes, perfumantes, emulsionantes y de dispensado. La prevención de la acción de los microorganismos se puede asegurar con varios agentes antibacterianos y antifúngicos, por ejemplo, parabenos, clorobutanol, fenol, ácido sórbico y similares. También puede ser conveniente incluir agentes isotónicos, por ejemplo, azúcares, cloruro de sodio y similares. La absorción prolongada de la forma farmacéutica inyectable se puede producir por el uso de agentes que retardan la absorción, por ejemplo, monoestearato de aluminio y gelatina.

**[00241]** Si se desea, una composición farmacéutica de la invención también puede contener cantidades menores de sustancias auxiliares tales como agentes humectantes o emulsionantes, agentes tamponantes de pH, antioxidantes, y similares, tales como, por ejemplo, ácido cítrico, monolaurato de sorbitano, oleato de trietanolamina, hidroxitolueno butilado, etc.

**[00242]** La elección de la formulación depende de varios factores tales como el modo de administración del fármaco (por ejemplo, para administración oral, formulaciones en forma de comprimidos, pastillas o cápsulas) y biodisponibilidad de la sustancia fármaco. Recientemente, se han desarrollado formulaciones farmacéuticas especialmente para fármacos que muestran baja biodisponibilidad sobre la base del principio de que la biodisponibilidad se puede aumentar por incremento del área de superficie, es decir, disminuyendo el tamaño de partícula. Por ejemplo, la patente estadounidense No.

4.107.288 describe una formulación farmacéutica que tiene partículas en el rango de tamaño de 10 a 1,000 nm en el que el material activo está soportado en una matriz de macromoléculas entrecruzadas. La patente estadounidense No. 5.145.684 describe la producción de una formulación farmacéutica en que la sustancia fármaco se pulveriza a nanopartículas (tamaño de partículas promedio de 400 nm) en presencia de un modificador de matriz y luego se dispersa en un medio líquido para dar una formulación farmacéutica que exhibe biodisponibilidad muy marcada.

**[00243]** Las composiciones adecuadas para la inyección parenteral pueden comprender soluciones, dispersiones, suspensiones o emulsiones acuosas o no acuosas estériles y fisiológicamente aceptables y polvos estériles para la reconstitución en soluciones o dispersiones inyectables estériles. Los ejemplos de portadores, diluyentes, solventes o vehículos acuosos o no acuosos adecuados incluyen agua, etanol, polioles (propilenglicol, polietilenglicol, glicerol, y similares), sus mezclas adecuadas, aceites vegetales (tales como, aceite de oliva) y ésteres orgánicos inyectables tales como oleato de etilo. La fluidez apropiada se puede mantener, por ejemplo, por el uso de una cubierta tal como lecitina, por el mantenimiento del tamaño de partícula requerido en el caso de las dispersiones y por el uso de tensioactivos.

**[00244]** Una vía de administración específica es la oral, mediante un régimen de dosis diario conveniente que se puede ajustar de acuerdo con el grado de gravedad del estado de enfermedad tratado.

**[00245]** Las formas de dosis sólidas para la administración oral incluyen cápsulas, comprimidos, pastillas, polvos y gránulos. En dichas formas de dosis sólidas, el compuesto activo se mezcla con al menos un excipiente (o portador) inerte, tal como citrato de sodio o fosfato dicálcico o (a)

rellenos o expansores tales como almidones, lactosa, sacarosa, glucosa, manitol, y ácido silícico, (b) aglutinantes tales como, por ejemplo, derivados de celulosa, almidón, alginatos, gelatina, polivinilpirrolidinona, sacarosa, y goma de acacia, (c) humectantes como por ejemplo, glicerol, (d) agentes desintegrantes como por ejemplo, agar-agar, carbonato de calcio, almidón de papa o mandioca, ácido algínico, croscarmelosa sódica, silicatos complejos y carbonato de sodio, (e) agentes retardadores de solución como por ejemplo, parafina, (f) aceleradores de absorción como por ejemplo, compuestos de amonio cuaternario, (g) agentes humectantes como por ejemplo, alcohol cetílico y monoestearato de glicerol, estearato de magnesio y similares (h) adsorbentes como por ejemplo, caolín y bentonita, e i) lubricantes como por ejemplo, talco, estearato de calcio, estearato de magnesio, polietilenglicoles sólidos, laurilsulfato de sodio o sus mezclas. En el caso de cápsulas, comprimidos y pastillas, la forma de dosis también puede comprender agentes amortiguadores.

**[00246]** Las formas de dosis sólidas descriptas anteriormente se pueden preparar con cubiertas y cáscaras tales como cubiertas entéricas y otras cubiertas bien conocidas en la técnica. Estas pueden comprender agentes opacificantes y también pueden ser de una composición tal que solo liberen el compuesto o compuestos activos en una parte determinada del aparato intestinal en una forma retardada. Los ejemplos de composiciones incluidas que se pueden usar son sustancias y ceras poliméricas. Los compuestos activos también pueden estar en forma microencapsulada, según corresponda con uno o más excipientes mencionados anteriormente.

**[00247]** Las formas de dosis líquidas para administración oral y parenteral incluyen, emulsiones, soluciones, suspensiones, jarabes y elixires farmacéuticamente aceptables. Dichas formas de dosis se preparan, por ejemplo, por disolución, dispersión, etc., un compuesto(s) de la invención, o una de sus sales o solvatos farmacéuticamente aceptables y adyuvantes farmacéuticos opcionales en un portador tal como, por ejemplo, agua, solución salina, dextrosa acuosa, glicerol, etanol y similares; agentes solubilizantes y emulsionantes como por ejemplo, alcohol etílico, alcohol isopropílico, carbonato de etilo, acetato de etilo, alcohol bencílico, benzoato de bencilo, propilenglicol, 1,3-butilenglicol, dimetilformamida; aceites, en particular, aceites de semilla de algodón, aceite de maní, aceite de germen de maíz, aceite de oliva, aceite de ricino y aceite de sésamo), glicerol, alcohol tetrahidrofurfurílico, polietilenglicoles y ésteres de ácido graso de sorbitanos; o mezcla de estas sustancias, y similares, para formar de este modo una solución o suspensión.

**[00248]** Las suspensiones, además de los compuestos activos, pueden contener agentes de suspensión, como por ejemplo, alcoholes isotearílicos etoxilados, polioxietilen sorbitol y ésteres de sorbitano, celulosa microcristalina, metahidróxido de aluminio, bentonita, agar-agar y tragacanto, o mezclas de estas sustancias, y similares.

**[00249]** Las composiciones para administración rectal o vaginal son por ejemplo, supositorios que se pueden preparar por la mezcla de los compuestos de la presente invención con por ejemplo excipientes o portadores no irritantes adecuados tales como manteca de cacao, polietilenglicol o una cera de supositorio que son sólidos a temperaturas ordinarias pero líquidos a temperatura

corporal y en consecuencia se funden en una cavidad adecuada y liberan allí el componente activo-

**[00250]** Las formas de dosis para administración tópica de un compuesto de esta invención incluye ungüentos, polvos, spray e inhalantes. El componente activo se mezcla en condiciones estériles con un portador farmacéuticamente aceptable y/o cualquiera de los conservantes, amortiguadores o propelentes, según sea necesario. Las formulaciones oftálmicas, ungüentos, polvos y soluciones oculares también están contempladas en el alcance de esta invención.

**[00251]** Los gases comprimidos se pueden usar para dispersar un compuesto de esta invención en forma de aerosol. Los gases inertes adecuados para este fin son nitrógeno, dióxido de carbono, etc.

**[00252]** Generalmente, de acuerdo con el modo de administración deseado, las composiciones farmacéuticamente aceptables contendrán aproximadamente 1% a aproximadamente 99% en peso de un compuesto(s) de la invención, o una de sus sales o solvatos farmacéuticamente aceptables, y 99% a 1% en peso de un excipiente farmacéutico adecuado. En un ejemplo, la composición estará entre aproximadamente 5% y aproximadamente 75% en peso de un compuesto(s) de la invención, o a una de sus sales o solvatos farmacéuticamente aceptables, con el resto de excipientes farmacéuticos adecuados.

**[00253]** Los métodos reales de preparación de dichas formas de dosis son conocidas, o serán evidentes para los expertos en esta técnica; por ejemplo, ver Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). La composición que se administra, en cualquier caso, contendrá una cantidad terapéuticamente efectiva de un compuesto de la invención, o a una de sus sales o solvatos farmacéuticamente

aceptables, para el tratamiento de un estado de enfermedad de acuerdo con las enseñanzas de esta invención.

**[00254]** Los compuestos de la invención, o sus sales farmacéuticamente aceptables, se administran en una cantidad terapéuticamente efectiva que variará de acuerdo con una variedad de factores que incluye la actividad del compuesto específico empleado, la estabilidad metabólica y la duración de acción del compuesto, la edad, peso corporal, salud general, sexo, dieta, modo y tiempo de administración, tasa de excreción, combinación farmacológica, la gravedad de los estados de enfermedad particulares, y la terapia a la se somete el huésped. Los compuestos de la presente invención se pueden administrar a un paciente a niveles de dosis en el rango de aproximadamente 0,1 a aproximadamente 1,000 mg por día. Para un adulto humano normal que tiene un peso corporal de aproximadamente 70 kilogramos, un ejemplo es una dosis en el rango de aproximadamente 0,01 a aproximadamente 100 mg por kilo de peso corporal por día. La dosis específica usada, sin embargo, puede variar. Por ejemplo, la dosis puede depender de numerosos factores que incluyen las necesidades del paciente, la gravedad de la enfermedad tratada, y la actividad farmacológica del compuesto usado. La determinación de las dosis óptimas para un paciente particular es bien conocida para los expertos en la técnica.

**[00255]** Si se formula en forma de dosis fija, dichos productos de combinación emplean los compuestos de esta invención dentro del rango de dosis descripto anteriormente y otros agentes farmacéuticamente activos dentro de su rango de dosis aprobado. Los compuestos de la presente invención en forma alternativa se pueden usar secuencialmente con agentes farmacéuticamente aceptables conocidos cuando una formulación combinada es inapropiada.

**[00256]** Las formulaciones farmacéuticas representativas que contienen un compuesto de Fórmula I o II se describen a continuación en los Ejemplos de la composición farmacéutica.

**UTILIDAD**

**[00257]** Ciertos compuestos de Fórmula I se han analizado usando el ensayo descripto en el Ejemplo biológico 1 y se han determinado como inhibidores de PI3K. Como tal, los compuestos de Fórmula I son útiles para tratar enfermedades, en particular cáncer en el que la actividad de PI3K contribuye a la patología y/o sintomatología de la enfermedad. Por ejemplo, el cáncer en que la actividad de PI3K contribuye a su patología y/o sintomatología incluye cáncer de mamas, cáncer de colon, cáncer rectal, cáncer de endometrio, carcinoma gástrico, glioblastoma, carcinoma hepatocelular, cáncer pulmonar de células pequeñas, cáncer pulmonar de células no pequeñas, melanoma, cáncer ovárico, cáncer pancreático, carcinoma prostático, leucemia mielógena aguda (AML), leucemia mielógena crónica (CML), y carcinoma tiroideo, y similares.

Los ensayo *in vitro* adecuados para medir la actividad de PI3K y su inhibición por los compuestos son conocidos en la técnica. Normalmente, el ensayo medirá el consumo de ART inducido por PI3K. Para mayores detalles de un ensayo *in vitro* para medir la actividad de PI3K ver Ejemplos biológicos, Ejemplo 1 *infra*. La actividad celular se puede determinar usando los ensayos descriptos en los Ejemplos biológicos 2, 3, y 4 *infra*. Los modelos *in vivo* adecuados para el cáncer son conocidos para los expertos en la técnica. Para mayores detalles de ensayos *in vivo* para adenocarcinoma de próstata, glioblastoma, carcinoma de pulmón y ver los Ejemplos biológicos 5-10, *infra*. Los ejemplos que describen la administración de un compuesto de Fórmula I en combinación con agentes anticáncer se

describen en los Ejemplos Biológicos 11-14, *infra*. . Siguiendo los ejemplos descriptos en la presente, así como los descriptos en la técnica, los expertos en la técnica pueden determinar que combianaciones de un compuesto de Fórmula I y agentes anticáncer deben ser efectivos para tratar cáncer.

**PREPARACIONES DE LOS INTERMEDIARIOS Y COMPUESTOS DE LA INVENCIÓN**

**[00258]** Los compuestos de esta invención se pueden obtener por los procedimientos de síntesis que se describen en WO 2007/044729, cuya descripción se incorpora por referencia en la presente.

**[00259]** Los materiales de partida y reactivos usados para preparar estos compuestos están disponibles en proveedores comerciales tales como Aldrich Chemical Co. (Milwaukee, Wis.), o Bachem (Torrance, Calif.), o se preparan por métodos conocidos por los expertos en la técnica siguiendo los procedimientos expuestos en referencias tales como como Fieser y Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley y Sons, 1991); Rodd's Chemistry de Carbon Compounds, Volumes 1-5 y Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley y Sons, 1991), March's Advanced Organic Chemistry, (John Wiley y Sons, 4$^{th}$ Edition) y Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). Estos esquemas son simplemente ilustrativos de algunos métodos por los que se pueden sintetizar los compuestos de esta invención, y se pueden realizar diversas modificaciones a estos esquemas y serán sugeridas por los expertos en la técnica con referencia a esta descripción. Los materiales de partida y los intermediarios de la reacción se pueden aislar y purificar si se desea usando técnicas convencionales, que incluye pero sin limitación filtración, destilación, cristalización, cromatografía y similares.

Dichos materiales se pueden caracterizar usando medios convencionales, que incluyen constantes físicas y datos de espectros.


**[00260]** A menos que se especifique lo contrario, las reacciones descriptas en la presente ocurren a presión atmosféricas y en un rango de temperatura de aproximadamente -78 °C a aproximadamente 150 °C, en otra forma de realización de aproximadamente a 0 °C a aproximadamente 125 °C y más específicamente a aproximadamente temperatura ambiente (o ambiente), por ejemplo, aproximadamente 20 °C. A menos que indique de otro modo (como en el caso de una hidrogenación), todas las reacciones se realizan bajo una atmósfera de nitrógeno.

**[00261]** Los profármacos se pueden preparar por técnicas conocidas por los expertos en la técnica. Estas técnicas generalmente modifican grupos funcionales apropiados en un compuesto dado. Estos grupos funcionales modificados regeneran grupos funcionales originales por manipulación de rutina o *in vivo*. Las amidas y los ésteres de los compuestos de la presente invención se pueden preparar de acuerdo con métodos convencionales. Una descripción completa de profármacos se proporciona en T. Higuchi y V. Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 del A.C.S. Symposio Series, y en Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, los cuales se incorporan en la presente por referencia para todos los propósitos.

**[00262]** Los compuestos de la invención, o sus sales farmacéuticamente aceptables, puede tener átomos de carbono asimétricos o átomos de nitrógeno cuaternizados en su estructura. Los compuestos de Fórmula I que se pueden preparar mediante la síntesis descripta en la presente pueden existir como estereoisómeros simples, racematos y


como mezclas de enantiómeros y diastereómeros. Los compuestos también pueden existir como isómeros geométricos. Todos estos estereoisómeros simples, racematos y sus mezclas, y los isómeros geométricos se consideran dentro del alcance de esta invención. Algunos de los compuestos de la invención pueden existir como tautómeros. Por ejemplo, cuando está presente una cetona o aldehído, la molécula puede existir en la forma enol; cuando una amida está presente, la molécula puede existir como ácido imídico; y cuando está presente una enamina, la molécula puede existir como una imina. Todos estos tautómeros están dentro del alcance de la invención.

**[00263]** En particular, en esta aplicación B puede ser 2-hidroxi-piridinilo, también descripta como su estructura:




14.

Tanto 2-hidroxi-piridinilo como la anterior estructura 14 incluyen y son equivalentesa , piridin-2(1*H*)-ona y su estructura 15:




15.

Independientemente de que estructura o terminología se use, cada tautómero está incluido dentro del alcance de la invención.

**[00264]** La presente invención también incluye derivados de N-óxidos y derivados protegidos de los compuestos de Fórmula I. Por ejemplo, cuando los compuestos de Fórmula I contienen un átomo de nitrógeno oxidable, el átomo de nitrógeno se puede convertir a un N-óxido por métodos bien


conocidos en la técnica. Cuando los compuestos de Fórmula I contienen grupos tales como hidroxi, carboxi, tiol o cualquier grupo que contiene un átomo de nitrógeno, estos grupos pueden estar protegidos con un "grupo protector" o "grupo que protege". Una lista exhaustiva de grupos protectores adecuados se puede hallar en T.W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc. 1991, cuya descripción se incorpora en la presente por referencia en su totalidad. Los derivados protegidos de los compuestos de Fórmula I se pueden preparar por métodos conocidos en la técnica.

**[00265]** Los métodos para la preparación y/o separación y aislamiento de estereoisómeros de las mezclas racémicas o mezclas no racémicas de estereoisómeros son bien conocidos en la técnica. Por ejemplo, los isómeros (R)- y (S)- óptimamente activos se pueden preparar usando sintones de síntesis quiral o reactivos quirales o resueltos usando técnicas convencionales. Los enantiómeros (R- y S-isómeros) se pueden resolver por métodos conocidos por los expertos en la técnica, por ejemplo por: formación de sales o complejos diastereoisoméricos que se pueden separar, por ejemplo, por cristalización; por medio de la formación de derivados diastereoisoméricas que se pueden separar, por ejemplo, por cristalización, reacción selectiva de un enantiómero con un reactivo específico de enantiómero, por ejemplo oxidación o reducción enzimática, seguido por la separación de enantiómeros modificados o no modificados; o cromatografía gas-líquido o líquida en un ambiente quiral, por ejemplo en un soporte quiral, tal como sílice con un ligando quiral unido o en presencia de un solvente quiral. Se apreciará que cuando un enantiómero deseado se convierte en otra entidad química por uno de los procedimientos de separación descriptos anteriormente, se puede requerir una etapa adicional para liberar la forma enantiomérica

deseada. Alternativamente, el enantiómero específico se puede sintetizar por síntesis asimétrica usando reactivos, sustratos, catalizadores o solventes ópticamente activos o por la conversión de enantiómero al otro por transformación asimétrica. Para una mezcla de enantiómeros, enriquecida en un enantiómero particular, el mayor componente enantiómero se puede enriquecer adicionalmente (con pérdida concomitante de rendimiento) por recristalización.

**[00266]** Además, los compuestos de la presente invención pueden existir en forma no solvatada así como solvatada con solventes farmacéuticamente aceptables tales como agua, etanol y similares. En general, las formas solvatadas se consideran equivalentes a las formas no solvatadas para los fines de la presente invención.

**[00267]** En los Compuestos de Fórmula I





el hidrógeno del grupo $-NHS(O)_2-$ es altamente ácido. En consecuencia, los intermediarios que conducen a los Compuestos de Fórmula I, así como los Compuestos de Fórmula I mismos, se pueden recuperar como moléculas no cargadas o zwitteriónicas, o sales catiónicas tales como sodio o potasio, de acuerdo con las sustituciones en el anillo B y las condiciones de reacción. En los siguientes ejemplos, a menos que se especifique lo contrario, se asume que la forma final del compuesto es la molécula no cargada en ausencia de técnicas analíticas que deberían haber determinado de otro modo.

**[00268]** Los compuestos de Fórmula I se pueden preparar usando métodos conocidos por los expertos en la técnica. En otra forma de realización, se sabe que la fusión de reactivos apropiados a 180 °C en presencia de una base tal como $K_2CO_3$ y cobre metálico proporciona intermediarios de la fórmula 1 (ver S. H. Dandegaonker y C. K. Mesta, *J. Med. Chem.* 1965, *8*, 884).

**[00269]** Alternativamente, el intermediario de la fórmula 3 se puede preparar de acuerdo con el siguiente esquema donde cada $LG^1$ es un grupo saliente (en una forma de realización halo, en otra forma de realización cloro) y todos los otros grupos son como se definieron en la Descripción detallada de la invención.

Esquema 1




**[00270]** En el esquema 1, un intermediario de fórmula 3 se puede preparar por calentamiento breve de 2,3-dicloroquinoxalina disponible en el comercio y un intermediario de fórmula 2 (que está disponible en el comercio o puede ser preparado por los expertos en la técnica), una base tal como $K_2CO_3$, en solvente, tal como DMF o DMSO. Después de la finalización (aproximadamente 2 horas), la mezcla de reacción luego se vierte en agua y seguido por HCl 2 N. El producto luego se extrae en un solvente tal como acetato de etilo y se lava con agua y salmuera. Las fases orgánicas se combinan y secan en un agente de secado tal como sulfato de sodio, se filtra y se concentra al vacío.

**[00271]** El intermediario de fórmula 3 luego se trata con un intermediario de fórmula 4 en solvente tal como DMF o p-xileno a temperatura de reflujo. Despues de finalizar la reacción (aproximadamente 16 horas o menos), la reacción se deja a enfriar, se extrae en DCM, se lava con HCl 2 N y salmuera, se secan en un agente de secado tal como sulfato de sodio, o sulfato de magnesio, se filtra y se concentra para dar un compuesto de Fórmula I.

**[00272]** Alternativamente, los expertos en la técnica conocen otros métodos para preparar derivados de quinoxalina e incluyen, pero sin limitación S. V. Litvinenko, V. I. Savich, D. D. Bobrovnik, *Chem. Heterocicl. Compd.* (Engl. Transl), 1994, *30*, 340 y W. C. Lumma, R. D. Hartman, *J. Med. Chem.* 1981, *24*, 93.

**[00273]** Los siguientes compuestos se prepararon de una manera similar a la que se describió anteriormente.

Ejemplo 1: *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida.

Ejemplo 2: *N*-(3-{[2,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-4-clorobencensulfonamida.

Ejemplo 3: *N*-(3-cloroquinoxalin-2-il)-3-nitrobencensulfonamida.

Ejemplo 4: 4-cloro-*N*-(3-cloroquinoxalin-2-il)bencensulfonamida.

Ejemplo 1: 4-cloro-*N*-(3-(2,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. $^1$H NMR (400 MHz, DMSO-$d_6$) δ9,18(s, 1H) (s, 1H), 8,78 (s, 1H), 8,40-8,60 (m, 3H), 7,98 (t, 2H), 7,62 (d, 1H), 7,41 (m, 2H), 6,98 (d, 1H), 6,59 (d, 1H), 3,78 (s, 3H), 3,76 (s, 3H); EM (EI) m/z para $C_{22}H_{19}N_5O_6S$: 482,1 ($MH^+$).


Ejemplo 6: *N*-(3-(2,5-dimetoxifenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. $^1$H RMN (400 MHz, $CDCl_3$) δ12, 68 (br s, 1H), 9,18(s, 1H), 8,55 (s, 1H), 8,08 (d, 2H), 7,98 (d, 1H), 7,78 (d, 2H), 7,62 (dd, 1H), 7,40 (m, 2H), 7,00 (d,

1H), 6,60 (dd, 1H), 3,78 (s, 6H) ; EM (EI) m/z para $C_{22}H_{19}ClN_4O_4S$: 471,1 ($MH^+$).

Ejemplo 7: *N*-(3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-4-metilfenil)-2-(dimetilamino)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ 12,0 (br s, 1 H), 10,6 (s, 1 H), 10,0 (br s, 1 H), 9,52 (s, 1 H), 8,91 (d, 1 H), 8,25 (d, 1 H), 7,69 (dd, 1H), 7,47 (m, 1 H), 7,39 (d, 1 H), 7,16 (m, 3 H), 6,01 (dd, 1 H); EM (EI) m/z para $C_{26}H_{27}ClN_6O_4S$: 555 ($MH^+$).

**[00274]** Los compuestos de Fórmula I donde B es fenilo sustituido con $R^{3a}$ donde $R^{3A\ es}$ alquilamino o dialquilamino o B es heteroarilo sustituido con $R^3$ donde $R^3$ es amino, alquilamino, o dialquilamino, y los otros grupos son como se definieron en la Síntesis de la invención se pueden preparar de acuerdo con el Esquema 2.

**Esquema 2**





**5** **I(c)**

LG es un grupo saliente tales como cloro. 5 se hace reaccionar con $NHR^aR^b$ o HO-alquilen $C_1$-$C_6$-$NHR^aR^b$ donde $R^a$ y $R^b$ son de modo independiente hidrógeno o alquilo. La reacción se lleva a cabo en presencia de una base, tales como $KHCO_3$, en solvente tales como DMF.

**[00275]** Compuestos de Fórmula I donde B es fenilo sustituido con $R^{3a}$ donde $R^{3a}$ es aminoalquiloxi, alquilaminoalquiloxi, o dialquilaminoalquiloxi o B es heteroarilo sustituido con $R^3$ donde $R^3$ es aminoalquiloxi, alquilaminoalquiloxi, o dialquilaminoalquiloxi, y los otros

grupos son como se definieron en la Síntesis de la invención se pueden preparar de acuerdo con el Esquema 3.

**Esquema 3**




I(c) alquilen-$C_1$-$C_6$-$NR^aR^b$

La reacción se lleva a cabo en presencia de una base tales como NaH en solvente tales como DMF.

**[00276]** Compuestos de Fórmula I donde B es fenilo sustituido con $R^{3a}$ o B es heteroarilo sustituido con $R^3$ donde $R^{3a}$ y $R^3$ son

i. $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$ donde $R^7$, $R^{7a}$, y $R^{7b}$ son como se definen en la Síntesis de la invención;

ii. $-NR^9C(O)R^{9a}$ donde $R^9$ es como se define en la Síntesis de la invención;

iii. $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$, $R^{11a}$, y $R^{11b}$ son como se definen en la Síntesis de la invención;

iv. $-NR^{13}C(O)OR^{13a}$ donde $R^{13}$ y $R^{13a}$ son como se definen en la Síntesis de la invención;

v. $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$ donde $R^{18}$, $R^{18a}$, y $R^{18b}$ son como se definen en la Síntesis de la invención;

vi. $-N(R^{20})C(O)$-alquilen $C_1$-$C_6$-$C(O)R^{20a}$ donde $R^{20}$ y $R^{20a}$ como se define en la Síntesis de la invención;

vii. $-NR^{21}S(O)_2$-alquilen $C_1$-$C_6$-$N(R^{21b})R^{21a}$ donde $R^{21}$, $R^{21a}$, y $R^{21b}$ son como se definen en la Síntesis de la invención;

viii. $-N(R^{22})C(O)$-alquilen $C_0$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, donde $R^{22}$, $R^{22a}$ y $R^{22b}$ son como se definen en la Síntesis de la invención;

ix. $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$ donde $R^{24}$ y $R^{24a}$ son como se definen en la Síntesis de la invención;

y donde el alquileno en $R^3$ y $R^{3a}$ son de modo independiente opcionalmente sustituido como se describe en la Síntesis de la invención se pueden preparar de acuerdo con el Esquema 4 poe la reacción con un intermediario de fórmula 9(a), 9(b), 9(c), 9(d), 9(e), 9(f), o 9(g):

9(a) HOC(O)-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$ donde $R^A$ es $R^{7a}$ o un grupo protector de N, tal como Boc o Fmoc;

9(b) $HOC(O)R^{9a}$;

9(c) $HOC(O)NR^{11a}R^{11b}$;


9(d) $HOC(O)OR^{13a}$;

9(e) HOC(O)-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$;

9(f) HOC(O)-alquilen $C_1$-$C_6$-$C(O)R^{20a}$;

9(g) LG-$S(O)_2$-alquilen $C_1$-$C_6$-$N(R^{21b})R^a$ donde $R^A$ es $R^{21a}$ o un grupo protector de N, tales como Boc o Fmoc.

**Esquema 4**




**8** **I(e)**

$R^{100}$ en el esquema 4 es $-C(O)R^{9a}$, $-C(O)NR^{11a}R^{11b}$, $-C(O)OR^{13a}$, -C(O)-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$, -C(O)-alquilen $C_1$-$C_6$-$C(O)R^{20a}$, o $-S(O)_2$-alquilen $C_1$-$C_6$-$N(R^{21b})R^a$. La reacción se lleva a cabo en condiciones de acoplamiento de amidas estándares conocidas por los expertos en la técnica. En particular, la reacción se lleva a cabo en presencia de un agente de acoplamiento tal como HATU, una base tal como DIEA, y en un solvente tal como DMF. Cuando sea aplicable, el grupo protector de N se limina posteriormente usando

procedimientos conocidos por los expertos en la técnica, tales como tratamiento con ácido donde PG es Boc.

**[00277]** Procediendo como se describe en el Esquema 4, los compuestos de la invención donde B es fenilo sustituido con $R^{3a}$ o B es heteroarilo sustituido con $R^3$ donde $R^{3a}$ y $R^3$ son

a) $-C(O)NR^8R^{8a}$;

b) $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$;


c) $-C(O)R^{12}$ donde $R^{12}$ es heterocicloalquilo sustituido con N;

d) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$;

e) $-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$; o

f) $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$; o

se puede preparar por intercambio de los materiales de partida, según sea necesario. En particular, el intermediario de fórmula 11:





11

se usa en lugar de 8.

**[00278]** Los compuestos de Fórmula I donde B es fenilo sustituido con $R^{3a}$ o B es heteroarilo sustituido con $R^3$ donde $R^{3a}$ y $R^3$ son $-NHC(O)CH_2NR^{7a}R^{7b}$ donde $R^{7a}$ y $R^{7b}$ son como se definen en la Síntesis de la invención se pueden preparar de acuerdo con el Esquema 5.

**Esquema 5**





12 I(f)

LG es un grupo saliente tal como bromo o cloro. 12 se hace reaccionar con $NH(R^{7b})R^{7a}$ en presencia de una base, tales como DIEA, en solvente tales como ACN.

**[00279]** Los compuestos de Fórmula I se pueden preparar de acuerdo con el Esquema 6.

**Esquema 6**





13 I(h)

LG en el esquema 6 es un grupo saliente tales como cloro. La reacción se puede llevar a cabo por irradiación en solvente tales como DMA. En forma alternativa, la reacción se puede llevar a cabo en presencia de ácido acético en solvente tales como DMA y por calentamiento.

Ejemplo 8

6-cloro-*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)piridino-3-sulfonamida




**[00280]** 6-cloropiridino-3-sulfonamida. Se agitó cloruro de 6-cloropiridino-3-sulfonilo (4,1 g, 19,3 mmol) en hidróxido de amonio (30 ml) a temperatura ambiente durante 2 hr. La mezcla de reacción se diluyó con EtOAc (150 ml) y se filtró cualquier material insoluble. El filtrado se transfirió a un embudo de separación y las fases se separaron. La fase acuosa también se extrajo con EtOAc (1 x 15 ml). Las extracciones en EtOAc se lavaron con $H_2O$ (1 x 50 ml) y NaCl saturado (1 x 50 ml), se secaron con $Na_2SO_4$, y se concentraron *in vacuo* para dar 6-cloropiridino-3-sulfonamida (2,58 g, 69%). EM (EI) m/z para $C_5H_5Cl_2N_2O_2S$: 190,9 ($MH^-$).


**[00281]** 6-cloro-*N*-(3-cloroquinoxalin-2-il)piridino-3-sulfonamida. Se combinaron 2,3-dicloroquinoxalina (1,09 g, 5,48 mmol), 6-cloropiridino-3-sulfonamida (1,05 g, 5,45 mmol), $K_2CO_3$ (753 mg, 5,45 mmol) y DMSO seco (30 ml) y se calentaron a 150 °C con agitación vigorosa durante 3-4 hr. La mezcla de reacción se dejó enfriar a temperatura ambiente, luego se vertió en 1% de AcOH en agua con hielo (300 ml) con agitación vigorosa. Los sólidos resultantes se filtraron, lavaron con $H_2O$ y se secaron bajo alto vacío para dar 6-cloro-*N*-(3-cloroquinoxalin-2-il)piridino-3-

sulfonamida (1,87g, 96%). EM (EI) m/z para $C_{13}H_8Cl_2N_4O_2S$: 354,99 ($MH^+$).

**[00282]** 6-cloro-*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)piridino-3-sulfonamida. Se combinaron 6 -Cloro-*N*-(3-cloroquinoxalin-2-il)piridino-3-sulfonamida (775 mg, 2,2 mmol), 3,5-dimetoxianilina (355 mg, 2,3 mmol) y tolueno (12 ml) y se calentaron a 125 °C con agitación toda la noche. La reacción se dejó enfriar a temperatura ambiente y se diluyó con $Et_2O$ con agitación vigorosa. Los sólidos resultantes se filtraron, se lavaron con $Et_2O$ y se secaron para dar 6-cloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)piridino-3-sulfonamida (920 mg, 89%). $^1H$ RMN (400 MHz, DMSO-$d_6$) δ 12,20 (br s, 1H), 9,12 (d, 1H), 9,01 (br s, 1H), 8,53 (dd, 1H), 7,91 (br d, 1H), 7,77 (d, 1H), 7,60 (dd, 1H), 7,40 (m, 4H), 6,26 (m, 1H), 3,78 (s, 6H). EM (EI) m/z para $C_{21}H_{18}ClN_5O_4S$: 472,0 ($MH^+$).

Ejemplo 9

*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-6-(2-(dimetilamino)-etilamino)piridino-3-sulfonamida





**[00283]** 6-cloro-*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-piridino-3-sulfonamida (100 mg, 0,21 mmol), se preparó usando procedimientos similares a los usados en el Ejemplo 8, se combinaron $KHCO_3$ (40 mg, 0,40 mmol), $N^1$,$N^1$-dimetiletano-1,2-diamina (225 □L, 2,0 mmol) y dry DMF (1,0 ml) y calentaron a 130 °C con agitación toda la noche. La mezcla de reacción se concentró *in vacuo* y se purificó por HPLC preparativa para dar *N*-(3-(3,5-dimetoxi-fenilamino)-quinoxalin-2-il)-6-(2-(dimetilamino)etilamino)piridino-

3-sulfonamida (21,0 mg, 19%). $^1$H RMN (400 MHz, DMSO-$d_6$) δ 8,76 (br s, 1H), 8,63 (d, 1H), 8,07 (dd, 1H), 7,40 (m, 1H), 7,34 (m, 1H), 7,28 (d, 2H), 7,14 (m, 4H), 6,47 (d, 1H), 6,12 (m, 1H), 3,75 (s, 6H), 3,35 (m, 2H), 3,14 (m, 2H), 2,74 (s, 6H). EM (EI) m/z para $C_{25}H_{29}N_7O_4S$: 524,1 ($MH^+$).

**[00284]** Ejemplo 10: *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-6-(dimetilamino)piridino-3-sulfonamida se preparó usando procedimientos similares a los usados en el Ejemplo 9. $^1$H RMN (400 MHz, DMSO-$d_6$) δ 12,00 (br s, 1H), 8,92 (br s, 1H), 8,74 (d, 1H), 8,10 (dd, 1H), 7,38 (br s, 1H), 7,54 (m, 1H), 7,33 (m, 4H), 6,70 (d, 1H), 6,22 (s, 1H), 3,77 (s, 6H), 3,08 (s, 6H). EM (EI) m/z para $C_{23}H_{24}N_6O_4S$: 481,1 ($MH^+$).

Ejemplo 11

*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-6-(2-(dimetilamino)-etoxi)piridino-3-sulfonamida





**[00285]** *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)piridino-3-sulfonamida (100 mg, 0,21 mmol), se preparó usando procedimientos similares a los descriptos antes en el Ejemplo 1, 2-(dimetilamino)etanol (50 µL, 0,50 mmol) y DMF seco se combinaron y se añadió 60% de NaH en aceite (80 mg, 2,0 mmol). La mezcla se agitó a temperatura ambiente toda la noche. La mezcla de reacción se concentró in vacuo y se purificó por HPLC preparativa para dar *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-6-(2-(dimetilamino)etoxi)piridino-3-sulfonamida (23 mg, 21%). $^1$H RMN (400 MHz, DMSO-$d_6$) δ 8,78 (d, 1H), 8,73 (s, 1H), 8,38

(dd, 1H), 7,40 (dd, 1H), 7,31 (m, 3H), 7,14 (m, 2H), 6,85 (d, 1H), 6,12 (m, 1H), 4,56 (m, 2H), 3,76 (s, 6H), 3,43 (m, 2H), 2,77 (s, 6H). EM (EI) m/z para $C_{25}H_{28}N_6O_5S$: 525,1 ($MH^+$).

Ejemplo 12

*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-6-oxo-1,6-dihidropiridino-3-sulfonamida





**[00286]** *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)piridino-3-sulfonamida (220 mg, 0,47 mmol), se preparó usando procedimientos similares a los descriptos antes en el Ejemplo 8, DMSO (5 ml), y 3N NaOH (5 ml) se combinan y calientan a 100 °C toda la noche con agitación. Después de enfriar a temperatura ambiente, la mezcla de reacción se diluyó con $H_20$ y el pH se ajustó a 7,0 con HCl 1N. El sólido resultante se filtró, se lavó con $H_20$, y se secó al aire. El sólido luego se sonicó en EtOAc, se filtró, se lavó con EtOAc, y secó bajo alto vacío para dar *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-6-oxo-1,6-dihidropiridino-3-sulfonamida (190 mg, 90%). $^1H$ RMN (400 MHz, DMSO-$d_6$) δ 12,23 (br s, 1H), 12,10 (br s, 1H), 8,97 (s, 1H), 8,23 (s, 1H), 7,95 (m, 2H), 7,59 (m, 1H), 7,37 (m, 4H), 6,43 (d, 1H), 6,25 (s, 1H), 3,77 (s, 6H). EM (EI) m/z para $C_{21}H_{19}N_5O_5S$: 454,0 ($MH^+$).

**[0185]** Ejemplo 13: *N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-6-oxo-1,6-dihidropiridino-3-sulfonamida. El compuesto del título se preparó de acuerdo con el anterior Ejemplo 12. $^1H$ RMN (400 MHz, DMSO-$d_6$) δ

12,22 (br s, 1H), 12,10 (br s, 1H), 9,16 (s, 1H), 8,60 (s, 1H), 8,14 (d, 1H), 7,94 (m, 1H), 7,85 (dd, 1H), 7,62 (m, 1H), 7,40 (m, 3H) 6,69 (dd, 1H), 6,43 (d, 1H), 3,81 (s, 3H). EM (EI) m/z para $C_{20}H_{16}ClN_5O_4S$: 456,0 ($MH^-$).


Ejemplo 14

3-amino-*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)bencensulfonamida.




**[00287]** *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. Se cargó un matraz con *N*-(3-cloroquinoxalin-2-il)-3-nitrobencensulfonamida (5 g, 13,7 mmol), se preparó usando procedimientos similares a los del Ejemplo 1, 3,5-dimetoxianilina (4,2 g, 27,4 mmol), y 80 ml de xileno. La mezcla de reacción se agitó bajo atmósfera de $N_2$ a 150 °C durante 3 horas, después de este tiempo, se extrajo el solvente en un evaporador giratorio, y se añadieron 10 ml de diclorometano y 50 ml de metanol. La suspensión se calentó a reflujo y se filtró con calor, dando como resultado 4,6 g (69,7 %) de *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida EM (EI) m/z para $C_{22}H_{19}N_5O_6S$: 482,2 ($MH^+$).

Ejemplo 153-amino-*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)bencensulfonamida




**[00288]** Se cargó un matraz con *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-3-nitro-bencensulfonamida (3,4g, 7,06 mmol), se preparó usando procedimientos similares a los del Ejemplo 14, se añadieron solvato cloruro (6,4 g, 28,2 mmol), y 30 ml de DMA. Se añadieron unas pocas gotas de agua y la mezcla de reacción se agitó a 80 °C durante 3 horas, después de este tiempo, se extrajo el solvente en un evaporador giratorio, y 50 ml de agua y se añadieron 10 ml de metanol. La suspensión se filtró, y el filtrado se lavó con MeOH, agua, y éter dietílico (20 ml de cada uno), dando como resultado 3,25 g 3-amino-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. $^1$H RMN (400 MHz, DMSO) δ 12,2 (br s, 1H), 8,85 (s, 1H), 7,90 (br s, 1H), 7,50-7,60 (m, 1H), 7,3-7,4 (m, 4H), 7,2 (m, 3H), 6,74 (m, 1H), 6,24 (m, 1H), 5,56 (br s, 2H), 3,76 (s, 6H). EM (EI) m/z para $C_{22}H_{21}N_5O_4S$: 452,0 ($MH^+$).

**[00289]** Los siguientes compuestos se obtuvieron usando procedimientos a los usados en el Ejemplo 15.

Ejemplo 16: Procediendo como antes, se preparó 3-amino-*N*-(3-(2,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. $^1$H RMN (400 MHz, DMSO) δ 12,4 (br s, 1H), 9,20 (s, 1H), 8,56 (d, 1H), 7,95 (d, 1H), 7,62 (m, 1H), 7,38 (m, 2H), 7,24 (q, 2H), 7,14 (d, 1H), 6,98 (d,

1H), 6,8 (m, 1H), 6,60 (m, 1H), 5,6 (br s, 2H), 3,78 (d, 6H). EM (EI) m/z para $C_{22}H_{21}N_5O_4S$: 452,3 ($MH^+$).

Ejemplo 17: Procediendo como antes, se preparó 3-amino-*N*-(3-(2-cloro-5-hidroxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{20}H_{16}ClN_5O_3S$ 1,0 x $C_2H_1O_2F_3$: 442,2, 444,2 ($MH^+$).

Ejemplo 18: Procediendo como antes, se preparó 3-amino-*N*-(3-(6-metoxiquinolin-8-ilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{24}H_{20}N_6O_3S$: 473,0 ($MH^+$).


Ejemplo 19: 3-amino-*N*-(3-(3-fluoro-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{21}H_{18}FN_5O_3S$: 439,99 ($MH^+$).

Ejemplo 20: 3-amino-*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{21}H_{18}ClN_5O_3S$: 457,02 ($MH^+$).

Ejemplo 21: 3-amino-*N*-(3-(5-metoxi-2-metil-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{21}N_5O_3S$: 436,32 ($MH^+$).

Ejemplo 22a y Ejemplo 22b

3-amino-*N*-(3-(3-metoxi-5-nitro-fenilamino)quinoxalin-2-il)bencensulfonamida y 3-amino-*N*-(3-(3-amino-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida





**[00290]** A una mezcla de *N*-(3-{[3-(metiloxi)-5-nitrofenil]amino}quinoxalin-2-il)-3-nitrobencensulfonamida (400 mg), THF (2 ml) y EtOH (2 ml) se añadió ácido fórmico (938 µL), formiato de potasio (203 mg). Después la mezcla se lavó con $N_2$, se añadió 10% en peso de Pd/C (50 mg). La

mezcla resultante se calentó a 60 °C con agitación. El análisis LC/EM indicó que la mezcla de reacción contenía el compuesto diamino completamente reducido como el producto mayor y el compuesto monoamino parcialmente reducido como un producto menor. Una porción de la mezcla se purificó por HPLC para dar los dos productos. Producto A: 3-amino-*N*-(3-(3-metoxi-5-nitro-fenilamino)quinoxalin-2-il)bencensulfonamida. $^1$H RMN (400 MHz, DMSO) δ 12,2 (br s, 1H), 9,51 (s, 1H), 8,77 (s, 1H), 8,21 (s, 1H), 7,92 (s, 1H), 7,48 (m, 1H), 7,43-7,38 (m, 3H), 7,24-7,16 (m, 3H), 6,75 (d, 1H), 5,57 (br s, 2H), 3,90 (s, 3H). EM (EI) para $C_{21}H_{18}N_6O_5S$: 467,00 (MH+). Producto B: 3-amino-*N*-(3-(3-amino-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. $^1$H RMN (400 MHz, DMSO) δ 12,0 (br. s, 1H), 8,53 (s, 1H), 7,84 (s, 1H), 7,56 (d, 1H), 7,37-7,30 (m, 2H), 7,21-7,17 (m, 3H), 6,87 (s, 1H), 6,81 (s, 1H), 6,74 (br s, 2H), 5,91 (s, 1H), 5,56 (br s, 3H), 3,69 (s, 3H). EM (EI) para $C_{21}H_{20}N_6O_3S$: 437,2 (MH+).

Ejemplo 23a y Ejemplo 23b

*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-(hidroxiamino)-bencensulfonamida y 3-amino-N-(3-{[3,5-(dimetoxi)fenil]amino}quinoxalin-2-il)bencensulfonamida





**[00291]** A una solución *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida (1,3g) en 20 ml de THF y 10 ml de MeOH se añadió 10% en peso de Pd/C (100 mg). La mezcla se agitó bajo un balón de $H_2$ toda la noche. Se tomó una

porción de la mezcla de reacción y se filtró, luego se purificó por HPLC para proporcionar dos productos. Producto A: *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-(hidroxiamino)bencensulfonamida. EM (EI) para $C_{22}H_{21}N_5O_5S$: 468,1 ($MH^+$). Producto B: 3-amino-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. $^1H$ RMN (400 MHz, DMSO) δ 12,2 (br s, 1H), 8,85 (s, 1H), 7,90 (br s, 1H), 7,50-7,60 (m, 1H), 7,3-7,4 (m, 4H), 7,2 (m, 3H), 6,74 (m, 1H), 6,24 (m, 1H), 5,56 (br s, 2H), 3,76 (s, 6H). EM (EI) para $C_{22}H_{21}N_5O_4S$: 452,0 ($MH^+$).

Ejemplo 24

(*S*)-2-amino-*N*-(3-(*N*-(3-(3,5-Clorhidrato de dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)propanamida.




**[00292]** 1-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenilamino)-1-oxopropan-2-ilcarbamato de (*S*)-*ter*-butilo. 3-amino-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida (1,1 mmol, 500 mg), se preparó usando procedimientos similares a los descriptos antes en el Ejemplo 15, (L)-Boc-Ala-OH (1,5 mmol, 284 mg), diclorometano (15 ml), DMF (10 ml), DIEA (2

mmol, 330 µL), y HATU (2 mmol, 760 mg) se agitaron a temperatura ambiente durante la noche. La mezcla bruta se purificó en columna usando 1/1 acetato de etilo/hexanos en sílice para dar 160 mg.

**[00293]** Clorhidrato de (*S*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)propanamida. Se añadió HCl 4 N en dioxano (10 ml) a una solución de 1-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenilamino)-1-oxopropan-2-ilcarbamato de (*S*)-*ter*-butilo (160 mg) y DCM (15 ml). La mezcla se agitó a temperatura ambiente durante 3 horas. El solvente decantó y se añadió éter al sólido, el éter decantó para dar 80 mg de producto como sal de HCl. $^1$H RMN (400 MHz, $CD_3OD$) δ8,50-8,49 (t, 1H), 7,89-7,87 (m, 1H), 7,74-7,72 (m, 1H), 7,61-7,5 (m, 3H), 7,40-7,36 (m, 2H), 7,21-7,20 (d, 2H), 6,23-6,21 (t, 1H), 4,09-4,03 (q, 1H), 3,78 (s, 6H), 1,60-1,58 (d, 3H); EM (EI) m/z para $C_{25}H_{26}N_6O_5S \cdot HCl$: 523,1 ($MH^+$).

**[00294]** Los siguientes compuestos se prepararon como amina libre y/o sal de HCl usando procedimientos similares a los del Ejemplo 24. Cuando no es necesaria la etapa de desprotección, la etapa B del esquema anterior no se realiza.

Ejemplo 25: *N*-(2-cloro-5-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)acetamida. El compuesto del título se preparó de acuerdo con los Ejemplos anteriores. $^1$H RMN (400 MHz, DMSO-$d_6$) δ 10,50 (s, 1H), 9,14 (s, 1H), 9,03 (m, 2H), 8,63 (d, 1H), 8,44 (d, 1H), 7,98 (m, 1H), 7,91 (dd, 1H), 7,80 (d, 1H), 7,67 (m, 1H), 7,44 (m, 3H), 6,71 (dd, 1H), 4,06 (m, 2H), 3,83 (s, 3H), 2,64 (t, 3H). EM (EI) m/z para $C_{24}H_{22}Cl_2N_6O_4S$: 561,0 ($MH^+$).

Ejemplo 26: Clorhidrato de (*S*)-2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-

il)sulfamoil)fenil)propanamida. $^1$H RMN (400 MHz, $CD_3OD$) δ 8,72-8,71 (d, 1H), 8,48-8,46 (t, 1H), 7,86-7,84 (m, 1H), 7,80-7,78 (m, 1H), 7,63-7,59 (m, 2H), 7,58-7,55 (t, 1H), 7,41-7,38 (m, 2H), 7,24-7,22 (d, 1H), 6,60-6,58 (dd, 1H), 4,10-4,04 (q, 1H), 3,83 (s, 3H), 1,61-1,60 (d, 3H); EM (EI) m/z para $C_{24}H_{23}ClN_6O_4S \cdot HCl$: 527,2 ($MH^+$).

Ejemplo 27: Clorhidrato de (*S*)-2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)butanamida. $^1$H RMN (400 MHz, $CD_3OD$) δ8,74-8,73 (d, 1H), 8,80-8,47 (t, 1H), 7,87-7,85 (m, 1H), 7,80-7,78 (m, 1H), 7,67-7,61 (m, 2H), 7,59-7,55 (t, 1H), 7,42-7,39 (m, 2H), 7,26-7,24 (d, 1H), 6,62-6,59 (dd, 1H), 3,96-3,93 (t, 1H), 3,84 (s, 3H), 2,02-1,94 (m, 2H, 1,09-1,06 (t, 3H); EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S \cdot HCl$: 541,3 ($MH^+$).

Ejemplo 28: Clorhidrato de (*S*)-*N*-(3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)pirrolidine-2-carboxamida. $^1$H RMN (400 MHz, $CD_3OD$) δ8,78-8,77 (d, 1H), 8,47-8,46 (t, 1H), 7,87-7,85 (m, 1H), 7,80-7,75 (m, 1H), 7,69-7,65 (m, 2H), 7,59-7,55 (t, 1H), 7,45-7,41 (m, 2H), 7,31-7,28 (d, 1H), 6,65-6,63 (dd, 1H), 4,42-4,38 (m, 1H), 3,86 (s, 3H), 3,48-3,42 (m, 2H), 2,55-2,49 (m, 1H), 2,18-2,08 (m, 3H); EM (EI) m/z para $C_{26}H_{25}ClN_6O_4S \cdot HCl$: 553,3 ($MH^+$).

Ejmeplo 29: Clorhidrato de (*S*)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pirrolidine-2-carboxamida. $^1$H RMN (400 MHz, $CD_3OD$) δ10,62 (br s, 1H), 8,50-8,49 (t, 1H), 7,90-7,87 (m, 1H), 7,76-7,73 (m, 1H), 7,63-7,58 (m, 3H), 7,43-7,35 (m, 2H), 7,14 (s, 2H), 6,27-6,26 (t, 1H), 4,43-4,38 (m, 1H), 3,78 (s, 6H), 3,48-3,41 (m, 1H), 3,40-3,36 (m, 1H(, 2,54-2,48 (m, 1H), 2,19-2,05 (m, 3H); EM (EI) m/z para $C_{27}H_{28}N_6O_5S \cdot HCl$: 549,3 ($MH^+$).

Ejemplo 30: Clorhidrato de (*R*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-

hidroxipropanamida. $^1$H RMN (400 MHz, $CD_3OD$) δ8,49-8,48 (t, 1H), 7,89-7,87 (m, 1H), 7,75-7,72 (m, 1H), 7,65-7,62 (m, 2H), 7,62-7,55 (t, 1H), 7,44-7,38 (m, 2H), 7,23-7,22 (d, 2H), 6,27-6,26 (t, 1H), 4,07-4,05 (m, 1H), 3,99-3,93 (m, 2H), 3,80 (s, 6H); EM (EI) m/z para $C_{25}H_{26}N_6O_6S \cdot HCl$: 539,1 ($MH^+$).

Ejemplo 31: Clorhidrato de *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)piperidino-3-carboxamida. $^1$H RMN (400 MHz, $CD_3OD$) δ8,79-8,78 (d, 1H), 8,45 (m, 1H), 7,83-7,81 (d, 1H), 7,76-7,74 (m, 1H), 7,636 (m, 2H), 7,54-7,50 (t, 1H), 7,41 (m, 2H), 7,30-7,28 (d, 1H), 6,65-6,62 (dd, 1H), 3,86 (s, 3H), 3,40-3,32 (m, 2H), 3,20-3,13 (m, 3H), 2,93 (m, 1H), 2,15-2,11 (m, 1H), 1,98-1,93 (m, 2H), 1,83 (m, 1H); EM (EI) m/z para $C_{27}H_{27}ClN_6O_4S \cdot HCl$: 567,3 ($MH^+$).

Ejemplo 32: Clorhidrato de (*S*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)butanamida. EM (EI) m/z para $C_{26}H_{28}N_6O_5S \cdot HCl$: 537,1 ($MH^+$).

Ejemplo 33: Clorhidrato de (*R*)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pirrolidine-2-carboxamida. EM (EI) m/z para $C_{27}H_{28}N_6O_5S \cdot HCl$: 549,1 ($MH^+$).

Ejemplo 34: Clorhidrato de (*R*)-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pirrolidine-2-carboxamida. EM (EI) m/z para $C_{26}H_{25}ClN_6O_4S \cdot HCl$: 553 ($MH^+$).

Ejemplo 35: (*R*)-2-amino-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)propanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,2 br s, 1 H), 8,82 (s, 1 H), 8,27 (m, 1 H), 7,75 (m, 2 H), 7,33 (m, 5 H), 7,13 (m, 2 H), 6,14 (t, 1 H), 3,77 (s, 6 H), 1,39 (d, 3 H); EM (EI) m/z para $C_{25}H_{26}N_6O_5S$: 523 ($MH^+$).

Ejemplo 36:*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-

(metilamino)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,6 s, 1 H), 9,48 (s, 1 H), 8,95 (br s, 1 H), 8,75 (br s, 1 H), 8,19 (br s, 1 H), 7,77 (dd, 1 H), 7,69 (dd, 1 H), 7,41 (m, 4 H), 7,17 (m, 2 H), 6,60 (dd, 1 H), 3,91 (s, 2 H), 3,82 (s, 6 H), 2,62 (s, 3 H); EM (EI) m/z para $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

Ejemplo 37: (*R*)-2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)propanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,5 s, 1 H), 9,47 (s, 1 H), 8,95 (d, 1 H), 8,22 (d, 2 H), 8,14 (br s, 2 H), 7,76 (m, 2 H), 7,40 (m, 4 H), 7,17 (m, 2 H), 6,60 (m, 1 H), 3,97 (q, 1 H), 3,96 (s, 3 H), 1,45 (d, 3 H); EM (EI) m/z para $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

Ejemplo 38: 2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metilpropanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,1 (s, 1 H), 9,46 (s, 1 H), 8,95 (d, 1 H), 8,50 (br s, 1 H), 8,27 (m, 1 H), 7,81 (m, 2 H), 7,47 (m, 1 H), 7,37 (m, 3 H), 7,17 (m, 2 H), 6,61 (dd, 1 H), 3,83 (s, 3 H), 1,60 (s, 6 H); EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$: 541 ($MH^+$).

Ejemplo 39: 2-amino-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metilpropanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,33 (s, 1 H), 8,89 (s, 1 H), 8,32 (br s, 4 H), 7,92 (m, 3 H), 7,59 (m, 2 H), 7,37 (m, 4 H), 6,24 (s, 1 H), 3,76 (s, 6 H), 1,61 (s, 6 H); EM (EI) m/z para $C_{26}H_{28}N_6O_5S$: 537 ($MH^+$).

Ejemplo 40: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)-4-metilfenil)-2-(dimetilamino)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,58 (s, 1 H), 9,80 (br s, 1 H), 8,85 (s, 1 H), 8,25 (s, 1 H), 7,67 (dd, 1 H), 7,30 (m, 7 H), 6,16 (m, 1 H), 4,02 (br s, 2 H), 3,77 (s, 6 H), 2,81 (s, 6 H), 2,54 (s, 3 H); EM (EI) m/z para $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

Ejemplo 41: *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-((2-(dimetilamino)etil)(metil)amino)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,0 (s, 1 H), 9,48 (s, 1 H), 8,96 (d, 1 H), 8,16 (m, 1 H), 7,76 (m, 2 H), 7,39 (m, 4 H), 7,17 (m, 2 H), 6,61 (dd, 1 H), 3,82 (s, 3 H), 3,40 (br s, 2 H), 2,94 (br s, 2 H), 2,71 (br t, 2 H), 2,60 (s, 6 H), 2,33 (s, 3 H); EM (EI) m/z para $C_{28}H_{32}ClN_7O_4S$: 598 ($MH^+$).

Ejemplo 42: 2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,5 (s, 1 H), 9,48 (s, 1 H), 8,94 (s, 1 H), 8,15 (s, 1 H), 8,06 (br s, 3 H), 7,74 (m, 2 H), 7,39 (m, 4 H), 7,18 (m, 2 H), 6,61 (dd, 1 H), 3,83 (s, 3 H), 3,77 (s, 2 H); EM (EI) m/z para $C_{23}H_{21}ClN_6O_4S$: 513 ($MH^+$).

Ejemplo 43: *N*-(3-(*N*-(3-(2-acetil-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ.12,4 (s, 1 H), 10,5 (s, 1 H), 9,27 (s, 1 H), 8,25 (s, 1 H), 8,01 (d, 1 H), 7,82 (d, 1 H), 7,71 (d, 1 H), 7,42 (m, 3 H), 7,21 (m, 2 H), 6,63 (dd, 1H),3,91 (m, 5 H), 2,75 (s, 6 H), 2,61 (s, 3 H); EM (EI) m/z para $C_{27}H_{28}N_6O_5S$: 549 ($MH^+$).

Ejemplo 44: *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)formamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ12,6 (s, 1 H), 10,5 (s, 1 H), 9,16 (s, 1 H), 8,53 (br s, 1 H), 8,35 (m, 2 H), 8,02 (s, 1 H), 7,56 (m, 7 H), 6,70 (dd, 1 H), 3,83 (s, 3 H); EM (EI) m/z para $C_{22}H_{18}ClN_5O_4S$: 484 ($MH^+$).

Ejemplo 45: 2-amino-*N*-(5-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)-2-metilfenil)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ12,4 (s, 1 H), 10,1 (br s, 1 H), 8,82 (s, 1 H), 8,20 (m, 3 H), 7,82 (m, 1 H), 7,30 (m, 6 H), 6,20 (s, 1 H), 3,85 (s, 2 H), 3,77

(s, 6 H), 2,26 (s, 3 H); EM (EI) m/z para $C_{25}H_{26}N_6O_5S$: 523 ($MH^+$).

Ejemplo 46: *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metil-2-(metilamino)propanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,09 (s, 1 H), 9,46 (s, 1 H), 8,95 (m, 3 H), 8,28 (s, 1 H), 7,81 (m, 2 H), 7,41 (m, 4 H), 7,17 (m, 2 H), 6,60 (dd, 1 H), 3,82 (s, 3 H), 2,53 (s, 3 H), 1,60 (s, 6 H); EM (EI) m/z para $C_{26}H_{27}ClN_6O_4S$: 555 ($MH^+$).

Ejemplo 47: (*S*)-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)propanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,61 (s, 1 H), 9,47 (s, 1 H), 8,95 (s, 1 H), 8,82 (br s, 2 H), 8,27 (m, 1 H), 7,74 (m, 2 H), 7,42 (m, 4 H), 7,17 (m, 2 H), 6,60 (dd, 1 H), 3,90 (m, 1 H), 3,82 (s, 3 H), 2,59 (s, 3 H), 1,49 (d, 3 H); EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$: 541 ($MH^+$).

Ejemplo 48: 3-amino-*N*-(5-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-2-metilfenil)propanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ12,25 (s, 1 H), 9,77 (s, 1 H), 8,82 (s, 1 H), 7,84 (m, 5 H), 7,50 (d, 1 H), 7,37 (m, 5 H), 6,22 (m, 1 H), 3,74 (s, 6 H), 3,08 (m, 2 H), 2,77 (m, 2 H), 2,27 (s, 3 H); EM (EI) m/z para $C_{26}H_{28}N_6O_5S$: 537 ($MH^+$).

Ejemplo 49: 1-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)ciclopropanocarboxamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ9,54 (br s, 1 H), 9,42 (s, 1 H), 8,91 (s, 1 H), 8,21 (s, 1 H), 8,20 (br s, 2 H), 7,81 (m, 2 H), 7,48 (m, 4 H), 7,22 (m, 2 H), 6,61 (dd, 1 H), 3,82 (s, 3 H), 1,63 (m, 2 H), 1,26 (m, 2 H); EM (EI) m/z para $C_{25}H_{23}ClN_6O_4S$: 539 ($MH^+$).

Ejemplo 50: (*S*)-2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-6-

(dimetilamino)hexanamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ9,47 (br s, 1 H), 8,95 (d, 1 H), 8,26 (m, 1 H), 7,73 (m, 2 H), 7,30 (m, 4 H), 7,26 (m, 4 H), 7,16 (m, 2 H), 6,59 (dd, 1 H), 3,82 (s, 3 H), 3,34 (m, 1 H), 2,20 (m, 2 H), 2,09 (s, 6 H), 1,50 (m, 6 H); EM (EI) m/z para $C_{29}H_{34}ClN_7O_4S$: 610 ($MH^+$).

Ejemplo 51: 1-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)ciclopentanocarboxamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,12 (br s, 1 H), 9,46 (s, 1 H), 8,95 (d, 1 H), 8,26 (m, 1 H), 8,16 (m, 3 H), 7,84 (m, 2 H), 7,35 (m, 6 H), 6,60 (dd, 1 H), 3,82 (s, 3 H), 2,34 (m, 2 H), 1,91 (m, 6 H); EM (EI) m/z para $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

Ejemplo 52: *N*-(5-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-2-metilfenil)-2-(dimetilamino)acetamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ12,0 (br s, 1 H), 9,98 (s, 1 H), 9,43 (s, 1 H), 8,91 (m, 1 H), 8,08 (s, 1 H), 7,84 (dd, 1 H), 7,32 (m, 6 H), 6,61 (dd, 1 H), 4,07 (s, 2 H), 3,82 (s, 3 H), 2,82 (s, 6 H), 2,21 (s, 3 H); EM (EI) m/z para $C_{26}H_{27}ClN_6O_4S$: 555 ($MH^+$).

Ejemplo 53: 1-amino-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-ciclobutanocarboxamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ10,34 (br s, 1 H), 8,81 (s, 1 H), 8,49 (br s, 3 H), 8,34 (s, 1 H), 7,83 (m, 2 H), 7,43 (m, 3 H), 7,31 (m, 2 H), 7,16 (m, 2 H), 6,16 (s, 1 H), 3,77 (s, 6 H), 2,83 (m, 2 H), 2,25 (m, 3 H), 2,05 (m, 1 H); EM (EI) m/z para $C_{27}H_{28}N_6O_5S$: 549 ($MH^+$).

Ejemplo 54: *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-3-(3-(2-(dimetilamino)etil)ureido)bencensulfonamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ8,91 (br s, 1 H), 8,81 (s, 1 H), 8,08 (s, 1 H), 7,60 (s, 1 H), 7,38 (m, 9 H), 6,28 (m, 1 H), 6,15 (s, 1 H), 3,78 (s, 6 H), 3,40 (m, 2 H), 3,08 (m, 2 H), 2,74 (s, 6 H); EM (EI) m/z para $C_{27}H_{31}N_7O_5S$: 566 ($MH^+$).

Ejemplo 55: 1-amino-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-

ciclopentanocarboxamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ12,40 (br s, 1 H), 10,58 (s, 1 H), 8,46 (m, 4 H), 7,80 (m, 3 H), 7,59 (m, 2 H), 7,34 (m, 4 H), 6,25 (m, 1 H), 3,76 (s, 6 H), 2,35 (m, 2 H), 1,90 (m, 8 H); EM (EI) m/z para $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).

Ejemplo 56: 1-amino-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-ciclopropanocarboxamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ.9,54 (br s, 1 H), 8,84 (s, 1 H), 8,29 (s, 1 H), 7,75 (m, 2 H), 7,39 (m, 6 H), 7,17 (m, 2 H), 6,16 (m, 1 H), 3,78 (s, 6 H), 1,52 (m, 2 H), 1,17 (m, 2 H); EM (EI) m/z para $C_{26}H_{26}N_6O_5S$: 535 ($MH^+$).

Ejemplo 57: 3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenilcarbamato de 2-(dimetilamino)etilo. $^1$H RMN (400 MHz, DMSO-$d_6$) δ9,78 (br s, 1 H), 8,79 (s, 1 H), 8,19 (s, 1 H), 7,66 (d, 1 H), 7,31 (m, 9 H), 6,14 (m, 1 H), 4,17 (t, 2 H), 3,78 (s, 6 H), 2,54 (t, 2 H), 2,21 (s, 6 H): EM (EI) m/z para $C_{27}H_{30}N_6O_6S$: 567 ($MH^+$).

Ejemplo 58: 4-amino-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)tetrahidro-2H-piran-4-carboxamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ12,2 (br s, 1 H), 10,6 (s, 1 H), 8,74 (m, 5 H), 7,93 (m, 2 H), 7,47 (m, 6 H), 6,24 (m, 1 H), 3,77 (m, 10 H), 2,45 (m, 2 H), 1,81 (m, 2 H); EM (EI) m/z para $C_{28}H_{30}N_6O_6S$: 579 ($MH^+$).

Ejemplo 59: *N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-*N*3-(2-(dimetilamino)etil)benceno-1,3-disulfonamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ9,35 (m, 2 H), 8,92 (m, 1 H), 8,64 (s, 1 H), 8,30 (m, 1 H), 8,11 (s, 1 H), 7,86 (m, 1 H), 7,68 (m, 1 H), 7,49 (s, 1 H), 7,42 (m, 2 H), 7,21 (m, 2 H), 6,61 (m, 1 H), 3,82 (s, 3 H), 3,05 (m, 4 H), 2,74 (s, 6 H); EM (EI) m/z para $C_{25}H_{27}ClN_6O_5S_2$: 591 ($MH^+$).

Ejemplo 60: *N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-*N*3-(3-(dimetilamino)propil)benceno-1,3-disulfonamida. $^1$H RMN (400 MHz, DMSO-$d_6$) δ9,38 (m, 2 H), 8,90 (m, 1 H),

8,60 (s, 1 H), 8,32 (m, 1 H), 8,12 (s, 1 H), 7,88 (m, 1 H), 7,72 (m, 1 H), 7,59 (s, 1 H), 7,40 (m, 2 H), 7,20 (m, 2 H), 6,67 (m, 1 H), 3,82 (s, 3 H), 2,97 (m, 2 H), 2,78 (m, 2 H), 2,71 (s, 6 H), 1,70 (m, 2 H); EM (EI) m/z para $C_{26}H_{29}ClN_6O_5S_2$: 605 ($MH^+$).

Ejemplo 61: *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-4-metilfenil)-2-(metilamino)acetamida. EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$: 541,0 ($MH^+$).

Ejemplo 62: (*S*)-2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-4-metilfenil)propanamida. EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$: 541,2 ($MH^+$).

Ejemplo 63: (*R*)-2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-4-metilfenil)propanamida. EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$: 541,0 ($MH^+$).

Ejemplo 64: (*S*)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)propanamida. EM (EI) m/z para $C_{26}H_{28}N_6O_5S$: 537,1 ($MH^+$).

Ejemplo 65: (*R*)-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)propanamida. EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$: 541,1($MH^+$).

Ejemplo 66: (*R*)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)propanamida. EM (EI) m/z para $C_{26}H_{28}N_6O_5S$: 537,3 ($MH^+$).

Ejemplo 67: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)piperidino-2-carboxamida. EM (EI) m/z para $C_{28}H_{30}N_6O_5S$: 563,1 ($MH^+$).

Ejemplo 68: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-

(dimetilamino)etilamino)acetamida. EM (EI) m/z para $C_{28}H_{33}N_7O_5S$: 580,1 ($MH^+$).

Ejemplo 69: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-(metilamino)piperidin-1-il)acetamida. EM (EI) m/z para $C_{30}H_{35}N_7O_6S$: 606,1 ($MH^+$).

Ejemplo 70: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-(dimetilamino)piperidin-1-il)acetamida. EM (EI) m/z para $C_{31}H_{37}N_7O_5S$: 620,1 ($MH^+$).

Ejemplo 71: *N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 12,4 (br s, 1H), 10,9 (s, 1H), 9,8 (s, 1H), 8,9 (s, 1H), 8,3 (br s, 1H), 7,9 (d, 2H), 7,8 (d, 1H), 7,6 (t, 2H), 7,4 (q, 2H), 7,3 (s, 1H), 6,25 (s, 1H), 4,15 (s, 2H), 3,8 (s, 6H), 2,9 (s, 6H). EM (EI) m/z para $C_{26}H_{28}N_6O_5S$ 2,0 x $C_2H_1O_2F_3$: 537,1 ($MH^+$).

Ejemplo 72: *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(etilamino)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 10,8 (s, 1H), 9,20 (s, 1H), 8,84 (br s, 2H), 8,64 (br s, 1H), 8,30 (s, 1H), 7,9-8,0 (br s, 1H), 7,80 (t, 2H), 7,55-7,68 (m, 2H), 7,4 (d, 3H), 6,70 (m, 1H), 3,97 (br s, 2H), 3,83 (s, 3H), 3,04 (br s, 2H), 1,3 (t, 3H). EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$ 2,0 x $C_2H_1O_2F_3$: 541,3, 543,2 ($MH^+$).

Ejemplo 73: 2-(azetidin-1-il)-*N*-(3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 10,8 (s, 1H), 10,2 (s, 1H), 9,2 (s, 1H), 8,7 (s, 1H), 8,3 (s, 1H), 7,9-8,0 (br s, 1H), 7,80 (d, 1H), 7,72 (d, 1H), 7,65 (br s, 1H), 7,56 (t, 1H), 7,40 (d, 3H), 6,70 (m, 1H), 4,28 (s, 2H), 4,15 (m, 4H), 3,82 (s, 3H), 2,32 (br s, 1H). EM (EI) m/z para $C_{26}H_{25}ClN_6O_4S$ 2,0 x $C_2H_1O_2F_3$: 553,3, 555,2 ($MH^+$).

Ejemplo 74: *N*-(3-(*N*-(3-(2-bromo-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)acetamida. El compuesto del título se preparó

de acuerdo con los Ejemplos anteriores. $^1$H RMN (400 MHz, DMSO) δ 10,6 (s, 1H), 9,5 (s, 1H), 8,95 (d, 1H), 8,18 (t, 1H), 7,78 (m, 1H), 7,70 (m, 1H), 7,54 (d, 1H), 7,46 (m, 1H), 7,38 (t, 1H), 7,32 (d, 1H), 7,12-7,22 (m, 2H), 6,56 (m, 1H), 3,90 (s, 2H), 3,82 (s, 3H), 2,62 (s, 3H). EM (EI) m/z para $C_{24}H_{23}BrN_6O_4S$: 572,77, 570,90 ($MH^+$).

Ejemplo 75: 2-(dimetilamino)-*N*-(3-(*N*-(3-(6-metoxi-quinolin-8-ilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. El compuesto del título se preparó de acuerdo con los Ejemplos anteriores. $^1$H RMN (400 MHz, DMSO) δ 10,9 (s, 1H), 10,6 (s, 1H), 9,13 (s, 1H), 8,80 (d, 1H), 8,26-8,30 (m, 2H), 7,85 (d, 1H), 7,70 (d, 1H), 7,60 (q, 1H), 7,54 (m, 1H), 7,44 (t, 2H), 7,20 (t, 2H), 6,80 (d, 1H), 4,00 (s, 2H), 3,94 (s, 3H), 2,78 (s, 6H). EM (EI) m/z para $C_{28}H_{27}N_7O_4S$: 558,3 ($MH^+$).

Ejemplo 76: *N*-(3-(*N*-(3-(2-bromo-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. $^1$H RMN (400 MHz, DMSO) δ 10,6 (s, 1H), 9,4 (s, 1H), 8,9 (s, 1H), 8,25 (s, 1H), 7,78 (d, 1H), 7,70 (d, 1H), 7,54 (d, 1H), 7,48 (d, 1H), 7,40 (t, 2H), 6,56 (d, 1H), 4,02 (s, 2H), 3,82 (s, 3H), 2,80 (s, 6H). EM (EI) m/z para $C_{25}H_{25}BrN_6O_4S$: 586,79, 584,91 ($MH^+$).

Ejemplo 77: N-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fluoroetilamino)acetamida. $^1$H RMN (400 MHz, DMSO) δ 10,6 (s, 1H), 9,4 (s, 1H), 8,9 (d, 1H), 8,20 (s, 1H), 7,78 (d, 1H), 7,70 (d, 1H), 7,48 (m, 1H), 7,36-7,44 (m, 3H), 7,20 (q, 3H), 6,6 (m, 1H), 4,78 (t, 1H), 4,66 (t, 1H), 3,94 (s, 2H), 3,82 (s, 3H), 3,4 (t, 1H), 3,3 (t, 1H). EM (EI) m/z para $C_{25}H_{24}ClFN_6O_4S$: 559,2, 561,2 ($MH^+$).

Ejemplo 78: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)formamida. $^1$H RMN (400 MHz, DMSO) δ 12,4 (br s, 1H), 10,5 (s, 1H), 8,90 (s, 1H), 8,3 (s, 1H), 7,9 (br s, 1H), 7,85 (d, 1H), 7,75 (d, 1H), 7,5-7,6 (m,

2H), 7,3-7,4 (m, 4H), 6,2 (s, 1H), 3,8 (s, 3H). EM (EI) m/z para $C_{23}H_{21}N_5O_5S$: 480,1 ($MH^+$).

Ejemplo 79: N-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-(dimetilamino)azetidin-1-il)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 10,2 (br s, 1H), 9,5 (s, 1H), 8,95 (d, 1H), 8,2 (s, 1H), 7,75 (d, 1H), 7,65 (d, 1H), 7,45 (d, 1H), 7,40 (d, 1H), 7,30-7,35 (t, 1H), 7,1-7,2 (q, 2H), 6,60 (m, 1H), 3,82 (s, 3H). EM (EI) m/z para $C_{28}H_{30}ClN_7O_4S$: 480,1 ($MH^+$).

Ejemplo 80: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(pirrolidin-1-il)acetamida. EM (EI) m/z para $C_{28}H_{30}N_6O_5S$: 563,18 ($MH^+$).

Ejemplo 81: N-(3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(etil(metil)amino)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 12,0 (s, 1H), 10,6 (s, 1H), 9,65 (s, 1H), 9,5 (s, 1H), 8,95 (s, 1H), 8,25 (s, 1H), 7,8 (d, 1H), 7,70 (d, 1H), 7,45-7,50 (d, 1H), 7,3-7,4 (m, 3H), 7,2 (t, 2H), 6,60 (d, 1H), 4,02 (br s, 2H), 3,82 (s, 3H), 3,14 (br s, 2H), 2,80 (s, 3H) 1,2 (t, 3H). EM (EI) m/z para $C_{26}H_{27}ClN_6O_4S$: 555,2, 557,3 ($MH^+$).

Ejemplo 82: N-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-(piperidin-1-il)azetidin-1-il)acetamida. EM (EI) m/z para $C_{31}H_{34}ClN_7O_4S$ 2,0 x $C_2H_1O_2F_3$: 636,3, 638,3 ($MH^+$).

Ejemplo 83: N-(3-(*N*-(3-(3-fluoro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)acetamida. EM (EI) m/z para $C_{24}H_{23}FN_6O_4S$: 511,04 ($MH^+$).

Ejemplo 84: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-metilpiperidino-4-carboxamida. EM (EI) m/z para $C_{29}H_{32}N_6O_5S$ 1,0 x $C_2H_4O_2$: 577,2 ($MH^+$).

Ejemplo 85: N-(3-(*N*-(3-(3-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)acetamida. $^1H$ RMN (400

MHz, DMSO) δ 10,6 (s, 1H), 8,82 (s, 1H), 8,22 (t, 1H), 7,86 (t, 1H), 7,76 (m, 1H), 7,66 (m, 1H), 7,46 (m, 1H), 7,41 (m, 1H), 7,38 (t, 1H), 7,28 (m 1H), 7,24 (t, 1H), 7,12 (m, 2H), 6,56 (d, 1H), 3,88 (s, 2H), 3,80 (s, 3H), 2,60 (s, 3H). EM (EI) m/z para $C_{24}H_{24}N_6O_4S$: 492,99 ($MH^+$).

Ejemplo 86: *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2,2,2-trifluoroetilamino)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 10,4 (s, 1H), 9,2 (s, 1H), 8,65 (s, 1H), 8,4 (s, 1H), 8,00 (m, 1H), 7,80 (d, 1H), 7,75 (d, 1H), 7,65 (q, 1H), 7,55 (t, 1H), 7,40-7,5 (m, 3H), 6,7 (m, 1H), 3,82 (s, 3H), 3,62 (br s, 2H), 3,55 (br d, 2H). EM (EI) m/z para $C_{25}H_{22}ClF_3N_6O_4S$ 1,0 x $C_2H_1O_2F_3$: 595,0, 597,0 ($MH^+$).

Ejemplo 87: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-(piperidin-1-il)propanamida. EM (EI) m/z para $C_{30}H_{34}N_6O_5S$: 591,2 ($MH^+$).

Ejemplo 88: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-(dimetilamino)butanamida. EM (EI) m/z para $C_{28}H_{32}N_6O_5S$ 1,0 x $C_2H_4O_2$: 565,2 ($MH^+$).

Ejemplo 89: 2-(dimetilamino)-*N*-(3-(*N*-(3-(3-fluoro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 10,9 (s, 1H), 9,8 (br s, 1H), 9,1 (s, 1H), 8,34 (s, 1H), 7,90 (d, 1H), 7,76 (d, 1H), 7,52-7,68 (m, 4H), 7,40 (m, 2H), 6,54 (m, 1H), 4,16 (s, 2H), 3,82 (s, 3H), 2,86 (s, 6H). EM (EI) m/z para $C_{25}H_{25}FN_6O_4S$: 525,05 ($MH^+$).

Ejemplo 90: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(piperidin-1-il)acetamida. EM (EI) m/z para $C_{29}H_{32}N_6O_5S$: 577,37 ($MH^+$).

Ejemplo 91: 2-(dimetilamino)-*N*-(3-(*N*-(3-(3-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 10,5 (s, 1H), 8,8 (s, 1H), 8,25 (s, 1H), 7,83 (t, 1H), 7,76 (d, 1H), 7,64 (d, 1H), 7,3-7,48 (m, 4H), 7,22 (t, 1H), 7,12 (t, 2H), 6,56 (m, 1H), 3,96 (s,

2H), 3,78 (s, 3H), 2,76 (s, 6H). EM (EI) m/z para $C_{25}H_{26}N_6O_4S$: 507,1 ($MH^+$).

Ejemplo 92: N-(3-(*N*-(3-(2-cloro-5-hidroxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. $^1H$ RMN (400 MHz, DMSO) δ 10,8 (s, 1H), 9,9 (s, 1H), 9,8 (s, 1H), 9,1 (s, 1H), 8,55 (s, 1H), 8,34 (s, 1H), 7,9-8,0 (br s, 1H), 7,82 (d, 1H), 7,76 (d, 1H), 7,52-7,66 (m, 2H), 7,42 (t, 1H), 7,26 (d, 1H), 6,50 (m, 1H), 4,16 (s, 2H), 2,86 (s, 6H). EM (EI) m/z para $C_{24}H_{23}ClN_6O_4S$: 527,1, 529,0 ($MH^+$).

Ejemplo 93: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-morfolinoacetamida. EM (EI) m/z para $C_{28}H_{30}N_6O_6S$: 579,1 ($MH^+$).

Ejemplo 94: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z para $C_{24}H_{23}N_5O_5S$: 494,0 ($MH^+$).


Ejemplo 97: 2-amino-*N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-4-metilfenil)-2-metilpropanamida. EM (EI) m/z para $C_{26}H_{27}ClN_6O_4S$: 556,12 ($MH^+$).

Ejemplo 98: N-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. EM (EI) m/z para $C_{25}H_{25}ClN_6O_4S$: 542,05 ($MH^+$).

Ejemplo 99: 2-amino-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z para $C_{24}H_{24}N_6O_5S$: 509,59 ($MH^+$).

Ejemplo 100

Ácido 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)benzoico




**[00295]** A una solución de *N*-(3-{[2-cloro-5-(metoxi)-fenil]amino}quinoxalin-2-il)-3-cianobencensulfonamida (6,02 g, 12,95 mmol), preparada usando procedimientos similares a los del Ejemplo 115 o Ejemplo 423, en metanol (20 ml) y 1,4-dioxano (20 ml) se añadió hidróxido de sodio 6,0 *N* acuoso (40 ml) a temperatura ambiente. La solución se agitó a 90 $^{0}$C durante 3,5 h. La reacción se enfrió a temperatura ambiente y se neutralizó lentamente por la adición de ácido clorhídrico 2,0 *N* hasta que el pH de la solución estuvo en el rango 2-3 a 0° C. La solución se diluyó con acetato de etilo (300 ml). La fase orgánica se lavó con cloruro de sodio acuoso saturado (50 ml) y se secó con sulfato de magnesio. La filtración y concentración a presión reducida proporcionó ácido 3-{[(3-{[2-cloro-5-(metoxi)-fenil]amino}quinoxalin-2-il)amino]sulfonil}benzoico (5,921 g, 94%). EM (EI) m/z para $C_{22}H_{17}ClN_4O_5S$: 485,0 ($MH^+$).

**[00296]** Los siguientes compuestos se prepararon usando procedimientos similares a los usados en el Ejemplo 100.

Ejemplo 101: Procediendo como antes, se preparó ácido 3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-


il)sulfamoil)benzoico. EM (EI) m/z para $C_{23}H_{20}N_4O_6S$: 481,0 ($MH^+$).

Ejemplo 102: 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-metil-1-(piperidin-1-il)propan-2-il)benzamida. EM (EI) m/z para $C_{31}H_{35}ClN_6O_4S$: 623,06 ($MH^+$).

Ejemplo 103: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-metil-1-oxo-1-(piperidin-1-il)propan-2-il)benzamida. EM (EI) m/z para $C_{31}H_{33}ClN_6O_5S$: 637,65 ($MH^+$).

Ejemplo 104

3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]benzamida




**[00297]** A una solución de ácido 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzoico (0,20 g, 0,42 mmol), preparadas usando procedimientos similares al Ejemplo 100, in dimetilformamida (4 ml) se añadieron hexafluorofosfato de 2-(7-aza-1H-benzotriazol-1-il)-1,1,3,3-tetrametiluronio (HATU, 0,32 g, 0,83 mmol) y *N*-etildiisopropilamina (DIEA, 0,13 g, 1,04 mmol) a temperatura ambiente. La reacción se agitó durante 15 min antes de agregar *N*, *N*-dimetiletan-1,2-diamina (73 mg, 0,83 mmol). La mezcla de reacción se dejó agitar toda la noche. La reacción se diluyó con acetato de etilo (200 ml) y se lavó con agua (50 ml), bicarbonato de sodio acuoso saturado (40 ml), ácido clorhídrico acuoso 1,0 N (30 ml), y cloruro de sodio acuoso saturado (25 ml). La fase orgánica se secó

en sulfato de magnesio, se filtró y concentró a presión reducida para proporcionar 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]benzamida (0,20 g, 87%) como un sólido amarillo. EM (EI) m/z para $C_{26}H_{27}ClN_6O_4S$: 555,1 ($MH^+$).

**[00298]** Los siguientes compuestos se prepararon usando procedimientos similares a los del Ejemplo 104.

Ejemplo 105: 5-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(dimetilamino)etil)-2-metoxibenzamida. $^1H$ RMN (400 MHz, DMSO-$d_6$) δ 9,45 (s, 1H), 8,95 (d, 1H), 8,57 (d, 1H), 8,28 (t, 1H), 8,14 (dd, 1H), 7,46 (dd, 1H), 7,39 (m, 2H), 7,17 (m, 4H), 6,60 (dd, 1H), 3,89 (s, 3H), 3,82 (s, 3H), 3,38 (m, 2H), 2,43 (m, 2H), 2,21 (s, 6H). EM (EI) m/z para $C_{27}H_{29}ClN_6O_5S$: 585,3 ($MH^+$).

Ejemplo 106: 5-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(dimetilamino)etil)-2-fluorobenzamida. $^1H$ RMN (400 MHz, DMSO-$d_6$) δ 9,40 (br s, 1H), 9,16 (s, 1H), 8,73 (m, 1H), 8,67 (d, 1H), 8,36 (dd, 1H), 8,26 (m, 1H), 7,94 (br s, 1H), 7,66 (m, 1H), 7,59 (t, 1H), 7,43 (m, 3H), 6,71 (dd, 1H), 3,83 (s, 3H), 3,62 (m, 2H), 3,27 (m, 2H), 2,85 (d, 6H). EM (EI) m/z para $C_{26}H_{26}ClFN_6O_4S$: 573,1 ($MH^+$).

Ejemplo 107: 3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(dimetilamino)etil)benzamida. EM (EI) m/z para $C_{27}H_{30}N_6O_5S$: 551,1 ($MH^+$).

Ejemplo 108: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(dimetilamino)etil)-*N*-metilbenzamida. EM (EI) m/z para $C_{27}H_{29}ClN_6O_4S$: 569,1 ($MH^+$).

Ejemplo 109: 3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(dimetilamino)etil)-*N*-metilbenzamida. EM (EI) m/z para $C_{28}H_{32}N_6O_5S$: 565,1 ($MH^+$).

Ejemplo 110: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)benzamida. EM (EI) m/z para $C_{22}H_{18}ClN_5O_4S$: 484,0 ($MH^+$).


Ejemplo 111: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-morfolinoetil)benzamida. EM (EI) m/z para $C_{28}H_{29}ClN_6O_5S$: 597,0 ($MH^+$).

Ejemplo 112: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-metilbenzamida. EM (EI) m/z para $C_{23}H_{20}ClN_5O_4S$: 498,0 ($MH^+$).

Ejemplo 113: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-morfolinobenzamida. EM (EI) m/z para $C_{26}H_{25}ClN_6O_5S$: 569,0 ($MH^+$).

Ejemplo 114

*N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-{5-[(dimetilamino)metil]-1,3,4-oxadiazol-2-il}bencensulfonamida





**[00299]** A una solución de ácido 3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzoico (0,25 g, 0,52 mmol), preparado como se describió antes en el Ejemplo 100, en dimetilformamida (2,6 ml) se añadieron hexafluorofosfato de 2-(7-aza-1H-benzotriazol-1-il)-1,1,3,3-tetrametiluronio (HATU, 0,25 g, 0,67 mmol) y *N*-etildiisopropilamina (DIEA, 0,11 g, 0,88 mmol) a temperatura ambiente. La reacción se agitó durante 15 min antes de añadir 2-(dimetilamino)acetohidrazida (78 mg, 0,67 mmol). La mezcla de reacción se dejó agitar toda la noche. La reacción se diluyó con acetato de etilo (200 ml) y se

lavó con agua (30 ml), bicarbonato de sodio acuoso saturado (30 ml), ácido clorhídrico acuoso 1,0 N (20 ml), y cloruro de sodio acuoso saturado (25 ml). La fase orgánica se secó en sulfato de magnesio, se filtró y concentró a presión reducida para proporcionar 180 mg de un intermediario acoplado que luego se calentó en oxicloruro de fósforo (5 ml) a 100 °C durante 4h. La reacción se enfrió a temperatura ambiente y se trató con agua helada (50 ml) y se extrajo con diclorometano (3 X 50 ml). La fase orgánica se secó en sulfato de magnesio, se filtró y concentró a presión reducida para proporcionar un producto bruto que se sometió a HPLC en fase reversa para proporcionar *N*-(3-{[2-cloro-5-(metoxi)-fenil]amino}quinoxalin-2-il)-3-{5-[(dimetilamino)metil]-1,3,4-oxadiazol-2-il}-bencensulfonamida (16 mg, 5 %) como un sólido amarillo. EM (EI) m/z para $C_{26}H_{24}ClN_7O_4S$: 566,0 ($MH^+$).

Ejemplo 115

*N*-(3-(3-metoxi-5-nitro-fenilamino)-quinoxalin-2-il)-3-nitrobencensulfonamida




**[00300]** Se disolvieron *N*-(3-cloroquinoxalin-2-il)-3-nitrobencensulfonamida. 2,3-Dicloroquinoxalina (26,1 g, 131,1 mmol), m-Nitrobencensulfonamida (26,5 g, 131,1 mmol) y carbonato de potasio (18,1 g, 131,1) en DMSO anhidro (500 ml). La reacción se calentó a 150 °C durante 2 h. La mezcla de reacción se vertió en agua (400 ml), seguido por la adición de HCl 2M (60 ml). El producto se extrajo con EtOAc (3 x 500 ml). Las fases orgánicas se combinaron y se lavaron con agua (2 x 500 ml) y salmuera (2 x 500 ml). El

producto luego se secó con sulfato de sodio para dar *N*-(3-cloroquinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{14}H_9ClN_4O_4S$: 364,94, 366,97 ($MH^+$)

**[00301]** *N*-(3-(3-metoxi-5-nitrofenilamino)quinoxalin-2-il)-3-nitro-bencensulfonamida. *N*-(3-cloroquinoxalin-2-il)-3-nitrobencensulfonamida (700 mg, 1,92 mmol), 3-metoxi-5-nitroanilina (645 mg, 3,84 mmol) y p-xilene (7 ml) se combinaron y calentaron a 140°C, luego se agitaron durante 16 horas a 130 °C. La reacción se dejó enfriar, se colocó en un embudo de separación, se diluyó con DCM, y se lavó con HCl 2M y salmuera y se concentró in vacuo. El sólido resultante se lavó con $Et_2O$ para dar *N*-(3-(3-metoxi-5-nitro-fenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida (400 mg, 42%). EM (EI) m/z para $C_{21}H_{16}N_6O_7S$: 496,94 ($MH^+$).

**[00302]** Los siguientes compuestos se prepararon usando procedimientos similares a los del Ejemplo 115.

Ejemplo 116: *N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)-3-cianobencensulfonamida. EM (EI) m/z para $C_{22}H_{16}ClN_5O_3S$: 465,9 ($MH^+$).

Ejemplo 117: 3-ciano-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{23}H_{19}N_5O_4S$: 462,3 ($MH^+$).

Ejemplo 118: *N*-(3-(2,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-fluorobencensulfonamida. EM (EI) m/z para $C_{22}H_{19}FN_4O_4S$: 456,0 ($MH^+$).

Ejemplo 119: 3-bromo-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{19}BrN_4O_4S$: 516,9 ($MH^+$).

Ejemplo 120: 3-bromo-*N*-(3-(2,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{19}BrN_4O_4S$: 516,9 ($MH^+$).

Ejemplo 121: *N*-(3-(3-metoxifenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{21}H_{18}N_4O_3S$: 407,0 ($MH^+$).

Ejemplo 122: *N*-(3-(4-fluoro-3-metoxifenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{21}H_{17}FN_4O_3S$: 425,0 ($MH^+$).

Ejemplo 123: *N*-(3-(2,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-metoxibencensulfonamida. EM (EI) m/z para $C_{23}H_{22}N_4O_5S$: 467,0 ($MH^+$).

Ejemplo 124: *N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-metoxibencensulfonamida. EM (EI) m/z para $C_{23}H_{22}N_4O_5S$: 467,0 ($MH^+$).

Ejemplo 125: *N*-(3-(4-cloro-3-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{21}H_{17}ClN_4O_3S$: 440,9 ($MH^+$).

Ejemplo 126: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)tiofeno-2-sulfonamida. EM (EI) m/z para $C_{20}H_{18}N_4O_4S_2$: 443,0 ($MH^+$).

Ejemplo 127: N-(3-(6-metoxiquinolin-8-ilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{24}H_{18}N_6O_5S$: 502,95 ($MH^+$).

Ejemplo 128: 3-nitro-*N*-(3-(piridin-4-ilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{19}H_{14}N_6O_4S$: 423,2 ($MH^+$).

Ejemplo 129: N-(3-(2-cloropiridin-4-ilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{19}H_{13}ClN_6O_4S$: 456,93, 458,90 ($MH^+$).

Ejemplo 130: N-(3-(4,6-dimetoxipirimidin-2-ilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{20}H_{17}N_7O_6S$: 484,03 ($MH^+$).

Ejemplo 131: N-(3-(4-hidroxi-6-metoxipirimidin-2-ilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{19}H_{15}N_7O_6S$: 469,97 ($MH^+$).

Ejemplo 132: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-2-fluorobencensulfonamida. EM (EI) m/z para $C_{22}H_{19}FN_4O_4S$: 455,3 ($MH^+$).

Ejemplo 133: N-(3-(2-bromo-5-metoxi-fenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{21}H_{16}BrN_5O_5S$: 531,82, 532,84 ($MH^+$).

Ejemplo 134: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-metilbencensulfonamida. EM (EI) m/z para $C_{23}H_{22}N_4O_4S$: 451,0 ($MH^+$).

Ejemplo 136: N-(3-(2,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-metilbencensulfonamida. EM (EI) m/z para $C_{23}H_{22}N_4O_4S$: 451,0 ($MH^+$).

Ejemplo 137: N-(3-(3-fluoro-5-metoxi-fenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{21}H_{16}FN_5O_5S$: 470,0 ($MH^+$).

Ejemplo 138: 4-bromo-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{19}BrN_4O_4S$: 516,9, 514,9 ($MH^+$).

Ejemplo 139: *N*-(3-(3-metoxifenilamino)quinoxalin-2-il)-3-nitro-bencensulfonamida. EM (EI) m/z para $C_{21}H_{17}N_5O_5S$: 451,93 ($MH^+$).

Ejemplo 140: N-(3-(2-cloro-5-hidroxi-fenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{20}H_{14}ClN_5O_5S$: 472,15, 474,13 ($MH^+$).

Ejemplo 141: 3-acetil-*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{23}H_{19}ClN_4O_4S$: 483,08 ($MH^+$).

Ejemplo 142: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{20}N_4O_4S$: 437,49 ($MH^+$).

Ejemplo 143: N-(3-(5-metoxi-2-metil-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{20}N_4O_3S$: 421,46 ($MH^+$).

Ejemplo 144: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{21}H_{17}ClN_4O_3S$: 440,59 ($MH^+$).

Ejemplo 145: N-(3-(2,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{20}N_4O_4S$: 437,53 ($MH^+$).

Ejemplo 146: 4-cloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{19}ClN_4O_4S$: 470,54 ($MH^+$).


Ejemplo 147: N-(3-(5-metoxi-2-metil-fenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{22}H_{19}N_5O_5S$: 466,32 ($MH^+$).

Ejemplo 148: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida. EM (EI) m/z para $C_{21}H_{16}ClN_5O_5S$: 485,86 ($MH^+$).

Ejemplo 149: N-(3-(4-cloro-2,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{22}H_{19}ClN_4O_4S$: 470,99 ($MH^+$).

Ejemplo 150

*N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(2H-tetrazol-5-il)bencensulfonamida




**[00303]** A una solución agitada de 3-ciano-*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)bencensulfonamida (0,20 g, 0,44 mmol), preparada usando procedimientos similares a los descriptos en el Ejemplo 115, en dimetilformamida (1,2 ml) a 50 °C se añadieron azida sódica (0,11 g, 1,76 mmol) y cloruro de amonio (94 mg, 1,76 mmol). La mezcla bruta se calentó at 100 $^0$C toda la noche. La reacción se enfrió a temperatura ambiente se trató con agua helada (20 ml) seguido por ácido clorhídrico concentrado (10 ml). El

sólido obtenido se filtró a presión reducida y se lavó con hexano (20 ml), éter dietílico (20 ml), y acetato de etilo (5 ml) para proporcionar *N*-(3-{[3,5-bis(metoxi)fenil]amino}quinoxalin-2-il)-3-(2*H*-tetrazol-5-il)bencensulfonamida (55 mg, 25%) como un sólido amarillo claro. EM (EI) m/z para $C_{23}H_{20}N_8O_4S$: 505,0 ($MH^+$).

Ejemplo 151

*N*-(3-(2,6-dicloropiridin-4-ilamino)quinoxalin-2-il)-3-nitrobencensulfonamida.

**[00304]** Una mezcla de *N*-(3-cloroquinoxalin-2-il)-3-nitrobencensulfonamida (1 g), 2,6-dicloropiridin-4-amina (760 mg) y p-xileno (10 ml) se calentó a 135 °C con agitación toda la noche. Después de enfriar a temperatura ambiente, la mezcla se disolvió en diclorometano, se lavó con HCl 2 N (2 x) y salmuera, se concentró in vacuo para dar un producto bruto de *N*-{3-[(2,6-dicloropiridin-4-il)amino]quinoxalin-2-il}-3-nitrobencensulfonamida. Una pequeña porción de este producto bruto se purificó por HPLC para dar *N*-{3-[(2,6-dicloropiridin-4-il)amino]quinoxalin-2-il}-3-nitro-bencensulfonamida. $^1H$ RMN (400 MHz, DMSO) δ 9,71 (s, 1H), 8,90 (s, 1H), 8,50 (d, 2H), 8,8,41 (d, 1H), 8,30 (s, 2H), 7,88-7,78 (m, 27,65 (d, 1H), 7,47-7,37 (m, 2H); EM (EI) m/z para $C_{19}H_{12}Cl_2N_6O_4S$: 491,1, 493,1 ($MH^+$).

Ejemplo 152


*N*-(3-(2-cloro-6-metoxipiridin-4-ilamino)quinoxalin-2-il)-3-nitrobencensulfonamida

**[00305]** A un producto bruto de N-{3-[(2,6-dicloropiridin-4-il)amino]quinoxalin-2-il}-3-nitrobencensulfonamida (1,24 g) preparado usando procedimientos similares a los del ejemplo 151, se añadió DMSO anhidro (10 ml), seguido por metóxido de sodio (273 mg). La mezcla resultante se calentó at 100 °C durante 3 días. La mezcla se diluyó con EtOAc y agua, y

el pH se ajustó a aproximadamente 4 por agregado de ácido acético. El producto se extrajo con EtOAc (3 x). Los extractos combinados se lavaron con salmuera para dar el producto bruto. Una porción del producto bruto se purificó por HPLC preparativa para dar *N*-(3-{[2-cloro-6-(metiloxi)piridin-4-il]amino}quinoxalin-2-il)-3-nitrobencensulfonamida. 1H RMN (400 MHz, DMSO) δ 9,44 (s, 1H), 8,90 (s, 1H), 8,50 (d, 1H), 8,42 (d, 1H), 7,88-7,84 (m, 2H), 7,77 (s, 1H), 7,74 (s, 1H), 7,64 (d, 1H), 7,45-7,38 (m, 2H), 3,82 (s, 3H); EM (EI) m/z para $C_{20}H_{15}ClN_6O_5S$: 496,94 ($MH^+$).

Ejemplo 153

2-(dimetilamino)-*N*-(3-(*N*-(3-(3-(2-(dimetilamino)acetamido)-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida




**[00306]** 3-amino-*N*-(3-(3-amino-5-metoxifenilamino)quinoxalin-2-il)bencensulfonamida. *N*-(3-(3-Metoxi-5-nitrofenilamino)quinoxalin-2-il)-3-nitrobencensulfonamida (400 mg, 0,81 mmol), preparado como se describió antes en el Ejemplo 115, se disolvió en 1:1 THF:EtOH (4 ml), al que se añadió ácido fórmico (938 µl, 2,42 mmol) y formiato de potasio (203 mg, 2,42 mmol). El sistema se lavó con nitrógeno y luego se añadió 10% en peso de Pd/C (50 mg). La reacción luego se calentó a 60°C. Una vez que la reacción se determinó finalizada por LC-EM, se dejó enfriar, y se añadió DMF para solubilidad. La solución luego se filtró a través de un filtro de nylon para

eliminar el catalizador. El filtrado se diluyó con agua y el pH se ajustó a 7 y se extrajo con DCM (2x) y EtOAc (2x). Todas las fases orgánicas se combinaron y evaporaron a sequedad para dar 3-amino-*N*-(3-(3-amino-5-metoxifenilamino)quinoxalin-2-il)bencensulfonamida (330 mg, 93%). EM (EI) m/z para $C_{21}H_{20}N_6O_3S$: 437,06 ($MH^+$)

**[00307]** 2-(dimetilamino)-*N*-(3-(*N*-(3-(3-(2-(dimetilamino)-acetamido)-5-metoxifenilamino)quinoxalin-2-il)-sulfamoil)fenil)acetamida. 3-Amino-*N*-(3-(3-amino-5-metoxifenilamino)quinoxalin-2-il)bencensulfonamida (330 mg, 0,76 mmol), DMF (4 ml), *N,N,*-Dimetilglicina (312 mg, 3,02 mmol), HATU (1,15 g, 3,02 mmol), y 1,29(ml) (7,56 mmol) DIEA (1,29 ml, 7,56 mmol) se combinaron y calentaron a 90°C, seguido por calentamiento a 50°C durante 16 horas. La reacción se dejó enfriar, se colocó en un embudo de separación, se diluyó con agua y LiCl acuoso y se extrajo con EtOAc. El compuesto final luego se purificó por HPLC preparativa para dar 2-(dimetilamino)-*N*-(3-(*N*-(3-(3-(2-(dimetilamino)acetamido)-5-metoxi-fenilamino)-quinoxalin-2-il)sulfamoil)fenil)acetamida. $^1H$ RMN (400 MHz, $CD_3OD$) δ 8,45 (t, 1H), 7,93 (t, 1H), 7,85-7,88 (m, 1H), 7,70-7,74 (m, 1H), 7,65-7,68 (m, 1H), 7,58-7,62 (m, 1H), 7,58 (t, 1H), 7,34-7,42 (m, 3H), 7,0 (t, 1H), 4,05 (d, 2H), 3,8 (s, 3H), 2,9-3,0 (d, 12H). EM (EI) m/z para $C_{29}H_{34}N_8O_5S$: 607,2 ($MH^+$).


**[00308]** Los siguientes compuestos del título se prepararon usando procedimientos similares a los del Ejemplo 153.

Ejemplo 154: N-(3-(2,5-dimetoxifenilamino)-7-metilquinoxalin-2-il)bencensulfonamida. EM (EI) m/z para $C_{23}H_{22}N_4O_4S$: 451,0 ($MH^+$).

Ejemplo 155a y Ejemplo 155b

*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-(metilamino)bencensulfonamida y *N*-(3-(3,5-dimetoxi-


fenilamino)quinoxalin-2-il)-3-
(dimetilamino)bencensulfonamida.




**[00309]** A una solución de 3-amino-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida (414 mg) in DMF (4,5 ml) se añadió yodometano (114 µL). La mezcla de reacción se calentó a 35-50 °C hasta que se detectó la formación de productos mono-metilados y di-metilados por LC/EM. La mezcla se diluyó con EtOAc, se lavó con agua, 10% LiCl (2 x) y salmuera. Después deliminar el solvente in vacuo, la mezcla bruta se purificó por cromatografía flash en columna de sílice eluyendo con 15% EtOAc en hexanos, lo que proporciona productos mono-metilados y di-metilados. Producto A: *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-3-(metilamino)-bencensulfonamida (35 mg). $^1$H RMN (400 MHz, DMSO) δ 12,2 (s, 1H), 8,93 (s, 1H), 7,85 (d, 1H), 7,58 (d, 1H), 7,40-7,20 (m, 7H), 6,76 (m, 1H), 6,24 (m, 1H), 6,16 (br s, 1H), 3,77 (s, 6H), 2,71 (s, 3H). EM (EI) para $C_{23}H_{23}N_5O_4S$: 466,05 (MH+). Producto B: *N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)-3-(dimetilamino)bencensulfonamida (33 mg). $^1$H RMN (400 MHz, DMSO) δ 1220 (s, 1H), 8,98 (s, 1H), 7,98 (d, 1H), 7,56 (d, 1H), 7,42-7,32 (m, 7H), 6,74 (m, 1H), 6,24 (m, 1H), 3,77 (s, 6H), 2,97 (s, 6H). EM (EI) para $C_{24}H_{25}N_5O_4S$: 480,04 (MH+).

Ejemplo 156

*N*-(3-{[(2-{[3,5-bis(metoxi)fenil]amino}pirido[2,3-b]pirazin-3-il)amino]sulfonil}fenil)-*N*-2-[2-(dimetilamino)etil]-*N*-2-metilglicinamida



**[00310]** A una suspensión de THF (1,3 ml) de 3-amino-*N*-(3-{[3,5-(dimetoxi)-fenil]amino}-quinoxalin-2-il)bencensulfonamida (126 mg, 0,28 mmol), preparado usando procedimientos similares a los descriptos en el ejemplo 15, se añadió 0,143 ml de $Na_2CO_3$ acuoso 2M. A esta suspensión amarilla se añaden gota a gota 33 µL (0,42 mmol) de cloruro de clororacetilo. La mezcla de reacción se torna clara después de unos pocos minutos y se deja agitar a 23°C durante 1h. A la reacción se añade una solución de DMSO (1 ml) que contiene 180 µL (1,4 mmol) de *N,N',N'* trimetiletilendiamina. La reacción luego se calienta a 60°C y se agita durante 18 h. El producto se aísla por gradiente de RP-HPLC preparativa (*NH*$_4$OAc/AC*N*)t, las fracciones apropiadas se mezclaron y liofilizaron para dar un sólido amarillo en forma de sal de ácido acético: 59 mg (51%). $^1$H-RMN (400 MHz, $CDCL_3$): δ 10,1 (br s, 1H), 8,37 (br s, 2H), 8,18 (d, 1H), 7,97 (d, 1H), 7,60 (br d, 1H), 7,27 (s, 2H), 7,20 (br s, 3H), 6,15 (s, 1H), 3,82 (m, 2H), 3,65 (s, 6H), 3,20 (br m, 2H), 2,82 (br s, 8H), 2,42 (s, 3H), 2,02 (s, 3H). EM (EI) m/z para $C_{28}H_{34}N_8O_5S$: 595,84 ($MH^+$).

**[00311]** Los siguientes compuestos del título se prepararon usando procedimientos similares a los del Ejemplo 156.

Ejemplo 157: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-((3-

(dimetilamino)propil)(metil)amino)acetamida. EM (EI) m/z para $C_{30}H_{37}N_7O_5S$: 608,1 ($MH^+$).

Ejemplo 158: 2-(1,4'-bipiperidin-1'-il)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z para $C_{34}H_{41}N_7O_5S$: 660,1 ($MH^+$).

Ejemplo 159: 2-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenilcarbamoil)piperidino-1-carboxilato de *ter*-butilo. EM (EI) m/z para $C_{33}H_{38}N_6O_7S$: 663,1 ($MH^+$).

Ejemplo 160: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(1-(dimetilamino)propan-2-il)benzamida. EM (EI) m/z para $C_{27}H_{29}ClN_6O_4S$: 569,0 ($MH^+$).

Ejemplo 161: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-ureidobencensulfonamida. EM (EI) m/z para $C_{23}H_{22}N_6O_5S$: 495,40 ($MH^+$).

Ejemplo 162: 2-(dimetilamino)-*N*-(3-(*N*-(3-(5-metoxi-2-metilfenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z para $C_{26}H_{28}N_6O_4S$: 521,69 ($MH^+$).


Ejemplo 163: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-metilpiperazin-1-il)acetamida. EM (EI) m/z para $C_{29}H_{33}N_7O_5S$: 592,61 ($MH^+$).

Ejemplo 164: 2-acetamido-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z para $C_{26}H_{26}N_6O_6S$: 550,59 ($MH^+$).

Ejemplo 165: 2-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenilamino)-2-oxoetilcarbamato de *ter*-butilo. EM (EI) m/z para $C_{29}H_{32}N_6O_7S$: 609,32 ($MH^+$).

Ejemplo 166

*N*-(2-(3,5-dimetoxi-fenilamino)pirido[2,3-b]pirazin-3-il)-3-nitrobencensulfonamida



**[00312]** A una suspensión de xileno (15 ml) de *N*-(2-cloropirido[2,3-b]pirazin-3-il)-3-nitrobencensulfonamida (1 g, 2,7 mmol) (preparada usando procedimientos similares a los del Asier, et al *J. Org Chem* 2005, *70(7)*, 2878 y Leeson, et al *J. Med.Chem* 1991, *34*, 1243) se añadió 420 mg (2,7 mmol) de 3,5 dimetoxianilina. Después de someter a reflujo la reacción durante 1 h, la reacción se enfría, el precipitado se recolecta por filtración y se seca al vacío para dar 830 mg del producto como una mezcla ~6:1 de isómeros con el mayor que es N-(2-(3,5-dimetoxi-fenilamino)pirido[2,3-b]pirazin-3-il)-3-nitrobencensulfonamida que fue asignado por reactividad química conocida. HPLC analítica, tiempo de retención = 3,3 min (14%), 3,05 min (86%), (condiciones: columna Phenomenex Gemini $C_18$ 50x4,6, gradiente 5% a 95% MeCN/$H_2O$, en presencia de 0,1% de TFA, 5 min de corrida a una velocidad de flujo de 3,5 ml/min, $\lambda$ =254 nm). $^1$H-RMN (400 MHz, DMSO-d6): major isomer $\delta$ 9,14 (br s, 1H), 8,69 (dd, 1H), 8,60 (dd, 1H), 8,33 (dt, 2H), 7,77 (t, 1H), 7,49 (dd, 1H), 7,37 d, 2H), 7,05 (s, 1H), 6,26 (t, 1H), 3,77 (s, 6H); EM (EI) m/z para $C_{21}H_{18}N_6O_6S$: 483,08 ($MH^+$).


Ejemplo 167

3-amino-*N*-(2-(3,5-dimetoxi-fenilamino)pirido[2,3-b]pirazin-3-il)bencensulfonamida.

**[00313]** A una suspensión 1:1 en THF/EtOH (1 ml) de *N*-(3-(3,5-dimetoxifenilamino)-pirido[3,2-b]pirazin-2-il)-3-nitrobencensulfonamida (190 mg, 0,21 mmol) (preparada usando procedimientos similares a los del Ejemplos 166) se añadieron 47 µL (1,26 mmol) de ácido fórmico plus 99 mg (1,17 mmol) de formiato de potasio y 50 mg de 10% paladio en carbono. Después de someter a reflujo la reacción durante 1 h, a filtración en caliente a través de celite (lavando con una pequeña porción de DMF), dilución con 30 ml de agua, se ajustó el pH a 5,5 con 5% de $NaHCO_3$, el producto se aisló como un precipitado 140 mg (80%) de polvo blanco. HPLC analítica, tiempo de retención = 2,6 min (90%), 3,05 min (10%), 100% de pureza condiciones: columna YMC $C_18$ 5x4,6, gradiente 10% a 90% MeCN/$H_2O$, en presencia de 0,1% de TFA, 9 min de corrida a velocidad de flujo de 1 ml/min, λ =254 nm). $^1$H-RMN (400 MHz, $CDCL_3$): δ.8,48 (br s, 1H), 8,34 (dd, 1H), 7,92 (dd, 1H), 7,41 (dd, 1H), 7,15 (m, 3H), 7,13 (d, 2H), 6,86 (dd, 1H), 6. 28 (t, 1H), 3,83 (s, 6H); EM (EI) m/z para $C_{21}H_{20}N_6O_4S$: 453,03 ($MH^+$).

Ejemplo 168

3-amino-*N*-(3-{[3,5-bis(metoxi)fenil]amino}pirido[2,3-b]pirazin-2-il)bencensulfonamida





**[00314]** A una suspensión 1:1 en THF/EtOH (1 ml) de 3-nitro-*N*-(3-{[3,5-bis(metoxi)-fenil]amino}pirido[2,3-b]pirazin-2-il)bencensulfonamida (100 mg, 0,21 mmol) (preparado usando procedimientos similares a los usados en el Ejemplo 166) se añadieron 46 µL (0,63 mmol) de ácido fórmico más 100 mg

(0,63 mmol) de formiato de potasio y 100 mg de 10% paladio en carbono. Después de someter a reflujo la reacción durante 1 h, a filtración en caliente a través de celite y concentración, el producto se aísla por gradiente de RP-HPLC preparativa (*N*$H_4$OAc/AC*N*). Las fracciones apropiadas se mezclaron y liofilizaron para dar un sólido amarillo Producto: 3,2 mg (4%). $^1$H-RMN (400 MHz, $CDCl_3$): δ8,62 (d, 1H), 8,52 (s, 1H), 7,62 (d, 1H), 7,3 (m, 4H), 7,18 (d, 2H), 6,88 (d, 1H), 6,27 (t, 1H), 3,96 (br s, 2H), 3,83 (s, 6H). EM (EI) m/z para $C_{21}H_{20}N_6O_4S$: 453,22 ($MH^+$).

Ejemplo 169

Sal de trifluoroacético de *N*-(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)-3-(1-{[2-(dimetilamino)-etil]amino}etil)bencensulfonamida





**[00315]** A una solución de dicloroetano (0,6 ml) de 3-acetil-*N*-(3-{[2-cloro-5-(metoxi)-fenil]amino}quinoxalin-2-il)bencensulfonamida (150 mg, 0,31 mmol), preparada usando procedimientos similares a los del Ejemplo 115, y 51 µL (0,37 mmol) de *N,N*-dimetiletilenediamina se añadieron 19 µL de ácido acético seguido por 132 mg (0,62 mmol) de cianoborohidruro de sodio. La mezcla de reacción se sometió a reflujo durante 18 h bajo atmósfera de nitrógeno. Después de la concentración (in vacuo), el producto se aísla por gradiente de RP-HPLC preparativa (0,1 % TFA/AC*N*), seguido por liofilización de las fracciones apropiadas para dar sólido amarillo: 189 mg (90%). $^1$H-RMN (400 MHz, $d_3$-MeOD): δ 8,74 (s, 1H), 8,18 (s, 1H), 8,12 (d, 1H), 7,71 (m, 3H), 7,48 (m, 4H), 7,28 (d, 1H), 6,63 (d, 1H), 4,38 (q, 1H),

3,80 (s, 3H), 3,30 (m, 3H), 3,12 (m, 1H), 2,84 (s, 3H), 1,60 (d, 3H). EM (EI) m/z para $C_{27}H_{31}ClN_6O_3S$: 555,56 ($MH^+$).

Ejemplo 170


*N*,*N*-{[(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)amino](dimetilamino)metiliden}-*N*-metilmetanaminio




**[00316]** A una solución de dimetilformamida (1 ml) de 3-amino-*N*-(3-{[2-cloro-5-(metoxi)-fenil]amino}quinoxalin-2-il)2-metilbencensulfonamida (200 mg, 0,40 mmol), preparada usando procedimientos similares a los descriptos en el Ejemplo 115, se añaden 312 µL (1,8 mmol) de DIEA y 122 mg (0,6 mmol) de HATU. Después de agitar durante 18 h a 60 °C, el producto se precipitó en una mezcla 1:1 de hexano/acetato de etilo, se filtró y se secó para proporcionar 60 mg (26%). $^1H$ RMN (400 MHz, DMSO-$d_6$): δ 9,26 (b rs, 1H), 8,96 (br s, 1H), 7,80 (s, 1H), 7,51 (br s, 1H), 7,45 (d, 1H), 7,18 (brm, 4H), 6,91 (br s, 1H), 6,60 (br d, 1H), 3,82 (s, 3H), 3,36 (s, 3H), 2,85 (s, 6H), 2,58 (s, 3H). EM (EI) m/z para $C_{27}H_{31}ClN_7O_3S^+$: 569,32 ($MH^+$).


Ejemplo 171

2-Bromo-N-(3-(N-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida




**[00317]** En un balón de 50 ml se añadió ácido 2-bromoacético (1,87 g, 13,5 mmol), *N,N*-diisopropilcarbodiimida (860 mg, 6,8 mmol) y 10 ml DCM. A esta mezcla se añadió 3-amino-*N*-(3-(3,5-dimetoxifenilamino) quinoxalin-2-il) bencensulfonamida (2,03 g, 4,5 mmol), se preparó usando procedimientos similares a los del Ejemplo 168. La reacción se agitó toda la noche a temperatura ambiente. Se confirmó el consumo completo de la anilina de partida por LCMS. El solvente se evaporó para producir el producto bruto (2-bromo-N-(3-(N-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida). Esto se usó directamente en la etapa próxima sin purificación adicioanl.

Procedimiento de alquilación general 1




**[00318]** En un vial de 2 dram se colocó 2-bromo-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida (86 mg, 0,15 mmol), preparado usando procedimientos similares a los del Ejemplo 171, junto con 2 ml de acetonitrilo. Ocho equivalentes (1,2

mmol) de amina, anilina, hidrazina o alcoxiamina deseadas se añadieron seguido por la adición de base de Hunig (41 µL, 0,25 mmol). La reacción luego se agitó a 50 °C durante una hora (toda la noche para los reactivos de anilina). Ser usó HPLC en fase inversa para aislar el producto deseado directamente a partir de la mezcla de reacción. Se usó una HPLC de fase inversa preparativa Waters Fractionlynx equipada con una columna Waters SunFire Prep $C_18$, OCD 5 µM, 30 X 70 mm y que corre un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación.

**[0186]** Los siguientes compuestos del título se prepararon de acuerdo con el Procedimiento de alquilación de biblioteca general 1.

Ejemplo 172: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metilamino)acetamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 8,81 (s, 1H), 8,23 (t, 1H), 7,75 (d, 1H), 7,66 (d, 1H), 7,41-7,38 (m, 1H), 7,35 (m, 1H), 7,32 (d, 2H), 7,29-7,27 (m, 1H), 7,14-7,11 (m, 2H), 6,14 (t, 1H), 3,80 (s, 1H), 3,78 (s, 6H), 2,58 (s, 3H), 1,91 (s, 2H); EM (EI) m/z $C_{25}H_{26}N_6O_5S$: 523,6 ($MH^+$).

Ejemplo 173: 2-(ciclopropilmetilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 10,58 (s, 1H), 8,81 (s, 1H), 8,20 (t, 1H), 7,76 (d, 1H), 7,67 (d, 1H), 7,42-7,36 (m, 2H), 7,32 (d, 2H), 7,27 (s, 1H), 7,14-7,12 (m, 2H), 6,15 (t, 1H), 3,93 (s, 2H), 3,78 (s, 6H), 2,89 (s, 1H), 2,88 (s, 1H), 1,05-1,00 (m, 1H), 0,59 (d, 1H), 0,57 (d, 1H), 0,35 (d, 1H), 0,34 (d, 1H); EM (EI) m/z $C_{28}H_{30}N_6O_5S$: 563,6 ($MH^+$).

Ejemplo 174: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-hidroxi-propilamino)acetamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 10,49

ppm (s, 1H), 8,81 ppm (s, 1H), 8,23 ppm (t, 1H), 8,13 ppm (s, 1H), 7,76 ppm (d, 1H), 7,765-7,763 (dd, 1H), 7,41-7,37 ppm (m, 2H), 7,33-7,32 ppm (d, 1H), 7,30-7,28 ppm (m, 1H), 7,16-7,09 ppm (m, 2H), 6,55 ppm (s, 1H), 6,14 ppm (t, 1H), 5,49 ppm (d, 2H), 5,25 ppm (s, 1H), 3,85 ppm (s, 1H), 3,78 ppm (s, 6H) 3,67-3,59 ppm (m, 1H), 3,00-2,89 ppm (dd, 1H), 2,79-2,76 ppm ( m, 1H), 1,10 ppm (d, 1H), 1,01-0,99 ppm (d, 1H); EM (EI) m/z $C_{27}H_{30}N_6O_6S$: 566,6 ($MH^+$).

Ejemplo 175: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-fluorobencilamino)acetamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 10,42 ppm (s, 1H), 8,82 ppm (s, 1H), 8,23 ppm (s, 1H), 8,14 ppm (s, 1H), 7,75 ppm (d, 1H), 7,65 ppm (d, 1H), 7,49-7,32 ppm (m, 6H), 7,25-7,20 ppm (m, 1H), 7,14-7,12 ppm (m, 2H), 6,55 ppm (s, 1H), 6,15 ppm (t, 1H), 4,14 ppm (s, 2H), 3,78 ppm (s, 6H), 3,74 ppm (s, 2H); EM (EI) m/z $C_{31}H_{29}FN_6O_5S$: 616,7 ($MH^+$).

Ejemplo 176: 2-(bencilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

Ejemplo 177: 2-(dietilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

Ejemplo 178: 2-(4-(3,4-diclorofenil)piperazin-1-il)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{34}H_{33}Cl_2N_7O_5S$: 722 ($MH^+$).

Ejemplo 179: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2,2-dimetilhydrazinil)acetamida. EM (EI) m/z $C_{26}H_{29}N_7O_5S$: 552 ($MH^+$).

Ejemplo 180: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(p-tolilamino)acetamida. EM (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

Ejemplo 181: 2-(benciloxiamino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

Ejemplo 182: 2-(2-clorofenilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{27}ClN_6O_5S$: 619 ($MH^+$).

Ejemplo 183: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(isopropilamino)acetamida. EM (EI) m/z $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

Ejemplo 184: 2-(4-ciclopentilpiperazin-1-il)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{33}H_{39}N_7O_5S$: 646 ($MH^+$).

Ejemplo 185: *N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-propilpiperidin-1-il)acetamida. EM (EI) m/z $C_{32}H_{38}N_6O_5S$: 619 ($MH^+$).

Ejemplo 186: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(isobutoxiamino)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_6S$: 581 ($MH^+$).

Ejemplo 187: 2-(3-*tert*-butilfenilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{34}H_{36}N_6O_5S$: 641 ($MH^+$).

Ejemplo 188: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fenilpropan-2-ilamino)acetamida. EM (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

Ejemplo 189: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-fluoro-4-hidroxifenilamino)acetamida. EM (EI) m/z $C_{30}H_{27}FN_6O_6S$: 619 ($MH^+$).

Ejemplo 190: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-(metiltio)bencilamino)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_5S_2$: 645 ($MH^+$).

Ejemplo 191: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(5-fluoro-2-metilbencilamino)acetamida. EM (EI) m/z $C_{32}H_{31}FN_6O_5S$: 631 ($MH^+$).

Ejemplo192: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fenilpirrolidin-1-il)acetamida. EM (EI) m/z $C_{34}H_{34}N_6O_5S$: 639 ($MH^+$).

Ejemplo 193: 2-(2-bencilpirrolidin-1-il)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{35}H_{36}N_6O_5S$: 653 ($MH^+$).

Ejemplo 194: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fenilmorfolino)acetamida. EM (EI) m/z $C_{34}H_{34}N_6O_6S$: 655 ($MH^+$).

Ejemplo 195: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-(piridin-4-il)piperidin-1-il)acetamida. EM (EI) m/z $C_{34}H_{35}N_7O_5S$: 654 ($MH^+$).

Ejemplo 196: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(o-tolilamino)acetamida. EM (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

Ejemplo 197: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2,4-dimetilbencilamino)acetamida. EM (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

Ejemplo 198: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metil(piridin-3-ilmetil)amino)acetamida. EM (EI) m/z $C_{31}H_{31}N_7O_5S$: 614 ($MH^+$).

Ejemplo 199: 2-(3-cloro-4-metilbencilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{32}H_{31}ClN_6O_5S$: 647 ($MH^+$).

Ejemplo 200: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-((2-(dimetilamino)-etil)(metil)amino)acetamida. EM (EI) m/z $C_{29}H_{35}N_7O_5S$: 594 ($MH^+$).

Ejemplo 201: 2-(4-acetilpiperazin-1-il)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{33}N_7O_6S$: 620 ($MH^+$).

Ejemplo 202: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(metil(1-metilpirrolidin-3-il)amino)acetamida. EM (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

Ejemplo 203: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-metil-1,4-diazepan-1-il)acetamida. EM (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

Ejemplo 204: 2-(4-alilpiperazin-1-il)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{31}H_{35}N_7O_5S$: 618 ($MH^+$).

Ejemplo 205: *N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-isopropilpiperazin-1-il)acetamida EM (EI) m/z $C_{31}H_{37}N_7O_5S$: 620 ($MH^+$).

Ejemplo 206: *N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-(dimetilamino)pirrolidin-1-il)acetamida. EM (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

Ejemplo 207: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-(dimetilamino)azetidin-1-il)acetamida. EM (EI) m/z $C_{29}H_{33}N_7O_5S$: 592 ($MH^+$).

Ejemplo 208: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-oxopiperidin-1-il)acetamida. EM (EI) m/z $C_{29}H_{30}N_6O_6S$: 591 ($MH^+$).

Ejemplo 209: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-((2-metoxietil)(metil)amino)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_6S$: 581 ($MH^+$).

Ejemplo 210: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-metilbenciloxiamino)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_6S$: 629 ($MH^+$).

Ejemplo 211: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-metoxibenciloxiamino)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_7S$: 645 ($MH^+$).

Ejemplo 212: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(propilamino)acetamida. EM (EI) m/z $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

Ejemplo 213: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(etil(metil)amino)acetamida. EM (EI) m/z $C_{27}H_{30}N_6O_5S$: 551 ($MH^+$).

Ejemplo 214: 2-(alil(metil)amino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).

Ejemplo 215: 2-(*tert*-butilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

Ejemplo 216: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(isobutilamino)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

Ejemplo 217: 2-(butilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

Ejemplo 218: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(isopropil(metil)amino)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_5S$: 565 ($MH^+$).

Ejemplo 219: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-formilpiperazin-1-il)acetamida. EM (EI) m/z $C_{29}H_{31}N_7O_6S$: 606 ($MH^+$).

Ejemplo 220: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-etilpiperazin-1-il)acetamida. EM (EI) m/z $C_{30}H_{35}N_7O_5S$: 606 ($MH^+$).

Ejemplo 221: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-formil-1,4-diazepan-1-il)acetamida. EM (EI) m/z $C_{30}H_{33}N_7O_6S$: 620 ($MH^+$).

Ejemplo 222: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(etil(2-hidroxietil)amino)acetamida. EM (EI) m/z $C_{28}H_{32}N_6O_6S$: 581 ($MH^+$).

Ejemplo 223: (*S*)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-hidroxipirrolidin-1-il)acetamida. EM (EI) m/z $C_{28}H_{30}N_6O_6S$: 579 ($MH^+$).

Ejemplo 224: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2,6-dimetilmorfolino)acetamida. EM (EI) m/z $C_{30}H_{34}N_6O_6S$: 607 ($MH^+$).

Ejemplo 225: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-

metilbencilamino)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

Ejemplo 226: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-metoxi-etilamino)acetamida. EM (EI) m/z $C_{27}H_{30}N_6O_6S$: 567 ($MH^+$).

Ejemplo 227: N-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(tiazolidin-3-il)acetamida. EM (EI) m/z $C_{27}H_{28}N_6O_5S_2$: 581 ($MH^+$).

Ejemplo 228: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-(hidroximetil)piperidin-1-il)acetamida. EM (EI) m/z $C_{30}H_{34}N_6O_6S$: 607 ($MH^+$).

Ejemplo 229: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fenilpropilamino)acetamida. EM (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

Ejemplo 230: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(isobutil(metil)amino)acetamida. EM (EI) m/z $C_{29}H_{34}N_6O_5S$: 579 ($MH^+$).

Ejemplo 231: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(fenilamino)acetamida. EM (EI) m/z $C_{30}H_{28}N_6O_5S$: 585 ($MH^+$).

Ejemplo 232: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-propilfenilamino)acetamida. EM (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

Ejemplo 233: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-isopropilfenilamino)acetamida. EM (EI) m/z $C_{33}H_{34}N_6O_5S$: 627 ($MH^+$).

Ejemplo 234: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fluoro-4-

metilfenilamino)acetamida. EM (EI) m/z $C_{31}H_{29}FN_6O_5S$: 617 ($MH^+$).

Ejemplo 235: 2-(4-clorofenilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{27}ClN_6O_5S$: 619 ($MH^+$).

Ejemplo 236: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-metoxifenilamino)acetamida. EM (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

Ejemplo 237: 2-(3-clorofenilamino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{27}ClN_6O_5S$: 619 ($MH^+$).

Ejemplo 238: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2,3-dimetilfenilamino)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

Ejemplo 239: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fluorofenilamino)acetamida. EM (EI) m/z $C_{30}H_{27}FN_6O_5S$: 603 ($MH^+$).

Ejemplo 240: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-fluorofenilamino)acetamida. EM (EI) m/z $C_{30}H_{27}FN_6O_5S$: 603 ($MH^+$).

Ejemplo 241: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(tiophen-2-ilmetilamino)acetamida. EM (EI) m/z $C_{29}H_{28}N_6O_5S_2$: 605 ($MH^+$).

Ejemplo 242: 2-(ciclohexil(etil)amino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{32}H_{38}N_6O_5S$: 619 ($MH^+$).

Ejemplo 243: 2-((ciclopropilmetil)(propil)amino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{31}H_{36}N_6O_5S$: 605 ($MH^+$).

Ejemplo 244: 2-(alil(ciclopentil)amino)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{32}H_{36}N_6O_5S$: 617 ($MH^+$).

Ejemplo 245: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(etil(isopropil)amino)acetamida. EM (EI) m/z $C_{29}H_{34}N_6O_5S$: 579 ($MH^+$).

Ejemplo 246: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(etil(fenil)amino)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

Ejemplo 247: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-metilpirrolidin-1-il)acetamida. EM (EI) m/z $C_{29}H_{32}N_6O_5S$: 577 ($MH^+$).

Ejemplo 248: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-metilpiperidin-1-il)acetamida. EM (EI) m/z $C_{30}H_{34}N_6O_5S$: 591 ($MH^+$).

Ejemplo 249: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(piridin-2-ilmetilamino)acetamida. EM (EI) m/z $C_{30}H_{29}N_7O_5S$: 600 ($MH^+$).

Ejemplo 250: 2-(bencil(metil)amino)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

Ejemplo 251: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(1-

feniletilamino)acetamida. EM (EI) m/z $C_{32}H_{32}N_6O_5S$: 613 ($MH^+$).

Ejemplo 252: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-metilpiperidin-1-il)acetamida. EM (EI) m/z $C_{30}H_{34}N_6O_5S$: 591 ($MH^+$).


Ejemplo 253: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-metilpiperidin-1-il)acetamida. EM (EI) m/z $C_{30}H_{34}N_6O_5S$: 591 ($MH^+$).

Ejemplo 254: 2-(3,4-dihidroisoquinolin-2(1H)-il)-*N*-(3-(*N*-(3-(3,5-dimetoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{33}H_{32}N_6O_5S$: 625 ($MH^+$).

Ejemplo 255: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2,6-dimetilpiperidin-1-il)acetamida. EM (EI) m/z $C_{31}H_{36}N_6O_5S$: 605 ($MH^+$).

Ejemplo 256: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-hidroxibencilamino)acetamida. EM (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

Procedimiento de acilación de biblioteca general 1




**[00319]** En un vial de 2 dram se añadieron 3-amino-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida (54 mg, 0,12 mmol), preparada usando procedimientos similares a los descriptos en el Ejemplo 15, DMA (2 ml) y el ácido carboxílico deseado (0,17 mmol). Se añadieron DIEA

(70 µL, 0,4 mmol) seguido por HATU (53 mg,0,14 mmol) al vial y la mezcla de reacción se agitó a 50 °C toda la noche. Se usó HPLC de fase preparativa para aislar el producto deseado directamente de la mezcla de reacción bruta. Se use usó una HPLC de fase inversa preparativa Waters Fractionlynx equipada con una columna Waters SunFire Prep $C_18$, OCD 5 µM, 30 X 70 mm y que corre un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación.

**[00320]** Los siguientes compuestos del título se prepararon de acuerdo con el Procedimiento de acilación de biblioteca general 1.

Ejemplo 257: *N*-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)morfolino-4-carboxamida: EM (EI) m/z para $C_{26}H_{25}ClN_6O_5S$: 567 ($MH^-$).

Ejemplo 258: *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. EM (EI) m/z para $C_{26}H_{28}N_6O_5S$: 535,1 ($MH^-$).

Ejemplo 259: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)propionamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 12,37 (s,1H), 10,20 (s, 1H), 8,88 (s, 1H), 8,37 (s, 1H), 7,93 (s, 1H), 7,77 (t, 2H), 7,59 (t, 1H), 7,51 (t, 1H), 7,41-7,34 (m, 4H), 6,24 (t, 1H), 3,76 (s, 6H), 2,36-2,31 (dd, 2H), 1,10 (s, 1H), 1,08 (s, 1H), 1,06 (s, 1H); EM (EI) m/z $C_{25}H_{25}N_5O_5S$: 508,6 ($MH^+$).

Ejemplo 260: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)piridazino-4-carboxamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 11,01 (s, 1H), 9,66 (dd, 1H), 9,52 (dd, 1H), 8,90 (s, 1H), 8,55 (s, 1H), 8,13 (dd, 1H), 7,99 (d, 1H), 7,93 (d, 1H), 7,65-7,58 (m, 2H), 7,42-7,35 (m, 4H), 6,24 (t, 1H), 3,75 (s, 6H); EM (EI) m/z $C_{27}H_{23}N_7O_5S$: 558,6 ($MH^+$).

Ejemplo 261: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metilnicotinamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 10,78 ppm (s, 1H), 8,90 ppm (s, 1H), 8,58-8,57 ppm (dd, 2H), 7,90-7,86 (m, 4H), 7,60-7,56 ppm (m, 2H), 7,42-7,34 (m, 5H), 6,23 ppm (t, 1H), 3,74 ppm (s, 6H), 2,57 ppm (s, 3H); EM (EI) m/z $C_{29}H_{26}N_5O_5S$: 570,6 ($MH^+$).

Ejemplo 262: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(o-toliloxi)acetamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 12,37 ppm (s, 1H), 10,41 ppm (s, 1H), 8,90 ppm (s, 1H), 8,41 ppm (s, 1H), 7,93 ppm (s, 1H), 7,90-7,8 (m, 2H), 7,59-7,53 ppm (m, 2H), 7,42-7,33 ppm (m, 4H), 7,17-7,12 ppm (m, 2H), 6,89-6,85 ppm (m, 2H), 6,24 ppm (t, 1H), 4,74 ppm (s, 2H), 3,76 ppm (s, 6H), 2,33 ppm (s, 2H); EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 599,7 ($MH^+$).

Ejemplo 263: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-metoxi-4-metilbenzamida. EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

Ejemplo 264: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-metoxi-4-metilbenzamida. EM (EI) m/z $C_{28}H_{24}N_6O_5S$: 557 ($MH^+$).

Ejemplo 265: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)tiazol-4-carboxamida. EM (EI) m/z $C_{26}H_{22}N_6O_5S_2$: 563 ($MH^+$).

Ejemplo 266: 2-bromo-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)tiofeno-3-carboxamida. EM (EI) m/z $C_{27}H_{22}BrN_5O_5S_2$ 640 ($MH^+$).

Ejemplo 267: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pivalamida. EM (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

Ejemplo 268: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pent-4-enamida. EM (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

Ejemplo 269: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{25}N_5O_5S$: 556 ($MH^+$).

Ejemplo 270: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)butiramida. EM (EI) m/z $C_{26}H_{27}N_5O_5S$: 522 ($MH^+$).

Ejemplo 271: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metoxiacetamida. EM (EI) m/z $C_{25}H_{25}N_5O_6S$: 524 ($MH^+$).

Ejemplo 272: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)ciclobutanocarboxamida. EM (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

Ejemplo 273: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metilciclopropanocarboxamida. EM (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

Ejemplo 274: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-metilciclopropanocarboxamida. EM (EI) m/z $C_{27}H_{27}N_5O_5S$: 534 ($MH^+$).

Ejemplo 275: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-metilbutanamida. EM (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

Ejemplo 276: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-etoxiacetamida. EM (EI) m/z $C_{26}H_{27}N_5O_6S$: 538 ($MH^+$).

Ejemplo 277: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-metoxipropanamida. EM (EI) m/z $C_{26}H_{27}N_5O_6S$: 538 ($MH^+$).

Ejemplo 278: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-hidroxiacetamida. EM (EI) m/z $C_{24}H_{23}N_5O_6S$: 510 ($MH^+$).

Ejemplo 279: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)isobutiramida. EM (EI) m/z $C_{26}H_{27}N_5O_5S$: 522 ($MH^+$).

Ejemplo 280: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-hidroxiciclopropanocarboxamida. EM (EI) m/z $C_{26}H_{25}N_5O_6S$: 536 ($MH^+$).

Ejemplo 281: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)furan-3-carboxamida. EM (EI) m/z $C_{27}H_{23}N_5O_6S$: 546 ($MH^+$).

Ejemplo 282: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)tetrahidrofuran-3-carboxamida. EM (EI) m/z $C_{27}H_{27}N_5O_6S$: 550 ($MH^+$).

Ejemplo 283: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)tetrahidrofuran-2-carboxamida. EM (EI) m/z $C_{27}H_{27}N_5O_6S$: 550 ($MH^+$).

Ejemplo 284: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)furan-2-carboxamida. EM (EI) m/z $C_{27}H_{23}N_5O_6S$: 546 ($MH^+$).

Ejemplo 285: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)isonicotinamida. EM (EI) m/z $C_{28}H_{24}N_6O_5S$: 557 ($MH^+$).

Ejemplo 286: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1H-pirrol-2-carboxamida. EM (EI) m/z $C_{27}H_{24}N_6O_5S$: 545 ($MH^+$).

Ejemplo 287: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pirazino-2-carboxamida. EM (EI) m/z $C_{27}H_{23}N_7O_5S$: 558 ($MH^+$).

Ejemplo 288: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-metil-1H-pirrol-2-carboxamida. EM (EI) m/z $C_{28}H_{26}N_6O_5S$: 559 ($MH^+$).

Ejemplo 289: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-5-

metilisoxazol-3-carboxamida. EM (EI) m/z $C_{27}H_{24}N_6O_6S$: 561 ($MH^+$).

Ejemplo 290: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)tiofeno-2-carboxamida. EM (EI) m/z $C_{27}H_{23}N_5O_5S_2$: 562 ($MH^+$).

Ejemplo 291: (*S*)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-metilpirrolidine-2-carboxamida. EM (EI) m/z $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).

Ejemplo 292: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metilbenzamida. EM (EI) m/z $C_{30}H_{27}N_5O_5S$: 570 ($MH^+$).

Ejemplo 293: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-fenilacetamida. EM (EI) m/z $C_{30}H_{27}N_5O_5S$: 570 ($MH^+$).

Ejemplo 294: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-metilpicolinamida. EM (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

Ejemplo 295: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(piridin-3-il)acetamida. EM (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

Ejemplo 296: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-6-hidroxipicolinamida. EM (EI) m/z $C_{28}H_{24}N_6O_6S$: 573 ($MH^+$).

Ejemplo 297: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-fluorobenzamida EM (EI) m/z $C_{29}H_{24}FN_5O_5S$: 574 ($MH^+$).

Ejemplo 298: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-fluorobenzamida. EM (EI) m/z $C_{29}H_{24}FN_5O_5S$: 574 ($MH^+$).

Ejemplo 299: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-fluorobenzamida. EM (EI) m/z $C_{29}H_{24}FN_5O_5S$: 574 ($MH^+$).

Ejemplo 300: 2-ciclohexil-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{33}N_5O_5S$: 576 ($MH^+$).

Ejemplo 301: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-oxociclopentil)acetamida. EM (EI) m/z $C_{29}H_{29}N_5O_6S$: 576 ($MH^+$).

Ejemplo 302: 4-ciclopropil-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-oxobutanamida. EM (EI) m/z $C_{29}H_{29}N_5O_6S$: 576 ($MH^+$).

Ejemplo 303: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-oxociclohexanocarboxamida. EM (EI) m/z $C_{29}H_{29}N_5O_6S$: 576 ($MH^+$).

Ejemplo 304: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-(piridin-3-il)propanamida. EM (EI) m/z $C_{30}H_{28}N_6O_5S$: 585 ($MH^+$).

Ejemplo 305: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metoxibenzamida. EM (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

Ejemplo 306: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-metoxibenzamida. EM (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

Ejemplo 307: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-fenoxiacetamida. EM (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

Ejemplo 308: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-metoxibenzamida. EM (EI) m/z $C_{30}H_{27}N_5O_6S$: 586 ($MH^+$).

Ejemplo 309: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-fluorofenil)acetamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 310: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-fluorofenil)acetamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 311: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-fluorofenil)acetamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 312: 2-cloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{24}ClN_5O_5S$: 590 ($MH^+$).

Ejemplo 313: 4-cloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{24}ClN_5O_5S$: 590 ($MH^+$).

Ejemplo 314: 3-cloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{24}ClN_5O_5S$: 590 ($MH^+$).

Ejemplo 315: (1R,2R)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-fenilciclopropanocarboxamida. EM (EI) m/z $C_{32}H_{29}N_5O_5S$: 596 ($MH^+$).

Ejemplo 316: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-fenilciclopropanocarboxamida. EM (EI) m/z $C_{32}H_{29}N_5O_5S$: 596 ($MH^+$).

Ejemplo 317: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(1H-imidazol-4-il)acetamida. EM (EI) m/z $C_{27}H_{25}N_7O_5S$: 560 ($MH^+$).

Ejemplo 318: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-metoxi-2-metilbenzamida. EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

Ejemplo 319: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-fluorofenoxi)acetamida. EM (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

Ejemplo 320: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-5-fluoro-2-metoxibenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

Ejemplo 321: 2-(4-clorofenil)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{26}ClN_5O_5S$: 604 ($MH^+$).

Ejemplo 322: 2-(2-clorofenil)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{26}ClN_5O_5S$: 604 ($MH^+$).

Ejemplo 323: 2-(3-clorofenil)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{30}H_{26}ClN_5O_5S$: 604 ($MH^+$).

Ejemplo 324: 1-acetil-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)piperidino-4-carboxamida. EM (EI) m/z $C_{30}H_{32}N_6O_6S$: 605 ($MH^+$).

Ejemplo 325: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(piridin-4-il)acetamida. EM (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

Ejemplo 326: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(piridin-2-il)acetamida. EM (EI) m/z $C_{29}H_{26}N_6O_5S$: 571 ($MH^+$).

Ejemplo 327: 2,4-dicloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

Ejemplo 328: 3,4-dicloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

Ejemplo 329: 2,5-dicloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

Ejemplo 330: 3,5-dicloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

Ejemplo 331: 2,3-dicloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzamida. EM (EI) m/z $C_{29}H_{23}Cl_2N_5O_5S$: 624 ($MH^+$).

Ejemplo 332: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pentanamida. EM (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

Ejemplo 333: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metilbutanamida. EM (EI) m/z $C_{27}H_{29}N_5O_5S$: 536 ($MH^+$).

Ejemplo 334: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1H-imidazol-2-carboxamida. EM (EI) m/z $C_{26}H_{23}N_7O_5S$: 546 ($MH^+$).

Ejemplo 335: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1H-imidazol-4-carboxamida. EM (EI) m/z $C_{26}H_{23}N_7O_5S$: 546 ($MH^+$).

Ejemplo 336: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)isoxazol-5-carboxamida. EM (EI) m/z $C_{26}H_{22}N_6O_6S$: 547 ($MH^+$).

Ejemplo 337: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3,3-dimetilbutanamida. EM (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

Ejemplo 338: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metilpentanamida. EM (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

Ejemplo 339: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2,2-dimetilbutanamida. EM (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

Ejemplo 340: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-metilpentanamida. EM (EI) m/z $C_{28}H_{31}N_5O_5S$: 550 ($MH^+$).

Ejemplo 341: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)pirimidino-5-carboxamida. EM (EI) m/z $C_{27}H_{23}N_7O_5S$: 558 ($MH^+$).

Ejemplo 342: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-metilfuran-2-carboxamida. EM (EI) m/z $C_{28}H_{25}N_5O_6S$: 560 ($MH^+$).

Ejemplo 343: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)tiofeno-3-carboxamida. EM (EI) m/z $C_{27}H_{23}N_5O_5S_2$: 562 ($MH^+$).

Ejemplo 344: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-oxociclopentanocarboxamida. EM (EI) m/z $C_{28}H_{27}N_5O_6S$: 562 ($MH^+$).

Ejemplo 345: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-metoxietoxi)acetamida. EM (EI) m/z $C_{27}H_{29}N_5O_7S$: 568 ($MH^+$).

Ejemplo 346: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-metilbenzamida. EM (EI) m/z $C_{30}H_{27}N_5O_5S$: 570 ($MH^+$).

Ejemplo 347: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-metilisoxazol-4-il)acetamida. EM (EI) m/z $C_{28}H_{26}N_6O_6S$: 575 ($MH^+$).

Ejemplo 348: 3-ciclopentil-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)propanamida. EM (EI) m/z $C_{30}H_{33}N_5O_5S$: 576 ($MH^+$).

Ejemplo 349: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-o-tolilacetamida. EM (EI) m/z $C_{31}H_{29}N_5O_5S$: 584 ($MH^+$).

Ejemplo 350: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metoxinicotinamida. EM (EI) m/z $C_{29}H_{26}N_6O_6S$: 587 ($MH^+$).

Ejemplo 351: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-fluoro-3-metilbenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 352: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-fluoro-2-metilbenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 353 : N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-fluoro-4-metilbenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 354: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-fluoro-5-metilbenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 355: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-5-fluoro-2-metilbenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_5S$: 588 ($MH^+$).

Ejemplo 356: 6-cloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)nicotinamida. EM (EI) m/z $C_{28}H_{23}ClN_6O_5S$: 591 ($MH^+$).

Ejemplo 357: 2-cloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)nicotinamida. EM (EI) m/z $C_{28}H_{23}ClN_6O_5S$: 591 ($MH^+$).

Ejemplo 358: 2-cloro-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)isonicotinamida. EM (EI) m/z $C_{28}H_{23}ClN_6O_5S$: 591 ($MH^+$).

Ejemplo 359: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-4-(dimetilamino)benzamida. EM (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

Ejemplo 360: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-(dimetilamino)benzamida. EM (EI) m/z $C_{31}H_{30}N_6O_5S$: 599 ($MH^+$).

Ejemplo 361: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)benzo[d][1,3]dioxol-5-carboxamida. EM (EI) m/z $C_{30}H_{25}N_5O_7S$: 600 ($MH^+$).

Ejemplo 362: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(m-toliloxi)acetamida. EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

Ejemplo 363: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(4-metoxifenil)acetamida. EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

Ejemplo 364: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(2-metoxifenil)acetamida. EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

Ejemplo 365: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(3-metoxifenil)acetamida. EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

Ejemplo 366: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-metoxi-4-metilbenzamida. EM (EI) m/z $C_{31}H_{29}N_5O_6S$: 600 ($MH^+$).

Ejemplo 367: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-fluoro-4-metoxibenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).

Ejemplo 368: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-fluoro-6-metoxibenzamida. EM (EI) m/z $C_{30}H_{26}FN_5O_6S$: 604 ($MH^+$).


Ejemplo 369: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-(4-metoxifenil)propanamida. EM (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

Ejemplo 370: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-(2-metoxifenil)propanamida. EM (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

Ejemplo 371: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-3-(3-metoxifenil)propanamida. EM (EI) m/z $C_{32}H_{31}N_5O_6S$: 614 ($MH^+$).

Ejemplo 372

*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)azetidin-3-carboxamida.





**[00321]** En un vial de 20 ml se añadió 3-amino-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida (0,24 mmol, 1 equiv), preparada usando procedimientos similares a los descriptos en el Ejemplo 15, DMA ( 5 ml) y ácido 1-(*ter*-butoxicarbonil)azetidin-3-carboxílico (0,336 mmol, 1,4 equiv). Se añadieron base de Hunig (0,792 mmol, 3,3 equiv) y HATU (0,288 mmol, 1,2 equiv) al vial y la mezcla de reacción luego se agitó a temperatura ambiente toda la noche. La finalización de la reacción fue indicada por LCMS. El solvente se extrajo por evaporación giratoria. La mezcla bruta se usó si purificación adicional. El residuo se suspendió en 5 ml de acetato de etilo y se enfrió en un baño de hielo. Una solución de HCl 4 N en dioxano (3 ml, 5 equiv) se añadió con agitación. La mezcla de reacción luego se agitó a temperatura ambiente toda la noche. Los materiales sólidos se recolectaron por filtración, se lavaron con acetato de etilo y luego se purificaron adicionalmente por usó HPLC en fase inversa (acetato de amonio/ACN). Se usó una HPLC de fase inversa preparativa Waters Fractionlynx equipada con una columna Waters SunFire Prep $C_1$8, OCD 5 µM, 30 X 70 mm y que corre un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación. Se obtuvo *N*-(3-(*N*-(3-

(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)azetidin-3-carboxamida (26 mg, 20%). $^1$H-RMN (400MHz, $d_6$-DMSO): 10,26 (s, 1H), 8,81 (s, 1H), 8,25 (t, 1H), 8,14 (s, 1H), 7,74 (d, 1H), 7,69 (d, 1H), 7,41-7,39 (m, 1H), 7,36 (d, 1H), 7,32 (d, 2H), 7,30-7,28 (dd, 1H), 7,14-7,11 (m, 2H), 6,14 (t, 1H), 4,09 (d, 4H), 3,78 (s, 6H); EM (EI) m/z $C_{26}H_{26}N_6O_5S$: 535,6 ($MH^+$).

Ejemplo 373

*N*-(3-(4-fluorofenilamino)quinoxalin-2-il)bencensulfonamida




**[00322]** Se cargó un matraz con 2,3-dicloroquinoxalina (3,5 g, 18 mmol), 85 ml de dimetilsulfóxido, bencensulfonamida (2,8 g, 18 mmol), y carbonato de cesio (5,8 g, 18 mmol). La mezcla de reacción se agitó bajo atmósfera de $N_2$ durante 15 h a 150 °C, después de lo cual, se transfirió a un embudo de separación y se añadieron 100 ml de agua. Luego se agregó HCl concentrado para acidificar la mezcla de reacción a pH<2. La fase acuosa se lavó posteriormente tres veces cpn 90 ml de acetato de etilo. Las fases de acetato de etilo luego se lavaron dos veces con 150 ml agua, tres veces con 100 ml de salmuera y luego se secaron con sulfato de sodio. El acetato de etilo se extrajo en un evaporador giratorio. Se formó una suspensión por agregado de acetato


de etilo y diclorometano al producto bruto seco, la filtración produjo *N*-(3-cloroquinoxalin-2-il)-bencensulfonamida que se usó sin purificación adicional. EM (EI) m/z $C_{14}H_{10}ClN_3O_2S$: 319,9 ($MH^+$).

**[00323]** Se cargó un recipiente de reacción de microondas CEM con *N*-(3-cloroquinoxalin-2-il)bencensulfonamida (52 mg, 0,16 mmol), preparada usando procedimientos similares a los descriptos en la etapa anterior, 4-fluoroanilina (36 mg, 0,32 mmol), y 0,8 ml de dimetilacetamida. El recipiente se selló y la mezcla de reacción se calentó con radiación de microondas durante 25 m a 120 °C en un instrumento de microonda CEM Discover. Se añadió metanol (1 ml) a la mezcla de reacción y después de 20 minutes el producto precipitó de la solución. La filtración produjo *N*-(3-(4-fluorofenilamino)quinoxalin-2-il)bencensulfonamida (39 mg, 62 %). $^1$H-RMN (400MHz, $d_6$-DMSO): δ 12,30 (s, 1H), 9,11 (s, 1H), 8,16-8,10 (d, 2H), 8,02-7,90 (m, 3H), 7,68-7,58 (m, 3H), 7,55-7,51 (m, 1H), 7,41-7,32 (m, 2H), 7,25-7,16 (m, 2H); EM (EI) m/z $C_{20}H_{15}FN_4O_2S$: 395,0 ($MH^+$).


Ejemplo 374

*N*-(3-(*N*-(3-cloroquinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida

**Esquema A**




**Esquema B**





Esquema A

**[00324]** Se cargó un matraz con 3-aminobencensulfonamida (3,3 g, 19 mmol), y 20 ml de 1:1 acetona:$H_2O$. La solución se agitó a temperatura ambiente hasta que se disolvió la aminobencensulfonamida. Luego el matraz se enfrió en un baño de hielo y se añadió cloruro de dimetilamino-acetilo (4,6 g, 29 mmol). Se añadió la suspensión de bicarbonato resultante (4,8 g, 57 mmol) se añadió durante un período de 15 m. Después de 30 min la reacción se extrajo del baño de hielo y se dejó agitar a temperatura ambiente durante 15 h. La mezcla de reacción luego se filtró y se lavó con metanol y acetonitrilo. El filtrado se secó en un evaporador giratorio para producir 2-(dimetilamino)-*N*-(3-sulfamoil-fenil)acetamida, que se remitió a la etapa siguiente sin purificación adicional. EM (EI) m/z $C_{10}H_{15}N_3O_3S$: 258,0 ($MH^+$).

Esquema B

**[00325]** Se cargó un matraz con dicloroquinozalina (1,0 g, 5,8 mmol), 10 ml de dimetilacetamida, 2-(dimetilamino)-*N*-(3-sulfamoilfenil)acetamida (0,70 g, 2,7 mmol), y carbonato de cesio (1,8 g, 5,5 mmol). La mezcla de reacción se agitó durante 3 h a 140 °C y luego se filtró. El solvente se evaporó del filtrado en un evaporador giratorio para producir (*N*-(3-(*N*-(3-cloroquinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida) que se remitió a la etapa siguiente sin purificación adicional. EM (EI) m/z $C_{18}H_{18}ClN_5O_3S$: 420,0 ($MH^+$).

Procedimiento de aminación general 1a




**[00326]** Se cargó un recipiente de reacción de microondas CEM con *N*-(3-(*N*-(3-cloroquinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida (30 mg, 0,071 mmol), preparada usando procedimientos similares a los descriptos en el Ejemplo 374, la anilina deseada (16 mg, 0,14 mmol, 2 eq), y 0,5 ml de dimetilacetamida. El recipiente se selló y la mezcla de reacción se calentó bajo radiación de microondas durante 70 min a 140 °C en un instrumento de microondas CEM Discover. El solvente luego se extrajo por evaporación giratoria. La purificación del producto final se logró por HPLC en fase inversa preparatoria con los eluyentes eluents $NH_4OAc$ acuoso 25 mM /ACN al producto deseado.


**[00327]** Los siguientes compuestos se prepararon de acuerdo con el procedimiento de aminación general 1a.

Ejemplo 375: 2-(dimetilamino)-*N*-(3-(*N*-(3-(3-fluorofenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. $^1$H-RMN (400MHz, $CDCl_3$): 9,40 ppm (s, 1H), 8,43 ppm (s, 1H), 8,22 ppm (s, 1H), 8,07-8,02 ppm (d, 1H), 7,97-7,93 ppm (d, 1H), 7,76-7,71 (m, 2H), 7,53-7,48 ppm (t, 1H), 7,45-7,36 ppm (m, 4H), 7,35-7,28 ppm (m, 2H), 6,84-6,77 ppm (t, 1H), 3,10 ppm (s, 2H), 2,38 ppm (s, 6H); EM (EI) m/z $C_{24}H_{23}FN_6O_3S$: 495 ($MH^+$).

Ejemplo 376: 2-(dimetilamino)-*N*-(3-(*N*-(3-(4-fluorofenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{24}H_{23}FN_6O_3S$: 495 ($MH^+$).

Ejemplo 377: N-(3-(*N*-(3-(4-cloro-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. EM (EI) m/z $C_{24}H_{23}ClN_6O_3S$: 511 ($MH^+$).

Procedimiento de aminación general 1b




**[00328]** Se cargó un recipiente de reacción de microondas CEM con *N*-(3-(*N*-(3-cloroquinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida (62 mg, 0,147 mmol), preparada usando procedimientos similares a los del Ejemplo 374, la anilina deseada (0,567 mmol, 4 eq), y 1,0 ml de tolueno. El recipiente se selló y la mezcla de reacción se calentó bajo radiación de microondas durante 60 min a 180 °C en un instrumento de microondas CEM Discover. El solvente luego se extrajo por evaporación giratoria. La purificación del producto final se logró por HPLC preparatoria con $NH_4OAc$/ACN como eluyente para producir el producto deseado.

Organizacion y
Digitalizacion CSA Ltda
JDVN
NOV

7/7

# PATENTES DE INVENCIÓN

09-126923


**[00329]** Los siguientes compuestos se prepararon se prepararon de acuerdo con el procedimiento de aminación general anterior 1b.

Ejemplo 378 *N*-(3-(*N*-(3-(3-cloro-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-2-(dimetilamino)acetamida. EM (EI) m/z $C_{24}H_{23}ClN_6O_3S$: 511 ($MH^+$).

Ejemplo 379: 2-(dimetilamino)-*N*-(3-(*N*-(3-(4-fluoro-3-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. 2-(dimetilamino)-*N*-(3-(*N*-(3-(4-fluoro-3-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenilo). $^1$H-RMN (400MHz, $CDCl_3$): δ 9,47 (s, 1H), 8,36 (s, 1H), 8,29 (s, 1H), 7,91-7,87 (d, 1H), 7,80-7,73 (m, 2H), 7,66-7,63 (d, 1H), 7,53-7,47 (t, 1H), 7,43-7,30 (m, 4H), 7,10-7,04 (t, 1H), 6,55-5,95 (br s, 1H), 3,96 (s, 3H), 3,12 (s, 2H), 2,39 (s, 6H), 2,08 (s,3H(*AC$_0$H)*; EM (EI) m/z $C_{25}H_{25}FN_6O_4S$: 525 ($MH^+$).

Ejemplo 380

*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-isopropoxibencensulfonamida




**[00330]** *N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-isopropoxi-bencensulfonamida. Una solución de 2,3-dicloroquinoxalina (2,0 ml, 0,38 M) se combinó con $K_2CO_3$ (105 mg, 0,76 mmol) en un vial de vidrio. Una solución de 4-isopropoxibencensulfonamida (1,75 ml, 0,43 M) se añadió y la solución se agitó toda la noche at 125 °C. Después de enfriar, se añadieron ácido acético (45 ml, 0,79 mmol) y 3,5-dimetoxianilina (230 mg, 1,5 mmol). La mezcla de reacción se agitó nuevamente a 125 °C toda la noche.

Después de enfriar, la mezcla de reacción se diluyó con 8 ml de metanol y luego 8 ml de agua. El precipitado se recolectó por filtración y se recristalizó en *N,N*-dimetilacetamida/agua para dar *N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-isopropoxi-bencensulfonamida (45 mg, 12%). $^1$H-RMN (400MHz, $d_6$-DMSO): 12,16 (bs, 1H), 8,93 (s, 1H), 8,03 (d, 2H), 7,92 (bs, 1H), 7,56 (d, 1H), 7,36 (m, 4H), 7,07 (d, 2H), 6,24 (s, 1H), 4,72 (m, 1H), 3,76 (s, 6H), 1,27 (d, 6H); EM (EI) m/z $C_{25}H_{26}N_4O_5S$: 495 ($MH^+$).

**[0187]** Los Ejemplos 381-411 se sintetizaron procediendo como antes en el Ejemplo 423. En los casos en que el producto precipitó, la mezcla se purificó por HPLC de fase inversa.

Ejemplo 381: 3-cloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-metilbencensulfonamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 12,31 (bs, 1H), 8,96 (s, 1H), 8,18 (s, 1H), 7,98 (d, 1H), 7,92 (bs, 1H), 7,58 (d, 2H), 7,43-7,33 (m, 4H), 6,24 (t, 1H), 3,76 (s, 6H), 2,39 (s, 3H); EM (EI) m/z $C_{23}H_{21}ClN_4O_4S$: 485 ($MH^+$).

Ejemplo 382: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)naftaleno-1-sulfonamida. EM (EI) m/z $C_{26}H_{22}N_4O_4S$: 487 ($MH^+$).

Ejemplo 383: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-fluorobencensulfonamida. EM (EI) m/z $C_{22}H_{19}FN_4O_4S$: 455 ($MH^+$).

Ejemplo 384: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-fluorobencensulfonamida. EM (EI) m/z $C_{22}H_{19}FN_4O_4S$: 455 ($MH^+$).

Ejemplo 385: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-(trifluorometil)bencensulfonamida. EM (EI) m/z $C_{23}H_{19}F_3N_4O_4S$: 505 ($MH^+$).

Ejemplo 386: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-(trifluorometil)bencensulfonamida. EM (EI) m/z $C_{23}H_{19}F_3N_4O_4S$: 505 ($MH^+$).

Ejemplo 387: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-(trifluorometoxi)bencensulfonamida. EM (EI) m/z $C_{23}H_{19}F_3N_4O_5S$: 521 ($MH^+$).

Ejemplo 388: N-(4-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida. EM (EI) m/z $C_{24}H_{23}N_5O_5S$: 494 ($MH^+$).

Ejemplo 389: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-fluoro-2-metilbencensulfonamida. EM (EI) m/z $C_{23}H_{21}FN_4O_4S$: 469 ($MH^+$).

Ejemplo 390: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-2-metilbencensulfonamida. EM (EI) m/z $C_{23}H_{22}N_4O_4S$: 451 ($MH^+$).

Ejemplo 391: 2-cloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z $C_{22}H_{19}ClN_4O_4S$: 471 ($MH^+$).

Ejemplo 392: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3,5-difluorobencensulfonamida. EM (EI) m/z $C_{22}H_{18}F_2N_4O_4S$: 473 ($MH^+$).

Ejemplo 393: 3,5-dicloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z $C_{22}H_{18}Cl_2N_4O_4S$: 505 ($MH^+$).

Ejemplo 394: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-fluoro-4-metilbencensulfonamida. EM (EI) m/z $C_{23}H_{21}FN_4O_4S$: 469 ($MH^+$).

Ejemplo 395: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-2-(trifluorometil)bencensulfonamida. EM (EI) m/z $C_{23}H_{19}F_3N_4O_4S$: 505 ($MH^+$).

Ejemplo 396: 4-ciano-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z $C_{23}H_{19}N_5O_4S$: 462 ($MH^+$).

Ejemplo 397: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-1-fenilmetansulfonamida. EM (EI) m/z $C_{23}H_{22}N_4O_4S$: 451 ($MH^+$).

Ejemplo 398: 4,5-dicloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)tiofeno-2-sulfonamida. EM (EI) m/z $C_{20}H_{16}Cl_2N_4O_4S_2$: 511 ($MH^+$).

Ejemplo 399: 1-(3-clorofenil)-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)metansulfonamida. EM (EI) m/z $C_{23}H_{21}ClN_4O_4S$: 485 ($MH^+$).

Ejemplo 400: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-2,5-dimetiltiofeno-3-sulfonamida. EM (EI) m/z $C_{22}H_{22}N_4O_4S_2$: 471 ($MH^+$).

Ejemplo 401: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3,5-bis(trifluorometil)bencensulfonamida. EM (EI) m/z $C_{24}H_{18}F_6N_4O_4S$: 573 ($MH^+$).

Ejemplo 402: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-fluoro-3-(trifluorometil)bencensulfonamida. EM (EI) m/z $C_{23}H_{18}F_4N_4O_4S$: 523 ($MH^+$).

Ejemplo 403: 5-cloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-1,3-dimetil-1H-pirazol-4-sulfonamida. EM (EI) m/z $C_{21}H_{21}ClN_6O_4S$: 489 ($MH^+$).

Ejemplo 404: 5-cloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-2-metoxibencensulfonamida. EM (EI) m/z $C_{23}H_{21}ClN_4O_5S$: 501 ($MH^+$).

Ejemplo 405: 5-bromo-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-2-metoxibencensulfonamida. EM (EI) m/z $C_{23}H_{21}BrN_4O_5S$: 545 ($MH^+$).

Ejemplo 406: 2,5-dicloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)tiofeno-3-sulfonamida. EM (EI) m/z $C_{20}H_{16}Cl_2N_4O_4S_2$: 511 ($MH^+$).

Ejemplo 407: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3,5-dimetilisoxazol-4-sulfonamida. EM (EI) m/z $C_{21}H_{21}N_5O_5S$: 456 ($MH^+$).


Ejemplo 408: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-2,5-dimetoxibencensulfonamida. EM (EI) m/z $C_{24}H_{24}N_4O_6S$: 497 ($MH^+$).

Ejemplo 409: 3-cloro-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-4-fluorobencensulfonamida. EM (EI) m/z $C_{22}H_{18}ClFN_4O_4S$: 489 ($MH^+$).

Ejemplo 410: 4-(difluorometoxi)-*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)bencensulfonamida EM (EI) m/z $C_{23}H_{20}F_2N_4O_5S$: 503 ($MH^+$).

Ejemplo 411: N-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-3-(metilsulfonil)bencensulfonamida. EM (EI) m/z $C_{23}H_{22}N_4O_6S_2$: 515 ($MH^+$).

General Acilation Procedure 2




**[00331]** *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)-sulfamoil)fenil)azetidin-3-carboxamida (125 mg, 0,23 mmol), preparada usando procedimientos similares a los descriptos en el Ejemplo 372, se disolvió en 5 ml de DCE en un balón de 10 ml. Luego se añadió DIEA (1,17 mmol, 5,0 equiv.) con agitación seguido por cloruro ácido (0,47 mmol, 2,0 equiv.). La reacción luego se agitó a temperatura ambiente durante 1 hora o hasta la finalización indicada por LCMS. El solvente posteriormente se extrajo a presión reducida en un evaporador giratorio. El material bruto luego se redisolvió en metanol. La purificación del producto final se obtuvo por HPLC de fase inversa preparatoria con los eluyentes 25 mM de $NH_4OAc$ /CAN. Se usó una HPLC de fase inversa preparativa Waters Fractionlynx

equipada con una columna Waters SunFire Prep $C_18$, OCD 5 µM, 30 X 70 mm y que corre un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación.


**[00332]** Los siguientes compuestos se prepararon de acuerdo con el procedimiento de acilación general 2.

Ejemplo 412: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-propionilazetidin-3-carboxamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 12,40 (s, 1H), 10,45 (s, 1H), 8,88 (s, 1H), 8,40 (s, 1H), 7,93 (s, 1H), 7,82 (d, 1H), 7,77 (d, 1H), 7,60-7,45 (m, 2H), 7,41-7,30 (m, 4H), 6,24 (s, 1H), 4,26 (t, 1H), 4,22-4,17 (m, 1H), 3,99 (t, 1H), 3,95-3,89 (m, 1H), 3,76 (s, 6H), 3,59-3,45 (m, 1H), 2,05 (dd, 2H), 0,95 (t, 3H); EM (EI) m/z $C_{29}H_{30}N_6O_6S$: 591 ($MH^+$).

Ejemplo 413: 1-acetil-*N*-(3-{[(3-{[3,5-bis(metoxi)-fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)azetidin-3-carboxamida. EM (EI) m/z $C_{28}H_{28}N_6O_6S$: 577 ($MH^+$).

Ejemplo 414: 1-(ciclopropanocarbonil)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)azetidin-3-carboxamida. EM (EI) m/z $C_{30}H_{30}N_6O_6S$: 603 ($MH^+$).

General Reductive Amination Procedure 1




**[00333]** A una solución de *N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)azetidin-3-

carboxamida (110 mg, 0,19 mmol), preparada usando procedimientos similares a los descriptos en el Ejemplo 372, en 3 ml de DCE y 200 µL de DMF, se añadió lentamente aldehído (0,77 mmol, 4,0 eq.) seguido por triacetoxiborohidruro de tetrametilamonio (1,16 mmol, 6,0 eq). La reacción se agitó a temperatura ambiente toda la noche. LC/EM indicó que la reacción estaba completa. El solvente se extrajo posteriormente a presión reducida en un evaporador giratorio. El material bruto luego se redisolvió en metanol. La purificación del producto final se obtuvo por HPLC de fase inversa preparatoria con los eluyentes 25 mM de $NH_4OAc$ /CAN. Se usó una HPLC de fase inversa preparativa Waters Fractionlynx equipada con una columna Waters SunFire Prep $C_18$, OCD 5 µM, 30 X 70 mm y que corre un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación.

**[00334]** Los siguientes compuestos del título se prepararon de acuerdo con el procedimiento de aminación reductora general 1.

Ejemplo 415: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-etilazetidin-3-carboxamida. $^1$H-RMN (400MHz, $d_6$-DMSO): 10,29 (s, 1H), 8,82 (s, 1H), 8,25 (t, 1H), 7,75-7,68 (m, 2H), 7,43-7,38 (m, 1H), 7,375-7,340 (m, 1H), 7,338-7,310 (d, 2H), 7,305-7,262 (m, 1H), 7,15-7,08 (m, 2H), 6,56 (s, 1H), 6,15 (t, 1H), 4,15-4,08 (m, 2H), 4,06-3,95 (m, 2H), 3,78 (s, 6H), 3,65-3,56 (m, 1H), 3,12-3,04 (m, 2H), 1,03 (t, 3H); EM (EI) m/z $C_{28}H_{30}N_6O_5S$: 563 ($MH^+$).


Ejemplo 416: 1-(ciclopropilmetil)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)azetidin-3-carboxamida. EM (EI) m/z $C_{30}H_{32}N_6O_5S$: 589 ($MH^+$).

Ejemplo 417: 1-bencil-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)azetidin-3-carboxamida. EM (EI) m/z $C_{33}H_{32}N_6O_5S$: 625 ($MH^+$).

Ejemplo 418: N-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)-1-(furan-2-ilmetil)azetidin-3-carboxamida. EM (EI) m/z $C_{31}H_{30}N_6O_6S$: 615 ($MH^+$).

Ejemplo 419: 1-((1H-imidazol-5-il)metil)-*N*-(3-(*N*-(3-(3,5-dimetoxi-fenilamino)quinoxalin-2-il)sulfamoil)fenil)azetidin-3-carboxamida. EM (EI) m/z $C_{30}H_{30}N_8O_5S$: 615 ($MH^+$).

Procedimiento general de formación de amidas 1a




**[00335]** En un pequeño vial de 1 dram se añadió ácido 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)-quinoxalin-2-il)sulfamoil)benzoico (61 mg, 0,13 mmol, 1,1 equiv), preparado mediante los procedimientos descriptos para el ejemplo 100. El ácido se disolvió en DMA (1 ml) y luego se añadió DIEA (42 µL, 0,24 mmol, 2 equiv) a la solución. El agente de amina (1 ml de solución 0,12 M en DMA) se añadió a la solución con agitación seguido por HATU (64 mg, 0,17 mMol, 1,4 equiv). La reacción se agitó toda la noche a temperatura ambiente. Después de la finalización indicada por análisis LCMS, se añadieron 2 ml de metanol a la solución. Se usó HPLC de fase inversa preparativa para aislar el producto deseado. Se usó una HPLC de fase inversa preparativa Waters Fractionlynx equipada con una columna Waters SunFire Prep $C_18$, OCD 5 µM, 30 X 70 mm y que corre

un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación.

**[00336]** Los siguientes compuestos se prepararon de acuerdo con el procedimiento general de formación de amidas 1.

Ejemplo 420: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-(dimetilamino)propil)benzamida. 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-(dimetilamino)propil)benzamida: $^1$H RMN (400 MHz, $d_6$-DMSO): 9,44 (s, 1H), 8,94 (s, 1H), 8,79 (t, 1H), 8,54 (s, 1H), 8,24 (d, 1H), 7,87 (d, 1H), 7,48 (m, 3H), 7,33 (d, 1H), 7,18 (m, 2H), 6,60 (dd, 1H), 3,82 (1H), 3,04 (m, 3H), 2,51 (m, 5H), 1,91 (s, 1H), 1,86 (m, 3H); EM (EI) m/z para $C_{27}H_{29}ClN_6O_4S$: 569 ($MH^+$).

Ejemplo 421: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(1-metilazetidin-3-il)benzamida. 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(1-metilazetidin-3-il)benzamida: $^1$H RMN (400 MHz, $d_6$-DMSO): 9,43 (s, 1H), 9,23 (d, 1H), 8,94 (d, 1H), 8,58 (s, 1H), 8,29 (d, 1H), 7,89 (d, 1H), 7,56 (t, 1H), 7,47 (d, 1H), 7,44 (d, 1H), 7,33 (d, 1H), 7,18 (m, 2H), 6,60 (dd, 1H), 4,81 (m, 1H), 4,33 (m, 2H), 4,19 (m, 2H), 3,82 (s, 1H), 2,51 (s, 3H); EM (EI) m/z para $C_{26}H_{25}ClN_6O_4S$: 553 ($MH^+$).

Ejemplo 422: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piridin-4-ilmetil)benzamida. EM (EI) m/z $C_{28}H_{23}ClN_6O_4S$: 575 ($MH^+$).

Ejemplo 423: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-(dimetilamino)propil)benzamida. EM (EI) m/z $C_{28}H_{26}ClN_7O_4S$: 592 ($MH^+$).

Ejemplo 424: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-(2,2-dimetilhidrazinocarbonil)bencensulfonamida. EM (EI) m/z $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

Ejemplo 425: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-metoxietil)benzamida. EM (EI) m/z $C_{25}H_{24}ClN_5O_5S$: 542 ($MH^+$).

Ejemplo 426: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-(4-metilpiperazino-1-carbonil)bencensulfonamida. EM (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

Ejemplo 427: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(pirrolidin-1-il)etil)benzamida. EM (EI) m/z $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

Ejemplo 428: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(piridin-4-il)etil)benzamida. EM (EI) m/z $C_{29}H_{25}ClN_6O_4S$: 589 ($MH^+$).

Ejemplo 429: N-(2-(1H-imidazol-4-il)etil)-3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)benzamida. EM (EI) m/z $C_{27}H_{24}ClN_7O_4S$: 578 ($MH^+$).

Ejemplo 430: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piperidin-1-il)benzamida. EM (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

Ejemplo 431: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-hidroxietil)benzamida. EM (EI) m/z $C_{24}H_{22}ClN_5O_5S$: 528 ($MH^+$).

Ejemplo 432: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-etoxipropil)benzamida. EM (EI) m/z $C_{27}H_{28}ClN_5O_5S$: 570 ($MH^+$).

Ejemplo 433: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-(pirrolidin-1-il)propil)benzamida. EM (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

Ejemplo 434: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-(dietilamino)propil)benzamida. EM (EI) m/z $C_{29}H_{33}ClN_6O_4S$: 597 ($MH^+$).

Ejemplo 435: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-(2-oxopirrolidin-1-il)propil)benzamida. EM (EI) m/z $C_{29}H_{29}ClN_6O_5S$: 609 ($MH^+$).

Ejemplo 436: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piridin-2-ilmetil)benzamida. EM (EI) m/z $C_{28}H_{23}ClN_6O_4S$: 575 ($MH^+$).

Ejemplo 437: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-cianoetil)-*N*-metilbenzamida. EM (EI) m/z $C_{26}H_{23}ClN_6O_4S$: 551 ($MH^+$).

Ejemplo 438: 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-cianoetil)-*N*-etilbenzamida. EM (EI) m/z $C_{27}H_{25}ClN_6O_4S$: 565 ($MH^+$).

Ejemplo 439: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(etiltio)etil)benzamida. EM (EI) m/z $C_{26}H_{26}ClN_5O_4S_2$: 572 ($MH^+$).

Ejemplo 440: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-propoxipropil)benzamida. EM (EI) m/z $C_{28}H_{30}ClN_5O_5S$: 584 ($MH^+$).

Ejemplo 441: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(5-(dietilamino)pentan-2-il)benzamida. EM (EI) m/z $C_{31}H_{37}ClN_6O_4S$: 625 ($MH^+$).

Ejemplo 442: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-metoxipropil)benzamida. EM (EI) m/z $C_{26}H_{26}ClN_5O_5S$: 556 ($MH^+$).

Ejemplo 443: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-morfolinopropil)benzamida EM (EI) m/z $C_{29}H_{31}ClN_6O_5S$: 611 ($MH^+$).

Ejemplo 444: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piridin-3-ilmetil)benzamida EM (EI) m/z $C_{28}H_{23}ClN_6O_4S$: 575 ($MH^+$).

Ejemplo 445: 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-cianoetil)benzamida. EM (EI) m/z $C_{25}H_{21}ClN_6O_4S$: 537 ($MH^+$).

Ejemplo 446: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(1-metoxipropan-2-il)benzamida. EM (EI) m/z $C_{26}H_{26}ClN_5O_5S$: 556 ($MH^+$).

Ejemplo 447: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(metiltio)etil)benzamida. EM (EI) m/z $C_{25}H_{24}ClN_5O_4S_2$: 558 ($MH^+$).

Ejemplo 448: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-(dimetilamino)propil)-*N*-metilbenzamida. EM (EI) m/z $C_{28}H_{31}ClN_6O_4S$: 583 ($MH^+$).

Ejemplo 449: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-isopropoxipropil)benzamida. EM (EI) m/z $C_{28}H_{30}ClN_5O_5S$: 584 ($MH^+$).

Ejemplo 450: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(dimetilamino)etil)-*N*-etilbenzamida. EM (EI) m/z $C_{28}H_{31}ClN_6O_4S$: 583 ($MH^+$).

Ejemplo 451: N-(3-butoxipropil)-3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)benzamida. EM (EI) m/z $C_{29}H_{32}ClN_5O_5S$: 598 ($MH^+$).

Ejemplo 452: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(dietilamino)etil)benzamida. EM (EI) m/z $C_{28}H_{31}ClN_6O_4S$: 583 ($MH^+$).

Ejemplo 453: metil 3-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)benzamido)propanoate. EM (EI) m/z $C_{26}H_{24}ClN_5O_6S$: 570 ($MH^+$).

Ejemplo 454: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-metil-*N*-propilbenzamida. EM (EI) m/z $C_{26}H_{26}ClN_5O_4S$: 540 ($MH^+$).

Ejemplo 455: etil 3-(3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)benzamido)propanoate. EM (EI) m/z $C_{27}H_{26}ClN_5O_6S$: 584 ($MH^+$).

Ejemplo 456: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-(piperidin-1-il)etil)benzamida. EM (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

Ejemplo 457: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-((1-etilpirrolidin-2-il)metil)benzamida. EM (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

Ejemplo 458: N-(2-(bis(2-hidroxietil)amino)etil)-3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)benzamida. EM (EI) m/z $C_{28}H_{31}ClN_6O_6S$: 615 ($MH^+$).

Ejemplo 459: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-(3-(dietilamino)pirrolidine-1-carbonil)bencensulfonamida. EM (EI) m/z $C_{30}H_{33}ClN_6O_4S$: 609 ($MH^+$).

Ejemplo 460: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-metil-*N*-(1-metilpirrolidin-3-il)benzamida. EM (EI) m/z $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

Ejemplo 461: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-(3-(dimetilamino)pirrolidine-1-carbonil)bencensulfonamida. EM (EI) m/z $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

Ejemplo 462: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(2-metil-1-

morfolinopropan-2-il)benzamida. EM (EI) m/z $C_{30}H_{33}ClN_6O_5S$: 625 ($MH^+$).

Ejemplo 463: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(1H-pirrol-1-il)benzamida. EM (EI) m/z $C_{26}H_{21}ClN_6O_4S$: 549 ($MH^+$).

Ejemplo 464: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(3-oxopirazolidin-4-il)benzamida. EM (EI) m/z $C_{25}H_{22}ClN_7O_5S$: 568 ($MH^+$).

Ejemplo 465: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-(2-((dimetilamino)metil)piperidino-1-carbonil)bencensulfonamida. EM (EI) m/z $C_{30}H_{33}ClN_6O_4S$: 609 ($MH^+$).

Ejemplo 466: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-(2-(piperidin-1-ilmetil)piperidino-1-carbonil)bencensulfonamida. EM (EI) m/z $C_{33}H_{37}ClN_6O_4S$: 649 ($MH^+$).

Ejemplo 467: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(1-etilpiperidin-3-il)benzamida EM (EI) m/z $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

Procedimiento general de formación de amidas 1b

**[00337]** El procedimiento descripto en el procedimiento general de formación de amidas 1a se usó para incorporar una cantidad de amines que contenían un segundo grupo amina protegido como *ter*-butilcarbamato de metilo (es decir donde R', dentro de NHR'R", contenía un grupo amina protegido por Boc). La desprotección se llevó a cabo después de la purificación de HPLC del precursor protegido por Boc.

**[00338]** En un pequeño vial de 1 dram se añadió ácido 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)benzoico (61 mg, 0,13 mmol, 1,1 equiv). El ácido se disolvió en 1 ml de DMA y luego se añadió DIEA (42 µL, 0,24 mmol, 2 equiv) a la solución. El reactivo de diamina protegido por mono-Boc (1 ml de solución 0,12 M en

DMA, 1 equiv) se añadió a la solución con agitación seguido por HATU (64 mg, 0,17 mmol, 1,4 equiv). La reacción se agitó toda la noche a temperatura ambiente. Después de la finalización indicada por análisis LCMS, se añadieron 2 ml de metanol a la solución. Se usó HPLC de fase inversa preparativa para aislar el producto deseado directamente de esta solución de reacción bruta. Se usó una HPLC de fase inversa preparativa Waters Fractionlynx equipada con una columna Waters SunFire Prep $C_18$, OCD 5 μM, 30 X 70 mm y que corre un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación. Las fracciones del producto se combinaron y concentraron a sequedad a presión reducida por evaporación giratoria. Se añadió una solución de HCl 4 N en dioxano (2 ml). La solución luego se agitó a temperatura ambiente hasta que no se detectó material de partida. El producto desprotegido precipitó de la solución como una sal HCL y se recolectó por filtración, se lavó con éter y se secó al vacío.

**[00339]** Los siguientes compuestos se prepararon de acuerdo con el procedimiento general de formación de amida anterior 1b.

Ejemplo 468: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piperidin-3-il)benzamida. 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piperidin-3-il)benzamida: $^1$H RMN (400 MHz, $d_6$-DMSO): 12,82 (s, 1H), 9,12 (s, 1H), 9,04 (s, 1H), 8,85 (d, 1H), 8,65 (s, 1H), 8,55 (s, 1H), 8,18 (m, 1H), 7,98 (s, 1H), 7,69 (m, 2H), 7,43 (m, 2H), 6,69 (dd, 1H), 4,21 (s, 1H), 3,83 (s, 3H), 3,69 (m, 1H), 3,48 (m, 1H), 3,18 (s, 1H), 2,84 (q, 2H), 1,91 (s, 2H); EM (EI) m/z para $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

Ejemplo 469: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piperidin-2-

ilmetil)benzamida. 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piperidin-2-ilmetil)benzamida: RMN (400 MHz, $d_6$-DMSO): 12,78 (s, 1H), 9,16 (s, 1H), 9,09 (s, 1H), 8,79 (s, 1H), 8,59 (d, 2H), 8,22 (t, 2H), 7,99 (s, 1H), 7,74 (t, 1H), 7,66 (s, 1H), 7,42 (m, 2H), 6,69 (dd, 1H), 3,82 (s, 3H), 3,69 (dd, 1H), 3,57 (m, 1H), 3,50 (m, 3H), 3,22 (s, 2H), 2,82 (d, 1H), 1,68 (m, 5H); EM (EI) m/z para $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

Ejemplo 470: 3-(3-aminopirrolidine-1-carbonil)-*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z $C_{26}H_{25}ClN_6O_4S$: 553 ($MH^+$).

Ejemplo 471: 3-(3-aminoazetidin-1-carbonil)-*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z $C_{25}H_{23}ClN_6O_4S$: 539 ($MH^+$).

Ejemplo 472: 3-(3-aminopiperidino-1-carbonil)-*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

Ejemplo 473: 3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)-*N*-(pirrolidin-3-il)benzamida. EM (EI) m/z $C_{26}H_{25}ClN_6O_4S$: 553 ($MH^+$).

Ejemplo 474: N-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)-3-(3-(metilamino)pirrolidine-1-carbonil)bencensulfonamida. EM (EI) m/z $C_{27}H_{27}ClN_6O_4S$: 567 ($MH^+$).

Ejemplo 475: N-(2-aminoetil)-3-(*N*-(3-(2-cloro-5-metoxi-fenilamino)quinoxalin-2-il)sulfamoil)benzamida. EM (EI) m/z $C_{24}H_{23}ClN_6O_4S$: 527 ($MH^+$).

Ejemplo 476: 3-(4-amino-3-oxopirazolidine-1-carbonil)-*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)bencensulfonamida. EM (EI) m/z $C_{25}H_{22}ClN_7O_5S$: 568 ($MH^+$).

Ejemplo 477

3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-((1-metilpiperidin-2-il)metil)benzamida

**[00340]** 3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(piperidin-2-ilmetil)benzamida (299 mg, 0,51 mmol, 1 equiv), preparado usando procedimientos similares a los descriptos en el por ejemplo 514, se disolvió en 2,3 ml de DMA. Se añadió ácido fórmico (388 µL, 10,28 mmol, 20 equiv) a la solución con agitación seguido por la adición de formaldehído (508 µL de 37% de solución acuosa). La reacción luego se agitó a temperatura ambiente toda la noche. El análisis de una alícuota de la mezcla de reacción por LCMS indicó el consumo completo del material de partida. La reacción se diluyó con metanol (2 ml). Se usó HPLC de fase inversa preparativa para aislar el producto deseado directamente de esta solución de reacción bruta. Se usó una HPLC de fase inversa preparativa Waters Fractionlynx equipada con una columna Waters SunFire Prep $C_18$, OCD 5 µM, 30 X 70 mm y que corre un gradiente 5-100% de gradiente con un sistema solvente binario de 25 mM de acetato de amonio en agua/acetonitrilo para llevar a cabo la purificación $^1$H RMN (400 MHz, $d_6$-DMSO): 9,44 (s, 1H), 8,94 (s, 1H), 8,79 (t, 1H), 8,57 (s, 1H), 8,27 (d, 1H), 7,90 (d, 1H) 7,54 (t, 1H), 7,46 (d, 1H), 7,39 (d, 1H), 7,33 (d, 1H), 7,18 (m, 2H), 6,60 (dd, 1H), 3,82 (s, 3H), 3,59 (m, 2H), 3,00 (s, 1H), 2,90 (s, 3H), 1,62 (m, 7H); EM (EI) m/z para $C_{29}H_{31}ClN_6O_4S$: 595 ($MH^+$).

Ejemplo 478

3-(*N*-(3-(2-cloro-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)-*N*-(1-metilpiperidin-3-il)benzamida

**[00341]** El compuesto del título se preparó usando procedimientos simlares a los usados en el Ejemplo 522. $^1$H RMN (400 MHz, $d_6$-DMSO): 9,43 (s, 1H), 8,93 (s, 1H), 8,59 (s, 1H), 8,24 (d, 1H), 7,87 (d, 1H), 7,47 (m, 2H), 7,40 (d, 1H), 7,33 (d, 1H), 7,19 (m, 2H), 6,60 (dd, 1H), 4,21 (s,

1H), 3,82 (s, 1H), 2,76 (s, 1H), 2,50 (m, 7H), 1,91 (m, 2H), 1,63 (m, 2H); EM (EI) m/z para $C_{28}H_{29}ClN_6O_4S$: 581 ($MH^+$).

Ejemplo biológicos

Ejemplo biológico 1

Ensayo de quimioluminiscencia acoplada a PI3Kalfa luciferasa

**[00342]** La actividad de PI3Kα se midió como el porcentaje de ATP consumido después de la reacción de quinasa usando quimioluminiscencia acoplada a luciferasa-luciferi*N*. Las reacciones se realizaron en placas blancas de microtitulación de unión al medio de 384 pocillos (Greiner). Las reacciones de quinasa se iniciaron por la combinación de compuestos de ensayo, ATP, sustrato (PIP2), y quinasa en un volumen de 20 µL en una solución buffer. El buffer de ensayo de PI3Kalpha estándar esta compuesto de Tris 50 mM, pH 7,5, 1 mM de EGTA, 10 mM de MgCl, 1 mM de DTT y 0,03% de CHAPS. Las concentraciones de ensayo estándares para la enzima, ATP y sustrato eran 0,5-1,1 nM, 1 µM y 7,5 µM, respectivamente. La mezcla de reacción se incubó a temperatura ambiente durante aproximadamente 2 horas. Después de la reacción de quinasa, se añadió una alícuota de 10 µL de mezcla de luciferasa-luciferina (Promega Kinase-Glo) y se midió la señal de quimioluminiscencia usando un lector de placa Victor2 (Perkin Elmer). El consumo de ATP total se limitó a 40-60% y los valores de IC50 de los compuestos control se correlacionan bien con las referencias de la bibliografía.

**[00343]** Ciertos compuestos de la invención demostraron la capacidad de unirse al PI3K cuando se analizaron en este ensayo. Las siguientes formas de realización se refiere a los compuestos por sí mismos así como a su uso un método de tratamiento. Por ejemplo, en una forma de realización de la invención, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una Afinidad de unión a

PI3K de aproximadamente 8 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 4 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 3 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 2 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 1,5 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 1 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 0,750 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 0,5 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 0,3 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 0,2 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 0,1 μM o menos. En otra forma de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 0,075 μM o menos. En otra forma

de realización, el inhibidor de PI3K se selecciona de los compuestos de la Tabla 1 que tienen una afinidad de unión a PI3K de aproximadamente 0,050 µM o menos.

Ejemplo biológico 2

Ensayo de fosfo AKT

**[00344]** Se sembraron células PC-3 en placas de 6 pocillos a razón de 150.000 células/pocillo. Las células se cultivaron durante 3 días, luego se trataron con compuestos en medio libre de suero durante 3 horas. Se añadió EGF (100 ng/mL) durante los últimos 10 min. Las células se lisaron en buffer TENN. Las Akt fosfo T308 y Akt1 total se cuantificaron por ELISA realizado de acuerdo con el protocolo de ensayo de Biosource. Las lecturas de fosfo Akt se normalizaron a las lecturas de Akt total.

Ejemplo biológico 3

Ensayo de fosfo S6

**[00345]** Las células PC3 se sembraron en placas de 96 pocillos a razón de 8.000 células/pocillo. Para cada experimento, se sembraron células y se trataron en placas duplicadas: una placa para fosfo S6 CellELISA, y una placa para S6 CellELISA total. Las células se cultivaron en las placas durante 3 días, luego se trató con compuestos en medio libre de suero durante 3 horas por triplicado. Las células se fijaron con 4% formaldehído, se inactivaron con 0,6% de $H_2O$, se bloquearon con 5% de BSA, se incubaron con anticuerpo fosfo S6 o anticuerpo S6 total toda la noche, se incubó con IgG-HRP de conejo anti cabra durante 1 hora, y se desarrolló en sustrato quimioluminiscente.

Ejemplo biológico 4

Ensayo de $PIP_3$

**[00346]** Las células MCF-7 cultivadas en placas de 10 cm se privaron de nutrientes durante 3 horas en DMEM, y luego se trataron con compuestos durante 20 minutos. En los últimos 2 minutos de la incubación con los compuestos, se añadió EGF (100 ng/mL) para estimular la producción de PIP3. El medio se aspiró y las células se eliminaron con 10% de ácido tricloroacético. Los lípidos se extrajeron del pellet después de centrifugar los lisados celulares. Se cuantificó PIP3 en la extracción de lípidos celulares con el ensayo AlphaScreen [marca registrada de TM de PerkinElmer]en el que se usa Grp1-PH como sonda específica de PIP3. La cantidad de PIP3 celular se calcula a partir de la curva estándar de diC PI (3,4,5) P3.

Ejemplo biológico 5-10

Modelos in vivo

**[00347]** El compuesto A es un compuesto de Fórmula I. El compuesto B es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina.

**[00348]** Se usan ratones desnudos atímicos hembra y macho (NCr) de 5-8 semanas y de peso aproximado de 20-25 g en el siguiente modelo. Antes de la iniciación de un estudio, los animales se dejan aclimatar durante un mínimo de 48 horas. Durante estos estudios, se proveyó a los animales alimento y agua ad libitum y se alojaron en una habitación acondicionada a 70-75°F y 60% de humedad relativa. Un ciclo de 12 horas de luz y 12 horas de oscuridad se mantiene con temporizadores automáticos. Todos los animales se examinan diariamente en cuanto a muertes inducidas por el compuesto o relacionadas con el tumor.

**[00349]** Las células de adenocarcinoma de próstata humano PC-3 se cultivaron in vitro en DMEM (Mediatech) suplementado con 20% de suero fetal bovino (Hyclone), penicilina-estreptomicina y aminoácidos no esenciales a 37°C en una atmósfera de 5% de CO humidificado. En el día 0, las células se recolectaron por tripsinización y $3x10^6$ células (pasaje 13, 99% de viabilidad) en 0,1 mL de solución salina equilibrada de Hank enfriada en hielo se implantaron en forma subcutánea en el flanco trasero de ratones desnudos machos de 5-8 semanas. Se implantó un transmisor en cada ratón para la identificación, y los animales se controlaron diariamente para determinar síntomas clínicos y supervivencia. Los pesos corporales se registraron diariamente. Los experimentos se realizaron con el Compuesto A como un agente simple así como el Compuesto A en combinación con taxol y el Compuesto A en combinación con rapamicina. Este modelo se puede usar para evaluar la conveniencia de tratar con el Compuesto A en combinación con otros agentes anti-cáncer.

**[00350]** Las células de glioblastoma humano U-87 MG se cultivaron in vitro en DMEM (Mediatech) suplementado con 10% de suero fetal bovino (Hyclone), penicilina-estreptomicina y aminoácidos no esenciales a 37°C en una atmósfera de 5% de CO humidificado. En el día 0, las células se recolectaron por tripsinización y $2x10^6$ células (pasaje 5, 96% de viabilidad) en 0,1 mL de solución salina equilibrada de Hank enfriada en hielo se implantaron en forma intradérmica en el flanco trasero de ratones desnudos machos de 5 8 semanas. Se implantó un transmisor en cada ratón para la identificación, y los animales se controlaron diariamente para determinar síntomas clínicos y supervivencia. Los pesos corporales se registraron diariamente.

Los experimentos se realizaron con el Compuesto A como único agente y los resultados no están incluidos. Este modelo se puede usar para evaluar la conveniencia de tratar con el Compuesto A en combinación con con otros agentes anti-cáncer.

**[00351]** Las células de carcinoma de pulmón humano A549 se cultivaron in vitro en DMEM (Mediatech) suplementado con 10% de suero fetal bovino (Hyclone), penicilina-estreptomicina y aminoácidos no esenciales a 37°C en una atmósfera de 5% de CO humidificado. En el día 0, las células se recolectaron por tripsinización y $10x10^6$ de células (pasaje 12, 99% de viabilidad) en 0,1 mL de solución salina equilibrada de Hank enfriada en hielo se implantaron en forma intradérmica en el flanco trasero de ratones desnudos machos de 5 8 semanas. Se implantó un transmisor en cada ratón para la identificación, y los animales se controlaron diariamente para determinar síntomas clínicos y supervivencia. Los pesos corporales se registraron diariamente. Los experimentos se realizaron con el Compuesto A como agente único así como el Compuesto A en combinación con el Compuesto B. Este modelo se puede usar para evaluar la conveniencia de tratar con el Compuesto A en combinación con otros agentes anti-cáncer.

**[00352]** Células de adenocarcinoma de mamas humano MDA-MB-468, pasaje número <6, se mantienen y propagan en crecimiento en fase logarítmica en medio Eagle modificado por Dulbecco (DMEM; Mediatech) que contiene L-glutamina suplementada con 10% de suero fetal bovino (Hyclone), penicilina-estreptomicina y aminoácidos no esenciales a 37 °C en una atmósfera de 5% de CO humidificado. En el día 0, las células se recolectaron por tripsinización y $10x10^6$ de células (pasaje 12, 99% de viabilidad) en 0,1 mL de solución salina equilibrada de Hank enfriada en hielo se implantaron en forma intradérmica en el flanco trasero de

ratones desnudos machos de 5 8 semanas. en 50% solución salina equilibrada de Hank enfriada/50% Matrigel (100 µL de volumen total por ratón) se implantaron en forma subcutánea en tejido adiposo mamario de los ratones desnudos hembra. Los experimentos se realizaron con el Compuesto A como agente único así como el Compuesto A en combinación con erlotinib. Este modelo se puede usar para evaluar la conveniencia de tratar con el Compuesto A en combinación con otros agentes anti-cáncer.

**[00353]** Las células de carcinoma anaplásico de pulmón Calu-6 humanas se cultivaron *in vitro* en DMEM (Mediatech) suplementado con 10% de suero fetal bovino (Hyclone), penicilina-estreptomicina y aminoácidos no esenciales a 37 °C en una atmósfera de 5% de CO humidificado. En el día 0, las células se recolectaron por tripsinización, y $5x10^6$ células (pasaje #8, 96% de viabilidad) en 0,1 mL de solución salina equilibrada de Hank enfriada en hielo se implantaron en forma intradérmica en el flanco trasero de ratones desnudos hembra de 5 8 semanas. Se implantó un transmisor en cada ratón para la identificación, y los animales se controlaron diariamente para determinar síntomas clínicos y supervivencia. Los pesos corporales se registraron diariamente. Los experimentos se realizaron con el Compuesto A como agente único así como el Compuesto A en combinación con carboplatino. Este modelo se puede usar para evaluar la conveniencia de tratar con el Compuesto A en combinación con con otros agentes anti-cáncer.

**[00354]** Células de adenocarcinoma humano MCF7 se cultivaron in vitro en DMEM (Cellgro) suplementado con 10% de suero fetal bovino (Cellgro), penicilina-estreptomicina y aminoácidos no esenciales a 37 °C en una atmósfera de 5% de CO humidificado. En el día 0, las células se recolectaron por tripsinización, y $5x10^6$ células (pasaje #10 y 95% de

viabilidad para el Estudio 1, pasaje 9 y 90% de viabilidad para el Estudio 2)) en 100 µL de solución preparada de solución salina equilibrada de Hank con 50% de factor de crecimiento reducido matrigel (R&D Systems para el Estudio 1 y Becton Dickinson para el Estudio 2) se implantaron en forma subcutánea en el flanco trasero de los ratones desnudos hembra.

**[00355]** En los tumores subcutáneos o intradérmicos, se determinó dos veces por semana el peso del tumor medio de cada animal en los respectivos grupos control y tratamiento durante el estudio. Se determinó el peso tumoral (TW) por la medición de los diámetros perpendiculares con un calibre, usando la siguiente fórmula:

Peso del tumor (mg) = [volumen de tumor = longitud (mm) x ancho$^2$ (mm$^2$)]/2

Estos datos se registran y representan en un gráfico lineal de pesos de tumor versus días posimplantación y se presentan gráficamente como una indicación de las tasas de crecimiento del tumor. Se determina el porcentaje de inhibición del crecimiento tumoral (TGI) con la siguiente fórmula:

$$\left[1-\left(\frac{(X_f - X_0)}{(Y_f - X_0)}\right)\right]*100$$

donde $X_0$ = TW promedio de todos los tumores al día del grupo

$X_f$ = TW de grupo tratado en el día f

$Y_f$ = TW de grupo control con vehículo en el día f

Si los tumores regresan por debajo de sus tamaños iniciales, luego se determina el porcentaje de regresión del tumor con la siguiente fórmula:

$$\frac{(X_0 - X_f)}{X_0} * 100$$

El tamaño del tumor se calcula individualmente para cada tumor para obtener un valor de media ± para cada grupo experimental. Se determina la significación estadística usando la prueba t de Student de dos colas (significancia definida como P<0,05).

Ejemplos biológicos 11-14

**[00356]** El Compuesto A es un compuesto de Fórmula I y es un inhibidor de las I PI3-quinasas de Clase I. El Compuesto B es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina.

Modelo de xenoinjerto de cáncer de próstata - Un compuesto de Fórmula I en combinación con Taxol

**[00357]** El Compuesto A se analizó solo y en combinación con taxol en un modelo de tumor de carcinoma prostático. PC-3 es una línea celular de carcinoma prostático humano que alberga una mutación por supresión homocigota en PTEN, que produce una activación constitutiva de la vía de PI3K. En experimentos farmacodinámicos de dosis única, la administración oral del Compuesto A produce una reduccion dependiente de la dosis de la fosforilación de AKT, p70S6K, y S6 en tumores PC-3 que crecen en forma extópica en los ratones. La administración de una dosis repetida del Compuesto A también inhibe el crecimiento de estos tumores, pero no induce regresiones.

**[00358]** La administración oral del Compuesto A a 100 mg/kg qd o 300 mg/kg dos veces por semana (biw) produjo una substancial inhibición de crecimiento tumoral en los ratones. Ver Figura 1. La inhibición de crecimiento tumoral comparable se obtuvo con 7,5 mg/kg de taxol administrado i.v. dos veces por semana. Si bien el crecimiento tumoral fue inhibido sustancialmente con el Compuesto A solo, la

combinación de la dosis del Compuesto A con taxol fue superior al agente solo e indujo una significativa regresión de los tumores. La pérdida de peso corporal y el salteo de dosis fueron mínimos en todos los grupos y no se exacerbó en el grupo de combinación lo que indica que la combinación fue bien tolerada. Estos resultados respaldan el uso de un compuesto de Fórmula I en combinación con taxol en tumores con señalización de PI3K activada en forma constitutiva..

Modelo de xenoinjerto de cáncer de próstata - Un compuesto de Fórmula I en combinación con Rapamicina

**[00359]** El Compuesto A se analizó solo y en combinación con rapamicina en un modelo de tumor de carcinoma prostático (línea celular PC-3). La administración oral del Compuesto A a 100 mg/kg qd produjo una sustancial inhibición de crecimiento tumoral. Ver Figura 2. La inhibición de crecimiento tumoral comparable se obtuvo con 5 mg/kg rapamicina administrada i.p. en forma diaria. Si bien el crecimiento tumoral fue inhibido sustancialmente con el Compuesto A solo, la combinación de la dosis del Compuesto A con rapamicina fue superior al agente solo e indujo una significativa regresión de los tumores. La pérdida de peso corporal y el salteo de dosis fue mínimo con cada agente solo, pero la pérdida de peso corporal se exacerbó en el grupo de combinación que necesitan saltear la dosis. El hecho de que se observó regresión del tumor a pesar del salteo de dosis sugiere que usar un esquema de dosis intermitente debería mantener la eficacia y mejorar la tolerabilidad. Estos resultados respaldan el uso de un compuesto de Fórmula I en combinación con rapamicina en tumores con señalización de PI3K activada en forma constitutiva.

Modelo de xenoijerto de cáncer pulmonar de células no pequeñas - Un compuesto de Fórmula I en combinación con Carboplatino

**[00360]** El Compuesto A se analizó como agente único y en combinación con carboplatino en un modelo de tumor NSCLC.

**[00361]** Calu-6 es es una línea celular humana de NSCLC que alberga una mutación activadora heterocigota en K-Ras (Q61K). La administración oral del Compuesto A a 100 mg/kg qd o 300 mg/kg cada catorce días (q4d) a los ratones portadores de los tumores de Calu-6 produjo sustancial inhibición de crecimiento tumoral. Ver Figura 3. Ambos esquemas de dosis produjeron una similar inhibición de crecimiento tumoral. También se observó significativa inhibición de crecimiento tumoral con 50 mg/kg de carboplatino administrado i.v. q4d, pero no fue tan pronunciado como con el Compuesto A. Si bien el crecimiento tumoral fue inhibido sustancialmente con el Compuesto A solo, la combinación de los dos agentes fue superior a cada uno solo y produjo una inhibición del crecimiento tumoral casi completa. La pérdida de peso corporal y el salteo de dosis fueron mínimos en todos los grupos y no se exacerbó en el grupo de combinación lo que indica que la combinación fue bien tolerada. Estos resultados respaldan el uso de un compuesto de Fórmula I tanto como agente único y en combinación con platinos en los tumores con mutaciones activadoras en K-Ras.

Modelo de xenoijerto de cáncer pulmonar de células no pequeñas - Un compuesto de Fórmula I en combinación con el Compuesto B

**[00362]** El Compuesto A se analizó tanto como agente único como en combinación con el Compuesto B. La línea celular de carcinoma de pulmón de células no pequeñas A549 humanoas alberga una mutacíon de detención homocigota en el gen que codifica LKB1, y una mutación activadora G12S en K-Ras, que

promueve la activación de PI3K y mTOR. Las células A549 también expresan EGFR de tipo salvaje.

**[00363]** Como agente único, el Compuesto B, un inhibidor de EGFR, se administró por vía oral una vez por día a 30 mg/kg y el Compuesto A se administró por vía oral a 30 mg/kg qd o 100 mg/kg q2d. Las terapias de combinación consistían en el Compuesto B con el Compuesto A a 30 mg/kg o 100 mg/kg. La administración de cada agente de los grupos de combinación se separó en 6 h. La administración del agente único de Compuesto B durante 18 días causó una significativa inhibición del crecimiento tumoral de 80%. Ver Figura 4a. Se observó una inhibición de crecimiento tumoral significativa de 96% con el Compuesto A a 100 mg/kg q2d, mientras que el Compuesto A a 30 mg/kg qd produjo una menor pero aun significativa TGI de 76%. La combinación del Compuesto B 30 mg/kg qd con el Compuesto A 30 mg/kg qd o con el Compuesto A 100 mg/kg q2d dio como resultado una eficacia significativa asociada con 15% y 39% de regresión, respectivamente que fue significativamente superior que cualquiera de los tratamientos con agente único solo.

**[00364]** Como agente único el Compuesto B con una dosis de 30 mg/kg qd en general bien tolerado, con una pérdida de peso corporal de 1,5-6,9% y sin omisión de dosis. La administración del Compuesto A una dosis de 30 mg/kg fue bien tolerada con 4 salteos de dosis al comienzo del estudio, que no se relacionaron con el compuesto. El Compuesto A a una dosis de 100 mg/kg q2d también fue bien tolerada con 1 salteo de dosis al comienzo del estudio, que no se relacionó con el compuesto. La combinación del Compuesto B a 30 mg/kg qd con el Compuesto A a 30 mg/kg qd fue relativamente tolerada con pérdida de peso corporal de 1 a 8% y 2 dosis salteadas). Sin embargo, la combinación del Compuesto B a 30 mg/kg qd con el Compuesto A a 100 mg/kg q2d se asoció con pérdida de peso corporal de 2 a 11%

y 13 salteos de dosis dentro de los primeros 10 días; sin embargo, los pesos corporales al fin del estudio no fueron significativamente diferentes del grupo control tratado con vehículo. La administración como agente único del Compuesto B y el Compuesto A fueron bien toleradas con salteo de dosis mínimo. Cuando se administra en combinación, se observó una pérdida de peso corporal menor que los que necesitaron altear la dosis principalmente en el grupo de 100 mg/kg q2d.

Modelo de xenoinjerto de cáncer de mamas - Un compuesto de Fórmula I en combinación con el Compuesto B

**[00365]** El Compuesto A se analizó tanto como agente único como en combinación con el Compuesto B, un inhibidor de EGFR, en un modelo de tumor mamario. La línea celular de carcinoma de mamas humano MCF7 alberga una mutación activadora heterocigota en PI3K (PI3KCA/E545K) y expresa EGFR de tipo salvaje.

**[00366]** El Compuesto B se administró por vía oral una vez por día (qd) a 30 mg/kg, y el Compuesto A se administró una vez por día a 30 mg/kg o una vez cda dos días (q2d) a 100 mg/kg. Las terapias de combinación consistían en el Compuesto B junto con el Compuesto A a 30 mg/kg qd o 100 mg/kg q2d. La administración como agente único del compuesto B a 30 mg/kg qd durante 14 días produjo una inhibición de crecimiento tumoral de 38%-61%. Ver Figuras 4b-1 y 4b-2. Se observó una inhibición de crecimiento tumoral significativa de 83%-91% con el Compuesto A a 100 mg/kg q2d, mientras que el Compuesto A a 30 mg/kg qd produjo una menor pero aún significativa TGI de 57%. La combinación del Compuesto B at 30 mg/kg qd con el Compuesto A at 100 mg/kg q2d dio como resultado una eficacia significativa asociada con 16-22% de regresión, que fue significativamente mayor que cualquiera de los tratamientos con agente único solo. La combinación del Compuesto B a 30

mg/kg qd con el Compuesto A a 30 mg/kg qd llevó a una menor pero aún significativa inhibición de crecimiento tumoral de 66%, pero no agregó ningún beneficio a la eficacia antitumoral de los tratamientos simples.

**[00367]** Como agente único el Compuesto B a una dosis de 30 mg/kg qd fue generalmente bien tolerado, con una pérdida de peso corporal final no significativa de 4,5 a 6,1% y 7 a 13 omisiones de dosis. La administración del Compuesto A a 30 mg/kg qd y 100 mg/kg q2d fue bien tolerada con salteo de dosis y pérdida de peso corporal mínimos. La combinación del Compuesto B at 30 mg/kg qd con el Compuesto A a 30 mg/kg qd lleva a pérdida de peso corporal de 4 a 13% a lo largo del estudio y 14 salteos de dosis principalmente en los primeros 9 días. La combinación del Compuesto B a 30 mg/kg qd con el Compuesto A a 100 mg/kg q2d se asoció con una pérdida de peso corporal de 3,7 a 13% a lo largo del estudio y 20 a 32 omisiones de dosis.

Modelo de xenoijerto de cáncer de mamas – Un compuesto de Fórmula I en combinación con Erlotinib

**[00368]** El Compuesto A se analizó como agente único y en combinación con erlotinib, en un modelo de tumor resistente a erolitinib con señalización de PI3K

**[00369]** MDA-MB-468 es una línea celular de carcinoma de mamas humano que tiene un aumento del número de copias del gen EGFR y una supresión homocigota de PTEN. El tratamiento in vitro de estas células con los inhibidores de EGFR tales como erlotinib inhiben la actividad de EGFR pero no puede regular por disminución la vía de PI3K pathway. La administración oral de erlotinib a 100 mg/kg qd a los ratones que portan los tumores de MDA-MB-468 produjeron una inhibicion significativa pero incompleta del crecimiento tumoral. Ver Figura 5. La administración oral del Compuesto A a 100 mg/kg qd produjo una nivel de inhibición de crecimiento tumoral similar. Si bien el crecimiento

tumoral fue inhibido sustancialmente con el Compuesto A solo, la combinación de los dos agentes fue superior a cualquiera de los agentes solos y produjo una regresión de los tumores.


**[00370]** Los ratones a los que se administró el Compuesto A a 100 mg/kg qd exhibieron una modesta (~3%) pérdida de peso comparable con los vehículos control. Los ratones a los que se administró erlotinib exhibieron un reducción evidente de su tasa de aumento de peso corporal con respecto a los controles con vehículo. La coadministración con erlotinib produjo una pérdida sustancial del peso corporal en los ratones tratados con el Compuesto A (19% pérdida de peso corporal desde el inicio de la dosificación). Coherente con estos datos, se requirió solo un mínimo salteo de dosis cuando el Compuesto A se administró como monoterapia (1-3 dosis salteadas), pero se requirió un sustancial salteo de dosis para el Compuesto A cuando se coadministró con erlotinib. El hecho de que se observó regresión del tumor a pesar del salteo sugiere que el uso de un esquema intermitente podría mantener la eficacia y mejorar la tolerabilidad. Estos resultados respaldan el uso de un compuesto de Fórmula I en combinación con erlotinib en tumores que expresan receptores de EGF y albergan supresiones de PTEN.

**[00371]** La siguiente invención ha sido descripta en algún detalle a modo de ilustración y ejemplo con fines de claridad y comprensión. Será obvio para los expertos en la técnica que se pueden practicar cambios y modificaciones dentro del alcance de las reivindicaciones adjuntas. En consecuencia, se considera que la anterior descripción es ilustrativa y no restrictiva. El alcance de la invención debe, en consecuencia, ser determinado no con referencia a la anterior descripción, sino que en cambio se debe determinar con referencia a las siguientes reivindicaciones

adjuntas, junto con el alcance pleno de las equivalentes a lo que facultan dichas reivindicaciones. Todas las patentes, solicitudes de patente y publicaciones mencionadas en esta solicitud se incorporan en la presente por referencia en su totalidad para los fines en la misma medida que si cada patente, solicitud de patente y publicación individual fuera indicada individualmente de este modo.

REIVINDICACIONES

1. Un método de tratamiento del cáncer, dicho método comprende administrar a un paciente cantidad terapéuticamente efectiva de un compuesto de Fórmula I:



I

o un isómero simple de este donde el compuesto está opcionalmente como una sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este; o administrar una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de Fórmula I y al menos uno de un portador, excipiente o diluyente farmacéuticamente aceptable en combinación con uno o más y tratamientos seleccionados de modo independiente cirugía, uno o más agentes quimioterapéuticos, una o más de las terapias hormonales, uno o más anticuerpos, una o más inmunoterapias, terapia de yodo radiactivo, y radiación donde el Compuesto de Fórmula I es aquel donde:

$W^1$, $W^2$, $W^3$, y $W^4$ son $-C(R^1)=$; o uno o dos de $W^1$, $W^2$, $W^3$, y $W^4$ son de modo independiente $-N=$ y los restantes son $(R^1)=$; y donde cada $R^1$ es de modo independiente hidrógeno, alquilo, haloalquilo, nitro, alcoxi, haloalcoxi, halo, hidroxi, ciano, amino, alquilamino, o dialquilamino;

$R^{51}$ es hidrógeno o alquilo;

$R^{52}$ es hidrógeno o halo;

$R^{50}$, $R^{53}$, y $R^{54}$ son de modo independiente hidrógeno, alquilo, alquenilo, halo, haloalquilo, haloalquenilo, hidroxi, alcoxi, alqueniloxi, haloalcoxi, nitro, amino, alquilamino, dialquilamino, $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-$N(R^{55a})R^{55b}$, alquilcarbonilo, alquenilcarbonilo, carboxi, alcoxicarbonilo, ciano, alquiltio, $-S(O)_2NR^{55}R^{55a}$, o alquilcarbonilamino y donde $R^{55}$ y $R^{55b}$ son de modo independiente hidrógeno, alquilo, o alquenilo y $R^{55a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi; o $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 5 o 6 miembros o heterocicloalquilo de 5 o 6 miembros;

B es fenilo sustituido con $R^{3a}$ y opcionalmente también sustituido con uno, dos o tres $R^3$; o

B es heteroarilo opcionalmente sustituido con uno, dos o tres $R^3$;

$R^{3a}$ es ciano; hidroxiamino; carboxi; alcoxicarbonilo; alquilamino; dialquilamino; alquilcarbonilo; haloalcoxi; alquilsulfonilo; aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; o

a) $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$ donde $R^7$ es hidrógeno, alquilo, o alquenilo y $R^{7a}$ y $R^{7b}$ son de modo independiente hidrógeno, alquilo, alquenilo, hidroxialquilo, haloalquilo, alcoxi, alcoxialquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, arilalquilo, o arilalquiloxi y donde los anillos arilo, cicloalquilo, heterocicloalquilo y heteroarilo en $R^{7a}$ y $R^{7b}$ (ya sea solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente de alquilo, amino, alquilamino, dialquilamino, hidroxi, halo, alcoxi, alquiltio, y oxo);

b) $-C(O)NR^8R^{8a}$ donde $R^8$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{8a}$ es hidrógeno, alquilo, alquenilo, hidroxialquilo, cianoalquilo, alcoxialquilo, alquiltioalquilo, heterocicloalquilo, heterocicloalquilalquilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo y donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{8a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, halo, haloalquilo, haloalcoxi, hidroxi, hidroxialquilo, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxicarbonilo, y $-C(O)H$;

c) $-NR^9C(O)R^{9a}$ donde $R^9$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{9a}$ es hidrógeno, alquilo C2- $C_6$, alquenilo, hidroxialquilo, alcoxialquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo; donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{9a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, hidroxi, hidroxialquilo, halo, haloalquilo, haloalcoxi, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, alcoxicarbonilo, $-C(O)H$, arilo (opcionalmente sustituido con uno o dos halo), arilalquilo, heteroarilo, heteroarilalquilo, heterocicloalquilo,

heterocicloalquilalquilo, ciloalquilo, ciloalquilalquilo, y cicloalquilcarbonilo;

d) $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$ donde $R^{10a}$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, o hidroxialquilo y $R^{10}$ y $R^{10b}$ son de modo independiente hidrógeno, alquilo, alquenilo, haloalquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, o hidroxialquilo;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi y $R^{11}$ y $R^{11b}$ son de modo independiente hidrógeno, alquilo, alquenilo, aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo;

f) $-C(O)R^{12}$ donde $R^{12}$ es heterocicloalquilo opcionalmente sustituido con 1, 2, o 3 grupos seleccionados de alquilo, oxo, amino, alquilamino, y heterocicloalquilalquilo;

g) $-NR^{13}C(O)OR^{13a}$ donde $R^{13}$ es hidrógeno, alquilo, o alquenilo y $R^{13a}$ es aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, arilo, o arilalquilo;

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ donde $R^{14}$, $R^{14a}$, y $R^{14b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

i) $-S(O)_2N(R^{15})$-alquilen $C_1$-$C_6$-$N(R^{15a})R^{15b}$ donde $R^{15}$, $R^{15a}$, y $R^{15b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

j) $-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$ donde $R^{16}$ es hidrógeno, alquilo, o alquenilo y $R^{16a}$ es alquilo o alquenilo;

k) heteroarilo opcionalmente sustituido con uno o dos aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ donde $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, y $R^{17d}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

m) $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$ donde $R^{18a}$ es hidrógeno, alquilo, alquenilo, o alcoxi y $R^{18}$ y $R^{18b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

n) $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$ donde $R^{19}$ es hidrógeno, alquilo, o alquenilo y $R^{19a}$ es amino, alquilamino, dialquilamino, o heterocicloalquilo;

o) $-N(R^{20})C(O)$-alquilen $C_1$-$C_6$-$C(O)R^{20a}$ donde $R^{20}$ es hidrógeno, alquilo, o alquenilo y $R^{20a}$ es cicloalquilo o heterocicloalquilo;

p) $-NR^{21}S(O)_2$-alquilen $C_1$-$C_6$-$N(R^{21b})R^{21a}$ donde $R^{21}$ es hidrógeno, alquilo, o alquenilo y $R^{21a}$ y $R^{21b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

q) $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$ donde $R^{22}$, $R^{22a}$ y $R^{22b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

r) -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$ donde $R^{23}$, $R^{23a}$ y $R^{23b}$ son de modo independiente hidrógeno, alquilo, o alquenilo; o

s) $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$ donde $R^{24}$ es hidrógeno, alquilo, o alquenilo y $R^{24a}$ es es alcoxialquilo o arilo opcionalmente sustituido con uno o dos halo o alquilo; y

donde cada uno de los alquilenos en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, amino, alquilamino, y dialquilamino; y

cada $R^3$ (cuando $R^3$ está presente) es de modo independiente alquilo; alquenilo; alquinilo; halo; hidroxi; oxo; alcoxi; ciano; hidroxiamino; carboxi; alcoxicarbonilo; amino; alquilamino; dialquilamino; alquilcarbonilo; haloalcoxi; alquilsulfonilo; aminoalquiloxi; alquilaminoalquiloxi; dialquilaminoalquiloxi; o

a) $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$ donde $R^7$ es hidrógeno, alquilo, o alquenilo y $R^{7a}$ y $R^{7b}$ son de modo independiente hidrógeno, alquilo, alquenilo, hidroxialquilo, haloalquilo, alcoxi, alcoxialquilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo,

heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, arilalquilo, o arilalquiloxi y donde los anillos arilo, cicloalquilo, heterocicloalquilo y heteroarilo en $R^{7a}$ y $R^{7b}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, amino, alquilamino, dialquilamino, hidroxi, halo, alcoxi, alquiltio, y oxo);

b) $-C(O)NR^8R^{8a}$ donde $R^8$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{8a}$ es hidrógeno, alquilo, alquenilo, hidroxialquilo, cianoalquilo, alcoxialquilo, alquiltioalquilo, heterocicloalquilo, heterocicloalquilalquilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo y donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{8a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, halo, haloalquilo, haloalcoxi, hidroxi, hidroxialquilo, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, alcoxicarbonilo, y $-C(O)H$;

c) $-NR^9C(O)R^{9a}$ donde $R^9$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o haloalcoxi y $R^{9a}$ es hidrógeno, alquilo $C2-C_6$, alquenilo, hidroxialquilo, alcoxialquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, arilo, o arilalquilo; donde los anillos arilo, cicloalquilo, heteroarilo y heterocicloalquilo en $R^{9a}$ (tanto solo o como parte del arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y

heteroarilalquilo) están opcionalmente sustituidos de modo independiente con 1, 2, o 3 grupos seleccionados de modo independiente alquilo, alquenilo, alcoxi, hidroxi, hidroxialquilo, halo, haloalquilo, haloalcoxi, oxo, amino, alquilamino, dialquilamino, alquilcarbonilo, alcoxicarbonilo, -C(O)H, arilo (opcionalmente sustituido con uno o dos halo), arilalquilo, heteroarilo, heteroarilalquilo, heterocicloalquilo, heterocicloalquilalquilo, ciloalquilo, ciloalquilalquilo, y cicloalquilcarbonilo;

d) $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$ donde $R^{10a}$ es hidrógeno, hidroxi, alcoxi, alquilo, alquenilo, haloalquilo, o hidroxialquilo y $R^{10}$ y $R^{10b}$ son de modo independiente hidrógeno, alquilo, alquenilo, haloalquilo, o hidroxialquilo;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ donde $R^{11a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi y $R^{11}$ y $R^{11b}$ son de modo independiente hidrógeno, alquilo, alquenilo, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo;

f) $-C(O)R^{12}$ donde $R^{12}$ es heterocicloalquilo opcionalmente sustituido con 1, 2, o 3 grupos seleccionados de alquilo, oxo, amino, alquilamino, y heterocicloalquilalquilo;

g) $-NR^{13}C(O)OR^{13a}$ donde $R^{13}$ es hidrógeno, alquilo, o alquenilo y $R^{13a}$ es aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, arilo, o arilalquilo);

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ donde $R^{14}$, $R^{14a}$, y $R^{14b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

i) $-S(O)_2N(R^{15})$-alquilen $C_1$-$C_6$-$N(R^{15a})R^{15b}$ donde $R^{15}$, $R^{15a}$, y $R^{15b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

j) $-C(O)N(R^{16})$-alquilen $C_1$-$C_6$-$C(O)OR^{16a}$ donde $R^{16}$ es hidrógeno, alquilo, o alquenilo y $R^{16a}$ es alquilo o alquenilo;

k) heteroarilo opcionalmente sustituido con uno o dos aminoalquilo, alquilaminoalquilo, o dialquilaminoalquilo;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ donde $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, y $R^{17d}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

m) $-N(R^{18})C(O)$-alquilen $C_1$-$C_6$-$N(R^{18b})C(O)R^{18a}$ donde $R^{18a}$ es hidrógeno, alquilo, alquenilo, o alcoxi y $R^{18}$ y $R^{18b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

n) $-C(O)N(R^{19})$-alquilen $C_1$-$C_6$-$C(O)R^{19a}$ donde $R^{19}$ es hidrógeno, alquilo, o alquenilo y $R^{19a}$ es amino, alquilamino, dialquilamino, o heterocicloalquilo;

o) $-N(R^{20})C(O)$-alquilen $C_1$-$C_6$-$C(O)R^{20a}$ donde $R^{20}$ es hidrógeno, alquilo, o alquenilo y $R^{20a}$ es cicloalquilo o heterocicloalquilo;

p) $-NR^{21}S(O)_2$-alquilen $C_1$-$C_6$-$N(R^{21b})R^{21a}$ donde $R^{21}$ es hidrógeno, alquilo, o alquenilo y $R^{21a}$ y $R^{21b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

q) $-N(R^{22})C(O)$-alquilen $C_1$-$C_6$-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, donde $R^{22}$, $R^{22a}$ y $R^{22b}$ son de modo independiente hidrógeno, alquilo, o alquenilo;

r) -alquilen $C_0$-$C_6$-$N(R^{23})$-alquilen $C_1$-$C_6$-$N(R^{23b})R^{23a}$ donde $R^{23}$, $R^{23a}$ y $R^{23b}$ son de modo independiente hidrógeno, alquilo, o alquenilo; o

s) $-NR^{24}C(O)$-alquilen $C_1$-$C_6$-$OR^{24a}$ donde $R^{24}$ es hidrógeno, alquilo, o alquenilo y $R^{24a}$ es alcoxialquilo o arilo opcionalmente sustituido con uno o dos halo o alquilo;

donde cada alquileno en $R^3$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, amino, alquilamino, y dialquilamino; y

con la condición de que cuando $R^{50}$ y $R^{52}$ son hidrógeno, $R^{51}$ es hidrógeno o metilo, $R^{53}$ es hidrógeno o metoxi, y $R^{54}$ es hidrógeno o metoxi, por lo tanto B no es 2,3-dihidro-1,4-

benzodioxinilo, tien-2-ilo, o tien-2-ilo sustituido con un $R^3$ donde $R^3$ es halo.

2. El método de acuerdo con la reivindicación 1 donde el cáncer se selecciona de cáncer de mamas, cáncer de colon, cáncer rectal, cáncer de endometrio, tumores carcinoides gastrointestinales, tumores estromales gastrointestinales, glioblastoma, carcinoma hepatocelular, cáncer pulmonar de células pequeñas, cáncer pulmonar de células no pequeñas, melanoma, cáncer ovárico, cáncer cervical, cáncer pancreático, carcinoma prostático, leucemia mielógena aguda, leucemia mielógena crónica, linfoma no Hodgkin, y carcinoma tiroideo.

3. El método de acuerdo con la reivindicación 1 o 2 donde el tratamiento es uno o dos agentes quimioterapéuticos.

4. El método de acuerdo con las reivindicaciones 1 o 2 donde el tratamiento es un anticuerpo seleccionado de un anticuerpo EGFR y un anticuerpo ErbB2, o el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, un análogo de rapamicina, un agente alquilante, un taxano, un platino, un inhibidor de EGFR, y un inhibidor de ErbB2.

5. El método de acuerdo con la reivindicación 4 donde el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, paclitaxel, carboplatino, lapatinib, erlotinib, y *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal farmacéuticamente aceptable

y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

6. El método de acuerdo con la reivindicación 3 donde el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es un inhibidor de EGFR.

7. El método de acuerdo con la reivindicación 3 donde el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es un platino.

8. El método de acuerdo con la reivindicación 3 donde el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es un taxano.

9. El método de acuerdo con la reivindicación 3 donde el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es rapamicina o un análogo de rapamicina.

10. El método de acuerdo con la reivindicación 3 donde el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5r,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclopenta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, o *N*-(4-bromo-3-cloro-2-fluorofenil)-7-({[(3a*R*,5s,6a*S*)-2-metiloctahidrociclo-penta[c]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina; opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un

hidrato y en forma adicional opcionalmente como un solvato de este.

11. El método de acuerdo con la reivindicación 1 done el cáncer es cáncer de próstata y el tratamiento es uno o dos agentes quimioterapéuticos seleccionado de rapamicina, paclitaxel, y docetaxel.

12. El método de acuerdo con la reivindicación 1 donde el cáncer es cáncer de mamas y el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es lapatinib.


13. El método de acuerdo con la reivindicación 1 donde el cáncer es cáncer de mamas y el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es erlotinib.

14. El método de acuerdo con la reivindicación 1 donde el cáncer es cáncer de mamas y el tratamiento es un agente quimioterapéutico y el agente quimioterapéutico es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

15. El método de acuerdo con la reivindicación 1 donde el cáncer es cáncer pulmonar de células no pequeñas y el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es carboplatino.

16. El método de acuerdo con la reivindicación 1 donde el cáncer es cáncer pulmonar de células no pequeñas y el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

17. El método de acuerdo con la reivindicación 1 donde el Compuesto de Fórmula I de acuerdo con la Fórmula I(a)



I(a)

donde

$W^1$, $W^2$, $W^3$, y $W^4$ son $-C(R^1)=$; o uno o dos de $W^1$, $W^2$, $W^3$, y $W^4$ son de modo independiente -N= y los restantes son $-C(R^1)=$; y donde cada $R^1$ es de modo independiente hidrógeno, alquilo, haloalquilo, nitro, alcoxi, haloalcoxi, halo, hidroxi, ciano, amino, alquilamino, o dialquilamino;

$R^{51}$ es hidrógeno o alquilo;

$R^{52}$ es hidrógeno o halo;

$R^{50}$, $R^{53}$, y $R^{54}$ son de modo independiente hidrógeno, alquilo, alquenilo, halo, haloalquilo, haloalquenilo, hidroxi, alcoxi, alqueniloxi, haloalcoxi, nitro, amino, alquilamino, dialquilamino, $-N(R^{55})C(O)$-alquilen $C_1$-$C_6$-$N(R^{55a})R^{55b}$, alquilcarbonilo, alquenilcarbonilo, carboxi, alcoxicarbonilo, ciano, alquiltio, $-S(O)_2NR^{55}R^{55a}$, o

alquilcarbonilamino y donde $R^{55}$ y $R^{55b}$ son de modo independiente hidrógeno, alquilo, o alquenilo y $R^{55a}$ es hidrógeno, alquilo, alquenilo, hidroxi, o alcoxi; o $R^{53}$ y $R^{54}$ junto con los carbonos a los que están unidos forman un heteroarilo de 5 o 6 miembros o heterocicloalquilo de 5 o 6 miembros;

$R^3$ no está presente o $R^3$ es alquilo; y

$R^{3a}$ es $-N(R^7)C(O)$-alquilen $C_1$-$C_6$-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, o $-C(O)N(R^{10})$-alquilen $C_1$-$C_6$-$N(R^{10a})R^{10b}$; donde cada uno de los alquilenos en $R^{3a}$ está también opcionalmente sustituido de modo independiente con 1, 2, 3, 4, o 5 grupos seleccionados de halo, hidroxi, y amino; y

donde el compuesto está opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

18. El método de acuerdo con la reivindicación 1 o 2 donde el Compuesto de Fórmula I se selecciona de:

| |
|---|
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-6-oxo-1,6-dihidropiridino-3-sulfonamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-2,5-dimetiltiofeno-3-sulfonamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-2,5-diclorotiofeno-3-sulfonamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-6-oxo-1,6-dihidropiridino-3-sulfonamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-6-cloropiridino-3-sulfonamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3,5-dimetilisoxazol-4-sulfonamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-5-cloro-1,3-dimetil-1*H*-pirazol-4-sulfonamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-metil-*N*-propilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilbutanamida; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-metilbutanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pent-4-enamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)propanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)butanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,2-dimetilpropanamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)-1-metiletil]benzamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-$N^2$-metilglicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]benzamida; |
| 5-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-2-fluorobenzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-pirrolidin-3-ilbenzamida; |
| 3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]benzamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-pirrolidin-1-iletil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida; |
| *N*-(2-cloro-5-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metilglicinamida; |
| 2-(dimetilamino)-*N*-(3-(*N*-(3-(3-(2-(dimetilamino)acetamido)-5-metoxifenilamino)quinoxalin-2-il)sulfamoil)fenil)acetamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-L-alaninamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-2-metilalaninamida; |
| *N*-(2-aminoetil)-3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-alaninamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-*N*-metilbenzamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-D-alaninamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[2-acetil-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-(formilamino)bencensulfonamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-alaninamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-etilglicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-alaninamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(piperidin-2-ilmetil)benzamida; |
| *N*-(5-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-2-metilfenil)glicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1-metilazetidin-3-il)benzamida; |
| 2-azetidin-1-il-*N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-prolinamida; |
| *N*-(3-{[(3-{[2-bromo-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metilglicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-piperidin-1-iletil)benzamida; |
| $N^2$,$N^2$-dimetil-*N*-(3-{[(3-{[6-(metiloxi)quinolin-8-il]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dietilamino)etil]benzamida; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-alaninamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)-$N^2$,$N^2$-dimetilglicinamida; |
| 3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-*N*-metilbenzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1-metilpiperidin-3-il)benzamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-D-alaninamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-L-prolinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-piperidin-3-ilbenzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[(1-metilpiperidin-2-il)metil]benzamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-4-cianobencensulfonamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[2-(dimetilamino)etil]-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-serinamida; |
| (2S)-2-amino-*N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)butanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)azetidina-3-carboxamida; |
| *N*-{2-[bis(2-hidroxietil)amino]etil}-3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1-etilpiperidin-3-il)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[2-(dimetilamino)etil]-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,2-dimetilalaninamida; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-D-alaninamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida; |
| 3-[(3-aminopirrolidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)bencensulfonamida; |
| *N*-(3-{[(3-{[2-bromo-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-propilglicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-L-alaninamida; |
| *N*-(5-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-2-metilfenil)-beta-alaninamida; |
| 5-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-2-(metiloxi)benzamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-(hidroxiamino)bencensulfonamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piperidino-3-carboxamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-{[3-(metilamino)pirrolidin-1-il]carbonil}bencensulfonamida; |
| ácido 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzoicoo; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-morfolin-4-iletil)benzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[(1-etilpirrolidin-2-il)metil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-metil-1,4-diazepan-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,$N^2$-dimetilglicinamida; |
| 3-[(4-amino-3-oxopirazolidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)bencensulfonamida; |
| (2S)-2-amino-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)butanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-hidroxipropil)glicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-fluoroetil)glicinamida; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[(2-metilpropil)oxi]glicinamida; |
| 1-amino-*N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)ciclopropanocarboxamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-(formilamino)bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(ciclopropilmetil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-L-alaninamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-prolinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-metilbenzamida; |
| 3-[(3-aminoazetidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)bencensulfonamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(dimetilamino)azetidin-1-il]acetamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-D-prolinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(piridin-3-ilmetil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piperidino-2-carboxamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)morfolino-4-carboxamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-cianobencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-pirrolidin-1-ilacetamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-N~6~,N~6~-dimetil-L-lisinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-etil-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(1*H*-imidazol-4-il)acetamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(piridin-2-ilmetil)benzamida; |
| 1-amino-*N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)ciclopentanocarboxamida; |

| |
|---|
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-hidroxietil)benzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(3-oxopirazolidin-4-il)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-metilpropil)glicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-etil-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(1*H*-imidazol-4-ilmetil)azetidin-3-carboxamida; |
| *N*-(5-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-2-metilfenil)-$N^2$,$N^2$-dimetilglicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(1*H*-imidazol-4-il)etil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-etilazetidin-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-$N^2$-(1-metilpirrolidin-3-il)glicinamida; |
| *N*-(3-{[(2-{[3,5-bis(metiloxi)fenil]amino}pirido[2,3-b]pirazin-3-il)amino]sulfonil}fenil)-$N^2$-[2-(dimetilamino)etil]-$N^2$-metilglicinamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-(metilamino)bencensulfonamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-{[3-(dimetilamino)pirrolidin-1-il]carbonil}bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(3S)-3-hidroxipirrolidin-1-il]acetamida; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)ciclobutanocarboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-butilglicinamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-piperidin-1-ilazetidin-1-il)acetamida; |
| 3-[(aminocarbonil)amino]-*N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-hidroxiciclopropanocarboxamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}-*N*-(piridin-4-ilmetil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2,2-dimetilhidrazino)acetamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-[({[2-(dimetilamino)etil]amino}carbonil)amino]bencensulfonamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-metil-*N*-(1-metilpirrolidin-3-il)benzamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-{[3-(dietilamino)pirrolidin-1-il]carbonil}bencensulfonamida; |
| *N*-(3-{[(3-{[3-fluoro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-hidroxiacetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piridazino-4-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metilpiperidino-4-carboxamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-1*H*-pirrol-1-ilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(1-metiletil)glicinamida; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)ciclopentanocarboxamida; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)ciclopropanocarboxamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(3-pirrolidin-1-ilpropil)benzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-cianoetil)-*N*-metilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(dimetilamino)pirrolidin-1-il]acetamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(metiloxi)etil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[2-(dimetilamino)etil]glicinamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-cianobencensulfonamida; |
| 2-(dimetilamino)etil(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)carbamato de metilo; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-1-(ciclopropilmetil)azetidin-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(1,1-dimetiletil)glicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-cianoetil)-*N*-etilbenzamida; |
| 3-[(3-aminopiperidin-1-il)carbonil]-*N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)bencensulfonamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-(1-{[2-(dimetilamino)etil]amino}etil)bencensulfonamida; |
| $N^2$-metil-*N*-(3-{[(3-{[3-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1*H*-imidazol-2-carboxamida; |
| ácido 3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzoicoo; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(dimetilamino)propil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)isoxazol-5-carboxamida; |
| *N*-(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2,2,2-trifluoroetil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-piperidin-1-ilpropanamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-morfolin-4-ilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-oxociclopentanocarboxamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-[(2,2-dimetilhidrazino)carbonil]bencensulfonamida; |
| 3-acetil-*N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)bencensulfonamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(1*H*-imidazol-1-il)propil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-6-hidroxipiridino-2-carboxamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(dietilamino)propil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(3-fluoro-4-hidroxifenil)glicinamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-N'-[2- |

| |
|---|
| (dimetilamino)etil]benceno-1,3-disulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-(dimetilamino)butanamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-cianoetil)benzamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-4-[(difluorometil)oxi]bencensulfonamida; |
| metil*N*-[(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)carbonil]-beta-alaninate; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(metiltio)etil]benzamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-N'-[3-(dimetilamino)propil]benceno-1,3-disulfonamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(etiltio)etil]benzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[2-(dimetilamino)etil]-*N*-etilbenzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(2-oxopirrolidin-1-il)propil]benzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(2-piridin-4-iletil)benzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(etiloxi)propil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(furan-2-ilmetil)azetidin-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pirimidino-5-carboxamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-(2H-tetrazol-5-il)bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1*H*-pirrol-2-carboxamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(3-morfolin-4-ilpropil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-$N^2$-(1-metiletil)glicinamida; |
| *N*-(3-{[(3-{[3-fluoro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1*H*-imidazol-4-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-$N^2$,$N^2$-dietilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-metilisoxazol-5-il)acetamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(metiloxi)propil]benzamida; |
| $N^2$,$N^2$-dimetil-*N*-(3-{[(3-{[2-metil-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[(3-hidroxifenil)metil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metil-1*H*-pirrol-2-carboxamida; |
| 4-amino-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tetrahidro-2H-piran-4-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(metilamino)piperidin-1-il]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piperidin-1-ilacetamida; |
| *N*-(4-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metil-L-prolinamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-(metilsulfonil)bencensulfonamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(dimetilamino)propil]-*N*-metilbenzamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[3-(propiloxi)propil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tiofeno-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(ciclopropilcarbonil)azetidin-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-metilpiperazin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-(fenilmetil)azetidin-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-cloropiridino-3-carboxamida; |
| etil*N*-[(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)carbonil]-beta-alaninate; |

| |
|---|
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-{3-[(1-metiletil)oxi]propil}benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piridin-4-ilacetamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1,1-dimetil-2-piperidin-1-iletil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-$N^2$-prop-2-en-1-ilglicinamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-{5-[(dimetilamino)metil]-1,3,4-oxadiazol-2-il}bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(fenilmetil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(metiloxi)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-propanoilazetidin-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piridino-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[2-(metiloxi)etil]glicinamida; |
| 1-acetil-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)piperidino-4-carboxamida; |
| *N*-{[(3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-4-metilfenil)amino](dimetilamino)metilideno}-*N*-metilmetanaminio; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-4-[(trifluorometil)oxi]bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-metilpirrolidin-1-il)acetamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-piperidin-1-ilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)furan-3-carboxamida; |
| $N^2$,$N^2$-dimetil-*N*-(3-{[(3-{[3-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[1-metil-2-(metiloxi)etil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-6-cloropiridino-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-2-clorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piridin-2-ilacetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(dimetilamino)azetidin-1-il]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(dimetilamino)piperidin-1-il]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-piridin-3-ilacetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-clorofenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[3-(dimetilamino)propil]-$N^2$-metilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-etil-$N^2$-(2-hidroxietil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[2-(fenilmetil)pirrolidin-1-il]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)furan-2-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-cloropiridino-4-carboxamida; |
| $N^2$-acetil-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-clorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metilbenzamida; |
| 1,1-dimetiletil{2-[(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)amino]-2-oxoetil}carbamato de metilo; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1,1-dimetil-2-morfolin-4-iletil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1,3-benzodioxol-5-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-({[2-(metiloxi)fenil]metil}oxi)glicinamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-({2-[(dimetilamino)metil]piperidin-1-il}carbonil)bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)piridino-4-carboxamida; |
| *N*-(3-{[(3-{[4-fluoro-3-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(3,4-diclorofenil)piperazin-1-il]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-piridin-3-ilpropanamida; |
| *N*-[3-(butiloxi)propil]-3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tetrahidrofuran-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[(2-metilfenil)metil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-fluorofenil)acetamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-[4-(dietilamino)-1-metilbutil]benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(1-metil-1-feniletil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilciclopropanocarboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metil-4-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilpiridino-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-etilpiperazin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tiofeno-2-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluoro-2-metilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-bromotiofeno-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-fluorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-metilpiperidin-1-il)acetamida; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilpropanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pentanamida |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(etiloxi)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-fluorofenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-(dimetilamino)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-metilpiperidin-1-il)acetamida; |
| 3-{[(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}-*N*-(1,1-dimetil-2-oxo-2-piperidin-1-iletil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-propilfenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)pirazino-2-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluoro-4-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,2-dimetilbutanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(4-fluorofenil)oxi]acetamida; |
| 1-acetil-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)azetidin-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(4-metilfenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-fenilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-prop-2-en-1-ilpiperazin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-(metiloxi)propanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-3-metilfuran-2-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[(fenilmetil)oxi]glicinamida; |
| *N*-{3-[({3-[(2-cloro-5-hidroxifenil)amino]quinoxalin-2-il}amino)sulfonil]fenil}-$N^2$,$N^2$-dimetilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(3-clorofenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)ciclobutanocarboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(metiloxi)fenil]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-metilciclopropanocarboxamida; |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-[(4-metilpiperazin-1-il)carbonil]bencensulfonamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-6-{[2-(dimetilamino)etil]amino}piridino-3-sulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-(dimetilamino)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3,4-diclorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-{[2-(metiltio)fenil]metil}glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-fluorofenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-etil-$N^2$-(1-metiletil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1,3-tiazol-4-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-$N^2$-(fenilmetil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-tienilmetil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(piridin-2-ilmetil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-$N^2$-[(3-cloro-4-metilfenil)metil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilpentanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-clorofenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-fluoro-4-metilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(2-metilfenil)oxi]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-ciclohexilacetamida; |
| (1R,2R)-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fenilciclopropanocarboxamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-3-(dimetilamino)bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-clorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[2-(metiloxi)fenil]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-[3-(metiloxi)fenil]propanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-fluoro-4-metilfenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[(3-fluorofenil)metil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(metiloxi)fenil]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fenilacetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,4-diclorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-oxociclohexanocarboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(3-fluorofenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3-clorofenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-fenilpropil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-$N^2$-[(2,4-dimetilfenil)metil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-metilpiperidin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[2-(metiloxi)fenil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(3,4-dihidroisoquinolin-2(1*H*)-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-metilfenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-oxopiperidin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fluorobenzamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-6-{[2-(dimetilamino)etil]oxi}piridino-3-sulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(1-feniletil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fluoro-6-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metil-3-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[2-(1-metiletil)fenil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-[2-(metiloxi)fenil]propanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metilpentanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-fenilmorfolin-4-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-[4-(metiloxi)fenil]propanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-ciclopentil-$N^2$-prop-2-en-1-ilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-$N^2$-[2-(metiloxi)etil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-ciclopropil-4-oxobutanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[3-(1,1-dimetiletil)fenil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-$N^2$-(ciclopropilmetil)-$N^2$-propilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-oxociclopentil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(4-clorofenil)glicinamida; |
| 2-(1,4'-bipiperidin-1'-il)-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-ciclopentilpiperazin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-metilfenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-[(5-fluoro-2-metilfenil)metil]glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3,3-dimetilbutanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2-clorofenil)glicinamida |
| *N*-(3-{[2-cloro-5-(metiloxi)fenil]amino}quinoxalin-2-il)-3-{[2-(piperidin-1-ilmetil)piperidin-1-il]carbonil}bencensulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-5-fluoro-2-metilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-fluoro-3-metilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,3-diclorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(feniloxi)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-(2,3-dimetilfenil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-fluoro-5-metilbenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-{[(4-metilfenil)metil]oxi}glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[4-(1-metiletil)piperazin-1-il]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-fluorofenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-4-metil-2-(metiloxi)benzamida; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-propilpiperidin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[(3-metilfenil)oxi]acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)tetrahidrofuran-2-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-[3-(hidroximetil)piperidin-1-il]acetamida; |
| 1,1-dimetiletil2-{[(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)amino]carbonil}piperidino-1-carboxilate; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-$N^2$-(piridin-3-ilmetil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-etil-$N^2$-fenilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-{[2-(metiloxi)etil]oxi}acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-ciclopentilpropanamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2,5-diclorobenzamida; |
| 2-(4-acetilpiperazin-1-il)-*N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-5-fluoro-2-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-ciclohexil-$N^2$-etilglicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-5-metilisoxazol-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3-metilpiridino-2-carboxamida; |
| *N*-(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)-6-(dimetilamino)piridino-3-sulfonamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(metiloxi)piridino-3-carboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-3,5-diclorobenzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(1,3-tiazolidin-3-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2- |

| |
|---|
| il)amino]sulfonil}fenil)-2-(4-formilpiperazin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-piridin-4-ilpiperidin-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(metiloxi)benzamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-$N^2$-metil-$N^2$-(2-metilpropil)glicinamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(4-formil-1,4-diazepan-1-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-1-fenilciclopropanocarboxamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2,6-dimetilmorfolin-4-il)acetamida; |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-(2-fenilpirrolidin-1-il)acetamida; y |
| *N*-(3-{[(3-{[3,5-bis(metiloxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-morfolin-4-ilacetamida; |

donde el compuesto está opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

19. El método de acuerdo con las reivindicaciones 1, 2, 4, 17 o 18 donde el tratamiento es un anticuerpo seleccionado de un anticuerpo EGFR y un anticuerpo ErbB2, o el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, un análogo de rapamicina, un agente alquilante, un taxano, un platino, un inhibidor de EGFR, y un inhibidor de ErbB2.

20. El método de acuerdo con la reivindicación 19 donde el tratamiento es uno o dos agentes quimioterapéuticos seleccionados de modo independiente rapamicina, paclitaxel, carboplatino, lapatinib, erlotinib, y *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal

farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

21. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es *N*-(3,4-dicloro-2-fluorofenil)-7-({[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta-[*c*]pirrol-5-il]metil}oxi)-6-(metiloxi)quinazolin-4-amina, opcionalmente en forma de sal farmacéuticamente aceptable y en forma adicional opcionalmente como un hidrato y en forma adicional opcionalmente como un solvato de este.

22. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es erlotinib.

23. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es lapatinib.


24. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es carboplatino.

25. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es paclitaxel.

26. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es rapamicina.

27. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un anticuerpo seleccionado de bevacizumab, trastuzumab, cetuximab, y panitumumab.

28. El método de acuerdo con la reivindicación 1, 2, 3, 4, 17, o 18 donde el tratamiento es un agente quimioterapéutico donde el agente quimioterapéutico es de la fórmula 100:




100

donde q es 1, 2, o 3; E es $-NR^9-$, -O-, o ausente e Y es $-CH_2CH_2-$, $-CH_2-$, o ausente con la condición de que cuando E es $-NR^9-$ o -O-, por lo tanto Y es $-CH_2CH_2-$; $R^2$ se selecciona de halógeno, trihalometilo, -CN, $-NO_2$, $-OR^3$, y alquilo inferior; $R^8$ se selecciona de -H, alquilo inferior, $-C(O)OR^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, y $-C(O)R^3$; $R^9$ es hidrógeno o alquilo inferior; $R^3$ es hidrógeno o $R^4$; $R^4$ se selecciona de alquilo inferior, arilo, arilalquilo inferior, heterociclilo, y heterociclilalquilo inferior; o $R^3$ y $R^4$, cuando se toman juntos con un nitrógeno común al que están unidos, forma un heterociclilo de cinco a siete miembros, dicho heterociclilo de cinco a siete miembros opcionalmente que contiene uno o más heteroátomos adicionales seleccionados de N, O, S, y P; o uno de sus isómeros geométricos, estereoisómeros, racematos, enantiómeros o

diastereómeros simples y opcionalmente en forma de sal farmacéuticamente aceptable, en forma adicional opcionalmente como un solvato y en forma adicional como un hidrato de este.


RESUMEN

La presente invención proporciona métodos de tratar cáncer por la administración de un compuesto de Fórmula I, opcionalmente en forma de sus sales farmacéuticamente aceptable, sus solvatos y/o hidratos, en combinación con otros tratamientos de cáncer.


I

**Figura 1.** Compuesto A + Taxol en modelo de tumor de carcinoma prostático PC-3






i224

**Figura 2.** Compuesto A + Rapamicina en en modelo de tumor de carcinoma prostático PC-3




**Figura 3.** Compuesto A + Carboplatino in Calu-6 NSCLC Tumor Model





**Figura 4a.** Compuesto A + Compuesto B en modelo de tumor de cancer de pulmón de células no peequeñas A549






1227

**Figura 4b-1.** Compuesto A + Compuesto B en modelo de tumor de cancer de mamas en MCF7l (Estudio 1)





**Figura 4b-2.** Compuesto A + Compuesto B en modelo de tumor de cancer de mamas en MCF7l (Estudio 2)






**Figure 5.** Compuesto A + Erlotinib in MDA-MB-468 Breast Carcinoma Tumor Model






1229


R52
R53
OR51
R54
R50
W1
N
NH
W2
W3
W4
N
N
H
S
O
O
B

**Foregin Filings – marked up**

**In the Specification**

Please correct the heading which is located above paragraph [00356] as indicated below.

**Biological Examples 11-[[14]]<u>16</u>**

**In the Claims**


Claims 1, 2, and 17 are original.

Claims 3-6, 10-16, 21, and 28 are canceled.

Claims 7-9, 18-20, and 22-27 are currently amended.

Claims 29-33 are new.

1. (**original**) A method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a compound of Formula I:




I

or a single isomer thereof where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof; or administering a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula I and at least one of a pharmaceutically acceptable carrier, excipient, or diluent in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more of the hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation where the Compound of Formula I is that wherein:

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; and where each $R^1$ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen or halo;

$R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

B is phenyl substituted with $R^{3a}$ and optionally further substituted with one, two, or three $R^3$; or

B is heteroaryl optionally substituted with one, two, or three $R^3$;

$R^{3a}$ is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where $R^8$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently

selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where $R^9$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{9a}$ is hydrogen, $C_2$-$C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$ where $R^{10a}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and $R^{10}$ and $R^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and $R^{11}$ and $R^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

f) $-C(O)R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl;

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})-C_1-C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2-C_1-C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)-C_1-C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$ where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

r) $-C_0-C_6$-alkylene-$N(R^{23})-C_1-C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)-C_1-C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl; and

where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

each $R^3$ (when $R^3$ is present) is independently alkyl; alkenyl; alkynyl; halo; hydroxy; oxo; alkoxy; cyano; hydroxyamino; carboxy; alkoxycarbonyl; amino; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

a) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl,

haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

b) $-C(O)NR^8R^{8a}$ where $R^8$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

c) $-NR^9C(O)R^{9a}$ where $R^9$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{9a}$ is hydrogen, $C_2$-$C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

d) $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$ where $R^{10a}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or hydroxyalkyl and $R^{10}$ and $R^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, or hydroxyalkyl;

e) $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and $R^{11}$ and $R^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminooalkyl, dialkylaminoalkyl;

f) $-C(O)R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

g) $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl);

h) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

i) $-S(O)_2N(R^{15})-C_1-C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

j) $-C(O)N(R^{16})-C_1-C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

k) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

l) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

m) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

n) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

o) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

p) $-NR^{21}S(O)_2-C_1-C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;

q) $-N(R^{22})C(O)-C_1-C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$, where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

r) $-C_0$-$C_6$-alkylene-$N(R^{23})$-$C_1$-$C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

s) $-NR^{24}C(O)$-$C_1$-$C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;

wherein each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

provided that when $R^{50}$ and $R^{52}$ are hydrogen, $R^{51}$ is hydrogen or methyl, $R^{53}$ is hydrogen or methoxy, and $R^{54}$ is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one $R^3$ where $R^3$ is halo.

2. (**original**) The method of Claim 1 where the cancer is selected from breast cancer, colon cancer, rectal cancer, endometrial cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, and thyroid carcinoma.

Claims 3-6 (**canceled**)


7. (**currently amended**) The method of Claim ~~3~~ 1 or 2 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is a platin.

8. (**currently amended**) The method of Claim ~~3~~ 1 or 2 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is a taxane.

9. (**currently amended**) The method of Claim ~~3~~ 1 or 2 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is rapamycin or a rapamycin analogue.

Claims 10-16 (**canceled**)

17. (**original**) The method of Claim 1 where the Compound of Formula I is according to Formula I(a)



**I(a)**

where

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; and where each $R^1$ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen or halo;

$R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

$R^3$ is not present or $R^3$ is alkyl; and

$R^{3a}$ is $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and

where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

18. The method of Claim 1 or 2 where the Compound of Formula I is selected from:

| |
|---|
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-2,5-dimethylthiophene-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-2,5-dichlorothiophene-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-chloropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3,5-dimethylisoxazole-4-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-1,3-dimethyl-1*H*-pyrazole-4-sulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-propylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pent-4-enamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)-1-methylethyl]benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$-methylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide; |
| 5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-fluorobenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-pyrrolidin-3-ylbenzamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyrrolidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(2-chloro-5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |

| |
|---|
| 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-2-methylalaninamide; |
| *N*-(2-aminoethyl)-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-D-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-acetyl-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(piperidin-2-ylmethyl)benzamide; |
| *N*-(5-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylazetidin-3-yl)benzamide; |
| 2-azetidin-1-yl-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide; |
| *N*-(3-{[(3-{[2-bromo-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-piperidin-1-ylethyl)benzamide; |

| |
|---|
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[6-(methyloxy)quinolin-8-yl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(diethylamino)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylpiperidin-3-yl)benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-D-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-3-ylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-methylpiperidin-2-yl)methyl]benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-cyanobenzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-serinamide; |
| (2S)-2-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide; |
| *N*-{2-[bis(2-hydroxyethyl)amino]ethyl}-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-ethylpiperidin-3-yl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,2-dimethylalaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| 3-[(3-aminopyrrolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |

| |
|---|
| *N*-(3-{[(3-{[2-bromo-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-propylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-L-alaninamide; |
| *N*-(5-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-beta-alaninamide; |
| 5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-(methyloxy)benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(hydroxyamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-3-carboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-morpholin-4-ylethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-ethylpyrrolidin-2-yl)methyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methyl-1,4-diazepan-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-[(4-amino-3-oxopyrazolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| (2S)-2-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-hydroxypropyl)glycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluoroethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2-methylpropyl)oxy]glycinamide; |
| 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(cyclopropylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-L-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methylbenzamide; |

| |
|---|
| 3-[(3-aminoazetidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-3-ylmethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-2-carboxamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)morpholine-4-carboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N~6~,N~6~-dimethyl-L-lysinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1*H*-imidazol-4-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-2-ylmethyl)benzamide; |
| 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-hydroxyethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-oxopyrazolidin-4-yl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-methylpropyl)glycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(1*H*-imidazol-4-ylmethyl)azetidine-3-carboxamide; |
| *N*-(5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(1*H*-imidazol-4-yl)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-ethylazetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(1-methylpyrrolidin-3-yl)glycinamide; |
| *N*-(3-{[(2-{[3,5-bis(methyloxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |

| |
|---|
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(methylamino)benzenesulfonamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3S)-3-hydroxypyrrolidin-1-yl]acetamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-butylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-piperidin-1-ylazetidin-1-yl)acetamide; |
| 3-[(aminocarbonyl)amino]-*N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-hydroxycyclopropanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-4-ylmethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,2-dimethylhydrazino)acetamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[({[2-(dimethylamino)ethyl]amino}carbonyl)amino]benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-(1-methylpyrrolidin-3-yl)benzamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(diethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3-fluoro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-hydroxyacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridazine-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylpiperidine-4-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-1*H*-pyrrol-1-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-methylethyl)glycinamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-pyrrolidin-1-ylpropyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-methylbenzamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)pyrrolidin-1-yl]acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methyloxy)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]glycinamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide; |
| 2-(dimethylamino)ethyl(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbamate; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1,1-dimethylethyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-ethylbenzamide; |
| 3-[(3-aminopiperidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(1-{[2-(dimethylamino)ethyl]amino}ethyl)benzenesulfonamide; |
| $N^2$-methyl-*N*-(3-{[(3-{[3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-2-carboxamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)isoxazole-5-carboxamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2,2,2-trifluoroethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-piperidin-1-ylpropanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-morpholin-4-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclopentanecarboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[(2,2-dimethylhydrazino)carbonyl]benzenesulfonamide; |
| 3-acetyl-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(1*H*-imidazol-1-yl)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-hydroxypyridine-2-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3- |

| |
|---|
| (diethylamino)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-fluoro-4-hydroxyphenyl)glycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-N'-[2-(dimethylamino)ethyl]benzene-1,3-disulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)butanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-[(difluoromethyl)oxy]benzenesulfonamide; |
| methyl*N*-[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methylthio)ethyl]benzamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-N'-[3-(dimethylamino)propyl]benzene-1,3-disulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(ethylthio)ethyl]benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-ethylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyridin-4-ylethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(ethyloxy)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(furan-2-ylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrimidine-5-carboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(2H-tetrazol-5-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-pyrrole-2-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-morpholin-4-ylpropyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(1-methylethyl)glycinamide; |
| *N*-(3-{[(3-{[3-fluoro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-diethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3- |

| |
|---|
| methylisoxazol-5-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(methyloxy)propyl]benzamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[2-methyl-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-hydroxyphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-1*H*-pyrrole-2-carboxamide; |
| 4-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydro-2H-pyran-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methylamino)piperidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-piperidin-1-ylacetamide; |
| *N*-(4-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-L-prolinamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(methylsulfonyl)benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]-*N*-methylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(propyloxy)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylcarbonyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(phenylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-3-carboxamide; |
| ethyl*N*-[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-{3-[(1-methylethyl)oxy]propyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-4-ylacetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-piperidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-prop-2-en-1-ylglycinamide; |

| |
|---|
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(phenylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-propanoylazetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(methyloxy)ethyl]glycinamide; |
| 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-4-carboxamide; |
| *N*-{[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)amino](dimethylamino)methylidene}-*N*-methylmethanaminium; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-[(trifluoromethyl)oxy]benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpyrrolidin-1-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-1-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-3-carboxamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[1-methyl-2-(methyloxy)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-chloropyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-2-ylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(dimethylamino)piperidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-3-ylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-chlorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[3-(dimethylamino)propyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-(2-hydroxyethyl)glycinamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(phenylmethyl)pyrrolidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-4-carboxamide; |
| $N^2$-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylbenzamide; |
| 1,1-dimethylethyl{2-[(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]-2-oxoethyl}carbamate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-morpholin-4-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-benzodioxole-5-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-({[2-(methyloxy)phenyl]methyl}oxy)glycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-({2-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-4-carboxamide; |
| *N*-(3-{[(3-{[4-fluoro-3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(3,4-dichlorophenyl)piperazin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-pyridin-3-ylpropanamide; |
| *N*-[3-(butyloxy)propyl]-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-fluorophenyl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[4-(diethylamino)-1-methylbutyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-methyl-1-phenylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylcyclopropanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methyl-4- |

| |
|---|
| (methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-ethylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-bromothiophene-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpropanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pentanamide |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(ethyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(dimethylamino)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperidin-1-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-oxo-2-piperidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-propylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrazine-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(4-fluorophenyl)oxy]acetamide; |
| 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(4- |

| |
|---|
| methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-phenylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-prop-2-en-1-ylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methyloxy)propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylfuran-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(phenylmethyl)oxy]glycinamide; |
| *N*-{3-[({3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-chlorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylcyclopropanecarboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]amino}pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,4-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-{[2-(methylthio)phenyl]methyl}glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-fluorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-(1-methylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-thiazole-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(phenylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-thienylmethyl)glycinamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(pyridin-2-ylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-chloro-4-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpentanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-chlorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(2-methylphenyl)oxy]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-cyclohexylacetamide; |
| (1R,2R)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylcyclopropanecarboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[3-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluoro-4-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-fluorophenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,4-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclohexanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-fluorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-chlorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-phenylpropyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2,4-dimethylphenyl)methyl]glycinamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(methyloxy)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3,4-dihydroisoquinolin-2(1*H*)-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-oxopiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluorobenzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]oxy}pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-phenylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-6-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-3-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(1-methylethyl)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[2-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylpentanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylmorpholin-4-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[4-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-cyclopentyl-$N^2$-prop-2-en-1-ylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-[2-(methyloxy)ethyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-cyclopropyl-4-oxobutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[3-(1,1-dimethylethyl)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(cyclopropylmethyl)-$N^2$-propylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-oxocyclopentyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(4-chlorophenyl)glycinamide; |
| 2-(1,4'-bipiperidin-1'-yl)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2- |

| |
|---|
| yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-cyclopentylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylphenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(5-fluoro-2-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,3-dimethylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-chlorophenyl)glycinamide |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[2-(piperidin-1-ylmethyl)piperidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluoro-3-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,3-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(phenyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2,3-dimethylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-5-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-{[(4-methylphenyl)methyl]oxy}glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(1-methylethyl)piperazin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-fluorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-propylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3-methylphenyl)oxy]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(hydroxymethyl)piperidin-1-yl]acetamide; |
| 1,1-dimethylethyl2-{[(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]carbonyl}piperidine-1-carboxylate; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(pyridin-3-ylmethyl)glycinamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-phenylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-{[2-(methyloxy)ethyl]oxy}acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-cyclopentylpropanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,5-dichlorobenzamide; |
| 2-(4-acetylpiperazin-1-yl)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-cyclohexyl-$N^2$-ethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-methylisoxazole-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylpyridine-2-carboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)pyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,5-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1,3-thiazolidin-3-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-pyridin-4-ylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(2-methylpropyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formyl-1,4-diazepan-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-phenylcyclopropanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,6-dimethylmorpholin-4-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylpyrrolidin-1-yl)acetamide; and |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide; |

where the Compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

19. (**currently amended**) The method of Claims 1, 2, [[4, ]]17, or 18 where the treatment is one antibody selected from an EGFR antibody and an ErbB2 antibody, or the treatment is one or two chemotherapeutic agents independently selected from rapamycin, a rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor.

20. (**currently amended**) The method of Claim 19 where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, paclitaxel, carboplatin, lapatinib, and erlotinib~~, and *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta-[*c*]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof~~.

Claim 21 (**canceled**)

22. (**currently amended**) The method of Claim 1, 2, [[3, 4, ]]17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is erlotinib.

23. (**currently amended**) The method of Claim 1, 2, [[3, 4, ]]17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is lapatinib.

24. (**currently amended**) The method of Claim 1, 2, [[3, 4, ]]17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is carboplatin.

25. (**currently amended**) The method of Claim 1, 2, [[3, 4, ]]17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is paclitaxel.

26. (**currently amended**) The method of Claim 1, 2, [[3, 4, ]]17, or 18 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is rapamycin.

27. (**currently amended**) The method of Claim 1, 2, [[3, 4, ]]17, or 18 where the treatment is one antibody selected from bevacizumab, trastuzumab, cetuximab, and panitumumab.

Claim 28 (**canceled**)

29. (**new**) The method of Claim 1, 17, or 18 where the treatment is one hormone therapy where the hormone therapy is an aromatase inhibitor.

30. (**new**) The method of Claim 29 where the aromatase inhibitor is selected from selected from letrozole, anastrozole, and exemestane.

31. (**new**) The method of Claim 1 or 2 where the treatment is one antibody and the antibody is an ErbB2 antibody.

32. (**new**) The method of Claim 17, 18, or 31 where the treatment is one antibody and the antibody is an ErbB2 antibody where the ErbB2 antibody is trastuzumab.

33. (**new**) The method of Claim 1, 17, or 18 where the treatment is one or two agents independently selected from rapamycin, temozolomide, paclitaxel, docetaxel, carboplatin, trastuzumab, erlotinib, and lapatinib.


**Remarks**

The Specification is amended to correct a typographical error in the number of biological examples in the heading "Biological Examples 11-14."

Claims 7-9, 19, and 22-27 are amended so that they no longer depend from canceled claims. Claim 20 is amended to more distinctly claim what the Applicants regard as their Invention. Claims 29 and 30 are new and support for which can be found in paragraph [0158] and [0159]. Claims 31 and 32 are new and support for which can be found in paragraphs [0078], [00148], and [00160]. Claim 33 is new and support for which can be found in paragraph [0115]. No new matter is added with these amendements and new claims.

**Foregin Filings - clean**

1. A method of treating cancer which method comprises administering to a patient a therapeutically effective amount of a compound of Formula I:



I

or a single isomer thereof where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof; or administering a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula I and at least one of a pharmaceutically acceptable carrier, excipient, or diluent in combination with one or more treatments independently selected from surgery, one or more chemotherapeutic agents, one or more of the hormone therapies, one or more antibodies, one or more immunotherapies, radioactive iodine therapy, and radiation where the Compound of Formula I is that wherein:

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; and where each $R^1$ is independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen or halo;

$R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$ together with the carbons to which they

are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

B is phenyl substituted with $R^{3a}$ and optionally further substituted with one, two, or three $R^3$; or

B is heteroaryl optionally substituted with one, two, or three $R^3$;

$R^{3a}$ is cyano; hydroxyamino; carboxy; alkoxycarbonyl; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

t) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

u) $-C(O)NR^8R^{8a}$ where $R^8$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

v) $-NR^9C(O)R^{9a}$ where $R^9$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{9a}$ is hydrogen, $C_2-C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl,

heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

w) $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$ where $R^{10a}$ is hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and $R^{10}$ and $R^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl;

x) $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and $R^{11}$ and $R^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

y) $-C(O)R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

z) $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl;

aa) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

bb) $-S(O)_2N(R^{15})-C_1-C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

cc) $-C(O)N(R^{16})-C_1-C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

dd) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

ee) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

ff) $-N(R^{18})C(O)-C_1-C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

gg) $-C(O)N(R^{19})-C_1-C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

hh) $-N(R^{20})C(O)-C_1-C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

ii) $-NR^{21}S(O)_2-C_1-C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;

jj) $-N(R^{22})C(O)-C_1-C_6$-alkylene-$N(R^{22b})-N(R^{22c})(R^{22a})$ where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

kk) $-C_0.C_6$-alkylene-$N(R^{23})-C_1.C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

ll) $-NR^{24}C(O)-C_1.C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl; and

where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

each $R^3$ (when $R^3$ is present) is independently alkyl; alkenyl; alkynyl; halo; hydroxy; oxo; alkoxy; cyano; hydroxyamino; carboxy; alkoxycarbonyl; amino; alkylamino; dialkylamino; alkylcarbonyl; haloalkoxy; alkylsulfonyl; aminoalkyloxy; alkylaminoalkyloxy; dialkylaminoalkyloxy; or

t) $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$ where $R^7$ is hydrogen, alkyl, or alkenyl and $R^{7a}$ and $R^{7b}$ are independently hydrogen, alkyl, alkenyl, hydroxyalkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, or arylalkyloxy and where the aryl, cycloalkyl, heterocycloalkyl and heteroaryl rings in $R^{7a}$ and $R^{7b}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently

selected from alkyl, amino, alkylamino, dialkylamino, hydroxy, halo, alkoxy, alkylthio, and oxo);

u) $-C(O)NR^8R^{8a}$ where $R^8$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{8a}$ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthioalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl and where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{8a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxycarbonyl, and -C(O)H;

v) $-NR^9C(O)R^{9a}$ where $R^9$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or haloalkoxy and $R^{9a}$ is hydrogen, $C_2$-$C_6$-alkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl, aryl, or arylalkyl; where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl rings in $R^{9a}$ (either alone or as part of arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl) are independently optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, halo, haloalkyl, haloalkoxy, oxo, amino, alkylamino, dialkylamino, alkylcarbonyl, alkoxycarbonyl, -C(O)H, aryl (optionally substituted with one or two halo), arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyloalkyl, cyloalkylalkyl, and cycloalkylcarbonyl;

w) $-C(O)N(R^{10})$-$C_1$-$C_6$-alkylene-$N(R^{10a})R^{10b}$ where $R^{10a}$ is hydrogen, hydroxy, alkoxy, alkyl, alkenyl, haloalkyl, or hydroxyalkyl and $R^{10}$ and $R^{10b}$ are independently hydrogen, alkyl, alkenyl, haloalkyl, or hydroxyalkyl;

x) $-NR^{11}C(O)NR^{11a}R^{11b}$ where $R^{11a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy and $R^{11}$ and $R^{11b}$ are independently hydrogen, alkyl, alkenyl, aminoalkyl, alkylaminooalkyl, dialkylaminoalkyl;

y) $-C(O)R^{12}$ where $R^{12}$ is heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, oxo, amino, alkylamino, and heterocycloalkylalkyl;

z) $-NR^{13}C(O)OR^{13a}$ where $R^{13}$ is hydrogen, alkyl, or alkenyl and $R^{13a}$ is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, or arylalkyl);

aa) $-C(O)N(R^{14})N(R^{14a})(R^{14b})$ where $R^{14}$, $R^{14a}$, and $R^{14b}$ are independently hydrogen, alkyl, or alkenyl;

bb) $-S(O)_2N(R^{15})$-$C_1$-$C_6$-alkylene-$N(R^{15a})R^{15b}$ where $R^{15}$, $R^{15a}$, and $R^{15b}$ are independently hydrogen, alkyl, or alkenyl;

cc) $-C(O)N(R^{16})$-$C_1$-$C_6$-alkylene-$C(O)OR^{16a}$ where $R^{16}$ is hydrogen, alkyl, or alkenyl and $R^{16a}$ is alkyl or alkenyl;

dd) heteroaryl optionally substituted with one or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl;

ee) $-N(R^{17})-C(=N(R^{17b})(R^{17a}))(NR^{17c}R^{17d})$ where $R^{17}$, $R^{17a}$, $R^{17b}$, $R^{17c}$, and $R^{17d}$ are independently hydrogen, alkyl, or alkenyl;

ff) $-N(R^{18})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{18b})C(O)R^{18a}$ where $R^{18a}$ is hydrogen, alkyl, alkenyl, or alkoxy and $R^{18}$ and $R^{18b}$ are independently hydrogen, alkyl, or alkenyl;

gg) $-C(O)N(R^{19})$-$C_1$-$C_6$-alkylene-$C(O)R^{19a}$ where $R^{19}$ is hydrogen, alkyl, or alkenyl and $R^{19a}$ is amino, alkylamino, dialkylamino, or heterocycloalkyl;

hh) $-N(R^{20})C(O)$-$C_1$-$C_6$-alkylene-$C(O)R^{20a}$ where $R^{20}$ is hydrogen, alkyl, or alkenyl and $R^{20a}$ is cycloalkyl or heterocycloalkyl;

ii) $-NR^{21}S(O)_2$-$C_1$-$C_6$-alkylene-$N(R^{21b})R^{21a}$ where $R^{21}$ is hydrogen, alkyl, or alkenyl and $R^{21a}$ and $R^{21b}$ are independently hydrogen, alkyl, or alkenyl;

jj) $-N(R^{22})C(O)$-$C_1$-$C_6$-alkylene-$N(R^{22b})$-$N(R^{22c})(R^{22a})$, where $R^{22}$, $R^{22a}$ and $R^{22b}$ are independently hydrogen, alkyl, or alkenyl;

kk) $-C_0$-$C_6$-alkylene-$N(R^{23})$-$C_1$-$C_6$-alkylene-$N(R^{23b})R^{23a}$ where $R^{23}$, $R^{23a}$ and $R^{23b}$ are independently hydrogen, alkyl, or alkenyl; or

ll) $-NR^{24}C(O)$-$C_1$-$C_6$-alkylene-$OR^{24a}$ where $R^{24}$ is hydrogen, alkyl, or alkenyl and $R^{24a}$ is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;

wherein each of the alkylene in $R^3$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkylamino; and

provided that when $R^{50}$ and $R^{52}$ are hydrogen, $R^{51}$ is hydrogen or methyl, $R^{53}$ is hydrogen or methoxy, and $R^{54}$ is hydrogen or methoxy, then B is not 2,3-dihydro-1,4-benzodioxinyl, thien-2-yl, or thien-2-yl substituted with one $R^3$ where $R^3$ is halo.


2. The method of Claim 1 where the cancer is selected from breast cancer, colon cancer, rectal cancer, endometrial cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, and thyroid carcinoma.

3. The method of Claim 1 or 2 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is a platin.

4. The method of Claim 1 or 2 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is a taxane.

5. The method of Claim 1 or 2 where the treatment is one chemotherapeutic agent and the chemotherapeutic agent is rapamycin or a rapamycin analogue.

6. The method of Claim 1 where the Compound of Formula I is according to Formula I(a)




**I(a)**

where

$W^1$, $W^2$, $W^3$, and $W^4$ are $-C(R^1)=$; or one or two of $W^1$, $W^2$, $W^3$, and $W^4$ are independently $-N=$ and the remaining are $-C(R^1)=$; and where each $R^1$ is

independently hydrogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkylamino, or dialkylamino;

$R^{51}$ is hydrogen or alkyl;

$R^{52}$ is hydrogen or halo;

$R^{50}$, $R^{53}$, and $R^{54}$ are independently hydrogen, alkyl, alkenyl, halo, haloalkyl, haloalkenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitro, amino, alkylamino, dialkylamino, $-N(R^{55})C(O)-C_1-C_6$-alkylene-$N(R^{55a})R^{55b}$, alkylcarbonyl, alkenylcarbonyl, carboxy, alkoxycarbonyl, cyano, alkylthio, $-S(O)_2NR^{55}R^{55a}$, or alkylcarbonylamino and where $R^{55}$ and $R^{55b}$ are indepedently hydrogen, alkyl, or alkenyl and $R^{55a}$ is hydrogen, alkyl, alkenyl, hydroxy, or alkoxy; or $R^{53}$ and $R^{54}$ together with the carbons to which they are attached form a 5- or 6-membered heteroaryl or 5- or 6-membered heterocycloalkyl;

$R^3$ is not present or $R^3$ is alkyl; and

$R^{3a}$ is $-N(R^7)C(O)-C_1-C_6$-alkylene-$N(R^{7a})(R^{7b})$, $-C(O)NR^8R^{8a}$, $-NR^9C(O)R^{9a}$, or $-C(O)N(R^{10})-C_1-C_6$-alkylene-$N(R^{10a})R^{10b}$; where each of the alkylene in $R^{3a}$ is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, and amino; and

where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

7. The method of Claim 1 or 2 where the Compound of Formula I is selected from:

| |
|---|
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-2,5-dimethylthiophene-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-2,5-dichlorothiophene-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-oxo-1,6-dihydropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-chloropyridine-3-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3,5-dimethylisoxazole-4-sulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-5-chloro-1,3-dimethyl-1*H*-pyrazole-4-sulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-propylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3- |

| |
|---|
| methylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pent-4-enamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)-1-methylethyl]benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$-methylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide; |
| 5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-fluorobenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-pyrrolidin-3-ylbenzamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyrrolidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(2-chloro-5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| 2-(dimethylamino)-*N*-(3-(*N*-(3-(3-(2-(dimethylamino)acetamido)-5-methoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-2-methylalaninamide; |
| *N*-(2-aminoethyl)-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-D-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |

| |
|---|
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-acetyl-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(piperidin-2-ylmethyl)benzamide; |
| *N*-(5-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylazetidin-3-yl)benzamide; |
| 2-azetidin-1-yl-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide; |
| *N*-(3-{[(3-{[2-bromo-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-piperidin-1-ylethyl)benzamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[6-(methyloxy)quinolin-8-yl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(diethylamino)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-*N*-methylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-methylpiperidin-3-yl)benzamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-D-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-L-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-3-ylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-methylpiperidin- |

| |
|---|
| 2-yl)methyl]benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-cyanobenzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-serinamide; |
| (2S)-2-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide; |
| *N*-{2-[bis(2-hydroxyethyl)amino]ethyl}-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1-ethylpiperidin-3-yl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,2-dimethylalaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-D-alaninamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| 3-[(3-aminopyrrolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-bromo-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-propylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-L-alaninamide; |
| *N*-(5-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-beta-alaninamide; |
| 5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(dimethylamino)ethyl]-2-(methyloxy)benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(hydroxyamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-3-carboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-morpholin-4-ylethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[(1-ethylpyrrolidin- |

| |
|---|
| 2-yl)methyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methyl-1,4-diazepan-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-[(4-amino-3-oxopyrazolidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| (2S)-2-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)butanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-hydroxypropyl)glycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluoroethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2-methylpropyl)oxy]glycinamide; |
| 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(formylamino)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(cyclopropylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-L-alaninamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methylbenzamide; |
| 3-[(3-aminoazetidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-D-prolinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-3-ylmethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-2-carboxamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)morpholine-4-carboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-N~6~,N~6~-dimethyl-L-lysinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-methylglycinamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1*H*-imidazol-4-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-2-ylmethyl)benzamide; |
| 1-amino-*N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-hydroxyethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-oxopyrazolidin-4-yl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-methylpropyl)glycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(1*H*-imidazol-4-ylmethyl)azetidine-3-carboxamide; |
| *N*-(5-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-2-methylphenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(1*H*-imidazol-4-yl)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-ethylazetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(1-methylpyrrolidin-3-yl)glycinamide; |
| *N*-(3-{[(2-{[3,5-bis(methyloxy)phenyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(methylamino)benzenesulfonamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3S)-3-hydroxypyrrolidin-1-yl]acetamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-butylglycinamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-piperidin-1-ylazetidin-1-yl)acetamide; |
| 3-[(aminocarbonyl)amino]-*N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-hydroxycyclopropanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(pyridin-4-ylmethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,2-dimethylhydrazino)acetamide; |

| |
|---|
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[({[2-(dimethylamino)ethyl]amino}carbonyl)amino]benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-methyl-*N*-(1-methylpyrrolidin-3-yl)benzamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[3-(diethylamino)pyrrolidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3-fluoro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-hydroxyacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridazine-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylpiperidine-4-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-1*H*-pyrrol-1-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-methylethyl)glycinamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopentanecarboxamide; |
| 1-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclopropanecarboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-pyrrolidin-1-ylpropyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)pyrrolidin-1-yl]acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methyloxy)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(dimethylamino)ethyl]glycinamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-cyanobenzenesulfonamide; |
| 2-(dimethylamino)ethyl(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbamate; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1,1-dimethylethyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)-*N*-ethylbenzamide; |
| 3-[(3-aminopiperidin-1-yl)carbonyl]-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(1-{[2-(dimethylamino)ethyl]amino}ethyl)benzenesulfonamide; |

| |
|---|
| $N^2$-methyl-*N*-(3-{[(3-{[3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-2-carboxamide; |
| 3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzoicacid; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)isoxazole-5-carboxamide; |
| *N*-(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2,2,2-trifluoroethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-piperidin-1-ylpropanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-morpholin-4-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclopentanecarboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[(2,2-dimethylhydrazino)carbonyl]benzenesulfonamide; |
| 3-acetyl-*N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(1*H*-imidazol-1-yl)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-hydroxypyridine-2-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(diethylamino)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-fluoro-4-hydroxyphenyl)glycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-N'-[2-(dimethylamino)ethyl]benzene-1,3-disulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)butanamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-cyanoethyl)benzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-[(difluoromethyl)oxy]benzenesulfonamide; |
| methyl*N*-[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(methylthio)ethyl]benzamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-N'-[3-(dimethylamino)propyl]benzene-1,3-disulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2-(ethylthio)ethyl]benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[2- |

| |
|---|
| (dimethylamino)ethyl]-*N*-ethylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(2-pyridin-4-ylethyl)benzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(ethyloxy)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(furan-2-ylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrimidine-5-carboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(2H-tetrazol-5-yl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-pyrrole-2-carboxamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(3-morpholin-4-ylpropyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(1-methylethyl)glycinamide; |
| *N*-(3-{[(3-{[3-fluoro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1*H*-imidazole-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-diethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylisoxazol-5-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(methyloxy)propyl]benzamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[2-methyl-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-hydroxyphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-1*H*-pyrrole-2-carboxamide; |
| 4-amino-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydro-2H-pyran-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methylamino)piperidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-piperidin-1-ylacetamide; |
| *N*-(4-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methyl-L-prolinamide; |

| |
|---|
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(methylsulfonyl)benzenesulfonamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(dimethylamino)propyl]-*N*-methylbenzamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[3-(propyloxy)propyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(cyclopropylcarbonyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-(phenylmethyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-3-carboxamide; |
| ethyl*N*-[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)carbonyl]-beta-alaninate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-{3-[(1-methylethyl)oxy]propyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-4-ylacetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-piperidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-prop-2-en-1-ylglycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(phenylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-propanoylazetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(methyloxy)ethyl]glycinamide; |
| 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)piperidine-4-carboxamide; |
| *N*-{[(3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-4-methylphenyl)amino](dimethylamino)methylidene}-*N*-methylmethanaminium; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-4-[(trifluoromethyl)oxy]benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpyrrolidin-1-yl)acetamide; |

| |
|---|
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-piperidin-1-ylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-3-carboxamide; |
| $N^2$,$N^2$-dimethyl-*N*-(3-{[(3-{[3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[1-methyl-2-(methyloxy)ethyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-6-chloropyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-2-ylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(dimethylamino)azetidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(dimethylamino)piperidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-pyridin-3-ylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-chlorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[3-(dimethylamino)propyl]-$N^2$-methylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-(2-hydroxyethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(phenylmethyl)pyrrolidin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)furan-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-chloropyridine-4-carboxamide; |
| $N^2$-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylbenzamide; |
| 1,1-dimethylethyl{2-[(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]-2-oxoethyl}carbamate; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-morpholin-4-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-benzodioxole-5-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-({[2- |

| |
|---|
| (methyloxy)phenyl]methyl}oxy)glycinamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-({2-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyridine-4-carboxamide; |
| *N*-(3-{[(3-{[4-fluoro-3-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(3,4-dichlorophenyl)piperazin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-pyridin-3-ylpropanamide; |
| *N*-[3-(butyloxy)propyl]-3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-fluorophenyl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-[4-(diethylamino)-1-methylbutyl]benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-methyl-1-phenylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylcyclopropanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methyl-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-ethylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)thiophene-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-bromothiophene-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-methylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpropanamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pentanamide |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(ethyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(dimethylamino)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-methylpiperidin-1-yl)acetamide; |
| 3-{[(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}-*N*-(1,1-dimethyl-2-oxo-2-piperidin-1-ylethyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-propylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)pyrazine-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,2-dimethylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(4-fluorophenyl)oxy]acetamide; |
| 1-acetyl-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)azetidine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(4-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-phenylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-prop-2-en-1-ylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methyloxy)propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylfuran-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(phenylmethyl)oxy]glycinamide; |
| *N*-{3-[({3-[(2-chloro-5-hydroxyphenyl)amino]quinoxalin-2-yl}amino)sulfonyl]phenyl}-$N^2$,$N^2$-dimethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-chlorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)cyclobutanecarboxamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-methylcyclopropanecarboxamide; |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-[(4-methylpiperazin-1-yl)carbonyl]benzenesulfonamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]amino}pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-(dimethylamino)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,4-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-{[2-(methylthio)phenyl]methyl}glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-fluorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-(1-methylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1,3-thiazole-4-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(phenylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-thienylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(pyridin-2-ylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-chloro-4-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylpentanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-chlorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-fluoro-4-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(2-methylphenyl)oxy]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-cyclohexylacetamide; |
| (1R,2R)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylcyclopropanecarboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-(dimethylamino)benzenesulfonamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-chlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[2-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[3-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-fluoro-4-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(3-fluorophenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(methyloxy)phenyl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-phenylacetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,4-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-oxocyclohexanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(3-fluorophenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3-chlorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-phenylpropyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(2,4-dimethylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(methyloxy)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(3,4-dihydroisoquinolin-2(1*H*)-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-methylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-oxopiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluorobenzamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-{[2-(dimethylamino)ethyl]oxy}pyridine-3-sulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(1-phenylethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-6-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-3- |

| |
|---|
| (methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[2-(1-methylethyl)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[2-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methylpentanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylmorpholin-4-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-[4-(methyloxy)phenyl]propanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-cyclopentyl-$N^2$-prop-2-en-1-ylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-[2-(methyloxy)ethyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-cyclopropyl-4-oxobutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[3-(1,1-dimethylethyl)phenyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(cyclopropylmethyl)-$N^2$-propylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-oxocyclopentyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(4-chlorophenyl)glycinamide; |
| 2-(1,4'-bipiperidin-1'-yl)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-cyclopentylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-methylphenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-[(5-fluoro-2-methylphenyl)methyl]glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,3-dimethylbutanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2-chlorophenyl)glycinamide |
| *N*-(3-{[2-chloro-5-(methyloxy)phenyl]amino}quinoxalin-2-yl)-3-{[2-(piperidin-1-ylmethyl)piperidin-1-yl]carbonyl}benzenesulfonamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-fluoro-3-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,3-dichlorobenzamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(phenyloxy)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-(2,3-dimethylphenyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-fluoro-5-methylbenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-{[(4-methylphenyl)methyl]oxy}glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[4-(1-methylethyl)piperazin-1-yl]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-fluorophenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-4-methyl-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-propylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[(3-methylphenyl)oxy]acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)tetrahydrofuran-2-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-[3-(hydroxymethyl)piperidin-1-yl]acetamide; |
| 1,1-dimethylethyl2-{[(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)amino]carbonyl}piperidine-1-carboxylate; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(pyridin-3-ylmethyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-ethyl-$N^2$-phenylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-{[2-(methyloxy)ethyl]oxy}acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-cyclopentylpropanamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2,5-dichlorobenzamide; |
| 2-(4-acetylpiperazin-1-yl)-*N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-fluoro-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-cyclohexyl-$N^2$-ethylglycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-5-methylisoxazole-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3-methylpyridine-2-carboxamide; |
| *N*-(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)-6-(dimethylamino)pyridine-3-sulfonamide; |

| |
|---|
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)pyridine-3-carboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-3,5-dichlorobenzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(1,3-thiazolidin-3-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formylpiperazin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-pyridin-4-ylpiperidin-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(methyloxy)benzamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-$N^2$-methyl-$N^2$-(2-methylpropyl)glycinamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(4-formyl-1,4-diazepan-1-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-1-phenylcyclopropanecarboxamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2,6-dimethylmorpholin-4-yl)acetamide; |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-(2-phenylpyrrolidin-1-yl)acetamide; and |
| *N*-(3-{[(3-{[3,5-bis(methyloxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide; |

where the Compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof.

8. The method of Claims 1, 2, 6, or 7 where the treatment is one antibody selected from an EGFR antibody and an ErbB2 antibody, or the treatment is one or two chemotherapeutic agents independently selected from rapamycin, a rapamycin analogue, an alkylating agent, a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor.

9. The method of Claim 8 where the treatment is one or two chemotherapeutic agents independently selected from rapamycin, paclitaxel, carboplatin, lapatinib, and erlotinib.

10. The method of Claim 1, 2, 6, or 7 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is erlotinib.

11. The method of Claim 1, 2, 6, or 7 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is lapatinib.

12. The method of Claim 1, 2, 6, or 7 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is carboplatin.

13. The method of Claim 1, 2, 6, or 7 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is paclitaxel.

14. The method of Claim 1, 2, 6, or 7 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is rapamycin.

15. The method of Claim 1, 2, 6, or 7 where the treatment is one antibody selected from bevacizumab, trastuzumab, cetuximab, and panitumumab.

16. The method of Claim 1, 2, 6, or 7 where the treatment is one hormone therapy where the hormone therapy is an aromatase inhibitor.

17. The method of Claim 16 where the aromatase inhibitor is selected from selected from letrozole, anastrozole, and exemestane.

18. The method of Claim 1 or 2 where the treatment is one antibody and the antibody is an ErbB2 antibody.

19. The method of Claim 6, 7, or 18 where the treatment is one antibody and the antibody is an ErbB2 antibody where the ErbB2 antibody is trastuzumab.

20. The method of Claim 1, 6, or 7 where the treatment is one or two agents independently selected from rapamycin, temozolomide, paclitaxel, docetaxel, carboplatin, trastuzumab, erlotinib, and lapatinib.

**Remarks**

New Claims 1, 2, 6, and 7 correspond to original Claims 1, 2, 17, and 18. New Claims 3-5, 8, and 10-15 correspond to original claims 7-9, 19, and 22-27, repectively, which were amended to no longer depend from canceled claims. Claim 9 corresponds to original Claim 20 which was amended to more distinctly claim what the Applicants regard as their Invention. Claims 16 and 17 are new and support for which can be found in paragraph [00158] and [00159]. Claims 18 and 19 are new and support for which can be found in paragraphs [0078], [00148], and [00160]. Claim 20 is new and support for which can be found in paragraph [00115]. No new matter is added with these amendements and new claims.

Industria y Comercio
SUPERINTENDENCIA

# REQUISITOS MÍNIMOS PARA ADMISIÓN A TRAMITE
# PCT

PATENTE DE INVENCIÓN [X] MODELO DE UTILIDAD [ ]

- Indicación de que se solicita la concesión de una patente [X]
- Datos de identificación del solicitante o de la persona que presenta la solicitud [X]
- Descripción de la invención [X]
- Dibujos de ser estos pertinentes [ ]
- Comprobante de pago de las tasas establecidas [X]

COMPLETA [ ] INCOMPLETA [ ]

DISEÑO INDUSTRIAL [ ]

- Indicación de que se solicita el registro de Diseño Industrial [ ]
- Datos de identificación del solicitante o de la persona que presenta la solicitud [ ]
- Representación gráfica y fotográfica del Diseño Industrial o muestra del material que incorpora el diseño [ ]
- Comprobante de pago de las tasas establecidas [ ]

COMPLETA [ ] INCOMPLETA [ ]

ESQUEMA DE TRAZADO [ ]

- Indicación de que se solicita el registro de un Esquema de Trazado [ ]
- Datos de identificación del solicitante o de la persona que presenta la solicitud [ ]
- Representación gráfica del esquema trazado [ ]
- Comprobante de pago de las tasas establecidas [ ]

COMPLETA [ ] INCOMPLETA [ ]

Firma Responsable

Fecha

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 09-126923- -00000-0000
Fecha: 2009-11-09 16:43:03 Dep. 2020 NUECREACIONI
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 1292

Carrera 13 No. 27-00 Piso 5,7y10
Conmutador: 3 82 0840
Fax: 3505220
E-mail: info@sic.gov.co
www.sic.gov.co
Bogotá D.C. - Colombia